Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2011, 40040-40709 [2010-15900]
Download as PDF
40040
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Parts 405, 409, 410, 411, 413,
414, 415, and 424
[CMS–1503–P]
RIN 0938–AP79
Medicare Program; Payment Policies
Under the Physician Fee Schedule and
Other Revisions to Part B for CY 2011
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
AGENCY: Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Proposed rule.
SUMMARY: This proposed rule addresses
proposed changes to the physician fee
schedule and other Medicare Part B
payment policies to ensure that our
payment systems are updated to reflect
changes in medical practice and the
relative value of services. It also
addresses, implements or discusses
certain provisions of both the Affordable
Care Act and the Medicare
Improvements for Patients and
Providers Act of 2008. In addition, this
proposed rule discusses payments
under the Ambulance Fee Schedule,
Clinical Laboratory Fee Schedule,
payments to ESRD facilities, and
payments for Part B drugs. Finally, the
proposed rule includes a discussion
regarding the Chiropractic Services
Demonstration program, the
Competitive Bidding Program for
Durable Medical Equipment and
Provider and Supplier Enrollment
Issues associated with Air Ambulances.
(See the Table of Contents for a listing
of the specific issues addressed in this
proposed rule.)
DATES: To be assured consideration,
comments must be received at one of
the addresses provided below, no later
than 5 p.m. on August 24, 2010.
ADDRESSES: In commenting, please refer
to file code CMS–1503–P. Because of
staff and resource limitations, we cannot
accept comments by facsimile (FAX)
transmission.
You may submit comments in one of
four ways (please choose only one of the
ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the instructions for ‘‘submitting a
comment.’’
2. By regular mail. You may mail
written comments to the following
address only:
Centers for Medicare & Medicaid
Services, Department of Health and
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Human Services, Attention: CMS–1503–
P, P.O. Box 8013, Baltimore, MD 21244–
8013.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address only:
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services, Attention: CMS–1503–
P, Mail Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
4. By hand or courier. If you prefer,
you may deliver (by hand or courier)
your written comments before the close
of the comment period to either of the
following addresses:
a. For delivery in Washington, DC—
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services, Room 445–G, Hubert
H. Humphrey Building, 200
Independence Avenue, SW.,
Washington, DC 20201.
(Because access to the interior of the
Hubert H. Humphrey Building is not
readily available to persons without
Federal government identification,
commenters are encouraged to leave
their comments in the CMS drop slots
located in the main lobby of the
building. A stamp-in clock is available
for persons wishing to retain a proof of
filing by stamping in and retaining an
extra copy of the comments being filed.)
b. For delivery in Baltimore, MD—
Centers for Medicare & Medicaid
Services, Department of Health and
Human Services, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
If you intend to deliver your
comments to the Baltimore address,
please call telephone number (410) 786–
9994 in advance to schedule your
arrival with one of our staff members.
Comments mailed to the addresses
indicated as appropriate for hand or
courier delivery may be delayed and
received after the comment period.
FOR FURTHER INFORMATION CONTACT:
Rebecca Cole, (410) 786–4497, for issues
related to physician payment and for
all other issues not identified below.
Cheryl Gilbreath, (410) 786–5919, for
issues related to payment for covered
outpatient drugs and biologicals.
Roechel Kujawa, (410) 786–9111, for
issues related to ambulance services.
Glenn McGuirk, (410) 786–5723, for
clinical laboratory issues.
Randall Ricktor, (410) 786–4632, for
Federally Qualified Health Center
Issues.
Pauline Lapin, (410) 786–6883, for
issues related to the chiropractic
services demonstration BN issue.
PO 00000
Frm 00002
Fmt 4701
Sfmt 4702
Troy Barsky, (410)786–8873, or Kristin
Bohl, (410)786–8680, for issues
related to physician self-referral.
Troy Barsky, (410)786–8873, or Fred
Grabau (410)786–0206, for issues
related to timely filing rules.
Henry Richter, (410)786–4562, or Lisa
Hubbard, (410)786–5472, for issues
related to renal dialysis provisions
and payments for end-stage renal
disease facilities.
Diane Stern, (410)786–1133, for issues
related to the physician quality
reporting initiative and incentives for
e-prescribing.
Sheila Roman, 410–786–6004, or
Pamela Cheetham, 410–786–2259, for
issues related to the Physician
Resource Use Feedback Program and
value-based purchasing.
Joel Kaiser, (410)786–4499, for issues
related to the DME provisions.
Jim Bossenmeyer, (410)786–9317, for
issues related to provider and
supplier enrollment issues.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All
comments received before the close of
the comment period are available for
viewing by the public, including any
personally identifiable or confidential
business information that is included in
a comment. We post all comments
received before the close of the
comment period on the following Web
site as soon as possible after they have
been received: https://
www.regulations.gov. Follow the search
instructions on that Web site to view
public comments.
Comments received timely will also
be available for public inspection as
they are received, generally beginning
approximately 3 weeks after publication
of a document, at the headquarters of
the Centers for Medicare & Medicaid
Services, 7500 Security Boulevard,
Baltimore, Maryland 21244, Monday
through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an
appointment to view public comments,
phone 1–800–743–3951.
Table of Contents
To assist readers in referencing
sections contained in this preamble, we
are providing a table of contents. Some
of the issues discussed in this preamble
affect the payment policies, but do not
require changes to the regulations in the
Code of Federal Regulations (CFR).
Information on the regulation’s impact
appears throughout the preamble, and
therefore, is not discussed exclusively
in section V. of this proposed rule.
I. Background
A. Development of the Relative Value
System
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
1. Work RVUs
2. Practice Expense Relative Value Units
(PE RVUs)
3. Resource-Based Malpractice (MP) RVUs
4. Refinements to the RVUs
5. Adjustments to RVUs Are Budget
Neutral
B. Components of the Fee Schedule
Payment Amounts
C. Most Recent Changes to Fee Schedule
II. Provisions of the Proposed Rule for the
Physician Fee Schedule
A. Resource-Based Practice Expense (PE)
Relative Value Units (RVUs)
1. Overview
2. Practice Expense Methodology
a. Direct Practice Expense
b. Indirect Practice Expense per Hour Data
c. Allocation of PE to Services
(i) Direct Costs
(ii) Indirect Costs
d. Facility and Nonfacility Costs
e. Services with Technical Components
(TCs) and Professional Components
(PCs)
f. Alternative Data Sources and Public
Comments on Final Rule for 2010
g. PE RVU Methodology
(i) Setup File
(ii) Calculate the Direct Cost PE RVUs
(iii) Create the Indirect Cost PE RVUs
(iv) Calculate the Final PE RVUs
(v) Setup File Information
(vi) Equipment Cost per Minute
3. Proposed PE Revisions for CY 2011
a. Equipment Utilization Rate
b. HCPCS Code-Specific PE Proposals
(1) Biohazard Bags
(2) PE Inputs for Professional Component
(PC) Only and Technical Component
(TC) Only Codes Summing to Global
Only Codes
(3) Equipment Time Inputs for Certain
Diagnostic Tests
(4) Cobalt-57 Flood Source
(5) Venom Immunotherapy
(6) Equipment Redundancy
(7) Equipment Duplication
(8) Establishing Overall Direct PE Supply
Price Inputs Based on Unit Prices and
Quantities
c. AMA RUC Recommendations in CY
2010 for Changes to Direct PE Inputs
(1) Electrogastrography and Esophageal
Function Test
(2) 64-Slice CT Scanner and Software
(3) Cystometrogram
(4) Breath Hydrogen Test
(5) Radiographic Fluoroscopic Room
d. Referral of Existing CPT Codes for AMA
RUC Review
e. Updating Equipment and Supply Price
Inputs for Existing Codes
B. Malpractice Relative Value Units (RVUs)
1. Background
2. Malpractice RVUs for New and Revised
Services Effective Before the Next 5-Year
Review
3. Revised Malpractice RVUs for Selected
Disc Arthroplasty Services
C. Potentially Misvalued Codes Under the
Physician Fee Schedule
1. Valuing Services Under the PFS
2. Identifying, Reviewing, and Validating
the RVUs of Potentially Misvalued
Services Under the PFS
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
a. Background
b. Progress in Identifying and Reviewing
Potentially Misvalued Codes
c. Validating RVUs of Potentially
Misvalued Codes
3. CY 2011 Identification and Review of
Potentially Misvalued Services
a. Codes on the Multi-Specialty Points of
Comparison List
b. Codes With Low Work RVUs Commonly
Billed in Multiple Units Per Single
Encounter
c. Codes With High Volume and Low Work
RVUs
d. Codes With Site-of-Service-Anomalies
e. Codes With ‘‘23-hour’’ Stays
4. Expanding the Multiple Procedure
Payment Reduction (MPPR) Policy to
Additional Nonsurgical Services
a. Background
b. Proposed CY 2011 Expansion of the
Imaging Technical Component MPPR
Policy to Additional Combinations of
Imaging Services
c. Proposed CY 2011 Expansion of the
MPPR Policy to Therapy Services
5. High Cost Supplies
a. Background
b. Future Updates to the Prices of HighCost Supplies
D. Geographic Practice Cost Indices
(GPCIs)
1. Background
2. GPCI Update
a. Physician Work GPCIs
b. Practice Expense GPCIs
(1) The Affordable Care Act Requirements
for PE GPCIs
(2) Summary of CY 2011 Proposed PE
GPCIs
c. Malpractice GPCIs
d. General GPCI Update Process
3. Payment Localities
E. Physician Fee Schedule Update for CY
2011
1. Rebasing the Medicare Economic Index
(MEI)
a. Background
b. Use of More Current Data
c. Rebasing and Revising Expense
Categories in the MEI
(1) Developing the Weights for Use in the
MEI
(2) Physician’s Own Time
(3) Physician’s Practice Expenses
(A) Non-Physician Employee
Compensation
(B) Office Expenses
(C) Professional Liability Insurance (PLI)
Expense
(D) Medical Equipment Expenses
(E) Medical Supplies Expenses
(F) All Other Professional Expenses
d. Selection of Price Proxies for Use in the
MEI
(1) Expense Categories in the MEI
(A) Physician’s Own Time (Physician
Compensation)
(B) Nonphysician Employee Compensation
(C) Utilities
(D) Chemicals
(E) Paper
(F) Rubber and Plastics
(G) Telephone
(H) Postage
(I) All Other Labor-Intensive Services
Frm 00003
Fmt 4701
Sfmt 4702
40041
(J) Fixed Capital
(K) Moveable Capital
(L) Professional Liability Insurance
(M) Medical Equipment
(N) Other Professional Expenses
(2) Productivity Adjustment to the MEI
e. Results of Rebasing
f. Adjustments to the RVU Shares to Match
the Proposed Rebased MEI Weights
III. Code-Specific Issues for the PFS
A. Therapy Services
1. Outpatient Therapy Caps for CY 2011
2. Alternatives to Therapy Caps
a. Background
b. Current Activities
c. Potential Short-Term Approaches to
Therapy Caps
B. Diabetes Self-Management Training
(DSMT) Services (HCPCS Codes G0108
and G0109)
1. Background
2. Proposed Payment for DSMT Services
C. End-State Renal Disease Related
Services for Home Dialysis (CPT Codes
90963, 90964, 90965, and 90966)
1. End-Stage Renal Disease Home Dialysis
Monthly Capitation Payment Services
(CPT Codes 90963, 90964, 90965, and
90966)
2. Daily and Monthly ESRD-Related
Services (CPT Codes 90951 Through
90970)
D. Portable X-Ray Set-Up (HCPCS Code
Q0092)
E. Pulmonary Rehabilitation Services
(HCPCS Code G0424)
F. Application of Tissue-Cultured Skin
Substitutes to Lower Extremities (HCPCS
Codes GXXX1 and GXXX2)
G. Canalith Repositioning (CPT Code
95992)
H. Intranasal/Oral Immunization Codes
(CPT Codes 90467, 90468, 90473, and
90474)
I. Refinement Panel Process
J. Remote Cardiac Monitoring Services
(CPT Codes 93012, 93229, 93268, and
93271)
IV. Medicare Telehealth Services for the
Physician Fee Schedule
A. Billing and Payment for Telehealth
Services
1. History
2. Current Telehealth Billing and Payment
Policies
B. Requests for Adding Services to the List
of Medicare Telehealth Services
C. Submitted Requests for Addition to the
List of Telehealth Services for CY 2011
(1) Individual KDE Services
(2) Individual DSMT Services
(3) Group KDE, MNT, DSMT, and HBAI
Services
(4) Initial, Subsequent, and Discharge Day
Management Hospital Care Services
(5) Initial, Subsequent, Discharge Day
Management, and Other Nursing Facility
Care Services
(6) Neuropsychological Testing Services
(7) Speech-Language Pathology Services
(8) Home Wound Care Services
D. Summary of CY 2011 Telehealth
Proposals
V. Provisions of the Patient Protection and
Affordable Care Act of 2010
A. Section 3002: Improvements to the
Physician Quality Reporting System
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40042
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
B. Section 3003: Improvements to the
Physician Feedback Program and Section
3007: Value-Based Payment Modifier
Under the Physician Fee Schedule
1. Background
2. Effect of the Patient Protection and
Affordable Care Act on the Program
3. Implementation of Sections 3003 and
3007 of the Affordable Care Act
4. Comments Sought on Specific Policy
Topics Related to Both PPACA Sections
3003 and 3007
a. Risk Adjustment
b. Attribution
c. Benchmarking and Peer Groups
d. Cost and Quality Measures and
Composite Measurement
C. Section 3102: Extension of the Work
Geographic Index Floor and Revisions to
the Practice Expense Geographic
Adjustment Under the Medicare
Physician Fee Schedule, and Protections
for Frontier States as Amended by
Section 10324 of the Affordable Care Act
D. Section 3103: Extension of Exceptions
Process for Medicare Therapy Caps
E. Section 3104: Extension of Payment for
Technical Component of Certain
Physician Pathology Services
F. Section 3105: Extension of Ambulance
Add-On
G. Section 3107: Extension of Physician
Fee Schedule Mental Health Add-On
H. Section 3108: Permitting Physician
Assistants to Order Post-Hospital
Extended Care Services
I. Section 3111: Payment for Bone Density
Tests
J. Section 3114: Improved Access for
Certified Nurse Midwife Services
K. Section 3122: Extension of Medicare
Reasonable Costs Payments for Certain
Clinical Diagnostic Laboratory Tests
Furnished to Hospital Patients in Certain
Rural Areas
L. Section 3134: Misvalued Codes Under
the Physician Fee Schedule
M. Section 3135: Modification of
Equipment Utilization Factor for
Advanced Imaging Services
1. Adjustment in Practice Expense to
Reflect Higher Presumed Utilization
2. Adjustment in Technical Component
‘‘Discount’’ on Single-Session Imaging to
Consecutive Body Parts
N. Section 3136: Revision for Payment for
Power-Driven Wheelchairs
a. Payment Rules for Power Wheelchairs
b. Elimination of Lump Sum Payment for
Standard Power Wheelchairs
c. Revision of Payment Amounts for Power
Wheelchairs
O. Section 3139: Payment for Biosimilar
Biological Products
P. Section 3401: Revision of Certain Market
Basket Updates and Incorporation of
Productivity Improvements Into Market
Basket Updates That Do Not Already
Incorporate Such Improvements
1. ESRD Market Basket Discussion
2. Productivity Adjustment Regarding
Ambulance and Clinical Laboratory Fee
Schedules
a. Ambulatory Surgery Centers (ASCs)
b. Ambulance Fee Schedule (AFS)
c. Clinical Lab Fee Schedule
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Q. Section 4103: Medicare Coverage of
Annual Wellness Visit Providing a
Personalized Prevention Plan
1. Background
a. Medicare Coverage of Preventive
Physical Examinations and Routine
Checkups
b. Requirements for Coverage of an Annual
Wellness Visit
2. Proposed Revisions
a. Proposed Revisions to § 411.15,
Particular Services Excluded From
Coverage
b. Proposed Revisions to Part 410, Subpart
B—Medical and Other Health Services
(1) Definitions
(2) Requirements of the First Visit for
Personalized Prevention Plan Services
(3) Requirements of Subsequent Visits for
Personalized Prevention Plan Services
3. Payment for the Annual Wellness Visit
Providing Personalized Prevention Plan
Services (PPPS)
R. Section 4104: Removal of Barriers to
Preventive Services in Medicare
1. Definition of ‘‘Preventive Services’’
2. Deductible and Coinsurance for
Preventive Services
3. Extension of Waiver of Deductible to
Services Furnished in Connection With
or in Relation to a Colorectal Cancer
Screening Test that Becomes Diagnostic
or Therapeutic
S. Section 5501: Expanding Access to
Primary Care Services and General
Surgery Services
1. Section 5501(a): Incentive Payment
Program for Primary Care Services
a. Background
b. Proposed Primary Care Incentive
Payment Program (PCIP)
2. Section 5501(b): Incentive Payment
Program for Major Surgical Procedures
Furnished in Health Professional
Shortage Areas
a. Background
b. Proposed HPSA Surgical Incentive
Payment Program (HSIP)
3. Sections 5501(a) and (b) of the
Affordable Care Act and Payment for
Critical Access Hospital Professional
Services Under the Optional Method
T. Section 6003: Disclosure Requirements
for In-Office Ancillary Services
Exception to the Prohibition on
Physician Self-Referral for Certain
Imaging Services
1. Background
2. Proposed Disclosure Requirement
U. Section 6404: Maximum Period for
Submission of Medicare Claims Reduced
to Not More Than 12 Months
1. Background
2. Provisions of Affordable Care Act
V. Section 6410 and MIPPA: Adjustments to
the Medicare Durable Medical
Equipment, Prosthetics, Orthotics, and
Supplies Competitive Acquisition
Program
1. Background
2. Subdividing Large MSAs Under Round
2
3. Exclusions of Certain Areas After Round
2 and Prior to 2015
4. Expansion of Round 2
W. Section 10501(i)(3)—Proposed
Collection of HCPCS Data for
PO 00000
Frm 00004
Fmt 4701
Sfmt 4702
Development and Implementation of a
Prospective Payment System for the
Medicare Federally Qualified Health
Center Program
VI. Other Provisions of the Proposed
Regulation
A. Part B Drug Payment: Average Sales
Price (ASP) Issues
1. ‘‘Carry Over’’ ASP
2. Partial Quarter ASP Data
3. Determining the Payment Amount for
Drugs and Biologicals Which Include
Intentional Overfill
4. WAMP/AMP
5. Price Substitutions
a. AMP threshold
b. AMP Price Substitution
B. Ambulance Fee Schedule: Proposed
Policy for Reporting Units When Billing
for Ambulance Fractional Mileage
1. Policy for Reporting Units When Billing
for Ambulance Fractional Mileage or
Other Services
a. History of Medicare Ambulance Services
(1) Statutory Coverage of Ambulance
Services
(2) Medicare Regulations for Ambulance
Services
b. Mileage Reporting
(1) Background and Current Process for
Reporting Ambulance Mileage
(2) Potential for Inaccuracies in Reporting
Units and Associated Risks
(3) Billing of Fractional Units for Mileage
C. Clinical Laboratory Fee Schedule:
Signature on Requisition
D. Discussion of Chiropractic Services
Demonstration
E. Provisions Related to Payment for Renal
Dialysis Services Furnished by EndStage Renal Disease (ESRD) Facilities
1. CY 2005 Provisions
2. CY 2006 Provisions
3. CY 2007 Provisions
4. CY 2008 Provisions
5. CY 2009 Updates
6. CY 2010 Updates
7. Proposals for CY 2011
a. MIPPA Provisions
b. Affordable Care Act Provision
8. Proposed Update to the Drug Add-On
Adjustment to the Composite Rate
a. Estimating Growth in Expenditures for
Drugs and Biologicals for CY 2010
b. Estimating Growth in Expenditures for
Drugs and Biologicals in CY 2011
c. Estimating Per Patient Growth
d. Applying the Proposed Growth Update
to the Drug Add-On Adjustment
e. Proposed Update to the Drug Add-On
Adjustment
f. Proposed Update to the Geographic
Adjustments to the Composite Rate
g. Proposed Updates to Core-Based
Statistical Area (CBSA) Definitions
h. Proposed Updated Wage Index Values
i. Reduction to the ESRD Wage Index Floor
j. Proposed Wage Index Values for Areas
With No Hospital Data
k. Budget Neutrality Adjustment
l. ESRD Wage Index Tables
F. Issues Related to the Medicare
Improvements for Patients and Providers
Act of 2008 (MIPPA)
1. Section 131: Physician Payment,
Efficiency, and Quality Improvements—
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Physician Quality Reporting Initiative
(PQRI)
a. Program Background and Statutory
Authority
b. Incentive Payments for the 2011 PQRI
c. Proposed 2011 Reporting Periods for
Individual Eligible Professionals
d. Proposed 2011 PQRI Reporting
Mechanisms for Individual Eligible
Professionals
(1) Proposed Requirements for Individual
Eligible Professionals Who Choose the
Claims-Based Reporting Mechanism
(2) Proposed Requirements for Individual
Eligible Professionals Who Choose the
Registry-Based Reporting Mechanism
(3) Proposed Requirements for Individual
Eligible Professionals Who Choose the
EHR-Based Reporting Mechanism
(4) Proposed Qualification Requirements
for Registries
(5) Proposed Qualification Requirements
for EHR Vendors and Their Products
e. Proposed Criteria for Satisfactory
Reporting of Individual Quality
Measures for Individual Eligible
Professionals
f. Proposed Criteria for Satisfactory
Reporting Measures Groups for
Individual Eligible Professionals
g. Proposed Reporting Option for
Satisfactory Reporting on Quality
Measures by Group Practices
(1) Group Practice Reporting Option—
GPRO I
(2) Process for Physician Group Practices to
Participate as Group Practices and
Criteria for Satisfactory Reporting
h. Statutory Requirements and Other
Considerations for 2011 PQRI Measures
(1) Statutory Requirements for 2011 PQRI
Measures
(2) Other Considerations for Measures
Proposed for Inclusion in the 2011 PQRI
i. Proposed 2011 PQRI Quality Measures
for Individual Eligible Professionals
(1) Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Claims Based Reporting and RegistryBased Reporting
(2) Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Registry Based Reporting Only
(3) New Individual Quality Measures
Selected for Proposed for 2011
(4) Proposed 2011 Measures Available for
EHR-Based Reporting
(5) Measures Proposed for Inclusion in
2011 Measures Groups
j. Proposed 2011 PQRI Quality Measures
for Physician Groups Selected to
Participate in the Group Practice
Reporting Option
k. Public Reporting of PQRI Data
l. Affordable Care Act Extension of
Incentive for PQRI Program
m. Affordable Care Act Timely Feedback
Reports
n. Affordable Care Act Informal Appeals
Process
o. Affordable Care Act Maintenance of
Certification Program
p. Affordable Care Act Physician Compare
Web Site
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
q. Affordable Care Act Integration of PQRI
EHR Measures and HITECH Measures in
Years After 2011
2. Section 132: Incentives for Electronic
Prescribing (eRx)—The Electronic
Prescribing Incentive Program
a. Program Background and Statutory
Authority
b. The 2011 Reporting Period for the eRx
Incentive Program
c. Proposed Criteria for Determination of
Successful Electronic Prescriber for
Eligible Professionals
(1) Reporting the Electronic Prescribing
Measure
(2) The Reporting Denominator for the
Electronic Prescribing Measure
(3) Qualified Electronic Prescribing
System—Required Functionalities and
Part D eRx Standards
(4) The Reporting Numerator for the
Electronic Prescribing Measure
(5) Criteria for Successful Reporting of the
Electronic Prescribing Measure
d. Determination of the 2011 Incentive
Payment Amount for Individual Eligible
Professionals Who Are Successful
Electronic Prescribers
e. Proposed Reporting Option for
Satisfactory Reporting of the Electronic
Prescribing Measure by Group Practices
(1) Definition of ‘‘Group Practice’’
(2) Process for Group Practices to
Participate as Group Practices and
Criteria for Successful Reporting of the
Electronic Prescribing Measure by Group
Practices
f. Public Reporting of Names of Successful
Electronic Prescribers
G. DMEPOS Competitive Bidding Program
Issues
1. Implementation of a National Mail Order
Competitive Bidding Program for
Diabetic Testing Supplies
a. Revision of the Definition of ‘‘Mail
Order’’
(1) Legislative and Regulatory History of
the Medicare Durable Medical
Equipment, Prosthetics, Orthotics, and
Supplies (DMEPOS) Competitive
Bidding Program
(2) National Mail Order Competitive
Bidding Program
(3) The MIPPA and the Medicare DMEPOS
Competitive Bidding Program
(4) Competition for Mail Order Diabetic
Supplies Under Round 1 of the Medicare
DMEPOS Competitive Bidding Program
b. Overview of Proposed Rule
c. Future Competitions for Diabetic Testing
Supplies
d. Definition of Mail Order Item
e. Special Rule in Case of National Mail
Order Competition for Diabetic Testing
Strips
f. Anti-Switching Rule in Case of National
Mail Order Competition for Diabetic Test
Strips
2. Off-the-Shelf (OTS) Orthotics Exemption
3. Changes to Payment for Oxygen and
Oxygen Equipment
a. Background
b. Furnishing Oxygen Equipment After the
36-Month Rental Period (Cap)
c. Furnishing Oxygen Equipment During
the 36-Month Rental Period (Cap)
Frm 00005
Fmt 4701
Sfmt 4702
40043
4. Grandfathering Rules Resulting in Extra
Payments to Contract Suppliers Under
the DMEPOS Competitive Bidding
Program
5. Appeals Process
a. Background
b. Proposed Appeals Process
(1) Purpose and Definitions: (§ 414.402)
(2) Applicability
(3) Contract Termination
(4) Notice of Termination
(5) Corrective Action Plan
(6) Right to Request a Hearing by the CBIC
Hearing Officer
(7) Scheduling of the Hearing
(8) Burden of Proof
(9) Role of the Hearing Officer
(10) CMS’s Final Determination
(11) Effective Date of the Contract
Termination
(12) Effect of Contract Termination
H. Provider and Supplier Enrollment Issue:
Air Ambulance Provision
I. Technical Corrections
1. Physical Therapy, Occupational
Therapy, and Speech-Language
Pathology
2. Scope of Benefits
VII. Collection of Information Requirements
VIII. Response to Comments
IX. Regulatory Impact Analysis
A. RVU Impacts
1. Resource Based Work, PE, and
Malpractice RVUs
2. CY 2011 PFS Impact Discussion
a. Changes in RVUs
b. Combined Impact
B. Geographic Practice Cost Indices (GPCIs)
C. Rebasing and Revising of the MEI
D. The Affordable Care Act Provisions
1. Section 3103: Extension of Exceptions
Process for Medicare Therapy Caps
2. Section 3104: Extension of Payment for
Technical Component of Certain
Physician Pathology Services
3. Sections 3105 and 10311: Extension of
Ambulance Add-Ons
4. Section 3107: Extension of Physician Fee
Schedule Mental Health Add-On
5. Section 3111: Payment for Bone Density
Tests
6. Section 3122: Extension of Medicare
Reasonable Costs Payments for Certain
Clinical Diagnostic Laboratory Tests
Furnished to Hospital Patients in Certain
Rural Areas
7. Section 3135: Modification of
Equipment Utilization Factor for
Advanced Imaging Services
8. Section 3136: Revisions in Payments for
Power Wheelchairs
9. Section 3401: Revisions of Certain
Market Basket Updates and
Incorporation of Productivity
Adjustments
10. Section 4103: Medicare Coverage of
Annual Wellness Visit Providing a
Personalized Prevention Plan
11. Section 4104: Removal of Barriers to
Preventive Services in Medicare
12. Section 5501: Expanding Access to
Primary Care Services and General
Surgery Services
13. Section 6003: Disclosure Requirements
for In-Office Ancillary Services
Exception to the Prohibition of Physician
Self-referral for Certain Imaging Services
E:\FR\FM\13JYP2.SGM
13JYP2
40044
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
14. Section 6404: Maximum Period for
Submission of Medicare Claims Reduced
to Not More Than 12 Months
E. Other Provisions of the Proposed
Regulation
1. Part B Drug Payment: ASP Issues
2. Ambulance Fee Schedule: Proposed
Policy for Reporting Units When Billing
for Ambulance Fractional Mileage
3. Chiropractic Services Demonstration
4. Renal Dialysis Services Furnished by
ESRD Facilities
5. Section 131(b) of the MIPPA: Physician
Payment, Efficiency, and Quality
Improvements—Physician Quality
Reporting Initiative (PQRI)
6. Section 132 of the MIPPA: Incentives for
Electronic Prescribing (eRx)—The eRx
Incentive Program
7 RHC/FQHC Issues
8. Durable Medical Equipment-Related
Issues
a. Off-the-Shelf (OTS) Orthotics Exemption
b. Changes to Payment for Oxygen
Equipment
F. Alternatives Considered
G. Impact on Beneficiaries
H. Accounting Statement
Regulation Text
Addendum A—Explanation and Use of
Addendum B
Addendum B—Proposed Relative Value
Units and Related Information Used in
Determining Medicare Payments for CY
2011
Addendum C—[Reserved]
Addendum D—Proposed CY 2011
Geographic Adjustment Factors (GAFs)
Addendum E—Proposed CY 2011
Geographic Practice Cost Indices (GPCIs)
by State and Medicare Locality
Addendum F—Proposed CY 2011 Diagnostic
Imaging Services Subject to the Multiple
Procedure Payment Reduction
Addendum G—CPT/HCPCS Imaging Codes
Defined by Section 5102(b) of the DRA
Addendum H—Proposed CY 2011 ‘‘Always
Therapy’’ Services* Subject to the
Multiple Procedure Payment Reduction
Addendum I—[Reserved]
Addendum J—[Reserved]
Addendum K—Proposed CY 2011 ESRD
Wage Index for Urban Areas Based on
CBSA Labor Market Areas
Addendum L—Proposed CY 2011 ESRD
Wage Index for Rural Areas Based on
CBSA Labor Market Areas
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Acronyms
In addition, because of the many
organizations and terms to which we
refer by acronym in this proposed rule,
we are listing these acronyms and their
corresponding terms in alphabetical
order below:
AA Anesthesiologist assistant
AACVPR American Association of
Cardiovascular and Pulmonary
Rehabilitation
AANA American Association of Nurse
Anesthetists
ABMS American Board of Medical
Specialties
ABN Advanced Beneficiary Notice
ACA ‘‘Affordable Care Act’’
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
ACC American College of Cardiology
ACGME Accreditation Council on Graduate
Medical Education
ACLS Advanced cardiac life support
ACR American College of Radiology
AED Automated external defibrillator
AFROC Association of Freestanding
Radiation Oncology Centers
AHA American Heart Association
AHFS–DI American Hospital Formulary
Service—Drug Information
AHRQ [HHS’] Agency for Healthcare
Research and Quality
AMA American Medical Association
AMA–DE American Medical Association
Drug Evaluations
AMP Average manufacturer price
AO Accreditation organization
AOA American Osteopathic Association
APA American Psychological Association
APTA American Physical Therapy
Association
ARRA American Recovery and
Reinvestment Act (Pub. L. 111–5)
ASC Ambulatory surgical center
ASP Average sales price
ASRT American Society of Radiologic
Technologists
ASTRO American Society for Therapeutic
Radiology and Oncology
ATA American Telemedicine Association
AWP Average wholesale price
BBA Balanced Budget Act of 1997 (Pub. L.
105–33)
BBRA [Medicare, Medicaid and State Child
Health Insurance Program] Balanced
Budget Refinement Act of 1999 (Pub. L.
106–113)
BIPA Medicare, Medicaid, and SCHIP
Benefits Improvement Protection Act of
2000 (Pub. L. 106–554)
BLS Basic Life support
BN Budget neutrality
BPM Benefit Policy Manual
CABG Coronary artery bypass graft
CAD Coronary artery disease
CAH Critical access hospital
CAHEA Committee on Allied Health
Education and Accreditation
CAP Competitive acquisition program
CBIC Competitive Bidding Implementation
Contractor
CBP Competitive Bidding Program
CBSA Core-Based Statistical Area
CF Conversion factor
CfC Conditions for Coverage
CFR Code of Federal Regulations
CKD Chronic kidney disease
CLFS Clinical laboratory fee schedule
CMA California Medical Association
CMHC Community mental health center
CMP Civil money penalty
CMS Centers for Medicare & Medicaid
Services
CNS Clinical nurse specialist
CoP Condition of participation
COPD Chronic obstructive pulmonary
disease
CORF Comprehensive Outpatient
Rehabilitation Facility
COS Cost of service
CPEP Clinical Practice Expert Panel
CPI Consumer Price Index
CPI–U Consumer price index for urban
customers
CPR Cardiopulmonary resuscitation
PO 00000
Frm 00006
Fmt 4701
Sfmt 4702
CPT [Physicians’] Current Procedural
Terminology (4th Edition, 2002,
copyrighted by the American Medical
Association)
CR Cardiac rehabilitation
CRNA Certified registered nurse anesthetist
CRP Canalith repositioning
CRT Certified respiratory therapist
CSW Clinical social worker
CY Calendar year
DEA Drug Enforcement Agency
DHS Designated health services
DME Durable medical equipment
DMEPOS Durable medical equipment,
prosthetics, orthotics, and supplies
DOQ Doctor’s Office Quality
DOS Date of service
DRA Deficit Reduction Act of 2005 (Pub. L.
109–171)
DSMT Diabetes self-management training
E/M Evaluation and management
EDI Electronic data interchange
EEG Electroencephalogram
EHR Electronic health record
EKG Electrocardiogram
EMG Electromyogram
EMTALA Emergency Medical Treatment
and Active Labor Act
EOG Electro-oculogram
EPO Erythopoeitin
ESRD End-stage renal disease
FAX Facsimile
FDA Food and Drug Administration (HHS)
FFS Fee-for-service
FR Federal Register
GAF Geographic adjustment factor
GAO General Accounting Office
GEM Generating Medicare [Physician
Quality Performance Measurement Results]
GFR Glomerular filtration rate
GPO Group purchasing organization
GPCI Geographic practice cost index
HAC Hospital-acquired conditions
HBAI Health and behavior assessment and
intervention
HCPAC Health Care Professional Advisory
Committee
HCPCS Healthcare Common Procedure
Coding System
HCRIS Healthcare Cost Report Information
System
HDRT High dose radiation therapy
HH PPS Home Health Prospective Payment
System
HHA Home health agency
HHRG Home health resource group
HHS [Department of] Health and Human
Services
HIPAA Health Insurance Portability and
Accountability Act of 1996 (Pub. L. 104–
191)
HIT Health information technology
HITECH Health Information Technology for
Economic and Clinical Health Act (Title IV
of Division B of the Recovery Act, together
with Title XIII of Division A of the
Recovery Act)
HITSP Healthcare Information Technology
Standards Panel
HIV Human immunodeficiency virus
HOPD Hospital outpatient department
HPSA Health Professional Shortage Area
HRSA Health Resources Services
Administration (HHS)
IACS Individuals Access to CMS Systems
ICD International Classification of Diseases
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
ICF Intermediate care facilities
ICR Intensive cardiac rehabilitation
ICR Information collection requirement
IDTF Independent diagnostic testing facility
IFC Interim final rule with comment period
IMRT Intensity-Modulated Radiation
Therapy
IPPE Initial preventive physical
examination
IPPS Inpatient prospective payment system
IRS Internal Revenue Service
ISO Insurance services office
IVD Ischemic Vascular Disease
IVIG Intravenous immune globulin
IWPUT Intra-service work per unit of time
JRCERT Joint Review Committee on
Education in Radiologic Technology
KDE Kidney disease education
LCD Local coverage determination
MA Medicare Advantage
MA–PD Medicare Advantage—Prescription
Drug Plans
MAV Measure Applicability Validation
MCMP Medicare Care Management
Performance
MDRD Modification of Diet in Renal
Disease
MedCAC Medicare Evidence Development
and Coverage Advisory Committee
(formerly the Medicare Coverage Advisory
Committee (MCAC))
MedPAC Medicare Payment Advisory
Commission
MEI Medicare Economic Index
MIEA–TRHCA Medicare Improvements and
Extension Act of 2006 (that is, Division B
of the Tax Relief and Health Care Act of
2006 (TRHCA)) (Pub. L. 109–432)
MIPPA Medicare Improvements for Patients
and Providers Act of 2008 (Pub. L. 110–
275)
MMA Medicare Prescription Drug,
Improvement, and Modernization Act of
2003 (Pub. L. 108–173)
MMSEA Medicare, Medicaid, and SCHIP
Extension Act of 2007 (Pub. L. 110–173)
MNT Medical nutrition therapy
MOC Maintenance of certification
MP Malpractice
MPPR Multiple procedure payment
reduction
MQSA Mammography Quality Standards
Act of 1992 (Pub. L. 102–539)
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
NBRC National Board for Respiratory Care
NCD National Coverage Determination
NCQDIS National Coalition of Quality
Diagnostic Imaging Services
NDC National drug code
NF Nursing facility
NISTA National Institute of Standards and
Technology Act
NP Nurse practitioner
NPI National Provider Identifier
NPP Nonphysician practitioner
NQF National Quality Forum
NRC Nuclear Regulatory Commission
OACT [CMS’] Office of the Actuary
OBRA Omnibus Budget Reconciliation Act
ODF Open door forum
OGPE Oxygen generating portable
equipment
OIG Office of Inspector General
OMB Office of Management and Budget
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
ONC [HHS’] Office of the National
Coordinator for Health IT
OPPS Outpatient prospective payment
system
OSCAR Online Survey and Certification
and Reporting
PA Physician assistant
PAT Performance assessment tool
PC Professional component
PCI Percutaneous coronary intervention
PDP Prescription drug plan
PE Practice expense
PE/HR Practice expense per hour
PEAC Practice Expense Advisory
Committee
PERC Practice Expense Review Committee
PFS Physician Fee Schedule
PGP [Medicare] Physician Group Practice
PHI Protected health information
PHP Partial hospitalization program
PIM [Medicare] Program Integrity Manual
PLI Professional liability insurance
POA Present on admission
POC Plan of care
PPI Producer price index
PPIS Physician Practice Information Survey
PPS Prospective payment system
PPTA Plasma Protein Therapeutics
Association
PQRI Physician Quality Reporting Initiative
PR Pulmonary rehabilitation
PRA Paperwork Reduction Act
PSA Physician scarcity areas
PT Physical therapy
PTCA Percutaneous transluminal coronary
angioplasty
PVBP Physician and Other Health
Professional Value-Based Purchasing
Workgroup
RA Radiology assistant
RBMA Radiology Business Management
Association
RFA Regulatory Flexibility Act
RHC Rural health clinic
RIA Regulatory impact analysis
RN Registered nurse
RNAC Reasonable net acquisition cost
RPA Radiology practitioner assistant
RRT Registered respiratory therapist
RUC [AMA’s Specialty Society] Relative
(Value) Update Committee
RVU Relative value unit
SBA Small Business Administration
SGR Sustainable growth rate
SLP Speech-language pathology
SMS [AMA’s] Socioeconomic Monitoring
System
SNF Skilled nursing facility
SOR System of record
SRS Stereotactic radiosurgery
STARS Services Tracking and Reporting
System
TC Technical Component
TIN Tax identification number
TRHCA Tax Relief and Health Care Act of
2006 (Pub. L. 109–432)
TTO Transtracheal oxygen
UPMC University of Pittsburgh Medical
Center
USDE United States Department of
Education
USP–DI United States Pharmacopoeia-Drug
Information
VBP Value-based purchasing
WAMP Widely available market price
PO 00000
Frm 00007
Fmt 4701
Sfmt 4702
40045
I. Background
Since January 1, 1992, Medicare has
paid for physicians’ services under
section 1848 of the Social Security Act
(the Act), ‘‘Payment for Physicians’
Services.’’ The Act requires that
payments under the physician fee
schedule (PFS) are based on national
uniform relative value units (RVUs)
based on the relative resources used in
furnishing a service. Section 1848(c) of
the Act requires that national RVUs be
established for physician work, practice
expense (PE), and malpractice expense.
Before the establishment of the
resource-based relative value system,
Medicare payment for physicians’
services was based on reasonable
charges. We note that throughout this
proposed rule, unless otherwise noted,
the term ‘‘practitioner’’ is used to
describe both physicians and eligible
nonphysician practitioners (such as
physician assistants, nurse practitioners,
clinical nurse specialists, certified nurse
midwives, psychologists, or social
workers) that are permitted to furnish
and bill Medicare under the PFS for the
services under discussion.
A. Development of the Relative Value
System
1. Work RVUs
The concepts and methodology
underlying the PFS were enacted as part
of the Omnibus Budget Reconciliation
Act (OBRA) of 1989 (Pub. L. 101–239),
and OBRA 1990, (Pub. L. 101–508). The
final rule, published on November 25,
1991 (56 FR 59502), set forth the fee
schedule for payment for physicians’
services beginning January 1, 1992.
Initially, only the physician work RVUs
were resource-based, and the PE and
malpractice RVUs were based on
average allowable charges.
The physician work RVUs established
for the implementation of the fee
schedule in January 1992 were
developed with extensive input from
the physician community. A research
team at the Harvard School of Public
Health developed the original physician
work RVUs for most codes in a
cooperative agreement with the
Department of Health and Human
Services (DHHS). In constructing the
code-specific vignettes for the original
physician work RVUs, Harvard worked
with panels of experts, both inside and
outside the Federal government, and
obtained input from numerous
physician specialty groups.
Section 1848(b)(2)(B) of the Act
specifies that the RVUs for anesthesia
services are based on RVUs from a
uniform relative value guide, with
appropriate adjustment of the
E:\FR\FM\13JYP2.SGM
13JYP2
40046
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
conversion factor (CF), in a manner to
assure that fee schedule amounts for
anesthesia services are consistent with
those for other services of comparable
value. We established a separate CF for
anesthesia services, and we continue to
utilize time units as a factor in
determining payment for these services.
As a result, there is a separate payment
methodology for anesthesia services.
We establish physician work RVUs for
new and revised codes based on our
review of recommendations received
from the American Medical
Association’s (AMA) Specialty Society
Relative Value Update Committee
(RUC).
2. Practice Expense Relative Value Units
(PE RVUs)
Section 121 of the Social Security Act
Amendments of 1994 (Pub. L. 103–432),
enacted on October 31, 1994, amended
section 1848(c)(2)(C)(ii) of the Act and
required us to develop resource-based
PE RVUs for each physician’s service
beginning in 1998. We were to consider
general categories of expenses (such as
office rent and wages of personnel, but
excluding malpractice expenses)
comprising PEs.
Section 4505(a) of the Balanced
Budget Act of 1997 (BBA) (Pub. L. 105–
33), amended section 1848(c)(2)(C)(ii) of
the Act to delay implementation of the
resource-based PE RVU system until
January 1, 1999. In addition, section
4505(b) of the BBA provided for a 4-year
transition period from charge-based PE
RVUs to resource-based RVUs.
We established the resource-based PE
RVUs for each physicians’ service in a
final rule, published November 2, 1998
(63 FR 58814), effective for services
furnished in 1999. Based on the
requirement to transition to a resourcebased system for PE over a 4-year
period, resource-based PE RVUs did not
become fully effective until 2002.
This resource-based system was based
on two significant sources of actual PE
data: the Clinical Practice Expert Panel
(CPEP) data; and the AMA’s
Socioeconomic Monitoring System
(SMS) data. The CPEP data were
collected from panels of physicians,
practice administrators, and
nonphysicians (for example, registered
nurses (RNs)) nominated by physician
specialty societies and other groups.
The CPEP panels identified the direct
inputs required for each physician’s
service in both the office setting and
out-of-office setting. We have since
refined and revised these inputs based
on recommendations from the RUC. The
AMA’s SMS data provided aggregate
specialty-specific information on hours
worked and PEs.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Separate PE RVUs are established for
procedures that can be performed in
both a nonfacility setting, such as a
physician’s office, and a facility setting,
such as a hospital outpatient
department. The difference between the
facility and nonfacility RVUs reflects
the fact that a facility typically receives
separate payment from Medicare for its
costs of providing the service, apart
from payment under the PFS. The
nonfacility RVUs reflect all of the direct
and indirect PEs of providing a
particular service.
Section 212 of the Balanced Budget
Refinement Act of 1999 (BBRA) (Pub. L.
106–113) directed the Secretary of
Health and Human Services (the
Secretary) to establish a process under
which we accept and use, to the
maximum extent practicable and
consistent with sound data practices,
data collected or developed by entities
and organizations to supplement the
data we normally collect in determining
the PE component. On May 3, 2000, we
published the interim final rule (65 FR
25664) that set forth the criteria for the
submission of these supplemental PE
survey data. The criteria were modified
in response to comments received, and
published in the Federal Register (65
FR 65376) as part of a November 1, 2000
final rule. The PFS final rules published
in 2001 and 2003, respectively, (66 FR
55246 and 68 FR 63196) extended the
period during which we would accept
these supplemental data through March
1, 2005.
In the calendar year (CY) 2007 PFS
final rule with comment period (71 FR
69624), we revised the methodology for
calculating direct PE RVUs from the topdown to the bottom-up methodology
beginning in CY 2007 and provided for
a 4-year transition for the new PE RVUs
under this new methodology. This
transition ended in CY 2010 and direct
PE RVUs are calculated in CY 2011
using this methodology, unless
otherwise noted.
In the CY 2010 PFS final rule with
comment period, we updated the PE/
hour (HR) data that are used in the
calculation of PE RVUs for most
specialties (74 FR 61749). For this
update, we used the Physician Practice
Information Survey (PPIS) conducted by
the AMA. The PPIS is a multispecialty,
nationally representative, PE survey of
both physicians and nonphysician
practitioners (NPPs) using a survey
instrument and methods highly
consistent with those of the SMS and
the supplemental surveys used prior to
CY 2010. We note that in CY 2010, for
oncology, clinical laboratories, and
independent diagnostic testing facilities
(IDTFs), we continued to use the
PO 00000
Frm 00008
Fmt 4701
Sfmt 4702
supplemental survey data to determine
PE/HR values (74 FR 61752).
3. Resource-Based Malpractice (MP)
RVUs
Section 4505(f) of the BBA amended
section 1848(c) of the Act requiring us
to implement resource-based
malpractice (MP) RVUs for services
furnished on or after 2000. The
resource-based MP RVUs were
implemented in the PFS final rule
published November 2, 1999 (64 FR
59380). The MP RVUs were based on
malpractice insurance premium data
collected from commercial and
physician-owned insurers from all the
States, the District of Columbia, and
Puerto Rico.
4. Refinements to the RVUs
Section 1848(c)(2)(B)(i) of the Act
requires that we review all RVUs no less
often than every 5 years. The first FiveYear Review of the physician work
RVUs was published on November 22,
1996 (61 FR 59489) and was effective in
1997. The second Five-Year Review was
published in the CY 2002 PFS final rule
with comment period (66 FR 55246) and
was effective in 2002. The third FiveYear Review of physician work RVUs
was published in the CY 2007 PFS final
rule with comment period (71 FR
69624) and was effective on January 1,
2007. (Note: Additional codes relating to
the third Five-Year Review of physician
work RVUs were addressed in the CY
2008 PFS final rule with comment
period (72 FR 66360).) The fourth FiveYear Review of physician work RVUs
was initiated in the CY 2010 PFS final
rule with comment period where we
solicited candidate codes from the
public for this review (74 FR 61941).
Changes due to the fourth Five-Year
Review of physician work RVUs will be
effective January 1, 2012.
In 1999, the AMA’s RUC established
the Practice Expense Advisory
Committee (PEAC) for the purpose of
refining the direct PE inputs. Through
March 2004, the PEAC provided
recommendations to CMS for over 7,600
codes (all but a few hundred of the
codes currently listed in the AMA’s
Current Procedural Terminology (CPT)
codes). As part of the CY 2007 PFS final
rule with comment period (71 FR
69624), we implemented a new bottomup methodology for determining
resource-based PE RVUs and
transitioned the new methodology over
a 4-year period. A comprehensive
review of PE was undertaken prior to
the 4-year transition period for the new
PE methodology from the top-down to
the bottom-up methodology, and this
transition was completed in CY 2010. In
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
CY 2010, we also incorporated the new
PPIS data to update the specialtyspecific PE/HR data used to develop PE
RVUs. Therefore, the next Five-Year
Review of PE RVUs will be addressed in
CY 2014.
In the CY 2005 PFS final rule with
comment period (69 FR 66236), we
implemented the first Five-Year Review
of the MP RVUs (69 FR 66263). Minor
modifications to the methodology were
addressed in the CY 2006 PFS final rule
with comment period (70 FR 70153).
The second Five-Year Review and
update of resource-based malpractice
RVUs was published in the CY 2010
PFS final rule with comment period (74
FR 61758) and was effective in CY 2010.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
5. Adjustments to RVUs Are Budget
Neutral
Section 1848(c)(2)(B)(ii)(II) of the Act
provides that adjustments in RVUs for a
year may not cause total PFS payments
to differ by more than $20 million from
what they would have been if the
adjustments were not made. In
accordance with section
1848(c)(2)(B)(ii)(II) of the Act, if
revisions to the RVUs cause
expenditures to change by more than
$20 million, we make adjustments to
ensure that expenditures do not increase
or decrease by more than $20 million.
As explained in the CY 2009 PFS final
rule with comment period (73FR
69730), as required by section 133(b) of
the Medicare Improvements for Patients
and Providers Act of 2008 (MIPPA)
(Pub. L. 110–275), the separate budget
neutrality (BN) adjustor resulting from
the third Five-Year Review of physician
work RVUs is being applied to the CF
beginning in CY 2009 rather than to the
work RVUs.
For CY 2010, we adopted a number of
new payment policies for which we
estimated the potential for a
redistributive effect under the PFS,
including the use of the new PPIS data
to develop the specialty-specific PE/HR
used for the PE RVUs (74 FR 61749
through 61752) and the elimination of
the reporting of all CPT consultation
codes in order to allow for correct and
consistent coding and appropriate
payment for evaluation and
management services under the PFS (74
FR 61767 through 61775). We recognize
that clinical experience with these new
PFS policies has been growing over the
first 6 months of CY 2010 and, as we
seek to improve future PFS payment
accuracy for services, we are interested
in public comments on the perspectives
of physicians and nonphysician
practitioners caring for Medicare
beneficiaries under the current PFS
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
coding and payment methodologies for
physicians’ services.
B. Components of the Fee Schedule
Payment Amounts
To calculate the payment for every
physicians’ service, the components of
the fee schedule (physician work, PE,
and MP RVUs) are adjusted by a
geographic practice cost index (GPCI).
The GPCIs reflect the relative costs of
physician work, PE, and malpractice
expense in an area compared to the
national average costs for each
component.
RVUs are converted to dollar amounts
through the application of a CF, which
is calculated by CMS’ Office of the
Actuary (OACT).
The formula for calculating the
Medicare fee schedule payment amount
for a given service and fee schedule area
can be expressed as:
Payment = [(RVU work × GPCI work) +
(RVU PE × GPCI PE) + (RVU
malpractice × GPCI malpractice)] ×
CF
C. Most Recent Changes to the Fee
Schedule
The CY 2010 PFS final rule with
comment period (74 FR 61738)
implemented changes to the PFS and
other Medicare Part B payment policies.
It also finalized some of the CY 2009
interim RVUs and implemented interim
RVUs for new and revised codes for CY
2010 to ensure that our payment
systems are updated to reflect changes
in medical practice and the relative
value of services. The CY 2010 PFS final
rule with comment period also
addressed other policies, as well as
certain provisions of the MIPPA.
As required by the statute at the time
of its issuance on October 30, 2009, the
CY 2010 PFS final rule with comment
period announced the following for CY
2010: The PFS update of ¥21.2 percent;
the initial estimate for the sustainable
growth rate of ¥8.8 percent; and the CF
of $28.4061.
On December 10, 2009, we published
a correction notice (74 FR 65449) to
correct several technical and
typographical errors that occurred in the
CY 2010 PFS final rule with comment
period. This correction notice
announced a revised CF for CY 2010 of
$28.3895.
On December 19, 2009, the
Department of Defense Appropriations
Act, 2010 (Pub. L. 111–118) was signed
into law. Section 1011 of Pub. L. 111–
118 provided a 2-month zero percent
update to the CY 2010 PFS effective
only for dates of service from January 1,
2010 through February 28, 2010.
PO 00000
Frm 00009
Fmt 4701
Sfmt 4702
40047
On March 2, 2010, the Temporary
Extension Act of 2010 (Pub. L. 111–144)
was signed into law. Section 2 of Pub.
L. 111–144 extended the zero percent
update to the PFS through March 31,
2010 that was in effect for claims with
dates of service from January 1, 2010
through February 28, 2010.
In addition, on April 15, 2010, the
Continuing Extension Act of 2010 (Pub.
L. 111–157) was signed into law.
Section 4 of Public Law 111–157
extended through May 31, 2010 the zero
percent update to the PFS that was in
effect for claims with dates of services
from January 1, 2010 through March 31,
2010. The law is retroactive to April 1,
2010.
In the May 11, 2010 Federal Register
(75 FR 26350), we published a
subsequent correction notice to correct
several technical and typographical
errors that occurred in the CY 2010 PFS
final rule with comment period and the
December 10, 2009 correction notice.
The May 11, 2010 correction notice
announced a revised CF for CY 2010 of
$28.3895.
Finally, on March 23, 2010 the Patient
Protection and Affordable Care Act
(Pub. L. 111–148) was signed into law.
Shortly thereafter, on March 30, 2010,
the Health Care and Education
Reconciliation Act of 2010 (Pub. L. 111–
152) was signed into law. These two
laws are discussed in this proposed rule
and are collectively referred to as the
‘‘Affordable Care Act’’ (ACA) throughout
this proposed rule.
II. Provisions of the Proposed Rule for
the Physician Fee Schedule
A. Resource-Based Practice Expense
(PE) Relative Value Units (RVUs)
1. Overview
Practice expense (PE) is the portion of
the resources used in furnishing the
service that reflects the general
categories of physician and practitioner
expenses, such as office rent and
personnel wages but excluding
malpractice expenses, as specified in
section 1848(c)(1)(B) of the Act. Section
121 of the Social Security Amendments
of 1994 (Pub. L. 103–432), enacted on
October 31, 1994, required CMS to
develop a methodology for a resourcebased system for determining PE RVUs
for each physician’s service. We develop
PE RVUs by looking at the direct and
indirect physician practice resources
involved in furnishing each service.
Direct expense categories include
clinical labor, medical supplies and
medical equipment. Indirect expenses
include administrative labor, office
expense, and all other expenses. The
sections that follow provide more
E:\FR\FM\13JYP2.SGM
13JYP2
40048
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
detailed information about the
methodology for translating the
resources involved in furnishing each
service into service-specific PE RVUs. In
addition, we note that section
1848(c)(2)(B)(ii)(II) of the Act provides
that adjustments in RVUs for a year may
not cause total PFS payments to differ
by more than $20 million from what
they would have been if the adjustments
were not made. Therefore, if revisions to
the RVUs cause expenditures to change
by more than $20 million, we make
adjustments to ensure that expenditures
do not increase or decrease by more
than $20 million. We refer readers to the
CY 2010 PFS final rule with comment
period (74 FR 61743 through 61748) for
a more detailed history of the PE
methodology.
2. Practice Expense Methodology
a. Direct Practice Expense
We use a bottom-up approach to
determine the direct PE by adding the
costs of the resources (that is, the
clinical staff, equipment, and supplies)
typically required to provide each
service. The costs of the resources are
calculated using the refined direct PE
inputs assigned to each CPT code in our
PE database, which are based on our
review of recommendations received
from the American Medical
Association’s (AMA’s) Relative Value
Update Committee (RUC). For a detailed
explanation of the bottom-up direct PE
methodology, including examples, we
refer readers to the Five-Year Review of
Work Relative Value Units Under the
PFS and Proposed Changes to the
Practice Expense Methodology proposed
notice (71 FR 37242) and the CY 2007
PFS final rule with comment period (71
FR 69629).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
b. Indirect Practice Expense per Hour
Data
We use survey data on indirect
practice expenses incurred per hour
worked (PE/HR) in developing the
indirect portion of the PE RVUs. Prior
to CY 2010, we primarily used the
practice expense per hour (PE/HR) by
specialty that was obtained from the
AMA’s Socioeconomic Monitoring
Surveys (SMS). These surveys were
conducted from 1995 through 1999. For
several specialties that collected
additional PE/HR data through
supplemental surveys, we incorporated
these data in developing the PE/HR
values used annually.
While the SMS was not specifically
designed for the purpose of establishing
PE RVUs, we found these data to be the
best available at the time. The SMS was
a multispecialty survey effort conducted
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
using a consistent survey instrument
and method across specialties. The
survey sample was randomly drawn
from the AMA Physician Masterfile to
ensure national representativeness. The
AMA discontinued the SMS survey in
1999. As required by the Balanced
Budget Refinement Act of 1999 (BBRA)
(Pub. L. 106–113), we also established a
process by which specialty groups could
submit supplemental PE data. In the
May 3, 2000 Federal Register, we issued
the Medicare Program; Criteria for
Submitting Supplemental Practice
Expense Survey Data interim final rule
(65 FR 25664) in which we established
criteria for acceptance of supplemental
data. The criteria were modified in the
CY 2001 and CY 2003 PFS final rules
with comment period (65 FR 65380 and
67 FR 79971, respectively). In addition
to the SMS, we previously used
supplemental survey data for the
following specialties: Cardiology;
dermatology; gastroenterology;
radiology; cardiothoracic surgery;
vascular surgery; physical and
occupational therapy; independent
laboratories; allergy/immunology;
independent diagnostic testing facilities
(IDTFs); radiation oncology; medical
oncology; and urology.
Because the SMS data and the
supplemental survey data were from
different time periods, we historically
inflated them by the Medicare Economic
Index (MEI) to put them on as
comparable a time basis as we could
when calculating the PE RVUs. This
MEI proxy was necessary in the past
due to the lack of contemporaneous,
consistently collected, and
comprehensive multispecialty survey
data.
The AMA administered a new survey
in CY 2007 and CY 2008, the Physician
Practice Expense Information Survey
(PPIS), which was expanded (relative to
the SMS) to include nonphysician
practitioners (NPPs) paid under the PFS.
The PPIS was designed to update the
specialty-specific PE/HR data used to
develop PE RVUs. The AMA and the
CMS contractor, The Lewin Group
(Lewin), analyzed the PPIS data and
calculated the PE/HR for physician and
nonphysician specialties, respectively.
The AMA’s summary worksheets and
Lewin’s final report are available on the
CMS Web site at https://www.cms.gov/
PhysicianFeeSched/PFSFRN/
itemdetail.asp?filterType=none&
filterByDID=-99&
sortByDID=4&sortOrder=
descending&itemID=CMS1223902&
intNumPerPage=10. (See downloads
labeled AMA PPIS Worksheets 1–3 and
Physician Practice Expense non MDDO
Final Report)
PO 00000
Frm 00010
Fmt 4701
Sfmt 4702
The PPIS is a multispecialty,
nationally representative, PE survey of
both physicians and NPPs using a
consistent survey instrument and
methods highly consistent with those
used for the SMS and the supplemental
surveys. The PPIS gathered information
from 3,656 respondents across 51
physician specialty and healthcare
professional groups.
We believe the PPIS is the most
comprehensive source of PE survey
information available to date. Therefore,
we used the PPIS data to update the PE/
HR data for almost all of the Medicarerecognized specialties that participated
in the survey for the CY 2010 PFS.
When we changed over to the PPIS data
beginning in CY 2010, we did not
change the PE RVU methodology itself
or the manner in which the PE/HR data
are used in that methodology. We only
updated the PE/HR data based on the
new survey. Furthermore, as we
explained in the CY 2010 PFS final rule
with comment period (74 FR 61751),
because of the magnitude of payment
reductions for some specialties resulting
from the use of the PPIS data, we
finalized a 4-year transition (75/25 for
CY 2010, 50/50 for CY 2011, 25/75 for
CY 2012, and 0/100 for CY 2013) from
the previous PE RVUs to the PE RVUs
developed using the new PPIS data.
Section 303 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) (Pub.
L. 108–173) added section
1848(c)(2)(H)(i) of the Act, which
requires us to use the medical oncology
supplemental survey data submitted in
2003 for oncology drug administration
services. Therefore, the PE/HR for
medical oncology, hematology, and
hematology/oncology reflects the
continued use of these supplemental
survey data.
We do not use the PPIS data for
reproductive endocrinology, sleep
medicine, and spine surgery since these
specialties are not separately recognized
by Medicare, and we do not know how
to blend these data with Medicarerecognized specialty data.
Supplemental survey data on
independent labs, from the College of
American Pathologists, were
implemented for payments in CY 2005.
Supplemental survey data from the
National Coalition of Quality Diagnostic
Imaging Services (NCQDIS),
representing IDTFs, were blended with
supplementary survey data from the
American College of Radiology (ACR)
and implemented for payments in CY
2007. Neither IDTFs nor independent
labs participated in the PPIS. Therefore,
we continue to use the PE/HR that was
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
developed from their supplemental
survey data.
Finally, consistent with our past
practice, the previous indirect PE/HR
values from the supplemental surveys
for medical oncology, independent
laboratories, and IDTFs were updated to
CY 2006 using the MEI to put them on
a comparable basis with the PPIS data.
In the CY 2010 PFS final rule with
comment period (74 FR 61753), we
miscalculated the indirect PE/HR for
IDTFs as part of this update process.
Therefore, for CY 2011, we are
proposing to use a revised indirect PE/
HR of $479.81 for IDTFs, consistent
with our final policy to update the
indirect PE/HR values from prior
supplemental survey data that we are
continuing to use in order to put these
data on a comparable basis with the
PPIS data. This revision changes the
IDTF indirect percentage from 51
percent to 50 percent.
Previously, CMS has established PE/
HR values for various specialties
without SMS or supplemental survey
data by crosswalking them to other
similar specialties to estimate a proxy
PE/HR. For specialties that were part of
the PPIS for which we previously used
a crosswalked PE/HR, we instead use
the PPIS-based PE/HR. We continue
previous crosswalks for specialties that
did not participate in the PPIS.
However, beginning in CY 2010 we
changed the PE/HR crosswalk for
portable x-ray suppliers from radiology
to IDTF, a more appropriate crosswalk
because these specialties are more
similar to each other with respect to
physician time.
In the CY 2010 PFS final rule with
comment period (74 FR 61752), we
agreed that, under the current PE
methodology, the PPIS data for
registered dieticians should not be used
in the calculation of PE RVUs since
these dieticians are paid 85 percent of
what a physician would be paid for
providing the service. To include their
survey data in the PE calculation would
influence the ratesetting by
incorporating what the services would
be paid if performed by registered
dieticians and not strictly what the
payment rates would be if provided by
physicians. We further stated that we
would utilize the ‘‘All Physicians’’ PE/
HR, as derived from the PPIS, in the
calculation of resource-based PE RVUs
in lieu of the PE/HR associated with
registered dieticians. In the resourcebased PE methodology for CY 2010,
while we removed the specialty of
registered dieticians from the ratesetting
step we did not assign the ‘‘All
Physicians’’ PE/HR to services furnished
by registered dieticians. Instead, we
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
allowed the PE/HR for those services to
be generated by a weighted average of
all the physician specialties that also
furnished the services. This method was
consistent with our policy to not use the
registered dietician PPIS PE/HR in
calculating the PE RVUs for services
furnished by registered dieticians but
we did not actually crosswalk the
specialty of registered dietician to the
‘‘All Physicians’’ PE/HR data as we had
intended according to the final policy.
Nevertheless, we are affirming for CY
2011 that the proposed resource-based
PE RVUs have been calculated in
accordance with the final policy
adopted in the CY 2010 PFS final rule
with comment period (74 FR 61752) for
registered dietician services that
crosswalks the specialty to the ‘‘All
Physicians’’ PE/HR data.
As provided in the CY 2010 PFS final
rule with comment period (74 FR
61751), CY 2011 is the second year of
the 4-year transition to the PE RVUs
calculated using the PPIS data.
Therefore, in general, the CY 2011 PE
RVUs are a 50/50 blend of the previous
PE RVUs based on the SMS and
supplemental survey data and the new
PE RVUS developed using the PPIS data
as described above. Note that the
reductions in the PE RVUs for expensive
diagnostic imaging equipment
attributable to the change to an
equipment utilization rate assumption
of 75 percent (see 74 FR 61753 through
61755 and section II.A.3. of this
proposed rule) are not subject to the
transition.
c. Allocation of PE to Services
To establish PE RVUs for specific
services, it is necessary to establish the
direct and indirect PE associated with
each service.
(i) Direct costs. The relative
relationship between the direct cost
portions of the PE RVUs for any two
services is determined by the relative
relationship between the sum of the
direct cost resources (that is, the clinical
staff, equipment, and supplies) typically
required to provide the services. The
costs of these resources are calculated
from the refined direct PE inputs in our
PE database. For example, if one service
has a direct cost sum of $400 from our
PE database and another service has a
direct cost sum of $200, the direct
portion of the PE RVUs of the first
service would be twice as much as the
direct portion of the PE RVUs for the
second service.
(ii) Indirect costs. Section II.A.2.b. of
this proposed rule describes the current
data sources for specialty-specific
indirect costs used in our PE
calculations. We allocate the indirect
PO 00000
Frm 00011
Fmt 4701
Sfmt 4702
40049
costs to the code level on the basis of
the direct costs specifically associated
with a code and the greater of either the
clinical labor costs or the physician
work RVUs. We also incorporate the
survey data described earlier in the PE/
HR discussion. The general approach to
developing the indirect portion of the
PE RVUs is described below.
• For a given service, we use the
direct portion of the PE RVUs calculated
as described above and the average
percentage that direct costs represent of
total costs (based on survey data) across
the specialties that perform the service
to determine an initial indirect
allocator. For example, if the direct
portion of the PE RVUs for a given
service were 2.00 and direct costs, on
average, represented 25 percent of total
costs for the specialties that performed
the service, the initial indirect allocator
would be 6.00 since 2.00 is 25 percent
of 8.00.
• We then add the greater of the work
RVUs or clinical labor portion of the
direct portion of the PE RVUs to this
initial indirect allocator. In our
example, if this service had work RVUs
of 4.00 and the clinical labor portion of
the direct PE RVUs was 1.50, we would
add 6.00 plus 4.00 (since the 4.00 work
RVUs are greater than the 1.50 clinical
labor portion) to get an indirect allocator
of 10.00. In the absence of any further
use of the survey data, the relative
relationship between the indirect cost
portions of the PE RVUs for any two
services would be determined by the
relative relationship between these
indirect cost allocators. For example, if
one service had an indirect cost
allocator of 10.00 and another service
had an indirect cost allocator of 5.00,
the indirect portion of the PE RVUs of
the first service would be twice as great
as the indirect portion of the PE RVUs
for the second service.
• We next incorporate the specialtyspecific indirect PE/HR data into the
calculation. As a relatively extreme
example for the sake of simplicity,
assume in our example above that,
based on the survey data, the average
indirect cost of the specialties
performing the first service with an
allocator of 10.00 was half of the average
indirect cost of the specialties
performing the second service with an
indirect allocator of 5.00. In this case,
the indirect portion of the PE RVUs of
the first service would be equal to that
of the second service.
d. Facility and Nonfacility Costs
For procedures that can be furnished
in a physician’s office, as well as in a
hospital or facility setting, we establish
two PE RVUs: facility and nonfacility.
E:\FR\FM\13JYP2.SGM
13JYP2
40050
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
The methodology for calculating PE
RVUs is the same for both the facility
and nonfacility RVUs, but is applied
independently to yield two separate PE
RVUs. Because Medicare makes a
separate payment to the facility for its
costs of furnishing a service, the facility
PE RVUs are generally lower than the
nonfacility PE RVUs.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
e. Services With Technical Components
(TCs) and Professional Components
(PCs)
Diagnostic services are generally
comprised of two components: a
professional component (PC) and a
technical component (TC), each of
which may be performed independently
or by different providers, or they may be
performed together as a ‘‘global’’ service.
When services have PC and TC
components that can be billed
separately, the payment for the global
component equals the sum of the
payment for the TC and PC. This is a
result of using a weighted average of the
ratio of indirect to direct costs across all
the specialties that furnish the global
components, TCs, and PCs; that is, we
apply the same weighted average
indirect percentage factor to allocate
indirect expenses to the global
components, PCs, and TCs for a service.
(The direct PE RVUs for the TC and PC
sum to the global under the bottom-up
methodology.)
f. Alternative Data Sources and Public
Comments on Final Rule for 2010.
In the CY 2010 PFS final rule with
comment period (74 FR 61749 through
61750), we discussed the Medicare
Payment Advisory Commission’s
(MedPAC’s) comment that in the future,
‘‘CMS should consider alternatives to
collecting specialty-specific cost data or
options to decrease the reliance on such
data.’’ We agreed with MedPAC that it
would be appropriate to consider the
future of the PE RVUs moving forward.
We sought comments from other
stakeholders on the issues raised by
MedPAC for the future. In particular, we
requested public comments regarding
MedPAC’s suggestion that we consider
alternatives for collecting specialtyspecific cost data or options to decrease
the reliance on such data. We noted
MedPAC’s comment that, ‘‘CMS should
consider if Medicare or provider groups
should sponsor future data collection
efforts, if participation should be
voluntary (such as surveys) or
mandatory (such as cost reports), and
whether a nationally representative
sample of practitioners would be
sufficient for either a survey or cost
reports.’’ MedPAC also stated that one
option for decreasing the reliance on
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
specialty-specific cost data would be the
elimination of the use of indirect PE/HR
data in the last step of establishing the
indirect cost portion of the PE RVUs as
described previously.
Almost all of the commenters on the
CY 2010 PFS final rule with comment
period that addressed this issue
expressed a general willingness to work
with CMS on methodological
improvements or future data collection
efforts. Although no commenters
detailed a comprehensive overall
alternative methodology, several
commenters did provide suggestions
regarding future data collection efforts
and specific aspects of the current
methodology.
The commenters that addressed the
issue of surveys supported the use of
surveys if they yielded accurate PE
information. The few commenters that
addressed the issue of cost reports were
opposed to physician cost reports. The
commenters varied with respect to their
opinions regarding whether data
collection efforts should be led by
organized medicine, individual
specialty societies, or CMS. Several
commenters that addressed the issue of
voluntary versus mandatory data
collection efforts supported voluntary
data collection efforts and opposed
mandatory data collection efforts.
Some commenters recommended no
changes to the methodology or PE data
in the near future. Other commenters
indicated that the methodology and data
changes needed to be made for CY 2011.
Although most commenters did not
directly address the use of the indirect
PE/HR data, those that did
predominately opposed the elimination
of the use of these data.
Many commenters addressed specifics
of the PE methodology (as further
described in section II.A.2.c. of this
proposed rule). Some were opposed to
the scaling factor applied in the
development of the direct PE portion of
the PE RVUs so that in the aggregate the
direct portion of the PE RVUs do not
exceed the proportion indicated by the
survey data (See Step 4 in g.(ii) below).
Several of these commenters advocated
the elimination of this direct scaling
factor, while others indicated that the
issue should be examined more closely.
A few commenters recommended that
physician work not be used as an
allocator in the development of the
indirect portion of the PE RVUs as
described earlier in this section. A few
indicated that physician time, but not
physician work, should be used in the
allocation. Other commenters suggested
that indirect costs should be allocated
solely on the basis of direct costs.
PO 00000
Frm 00012
Fmt 4701
Sfmt 4702
We note that many of the issues raised
by commenters on the CY 2010 PFS
final rule with comment period are
similar to issues raised in the
development of the original resourcebased PE methodology and in
subsequent revisions to the
methodology, including the adoption of
the bottom-up methodology. While we
are not proposing a broad
methodological change or broad data
collection effort in this CY 2011 PFS
proposed rule, we invite comments on
our summary of the issues raised by the
commenters on the CY 2010 PFS final
rule with comment period, as presented
above. The complete public comments
on that final rule are available for public
review at https://www.regulations.gov by
entering ‘‘CMS–1413–FC’’ in the search
box on the main page.
g. PE RVU Methodology
For a more detailed description of the
PE RVU methodology, we refer readers
to the CY 2010 PFS final rule with
comment period (74 FR 61745 through
61746).
(i) Setup File
First, we create a setup file for the PE
methodology. The setup file contains
the direct cost inputs, the utilization for
each procedure code at the specialty
and facility/nonfacility place of service
level, and the specialty-specific PE/HR
data from the surveys.
(ii) Calculate the Direct Cost PE RVUs
Sum the costs of each direct input.
Step 1: Sum the direct costs of the
inputs for each service. Apply a scaling
adjustment to the direct inputs.
Step 2: Calculate the current aggregate
pool of direct PE costs. This is the
product of the current aggregate PE
(aggregate direct and indirect) RVUs, the
CF, and the average direct PE percentage
from the survey data.
Step 3: Calculate the aggregate pool of
direct costs. This is the sum of the
product of the direct costs for each
service from Step 1 and the utilization
data for that service.
Step 4: Using the results of Step 2 and
Step 3 calculate a direct PE scaling
adjustment so that the aggregate direct
cost pool does not exceed the current
aggregate direct cost pool and apply it
to the direct costs from Step 1 for each
service.
Step 5: Convert the results of Step 4
to an RVU scale for each service. To do
this, divide the results of Step 4 by the
CF. Note that the actual value of the CF
used in this calculation does not
influence the final direct cost PE RVUs,
as long as the same CF is used in Step
2 and Step 5. Different CFs will result
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
in different direct PE scaling factors, but
this has no effect on the final direct cost
PE RVUs since changes in the CFs and
changes in the associated direct scaling
factors offset one another.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(iii) Create the Indirect Cost PE RVUs
Create indirect allocators.
Step 6: Based on the survey data,
calculate direct and indirect PE
percentages for each physician
specialty.
Step 7: Calculate direct and indirect
PE percentages at the service level by
taking a weighted average of the results
of Step 6 for the specialties that furnish
the service. Note that for services with
TCs and PCs, the direct and indirect
percentages for a given service do not
vary by the PC, TC, and global
components.
Step 8: Calculate the service level
allocators for the indirect PEs based on
the percentages calculated in Step 7.
The indirect PEs are allocated based on
the three components: the direct PE
RVUs, the clinical PE RVUs, and the
work RVUs.
For most services the indirect
allocator is:
indirect percentage * (direct PE RVUs/
direct percentage) + work RVUs.
There are two situations where this
formula is modified:
• If the service is a global service (that
is, a service with global, professional,
and technical components), then the
indirect allocator is: indirect percentage
* (direct PE RVUs/direct percentage) +
clinical PE RVUs + work RVUs.
• If the clinical labor PE RVUs exceed
the work RVUs (and the service is not
a global service), then the indirect
allocator is: indirect percentage * (direct
PE RVUs/direct percentage) + clinical
PE RVUs.
(Note: For global services, the indirect
allocator is based on both the work
RVUs and the clinical labor PE RVUs.
We do this to recognize that, for the PC
service, indirect PEs will be allocated
using the work RVUs, and for the TC
service, indirect PEs will be allocated
using the direct PE RVUs and the
clinical labor PE RVUs. This also allows
the global component RVUs to equal the
sum of the PC and TC RVUs.)
For presentation purposes in the
examples in the Table 2, the formulas
were divided into two parts for each
service. The first part does not vary by
service and is the: indirect percentage *
(direct PE RVUs/direct percentage). The
second part is either the work RVUs,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
clinical PE RVUs, or both depending on
whether the service is a global service
and whether the clinical PE RVUs
exceed the work RVUs (as described
earlier in this step).
Apply a scaling adjustment to the
indirect allocators.
Step 9: Calculate the current aggregate
pool of indirect PE RVUs by multiplying
the current aggregate pool of PE RVUs
by the average indirect PE percentage
from the survey data.
Step 10: Calculate an aggregate pool of
indirect PE RVUs for all PFS services by
adding the product of the indirect PE
allocators for a service from Step 8 and
the utilization data for that service.
Step 11: Using the results of Step 9
and Step 10, calculate an indirect PE
adjustment so that the aggregate indirect
allocation does not exceed the available
aggregate indirect PE RVUs and apply it
to indirect allocators calculated in Step
8.
Calculate the indirect practice cost
index.
Step 12: Using the results of Step 11,
calculate aggregate pools of specialtyspecific adjusted indirect PE allocators
for all PFS services for a specialty by
adding the product of the adjusted
indirect PE allocator for each service
and the utilization data for that service.
Step 13: Using the specialty-specific
indirect PE/HR data, calculate specialtyspecific aggregate pools of indirect PE
for all PFS services for that specialty by
adding the product of the indirect PE/
HR for the specialty, the physician time
for the service, and the specialty’s
utilization for the service across all
services performed by the specialty.
Step 14: Using the results of Step 12
and Step 13, calculate the specialtyspecific indirect PE scaling factors.
Step 15: Using the results of Step 14,
calculate an indirect practice cost index
at the specialty level by dividing each
specialty-specific indirect scaling factor
by the average indirect scaling factor for
the entire PFS.
Step 16: Calculate the indirect
practice cost index at the service level
to ensure the capture of all indirect
costs. Calculate a weighted average of
the practice cost index values for the
specialties that furnish the service.
(Note: For services with TCs and PCs,
we calculate the indirect practice cost
index across the global components,
PCs, and TCs. Under this method, the
indirect practice cost index for a given
service (for example, echocardiogram)
does not vary by the PC, TC, and global
component.)
PO 00000
Frm 00013
Fmt 4701
Sfmt 4702
40051
Step 17: Apply the service level
indirect practice cost index calculated
in Step 16 to the service level adjusted
indirect allocators calculated in Step 11
to get the indirect PE RVUs.
(iv) Calculate the Final PE RVUs
Step 18: Add the direct PE RVUs from
Step 6 to the indirect PE RVUs from
Step 17 and apply the final PE budget
neutrality (BN) adjustment, MEI
rebasing adjustment, and multiple
procedure payment reduction (MPPR)
adjustment.
The final PE BN adjustment is
calculated by comparing the results of
Step 18 (prior to the MEI rebasing and
MPPR adjustments) to the current pool
of PE RVUs. This final BN adjustment
is required primarily because certain
specialties are excluded from the PE
RVU calculation for ratesetting
purposes, but all specialties are
included for purposes of calculating the
final BN adjustment. (See ‘‘Specialties
excluded from ratesetting calculation’’
below in this section.)
As discussed in section II.E.1. of this
proposed rule, we are proposing to
rebase and revise the Medicare
Economic Index (MEI) for CY 2011. As
discussed in section II.C.4. of this
proposed rule, section 1848(c)(2)(K) of
the Act (as added by section 3134 of the
ACA) specifies that the Secretary shall
identify potentially misvalued codes by
examining multiple codes that are
frequently billed in conjunction with
furnishing a single service. There is
inherent duplication in the PE
associated with those services which are
frequently furnished together, so
reducing PFS payment for the second
and subsequent services to account for
the efficiencies in multiple service
sessions may be appropriate. Consistent
with this provision of the ACA, we are
proposing a limited expansion of the
current MPPR policy for imaging
services for CY 2011 and a new MPPR
policy for therapy services.
(v) Setup File Information
• Specialties excluded from
ratesetting calculation: For the purposes
of calculating the PE RVUs, we exclude
certain specialties, such as certain
nonphysician practitioners paid at a
percentage of the PFS and low volume
specialties, from the calculation. These
specialties are included for the purposes
of calculating the BN adjustment. They
are displayed in Table 1.
E:\FR\FM\13JYP2.SGM
13JYP2
40052
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 1—SPECIALTIES EXCLUDED FROM RATESETTING CALCULATION
Specialty code
Specialty description
42 ...............................................................................
49 ...............................................................................
50 ...............................................................................
51 ...............................................................................
52 ...............................................................................
53 ...............................................................................
54 ...............................................................................
55 ...............................................................................
56 ...............................................................................
57 ...............................................................................
58 ...............................................................................
59 ...............................................................................
60 ...............................................................................
61 ...............................................................................
73 ...............................................................................
74 ...............................................................................
87 ...............................................................................
88 ...............................................................................
89 ...............................................................................
95 ...............................................................................
96 ...............................................................................
A0 ...............................................................................
A1 ...............................................................................
A2 ...............................................................................
A3 ...............................................................................
A4 ...............................................................................
A5 ...............................................................................
A6 ...............................................................................
A7 ...............................................................................
1 .................................................................................
2 .................................................................................
3 .................................................................................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
• Crosswalk certain low volume
physician specialties: Crosswalk the
utilization of certain specialties with
relatively low PFS utilization to the
associated specialties.
• Physical therapy utilization:
Crosswalk the utilization associated
with all physical therapy services to the
specialty of physical therapy.
• Identify professional and technical
services not identified under the usual
TC and 26 modifiers: Flag the services
that are PC and TC services, but do not
use TC and 26 modifiers (for example,
electrocardiograms). This flag associates
the PC and TC with the associated
global code for use in creating the
indirect PE RVUs. For example, the
professional service, CPT code 93010
(Electrocardiogram, routine ECG with at
least 12 leads; interpretation and report
only), is associated with the global
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Certified nurse midwife.
Ambulatory surgical center.
Nurse practitioner.
Medical supply company with certified orthotist.
Medical supply company with certified prosthetist.
Medical supply company with certified prosthetist-orthotist.
Medical supply company not included in 51, 52, or 53.
Individual certified orthotist.
Individual certified prosthetist.
Individual certified prosthetist-orthotist.
Individuals not included in 55, 56, or 57.
Ambulance service supplier, e.g., private ambulance companies, funeral homes, etc.
Public health or welfare agencies.
Voluntary health or charitable agencies.
Mass immunization roster biller.
Radiation therapy centers.
All other suppliers (e.g., drug and department stores).
Unknown supplier/provider specialty.
Certified clinical nurse specialist.
Competitive Acquisition Program (CAP) Vendor.
Optician.
Hospital.
SNF.
Intermediate care nursing facility.
Nursing facility, other.
HHA.
Pharmacy.
Medical supply company with respiratory therapist.
Department store.
Supplier of oxygen and/or oxygen related equipment.
Pedorthic personnel.
Medical supply company with pedorthic personnel.
service, CPT code 93000
(Electrocardiogram, routine ECG with at
least 12 leads; with interpretation and
report).
• Payment modifiers: Payment
modifiers are accounted for in the
creation of the file. For example,
services billed with the assistant at
surgery modifier are paid 16 percent of
the PFS amount for that service;
therefore, the utilization file is modified
to only account for 16 percent of any
service that contains the assistant at
surgery modifier.
• Work RVUs: The setup file contains
the work RVUs from this proposed rule.
(vi) Equipment Cost per Minute
The equipment cost per minute is
calculated as:
(1/(minutes per year * usage)) * price *
((interest rate/(1 ¥ (1/((1 + interest
PO 00000
Frm 00014
Fmt 4701
Sfmt 4702
rate) * life of equipment)))) +
maintenance)
Where:
minutes per year = maximum minutes per
year if usage were continuous (that is,
usage = 1); generally 150,000 minutes.
usage = equipment utilization assumption;
0.75 for certain expensive diagnostic
imaging equipment (see 74 FR 61753
through 61755 and section II.A.3. of this
proposed rule) and 0.5 for others.
price = price of the particular piece of
equipment.
interest rate = 0.11.
life of equipment = useful life of the
particular piece of equipment.
maintenance = factor for maintenance; 0.05.
Note: The use of any particular conversion
factor (CF) in Table 2 to illustrate the PE
calculation has no effect on the resulting
RVUs.
E:\FR\FM\13JYP2.SGM
13JYP2
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00015
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
=Lab * Dir Adj ..............
=Sup * Dir Adj .............
=Eqp * Dir Adj .............
......................................
PFS ..............................
=(Lab * Dir Adj)/CF ......
Steps 2–4 ......
Steps 2–4 ......
Steps 2–4 ......
Steps 2–4 ......
Step 5 ............
Step 5 ............
=(Sup * Dir Adj)/CF .....
......................................
See footnote* ...............
Step 1 ............
Steps 2–4 ......
......................................
Step 8 ............
See footnote** .............
......................................
Step 8 ............
=Ind Alloc * Ind Adj .....
See Steps 12–16 .........
= Adj. Ind Alloc * PCI ..
PFS ..............................
PFS ..............................
=(Adj Dir+Adj Ind) *
budn * MEI Adj *
MPPR Adj.
Steps 9–11 ....
......................................
Setup File ......
Steps 6, 7 ......
Steps 6, 7 ......
Step 8 ............
See Step 8 ...................
PFS ..............................
Surveys ........................
Surveys ........................
See Step 8 ...................
Step 5 ............
Step 8 ............
......................................
Step 5 ............
Step 8 ............
=(Eqp * Dir Adj)/CF .....
Step 5 ............
AMA .............................
AMA .............................
AMA .............................
Source
Step 1 ............
Step 1 ............
Step 1 ............
Step
Steps 9–11 ....
Steps 12–16 ..
Step 17 ..........
Step 18 ..........
Step 18 ..........
Step 18 ..........
......................................
=((14)+(26)) * budn *
(27) * (28).
=(24) * (25) ..................
......................................
......................................
......................................
......................................
=(19)+(21) ....................
See (20) .......................
......................................
See (18) .......................
......................................
......................................
......................................
......................................
=(11)+(12)+(13) ...........
=(8)/(10) .......................
=(7)/(10) .......................
=(6)/(10) .......................
=(1) * (5) ......................
=(2) * (5) ......................
=(3) * (5) ......................
=(6)+(7)+(8) .................
......................................
=(1)+(2)+(3) .................
......................................
......................................
......................................
......................................
Formula
1.011
1.03
0.66
1.168
1.104
0.60
0.369
1.62
0.97
(15)
0.65
0.97
25.5%
74.5%
((14)/(16)) * (17)
0.22
0.00
0.04
0.18
6.45
1.44
0.09
7.99
36.0791
16.50
0.484
13.32
2.98
0.19
99213
Office visit, est
nonfacility
1.011
15.36
11.95
1.168
0.831
14.37
0.369
38.98
33.75
(15)
5.23
33.75
18.0%
82.0%
((14)/(16)) * (17)
1.15
0.01
0.10
1.04
37.52
3.55
0.32
41.39
36.0791
85.51
0.484
77.52
7.34
0.65
33533
CABG, arterial,
single facility
1.011
0.59
0.27
1.168
0.852
0.32
0.369
0.87
0.30
(15)+(11)
0.57
0.22
28.9%
71.2%
((14)/(16)) * (17)
0.23
0.11
0.05
0.08
2.78
1.64
3.96
8.38
36.0791
17.31
0.484
5.74
3.39
8.17
71020
Chest x-ray
nonfacility
1.011
0.51
0.20
1.168
0.852
0.24
0.369
0.65
0.08
(11)
0.57
0.00
28.9%
71.2%
((14)/(16)) * (17)
0.23
0.11
0.05
0.08
2.78
1.64
3.96
8.38
36.0791
17.31
0.484
5.74
3.39
8.17
71020–TC
Chest x-ray
nonfacility
1.011
0.08
0.07
1.168
0.852
0.08
0.369
0.22
0.22
(15)
0.00
0.22
28.9%
71.2%
((14)/(16)) * (17)
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
36.0791
0.00
0.484
0.00
0.00
0.00
71020–26
Chest x-ray
nonfacility
TABLE 2—CALCULATION OF PE RVUS UNDER METHODOLOGY FOR SELECTED CODES
Note: PE RVUs in Table 2, row 27, may not match Addendum B due to rounding.
* The direct adj = [current pe rvus * CF * avg dir pct]/[sum direct inputs] = [Step 2]/[Step 3].
** The indirect adj = [current pe rvus * avg ind pct]/[sum of ind allocators] = [Step 9]/[Step 10].
(1) Labor cost (Lab) .....
(2) Suppy cost (Sup) ....
(3) Equipment cost
(Eqp).
(4) Direct cost (Dir) ......
(5) Direct adjustment
(Dir Adj).
(6) Adjusted labor .........
(7) Adjusted supplies ...
(8) Adjusted equipment
(9) Adjusted direct ........
(10) Conversion Factor
(CF).
(11) Adj. labor cost converted.
(12) Adj. supply cost
converted.
(13) Adj. equip cost
converted.
(14) Adj. direct cost
converted.
(15) Wrk RVU ...............
(16) Dir_pct ...................
(17) Ind_pct ..................
(18) Ind. Alloc. formula
(1st part).
(19) Ind. Alloc. (1st
part).
(20) Ind. Alloc. formulas
(2nd part).
(21) Ind. Alloc. (2nd
part).
(22) Indirect Allocator
(1st+2nd).
(23) Indirect Adjustment
(Ind Adj).
(24) Adjusted Indirect
Allocator.
(25) Ind.Practice Cost
Index (PCI).
(26) Adjusted Indirect ...
(27) MEI Rebasing Adjustment.
(28) MPPR Adjustment
(29) PE RVU ................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
1.011
0.32
0.17
1.168
0.926
0.18
0.369
0.50
0.25
(15)+(11)
0.24
0.17
29.0%
71.1%
((14)/(16)) * (17)
0.10
0.00
0.02
0.08
2.96
0.58
0.06
3.60
36.0791
7.43
0.484
6.12
1.19
0.12
93000
ECG, complete
nonfacility
1.011
0.25
0.11
1.168
0.926
0.12
0.369
0.33
0.08
(11)
0.24
0.00
29.0%
71.1%
((14)/(16)) * (17)
0.10
0.00
0.02
0.08
2.96
0.58
0.06
3.60
36.0791
7.43
0.484
6.12
1.19
0.12
93005
ECG, tracing
nonfacility
1.011
0.07
0.06
1.168
0.926
0.06
0.369
0.17
0.17
(15)
0.00
0.17
29.0%
71.1%
((14)/(16)) * (17)
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
36.0791
0.00
0.484
0.00
0.00
0.00
93010
ECG, report
nonfacility
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40053
40054
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
3. Proposed PE Revisions for CY 2011
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Equipment Utilization Rate
As part of the PE methodology
associated with the allocation of
equipment costs for calculating PE
RVUs, we currently use an equipment
utilization rate assumption of 50 percent
for most equipment, with the exception
of expensive diagnostic imaging
equipment (which is equipment priced
at over $1 million, for example,
computed tomography (CT) and
magnetic resonance imaging (MRI)
scanners), for which we adopted a 90
percent utilization rate assumption and
provided for a 4-year transition
beginning in CY 2010 (74 FR 61755).
Therefore, CY 2010 is the first
transitional payment year. Payment is
made in CY 2010 for the diagnostic
services listed in Table 3 (those that
include expensive diagnostic imaging
equipment in their PE inputs) based on
25 percent of the new PE RVUs and 75
percent of the prior PE RVUs for those
services.
Section 1848(b)(4)(C) of the Act (as
added by section 3135(a) of the ACA)
requires that with respect to fee
schedules established for CY 2011 and
subsequent years, in the methodology
for determining PE RVUs for expensive
diagnostic imaging equipment under the
CY 2010 PFS final rule with comment
period, the Secretary shall use a 75
percent assumption instead of the
utilization rates otherwise established in
that rule. The provision also requires
that the reduced expenditures
attributable to this change in the
utilization rate for CY 2011 and
subsequent years shall not be taken into
account when applying the budget
neutrality limitation on annual
adjustments described in section
1848(c)(2)(B)(ii)(II) of the Act.
As a result, the 75 percent equipment
utilization rate assumption will be
applied to expensive diagnostic imaging
equipment in a nonbudget neutral
manner for CY 2011, and the changes to
PE RVUs will not be transitioned over
a period of years. We will apply the 75
percent utilization rate assumption in
CY 2011 to all of the services to which
we currently apply the transitional 90
percent utilization rate assumption in
CY 2010. These services are listed in a
file on the CMS Web site that is posted
under downloads for the CY 2010 PFS
final rule with comment period at:
(https://www.cms.gov/
physicianfeesched/downloads/CODES_
SUBJECT_TO_90PCT_
USAGE_RATE.zip). These codes are also
displayed in Table 3.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
TABLE 3—CURRENT CPT CODES SUBJECT TO FIRST YEAR (CY 2010) OF
4-YEAR TRANSITION TO 90 PERCENT
EQUIPMENT UTILIZATION RATE ASSUMPTION AND THAT WILL BE SUBJECT TO THE 75 PERCENT EQUIPMENT UTILIZATION RATE ASSUMPTION IN CY 2011
TABLE 3—CURRENT CPT CODES SUBJECT TO FIRST YEAR (CY 2010) OF
4-YEAR TRANSITION TO 90 PERCENT
EQUIPMENT UTILIZATION RATE ASSUMPTION AND THAT WILL BE SUBJECT TO THE 75 PERCENT EQUIPMENT UTILIZATION RATE ASSUMPTION IN CY 2011—Continued
CPT code
CPT code
70336
70450
70460
70470
70480
70481
70482
70486
70487
70488
70490
70491
70492
70540
70542
70543
70551
70552
70553
70554
71250
71260
71270
71550
71551
71552
72125
72126
72127
72128
72129
72130
72131
72132
72133
72141
72142
72146
72147
72148
72149
72156
72157
72158
72192
72193
72194
72195
72196
72197
73200
73201
73202
73218
73219
73220
73221
73222
73223
73700
73701
73702
73718
PO 00000
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
Frm 00016
Short descriptor
Mri, temporomandibular joint(s).
Ct head/brain w/o dye.
Ct head/brain w/dye.
Ct head/brain w/o & w/dye.
Ct orbit/ear/fossa w/o dye.
Ct orbit/ear/fossa w/dye.
Ct orbit/ear/fossa w/o & w/dye.
Ct maxillofacial w/o dye.
Ct maxillofacial w/dye.
Ct maxillofacial w/o & w/dye.
Ct soft tissue neck w/o dye.
Ct soft tissue neck w/dye.
Ct soft tissue neck w/o & w/dye.
Mri orbit/face/neck w/o dye.
Mri orbit/face/neck w/dye.
Mri orbit/face/neck w/o & w/dye.
Mri brain w/o dye.
Mri brain w/dye.
Mri brain w/o & w/dye.
Fmri brain by tech.
Ct thorax w/o dye.
Ct thorax w/dye.
Ct thorax w/o & w/dye.
Mri chest w/o dye.
Mri chest w/dye.
Mri chest w/o & w/dye.
CT neck spine w/o dye.
Ct neck spine w/dye.
Ct neck spine w/o & w/dye.
Ct chest spine w/o dye.
Ct chest spine w/dye.
Ct chest spine w/o & w/dye.
Ct lumbar spine w/o dye.
Ct lumbar spine w/dye.
Ct lumbar spine w/o & w/dye.
Mri neck spine w/o dye.
Mri neck spine w/dye.
Mri chest spine w/o dye.
Mri chest spine w/dye.
Mri lumbar spine w/o dye.
Mri lumbar spine w/dye.
Mri neck spine w/o & w/dye.
Mri chest spine w/o & w/dye.
Mri lumbar spine w/o & w/dye.
Ct pelvis w/o dye.
Ct pelvis w/dye.
Ct pelvis w/o & w/dye.
Mri pelvis w/o dye.
Mri pelvis w/dye.
Mri pelvis w/o & w/dye.
Ct upper extremity w/o dye.
Ct upper extremity w/dye.
Ct upper extremity w/o & w/dye.
Mri upper extr w/o dye.
Mri upper extr w/dye.
Mri upper extremity w/o & w/dye.
Mri joint upper extr w/o dye.
Mri joint upper extr w/dye.
Mri joint upper extr w/o & w/dye.
Ct lower extremity w/o dye.
Ct lower extremity w/dye.
Ct lower extremity w/o & w/dye.
Mri lower extremity w/o dye.
Fmt 4701
Sfmt 4702
73719
73720
73721
73722
73723
74150
74160
74170
74181
74182
74183
74261
74262
75557
75559
75561
75563
75571
75572
75573
77058
77059
77078
77084
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
Short descriptor
Mri lower extremity w/dye.
Mri lower ext w/dye & w/o dye.
Mri joint of lwr extr w/o dye.
Mri joint of lwr extr w/dye.
Mri joint of lwr extr w/o & w/dye.
Ct abdomen w/o dye.
Ct abdomen w/dye.
Ct abdomen w/o & w/dye.
Mri abdomen w/o dye.
Mri abdomen w/dye.
Mri abdomen w/o and w/dye.
Ct colonography, w/o dye.
Ct colonography, w/dye.
Cardiac mri for morph.
Cardiac mri w/stress img.
Cardiac mri for morph w/dye.
Cardiac mri w/stress img & dye.
Ct hrt w/o dye w/ca test.
Ct hrt w/3d image.
Ct hrt w/3d image, congen.
Mri, one breast.
Mri, both breasts.
Ct bone density, axial.
Magnetic image, bone marrow.
Additionally, for CY 2011, we are
proposing to expand the list of services
to which the higher equipment
utilization rate assumption applies to all
other diagnostic imaging services that
utilize similar expensive CT and MRI
scanners. The additional 24 CPT codes
(listed in Table 4) to which we are
proposing to apply the 75 percent
equipment utilization rate assumption
also have expensive diagnostic imaging
equipment (priced at over $1 million)
included in their PE inputs. These
services are predominantly diagnostic
computed tomographic angiography
(CTA) and magnetic resonance
angiography (MRA) procedures that
include similar expensive CT and MRI
scanners in their direct PE inputs. We
indicated in the CY 2010 PFS final rule
with comment period (74 FR 61754) that
we were persuaded by PPIS data on
angiography that the extrapolation of
MRI and CT data (and their higher
equipment utilization rate) may be
inappropriate. However, this reference
was limited to those procedures that
include an angiography room in the
direct PE inputs, such as CPT code
93510 (Left heart catheterization,
retrograde, from the brachial artery,
axillary artery or femoral artery;
percutaneous). In contrast, CTA and
MRA procedures include a CT room or
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
MRI room, respectively, in the direct PE
inputs, and the PPIS data confirm that
a higher assumed utilization rate than
50 percent would be appropriate. The
PPIS angiography room data that
reflected a 56 percent equipment
utilization rate would not specifically
apply to CTA and MRA procedures.
Thus, on further review, we believe it is
appropriate to include CTA and MRA
procedures in the list of procedures for
which we assume a 75 percent
equipment utilization rate, and we are
proposing to do so beginning in CY
2011.
Consistent with section
1848(c)(2)(B)(v)(III) of the Act (as
amended by section 3135 of the ACA),
the reduced expenditures attributable to
this change in the utilization rate
assumption applicable to CY 2011 shall
not be taken into account when
applying the budget neutrality
limitation on annual adjustments
described in section 1848(c)(2)(B)(ii)(III)
of the Act.
As provided in the CY 2010 PFS final
rule with comment period (74 FR
61751), CY 2011 is the second year of
the 4-year transition to the PE RVUs
calculated using the PPIS data. The
reductions in the PE RVUs for expensive
diagnostic imaging equipment
attributable to the change to an
equipment utilization rate assumption
of 75 percent for CY 2011 are not subject
to the transition.
TABLE 4—PROPOSED CPT CODE ADDITIONS TO THE 75 PERCENT EQUIPMENT UTILIZATION RATE ASSUMPTION CY 2011—Continued
from the CY 2011 direct PE database
and the changes in direct PE inputs for
the associated services are reflected in
the proposed CY 2011 direct PE
database.
CPT code
Short descriptor
70547 ......
70548 ......
70549 ......
Mr angiography neck w/o dye.
Mr angiography neck w/dye.
Mr angiography neck w/o & w/
dye.
Ct angiography, chest.
Mri angio chest w/ or w/o dye.
Mr angio spone w/o & w/dye.
Ct angiography, pelv w/o & w/
dye.
Mri angio pelvis w/ or w/o dye.
Ct angio upper extr w/o & w/dye.
Mr angio upr extr w/o & w/dye.
Ct angio lower ext w/o & w/dye.
Mr angio lower ext w/ or w/o
dye.
Ct angiography, abdom w/o & w/
dye.
Mri angio, abdom w/ or w/o dye.
Card mri vel flw map add-on.
Ct angio hrt w/3d image.
Ct angio abdominal arteries.
CAT scan follow up study.
Ct bone density, peripheral.
(2) PE Inputs for Professional
Component (PC) Only and Technical
Component (TC) Only Codes Summing
to Global Only Codes
71275
71555
72159
72191
......
......
......
......
72198
73206
73225
73706
73725
......
......
......
......
......
74175 ......
74185
75565
75574
75635
76380
77079
......
......
......
......
......
......
b. HCPCS Code-Specific PE Proposals
In this section, we discuss other
specific CY 2011 proposals and changes
related to direct PE inputs. The
proposed changes that follow are
included in the proposed CY 2011
direct PE database, which is available
on the CMS Web site under the
downloads for the CY 2011 PFS
proposed rule at https://www.cms.gov/
PhysicianFeeSched/.
TABLE 4—PROPOSED CPT CODE ADDITIONS TO THE 75 PERCENT EQUIPMENT UTILIZATION RATE ASSUMP(1) Biohazard Bags
TION CY 2011
CPT code
70496
70498
70544
70545
70546
......
......
......
......
......
Short descriptor
Ct angiography, head.
Ct angiography, neck.
Mr angiography head w/o dye.
Mr angiography head w/dye.
Mr angiography head w/o & w/
dye.
40055
We have identified 22 codes for
which the supply item ‘‘biohazard bag’’
(SM004) is currently considered a direct
PE input. The item is already properly
accounted for in the indirect PE because
it is not attributable to an individual
patient service. Therefore, we are
proposing to remove the biohazard bag
In the case of selected diagnostic tests,
different but related CPT codes are used
to describe global, professional, and
technical components of a service.
These codes are unlike the majority of
other diagnostic test CPT codes where
modifiers may be used in billing a single
CPT code in order to differentiate
professional and technical components.
When different but related CPT codes
are used to report the components of
these services, the different CPT codes
are referred to as ‘‘global only,’’
‘‘professional (PC) only,’’ and ‘‘technical
(TC) only’’ codes. Medicare payment
systems are programmed to ensure that
the PE RVUs for global only codes equal
the sum of the PE RVUs for the PC and
TC only codes. However, it has come to
our attention that the direct PE inputs
for certain global only codes do not
reflect the appropriate summation of
their related TC only and PC only
component code PE inputs as they
appear in the direct PE database. While
the PFS payment calculations have been
programmed to apply the correct PE
RVUs for the global only code based on
a summation of component code PE
RVUs, the direct PE database has
reflected incorrect inputs that are
overridden by the payment system.
Therefore, we are proposing to correct
the direct PE inputs for the global only
codes so that the inputs reflect the
appropriate summing of the PE inputs
for the associated PC only and TC only
codes. The proposed CY 2011 direct PE
database includes PE corrections to the
14 CPT codes listed in Table 5.
TABLE 5—GROUPS OF RELATED CPT CODES WITH PROPOSED CHANGES TO PE INPUTS SO THAT INPUTS FOR
PROFESSIONAL COMPONENT (PC) ONLY AND TECHNICAL COMPONENT (TC) ONLY CODES SUM TO GLOBAL ONLY CODES
CPT code
Long descriptor
93224 ................
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage, with visual superimposition scanning; includes recording, scanning analysis with report, physician review and interpretation.
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage, with visual superimposition scanning; recording (includes connection, recording, disconnection).
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage, with visual superimposition scanning; scanning analysis with report.
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage
without superimposition scanning utilizing a device capable of producing a full miniaturized printout; including recording,
microprocessor-based analysis with report, physician review and interpretation.
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage
without superimposition scanning utilizing a device capable of producing a full miniaturized printout; recording (includes
connection, recording, and disconnection.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
93225 ................
93226 ................
93230 ................
93231 ................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00017
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40056
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 5—GROUPS OF RELATED CPT CODES WITH PROPOSED CHANGES TO PE INPUTS SO THAT INPUTS FOR PROFESSIONAL COMPONENT (PC) ONLY AND TECHNICAL COMPONENT (TC) ONLY CODES SUM TO GLOBAL ONLY CODES—
Continued
CPT code
Long descriptor
93232 ................
Wearable electrocardiographic rhythm derived monitoring for 24 hours by continuous original waveform recording and storage
without superimposition scanning utilizing a device capable of producing a full miniaturized printout; microprocessor-based
analysis with report.
Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; includes transmission, physician review and interpretation.
Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; recording (includes connection, recording, and disconnection).
Wearable patient activated electrocardiographic rhythm derived event recording with presymptom memory loop, 24-hour attended monitoring, per 30 day period of time; monitoring, receipt of transmissions, and analysis.
Plethysmography, total body; with interpretation and report.
Plethysmography, total body; tracing only, without interpretation and report.
Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer;
including recording, scanning analysis, interpretation and report.
Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer;
recording only.
Ambulatory blood pressure monitoring, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer;
scanning analysis with report.
93268 ................
93270 ................
93271 ................
93720 ................
93721 ................
93784 ................
93786 ................
93788 ................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(3) Equipment Time Inputs for Certain
Diagnostic Tests
We have recently identified incorrect
equipment time inputs for four CPT
codes associated with certain diagnostic
tests (each is displayed in Table 5):
• CPT code 93225 is the TC only code
that includes the connection, recording,
and disconnection of the holter monitor
(CMS Equipment Code EQ127) used in
24 hour continuous
electrocardiographic rhythm derived
monitoring. The current equipment time
input for the holter monitor is 42
minutes, which parallels the intraservice clinical labor input time for the
CPT code. However, the equipment time
should reflect the 24 hours of
continuous monitoring in which the
device is used exclusively by the
patient. Therefore, we are proposing to
change the monitor equipment time for
CPT code 93225 to 1440 minutes, the
number of minutes in 24 hours.
• CPT code 93226 is the TC only code
that includes the scanning analysis with
report. The number of minutes the
monitor (CMS Equipment Code EQ127)
is used in this service should parallel
the intra-service clinical labor input
time of 52 minutes during which the
monitor is in use, instead of the current
equipment time of 1440 minutes,
because this code does not represent 24
hours of device use. Therefore, we are
proposing to change the monitor
equipment time for CPT code 93226 to
52 minutes.
• CPT 93224 is the global only code
that includes the connection, recording,
and disconnection of the monitor (CMS
Equipment Code EQ127) and the
scanning analysis with report, as well as
the physician review and interpretation.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Under our proposal, its direct PE inputs
have been appropriately summed to
include the 1492 total minutes of time
for the holter monitor that are included
in CPT codes 93225 and 93226.
• CPT code 93788 is the TC only code
that describes the scanning analysis
with report for ambulatory blood
pressure monitoring. The equipment
time input for the blood pressure
monitor should parallel the 10 minutes
of clinical labor input for the CPT code
since that is the time during which the
monitor is in use. Currently, the
equipment time input for the monitor is
1440 minutes, which is appropriate only
for CPT code 93786, the code that
describes the 24 hours of ambulatory
blood pressure monitoring recording. In
this case, CPT code 93786’s direct PE
inputs are correct. Therefore, we are
proposing to correct the equipment time
input for the ambulatory blood pressure
monitor in CPT code 93788 to 10
minutes.
• CPT code 93784 is the global only
code that includes the recording, the
scanning analysis with report, and the
physician interpretation and report for
ambulatory blood pressure monitoring.
Under our proposal, its direct PE inputs
have been appropriately summed to
include the 1450 total minutes of time
for the ambulatory blood pressure
monitor that are included in CPT codes
93786 and 93788.
We have modified the proposed CY
2011 direct PE database to reflect these
changes.
(4) Cobalt-57 Flood Source
Stakeholders have requested that CMS
reevaluate the useful life of the Cobalt57 flood source (CMS Equipment Code
ER001), given their estimate of
PO 00000
Frm 00018
Fmt 4701
Sfmt 4702
approximately 271 days for the source’s
half-life. The current useful life input
for the Colbalt-57 flood source is 5
years. Using publicly available catalogs,
we found that the Cobalt-57 flood
source is marketed with a useful life of
2 years. Therefore, we are proposing to
change the useful life input from the
current 5 years to 2 years. The Cobalt57 flood source is included with the
revised useful life input for 96 HCPCS
codes in the proposed CY 2011 direct
PE database.
(5) Venom Immunotherapy
One stakeholder provided updated
price information for the venoms used
for the five venom immunology CPT
codes, specifically 95145 (Professional
services for the supervision of
preparation and provision of antigens
for allergen immunotherapy (specify
number of doses); single stinging insect
venom); 95146 (Professional services for
the supervision of preparation and
provision of antigens for allergen
immunotherapy (specify number of
doses); 2 single stinging insect venoms);
95147 (Professional services for the
supervision of preparation and
provision of antigens for allergen
immunotherapy (specify number of
doses); 3 single stinging insect venoms);
95148 (Professional services for the
supervision of preparation and
provision of antigens for allergen
immunotherapy (specify number of
doses); 4 single stinging insect venoms);
95149 (Professional services for the
supervision of preparation and
provision of antigens for allergen
immunotherapy (specify number of
doses); 5 single stinging insect venoms).
In the CY 2004 PFS final rule with
comment period (68 FR 63206), we
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
adopted a pricing methodology that
utilizes the average price of a 1 milliliter
dose of venom and adds that price per
dose as direct PE inputs for CPT codes
95145 and 95146. When a patient
requires three stinging insect venoms, as
for CPT code 95147, the price input for
a 3-vespid mix is used. This 3-vespid
mix price is also used to value CPT
codes 95148 (four venoms) and 96149
(five venoms), with the single venom
price added once to CPT code 97148
and twice to CPT code 97149.
As requested by the stakeholder, we
are updating the price inputs for the 1milliliter dose of venom to $16.67 and
for the 3-vespid mix to $30.22 in the
proposed CY 2011 direct PE database.
(6) Equipment Redundancy
Stakeholders have recently brought to
our attention that the ECG, 3-channel
(with SpO2, NIBP, temp, resp) (CMS
Equipment Code EQ011) incorporates
all of the functionality of the pulse
oximeter with printer (CMS Equipment
Code EQ211). Therefore, in HCPCS
codes where CMS Equipment Code
EQ011 is present, CMS Equipment Code
EQ211 is redundant. On this basis, we
are proposing to remove the pulse
oximeter with printer (CMS Equipment
40057
Code EQ211) as an input for the 118
codes that also contain the ECG, 3channel (with SpO2, NIBP, temp, resp)
(CMS Equipment Code EQ011). We have
made these adjustments in the proposed
CY 2011 direct PE database.
(7) Equipment Duplication
We recently identified a number of
CPT codes with duplicate equipment
inputs in the PE database. We are
proposing to remove the duplicate
equipment items and have modified the
proposed CY 2011 direct PE database
accordingly as detailed in Table 6.
TABLE 6—CPT CODES WITH PROPOSED REMOVAL OF DUPLICATE EQUIPMENT ITEMS IN THE DIRECT PE DATABASE
CMS equipment
code for duplicate equipment
CPT code
19302
19361
P-mastectomy w/ln removal .........................................
Breast reconstr w/lat flap .............................................
44157
Colectomy w/ileoanal anast .........................................
44158
Colectomy w/neo-rectum pouch ..................................
56440
Surgery for vulva lesion ...............................................
57296
Revise vag graft, open abd ..........................................
58263
59610
67228
Vag hyst w/t/o & vag repair .........................................
Vbac delivery ................................................................
Treatment of retinal lesion ...........................................
76813
77371
93540
Ob us nuchal meas, 1 gest ..........................................
Srs, multisource ...........................................................
Injection, cardiac cath ..................................................
93542
Injection for heart x-rays ..............................................
(8) Establishing Overall Direct PE
Supply Price Inputs Based on Unit
Prices and Quantities
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
We have identified minor errors in
total price inputs for a number of supply
items due to mathematical mistakes in
multiplying the item unit price and the
EF014 ...............
ED005 ..............
EF031 ...............
EQ168 ..............
EF031 ...............
EQ168 ..............
EF031 ...............
EQ168 ..............
EF031 ...............
EQ170 ..............
EF031 ...............
EQ170 ..............
EF031 ...............
EF031 ...............
EL005 ...............
EQ230 ..............
ED024 ...............
EQ211 ..............
ED018 ..............
EL011 ...............
EQ011 ..............
EQ032 ..............
EQ088 ..............
EQ211 ..............
ED018 ..............
EL011 ...............
EQ011 ..............
EQ032 ..............
EQ088 ..............
EQ211 ..............
Description of equipment
light, surgical.
camera, digital system, 12 megapixel (medical grade).
table, power.
light, exam.
table, power.
light, exam.
table, power.
light, exam.
table, power.
light, fiberoptic headlight w-source.
table, power.
light, fiberoptic headlight w-source.
table, power.
table, power.
lane, exam (oph).
slit lamp (Haag-Streit), dedicated to laser use.
film processor, dry, laser.
pulse oximeter w-printer.
computer workstation, cardiac cath monitoring.
room, angiography.
ECG, 3-channel (with SpO2, NIBP, temp, resp).
IV infusion pump.
contrast media warmer.
pulse oximeter w-printer.
computer workstation, cardiac cath monitoring.
room, angiography.
ECG, 3-channel (with SpO2, NIBP, temp, resp).
IV infusion pump.
contrast media warmer.
pulse oximeter w-printer.
quantity used in particular CPT codes
for the associated services. We are
proposing to modify the direct PE
database to appropriately include the
overall supply price input for a supply
item as the product of the unit price and
the quantity of the supply item used in
the CPT code. Most of the overall
supply price input changes are small,
and we have adjusted the proposed CY
2011 direct PE database accordingly.
The CPT and Level II HCPCS codes and
associated supplies for nonfacility and
facility settings that are subject to these
corrections are displayed in Tables 7
and 8, respectively.
TABLE 7—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR NONFACILITY SETTINGS
CPT/HCPCS
code
Short descriptor
CMS Supply
code with overall
price corrections
11952 .................
11954 .................
15820 .................
Therapy for contour defects ..........
Therapy for contour defects ..........
Revision of lower eyelid ................
SC029 ..............
SC029 ..............
SA082 ...............
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00019
Fmt 4701
Description of supply
needle, 18–27g.
needle, 18–27g.
pack, ophthalmology visit (w-dilation).
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40058
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 7—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR NONFACILITY SETTINGS—Continued
Short descriptor
CPT/HCPCS
code
15821
15822
17311
17312
17313
17314
21011
21013
21073
21076
21081
21310
23075
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
24075 .................
25075 .................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
26115 .................
27327
27618
28039
28043
28045
28306
28307
28310
28312
28313
28315
28340
28344
28345
28496
28755
28820
28890
29870
32553
36475
36592
41530
41805
41806
42107
46505
49411
49440
49441
49442
49446
49450
49451
49452
49460
49465
50382
50384
50385
50386
50387
50389
51100
51101
51727
51728
51729
52649
53855
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
VerDate Mar<15>2010
CMS Supply
code with overall
price corrections
Revision of lower eyelid ................
Revision of upper eyelid ...............
Mohs, 1 stage, h/n/hf/g .................
Mohs addl stage ...........................
Mohs, 1 stage, t/a/l .......................
Mohs, addl stage, t/a/l ..................
Exc face les sc < 2 cm .................
Exc face tum deep < 2 cm ...........
Mnpj of tmj w/anesth .....................
Prepare face/oral prosthesis .........
Prepare face/oral prosthesis .........
Treatment of nose fracture ...........
Exc shoulder les sc < 3 cm ..........
.......................................................
Exc arm/elbow les sc < 3 cm .......
.......................................................
Exc forearm les sc < 3 cm ............
.......................................................
Exc hand les sc < 1.5 cm .............
.......................................................
Exc thigh/knee les sc < 3 cm .......
Exc leg/ankle tum < 3 cm .............
Exc foot/toe tum sc > 1.5 cm ........
Exc foot/toe tum sc < 1.5 cm ........
Exc foot/toe tum deep < 1.5cm ....
Incision of metatarsal ....................
Incision of metatarsal ....................
Revision of big toe ........................
Revision of toe ..............................
Repair deformity of toe .................
Removal of sesamoid bone ..........
Resect enlarged toe tissue ...........
Repair extra toe(s) ........................
Repair webbed toe(s) ...................
Treat big toe fracture ....................
Fusion of big toe joint ...................
Amputation of toe ..........................
High energy eswt, plantar f ...........
Knee arthroscopy, dx ....................
Ins mark thor for rt perq ................
Endovenous rf, 1st vein ................
Collect blood from picc .................
Tongue base vol reduction ...........
Removal foreign body, gum ..........
Removal foreign body, jawbone ...
Excision lesion, mouth roof ...........
Chemodenervation anal musc ......
Ins mark abd/pel for rt perq ..........
Place gastrostomy tube perc ........
Place duod/jej tube perc ...............
Place cecostomy tube perc ..........
Change g-tube to g-j perc .............
Replace g/c tube perc ...................
Replace duod/jej tube perc ...........
Replace g-j tube perc ...................
Fix g/colon tube w/device .............
Fluoro exam of g/colon tube .........
Change ureter stent, percut ..........
Remove ureter stent, percut .........
Change stent via transureth .........
Remove stent via transureth .........
Change ext/int ureter stent ...........
Remove renal tube w/fluoro ..........
Drain bladder by needle ...............
Drain bladder by trocar/cath .........
Cystometrogram w/up ...................
Cystometrogram w/vp ...................
Cystometrogram w/vp&up .............
Prostate laser enucleation ............
Insert prost urethral stent ..............
SA082 ...............
SA082 ...............
SG078 ..............
SG078 ..............
SG078 ..............
SG078 ..............
SH046 ..............
SH046 ..............
SG079 ..............
SL047 ...............
SK024 ...............
SB034 ...............
SG056 ..............
SH021 ...............
SG056 ..............
SH021 ...............
SG056 ..............
SH021 ...............
SG056 ..............
SH021 ...............
SG056 ..............
SG056 ..............
SG056 ..............
SG056 ..............
SG056 ..............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SA048 ...............
SC051 ..............
SG079 ..............
SB034 ...............
SC074 ...............
SG050 ..............
SD009 ..............
SD134 ..............
SD134 ..............
SD009 ..............
SD009 ..............
SB034 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SK089 ...............
SB034 ...............
SB034 ...............
SB034 ...............
SB034 ...............
SB034 ...............
SB034 ...............
SH047 ..............
SH047 ..............
SC051 ...............
SC051 ..............
SC051 ..............
SA048 ...............
SB024 ...............
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00020
Fmt 4701
Description of supply
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
tape, surgical occlusive 1in (Blenderm).
tape, surgical occlusive 1in (Blenderm).
tape, surgical occlusive 1in (Blenderm).
tape, surgical occlusive 1in (Blenderm).
lidocaine 1% w-epi inj (Xylocaine w-epi).
lidocaine 1% w-epi inj (Xylocaine w-epi).
tape, surgical paper 1in (Micropore).
dental stone powder.
film, dental.
mask, surgical, with face shield.
gauze, sterile 4in x 4in (10 pack uou).
bupivacaine 0.25% inj (Marcaine).
gauze, sterile 4in x 4in (10 pack uou).
bupivacaine 0.25% inj (Marcaine).
gauze, sterile 4in x 4in (10 pack uou).
bupivacaine 0.25% inj (Marcaine).
gauze, sterile 4in x 4in (10 pack uou).
bupivacaine 0.25% inj (Marcaine).
gauze, sterile 4in x 4in (10 pack uou).
gauze, sterile 4in x 4in (10 pack uou).
gauze, sterile 4in x 4in (10 pack uou).
gauze, sterile 4in x 4in (10 pack uou).
gauze, sterile 4in x 4in (10 pack uou).
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
syringe 10–12ml.
tape, surgical paper 1in (Micropore).
mask, surgical, with face shield.
iv pressure infusor bag.
gauze, non-sterile 2in x 2in.
canister, suction.
tubing, suction, non-latex (6ft) with Yankauer tip (1).
tubing, suction, non-latex (6ft) with Yankauer tip (1).
canister, suction.
canister, suction.
mask, surgical, with face shield.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
x-ray developer solution.
mask, surgical, with face shield.
mask, surgical, with face shield.
mask, surgical, with face shield.
mask, surgical, with face shield.
mask, surgical, with face shield.
mask, surgical, with face shield.
lidocaine 1%–2% inj (Xylocaine).
lidocaine 1%–2% inj (Xylocaine).
syringe 10–12ml.
syringe 10–12ml.
syringe 10–12ml.
pack, minimum multi-specialty visit.
gloves, sterile.
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 7—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR NONFACILITY SETTINGS—Continued
Short descriptor
CPT/HCPCS
code
59300
59812
64490
64493
.................
.................
.................
.................
65272
65286
66250
67031
67105
67110
67120
67228
67901
75571
75572
75573
75574
75960
76821
77371
77372
77373
78452
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
78454 .................
88125 .................
88355 .................
88356 .................
88365 .................
88367 .................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
88368 .................
88385 .................
88386 .................
VerDate Mar<15>2010
CMS Supply
code with overall
price corrections
Episiotomy or vaginal repair .........
Treatment of miscarriage ..............
Inj paravert f jnt c/t 1 lev ...............
Inj paravert f jnt l/s 1 lev ...............
.......................................................
Repair of eye wound .....................
Repair of eye wound .....................
Follow-up surgery of eye ..............
Laser surgery, eye strands ...........
Repair detached retina .................
Repair detached retina .................
Remove eye implant material .......
Treatment of retinal lesion ............
Repair eyelid defect ......................
Ct hrt w/o dye w/ca test ................
Ct hrt w/3d image .........................
Ct hrt w/3d image, congen ...........
Ct angio hrt w/3d image ...............
Transcath iv stent rs&i ..................
Middle cerebral artery echo ..........
Srs, multisource ............................
Srs, linear based ...........................
Sbrt delivery ..................................
Ht muscle image spect, mult ........
.......................................................
Ht musc image, planar, mult .........
Forensic cytopathology .................
Analysis, skeletal muscle ..............
.......................................................
.......................................................
.......................................................
Analysis, nerve ..............................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
Insitu hybridization (fish) ...............
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
Insitu hybridization, auto ...............
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
Insitu hybridization, manual ..........
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
.......................................................
Eval molecul probes, 51–250 .......
.......................................................
.......................................................
.......................................................
Eval molecul probes, 251–500 .....
.......................................................
SG062 ..............
SA052 ...............
SK025 ...............
SH021 ...............
SK025 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA048 ...............
SJ019 ...............
SJ019 ...............
SJ019 ...............
SJ019 ...............
SK034 ...............
SM013 ..............
SG079 ..............
SG079 ..............
SG079 ..............
SC051 ..............
SK092 ...............
SK092 ...............
SL026 ...............
SK073 ...............
SL061 ...............
SL078 ...............
SL201 ...............
SB023 ...............
SK073 ...............
SL061 ...............
SL078 ...............
SL108 ...............
SL201 ...............
SF004 ...............
SL179 ...............
SL183 ...............
SL189 ...............
SL190 ...............
SL194 ...............
SM016 ..............
SC057 ..............
SF004 ...............
SL030 ...............
SL085 ...............
SL178 ...............
SL179 ...............
SL181 ...............
SL183 ...............
SL189 ...............
SL190 ...............
SL191 ...............
SL194 ...............
SM016 ..............
SF004 ...............
SL179 ...............
SL183 ...............
SL189 ...............
SL190 ...............
SL194 ...............
SM016 ..............
SL207 ...............
SL218 ...............
SL220 ...............
SL225 ...............
SL207 ...............
SL218 ...............
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00021
Fmt 4701
Description of supply
packing, gauze plain 0.25–0.50in (5 yd uou).
pack, post-op incision care (staple).
film, dry, radiographic, 8in x 10in.
bupivacaine 0.25% inj (Marcaine).
film, dry, radiographic, 8in x 10in.
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, minimum multi-specialty visit.
electrode adhesive disk.
electrode adhesive disk.
electrode adhesive disk.
electrode adhesive disk.
film, x-ray 14in x 17in.
disinfectant, surface (Envirocide, Sanizide).
tape, surgical paper 1in (Micropore).
tape, surgical paper 1in (Micropore).
tape, surgical paper 1in (Micropore).
syringe 10–12ml.
x-ray fixer solution
x-ray fixer solution.
clearing agent (Histo-clear).
skin marking ink (tattoo).
embedding paraffin.
histology freezing spray (Freeze-It).
stain, eosin.
gloves, non-sterile, nitrile.
skin marking ink (tattoo).
embedding paraffin.
histology freezing spray (Freeze-It).
pipette.
stain, eosin.
blade, microtome.
1.0N NaOH.
slide, organosilane coated.
ethanol, 100%.
ethanol, 70%.
Hemo-De.
eye shield, splash protection.
syringe 5–6ml.
blade, microtome.
cover slip, glass.
label for microscope slides.
0.2N HCL.
1.0N NaOH.
pipette tips, sterile.
slide, organosilane coated.
ethanol, 100%.
ethanol, 70%.
ethanol, 85%.
Hemo-De.
eye shield, splash protection.
blade, microtome.
1.0N NaOH.
slide, organosilane coated.
ethanol, 100%.
ethanol, 70%.
Hemo-De.
eye shield, splash protection.
air, filtered, compressed.
DNA, Versagene, blood kit.
ethanol, 200%.
gas, nitogen, ultra-high purity (compressed), grade 5.0.
air, filtered, compressed.
DNA, Versagene, blood kit.
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40059
40060
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 7—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR NONFACILITY SETTINGS—Continued
Short descriptor
CPT/HCPCS
code
90470
91065
91132
91133
92550
92597
92610
92626
92627
92640
95004
95024
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
95027 .................
95044
95052
95148
95805
96040
96102
96360
.................
.................
.................
.................
.................
.................
.................
96365 .................
96366
96367
96369
96371
96372
96374
.................
.................
.................
.................
.................
.................
96375 .................
96401 .................
96402 .................
96409 .................
96411 .................
96413 .................
96417 .................
96445 .................
96542 .................
99366 .................
G0270 ................
G0271 ................
CMS Supply
code with overall
price corrections
.......................................................
.......................................................
Immune admin H1N1 im/nasal .....
Breath hydrogen test ....................
Electrogastrography ......................
Electrogastrography w/test ...........
Tympanometry & reflex thresh ......
Oral speech device eval ...............
Evaluate swallowing function ........
Eval aud rehab status ...................
Eval aud status rehab add-on ......
Aud brainstem implt programg ......
Percut allergy skin tests ................
Id allergy test, drug/bug ................
.......................................................
Id allergy titrate-airborne ...............
.......................................................
Allergy patch tests ........................
Photo patch test ............................
Antigen therapy services ..............
Multiple sleep latency test ............
Genetic counseling, 30 min ..........
Psycho testing by technician ........
Hydration iv infusion, init ...............
.......................................................
.......................................................
Ther/proph/diag iv inf, init .............
.......................................................
.......................................................
Ther/proph/diag iv inf addon .........
Tx/proph/dg addl seq iv inf ...........
Sc ther infusion, up to 1 hr ...........
Sc ther infusion, reset pump .........
Ther/proph/diag inj, sc/im .............
Ther/proph/diag inj, iv push ..........
.......................................................
.......................................................
Tx/pro/dx inj new drug addon .......
.......................................................
Chemo, anti-neopl, sq/im ..............
.......................................................
Chemo hormon antineopl sq/im ....
.......................................................
Chemo, iv push, sngl drug ............
.......................................................
Chemo, iv push, addl drug ...........
.......................................................
Chemo, iv infusion, 1 hr ................
.......................................................
Chemo iv infus each addl seq ......
Chemotherapy, intracavitary .........
.......................................................
Chemotherapy injection ................
Team conf w/pat by hc pro ...........
MNT subs tx for change dx ..........
.......................................................
Group MNT 2 or more 30 mins ....
SL220 ...............
SL225 ...............
SB036 ...............
(blank) ...............
SD062 ..............
SD062 ..............
SK059 ...............
SB022 ...............
SB022 ...............
SK008 ...............
SK008 ...............
SK068 ...............
SC023 ..............
SA048 ...............
SG050 ..............
SA048 ...............
SC052 ...............
SK087 ...............
SK087 ...............
SH009 ..............
SK094 ...............
SK062 ...............
SK057 ...............
SC018 ..............
SC051 ...............
SG050 ..............
SC018 ..............
SC051 ...............
SG050 ..............
SB022 ...............
SB022 ...............
SC013 ..............
SC013 ...............
SB022 ...............
SB022 ...............
SC051 ...............
SG050 ..............
SB022 ...............
SC051 ...............
SC051 ...............
SG050 ..............
SC051 ..............
SG050 ..............
SC018 ..............
SC051 ...............
SC018 ..............
SC051 ...............
SC018 ..............
SC051 ...............
SC018 ..............
SC018 ..............
SH069 ...............
SC018 ..............
SK062 ...............
SK057 ...............
SK062 ...............
SK057 ...............
Description of supply
ethanol, 200%.
gas, nitogen, ultra-high purity (compressed), grade 5.0.
paper, exam table.
Sivrite-4.
electrode, surface.
electrode, surface.
paper, recording (per sheet).
gloves, non-sterile.
gloves, non-sterile.
audiology scoring forms.
audiology scoring forms.
razor.
multi-tine device.
pack, minimum multi-specialty visit.
gauze, non-sterile 2in x 2in.
pack, minimum multi-specialty visit.
syringe 1ml.
water, distilled.
water, distilled.
antigen, venom.
x-ray marking pencil.
patient education booklet.
paper, laser printing (each sheet).
iv infusion set.
syringe 10–12ml.
gauze, non-sterile 2in x 2in.
iv infusion set.
syringe 10–12ml.
gauze, non-sterile 2in x 2in.
gloves, non-sterile.
gloves, non-sterile.
infusion pump cassette-reservoir.
infusion pump cassette-reservoir.
gloves, non-sterile.
gloves, non-sterile.
syringe 10–12ml.
gauze, non-sterile 2in x 2in.
gloves, non-sterile.
syringe 10–12ml.
syringe 10–12ml.
gauze, non-sterile 2in x 2in.
syringe 10–12ml.
gauze, non-sterile 2in x 2in.
iv infusion set 22.
syringe 10–12ml.
iv infusion set.
syringe 10–12ml.
iv infusion set.
syringe 10–12ml.
iv infusion set.
iv infusion set.
sodium chloride 0.9% irrigation (500–1000ml uou).
iv infusion set.
patient education booklet.
paper, laser printing (each sheet).
patient education booklet.
paper, laser printing (each sheet).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
TABLE 8—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR FACILITY SETTINGS
Short descriptor
CPT/HCPCS
Code
15738
15820
15821
15822
19303
20900
.................
.................
.................
.................
.................
.................
VerDate Mar<15>2010
CMS supply
code with overall
price corrections
Muscle-skin graft, leg ....................
Revision of lower eyelid ................
Revision of lower eyelid ................
Revision of upper eyelid ...............
Mast, simple, complete .................
Removal of bone for graft .............
SG017 ..............
SA082 ...............
SA082 ...............
SA082 ...............
SB006 ...............
SA054 ...............
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00022
Fmt 4701
Description of supply
bandage, Kling, non-sterile 2in.
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
drape, non-sterile, sheet 40in x 60in.
pack, post-op incision care (suture).
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 8—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR FACILITY SETTINGS—Continued
CPT/HCPCS
Code
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
Exc face les sc < 2 cm .................
Exc face tum deep < 2 cm ...........
Reconst lwr jaw w/o graft ..............
Reconst lwr jaw w/graft .................
Reconstruction of jaw joint ............
Treat cheek bone fracture ............
Treat craniofacial fracture .............
Exc neck les sc < 3 cm ................
Exc back les sc < 3 cm ................
Exc abd les sc < 3 cm ..................
Exc shoulder les sc < 3 cm ..........
Exc arm/elbow les sc < 3 cm .......
Exc forearm les sc < 3 cm ............
Exc hand les sc < 1.5 cm .............
Exc hip/pelvis les sc < 3 cm .........
Exc thigh/knee les sc < 3 cm .......
Exc leg/ankle tum < 3 cm .............
Incision of metatarsal ....................
Resect enlarged toe tissue ...........
Repair webbed toe(s) ...................
Amputation of toe ..........................
Cabg, vein, six or more ................
Transposition of vein valve ...........
Repair artery rupture, arm ............
Tongue, mouth, jaw surgery .........
Tongue, mouth, neck surgery .......
Tongue, jaw, & neck surgery ........
Removal foreign body, gum ..........
Removal foreign body, jawbone ...
Treatment mouth roof lesion .........
Hysterectomy/bladder repair .........
Partial removal of vulva ................
Repair paravag defect, open ........
57285 .................
Repair paravag defect, vag ..........
57423 .................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
21011
21013
21193
21194
21240
21366
21435
21555
21930
22902
23075
24075
25075
26115
27047
27327
27618
28307
28340
28345
28820
33516
34510
35013
41150
41153
41155
41805
41806
42160
51925
56620
57284
CMS supply
code with overall
price corrections
Short descriptor
Repair paravag defect, lap ...........
58660
58662
58670
58940
58952
64632
65112
65114
65235
65265
65272
65273
65280
65285
65286
65290
65770
65850
65865
65870
66180
66185
66220
66250
66500
66600
66605
66625
66630
66635
66682
66820
Laparoscopy, lysis ........................
Laparoscopy, excise lesions .........
Laparoscopy, tubal cautery ...........
Removal of ovary(s) ......................
Resect ovarian malignancy ...........
N block inj, common digit ..............
Remove eye/revise socket ............
Remove eye/revise socket ............
Remove foreign body from eye ....
Remove foreign body from eye ....
Repair of eye wound .....................
Repair of eye wound .....................
Repair of eye wound .....................
Repair of eye wound .....................
Repair of eye wound .....................
Repair of eye socket wound .........
Revise cornea with implant ...........
Incision of eye ...............................
Incise inner eye adhesions ...........
Incise inner eye adhesions ...........
Implant eye shunt .........................
Revise eye shunt ..........................
Repair eye lesion ..........................
Follow-up surgery of eye ..............
Incision of iris ................................
Remove iris and lesion .................
Removal of iris ..............................
Removal of iris ..............................
Removal of iris ..............................
Removal of iris ..............................
Repair iris & ciliary body ...............
Incision, secondary cataract .........
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
SA048
SA048
SJ061
SJ061
SJ061
SJ061
SJ061
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA048
SA052
SA054
SA048
SA048
SA048
SA048
SD134
SD134
SD122
SB006
SA048
SA051
SB006
SA051
SB006
SA051
SB006
SB006
SJ046
SJ046
SA052
SB006
SA048
SA050
SA050
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA050
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
SA082
Frm 00023
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
..............
..............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
...............
Fmt 4701
Description of supply
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
tongue depressor.
tongue depressor.
tongue depressor.
tongue depressor.
tongue depressor.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, post-op incision care (staple).
pack, post-op incision care (suture).
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
pack, minimum multi-specialty visit.
tubing, suction, non-latex (6ft) with Yankauer tip (1).
tubing, suction, non-latex (6ft) with Yankauer tip (1).
suction tip, Yankauer.
drape, non-sterile, sheet 40in x 60in.
pack, minimum multi-specialty visit.
pack, pelvic exam.
drape, non-sterile, sheet 40in x 60in.
pack, pelvic exam.
drape, non-sterile, sheet 40in x 60in.
pack, pelvic exam.
drape, non-sterile, sheet 40in x 60in.
drape, non-sterile, sheet 40in x 60in.
silver nitrate applicator.
silver nitrate applicator.
pack, post-op incision care (staple).
drape, non-sterile, sheet 40in x 60in.
pack, minimum multi-specialty visit.
pack, ophthalmology visit (no dilation).
pack, ophthalmology visit (no dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (no dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40061
40062
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 8—OVERALL SUPPLY PRICE CALCULATION CORRECTIONS FOR FACILITY SETTINGS—Continued
Short descriptor
CPT/HCPCS
Code
66850
66852
66930
66940
66983
67015
67031
67036
67040
67105
67107
67110
67115
67120
67228
67400
67412
67440
67908
88356
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
.................
CMS supply
code with overall
price corrections
Removal of lens material ..............
Removal of lens material ..............
Extraction of lens ..........................
Extraction of lens ..........................
Cataract surg w/iol, 1 stage ..........
Release of eye fluid ......................
Laser surgery, eye strands ...........
Removal of inner eye fluid ............
Laser treatment of retina ..............
Repair detached retina .................
Repair detached retina .................
Repair detached retina .................
Release encircling material ...........
Remove eye implant material .......
Treatment of retinal lesion ............
Explore/biopsy eye socket ............
Explore/treat eye socket ...............
Explore/drain eye socket ..............
Repair eyelid defect ......................
Analysis, nerve ..............................
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SA082 ...............
SG008 ..............
SL108 ...............
c. AMA RUC Recommendations in CY
2010 for Changes to Direct PE Inputs
In a March 2010 letter, the AMA RUC
made specific PE recommendations that
we consider below. As stated earlier, the
proposed changes that follow are
included in the proposed CY 2011
direct PE database, which is available
on the CMS Web site under the
downloads for the CY 2011 PFS
proposed rule at https://www.cms.gov/
PhysicianFeeSched/.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(1) Electrogastrography and Esophageal
Function Test
We are accepting the AMA RUC
recommendations for the CY 2011 PE
inputs for the following CPT codes:
91132 (Electrogastrography, diagnostic,
transcutaneous); 91133
(Electrogastrography, diagnostic,
transcutaneous; with provocative
testing); 91038 (Esophageal function
test, gastroesophageal reflux test with
nasal catheter intraluminal impedance
electrode(s) placement, recording,
analysis and interpretation; prolonged
(greater than 1 hour, up to 24 hours)).
For CPT code 91038, we have assumed
a useful life of 5 years for the equipment
item ‘‘ZEPHR impedance/pH reflux
monitoring system with data recorder,
software, monitor, workstation and
cart,’’ based on its entry in the AHA’s
publication, ‘‘Estimated Useful Lives of
Depreciable Hospital Assets,’’ which we
use as a standard reference. The
proposed CY 2011 direct PE database
has been changed accordingly.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Description of supply
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
pack, ophthalmology visit (w-dilation).
applicator, cotton-tipped, non-sterile 6in.
pipette.
(2) 64-Slice CT Scanner and Software
(3) Cystometrogram
The AMA RUC submitted an updated
recommendation regarding the correct
pricing of the 64-slice CT scanner and
its accompanying software. Based on the
documentation accompanying the
recommendation, we are accepting this
recommendation and updating the price
input for the 64-slice scanner and
software. This affects the following four
CPT codes that use either the scanner,
the software, or both: 75571 (computed
tomography, heart, without contrast
material, with quantitative evaluation of
coronary calcium); 75572 (Computed
tomography, heart, with contrast
material, for evaluation of cardiac
structure and morphology (including 3D
image postprocessing, assessment of
cardiac function, and evaluation of
venous structures, if performed)); 75573
(Computed tomography, heart, with
contrast material, for evaluation of
cardiac structure and morphology in the
setting of congenital heart disease
(including 3D image postprocessing,
assessment of LV cardiac function, RV
structure and function and evaluation of
venous structures, if performed)); and
75574 (Computed tomographic
angiography, heart, coronary arteries
and bypass grafts (when present), with
contrast material, including 3D image
postprocessing (including evaluation of
cardiac structure and morphology,
assessment of cardiac function, and
evaluation of venous structure, if
performed)). The proposed CY 2011
direct PE database has been modified
accordingly.
The AMA RUC recently identified a
rank order anomaly regarding CPT code
51726 (Complex cystometrogram (i.e.,
calibrated electronic equipment)).
Currently, this procedure has higher PE
RVUs, despite being less resourceintensive than the three CPT codes for
which it serves as the base: 51727
(Complex cystometrogram (i.e.,
calibrated electronic equipment); with
urethral pressure profile studies (i.e.,
urethral closure pressure profile), any
technique); 51728 (Complex
cystometrogram (i.e., calibrated
electronic equipment); with voiding
pressure studies (i.e., bladder voiding
pressure), any technique); and 51729
(Complex cystometrogram (i.e.,
calibrated electronic equipment); with
voiding pressure studies (i.e., bladder
voiding pressure) and urethral pressure
profile studies (i.e., urethral closure
pressure profile), any technique).
Since usual AMA RUC policy is that
CPT codes with a 0-day global period do
not have pre-service time associated
with the code, the AMA RUC
recommended removing the nonfacility
pre-service clinical staff time from the
PE inputs for 51726. Additionally, the
AMA RUC recommended that the
nonfacility clinical intra-service staff
time for CPT code 51276 be reduced
from the 118 minutes of intra-service
clinical staff time currently assigned to
the code to 85 minutes of intra-service
clinical staff time. These changes would
resolve the rank order anomaly and
bring the PE inputs for CPT code 51726
into alignment with the other three
codes. Finally, and for the reasons
PO 00000
Frm 00024
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
stated above, the AMA RUC
recommended that CMS remove the 23
minutes of pre-service nonfacility
clinical staff time from CPT code 51725
(Simple cystometrogram (CMG) (e.g.,
spinal manometer)). We are accepting
these recommendations and, therefore,
have changed the direct PE inputs for
CPT codes 51725 and 51726 in the
nonfacility setting in the proposed CY
2011 direct PE database.
(4) Breath Hydrogen Test
The AMA RUC provide
recommendations regarding the PE
inputs for CPT code 91065 (breath
hydrogen test (e.g., for detection of
lactase deficiency, fructose intolerance,
bacterial overgrowth, or oro-cecal
gastrointestinal transit). We are
accepting the recommendations with
two modifications. We have folded the
two pieces of equipment listed as
‘‘quinGas Table-Top Support Stand, 3
Tank’’ and ‘‘Drying Tube, Patient
Sample’’ into the ‘‘BreathTrackerDigital
SC Instrument’’ and summed their
inputs into one equipment line-item,
since these equipment items are used
together specifically for the service in
question. We have increased the useful
life input of the ‘‘BreathTrackerDigital
SC Instrument’’ from 7 to 8 years based
on our use of the American Hospital
Association (AHA)’s publication
entitled, ‘‘Estimated Useful Lives of
Depreciable Hospital Assets’’ as a
standard reference. Additionally,
because the AMA RUC did not include
equipment times in their
recommendations for this CPT code, we
have used 53 minutes as the total time
for all equipment items based on the
total intra-service period for the clinical
labor, consistent with our general policy
for establishing equipment times. These
modifications are reflected in the
proposed CY 2011 direct PE database.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(5) Radiographic Fluoroscopic Room
A recent AMA RUC review of services
that include the radiographic
fluoroscopic room (CMS Equipment
Code EL014) as a direct PE revealed that
the use of the item is no longer typical
for certain services in which it is
specified within the current direct cost
inputs. The AMA RUC recommended to
CMS that the radiographic fluoroscopic
room be deleted from CPT codes 64420
(Injection, anesthetic agent; intercostal
nerve, single); 64421 (Injection,
anesthetic agent; intercostal nerves,
multiple, regional block); and 64620
(Destruction by neurolytic agent,
intercostal nerve).
We are accepting these
recommendations and, therefore, these
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
changes are included in the proposed
CY 2011 direct PE database.
The AMA RUC also informed us that
it has convened a workgroup to examine
the inclusion of the fluoroscopic room
across a broader range of codes. We will
consider any future recommendations
from the AMA RUC on this topic when
they are submitted.
d. Referral of Existing CPT Codes for
AMA RUC Review
As part of our review of high cost
supplies, we conducted a clinical
review of the procedures associated
with high cost supplies to confirm that
those supplies currently are used in the
typical case described by the CPT codes.
While we confirmed that most high cost
supplies could be used in the
procedures for which they are currently
direct PE inputs, we noted that one of
the high cost supplies, fiducial screws
(CMS Supply Code SD073) with a
current price of $558, is included as a
direct PE input for two CPT codes,
specifically 77301 (Intensity modulated
radiotherapy plan, including dosevolume histograms for target and critical
structure partial tolerance
specifications) and 77011 (Computed
tomography guidance for stereotactic
localization). The documentation used
in the current pricing of the supply item
describes a kit that includes
instructions, skull screws, a drill bit,
and a collar for the TALON® System
manufactured by Best nomos. Best
nomos’ literature describes the insertion
of the screws into the patient’s skull to
ensure accurate set-up. When CPT codes
77301 and 77011 were established in CY
2002 and CY 2003, respectively, we
accepted the AMA RUC
recommendations to include fiducial
screws in the PE for these services.
Upon further review, while we
understand why this supply may be
considered a typical PE input for CPT
code 77011, we do not now believe that
fiducial screws, as described in the Best
nomos literature, would typically be
used in CPT code 77301, where the
most common clinical scenario would
be treatment of prostate cancer.
Therefore, in order to ensure that CPT
codes 77301 and 77011 are
appropriately valued for CY 2011
through the inclusion or exclusion of
fiducial screws in their PE, we are
asking the AMA RUC to review these
CPT codes with respect to the inclusion
of fiducial screws in their PE. We are
requesting that the AMA RUC make
recommendations to us regarding
whether this supply should be included
in the PE or removed from the PE for
CPT codes 77301 and 77011 in a
timeframe that would allow us to adopt
PO 00000
Frm 00025
Fmt 4701
Sfmt 4702
40063
interim values for these codes for CY
2011, should the AMA RUC recommend
a change. If the AMA RUC continues to
recommend the inclusion of fiducial
screws in the PE for CPT code 77301
and/or 77011 for CY 2011, we are
requesting that the AMA RUC provide
us with a detailed rationale for the
inclusion of this specialized supply in
the PE for the typical case reported
under the relevant CPT code. We would
also request that the AMA RUC furnish
updated pricing information for the
screws if they continue to recommend
the screws as a PE input for one or both
of these CPT codes in CY 2011.
e. Updating Equipment and Supply
Price Inputs for Existing Codes
Historically, we have periodically
received requests to change the PE price
inputs for supplies and equipment in
the PE database. In the past, we have
considered these requests on an ad hoc
basis and updated the price inputs as
part of quarterly or annual updates if we
believed them to be appropriate. In this
proposed rule, we are proposing to
establish a regular and more transparent
process for considering public requests
for changes to PE database price inputs
for supplies and equipment used in
existing codes.
We are proposing to act on public
requests to update equipment and
supply price inputs annually through
rulemaking by following a regular and
consistent process as discussed in the
following paragraphs. We are proposing
to use the annual PFS proposed rule
released in the summer and the final
rule released on or about November 1
each year as the vehicle for making
these changes.
We will accept requests for updating
the price inputs for supplies and
equipment on an ongoing basis; requests
must be received no later than
December 31 of each CY to be
considered for inclusion in the next
proposed rule. In that next proposed
rule, we would present our review of
submitted requests to update price
inputs for specific equipment or
supplies and our proposals for the
subsequent calendar year. We would
then finalize changes in the final rule
for the upcoming calendar year. Our
review of the issues and consideration
of public comments may result in the
following outcomes that would be
presented in the final rule with
comment period:
• Updating the equipment or supply
price inputs, as requested.
• Updating the equipment or supply
price inputs, with modifications.
• Rejecting the new price inputs.
E:\FR\FM\13JYP2.SGM
13JYP2
40064
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• Declining to act on the request
pending a recommendation from the
AMA RUC.
To facilitate our review and
preparation of issues for the proposed
rule, at a minimum, we would expect
that requesters would provide the
following information:
• Name and contact information for
the requestor.
• The name of the item exactly as it
appears in the direct PE file under
downloads for the most recent PFS final
rule with comment period, available on
the CMS Web site at https://
www.cms.gov/PhysicianFeeSched/
PFSFRN/list.asp#TopOfPage.
In order to best evaluate the requests
in the context of our goal of utilizing
accurate market prices for these items as
direct PE inputs, we also would expect
requestors to provide multiple invoices
from different suppliers/manufacturers.
In some cases, multiple sources may not
be available, whereupon a detailed
explanation should be provided to
support the request. When furnishing
invoices, requestors should take into
consideration the following parameters:
++ May be either print or electronic
but should be on supplier and/or
manufacturer stationery (for example,
letterhead, billing statement, etc.)
++ Should be for the typical,
common, and customary version of the
supply or equipment that is used to
furnish the services.
++ Price should be net of typical
rebates and/or any discounts available,
including information regarding the
magnitude and rationale for such
rebates or discounts.
++ If multiple items are presented on
the same invoice, relevant item(s)
should be clearly identified.
We are soliciting public comments on
this proposed process, including the
information that requestors should
furnish to facilitate our full analysis in
preparation for the next calendar year’s
rulemaking cycle.
B. Malpractice Relative Value Units
(RVUs)
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
1. Background
Section 1848(c) of the Act requires
that each service paid under the PFS be
comprised of three components: work,
PE, and malpractice. From 1992 to 1999,
malpractice RVUs were charge-based,
using weighted specialty-specific
malpractice expense percentages and
1991 average allowed charges.
Malpractice RVUs for new codes after
1991 were extrapolated from similar
existing codes or as a percentage of the
corresponding work RVU. Section
4505(f) of the BBA required us to
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
implement resource-based malpractice
RVUs for services furnished beginning
in 2000. Therefore, initial
implementation of resource-based
malpractice RVUs occurred in 2000.
The statute also requires that we
review, and if necessary adjust, RVUs
no less often than every 5 years. The
first review and update of resourcebased malpractice RVUs was addressed
in the CY 2005 PFS final rule with
comment period (69 FR 66263). Minor
modifications to the methodology were
addressed in the CY 2006 PFS final rule
with comment period (70 FR 70153). In
the CY 2010 PFS final rule with
comment period, we implemented the
second review and update of
malpractice RVUs. For a discussion of
the second review and update of
malpractice RVUs see the CY 2010 PFS
proposed rule (74 FR 33537) and final
rule with comment period (74 FR
61758).
2. Malpractice RVUs for New and
Revised Services Effective Before the
Next 5-Year Review
Currently, malpractice RVUs for new
and revised codes effective before the
next 5-Year Review (for example,
effective CY 2011 through CY 2014) are
determined by a direct crosswalk to a
similar ‘‘source’’ code or a modified
crosswalk to account for differences in
work RVUs between the new/revised
code and the source code. For the
modified crosswalk approach, we adjust
the malpractice RVUs for the new/
revised code to reflect the difference in
work RVUs between the source code
and the AMA RUC’s recommended
work value (or the work value we are
applying as an interim final value under
the PFS) for the new code. For example,
if the interim final work RVUs for the
new/revised code are 10 percent higher
than the work RVUs for the source code,
the malpractice RVUs for the new/
revised code would be increased by 10
percent over the source code RVUs. This
approach presumes the same risk factor
for the new/revised code and source
code but uses the work RVUs for the
new/revised code to adjust for risk-ofservice. The assigned malpractice RVUs
for new/revised codes effective between
updates remain in place until the next
5-Year Review.
We will continue our current
approach for determining malpractice
RVUs for new/revised codes that
become effective before the next 5-Year
Review and update. Under this
approach we will crosswalk the new/
revised code to the RVUs of a similar
source code and adjust for differences in
work (or, if greater, the clinical labor
portion of the fully implemented PE
PO 00000
Frm 00026
Fmt 4701
Sfmt 4702
RVUs), between the source code and the
new/revised code. Additionally, we will
publish a list of new/revised codes and
the analytic crosswalk(s) used for
determining their malpractice RVUs in
the final rule with comment period,
which we have not previously done.
The CY 2011 malpractice RVUs for new/
revised codes will be implemented as
interim final values in the CY 2011 PFS
final rule with comment period, where
they will be subject to public comment.
They will then be finalized in the CY
2012 PFS final rule with comment
period.
3. Revised Malpractice RVUs for
Selected Disc Arthroplasty Services
As discussed in the CY 2010 PFS
proposed rule (74 FR 33539), we assign
malpractice RVUs to each service based
upon a weighted average of the risk
factors of all specialties that furnish the
service. For the CY 2010 review of
malpractice RVUs, we used CY 2008
Medicare payment data on allowed
services to establish the frequency of a
service by specialty. CPT code 22856
(Total disc arthroplasty (artificial disc),
anterior approach, including discectomy
with end plate preparation (includes
osteophytectomy for nerve root or spinal
cord decompression and
microdissection), single interspace,
cervical) had zero allowed services for
CY 2008. Therefore, our contractor
initially set the level of services to 1,
and assigned a risk factor according to
the average risk factor for all services
that do not explicitly have a separate
technical or professional component.
We proposed to adopt our contractor’s
initial malpractice RVUs for CPT code
22856 in the CY 2010 proposed rule.
Application of the average physician
risk factor would have resulted in a
significant decrease in malpractice
RVUs for CPT code 22856 in CY 2010.
Several commenters on the CY 2010
PFS proposed rule expressed concern
regarding the proposed malpractice
RVUs for CPT code 22856, which
represented a proposed reduction of
more than 77 percent. The commenters
stated that this service is predominantly
furnished by neurosurgeons and
orthopedic surgeons. Given the high risk
factors associated with these specialty
types and the changes in malpractice
RVUs for comparable services, the
commenters stated that a reduction in
the malpractice RVUs of this magnitude
for CPT code 22856 could not be
correct.
After consideration of the public
comments, for CY 2010, we set the risk
factor for CPT code 22856 as the
weighted average risk factor of six
comparable procedures mentioned by
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
the commenters: CPT code 22554
(Arthrodesis, anterior interbody
technique, including minimal
discectomy to prepare interspace (other
than for decompression); cervical below
C2); CPT code 22558 (Arthrodesis,
anterior interbody technique, including
minimal discectomy to prepare
interspace (other than for
decompression); lumbar); CPT code
22857 (Total disc arthroplasty (artificial
disc), anterior approach, including
discectomy to prepare interspace (other
than for decompression), single
interspace, lumbar); CPT code 22845
(Anterior instrumentation; 2 to 3
vertebral segments (list separately in
addition to code for primary
procedure)); CPT code 63075
(Discectomy, anterior, with
decompression of spinal cord and/or
nerve root(s), including
osteophytectomy; cervical, single
interspace); and CPT code 20931
(Allograft for spine surgery only;
structural (list separately in addition to
code for primary procedure)). The
weighted average risk factor for these
services is 8.4.
Since publication of the CY 2010 PFS
final rule with comment period,
stakeholders have mentioned that we
made significant changes to the
malpractice RVUs for CPT code 22856
in CY 2010. The commenters also
brought to our attention that other
services are clinically similar to CPT
code 22856 and have similar work
RVUs, and therefore, some stakeholders
believe these services should all have
similar malpractice RVUs. Services
mentioned by the stakeholders that are
clinically similar to CPT code 22856
include CPT code 22857; CPT code
22861 (Revision including replacement
of total disc arthroplasty (artificial disc),
anterior approach, single interspace;
cervical); CPT code 22862 (Revision
including replacement of total disc
arthroplasty (artificial disc) anterior
approach, lumbar); CPT code 22864
(Removal of total disc arthroplasty
(artificial disc), anterior approach,
single interspace; cervical); and CPT
code 22865 (Removal of total disc
arthroplasty (artificial disc), anterior
approach, single interspace; lumbar).
After further review of this issue, we
are proposing to apply the same risk
factor used for CPT code 22856 to
certain other services within this family
of services (CPT codes 22857 through
22865) for which there were no allowed
services in CY 2008. CPT codes 22861
and 22864 had zero allowed services in
CY 2008 and our contractor initially set
their malpractice RVUs in the same way
as it did for CPT code 22856. Therefore,
we will assign the weighted average risk
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
factor we use for CPT code 22856 (that
is, the weighted average of the risk
factors for CPT codes 20931, 22554,
22558, 22845, 22857, and 63075) to CPT
codes 22861 and 22864. However, CPT
codes 22857, 22862, and 22865 are low
volume services (allowed services under
100). Our policy for low volume
services is to apply the risk factor of the
dominant specialty as indicated by our
claims data. We will continue to apply
our policy for low volume services to
CPT codes 22857, 22862, and 22865.
C. Potentially Misvalued Services Under
the Physician Fee Schedule
1. Valuing Services Under the PFS
As discussed in section I. of this
proposed rule, in order to value services
under the PFS, section 1848(c) of the
Act requires the Secretary to determine
relative values for physicians’ services
based on three components: the work,
practice expense (PE), and malpractice
components. Section 1848(c)(1)(A) of
the Act defines the work component to
include ‘‘the portion of the resources
used in furnishing the service that
reflects physician time and intensity in
furnishing the service.’’ Additionally,
the statute provides that the work
component shall include activities that
occur before and after direct patient
contact. Furthermore, the statute
specifies that with respect to surgical
procedures, the valuation of the work
component for the code would reflect a
‘‘global’’ concept in which pre-operative
and post-operative physicians’ services
related to the procedure would also be
included.
In addition, section 1848(c)(2)(C)(i) of
the Act specifies that ‘‘the Secretary
shall determine a number of work
relative value units (RVUs) for the
service based on the relative resources
incorporating physician time and
intensity required in furnishing the
service.’’ As discussed in detail in
sections I.A.2. and I.A.3 of this
proposed rule, the statute also defines
the PE and malpractice components and
provides specific guidance in the
calculation of the RVUs for each of these
components. Section 1848(c)(1)(B) of
the Act defines the PE component as
‘‘the portion of the resources used in
furnishing the service that reflects the
general categories of expenses (such as
office rent and wages of personnel, but
excluding malpractice expenses)
comprising practice expenses.’’
Section 1848(c)(2)(C)(ii) of the Act
specifies that the ‘‘Secretary shall
determine a number of practice expense
relative value units for the services for
years beginning with 1999 based on the
relative practice expense resources
PO 00000
Frm 00027
Fmt 4701
Sfmt 4702
40065
involved in furnishing the service.’’
Furthermore, section 1848(c)(2)(B) of
the Act directs the Secretary to conduct
a periodic review, not less often than
every 5 years, of the RVUs established
under the PFS. Finally, on March 23,
2010, the Affordable Care Act was
enacted, further requiring the Secretary
to periodically review and identify
potentially misvalued codes and make
appropriate adjustments to the relative
values of those services identified as
being potentially misvalued. Section
3134(a) of the ACA added a new section
1848(c)(2)(K) of the Act which requires
the Secretary to periodically identify
potentially misvalued services using
certain criteria, and to review and make
appropriate adjustments to the relative
values for those services. Section
3134(a) of the ACA also added a new
section 1848(c)(2)(L) which requires the
Secretary to develop a validation
process to validate the RVUs of
potentially misvalued codes under the
PFS and make appropriate adjustments.
As discussed in section I.A.1. of this
proposed rule, we establish physician
work RVUs for new and revised codes
based on our review of
recommendations received from the
AMA RUC. The AMA RUC also
provides recommendations to CMS on
the values for codes that have been
identified as potentially misvalued. To
respond to concerns expressed by
MedPAC, the Congress, and other
stakeholders regarding accurate
valuation of services under the PFS, the
AMA RUC created the Five-Year Review
Identification Workgroup. In addition to
providing recommendations to CMS for
work RVUs, the AMA RUC’s Practice
Expense Subcommittee reviews direct
PE (clinical labor, medical supplies, and
medical equipment) for individual
services and examines the many broad
and methodological issues relating to
the development of PE RVUs.
In accordance with section 1848(c) of
the Act, we determine appropriate
adjustments to the RVUs, taking into
account the recommendations provided
by the AMA RUC and MedPAC, and
publish the explanation for the basis of
these adjustments in the PFS proposed
and final rules. We note that section
1848(c)(2)(A)(ii) of the Act authorizes
the use of extrapolation and other
techniques to determine the RVUs for
physicians’ services for which specific
data are not available, in addition to
taking into account the results of
consultations with organizations
representing physicians.
E:\FR\FM\13JYP2.SGM
13JYP2
40066
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2. Identifying, Reviewing, and
Validating the RVUs of Potentially
Misvalued Services Under the PFS
a. Background
In its March 2006 Report to Congress,
MedPAC noted that ‘‘misvalued services
can distort the price signals for
physicians’ services as well as for other
health care services that physicians
order, such as hospital services.’’ In that
same report MedPAC postulated that
physicians’ services under the PFS can
become misvalued over time for a
number of reasons: ‘‘For example, when
a new service is added to the physician
fee schedule, it may be assigned a
relatively high value because of the
time, technical skill, and psychological
stress that are required to perform it.
Over time, skill, and stress involved
may decline as physicians become more
familiar with the service and more
efficient at providing it. The amount of
physician work needed to furnish an
existing service may decrease when new
technologies are incorporated. Services
can also become overvalued when
practice expenses decline. This can
happen when the costs of equipment
and supplies fall, or when equipment is
used more frequently, reducing its cost
per use. Likewise, services can become
undervalued when physician work
increases or practice expenses rise.’’ In
the ensuing years since MedPAC’s 2006
report, additional groups of potentially
misvalued services have been identified
by Congress, CMS, MedPAC, the AMA
RUC, and other stakeholders.
In recent years CMS and the AMA
RUC have taken increasingly significant
steps to address potentially misvalued
codes. As MedPAC noted in its March
2009 Report to Congress, in the
intervening years since MedPAC made
the initial recommendations, ‘‘CMS and
the AMA RUC have taken several steps
to improve the review process.’’ Most
recently, section 1848(c)(2)(K)(ii) of the
Act (as added by section 3134 of the
ACA) directed the Secretary to
specifically examine potentially
misvalued services in seven categories.
(1) Codes and families of codes for
which there has been the fastest growth.
(2) Codes or families of codes that
have experienced substantial changes in
practice expenses.
(3) Codes that are recently established
for new technologies or services.
(4) Multiple codes that are frequently
billed in conjunction with furnishing a
single service.
(5) Codes with low relative values,
particularly those that are often billed
multiple times for a single treatment.
(6) Codes which have not been subject
to review since the implementation of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
the RBRVS (the so-called ‘Harvardvalued codes’).
(7) Other codes determined to be
appropriate by the Secretary.
Section 1848(c)(2)(K)(iii) of the Act
(as added by section 3134 of the ACA)
also specifies that the Secretary may use
existing processes to receive
recommendations on the review and
appropriate adjustment of potentially
misvalued services. In addition, the
Secretary may conduct surveys, other
data collection activities, studies, or
other analyses as the Secretary
determines to be appropriate to facilitate
the review and appropriate adjustment
of potentially misvalued services. This
section authorizes the use of analytic
contractors to identify and analyze
potentially misvalued codes, conduct
surveys or collect data, and make
recommendations on the review and
appropriate adjustment of potentially
misvalued services. Finally, section
1848(c)(2)(K)(iii)(V) of the Act (as added
by section 3134 of the ACA) specifies
that the Secretary may make appropriate
coding revisions (including using
existing processes for consideration of
coding changes) which may include
consolidation of individual services into
bundled codes for payment under the
physician fee schedule.
b. Progress in Identifying and Reviewing
Potentially Misvalued Codes
Over the last several years, CMS, in
conjunction with the AMA RUC, has
identified and reviewed numerous
potentially misvalued codes in all seven
of the categories specified in section
1848(c)(2)(K)(ii) (as added by section
3134 of the ACA), and we plan to
continue our work examining
potentially misvalued codes in these
areas over the upcoming years,
consistent with the new legislative
mandate on this issue. In the current
process, the AMA RUC reviews
potentially misvalued codes that are
identified either by CMS or through its
own processes and recommends revised
work RVUs and/or direct PE inputs for
those codes to CMS. CMS then assesses
the recommended revised work RVUs
and/or direct PE inputs and, in
accordance with section 1848(c) of the
Act, we determine if the
recommendations constitute appropriate
adjustments to the RVUs under the PFS.
Since CY 2009, CMS and the AMA RUC
have identified over 700 potentially
misvalued codes.
For example, in regards to the first
category (codes and families of codes for
which there has been the fastest
growth), for CY 2009 CMS identified
over 100 potentially misvalued codes
for which an analysis of the utilization
PO 00000
Frm 00028
Fmt 4701
Sfmt 4702
data showed an annual growth in
allowed services of 10 percent (or more)
for 3 consecutive years (73 FR 38586).
Each of these codes had allowed charges
of $1 million or more in CY 2007. We
published this list in the CY 2009
proposed rule (73 FR 38586 through
38589) and requested that the AMA
RUC immediately begin a review of the
codes on this list. Meanwhile, in
parallel with CMS’ efforts, the AMA
RUC also initiated processes to identify
and review potentially misvalued codes
on an ongoing basis using certain
screens, including screens for ‘‘CMS
fastest growing procedures’’ and ‘‘high
volume growth.’’ Both of these AMA
RUC screens are applicable to the first
category of potentially misvalued codes
specified in ACA. We plan to continue
to analyze Medicare claims data over
future years to identify additional
services that exhibit rapid growth and
high Medicare expenditures for referral
to the AMA RUC for review as
potentially misvalued codes.
Pertaining to the second category
specified in section 1848(c)(2)(K)(ii) of
the Act (as added by section 3134 of
ACA) (codes or families of codes that
have experienced substantial changes in
practice expenses), in CY 2009 we
requested that the AMA RUC continue
its review of direct PE inputs, focusing
particularly on high-volume codes
where the PE payments are increasing
significantly under the transition to the
new PE methodology (73 FR 38589).
The AMA RUC has responded by
sending CMS recommendations for
revised direct PE inputs for codes
identified for PE review on an ongoing
basis.
Additionally in CY 2009, we began an
initiative to review and update the
prices for high-cost supplies in order to
ensure the accuracy and completeness
of the direct PE inputs. We discuss our
most recent efforts in refining the
process to update the prices of high-cost
supplies in section II.C.5. of this
proposed rule.
For the third category of potentially
misvalued codes identified in section
1848(c)(2)(K)(ii) (as added by section
3134 of the ACA) (codes that are
recently established for new
technologies or services), the AMA RUC
routinely identifies such codes through
a screen based on 3 years of Medicare
claims data, and sends CMS
recommendations for revised work
RVUs and/or direct PE inputs for these
codes on an ongoing basis. The AMA
RUC may determine that a code for a
new service requires reevaluation or
does not require reevaluation, or it may
conclude, on a case-by-case basis, that
more than 3 years of claims data are
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
necessary before the code can be
reviewed. In that case, it would
determine the appropriate future
timeframe for review.
We also note that in its June 2008
Report to Congress entitled ‘‘Reforming
the Health Care System’’ and in the
context of a discussion about primary
care, MedPAC acknowledges, ‘‘* * *
Efficiency can improve more easily for
other types of services, such as
procedures, with advances in
technology, technique, and other
factors. Ideally, when such efficiency
gains are achieved, the fee schedule’s
relative value units (RVUs) for the
affected services should decline
accordingly, while budget neutrality
would raise the RVUs for the fee
schedule’s primary care services.’’ (page
27). Section III.C.5. of this proposed rule
includes a discussion regarding periodic
updates to the costs of high cost
supplies. This discussion is highly
relevant to new technology services,
where growth in volume of a service as
it diffuses into clinical practice may
lead to a decrease in the cost of
expensive supplies. We also expect that
other efficiencies in physician work and
PE may be achieved after an initial
period of relative inefficiency that
reflects the ‘‘learning curve.’’ We plan to
pay particular attention to the work
values and direct PE inputs for these
new services and the AMA RUC’s
periodic review process to ensure that
any efficiencies are captured under the
PFS over time, recognizing that the
appropriate timing for revaluing these
services needs to be considered on a
case-by-case basis depending on the
growth rate in service volume.
We have also addressed the fourth
category (multiple codes that are
frequently billed in conjunction with
furnishing a single service) in
rulemaking prior to the enactment of the
ACA. As discussed in the CY 2009 PFS
proposed rule (73 FR 38586), we have
a longstanding policy of reducing
payment for multiple surgical
procedures performed on the same
patient, by the same physician, on the
same day. Over the ensuing years, the
multiple procedure payment reduction
(MPPR) policy has been extended to a
number of nuclear diagnostic and
diagnostic imaging procedures. We
continue our work to recognize
efficiencies in this area with a proposal
to expand the MPPR policy to
additional combinations of imaging
services and to therapy services for CY
2011 as described in section II.C.4. of
this proposed rule.
We note the AMA RUC has also
established a screen to identify services
performed by the same physician on the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
same date of service 95 percent of the
time or more. Over the past 2 years, the
CPT Editorial Panel has established new
bundled codes to describe a
comprehensive service for certain
combinations of these existing services
that are commonly furnished together,
and the AMA RUC has recommended
work values and direct PE inputs to
CMS for these comprehensive service
codes that recognize the associated
efficiencies. CMS looks forward to
working with the AMA RUC in this joint
effort to examine codes commonly
reported together and more
appropriately value common
combinations services.
We address the fifth category of
potentially misvalued codes (codes with
low relative values, particularly those
that are often billed multiple times for
a single treatment) in section II.C.3.b. of
this proposed rule. That is, we are
providing a list of services with low
work RVUs that are commonly reported
with multiple units in a single
encounter and requesting that the AMA
RUC review these codes that we have
identified as potentially misvalued.
The sixth category (codes which have
not been subject to review since the
implementation of the RBRVS (the socalled ‘Harvard-valued codes’)) also
continues to be addressed by CMS and
the AMA RUC on an ongoing basis. As
we noted in the CY 2009 PFS proposed
rule (73 FR 38589), there were at that
time approximately 2900 codes,
representing $5 billion in annual
spending, that were originally valued
using Harvard data and have not
subsequently been evaluated by the
AMA RUC. Consequently, in CY 2009,
we requested that the AMA RUC engage
in an ongoing effort to review the
remaining Harvard-valued codes,
focusing first on the high-volume, low
intensity codes (73 FR 38589). In
response to our request, the AMA RUC
initially conducted an analysis of
Harvard-valued services with utilization
above 10,000 services per year, which
resulted in a list of 296 distinct services
(73 FR 69883). The AMA RUC, in its
public comment on the CY 2009
proposed rule, stated that it believes it
would be effective to limit any review
to these 296 services and also noted that
of the 296 services identified, 23 had
already been identified by another
screen and were in the process of being
reviewed (73 FR 69883). To date, the
AMA RUC has reviewed and submitted
to CMS recommendations for revised
work RVUs and/or direct PE inputs for
a number of Harvard-valued codes,
prioritizing those codes with utilization
of over 1 million services. The AMA
RUC and CMS intend to continue our
PO 00000
Frm 00029
Fmt 4701
Sfmt 4702
40067
ongoing assessment of Harvard-valued
codes, next targeting codes with
utilization of over 100,000 services.
Finally, the seventh category of
potentially misvalued codes mentioned
in section 1848(c)(2)(K)(ii) (as added by
section 3134 of the ACA) is all other
codes determined to be appropriate by
the Secretary. In this category, CMS has
previously proposed policies and
requested that the AMA RUC review
codes for which there have been shifts
in the site-of-service (site-of-service
anomalies), as well as codes that qualify
as ‘‘23-hour stay’’ outpatient services.
The policies for valuation of both the
site-of-service anomaly codes and the
‘‘23-hour stay’’ codes are developed
further in sections II.C.3.d. and e.,
respectively, of this proposed rule. For
CY 2011, we are also identifying codes
with low work RVUs but are high
volume based on claims data as another
category of potentially misvalued codes
and are referring these codes to the
AMA RUC for review, as discussed in
section II.C.3.b. of this proposed rule. In
addition, for CY 2011 we are newly
targeting key codes that the AMA RUC
uses as reference services for valuing
other services, termed ‘‘multispecialty
points of comparison’’ services, and
referring these to the AMA RUC for
review as potentially misvalued codes
as described in section II.C.3.a. of this
proposed rule. Finally, we note the
AMA RUC has also established screens
to identify potentially misvalued codes
in additional categories, including codes
with a high intra-service work per unit
of time (IWPUT) and codes representing
services that had been surveyed by one
specialty, but are now performed by a
different specialty. We will continue to
review AMA RUC recommendations for
revised work RVUs and/or direct PE
inputs for codes that fall into these
categories.
As a result of the combined efforts of
CMS and the AMA RUC to address
potentially misvalued codes, for CY
2009 the AMA RUC recommended
revised work values and/or PE inputs
for 204 misvalued services (73 FR
69883). For CY 2010, an additional 113
codes were identified as misvalued and
the AMA RUC provided new
recommendations for revised work
RVUs and/or PE inputs to CMS as
discussed in the CY 2010 PFS final rule
with comment period (74 FR 61778).
Upon review of the AMA RUCrecommended work RVUs, CMS
accepted the majority of the values as
appropriate adjustments to the RVUs
under the PFS, in accordance with
section 1848(c) of the Act. However, for
a number of codes, mainly the site-ofservice anomaly codes, we indicated
E:\FR\FM\13JYP2.SGM
13JYP2
40068
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
that although we would accept the AMA
RUC valuations for these site-of-service
anomaly codes on an interim basis
through CY 2010, we had ongoing
concerns about the methodology used
by the AMA RUC to review these
services (73 FR 69883 and 74 FR 61776
through 61778, respectively). In the CY
2010 PFS final rule with comment
period, we requested that the AMA RUC
reexamine the site-of-service anomaly
codes and use the building block
methodology to revalue the services (74
FR 61777). In that same rule, we also
stated that we would continue to
examine these codes and consider
whether it would be appropriate to
propose additional changes in future
rulemaking. We discuss our CY 2011
proposal with respect to these codes in
section II.C.3.d. of this proposed rule.
c. Validating RVUs of Potentially
Misvalued Codes
In addition to identifying and
reviewing potentially misvalued codes,
section 1848(c)(2)(L) (as added by
section 3134 of the ACA) specifies that
the Secretary shall establish a formal
process to validate relative value units
under the PFS. The validation process
may include validation of work
elements (such as time, mental effort
and professional judgment, technical
skill and physical effort, and stress due
to risk) involved with furnishing a
service and may include validation of
the pre, post, and intra-service
components of work. The Secretary is
directed to validate a sampling of the
work RVUs of codes identified through
any of the seven categories of
potentially misvalued codes specified
by section 1848(c)(2)(K)(ii) (as added by
section 3134 of the ACA). Furthermore,
the Secretary may conduct the
validation using methods similar to
those used to review potentially
misvalued codes, including conducting
surveys, other data collection activities,
studies, or other analyses as the
Secretary determines to be appropriate
to facilitate the validation of RVUs of
services. Currently, while CMS does
assess the AMA RUC- recommended
work RVUs to determine if the
recommendations constitute appropriate
adjustments to the RVUs under the PFS,
we intend to establish a more extensive
validation process of RVUs in the future
in accordance with the requirements of
section 1848(c)(2)(L) (as added by
section 3134 of the ACA). Therefore, we
are soliciting public comments on this
proposed rule on possible approaches
and methodologies that we should
consider for a validation process. We are
especially interested in public
comments regarding approaches,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
including the use of time and motion
studies, to validate estimates of
physician time and intensity that are
factored into the work RVUs for services
with rapid growth in Medicare
expenditures, one of the categories that
the statute specifically directs CMS to
examine. We plan to discuss the
validation process in a future PFS rule
once we have considered the matter
further in conjunction with any public
comments and other input from
stakeholders that we receive.
3. CY 2011 Identification and Review of
Potentially Misvalued Services
In this section, we discuss codes that
may be misvalued according to five
different criteria:
• Codes on the multi-specialty points
of comparison list;
• Codes with low work RVUs
commonly billed in multiple units per
single encounter;
• Codes with high volume and low
work RVUs;
• Codes with site-of-service
anomalies; and
• Codes that qualify as ‘‘23-hour stay’’
outpatient services.
a. Codes on the Multispecialty Points of
Comparison List
The AMA RUC uses a scale referred
to as the multispecialty points of
comparison (MPC) to evaluate the
reasonableness of a specialty society’s
recommended RVU value for a service.
The MPC list contains reference codes
of established comparison services that
are used in the valuation of new codes.
The current MPC list consists of 316
codes which the AMA RUC may use to
compare and contrast the relativity of
codes under review to existing relative
values. Since the AMA RUC may use
the values on the MPC list as a basis for
relativity when determining the values
for new, revised, and newly reviewed
codes (including potentially misvalued
codes), it is essential that the services on
the MPC list be appropriately valued
since any codes misvalued on the MPC
list could contribute to the misvaluing
of other codes under review. While we
believe that the entire MPC list should
be assessed to ensure that services are
paid appropriately under the PFS, we
have prioritized the review of the MPC
list, ranking the codes by allowed
service units and charges based on CY
2009 claims data. We are proposing to
refer the codes in Table 9 to the AMA
RUC for review.
PO 00000
Frm 00030
Fmt 4701
Sfmt 4702
TABLE 9—CODES ON THE MPC LIST
REFERRED FOR AMA RUC REVIEW
CPT Code
66984
97110
43239
20610
78815
45385
45380
11721
17000
92980
74160
71020
11100
66821
52000
92083
73721
93010
77334
92250
95810
77003
11056
76700
77290
77300
43235
71275
95900
31231
95165
94060
31575
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
Short descriptor
Cataract surg w/iol, 1 stage.
Therapeutic exercises.
Upper GI endoscopy, biopsy.
Drain/inject, joint/bursa.
Pet image w/ct, skull-thigh.
Lesion removal colonoscopy.
Colonoscopy and biopsy.
Debride nail, 6 or more.
Destruct premalg lesion.
Insert intracoronary stent.
Ct abdomen w/dye.
Chest x-ray.
Biopsy, skin lesion.
After cataract laser surgery.
Cystoscopy.
Visual field examination(s).
Mri jnt of lwr extre w/o dye.
Electrocardiogram report.
Radiation treatment aid(s).
Eye exam with photos.
Polysomnography, 4 or more.
Fluoroguide for spine inject.
Trim skin lesions, 2 to 4.
Us exam, abdom, complete.
Set radiation therapy field.
Radiation therapy dose plan.
Uppr gi endoscopy, diagnosis.
Ct angiography, chest.
Motor nerve conduction test.
Nasal endoscopy, dx.
Antigen therapy services.
Evaluation of wheezing.
Diagnostic laryngoscopy.
b. Codes With Low Work RVUs
Commonly Billed in Multiple Units per
Single Encounter
Consistent with section
1848(c)(2)(K)(ii) (as added by section
3134 of the ACA) which identifies
categories of potentially misvalued
codes for our review, we believe
services with low work RVUs that are
commonly billed with multiple units in
a single encounter are an additional
appropriate category for identifying
potentially misvalued codes. An
example of a high multiple/low work
RVU service is CPT code 95004
(Percutaneous tests (scratch, puncture,
prick) with allergenic extracts,
immediate type reaction, including test
interpretation and report by a physician,
specify number of tests). For purposes of
compiling a list of the high multiple/
low work RVU services, we defined a
high multiple service as one that is
commonly performed in multiples of 5
or more per day. Then, we selected from
high multiple services with work RVUs
of less than or equal to 0.5 RVUs. We
note that in selecting 5 per day as the
minimum threshold for the number of
common services performed in a
multiple service encounter, we intended
to establish a meaningful threshold
which, in conjunction with the
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
threshold for work RVUs of 0.5 RVUs or
less, would produce a reasonable
number of services for the RUC to
review that have substantial total work
RVUs for the comprehensive service
furnished during a single treatment.
That is, as a general example, with a
work RVU threshold of 0.5 RVUs and a
multiple threshold of 5 per day, the total
work RVUs for a typical treatment
would equate to 2.5 RVUs, which is
approximately comparable to a high
level office visit, an interpretation of a
complex imaging procedure, or a minor
surgical procedure.
We are asking the AMA RUC to
review the codes in Table 10.
TABLE 10—CODES WITH LOW WORK
RVUS THAT ARE COMMONLY BILLED
IN MULTIPLE UNITS REFERRED FOR
AMA RUC REVIEW
CPT Code
95904
17003
95004
11101
95024
76000
95144
95010
88300
95027
95015
95148
......
......
......
......
......
......
......
......
......
......
......
......
Short descriptor
Sense nerve conduction test.
Destruct premalg les, 2–14.
Percut allergy skin tests.
Biopsy, skin add-on.
Id allergy test, drug/bug.
Fluoroscope examination.
Antigen therapy services.
Percut allergy titrate test.
Surgical path, gross.
Id allergy titrate-airborne.
Id allergy titrate-drug/bug.
Antigen therapy services.
c. Codes With High Volume and Low
Work RVUs
We believe that codes that have low
work RVUs but are high volume based
on claims data are another category of
potentially misvalued codes. Although
these codes have low work RVUs (less
than or equal to 0.25 RVUs), the high
utilization of these codes represents
significant expenditures under the PFS
such that their appropriate valuation is
especially important. Table 11 contains
a list of such codes and we are
requesting that the AMA RUC review
these codes.
TABLE 11—CODES WITH LOW WORK
RVUS THAT ARE HIGH VOLUME REFERRED FOR AMA RUC REVIEW
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
CPT Code
71010
73510
97035
88313
73630
72100
73030
73562
73560
94010
......
......
......
......
......
......
......
......
......
......
VerDate Mar<15>2010
Short descriptor
Chest x-ray.
X-ray exam of hip.
Ultrasound therapy.
Special stains group 2.
X-ray exam of foot.
X-ray exam of lower spine.
X-ray exam of shoulder.
X-ray exam of knee, 3.
X-ray exam of knee, 1 or 2.
Breathing capacity test.
20:23 Jul 12, 2010
Jkt 220001
40069
code) are warranted in the revaluation
of the code, we asked the AMA RUC to
adjust the site-of-service anomaly code
for the work RVUs associated with those
changes.
Additionally, we suggested that in
CPT Code
Short descriptor
cases where the AMA RUC has adjusted
77052 ...... Comp screen mammogram add- the pre-service, intra-service and poston.
service times of the code under review,
88304 ...... Tissue exam by pathologist.
the AMA RUC should also make
73564 ...... X-ray exam, knee, 4 or more.
associated work RVU adjustments to
72170 ...... X-ray exam of pelvis.
account for those changes. However, we
74000 ...... X-ray exam of abdomen.
remain concerned that in the AMA
73610 ...... X-ray exam of ankle.
RUC’s recommendations of the work
11719 ...... Trim nail(s).
RVUs for the CYs 2009 and 2010 site73620 ...... X-ray exam of foot.
of-service anomaly codes, the AMA
92567 ...... Tympanometry.
73110 ...... X-ray exam of wrist.
RUC may have determined that
73130 ...... X-ray exam of hand.
eliminating or reallocating pre-service
93701 ...... Bioimpedance, cv analysis.
and post-service times, hospital days,
72040 ...... X-ray exam of neck, spine.
office visits, and hospital discharge day
92543 ...... Caloric vestibular test
management services was appropriate to
reflect the typical case that is now
d. Codes With Site-of-Service
occurring in a different setting, but the
Anomalies
work RVUs associated with those
changes may not have been
In previous years, we requested that
systematically extracted or reallocated
the AMA RUC review codes that,
from the total work RVU value for the
according to the Medicare claims
service.
database, have experienced a change in
In the CYs 2009 and 2010 PFS final
the typical site of service since the
rules with comment period (73 FR
original valuation of the code. For
69883 and 74 FR 61776 through 61778,
example, we have found services that
respectively), we indicated that
originally were provided in the
although we would accept the AMA
inpatient setting but for which current
RUC valuations for these site-of-service
claims data show the typical case has
anomaly codes on an interim basis
shifted to being furnished outside the
through CY 2010, we had ongoing
inpatient setting. Since the procedures
concerns about the methodology used
were typically performed in the
by the AMA RUC to review these
inpatient setting when the codes were
services. We requested that the RUC
originally valued, the work RVUs for
reexamine the site-of-service anomaly
these codes would have been valued to
codes and use the building block
include the inpatient physician work
methodology to revalue the services (74
provided, as well as to reflect the
FR 61777). We also stated that we
intensive care and follow-up normally
would continue to examine these codes
associated with an inpatient procedure.
and consider whether it would be
If the typical case for the procedure has
appropriate to propose additional
shifted from the inpatient setting to an
changes in future rulemaking.
outpatient or physician’s office setting,
Accordingly, in preparation for CY
it is reasonable to expect that there have
2011 rulemaking, we conducted a
been changes in medical practice, and
comprehensive analysis of the codes
that such changes would represent a
that the AMA RUC reviewed for CYs
decrease in physician time or intensity
2009 and 2010 due to site-of-service
or both. The AMA RUC reviewed and
anomaly concerns. We systematically
recommended to CMS revised work
applied the reverse building block
RVUs for 29 codes for CY 2009 and 11
methodology to the 29 codes from CY
codes for CY 2010 that were identified
2009 and 11 codes from CY 2010 as
as having site-of-service anomalies.
follows:
In the CY 2010 PFS proposed and
• First, we obtained the original work
final rules with comment period (74 FR
RVU value assigned to the code (this is
33556 and 74 FR 61777, respectively),
the ‘‘starting value’’) and made a list of
we encouraged the AMA RUC to utilize
the building block services with RVUs
the building block methodology when
that were originally associated with the
revaluing services with site-of-service
anomalies. Specifically, where the AMA code (that is, before the AMA RUC
reviewed the code for site-of-service
RUC has determined in its review that
anomalies).
changes in the inclusion of inpatient
hospital days, office visits, and hospital
• Next, we examined the AMA RUCdischarge day management services
recommended changes to the building
(that is, the ‘‘building blocks’’ of the
blocks of the code.
TABLE 11—CODES WITH LOW WORK
RVUS THAT ARE HIGH VOLUME REFERRED FOR AMA RUC REVIEW—
Continued
PO 00000
Frm 00031
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40070
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• We then deducted the RVUs
associated with the AMA RUC’s
recommended eliminations from the
code’s starting RVU value.
Generally, the AMA RUC eliminated
inpatient hospital visit building blocks
from the value of the code since the siteof-service for the code has shifted from
the inpatient setting to another setting.
We note in some cases, the AMA RUC
left an inpatient hospital visit in the
valuation of the code. We believe this is
inconsistent with the change in the site
of service to non-inpatient settings.
Accordingly, we adhered to the
methodology and deducted the RVUs
associated with all inpatient hospital
visits from the starting value. In cases
where the AMA RUC recommended
adding or substituting outpatient visits,
we also added or substituted the RVUs
associated with those changes to the
starting value. If the AMA RUC
recommended changes to the pre-,
intra-, or post-service times, we
calculated the incremental change in
RVUs associated with that time and
either added or deducted that RVU
amount from the starting value. We note
that the RVU values associated with the
incremental time change are calculated
using the intensity associated with the
particular pre-, intra-, or post period.
For the intensity of the intra-service
period, we utilized the original IWPUT
associated with the code. The AMA
RUC generally recommended allowing
only half of a hospital discharge day
management service for the site-ofservice anomaly codes. That is, CPT
code 99238 (Hospital discharge day
management; 30 minutes or less) has a
work RVU value of 1.28; therefore, half
the value associated with CPT code
99238 is 0.64. Accordingly, if a code
had one CPT code 99238 listed as part
of the original valuation, we deducted
0.64 RVUs from the starting value.
We standardized the methodology so
that each of the site-of-service anomaly
codes has half of a hospital discharge
day management service value
accounted in the valuation. Finally, we
note that while we eliminated the RVUs
associated with all inpatient hospital
visits built into the code’s starting value,
because the typical case no longer
occurs in the inpatient setting, we
allowed for the possibility that in some
cases, some part of the work which had
been performed in the inpatient setting
may continue to be provided even in the
outpatient setting. Therefore, to be
conservative in our deductions of work
RVUs associated with the inpatient
hospital codes from the starting values,
we allowed the intra-time of any
inpatient hospital visits included in the
original valuation to migrate to the postservice period of the code. Accordingly,
while we deducted the full RVUs of an
inpatient hospital visit from the starting
value, we added the intra-service time
of the inpatient hospital visit to the
post-service time of the code and
accounted for the incremental change in
RVUs. The following description
provides an example of our
methodology.
CPT code 21025 (Excision of bone
(e.g., for osteomyelitis or bone abscess);
mandible) has a starting value of 11.07
RVUs. Table 12 shows the building
blocks that are included in the original
valuation of the code.
TABLE 12
Pre-service
time
Median intraservice time
Immediate
post-service
time
75 min ............
120 min .........
43 min ...........
99231
1 visit (0.76
RVUs).
The AMA RUC removed two inpatient
hospital visits and reduced the
outpatient visits from 6 to 4 visits. Table
99232
99238
1 visit (1.39
RVUs).
99211
99213
2 visits (0.36
RVUs).
1 visit (1.28
RVUs).
99212
2 visits (0.96
RVUs).
2 visits (1.94
RVUs).
13 shows the building blocks that were
recommended for CY 2009 by the AMA
Original
IWPUT
0.0145
RUC after its review of the code for siteof-service anomalies.
TABLE 13
Pre-service
time
Median intraservice time
Immediate
post-service
time
99231
99232
99238
99211
99212
99213
85 min ............
90 min ...........
30 min ...........
.......................
.......................
.......................
.......................
2 visits ...........
2 visits ...........
Next we calculated the RVUs
associated with the changes to the
building blocks recommended by the
AMA RUC. We note that the immediate
post-service value of 0.38 RVUs (Table
14) includes 30 minutes of intra-service
time from inpatient hospital CPT code
99231 (Level 1 subsequent hospital care,
per day). Also, the median intra-service
value of 0.44 RVUs (Table 14) was
determined using the starting IWPUT
value of 0.0145. Additionally, our
methodology accounted for a half of a
hospital discharge day management
Revised
IWPUT
0.0530
service (CPT code 99238) for the site-ofservice anomaly code. Table 14 shows
the RVU changes to the building blocks
that were calculated based on the
methodology discussed above.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
TABLE 14
Pre-service
time
Median intraservice time
Immediate
post-service
time
99231
99232
99238
99211
0.22 RVUs ....
¥0.44 RVUs
0.38 RVUs ...
¥0.76 RVUs
¥1.39 RVUs
¥0.64 RVUs
¥0.36 RVUs.
In the final step, the RVUs associated
with the changes to the building blocks
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
recommended by the AMA RUC (Table
14) were deducted from or added to the
PO 00000
Frm 00032
Fmt 4701
Sfmt 4702
99212
99213
starting value of 11.07 RVUs, which
resulted in the CY 2011 reverse building
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
block value of 8.08 RVUs
(11.07+0.22¥0.44+0.38¥0.76¥1.39
¥0.64¥0.36=8.08)
.
The methodology discussed above
was applied to each of the site-of-service
40071
anomaly codes from CYs 2009 and 2010
and the results are summarized in
Tables 15 and 16.
TABLE 15—CY 2009 SITE-OF-SERVICE ANOMALY CODES 1
CPT code
21025
23415
25116
42440
52341
52342
52343
52344
52345
52346
52400
52500
52640
53445
54410
54530
57287
62263
62350
62355
62360
62361
62362
62365
63650
63685
64708
64831
65285
CY 2008
RVUs
(‘‘starting
value’’)
Short descriptor
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
Excision of bone, lower jaw ..............................................................
Release of shoulder ligament ...........................................................
Remove wrist/forearm lesion ............................................................
Excise submaxillary gland ................................................................
Cysto w/ureter stricture tx .................................................................
Cysto w/up stricture tx ......................................................................
Cysto w/renal stricture tx ..................................................................
Cysto/uretero, stricture tx .................................................................
Cysto/uretero w/up stricture ..............................................................
Cystouretero w/renal strict ................................................................
Cystouretero w/congen repr .............................................................
Revision of bladder neck ..................................................................
Relieve bladder contracture ..............................................................
Insert uro/ves nck sphincter .............................................................
Remove/replace penis prosth ...........................................................
Removal of testis ..............................................................................
Revise/remove sling repair ...............................................................
Epidural lysis mult sessions .............................................................
Implant spinal canal cath ..................................................................
Remove spinal canal catheter ..........................................................
Insert spine infusion device ..............................................................
Implant spine infusion pump .............................................................
Implant spine infusion pump .............................................................
Remove spine infusion device ..........................................................
Implant neuroelectrodes ...................................................................
Insrt/redo spine n generator .............................................................
Revise arm/leg nerve ........................................................................
Repair of digit nerve .........................................................................
Repair of eye wound ........................................................................
RUC
Recommended
value for
CY 2009
11.07
10.09
7.38
7.05
6.11
6.61
7.31
7.81
8.31
9.34
10.06
9.39
6.89
15.21
16.48
9.31
11.49
6.41
8.04
6.60
3.68
6.59
8.58
6.57
7.57
7.87
6.22
10.23
14.43
9.87
9.07
7.38
7.05
5.35
5.85
6.55
7.05
7.55
8.58
8.66
7.99
4.73
15.21
15.00
8.35
10.97
6.41
6.00
4.35
4.28
5.60
6.05
4.60
7.15
6.00
6.22
9.00
14.43
CY 2011
Reverse building
block value
8.09
10.63
7.21
6.52
5.62
6.20
5.90
5.58
5.76
6.05
7.00
8.72
5.01
11.72
14.00
8.88
10.20
6.99
0.41
-0.43
-3.14
-0.92
-0.51
-0.35
4.25
4.80
6.17
8.87
13.52
1 We note that in this table, we have not adjusted the RVUs for these codes for the RVU changes to the evaluation and management codes
that resulted from the CY 2010 elimination of the consultation codes (74 FR 61775). However, we note that we may, if appropriate, adjust the
RVUs for services with global periods to account for relevant changes in the RVUs for evaluation and management services as necessary.
TABLE 16—CY 2010 SITE-OF-SERVICE ANOMALY CODES 2
CPT code
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
28120
28122
28725
28730
36825
42415
42420
49507
49521
49587
61885
CY 2009
RVUs
(‘‘starting
value’’)
Short descriptor
................
................
................
................
................
................
................
................
................
................
................
Part removal of ankle/heel ................................................................
Partial removal of foot bone .............................................................
Fusion of foot bones .........................................................................
Fusion of foot bones .........................................................................
Artery-vein autograft .........................................................................
Excise parotid gland/lesion ...............................................................
Excise parotid gland/lesion ...............................................................
Prp i/hern init block >5 yr .................................................................
Rerepairing hernia, blocked ..............................................................
Rpr umbil hern, block > 5 yr .............................................................
Insrt/redo neurostim 1 array .............................................................
RUC
Recommended
value for
CY 2010
5.64
7.56
11.97
12.21
10.00
17.99
20.87
9.97
12.36
7.96
7.37
8.08
7.56
11.97
12.21
15
17.99
20.87
9.97
12.36
7.96
7.57
CY 2011
Reverse building
block value
6.03
6.79
12.41
10.06
13.12
15.17
17.80
9.37
11.59
7.19
3.22
2 We note that in this table, we have not adjusted the RVUs for these codes for the RVU changes to the evaluation and management codes
that resulted from the CY 2010 elimination of the consultation codes (74 FR 61775). However, we note that we may, if appropriate, adjust the
RVUs for services with global periods to account for relevant changes in the RVUs for evaluation and management services as necessary.
For most codes in Tables 15 and 16,
the CY 2011 reverse building block
methodology produced a value that is
somewhat lower than the AMA RUCrecommended value. While our results
suggest that the majority of the codes
VerDate Mar<15>2010
22:46 Jul 12, 2010
Jkt 220001
with site-of-service anomalies continue
to be overvalued under the AMA RUC’s
most recent recommendations, we also
found that the methodology may
produce a result that is considerably
reduced or, in several cases, a negative
PO 00000
Frm 00033
Fmt 4701
Sfmt 4702
value. We understand that in previous
years, stakeholders have expressed
confusion as to why the application of
a building block methodology would
produce negative values. We believe in
some cases, the starting value, that is,
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40072
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
the original work RVU, may have been
misvalued using building block inputs
that were not consistent with the
service, although the overall work value
of the code may have been consistent
with the values for other similar
services. Moreover, a number of these
services are the Harvard-valued codes,
for which the RVUs were established
many years ago based on historical
inputs that may no longer be
appropriate for the code. An attempt to
extract the RVUs associated with these
inappropriate inputs through the reverse
building block methodology could
produce aberrant results. Furthermore,
in some cases, we noticed that the
original IWPUT of the code was
negative even before the code was
reviewed by the AMA RUC for a site-ofservice anomaly. A negative value for
the IWPUT is counterintuitive to the
IWPUT concept, indicating that the
code was originally misvalued at the
building block level. At a minimum, we
believe that in cases where the reverse
building block methodology produces
aberrant results, and where clinical
review indicates a need for further
analysis, the codes should be referred
back to the AMA RUC for review and
new valuation should be performed
based on the building block
methodology.
We note the application of the reverse
building block methodology is an
objective way to account for changes in
the resources resulting from the change
in the site-of-service in which the
typical service is provided. However,
because relative values under the PFS
are ‘‘relative,’’ that is, where work
relative value units for a code are
established relative to work relative
value units for other codes, the
recommended methodology of valuing
services based on input building blocks
is best applied within the context of the
AMA RUC discussion. For example, we
recognize that the AMA RUC looks at
families of codes and may assign RVUs
based on a particular code ranking
within the family. This method of
valuing services preserves relativity
within the relative value scale for that
code family. However, we have stated
that we believe the relative value scale
requires each service to be valued based
on the resources used in furnishing the
service as specified in section
1848(c)(1)(A) of the Act, which defines
the physician work component to
include ‘‘the portion of the resources
used in furnishing the service that
reflects physician time and intensity in
furnishing the service.’’ Furthermore,
section 1848(c)(2)(C)(i) of the Act
specifies that ‘‘the Secretary shall
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
determine a number of work relative
value units (RVUs) for the service based
on the relative resources incorporating
physician time and intensity required in
furnishing the service.’’ Read together,
these two sections of the statute support
our intention to rely on the building
block methodology to determine
appropriate work RVUs for codes.
We note that we continue to rely on
the extensive expertise provided by the
AMA RUC to recommend appropriate
input building blocks for codes.
Additionally, the AMA RUC’s unique
infrastructure and broad perspective
permits the valuation of a code within
the context of relativity to the entire
relative value system. Therefore, we
believe that the recommended
methodology of valuing services based
on input building blocks is best applied
within the context of the AMA RUC
discussion.
Accordingly, we are requesting that
the AMA RUC review the CPT codes
displayed in Tables 15 and 16. In
addition, where the application of the
CY 2011 reverse building block
methodology produces an aberrant
result that is clearly not a reflection of
physician work for the service, we are
requesting that the AMA RUC review
the input building blocks and
recommend an appropriate RVU value
that is both consistent with the building
blocks of the code and appropriate
relative to the values for other codes in
the family. For other codes where the
application of the CY 2011 reverse
building block methodology produces a
result that is consistent with the
physician work for the service, we
encourage the AMA RUC to confirm the
values and recommend these work
values for CY 2011. In this way, we
would hope to receive new AMA RUC
recommendations for all of the codes in
Tables 15 and 16 for CY 2011.
Furthermore, if the recommendations
that we receive from the AMA RUC are
not consistent with the building block
methodology and not appropriate
relative to the values of other services,
and the application of the CY 2011
reverse building block methodology
produces a result that CMS medical
advisors believe is consistent with the
work for the service, we are proposing
to adopt the CY 2011 reverse building
block methodology values that are listed
in Tables 15 and 16 for CY 2011. In
cases where the reverse building block
methodology produces a negative work
value, we are suggesting that the AMA
RUC review and revise the building
blocks of the code so that a new
valuation can be determined based on
the building block methodology. For
such codes, if the revised
PO 00000
Frm 00034
Fmt 4701
Sfmt 4702
recommendations that we would hope
to receive from the AMA RUC are still
not consistent with the building block
methodology upon revision, because we
cannot pay for these services based on
negative work RVUs, we are proposing
to modify the AMA RUC-recommended
values for these codes as CMS
determines clinically appropriate and
adopt the CMS-modified RVUs on a
interim final basis for CY 2011.
In their future work, we urge the
AMA RUC to use the building block
methodology when valuing services or
provide CMS with extensive rationale
for cases where the AMA RUC believes
the building block methodology is
inappropriate for a specific code. Since
section 1848(c)(2)(L) (as added by
section 3134 of the ACA) specifies that
the Secretary shall establish a process to
validate work RVUs of potentially
misvalued codes under the PFS, as we
have discussed earlier in this section,
we believe codes that are valued using
the building block methodology would
be more likely to meet the standards of
a systematic RVU validation process
that could be developed in accordance
with the requirements of the statute.
e. Codes With ‘‘23-hour’’ Stays
In the CY 2010 PFS proposed rule (74
FR 33557), we requested that the AMA
RUC review services that are typically
performed in the outpatient setting and
require a hospital stay of less than 24
hours. We stated in the proposed rule
that we believed these to be primarily
outpatient services and expressed
concern that the value of evaluation and
management (E/M) visits for inpatients
was inappropriately included in the
valuation of codes that qualify as ‘‘23hour stay’’ outpatient services.
We received a number of comments in
response to the discussion in the CY
2010 proposed rule. The AMA RUC
stated that it already values stays of less
than 23 hours appropriately by reducing
the hospital discharge day management
service (that is, CPT code 99238), from
1 day to a half day. The AMA RUC also
explained that when the AMA RUC
refers to 23-hour stay services in
discussions at AMA RUC meetings, it is
referring primarily to services that are
reported in the Medicare claims
database as typically outpatient
services, but where the patient is kept
overnight and, on occasion, even longer
in the hospital. Because the AMA RUC
believes the patient stays overnight in
the hospital, it believes the inclusion of
inpatient E/M visits to be appropriate in
the valuation of this category of codes.
We believe that the 23-hour stay issue
encompasses several scenarios. The
typical patient is commonly in the
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
hospital for less than 24 hours, which
often means the patient may indeed stay
overnight in the hospital. On occasion,
the patient may stay longer than a single
night in the hospital; however, in both
cases, the patient is considered for
Medicare purposes to be a hospital
outpatient, not an inpatient, and our
claims data support that the typical 23hour stay service is billed as an
outpatient service. Accordingly, we
believe that the valuation of the codes
that fall into the 23-hour stay category
should not reflect work that is typically
associated with an inpatient service. For
example, inpatient E/M visit codes such
as CPT codes 99231 (Level 1 subsequent
hospital care, per day); 99232 (Level 2
subsequent hospital care, per day); and
99233 (Level 3 subsequent hospital care,
per day), should not be included at the
full value in the valuation of 23-hour
stay services.
Currently, the valuation of 23-hour
stay services is conducted in a
nonuniform manner by the AMA RUC.
The AMA RUC has indicated that it
currently includes a half hospital
discharge day management service and
no hospital inpatient visits for
outpatient services with expected
hospital stays of 23 hours or less. In
contrast, for those outpatient services
where the AMA RUC believes that the
recovery period could be longer than 23
hours, the AMA RUC stated in its
comment on the CY 2010 PFS proposed
rule that it currently includes a full
hospital discharge day management
service and one or more inpatient E/M
visits in the code’s value. However, we
note the typical 23-hour stay service is
billed as an outpatient service and so
long as the typical case continues to be
billed as an outpatient service, we
believe the code should not incorporate
physician work values for services that
are typically associated with an
inpatient service. In the 2010 PFS
proposed and final rule with comment
period (74 FR 33556 and 74 FR 61777,
respectively), we stated that we believed
the use of inpatient E/M visit codes for
services rendered in the post-service
period for outpatient 23-hour stay
procedures would result in
overpayment for pre- and post-service
work that would not be provided.
Accordingly, we proposed in the CY
2010 proposed rule (74 FR 33556
through 33557) not to allow any
additional inpatient E/M service to be
billed for care furnished during the
post-procedure period when care is
furnished for an outpatient service
requiring less than a 24-hour hospital
stay.
However, we find it is plausible that
while the patient receiving the 23-hour
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
stay service remains a hospital
outpatient, the patient would typically
be cared for by the physician furnishing
the procedure during that postprocedure period. While we do not
believe that post-procedure hospital
‘‘visits’’ would be at the inpatient level
since the typical case is an outpatient
who would be ready to be discharged
from the hospital in 23 hours or less, we
agree that the intra-service time of the
inpatient hospital visit may be included
in the valuation for the 23-hour stay
code.
Accordingly, we are modifying our
proposed CY 2010 approach and
suggesting that in the future, when the
AMA RUC reviews new and potentially
misvalued codes that are identified as
23-hour stay services, the AMA RUC
would apply the following
methodology:
(1) Begin with the starting RVU value
of the 23-hour stay code under review
and decrease the hospital discharge day
management service from one day to a
half day.
(2) Deduct the RVUs of inpatient
hospital visits from the starting RVU
value.
(3) Reallocate the time associated with
the intra-service portion of the inpatient
hospital visits to the immediate postservice time of the 23-hour stay code
under review.
Example: A 23-hour stay code is
currently valued at 15 RVUs and has 1
hospital discharge day management
service and 1 level 3 subsequent
hospital care visit incorporated in this
value.
• Applying step (1): 15¥0.64* =
14.36
• Applying step (2): 14.36¥2** =
12.36
• Applying step (3): 12.36 + (30
minutes × 0.0224)*** = 13.032 RVUs
*Value associated with 1⁄2 hospital
discharge day management service.
**Value associated with an inpatient
hospital visit, CPT code 99233.
***Value associated with the
reallocated intra-service time multiplied
by the post-service intensity of the 23hour stay code.
Finally, we note that since work
relative value units are established by
the Secretary in the context of relativity
to other codes in the system, the
recommended methodology for the
evaluation of 23-hour stay codes is best
applied within the context of relativity.
We appreciate that the AMA RUC has
the ability to assess the 23-hour stay
code after application of the
recommended methodology to ensure
appropriate relativity of this code and
other codes within the system. We
strongly encourage the AMA RUC to
PO 00000
Frm 00035
Fmt 4701
Sfmt 4702
40073
apply the recommended methodology to
ensure the consistent and appropriate
valuation of the physician work for
these services.
4. Expanding the Multiple Procedure
Payment Reduction (MPPR) Policy to
Additional Nonsurgical Services
a. Background
Medicare has a longstanding policy to
reduce payment by 50 percent for the
second and subsequent surgical
procedures furnished to the same
patient by the same physician on the
same day, largely based on the presence
of efficiencies in the PE and pre- and
post-surgical physician work. Effective
January 1, 1995, the multiple procedure
payment reduction (MPPR) policy, with
the same percentage reduction, was
extended to nuclear medicine diagnostic
procedures (CPT codes 78306, 78320,
78802, 78803, 78806, and 78807). In the
CY 1995 PFS final rule with comment
period (59 FR 63410), we indicated that
we would consider applying the policy
to other diagnostic tests in the future.
Consistent with recommendations of
MedPAC in its March 2005 Report to
Congress on Medicare Payment Policy,
under the CY 2006 PFS, the MPPR
policy was extended to the technical
component (TC) of certain diagnostic
imaging procedures performed on
contiguous areas of the body in a single
session (70 FR 70261). The reduction
recognizes that, for the second and
subsequent imaging procedures, there
are some efficiencies in clinical labor,
supplies, and equipment time. In
particular, certain clinical labor
activities and supplies are not
duplicated for subsequent procedures
and, because equipment time and
indirect costs are allocated based on
clinical labor time, those would also be
reduced accordingly.
The imaging MPPR policy currently
applies to computed tomography (CT)
and computed tomographic angiography
(CTA), magnetic resonance imaging
(MRI) and magnetic resonance
angiography (MRA), and ultrasound
services within 11 families of codes
based on imaging modality and body
region. When we adopted the policy in
CY 2007, we stated that we believed
efficiencies were most likely to occur
when contiguous body areas are the
focus of the imaging because the patient
and equipment have already been
prepared for the second and subsequent
procedures, potentially yielding
resource savings in areas such as
clerical time, technical preparation, and
supplies (70 FR 45850). Therefore, the
MPPR policy currently applies only to
procedures involving contiguous body
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40074
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
areas within a family of codes, not
across families, and to those procedures
that are provided in a single session.
Additionally, while the MPPR policy
applies to TC-only services and to the
TC of global services, it does not apply
to professional component (PC) services.
Under the current imaging MPPR
policy, full payment is made for the TC
of the highest-paid procedure, and
payment is reduced by 25 percent of the
TC for each additional procedure when
an MPPR scenario applies. We had
originally planned to phase in the MPPR
policy over a 2-year period, with a 25
percent reduction in CY 2006 and a 50
percent reduction in CY 2007 (70 FR
70263). However, the Deficit Reduction
Act of 2005 (Pub. L. 109–171) (DRA)
capped the PFS payment amount for
most imaging procedures at the amount
paid under the hospital Outpatient
Prospective Payment System (OPPS). In
view of the DRA, we determined that it
would be prudent to retain the MPPR at
25 percent while we continued to
examine the appropriate payment levels
(71 FR 69659). The DRA also exempted
reduced expenditures attributable to the
MPPR policy from the PFS budget
neutrality provision. Most recently,
effective July 1, 2010, section 3135(b) of
the ACA increased the MPPR on the TC
of imaging services under the policy
established in the CY 2006 PFS final
rule with comment period from 25 to 50
percent and exempted the reduced
expenditures attributable to this further
change from the PFS budget neutrality
provision.
In the July 2009 GAO report entitled,
‘‘Medicare Physician Payments: Fees
Could Better Reflect Efficiencies
Achieved when Services are Provided
Together,’’ the GAO recommended that
we take further steps to ensure that fees
for services paid under the PFS reflect
efficiencies that occur when services are
performed by the same physician on the
same beneficiary on the same day. The
GAO recommended the following: (1)
Expanding the existing MPPR policy to
the PC to reflect efficiencies in
physician work for certain imaging
services; and (2) expanding the MPPR to
reflect PE efficiencies that occur when
certain nonsurgical, nonimaging
services are provided together. The GAO
also encouraged us to focus on service
pairs that have the most impact on
Medicare spending.
In the March 2010 report, MedPAC
noted its concerns about mispricing of
services under the PFS. MedPAC
indicated that it would explore whether
expanding the unit of payment through
packaging or bundling would improve
payment accuracy and encourage more
efficient use of services.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
In the CYs 2009 and 2010 PFS
proposed rules (73 FR 38586 and 74 FR
33554, respectively), we stated that we
planned to analyze nonsurgical services
commonly furnished together (for
example, 60 to 75 percent of the time)
to assess whether an expansion of the
MPPR policy could be warranted.
MedPAC encouraged us to consider
duplicative physician work, as well as
PE, in any expansion of the MPPR
policy.
b. Proposed CY 2011 Expansion of the
Imaging Technical Component MPPR
Policy to Additional Combinations of
Imaging Services
Over the past 2 years, the AMA RUC
has examined several services billed 90
percent or more of the time together as
part of the potentially misvalued service
initiative and, in several cases, created
one code to describe the complete
service, with a value that reflects the
expected efficiencies. Notwithstanding
the bundling work of the RUC, there
may be additional imaging and other
diagnostic services that are furnished
together less than 90 percent of the time
where we could still expect efficiencies
in the TC, and in some cases in the PC,
resulting in potential overpayment for
these services under current policy
when furnished together.
Section 1848(c)(2)(K) of the Act (as
added by section 3134 of the ACA)
specifies that the Secretary shall
identify potentially misvalued codes by
examining multiple codes that are
frequently billed in conjunction with
furnishing a single service, and review
and make appropriate adjustments to
their relative values. As a first step in
applying this provision, we are
proposing a limited expansion of the
current imaging MPPR policy for CY
2011. We will continue to review other
possible expansions of the MPPR policy
to the TC and/or PC of imaging
procedures or other diagnostic tests for
the future. Any further changes would
be addressed in future rulemaking.
In a related policy for hospital
outpatient payment of imaging services,
in the CY 2009 OPPS/ASC final rule
with comment period (73 FR 68559
through 68569), the OPPS adopted a
policy to pay for two or more CT and
CTA, MRI and MRA, or ultrasound
procedures furnished in the same
session through a single composite
ambulatory payment classification
(APC) group. These composite APC
payments were based on the 11 families
of codes subject to the MPPR under the
PFS that were collapsed into 3 imaging
families for the OPPS according to their
modality—1 for ultrasound, 1 for CT
PO 00000
Frm 00036
Fmt 4701
Sfmt 4702
and CTA, and 1 for MRI and MRA
services.
At that time, we stated our belief that
the contiguous body area concept that
was incorporated in the PFS imaging
families was not necessary for potential
efficiencies to be achieved in an imaging
session. We provided examples to
illustrate that we would not expect
second and subsequent imaging services
of the same modality involving
noncontiguous body areas to require
duplicate facility resources (comparable
to the TC under the PFS) for clinical
labor activities such as greeting the
patient, providing education and
obtaining consent, retrieving prior
exams, setting up an intravenous
infusion, and preparing and cleaning
the room, any more than second and
subsequent imaging procedures of the
same modality involving contiguous
body areas. While we noted that
multiple imaging claims under the
OPPS are generally within the same
imaging modality and involve
contiguous body areas the vast majority
of the time, we estimated that the
collapsed 3 families, as opposed to the
11 PFS families, would add 12 percent
additional claims to those eligible for a
single composite APC payment under
the OPPS based on the provision of 2 or
more imaging services in a single
session, allowing us to capture
additional claims with efficiencies.
Taking into consideration the OPPS
policy that was adopted in the CY 2009
OPPS/ASC final rule with comment
period, in this proposed rule, we are
proposing to apply the MPPR regardless
of family, that is, the policy would
apply to multiple imaging services
furnished within the same family of
codes or across families. This proposal
would simplify the current imaging
MPPR policy in a way that is consistent
with the standard PFS MPPR policy for
surgical procedures that does not group
procedures by body region. Therefore,
the MPPR would apply to CT and CTA,
MRI and MRA, and ultrasound
procedures services furnished to the
same patient in the same session,
regardless of the imaging modality, and
not limited to contiguous body areas.
Because of the different pieces of
equipment used for CT/CTA, MRI/MRA,
and ultrasound procedures, it would be
highly unlikely that a single practitioner
would furnish more than one imaging
procedure involving 2 different
modalities to one patient in a single
session where the proposed MPPR
policy would apply. On the other hand,
while most multiple procedures
furnished with a single modality in one
session would involve procedures
currently assigned to one of the 11
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
imaging families, it would not be
uncommon for more than one imaging
procedure of the same modality to be
furnished across families and, like the
scenario for hospital outpatient imaging
services, we would expect efficiencies
to occur in these cases. Therefore, we
believe that an expansion of the current
imaging MPPR policy to account for
efficiencies in such situations would
allow us to pay more appropriately for
these multiple imaging procedure
sessions, consistent with our ongoing
efforts to address misvalued services.
The proposed expansion of the
imaging MPPR policy to include all of
the current codes in a single family to
which the standard 50 percent
reduction for second and subsequent
procedures would apply would reduce
payment for 20 percent more services
than the current MPPR policy under the
PFS. Thus, under the CY 2011 proposal,
we would capture additional
efficiencies and pay more appropriately
in these cases. We note that, as
indicated above, section 3135(b)(2) of
the ACA specifies that reduced
expenditures attributable to the increase
in the imaging MPPR from 25 to 50
percent in CY 2011 are excluded from
the PFS budget neutrality adjustment.
However, the reduced payment for code
combinations that would newly be
subject to the imaging MPPR policy
under this proposal would be made in
a budget neutral manner under the PFS,
as these new combinations are not
included under section 1848(b)(4)(D)
(added by section 3135(b) of the ACA),
which addresses ‘‘single-session imaging
to consecutive body parts’’ under the
established imaging MPPR policy.
Finally, we are also proposing to add
the codes displayed in Table 17 to the
list of imaging services subject to the
MPPR policy in CY 2011. These codes
were newly created for CY 2010 and are
similar to codes currently in imaging
family 2, titled CT and CTA (Chest/
Thorax/Abdomen/Pelvis).
We further note that new CY 2010
CPT codes 74261 (Computed
tomography (CT) colonography,
diagnostic, including image
postprocessing; without contrast
material) and 74262 (Computed
tomography (CT) colonography,
diagnostic, including image
postprocessing; with contrast material(s)
including non-contrast images, if
performed) were added to the CY 2010
MPPR policy through the July 2010 PFS
quarterly update, with a retroactive
effective date of January 1, 2010. These
codes replaced CPT code 0067T
(Computed tomographic (CT)
colonography (i.e., virtual colonoscopy);
diagnostic) in CY 2010, which was on
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
the list of procedures subject to the
imaging MPPR policy prior to CY 2010.
As discussed earlier in this section,
reduced expenditures attributable to the
increase in the MPPR for multiple
imaging procedures to consecutive body
parts (that is, those previously
designated in the same family of codes)
are exempt from the budget neutrality
provision of the PFS. However, the
reduced expenditures attributable to the
MPPR for combinations of multiple
imaging procedures that we are
proposing for CY 2011 (the MPPR for
multiple imaging procedures not
involving consecutive body parts)
would be subject to budget neutrality
adjustment under the PFS. We note that
this formulation for whether reduced
expenditures are exempt from budget
neutrality applies both to procedures
currently subject to the imaging MPPR
and to new codes that are subject to the
policy in CY 2011 and in future years.
To the extent that imaging procedures
described by the new codes are
furnished in combination with other
procedures that are subject to the
imaging MPPR on consecutive body
areas, the reduced expenditures
attributable to the MPPR for these
combinations would be exempt from the
PFS budget neutrality adjustment.
The complete list of codes subject to
the proposed CY 2011 MPPR policy for
diagnostic imaging services is included
in Addendum F to this proposed rule.
40075
provided the example of time spent
testing range of motion or muscle
flexibility that was duplicated in
commonly observed code pairs.
In the typical clinical scenario for
therapy services, we believe that
therapy services are misvalued for PFS
payment when multiple services are
furnished to a patient in a single session
because duplicate clinical labor and
supplies are included in the PE of the
services furnished. We believe this
duplication should be accounted for
under the PFS, as we currently account
for efficiencies in multiple surgical and
multiple diagnostic imaging procedures
furnished in a single session. Over the
past 2 years, the AMA RUC has
examined several services billed 90
percent or more of the time together as
part of its potentially misvalued service
initiative and, in several cases, created
one code to describe the complete
service, with a value that reflects the
expected efficiencies. Notwithstanding
the AMA RUC’s analyses, in most cases
it has not created one code to describe
a complete therapy service, in part
because many of the core therapy CPT
codes are timed codes based on
increments of treatment time.
Therefore, we are proposing a further
step to implement section 1848(c)(2)(K)
of the Act (as added by section 3134 of
the ACA) that specifies that the
Secretary shall identify potentially
misvalued codes by examining multiple
codes that are frequently billed in
TABLE 17—PROPOSED CPT CODE AD- conjunction with furnishing a single
DITIONS TO THE DIAGNOSTIC IMAG- service. For CY 2011 we are proposing
an MPPR policy for the HCPCS codes
ING MPPR POLICY FOR CY 2011
listed in Table 18, specifically the
separately payable ‘‘always therapy’’
CPT code
Short descriptor
services that are only paid by Medicare
75571 ....... Ct hrt w/o dye w/ca test.
when furnished under a therapy plan of
75572 ....... Ct hrt w/3d image.
care. These services are designated
75573 ....... Ct hrt w/3d image, congen.
‘‘always therapy’’ services regardless of
75574 ....... Ct angio hrt w/3d image.
who furnishes them and always require
therapy modifiers to be reported,
c. Proposed CY 2011 Expansion of the
specifically –GP (Services rendered
MPPR Policy to Therapy Services
under outpatient physical therapy plan
In the July 2009 GAO report entitled,
of care); –GO (Services rendered under
‘‘Medicare Physician Payments: Fees
outpatient occupational therapy plan of
Could Better Reflect Efficiencies
care); or –GN (Services rendered under
Achieved when Services are Provided
outpatient speech pathology plan of
Together,’’ the GAO found efficiencies
care). The therapy codes are available in
when multiple physical therapy services a file on the CMS Web site at: https://
were furnished in one session and
www.cms.gov/TherapyServices/. We
concluded that an MPPR policy could
have excluded both contractor-priced
be appropriate for these services. In the
and bundled codes from Table 18
report, the GAO noted that officials from because, under our proposal, an MPPR
the AMA RUC explained that time spent would not be applicable for ‘‘always
on pre-service and post-service therapy
therapy’’ services furnished in
activities is spread across the number of combination with these codes. In the
services in a typical session in order to
case of bundled codes that are not
avoid duplication of the PE for the
separately paid, there are no explicit
services. Nevertheless, the GAO found
efficiencies in the direct PE to be
that there was duplication of certain
reflected in payment for the second and
activities in the intra-service period, and subsequent therapy services furnished
PO 00000
Frm 00037
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40076
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
At this time, we are not proposing an
MPPR policy for ‘‘sometimes therapy’’
services, specifically those services that
may be furnished under a therapy plan
of care or otherwise by physicians or
NPPs as medical services. We believe
that the care patterns are different for
the latter group of services that may
TABLE 18—SEPARATELY PAYABLE
‘‘ALWAYS THERAPY’’ SERVICES SUB- sometimes be furnished as therapy
JECT TO THE PROPOSED CY 2011 services, and note that they are less
commonly furnished with multiple
MPPR POLICY*
services in a single session than the
‘‘always therapy’’ services. In the
CPT/
discussion that follows, our reference to
HCPCS
Short descriptor
code
therapy services means those HCPCS
codes designated annually as ‘‘always
92506 ....... Speech/hearing evaluation.
therapy’’ services by CMS.
92507 ....... Speech/hearing therapy.
Based on CY 2009 PFS claims data,
92508 ....... Speech/hearing therapy.
we identified over 500 therapy service
92526 ....... Oral function therapy.
code pairs billed for the same patient in
92597 ....... Oral speech device eval.
a single session. We then reviewed a
92607 ....... Ex for speech device rx, 1hr.
sample of the most common therapy
92608 ....... Ex for speech device rx addl.
92609 ....... Use of speech device service.
code pairs, specifically those high
96125 ....... Cognitive test by hc pro.
volume code pairs with more than
97001 ....... Pt evaluation.
250,000 combined services per year, to
97002 ....... Pt re-evaluation.
examine the potential for duplication in
97003 ....... Ot evaluation.
the PE. These codes pairs represented
97004 ....... Ot re-evaluation.
more than half of the occurrences of
97010 ....... Hot or cold packs therapy.
therapy services billed together. While
97012 ....... Mechanical traction therapy.
we acknowledge that the PE inputs per
97016 ....... Vasopneumatic device therapy.
97018 ....... Paraffin bath therapy.
service for some therapy services were
97022 ....... Whirlpool therapy.
included in the direct PE database based
97024 ....... Diathermy eg, microwave.
on one-half of the total PE inputs
97026 ....... Infrared therapy.
required for two services provided in a
97028 ....... Ultraviolet therapy.
single session, which would account for
97032 ....... Electrical stimulation.
some duplication, this was not the case
97033 ....... Electric current therapy.
for all combinations of therapy services.
97034 ....... Contrast bath therapy.
Of the high volume therapy services
97035 ....... Ultrasound therapy.
97036 ....... Hydrotherapy.
examined, approximately one-fourth of
97110 ....... Therapeutic exercises.
the code pairs were not valued based on
97112 ....... Neuromuscular reeducation.
two services. In addition, we note that
97113 ....... Aquatic therapy/exercises.
the CY 2009 PFS claims data show that
97116 ....... Gait training therapy.
when multiple therapy services are
97124 ....... Massage therapy.
billed on a claim for the same date of
97140 ....... Manual therapy.
service, the median number is four
97150 ....... Group therapeutic procedures.
services per day. Therefore, even for
97530 ....... Therapeutic activities.
97533 ....... Sensory integration.
those clinical labor times that may
97535 ....... Self care mngment training.
reflect the allocation of total time across
97537 ....... Community/work reintegration.
two units of therapy services, we believe
97542 ....... Wheelchair mngment training.
that some elements of the current PE
97750 ....... Physical performance test.
inputs are duplicated based on current
97755 ....... Assistive technology assess.
patterns of therapy service delivery
97760 ....... Orthotic mgmt and training.
where most multiple service claims
97761 ....... Prosthetic training.
97762 ....... C/o for orthotic/prosth use.
involve delivery of more than 2 services
G0281 ...... Elec stim unattend for press.
in a session.
G0283 ...... Elec stim other than wound.
Duplicate labor activities currently
G0329 ...... Electromagntic tx for ulcers.
included in the PE for the service period
* Excludes contractor-priced and bundled for these high volume pairs of therapy
codes.
services are as follows: clean room/
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
to the patient on the same day. In the
case of contractor-priced codes, there is
no nationally established pricing that
could be uniformly adjusted to reflect
the expected efficiencies when multiple
therapy services are furnished.
Staff description
Labor task description
Physical Therapy Aide
Clean room/equipment ....................................
VerDate Mar<15>2010
23:56 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00038
Time period
Fmt 4701
equipment; education/instruction/
counseling/coordinating home care;
greet patient/provide gowning; obtain
measurements, for example, ROM/
strength/edema; and post-treatment
patient assistance. The most common
duplicate supply item included in the
PE was the multispecialty visit pack.
Examples of duplicated and
unduplicated labor activities and
supplies for two sample therapy code
pairs and our estimates of potential
clinically appropriate time and quantity
reductions for multiple service sessions
are displayed in Table 19. We note that
CY 2009 PFS claims data for these
sample code pairs include over 3.4
million pairs of CPT codes 97112
(Therapeutic procedure, 1 or more areas,
each 15 minutes; neuromuscular
reeducation of movement, balance,
coordination, kinesthetic sense, posture,
and/or proprioception for sitting and/or
standing activities) and 97110
(Therapeutic procedure, 1 or more areas,
each 15 minutes; therapeutic exercises
to develop strength and endurance,
range of motion and flexibility)
furnished by the same practitioner on
the same day and over 500,000 pairs of
CPT codes 97001 (Physical therapy
evaluation) and 97140 (Manual therapy
techniques (e.g., mobilization/
manipulation, manual lymphatic
drainage, manual traction), 1 or more
regions, each 15 minutes).
Table 19: Examples of Duplicate PE
Inputs for Therapy Services That
Should Be Accounted for When
Multiple Services Are Furnished in One
Session
Example 1: CPT code 97112
(Therapeutic procedure, 1 or more areas,
each 15 minutes; neuromuscular
reeducation of movement, balance,
coordination, kinesthetic sense, posture,
and/or proprioception for sitting and/or
standing activities) and CPT code 97110
(Therapeutic procedure, 1 or more areas,
each 15 minutes; therapeutic exercises
to develop strength and endurance,
range of motion and flexibility)
Code A
97112
labor task
time
Code B
97110
labor task
time
1
1
Service Period, PostService.
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Total minute
reduction
1
40077
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Code A
97112
labor task
time
Code B
97110
labor task
time
Total minute
reduction
Staff description
Labor task description
Time period
Physical Therapy Assistant.
Physical Therapy Aide
Education/instruction/counseling/coord home
care.
Greet patient/provide gowning ........................
2.5
2.5
2.5
1.5
1.5
1.5
Physical Therapy
sistant.
Physical Therapy
sistant.
Physical Therapy
sistant.
Physical Therapy
1.5
1.5
1.5
As-
Obtain measurements, e.g., ROM/strength/
edema.
Obtain vital signs ............................................
1
1
1
As-
Phone calls between visits with patient, family
Service Period, PostService.
Service Period, PreService.
Service Period, PreService.
Service Period, PreService.
Post-Service Period ...
1
1
1
Aide
Post treatment patient assistance ..................
1
1
1
Physical Therapy Assistant.
Physical Therapy Aide
Review/read documentation, plan of care,
treatment goals.
Verify/Coordinate availability of resources/
equip.
Service Period, PostService.
Pre-Service Period .....
1.5
1.5
1.5
Pre-Service Period .....
1.5
1.5
1.5
As-
Supply description
Price
pack, minimum multi-specialty visit .................................................................
Thera-bands (6in width) ...................................................................................
Example 2: CPT code 97001 (Physical
therapy evaluation) and CPT Code
$1.14
0.06
97140 (Manual therapy techniques (eg,
mobilization/manipulation, manual
1
2
1
1
3
1.5
1.5
8
1.5
1.5
3
1
1
2
1
1
Pre-Service Period .....
1
.5
.5
Pre-Service Period .....
3
1.5
1.5
Service Period, PreService.
Service Period, PreService.
Service Period, PostService.
2
0
0
2
0
0
0
1
0
Education/instruction/counseling/coord home
care.
Greet patient/provide gowning ........................
Physical Therapy
sistant.
Physical Therapy
sistant.
Physical Therapy
sistant.
Physical Therapy
sistant.
Physical Therapy
As-
Obtain measurements, e.g., ROM/strength/
edema.
Obtain vital signs ............................................
As-
Phone calls between visits with patient, family
As-
Physical Therapy Aide
Review/read documentation, plan of care,
treatment goals.
Verify/Coordinate availability of resources/
equip.
Prep and position patient ................................
Physical Therapy Aide
Prepare room, equipment, supplies ................
Physical Therapy Aide
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Physical Therapy Assistant.
Physical Therapy Aide
Post treatment assistance ..............................
Supply description
Price
pack, minimum multi-specialty visit .............................................................
lotion, message, unscented .........................................................................
PO 00000
Frm 00039
Fmt 4701
lymphatic drainage, manual traction), 1
or more regions, each 15 minutes)
1
Clean room/equipment ....................................
Jkt 220001
0
1.5
3
Physical Therapy Aide
20:23 Jul 12, 2010
0.5
1.5
Service Period, PostService.
Service Period, PostService.
Service Period, PreService.
Service Period, PreService.
Service Period, PreService.
Post-Service Period ...
Time period
VerDate Mar<15>2010
0.5
1.5
Code B
97140
labor task
time
Labor task description
Aide
Code B
97110
quantity reduction
Code B
97110
quantity
Code A
97001
labor task
time
Staff description
As-
Code A
97112
quantity
Sfmt 4702
Code A
97001
quantity
$1.14
0.158
E:\FR\FM\13JYP2.SGM
Code B
97140
quantity reduction
Code B
97140
quantity
1
0
13JYP2
Total minute
reduction
0.5
0.5
0.5
0
40078
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
We did not remove minutes for
clinical labor tasks that were not
duplicated. For example, for CPT code
pair 97001 and 97140 the following
tasks were not duplicated: Post
treatment patient assistance; prep and
position patient; and prepare room,
equipment, and supplies. In addition,
we did not remove any supply items
that would be required for only one of
the separate services because these
would not be duplicated in the PE
applicable to the combination of
services. We estimated no reduction for
equipment time, even though
efficiencies would be expected for
equipment that is used in both services
when they are furnished together.
Finally, a corresponding reduction to
the indirect expenses is appropriate
since indirect costs are allocated
partially based on direct costs. For five
high volume therapy code pairs that
each occur over 2 million time in PFS
claims for multiple therapy services and
account for almost half of such claims,
we estimated that the resulting
reduction in the PE for the lower paying
code would range from 28 to 56 percent.
In summary, given the duplicative
clinical labor activities and supplies as
shown in the code combination
examples, we believe it would be
appropriate to extend the 50 percent
MPPR policy that is currently applied to
surgical services and the TC of imaging
services, to the PE component of certain
therapy services. Specifically, we are
proposing to apply a 50 percent
payment reduction to the PE component
of the second and subsequent therapy
services for multiple ‘‘always therapy’’
services furnished to a single patient in
a single day. Because it would be
difficult to determine the precise
beginning and end of therapy sessions
and we do not believe that beneficiaries
would typically have more than one
therapy session in a single day, we are
proposing to apply the 50 percent MPPR
policy to the PE component of
subsequent therapy services provided to
the same patient on the same day, rather
than in the same session.
We note that many therapy services
are time-based CPT codes, so multiple
units of a single code may be billed for
a single session that lasts for a longer
period of time than one unit of the code.
The proposed MPPR policy would
apply to multiple units of the same
therapy service, as well as to multiple
different services, when furnished to the
same patient on the same day. Full
payment would be made for the service
or unit with the highest PE and payment
would be made at 50 percent of the PE
component for the second and
subsequent procedures or units of the
service. The work and malpractice
components of the therapy service
payment would not be reduced. For
therapy services furnished by a group
practice or ‘‘incident to’’ a physician’s
service, the MPPR would apply to all
‘‘always therapy’’ services furnished to a
patient on the same day, regardless of
whether the services are provided in
one therapy discipline or multiple
disciplines, for example, physical
therapy, occupational therapy, or
speech-language pathology. The
proposed CY 2011 MPPR policy would
apply to both those services paid under
the PFS that are furnished in the office
setting and those services paid at the
PFS rates that are furnished by
outpatient hospitals, home health
agencies, comprehensive outpatient
rehabilitation facilities (CORFs), and
other entities that are paid by Medicare
for outpatient therapy services. Table 20
provides a sample calculation of the
current and proposed CY 2011 payment
for multiple therapy services furnished
on the same day. For those services paid
under the PFS, the PFS budget
neutrality provision would apply so that
the estimated reduced expenditures for
therapy services would be redistributed
to increase payment for other PFS
services.
TABLE 20—SAMPLE PROPOSED PAYMENT CALCULATION FOR MULTIPLE THERAPY SERVICES FURNISHED TO A SINGLE
PATIENT ON THE SAME DAY
Procedure 1
Unit 1
Procedure 1
Unit 2
Procedure 2
$7.00
10.00
1.00
18.00
$7.00
10.00
1.00
18.00
$11.00
8.00
1.00
20.00
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Work ................................
PE ...................................
Malpractice ......................
Total .........................
We believe this proposed therapy
MPPR policy would provide more
appropriate payment for therapy
services that are commonly furnished
together by taking into account the
duplicative clinical labor activities and
supplies in the PE that are not furnished
more than once in the single therapy
session. This approach is consistent
with the statutory requirement for the
Secretary to identify, review, and adjust
the relative values of potentially
misvalued services under the PFS as
specified by section 3134 of the ACA.
We also believe this proposed policy is
responsive to Congressional concerns
about significant growth in therapy
spending and to MedPAC and GAO
recommendations regarding the
VerDate Mar<15>2010
Current
total
payment
20:23 Jul 12, 2010
Jkt 220001
Proposed
CY 2011
total
payment
$25.00
28.00
3.00
56.00
expansion of MPPR policies under the
PFS to account for additional
efficiencies. We note that paying more
appropriately for therapy services based
on PE relative values that are adjusted
for the clinical scenario under which
the services are furnished would result
in reduced therapy expenditures, and
beneficiaries would be able to receive
more medically necessary outpatient
therapy services before reaching the
therapy cap. For a further discussion of
potential alternatives to the therapy
caps, we refer readers to section III.A.2.
of this proposed rule.
PO 00000
Frm 00040
Fmt 4701
Sfmt 4702
$25.00
19.00
3.00
47.00
Proposed payment calculation
no reduction.
$10 + (0.5 × $10) + (0.5 × $8).
no reduction.
$18 + $7 + (0.5 × $10) + $1 + $11 +
(0.5 × $8) + $1.
5. High Cost Supplies
a. Background
MedPAC and the AMA RUC have
long recommended that CMS establish a
frequent price update process for highcost supplies that are direct PE inputs
in the PE database for services paid
under the PFS because of their
speculation that prices for these items
may decrease over time as competition
increases and new technologies
disseminate into medical practice.
MedPAC in particular has perennially
noted that it is important for CMS to
update the prices of high-priced
supplies on a regular basis as inaccurate
prices can distort PE RVUs over time,
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
contributing to the misvaluing of
established services under the PFS.
Most of the current prices for highcost supplies included in the direct PE
database are from 2004 or earlier. There
are currently 62 unique supplies with
prices of $150 or more in the proposed
CY 2011 PE database, which is available
on the CMS Web site under the
supporting data files for the CY 2011
PFS proposed rule at https://
www.cms.gov/PhysicianFeeSched/.
Finally, we note that we do not actually
pay the supply prices included in the
PE database but, instead, use them to
develop the PE RVUs according to our
standard PE methodology as described
in section II.A.2. of this proposed rule.
Payment for a procedure that uses a
supply is based upon the PE RVUs that
result from the PE methodology, and
supplies are among the direct PE inputs
for procedures. Therefore, it is the
relativity of high-cost supply prices to
prices for other PE items (equipment,
low-cost supplies, and clinical labor)
that is important.
Accordingly, in the CY 2009 PFS
proposed rule (73 FR 38582), we
proposed a process to update the prices
for high-cost supplies priced at $150 or
more that are included in the PE inputs
for procedures paid under the PFS PE
methodology. The CY 2009 proposed
rule described a publicly transparent
process in which CMS would publish a
list of the high-cost supplies in the PFS
proposed rule (65 supplies were
included in the CY 2009 PFS proposed
rule), and specialty societies or other
relevant organizations would provide
acceptable documentation supporting
the pricing for the supplies during the
60-day public comment period.
Furthermore, in that same proposed rule
(73 FR 38582), we provided guidance on
what constitutes valid, reliable
documentation that reflects the typical
price of the high-cost item in the
marketplace. We outlined examples of
acceptable documentation, such as a
detailed description (including system
components), sources, and current
pricing information, confirmed by
copies of catalog pages, invoices, and
quotes from manufacturers, vendors, or
distributors. We indicated that
documentation that does not include
specific pricing information such as
phone numbers and addresses of
manufacturers, vendors, or distributors
or Web site links without pricing
information would not be acceptable.
We also noted that if acceptable
documentation was not received within
the proposed rule’s 60-day public
comment period, we would use prices
from the Internet, retail vendors, and
supply catalogs to determine the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
appropriate cost, and that we would use
the lowest price identified by these
sources (73 FR 38582). Finally, we
solicited public comments on
alternatives that could be used to update
pricing information in the absence of
acceptable documentation provided by
specialty societies or other interested
organizations.
In the CY 2009 PFS final rule with
comment period (73 FR 69882), we
indicated that we received many
comments on the proposed process and,
while some commenters expressed
support, others believed the proposed
process was flawed and burdensome.
Moreover, although we received some
data in response to our request for
information on the 65 high-cost supplies
with prices of $150 or more, much of
what we received was not complete or
did not represent typical market prices.
In particular, we expressed concern that
the submitted data often represented
manufacturer list prices for the premier
models of many supplies, while we
believed there were less expensive
alternatives. Therefore, we were unable
to determine the most appropriate,
typical supply prices for our PFS
payment methodology that prices the
typical service described by a HCPCS
code. Rather than finalizing the
proposed process for updating high-cost
supplies and revising the prices for the
65 supplies based on inadequate pricing
information, we stated in the CY 2009
PFS final rule with comment period (73
FR 69882) that we would research the
possibility of using an independent
contractor to assist us in obtaining
accurate pricing information.
Furthermore, we informed the public
that we planned to study the limitations
of available pricing data and determine
how to revise our proposed process to
elicit better data.
In the CY 2010 PFS proposed rule and
final rule with comment period (74 FR
33554 and 61776, respectively), we
stated that we were continuing to
examine ways to obtain accurate pricing
information for high-cost supplies. We
noted again in the CY 2010 PFS
proposed rule that we would depend
upon the cooperation of the medical
community to obtain typical prices in
the marketplace, and we provided
stakeholders with another opportunity
to submit public comments on the
process. In the CY 2010 PFS final rule
with comment period, we
acknowledged commenters’ general
support for an initiative to ensure
accurate pricing of high-cost supplies.
In general, the commenters strongly
preferred a transparent and public
process, and we stated that we would
consider this perspective as we explore
PO 00000
Frm 00041
Fmt 4701
Sfmt 4702
40079
the best way to ensure that accurate
supply pricing information is used in
the PFS payment methodology.
b. Future Updates to the Prices of HighCost Supplies
In working towards refining a process
to update the prices of high-cost
supplies and consistent with our
intention expressed in the CY 2009 PFS
final rule with comment period (73 FR
69882), we contracted with an
independent contractor during CY 2009
to help us study the availability of
accurate pricing information. We
requested that the independent
contractor, L&M Policy Research,
research pricing information for the 65
high-cost supplies listed in the CY 2009
proposed rule (73 FR 38583 through
38585) and determine what, if any,
pricing information reflecting typical
market prices could be obtained for
these high-cost supplies.
We first requested that the contractor
explore publicly available sources to
obtain typical market prices for these
supplies. The contractor utilized supply
vendor catalogs and Web sites and
directly contacted vendors,
manufacturers, group purchasing
organizations (GPOs), and any other
suppliers that the contractor identified
in their research in order to identify
prices for each of the supplies. Where
more than one version of a supply item
appeared to match a description of a
high-cost supply and/or more than one
possible vendor or manufacturer was
identified, the contractor attempted to
obtain prices from the multiple sources.
Upon review of the high-cost supply
list, the contractor refined the list to 62
unique high-cost items with prices of
$150 or more for the study. The original
list only consisted of 64 items but
included one item inadvertently listed
twice (CMS Supply Code SD207 (suture
device for vessel closure (Perclose A–T))
and one item (CMS Supply Code SH079
(collagen implant)) that was deleted
from the PE database after CY 2007
because it was no longer used as an
input for any codes. While the
contractor was able to obtain prices for
37 of the 62 unique supplies, the
contractor was unable to obtain pricing
information for the remaining 25
supplies. Documentation of these prices,
a requirement we discussed in the CY
2009 PFS proposed rule (73 FR 38582),
was only obtained for 25 of the 36
supplies with new pricing information.
For the remainder, while the contractor
was given price quotes over the phone,
the sales agents or customer service
representatives declined to provide any
form of written documentation, in some
cases because company policies
E:\FR\FM\13JYP2.SGM
13JYP2
40080
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
restricted providing pricing
documentation to prospective customers
without an account. Moreover,
information on typical discounts was
obtained for only seven products, and
only one discount was documented. In
the case of these products, companies
disclosed the maximum available
discounts, ranging from 18 percent to 45
percent. Relative to prices currently
included in the PE database, the
contractor found higher prices for the
majority of the medical supplies that
were researched, specifically 23
supplies with higher prices, 8 with
lower prices, and 3 with the same price.
The high-cost supplies studied by the
contractor and their current database
prices are displayed in Table 20.
TABLE 20—HIGH-COST SUPPLIES WITH PRICES OF $150 OR GREATER IN THE PFS DIRECT PE DATABASE THAT WERE
STUDIED BY THE CMS CONTRACTOR
Current database
unit price
Associated CPT
codes
stent, ureteral, wguidewire, 3cm flexible tip ...........................................................................
probe, cryoablation, renal ......................................................................................................
catheter, intradiscal (spineCATH) ..........................................................................................
probe, cryoablation (Visica ICE 30 or 40) .............................................................................
kit, capsule, ESO, endoscopy w-application supplies (ESO) ................................................
catheter, balloon, lacrimal ......................................................................................................
catheter, CVA, system, tunneled w-port, dual (LifeSite) .......................................................
stent, vascular, deployment system, Cordis SMART ............................................................
agent, embolic, 2 ml uou .......................................................................................................
tube, jejunostomy ...................................................................................................................
$235
1,175
1,380
1,589
450
306
1,750
1,645
258
195
SA005 .........
SA010 .........
kit, capsule endoscopy w-application supplies (M2A) ...........................................................
kit, CVA catheter, tunneled, without portpump ......................................................................
450
308
SA011 .........
kit, CVA catheter, tunneled, with subcut port ........................................................................
495
SA015 .........
kit, for percutaneous thrombolytic device (Trerotola) ............................................................
488
SA020
SA022
SA024
SA025
.........
.........
.........
.........
kit,
kit,
kit,
kit,
loop snare (Microvena) ....................................................................................................
percutaneous neuro test stimulation ................................................................................
photopheresis procedure ..................................................................................................
PICC with subcut port ......................................................................................................
275
305
858
586
SA036
SA037
SA038
SA039
SA074
SA075
SA077
SA087
SA091
SA092
SA093
SC085
SD018
SD019
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
kit, transurethral microwave thermotherapy ...........................................................................
kit, transurethral needle ablation (TUNA) ..............................................................................
kit, transurethral waterinduced thermotherapy ......................................................................
kit, vertebroplasty (LP2, CDO) ...............................................................................................
kit, endovascular laser treatment ...........................................................................................
kit, hysteroscopic tubal implant for sterilization .....................................................................
kit, pleural catheter insertion ..................................................................................................
tray, RTS applicator (Mammosite) .........................................................................................
tray, scoop, fast track system ................................................................................................
kit, gene, MLL fusion ..............................................................................................................
kit, priming, random ...............................................................................................................
tubing set, plasma exchange .................................................................................................
catheter, balloon, thermal ablation (Thermachoice) ..............................................................
catheter, balloon, ureteral-GI (strictures) ...............................................................................
1,149
1,050
650
696
519
1,245
329
2,550
750
1,395
1 463
173
727
166
SD020 .........
SD023 .........
catheter, CVA, tunneled, dual (Tesio) ...................................................................................
catheter, enteroclysis .............................................................................................................
355
183
SD058
SD072
SD073
SD094
SD109
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
CMS supply
code
.........
.........
.........
.........
.........
electrode, grid ........................................................................................................................
eyelid weight implant, gold .....................................................................................................
fiducial screws (set of 4) ........................................................................................................
mammotome probe ................................................................................................................
probe, radiofrequency, 3 array (StarBurstSDE) .....................................................................
475
218
2 558
200
1,995
SD151 .........
catheter, balloon, low profile PTA ..........................................................................................
432
SD152 .........
catheter, balloon, PTA ...........................................................................................................
244
SD154 .........
catheter, microcatheter (selective 3rd order) .........................................................................
338
52332
50593
22526, 22527
19105
91111
68816
36566
37205, 37206
37210
49441, 49446,
49451, 49452
91110
36557, 36558,
36581
36560, 36561,
36563, 36582,
36583
36870, 37184,
37186, 37187,
37188
36595, 37203
63610, 64561
36522
36570, 36571,
36585
53850
53852
53853
22520, 22521
36478
58565
32550, 96440
19296
31730
88385
88385, 88386
36514
58353
43456, 45303,
45340, 45386,
46604
36565
74251, 74260,
89100, 89105,
89130, 89132,
89135, 89136,
89140, 89141
95829
67912
77011, 77301
19103
20982, 32998,
41530, 50592
35470, 35471,
35474
35472, 35473,
35475, 35476,
G0392, G0393
36217, 36247,
36481, 37183,
37210
VerDate Mar<15>2010
Supply description
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00042
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40081
TABLE 20—HIGH-COST SUPPLIES WITH PRICES OF $150 OR GREATER IN THE PFS DIRECT PE DATABASE THAT WERE
STUDIED BY THE CMS CONTRACTOR—Continued
CMS supply
code
Supply description
SD155 .........
SD175 .........
catheter, RF endovenous occlusion ......................................................................................
guidewire, steerable (Transcend) ..........................................................................................
725
180
SD177
SD185
SD186
SD189
SD191
.........
.........
.........
.........
.........
hysteroscope, ablation device ................................................................................................
plasma antibody adsorption column (Prosorba) ....................................................................
Plasma LDL adsorption column (Liposorber) ........................................................................
plate, surgical, mini-compression, 4 hole ..............................................................................
plate, surgical, reconstruction, left, 5 × 16 hole .....................................................................
1,146
1,150
1,380
226
719
SD193
SD204
SD205
SD207
.........
.........
.........
.........
plate, surgical, rigid comminuted fracture ..............................................................................
sensor, pH capsule (Bravo) ...................................................................................................
sheath, endoscope ultrasound balloon ..................................................................................
suture device for vessel closure (Perclose A–T) ...................................................................
389
225
154
225
SD215 .........
SD216 .........
SD218 .........
probe, endometrial cryoablation (Her Option) .......................................................................
catheter, balloon, esophageal or rectal (graded distention test) ...........................................
stent, ureteral, without guidewire ...........................................................................................
1,250
165
162
SF028 ..........
laser tip (single use) ...............................................................................................................
290
SF029
SF030
SL055
SL209
SL225
laser tip, bare (single use) .....................................................................................................
laser tip, diffuser fiber ............................................................................................................
DNA stain kit (per test) ..........................................................................................................
array kit, Genosensor .............................................................................................................
gas, nitogen, ultra-high purity (compressed) grade 5.0 .........................................................
150
850
3 150
2,121
190
..........
..........
..........
..........
..........
Current database
unit price
Associated CPT
codes
36475
36247,
37183,
37206,
49440,
49442,
49450,
49452,
49460
58563
36515
36516
21208
21125, 21127,
21215
21461, 21462
91035
31620
35470, 35471,
35472, 35473,
35474, 35475,
37184, 37187,
37188, 37205,
G0392
58356
91040, 91120
50382, 50384,
50385
30117, 52214,
52224, 52317
46917, 46924
52647, 52648
88358
88386
88385, 88386
36217,
36481,
37205,
37210,
49441,
49446,
49451,
1 Six
pack.
of 4.
3 10 pack.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2 Set
Next, we directed the contractor to
access the United States General
Services Administration (GSA) medical
supply schedule to augment the results
obtained through review of vendor
materials and direct contact with
vendors, manufacturers, and GPOs. We
note that the GSA establishes long-term
government-wide contracts with
commercial firms for many products,
negotiating contracts and determining
prices to be fair and reasonable prior to
placing them on schedule. Included on
the schedule are thousands of medical
supplies at prices that, in most cases,
are established through competition.
The GSA schedule is an open
solicitation and a business of any size,
if it is stable and financially sound, can
request to be included on the schedule.
GSA’s vendors usually are nationwide
vendors with substantial nongovernment sales, and products on the
schedule must be manufactured in the
U.S. or in a nation with a trade
agreement with the United States.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Submissions for the schedule are
received 365 days per year, vendor
contracts can be of varying lengths, and
vendors can add or delete products from
the schedule. Depending on the
aggregate cost estimate associated with
the vendor’s supply items, the time to
achieve inclusion on the schedule can
vary from as short as several months to
as long as 2 years. The GSA has
delegated authority to the Department of
Veterans Affairs (VA) to procure
medical supplies under the VA Federal
Supply Schedules Program.
Using the GSA general search engine
under the category ‘‘Laboratory,
Scientific, & Medical’’ available at
https://www.gsaadvantage.gov/advgsa/
advantage/main/start_page.do the
contractor obtained nine prices for items
similar to the high-cost supplies in the
PE database and that are displayed in
Table 20 from the publicly available
information on the Internet, including
pricing for one product for which its
prior work did not yield an updated
PO 00000
Frm 00043
Fmt 4701
Sfmt 4702
price. We believe that additional items
that are similar to the high-cost supplies
in the PE database and that may be used
with the same procedures may be on the
GSA schedule but we are still working
through the crosswalk between our
supplies and the way the supplies are
presented on the GSA schedule.
Examples of high-cost supplies in the
PE database that the contractor located
on the GSA schedule include: (1) Kit,
capsule, ESO, endoscopy w-application
supplies (ESO), priced at $450 in the PE
database and $444 on the GSA schedule;
and (2) tube, jejunostomy, priced at
$195 in the PE database and $60 to $83
on the GSA schedule, depending on the
characteristics of the tube.
Since the GSA medical supply
schedule is a source for pricing
information that is public and
transparent and reflects the best
government contract price for a product,
we believe it is a desirable resource for
us to use in a refined process for
updating the prices of high-cost
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40082
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
supplies. For historical context, CMS
has previously proposed to use VA
prices that result from the competitive
marketplace as comparison points to
limit the Medicare prices for oxygen and
certain items of durable medical
equipment and prosthetic devices (62
FR 38100 through 38107, and 64 FR
44227 through 44231) in 1997 and 1999,
respectively. These prior proposals were
based on our determination that the
Medicare payment amounts for these
items as durable medical equipment or
prosthetics (not as physicians’ services)
were not inherently reasonable. We
note, however, that our current interest
in the GSA schedule for pricing highcost supplies for payment of physicians’
services is not based on considerations
of inherent reasonableness, and we do
not actually pay the prices in the PE
database for supplies under the PFS.
We further note that public
commenters on pricing high-cost
supplies have consistently requested
that CMS ensure that the pricing
information used to update the prices is
provided publicly. The commenters
have observed that this transparency
would enable stakeholders to evaluate
and provide feedback to the agency on
pricing accuracy (74 FR 61776). We also
acknowledge that our past attempts over
several years to identify typical market
prices for the high-cost supplies have
been inhibited by the limited
availability of public data that meet the
documentation requirements we have
previously established. Individual
vendors do not always publish their
product prices or provide typical
discounts. Moreover, discounts may
vary depending on suppliers and the
volume of supplies purchased. Our
understanding of the GSA medical
supply schedule is that the publicly
listed fair and reasonable prices on the
schedule generally do not include
volume and or certain other discounts
that may be subsequently negotiated by
the buyer. Consequently, we would
consider the prices available on the GSA
schedule to represent the ‘‘individual
item ceiling’’ price for a single item
purchase, which we believe would be
appropriate to estimate the high-cost
supply prices for physicians’ office
purchases. We are soliciting public
comments regarding the high-cost
supplies in the direct PE database for
the CY 2011 PFS proposed rule,
available on the CMS Web site as noted
earlier in this section, and the
corresponding supplies or alternative
items that could be used for the same
function that are currently on the GSA
supply schedule. We encourage
commenters to provide a detailed
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
analysis of the current relationships
between the items in the PE database
and those on the GSA schedule.
At this time, we would like to
describe a refined process for regularly
updating prices for high-cost supplies
under the PFS and solicit comments on
how we could improve on this process.
The process could occur every 2 years
beginning as soon as CY 2013, although
we note that we would propose the
refined process through rulemaking
before revising the prices for any highcost supply item based on the GSA
schedule. We could also consider
establishing a different price update
period depending on whether a highcost supply was a new supply in the PE
database or had been in use for some
time, in which case we might expect
that the price would have stabilized
and, therefore, could be updated less
frequently. In general, we would expect
that the periodicity of updating prices
for high-cost supplies that we
eventually adopted would balance the
associated administrative burden with
the rate of price changes, to ensure that
the associated procedures remain
appropriately valued, rather than
increasingly misvalued, over time.
We envision that we would base highcost supply price inputs on the publicly
available price listed on the GSA
medical supply schedule. Since the
medical community would have several
years to examine the GSA medical
supply schedule before the refined
process would be adopted, and we have
found no apparent limitations on
vendors placing products on the GSA
schedule, beyond the schedule’s interest
in competitive, best value
procurements, stakeholders would have
the opportunity to ensure that any highcost direct PE input for a PFS service
that may currently be missing from the
GSA medical supply schedule would be
included before CMS needs to access
the publicly available price for the item.
If a supply price were not publicly
available on the GSA medical supply
schedule by the time CMS needs to
access the price, we would propose to
reduce the current price input for the
supply by a percentage that would be
based on the relationship between GSA
prices at that time and the existing PE
database prices for similar supplies
(currently an average 23 percent
reduction). We believe that this refined
process is desirable because it is
consistent with commenters’ repeated
requests for the updating methodology
to be transparent and predictable.
Moreover, the VA (with responsibility
delegated by the GSA) determines
whether prices are fair and reasonable
by comparing the prices and discounts
PO 00000
Frm 00044
Fmt 4701
Sfmt 4702
that a company offers the government
with the prices and discounts that the
company offers to commercial
customers. Therefore, using the GSA
medical supply schedule as a source for
publicly available prices would also
better account for product-specific
market dynamics than the alternative of
an across-the-board percentage
reduction for supplies not on the GSA
schedule based on general price trends
for the high-cost supplies on the
schedule. That is, if the market price of
a particular supply were not to drop
according to broad trends for other highcost supplies, suppliers would have the
opportunity to provide their price to the
public on the GSA schedule in order to
preclude any reduction in Medicare
payment for procedures associated with
that supply.
Finally, we would like to reiterate that
we are interested in receiving detailed
public comments on the refined process
discussed above, including all aspects of
the price update methodology that we
have presented. Moreover, we believe a
similar approach could potentially be
appropriate to update the prices for
other supplies in the PE database that
would not fall under our definition of
high-cost supplies, and we welcome
further public comments on that
possible extension. We also invite
further suggestions for alternative
approaches to updating high-cost
supply prices, specifically those that
would result in a predictable, public,
and transparent methodology that
would ensure that the prices in the PE
database reflect typical market prices.
These principles are particularly
important in order to ensure that the
services that utilize the high-cost
supplies when provided in the
physician’s office are appropriately
valued under the PFS and continue to
be appropriately valued over time.
D. Geographic Practice Cost Indices
(GPCIs)
1. Background
Section 1848(e)(1)(A) of the Act
requires us to develop separate
Geographic Practice Cost Indices
(GPCIs) to measure resource cost
differences among localities compared
to the national average for each of the
three fee schedule components (that is,
work, PE, and malpractice). While
requiring that the PE and malpractice
GPCIs reflect the full relative cost
differences, section 1848(e)(1)(A)(iii) of
the Act requires that the physician work
GPCIs reflect only one-quarter of the
relative cost differences compared to the
national average. In addition, section
1848(e)(1)(G) of the Act sets a
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
permanent 1.5 work GPCI floor in
Alaska for services furnished beginning
January 1, 2009. Section 1848(e)(1)(C) of
the Act requires us to review and, if
necessary, adjust the GPCIs at least
every 3 years. This section also specifies
that if more than 1 year has elapsed
since the last GPCI revision, we must
phase in the adjustment over 2 years,
applying only one-half of any
adjustment in each year. As discussed
in the CY 2009 PFS final rule with
comment period (73 FR 69740), the CY
2009 adjustment to the GPCIs reflected
the fully implemented fifth
comprehensive GPCI update. CY 2010
would have typically included no
adjustments to the GPCIs. However,
section 3102(a) of the ACA amends
section 1848(e)(1)(E) of the Act to
extend the 1.0 work GPCI floor for
services furnished through December
31, 2010. Additionally, section 3102(b)
of the ACA adds a new subparagraph
1848(e)(1)(H) to the Act, which specifies
that for CY 2010 and CY 2011, the
employee compensation and rent
portions of the PE GPCI must reflect
only one-half of the relative cost
differences for each locality compared
to the national average. The new
subparagraph also includes a ‘‘hold
harmless’’ provision for CY 2010 and CY
2011 for any PFS locality that would
otherwise receive a reduction to its PE
GPCI resulting from the limited
recognition of cost differences.
Additionally, section 1848(e)(1)(I) of the
Act (as added by section 10324(c) of
ACA) establishes a 1.0 PE GPCI floor for
services furnished in frontier States
effective January 1, 2011. In May 2010,
we provided our Medicare contractors
with an updated CY 2010 payment file
that included the 1.0 work GPCI floor
and the PE GPCIs calculated according
to the methodology required by section
1848(e)(1)(H) of the Act (as added by
section 3102(b) of ACA) for CY 2010, to
be used for payment of services
furnished on or after January 1, 2010.
For the CY 2011 PFS proposed rule,
we have completed the sixth review of
the GPCIs and are proposing new GPCIs.
We note that section 1848(e)(1)(E) of the
Act (as amended by section 3102(a) of
ACA) extends the 1.0 work GPCI floor
only through December 31, 2010. Under
current statute, the 1.0 work GPCI floor
will expire on January 1, 2011.
Therefore, the CY 2011 physician work
GPCIs and summarized geographic
adjustment factors (GAFs) do not reflect
the 1.0 work floor. However, section
1848(e)(1)(G) of the Act (as amended by
section 134(b) of the MIPPA) set a
permanent 1.5 work GPCI floor in
Alaska for services furnished beginning
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
January 1, 2009; and, as noted above,
section 1848(e)(1)(I) of the Act (as added
by section 10324(c) of ACA) provides
for a permanent 1.0 PE GPCI floor for
frontier States effective January 1, 2011.
Therefore, as required by the statute, the
1.5 work GPCI floor for Alaska and the
1.0 PE GPCI floor for frontier States will
be in effect for CY 2011. In addition to
the limited recognition of certain cost
differences for the PE GPCIs, section
1848(e)(1)(H) of the Act (as added by
section 3102(b) of ACA) also requires us
to complete an analysis of the data
sources used and cost share weights
assigned to the PE GPCIs.
Implementation of ACA provisions
related to the CY 2011 PE GPCIs is
discussed in more detail in the GPCI
update section below.
See Addenda D and E to this
proposed rule for the proposed CY 2011
GPCIs and summarized GAFs.
2. GPCI Update
The proposed updated GPCI values
were developed by Acumen, LLC
(Acumen) under contract to CMS. As
mentioned above, there are three GPCI
components (physician work, PE, and
malpractice), and all GPCIs are
developed through comparison to a
national average for each component.
Additionally, each of the three GPCIs
relies on its own data source(s) and
methodology for calculating its value as
described below.
a. Physician Work GPCIs
The physician work GPCIs are
designed to capture the relative cost of
physician labor by Medicare PFS
locality. Previously, the physician work
GPCIs were developed using the median
hourly earnings from the 2000 Census of
workers in seven professional specialty
occupation categories which we used as
a proxy for physicians’ wages and
calculated to reflect one-quarter of the
relative cost differences for each locality
compared to the national average.
Physicians’ wages are not included in
the occupation categories because
Medicare payments are a key
determinant of physicians’ earnings.
Including physicians’ wages in the
physician work GPCIs would, in effect,
have made the indices dependent upon
Medicare payments.
The physician work GPCIs were
updated in CYs 2001, 2003, 2005, and
2008 using professional earnings data
from the 2000 Census. However, wage
and earnings data are no longer
available from the Census long form and
the 2000 data are outdated. Therefore,
for the proposed sixth GPCI update, we
used the 2006 through 2008 Bureau of
Labor Statistics (BLS) Occupational
PO 00000
Frm 00045
Fmt 4701
Sfmt 4702
40083
Employment Statistics (OES) data as a
replacement for the 2000 Census data.
The use of BLS OES data as a
replacement for the 2000 Census data is
discussed in more detail in the update
of the PE GPCIs section. As noted above,
the 1.0 work GPCI floor is set to expire
under current statute on December 31,
2010. Therefore, the CY 2011 proposed
physician work GPCIs reflect the
removal of this floor.
b. Practice Expense GPCIs
(1) The Affordable Care Act
Requirements for PE GPCIs
General Methodology for the CY 2011
GPCIs
ACA added a new subparagraph
1848(e)(1)(H) to the Act which revises
the methodology for calculating the PE
GPCIs for CY 2010 and CY 2011 so that
the employee compensation and rent
portions of the PE GPCIs reflect only
one-half of the relative cost differences
for each locality compared to the
national average. Additionally, under
section 1848(e)(1)(H)(iii) of the Act (as
added by section 3102(b) of the ACA),
each PFS locality is held harmless so
that the PE GPCI will not be reduced as
a result of the change in methodology
for PE GPCIs. In accordance with
section 1848(e)(1)(H)(ii) of the Act (as
added by section 3102(b) of ACA), the
employee compensation and rent
components of the proposed CY 2011
PE GPCIs were calculated to reflect onehalf of the cost differences for each PFS
locality relative to the national average
cost. Additionally, as required by the
statute, physicians’ services furnished
in each PFS locality would be adjusted
by the higher of the locality’s PE GPCI
calculated with the limited recognition
of employee compensation and rent cost
differences or the PE GPCI calculated
without the limited recognition of cost
differences.
Phase-In of PE GPCIs
Section 1848(e)(1)(C) of the Act
requires us to phase in GPCI
adjustments over 2 years if there was
more than 1 year between GPCI
adjustments. In accordance with the
statute, we are proposing to phase in the
updated PE GPCIs using one-half of the
CY 2010 values and one-half of the fully
implemented values (as described in
this section). To apply the phase-in and
hold harmless provisions of the Act, we
calculated transitional PE GPCIs based
on two scenarios. Under the first
scenario, we calculated transitional CY
2011 PE GPCIs using the full recognition
of employee compensation and rent cost
differences for each locality as
compared to the national average. The
E:\FR\FM\13JYP2.SGM
13JYP2
40084
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
CY 2011 transitional PE GPCI values
with full recognition of cost differences
were calculated using one-half of the CY
2010 PE GPCI values with full
recognition of cost differences and onehalf of the updated PE GPCIs with full
recognition of cost differences. The first
scenario represents the transitional PE
GPCI values prior to the limited
recognition of cost differences. In other
words, this scenario does not include
the effects of sections 1848(e)(1)(H)(i)
and (ii) of the Act (as added by section
3102(b) of ACA).
For the second scenario, we
calculated transitional CY 2011 PE
GPCIs with the limited recognition of
cost differences for the employee
compensation and rent components (as
required by sections 1848(e)(1)(H)(i) and
(ii) of the Act (as added by section
3102(b) of ACA)). The CY 2011
transitional PE GPCI values with the
limited recognition of cost differences
were calculated using one-half of the CY
2010 PE GPCIs with the limited cost
differences and one-half of the updated
PE GPCIs with the limited cost
differences. The hold harmless
provision under section
1848(e)(1)(H)(iii) of the Act (as added by
section 3102(b) of ACA) was applied by
selecting the greater of the CY 2011
transitional PE GPCI value calculated
with the limited recognition of cost
differences or the CY 2011 transitional
PE GCPI value calculated with full
recognition of cost differences. The
phase-in of the CY 2011 PE GPCIs and
application of the hold harmless
provision are illustrated in Table 21
below.
TABLE 21—PHASE-IN OF THE CY 2011 PE GPCIS
CY 2011
(transitional year)
CY 2010
File 1
PE GPCI Without 3102(b) of
ACA.
File 2
PE GPCI With 3102(b) of
ACA.
Updated GPCIs
Hold harmless
Without ACA ..
Without ACA (Updated Data)
(1⁄2 of 2010) + (1⁄2 Updated
GPCI).
Greater of File 1 Transitional
Value.
With ACA .......
With ACA (Updated Data) .....
(1⁄2 of 2010 w/ACA) + (1⁄2 Updated GPCI w/ACA).
or File 2 Transitional Value.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*ACA in this table means the Affordable Care Act.
Data Analysis
Section 1848(e)(1)(H)(iv) of the Act (as
added by section 3102(b) of ACA) also
requires the Secretary to ‘‘analyze
current methods of establishing practice
expense adjustments under
subparagraph (A)(i) and evaluate data
that fairly and reliably establishes
distinctions in the cost of operating a
medical practice in different fee
schedule areas.’’ This section also
requires the Secretary to make
appropriate adjustments to the PE GPCIs
no later than by January 1, 2012. To
implement this statutory requirement,
we are proposing to implement changes
in PE data sources and cost share
weights discussed herein effective
beginning in CY 2011.
In accordance with section
1848(e)(1)(H)(iv) of the Act (as added by
section 3102(b) of ACA), we have
analyzed the current methods and data
sources used in the establishment of the
PE GPCIs. With respect to the method
used, we began with a review of the
GAO’s March 2005 Report entitled,
‘‘MEDICARE PHYSICIAN FEES:
Geographic Adjustment Indices Are
Valid in Design, but Data and Methods
Need Refinement’’ (GAO–05–119).
While we have raised concerns in the
past about some of the GAO’s GPCI
recommendations, we note that with
respect to the PE GPCIs, the GAO did
not indicate any significant issues with
the methods underlying the PE GPCIs.
Rather, the report focused on some of
the data sources used in the method.
For example, the GAO stated that the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
wage data used for the PE GPCIs are not
current. Similarly, upon our
reexamination of public comments we
have received on the PE GPCIs for
previous updates, we note that the
commenters predominately focused on
either the data sources used in the
method or raised issues such as
incentivizing the provision of care in
different geographic areas. However, the
latter issue (incentivizing the provision
of care) is outside the scope of the
statutory requirement that the PE GPCIs
reflect the relative costs of the mix of
goods and services comprising practice
expenses in the different fee schedule
areas relative to the national average.
One key component of the PE GPCI
method that our analysis identified
involved the office expense portion of
the PE GPCIs and the cost share weight
assigned to this component. Most
significantly, we are proposing that the
weight for the office rent component be
revised from 12.209 percent to 8.410
percent to reflect our more detailed
breakout of the types of office expenses
that are determined in local markets
instead of national markets. For
example, for previous GPCI updates, we
used the office expenses cost category as
the cost share weight for office rent and,
therefore, all individual components
previously included in the office
expenses category were adjusted for
local area cost differences by the GPCIs.
As discussed in section II.E.1. of this
proposed rule, we are proposing to
disaggregate the broader office expenses
component into 9 new cost categories as
PO 00000
Frm 00046
Fmt 4701
Sfmt 4702
part of the proposed CY 2011 MEI
rebasing. The disaggregation of the
office expenses category indicates that
the fixed capital cost category, for which
the consumer price index (CPI) for
owner’s equivalent rent is the price
proxy, is the office expense category
applicable to the office rent component
of the PE GPCI. Therefore, the fixed cost
capital cost category is the only
component of office expenses that we
are proposing to adjust for local area
cost differences beginning in CY 2011.
We are proposing to assign other newly
defined components of the office
expenses category (for example,
utilities, chemicals, paper, rubber and
plastics, telephone, postage, and
moveable capital) to the medical
equipment, supplies, and other
miscellaneous expenses cost component
of the PE GPCIs. As discussed later in
this section, the medical equipment,
supplies, and other miscellaneous
expenses component of the PE GPCIs is
assumed to have a national market and,
therefore, this component is not
adjusted for local area cost differences.
The proposed expense categories for
the PE GPCIs, along with their
respective cost share weights, are
primarily derived from the 2006
American Medical Association (AMA)
Physician Practice Information Survey
(PPIS) for self-employed physicians and
selected self-employed non-medical
doctor specialties. The PPIS is the most
comprehensive, multispecialty,
contemporaneous, and consistently
collected PE data source available. It
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
was developed by medical organizations
and captures the costs of operating a
medical practice, including office rents
and nonphysician staff wages.
Moreover, we also examined the
feasibility of using the American
Community Survey (ACS) and the
Bureau of Labor and Statistics (BLS)
Occupational Employment Statistics
(OES) data for the employee
compensation component of the PE
GPCI. For previous updates, the
employee compensation component was
based on the 2000 Decennial Census
long form data. Since the Census data
are significantly outdated and the 2010
Census no longer includes occupational
wage data, we believed the ACS or BLS
OES data might be viable alternatives.
While the ACS 3-year public use
microsample (PUMS) is currently
available, it reflects only about 3 percent
of households and the data exhibit
significant variation due to the small
sample. In particular, the ACS PUMS
has fewer than 10 observations of
pharmacists in the Manhattan,
Beaumont Texas, and Southern Maine
localities. Therefore, we believe it
would be premature to use the ACS data
for determining GPCI values. The 2006,
2007, and 2008 panels from the BLS
OES represent a larger sample than the
ACS PUMS and more recent data than
the 2000 Census. As such, we are
proposing to use the BLS OES data for
updating the GPCIs. We look forward to
exploring the use of the full ACS data
when they become available.
Additionally, we explored other
sources of rent data (including
commercial rental data and survey data)
for use in calculating the PE GPCIs. We
could not identify a reliable alternative
rental data source available on a
national basis with coverage of nonmetropolitan areas.
We do not believe there is a national
data source better than the Housing and
Urban Development (HUD) data for
determining the relative cost differences
in office rents. Therefore, based on our
review of the available data sources, we
are proposing to use the 2010 apartment
rental data produced by HUD at the 50th
percentile as a proxy for the relative cost
difference in physician office rents.
We believe our analysis of the current
methods of establishing PE GPCIs and
our evaluation of data that fairly and
reliably establish distinctions in the cost
of operating a medical practice in the
different fee schedule areas meet the
statutory requirements of section
1848(e)(1)(H)(iv) of the Act (as added by
section 3102(b) of ACA). A more
detailed discussion of our analysis of
current methods of establishing PE
GPCIs and evaluation of data sources is
included in Acumen’s draft report.
Acumen’s draft report and associated
analysis of the sixth GPCI update,
including the PE GPCIs, will be posted
on the CMS Web site after display of
this CY 2011 PFS proposed rule. The
draft report may be accessed from the
PFS Web site at: https://www.cms.gov/
PhysicianFeeSched/ under the
‘‘Downloads’’ section of the CY 2011
PFS proposed rule web page.
Determining the Proposed PE GPCI Cost
Share Weights
To determine the cost share weights
for the proposed CY 2011 GPCIs, we
used the proposed 2006-based Medicare
Economic Index (MEI) as discussed in
section II.E.1. of this proposed rule. The
proposed MEI was rebased and revised
to reflect the weighted-average annual
price change for various inputs needed
to provide physicians’ services. As
discussed in detail in that section, the
proposed expense categories in the MEI,
along with their respective weights, are
40085
primarily derived from data collected in
the 2006 AMA PPIS for self-employed
physicians and selected self-employed
non-medical doctor specialties.
For the cost share weight for the PE
GPCIs, we used the 2006-based MEI
weight for the PE category of 51.734
percent minus the professional liability
insurance category weight of 4.295
percent. Therefore, the proposed cost
share weight for the PE GPCIs is 47.439
percent. For the employee
compensation portion of the PE GPCIs,
we used the nonphysician employee
compensation category weight of 19.153
percent. The fixed capital category
weight of 8.410, for which the CPI for
owner’s equivalent rent is the price
proxy, was used for the office rent
component. To determine the medical
equipment, supplies, and other
miscellaneous expenses component, we
removed professional liability (4.295
percent), nonphysician employee
compensation (19.153 percent), and
fixed capital (8.410 percent) from the PE
category weight (51.734 percent).
Therefore, the proposed cost share
weight for the medical equipment,
supplies, and other miscellaneous
expenses component is 19.876 percent.
Furthermore, the physician
compensation cost category and its
weight of 48.266 percent reflect the
proposed work GPCI cost share weight
and the professional liability insurance
weight of 4.295 percent was used for the
malpractice GPCI cost share weight. We
believe our analysis and evaluation of
the weights assigned to each of the
categories within the PE GPCIs meets
the statutory requirements of section
1848(e)(1)(H)(iv) of the Act (as added by
section 3102(b) of ACA).
The proposed cost share weights for
the CY 2011 GPCIs are displayed in
Table 22 below.
TABLE 22—PROPOSED COST SHARE WEIGHTS FOR CY 2011 GPCI UPDATE
Current cost share
weight
(percent)
Expense category
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Physician Work ........................................................................................................................................
Practice Expense .....................................................................................................................................
—Employee Compensation ..............................................................................................................
—Office Rent ....................................................................................................................................
—Equipment, Supplies, Other ..........................................................................................................
Malpractice Insurance ..............................................................................................................................
52.466
43.669
18.654
12.209
12.806
3.865
Total ...........................................................................................................................................
PE GPCI Floor for Frontier States
Section 10324(c) of ACA added a new
subparagraph (I) under section
1848(e)(1) of the Act to establish a 1.0
PE GPCI floor for physicians’ services
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
furnished in frontier States. In
accordance with section 1848(e)(1)(I) of
the Act (as added by section 10324(c) of
ACA), beginning in CY 2011, we will
apply a 1.0 PE GPCI floor for physicians’
PO 00000
Frm 00047
Fmt 4701
Sfmt 4702
100
Proposed cost
share weight
(percent)
48.266
47.439
19.153
8.410
19.876
4.295
100
services furnished in States determined
to be frontier States. The statute requires
us to define any State as a frontier State
if at least 50 percent of the State’s
counties are determined to be frontier
E:\FR\FM\13JYP2.SGM
13JYP2
40086
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
counties, which the statute defines as
counties that have a population density
less than 6 persons per square mile.
However, section 1848(e)(1)(I) of the Act
(as added by section 10324(c) of ACA)
also specifies that this provision shall
not apply to States receiving a non-labor
related share adjustment under section
1886(d)(5)(H) of the Act (which
excludes Alaska and Hawaii from
qualifying as a frontier State).
Consistent with the proposed FY 2011
hospital inpatient prospective payment
system (IPPS) 1.0 wage index floor for
frontier States (as required by section
10324(a) of the ACA) (75 FR 30920
through 30921), we are proposing to
identify frontier counties by analyzing
population data and county definitions
based upon the most recent annual
population estimates published by the
U.S. Census Bureau. We divide each
county’s population total by each
county’s reported land area (according
to the decennial census) in square miles
to establish population density. We also
are proposing to update this analysis
from time to time, such as upon
publication of a subsequent decennial
census, and if necessary, add or remove
qualifying States from the list of frontier
States based on the updated analysis.
For a State that qualifies as a frontier
State, in accordance with section
1848(e)(1)(I) of the Act (as added by
section 10324(c) of the ACA), we are
proposing that physicians’ services
furnished within that State would
receive the higher of the applicable PE
GPCI value calculated according to the
standard CY 2011 methodology or a
minimum value of 1.00. Furthermore, in
accordance with section 1848(e)(1)(I) of
the Act (as added by section 10324(c) of
the ACA), the frontier State PE GPCI
floor is not subject to budget neutrality
and would only be extended to
physicians’ services furnished within a
frontier State.
For determining the proposed CY
2011 PFS PE GPCI values, the frontier
States are the following: Montana;
Wyoming; North Dakota; Nevada; and
South Dakota (as reflected in Table 23).
TABLE 23—FRONTIER STATES UNDER SECTION 1848(E)(1)(I) OF THE ACT (AS ADDED BY SECTION 10324(c) OF THE
AFFORDABLE CARE ACT)
State
Total counties
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Montana ...........................................................................................................................
Wyoming ..........................................................................................................................
North Dakota ....................................................................................................................
Nevada .............................................................................................................................
South Dakota ...................................................................................................................
(2) Summary of CY 2011 Proposed PE
GPCIs
The PE GPCIs include three
components: employee compensation,
office rent, and medical equipment,
supplies and miscellaneous expenses as
discussed below:
(i) Employee Compensation: We used
the 2006 through 2008 BLS OES data to
determine the proposed employee
compensation component of the PE
GPCIs. Employee compensation
accounts for 40.4 percent of the total PE
GPCIs.
(ii) Office Rents: Consistent with the
previous GPCI update, we used the most
recent residential apartment rental data
produced by HUD (2010) at the 50th
percentile as a proxy for the relative cost
differences in physician office rents.
Office rent accounts for 17.7 percent of
the PE GPCIs.
(iii) Medical Equipment, Supplies,
and other Miscellaneous Expenses: We
assumed that items such as medical
equipment and supplies have a national
market and that input prices do not vary
among geographic areas. As discussed
in previous GPCI updates in the CY
2005 and CY 2008 PFS proposed rules,
specifically the fourth GPCI update (69
FR 47503) and fifth GPCI update (72 FR
38138), respectively, some price
differences may exist, but we believe
these differences are more likely to be
based on volume discounts rather than
on geographic market differences.
VerDate Mar<15>2010
23:56 Jul 12, 2010
Jkt 220001
Medical equipment, supplies, and
miscellaneous expenses are factored
into the PE GPCIs with a component
index of 1.000. The medical equipment,
supplies, and other miscellaneous
expense component are 41.9 percent of
the PE GPCIs.
c. Malpractice GPCIs
The malpractice GPCIs are calculated
based on insurer rate filings of premium
data for $1 million to $3 million mature
claims-made policies (policies for
claims made rather than services
furnished during the policy term). The
proposed CY 2011 malpractice GPCI
update reflects 2006 and 2007 premium
data.
d. General GPCI Update Process
The periodic review and adjustment
of GPCIs is mandated by section
1848(e)(1)(C) of the Act. At each update,
the proposed GPCIs are published in the
PFS proposed rule the year before they
would take effect in order to provide an
opportunity for public comment and
further revisions in response to
comments prior to implementation. As
mentioned above, the proposed CY 2011
updated GPCIs for the first year of the
2-year transition and summarized GAFs
are displayed in Addenda D and E to
this proposed rule.
PO 00000
Frm 00048
Fmt 4701
Sfmt 4702
Frontier counties
56
23
53
17
66
45
17
36
11
34
Percent frontier
counties
80
74
68
65
52
3. Payment Localities
The current PFS locality structure was
developed and implemented in 1997.
There are currently 89 localities; 34
localities are Statewide areas. There are
52 localities in the other 18 States, with
10 States having 2 localities, 2 States
having 3 localities, 1 State having 4
localities, and 3 States having 5 or more
localities. The District of Columbia,
Maryland, and Virginia suburbs, Puerto
Rico, and the Virgin Islands are
additional localities that make up the
remainder of the total of 89 localities.
The development of the current locality
structure is described in detail in the CY
1997 PFS proposed rule (61 FR 34615)
and the subsequent final rule with
comment period (61 FR 59494).
As we have previously noted in the
CYs 2008 and 2009 proposed rules (72
FR 38139 and 73 FR 38513), any
changes to the locality configuration
must be made in a budget neutral
manner within a State and can lead to
significant redistributions in payments.
For many years, we have not considered
making changes to localities without the
support of a State medical association in
order to demonstrate consensus for the
change among the professionals whose
payments would be affected (with some
increasing and some decreasing).
However, we have recognized that, over
time, changes in demographics or local
economic conditions may lead us to
conduct a more comprehensive
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
examination of existing payment
localities.
For the past several years, we have
been involved in discussions with
physician groups and their
representatives about recent shifts in
relative demographics and economic
conditions, most notably within the
current California payment locality
structure. We explained in the CY 2008
PFS final rule with comment period that
we intended to conduct a thorough
analysis of potential approaches to
reconfiguring localities and would
address this issue again in future
rulemaking. For more information, we
refer readers to the CY 2008 PFS
proposed rule (72 FR 38139) and
subsequent final rule with comment
period (72 FR 66245).
As a follow-up to the CY 2008 PFS
final rule with comment period, we
contracted with Acumen to conduct a
preliminary study of several options for
revising the payment localities on a
nationwide basis. The contractor’s
interim report was posted on the CMS
Web site on August 21, 2008, and we
requested comments from the public.
The report entitled, ‘‘Review of
Alternative GPCI Payment Locality
Structures,’’ remains accessible from the
CMS PFS Web page under the heading
‘‘Interim Study of Alternative Payment
Localities under the PFS.’’ The report
may also be accessed directly from the
following link: https://www.cms.hhs.gov/
PhysicianFeeSched/
10_Interim_Study.asp#TopOfPage.
We accepted public comments on the
interim report through November 3,
2008. The alternative locality
configurations discussed in the report
are described briefly below in this
section.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Option 1: CMS Core-Based Statistical
Area (CBSA) Payment Locality
Configuration
This option uses the Office of
Management and Budget (OMB’s)
Metropolitan Statistical Area (MSA)
designations for the payment locality
configuration. MSAs would be
considered as urban CBSAs.
Micropolitan Areas (as defined by OMB)
and rural areas would be considered as
non-urban (rest of State) CBSAs. This
approach would be consistent with the
IPPS pre-reclassification CBSA
assignments and with the geographic
payment adjustments used in other
Medicare payment systems. This option
would increase the number of PFS
localities from 89 to 439.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Option 2: Separate High-Cost Counties
From Existing Localities (Separate
Counties)
E. PFS Update for CY 2010
Under this approach, higher cost
counties are removed from their existing
locality structure and they would each
be placed into their own locality. This
option would increase the number of
PFS localities from 89 to 214, using a 5
percent GAF differential to separate
high-cost counties.
40087
a. Background
Option 3: Separate MSAs From
Statewide Localities (Separate MSAs)
This option begins with statewide
localities and creates separate localities
for higher cost MSAs (rather than
removing higher cost counties from
their existing locality as described in
Option 2). This option would increase
the number of PFS localities from 89 to
130, using a 5 percent GAF differential
to separate high-cost MSAs.
Option 4: Group Counties Within a State
Into Locality Tiers Based on Costs
(Statewide Tiers)
This option creates tiers of counties
(within each State) that may or may not
be contiguous but share similar practice
costs. This option would increase the
number of PFS localities from 89 to 140,
using a 5 percent GAF differential to
group similar counties into statewide
tiers.
As discussed in Acumen’s interim
report, all four studied alternative
locality configurations would increase
the number of localities and separate
higher cost areas from rural ‘‘rest of
state’’ areas. As a result, payments to
urban areas would increase, while rural
areas would see a decrease in payment
because they would no longer be
grouped with higher cost ‘‘urbanized’’
areas. A number of public commenters
on the draft report expressed support for
Option 3 (separate MSAs from
Statewide localities) because the
commenters believed this alternative
would improve payment accuracy over
the current locality configuration and
could mitigate possible payment
reductions to rural areas as compared to
Option 1 (CMS CBSAs). Therefore,
Acumen is conducting a more in-depth
analysis of the dollar impacts that
would result from the application of
Option 3.
For a detailed discussion of the public
comments on the contractor’s interim
locality study report, we refer readers to
the CY 2010 PFS proposed rule (74 FR
33534) and subsequent final rule with
comment period (74 FR 61757).
PO 00000
Frm 00049
Fmt 4701
Sfmt 4702
1. Rebasing and Revising of the
Medicare Economic Index (MEI)
The Medicare Economic Index (MEI)
is required by section 1842(b)(3) of the
Act, which states that prevailing charge
levels beginning after June 30, 1973 may
not exceed the level from the previous
year except to the extent that the
Secretary finds, on the basis of
appropriate economic index data, that
such higher level is justified by year-toyear economic changes. Beginning July
1, 1975, and continuing through today,
the MEI has met this requirement by
reflecting the weighted-average annual
price change for various inputs needed
to provide physicians’ services. The MEI
is a fixed-weight input price index, with
an adjustment for the change in
economy-wide, private nonfarm
business multifactor productivity. This
index is comprised of two broad
categories: (1) Physician’s own time;
and (2) physician’s practice expense
(PE).
The current form of the MEI was
detailed in the November 25, 1992
Federal Register (57 FR 55896) and was
based in part on the recommendations
of a Congressionally-mandated meeting
of experts held in March 1987. Since
that time, the structure of the MEI has
remained essentially unchanged, with
three exceptions. First, the MEI was
rebased in 1998 (63 FR 58845), which
moved the cost structure of the index
from 1992 data to 1996 data. Second,
the methodology for the productivity
adjustment was revised in the CY 2003
PFS final rule (67 FR 80019) to reflect
the percentage change in the 10-year
moving average of economy-wide
private nonfarm business multifactor
productivity. Third, the MEI was
rebased in 2003 (68 FR 63239), which
moved the cost structure of the index
from 1996 data to 2000 data.
We are proposing to rebase and revise
the MEI and incorporate it into the CY
2011 PFS update. The terms ‘‘rebasing’’
and ‘‘revising’’, while often used
interchangeably, actually denote
different activities. Rebasing refers to
moving the base year for the structure of
costs of an input price index, while
revising relates to other types of changes
such as changing data sources, cost
categories, or price proxies used in the
input price index. As is always the case
with a rebasing and revising exercise,
we have attempted to use the most
recently available, relevant, and
appropriate information to develop the
proposed MEI cost category weights and
price proxies. In the following sections
E:\FR\FM\13JYP2.SGM
13JYP2
40088
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
of this proposed rule, we detail our
proposals regarding the updated cost
weights for the MEI expense categories,
our rationale for selecting the price
proxies in the MEI, and the results of
the proposed rebasing and revising of
the MEI.
b. Use of More Current Data
The MEI was last rebased and revised
in 2003 in the CY 2004 PFS final rule
with comment period (68 FR 63239).
The current base year for the MEI is
2000, which means that the cost weights
in the index reflect physicians’ expenses
in 2000. However, we believe it is
desirable to periodically rebase and
revise the index so that the expense
shares and their associated price proxies
reflect more current conditions. For this
reason, we propose to rebase the MEI to
reflect appropriate physicians’ expenses
in 2006.
We are proposing several changes to
the expenses that are eligible to be
included in the MEI. For instance, we
are proposing to remove all costs related
to drug expenses as drugs are not paid
for under the PFS nor are they included
in the definition of ‘‘physicians’
services’’ for purposes of the Sustainable
Growth Rate (SGR) system that is used
to update the PFS. The details of the
decision regarding the removal of
physician-administered drugs from the
SGR system can be found in the CY
2010 PFS proposed rule and finalized in
the CY 2010 final rule with comment
period (74 FR 33651 and 74 FR 61961,
respectively). Additionally, we are
proposing to remove costs associated
with separately billable supplies. The
rationale for removing the separately
billable supplies is discussed further
below in section III.E.1.X of this
proposed rule.
We are proposing to revise the cost
categories in the MEI by expanding the
Office Expense category into nine
detailed categories with additional price
proxies associated with these categories.
Additionally, we will continue to adjust
the MEI for economy-wide multifactor
productivity based on the 10-year
moving average of total private nonfarm
business multi-factor productivity.
c. Rebasing and Revising Expense
Categories in the MEI
The MEI is used in conjunction with
the SGR system to update the PFS and
represents the price component of that
update. The proposed expense
categories in the index, along with their
respective weights, are primarily
derived from data collected in the 2006
AMA Physician Practice Information
Survey (PPIS) for self-employed
physicians and selected self-employed
non-Medical Doctor (non-MD)
specialties. We included data from the
following specialties in the MEI cost
weight calculations (optometrists, oral
surgeons, podiatrists, and chiropractors)
consistent with the definition of the
term ‘‘physician’’ in section 1861(r) of
the Act. In summary, the term
‘‘physician’’ when used in connection
with the performance of functions or
actions an individual is legally
authorized to perform means the
following: (1) A doctor of medicine or
osteopathy; (2) a doctor of dental
surgery or of dental medicine; (3) a
doctor of podiatric medicine; (4) a
doctor of optometry; or (5) a
chiropractor. For a complete definition,
please see section 1861(r) of the Act. We
weighted the expense data from the
above-referenced specialties with the
self-employed physician expense data
using physician counts by specialty.
The AMA data from the PPIS were
used to determine expenditure weights
for total expenses, physicians’ earnings,
physicians’ benefits, employed
physician payroll, nonphysician
compensation, office expenses,
professional liability insurance (PLI),
medical equipment, medical supplies,
and all other expenses. To further
disaggregate into subcategories
reflecting more detailed expenses, we
used data from the 2002 Bureau of
Economic Analysis (BEA) Benchmark
Input-Output table (I/O), the 2006
Bureau of the Census Current
Population Survey (CPS), the 2006
Bureau of Labor Statistics (BLS)
Occupational Employment Survey
(OES) and Employment Cost for
Employee Compensation Survey
(ECEC), and the 2006 Internal Revenue
Service (IRS) Statistics of Income (SOI)
data. The development of each of the
cost categories using these sources is
described in detail below.
(1) Developing the Weights for Use in
the MEI
Developing a rebased and revised MEI
requires selecting a base year and
determining the appropriate expense
categories. We are proposing to rebase
the MEI to CY 2006. We choose CY 2006
as the base year for two primary reasons:
(1) CY 2006 is the most recent year for
which data were available; and (2) we
believe that the CY 2006 data provide a
representative distribution of
physicians’ compensation and PEs.
Compared to the 2000-based MEI, we
are proposing to include 9 new cost
categories (along with their respective
weights) that disaggregate the costs
under the broader Office Expenses cost
category. The 2000-based MEI did not
break these expenses into individual
categories. A more detailed discussion
is provided below in this section. In
addition, we are proposing to exclude
the Pharmaceutical cost category as
pharmaceuticals are neither paid for
under the PFS nor are they included in
the definition of ‘‘physicians’ services’’
for purposes of calculating the
physician update via the SGR system
(for more details see the CY 2010 PFS
final rule with comment period (74 FR
61961 through 61962)). Lastly, we are
proposing to exclude the expenses
associated with separately billable
supplies since these items are not paid
for under the PFS.
We determined the number and
composition of expense categories based
on the criteria used to develop the
current MEI and other CMS input price
index expenditure weights. These
criteria are timeliness, reliability,
relevance, and public availability. Table
24 lists the set of mutually exclusive
and exhaustive cost categories that make
up the proposed rebased and revised
MEI.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
TABLE 24—PROPOSED 2006 MEI COST CATEGORIES, WEIGHTS, AND PRICE PROXIES COMPARED TO THE 2000 MEI
COST CATEGORIES AND WEIGHTS
Proposed
2006–
expense
weights 1 2
Cost category
2000 Expense
weights
Total ...........................................................................................................
100.00
100.000
Physician’s Own Time 3 .............................................................................
Wages and Salaries ...........................................................................
48.266
43.880
52.466
42.730
Proposed 2006 price proxies
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00050
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
AHE Total Nonfarm Private.5
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40089
TABLE 24—PROPOSED 2006 MEI COST CATEGORIES, WEIGHTS, AND PRICE PROXIES COMPARED TO THE 2000 MEI
COST CATEGORIES AND WEIGHTS—Continued
Proposed
2006–
expense
weights 1 2
Cost category
2000 Expense
weights
Benefits 3 4 ...........................................................................................
4.386
9.735
Physician’s Practice Expense ....................................................................
Nonphysician Employee Compensation .............................................
Nonphysician Employee Wages and Salaries ...................................
Prof/Tech Wages .........................................................................
51.734
19.153
13.752
6.006
47.534
18.654
13.809
5.887
Managerial Wages ......................................................................
1.446
3.333
Clerical Wages ............................................................................
4.466
3.892
Services Wages ..........................................................................
1.834
0.696
Nonphysician Employee Benefits 4 ....................................................
Office Expenses .................................................................................
Utilities ................................................................................................
Chemicals ....................................................................................
5.401
20.035
1.139
0.679
4.845
12.209
........................
........................
Paper ...........................................................................................
Rubber & Plastics ........................................................................
Telephone ....................................................................................
Postage .......................................................................................
All Other Labor-Related ..............................................................
0.616
0.563
1.415
0.661
4.718
........................
........................
........................
........................
........................
Fixed Capital ...............................................................................
Moveable Capital .........................................................................
PLI ......................................................................................................
Medical Equipment .............................................................................
Pharmaceuticals and Medical Materials and Supplies ......................
Pharmaceuticals ........................................................................................
Medical Materials and Supplies ..................................................
8.410
1.834
4.295
1.978
1.760
........................
1.760
........................
........................
3.865
2.055
4.320
2.309
2.011
Other Professional Expenses .............................................................
4.513
6.433
Proposed 2006 price proxies
ECI–Benefits Total Nonfarm Private.6
ECI–Wages/Salaries: Private Professional &Technical.
ECI–Wages/Salaries: Private Managerial.
ECI–Wages/Salaries: Private Clerical.
ECI–Wages/Salaries: Private Service.
ECI–Ben: Private Blend.
CPI Fuel & Utilities.7
PPI for Other Basic Organic Chemical Manufacturing PPI325190.8
PPI for converted paper.
PPI for rubber and plastics.
CPI for Telephone Services.
CPI for Postage.
ECI Compensation Services Occupations (ECIPCSONS).
CPI for Owner’s Equivalent Rent.
PPI for Machinery and Equipment.
CMS–Prof. Liab. Phys. Premiums.
PPI–Medical Instruments & Equip.
PPI Surg. Appliances and Supplies/
CPI(U) Med Supplies.
CPI–U All Items Less Food and Energy.
(1) Due to rounding, weights may not sum to 100.000 percent.
(2) Sources: 2006 Physician Practice Information Survey (PPIS), Center for Health Policy Research, American Medical Association; 2006 Employment Cost for Employee Compensation, U.S. Department of Labor, Bureau of Labor Statistics; 2006 Occupational Employment Statistics
(OES), BLS; U.S. Department of Commerce, Bureau of Economic Analysis 2002 Benchmark Input Output Tables, and U.S. Department of Commerce, Bureau of the Census, 2006 Current Population Survey.
(3) Includes employed physician payroll.
(4) Includes paid leave.
(5) Average Hourly Earnings (AHE).
(6) Employment Cost Index (ECI).
(7) Consumer Price Index (CPI).
(8) Producer Price Index (PPI).
The development of each of the cost
categories in the proposed 2006 MEI is
described, in detail, below.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(2) Physician’s Own Time
The component of the MEI that
reflects the physician’s own time is
represented by the net income portion
of business receipts. The proposed 2006
cost weight associated with the
physician’s own time (otherwise
referred to as the Physician’s
Compensation cost weight) is based on
2006 AMA PPIS data for mean
physician net income (physician
compensation) for self-employed
physicians and for the selected selfemployed specialties referenced
previously in this rule.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
We are proposing to continue to add
employed physician compensation to
self-employed physician compensation
in order to calculate an aggregate
Physician Compensation cost weight. By
including the compensation of
employed physicians in the physician
compensation expense category, these
expenses will be adjusted by the
appropriate price proxies for a
physician’s own time. The proposed
2006 Physician Compensation cost
weight is 48.266 percent as compared to
a 52.466 percent share in the 2000-based
MEI. We split the physician
compensation component into
subcategories: Wages & Salaries and
Benefits. For Physician Compensation,
the ratio for Wages & Salaries and
PO 00000
Frm 00051
Fmt 4701
Sfmt 4702
Benefits was calculated using data from
the PPIS. Self-employed physician
wages & salaries accounted for 92.3
percent of physician earnings while
physician benefits accounted for the
remaining 7.8 percent. For employed
physician payroll, the distribution for
wages & salaries and benefits for 2006
was 85.8 percent and 14.2 percent,
respectively. This ratio was determined
by calculating a weighted average of
available SOI data for partnerships,
corporations, and S-corporations
specific to physicians and outpatient
care centers. Based on these proposed
methods, the proposed 2006 Physician
Wages & Salaries cost weight is 43.880
percent and the proposed 2006
E:\FR\FM\13JYP2.SGM
13JYP2
40090
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Physician Benefits cost weight is 4.386
percent.
(3) Physician’s Practice Expenses
To determine the remaining
individual Practice Expenses cost
weights, we use mean expense data
from the 2006 PPIS survey. The detailed
explanations for the derivation of the
individual weights under Practice
Expenses are listed below.
(A) Nonphysician Employee
Compensation
The cost weight for Nonphysician
Employee Compensation was developed
using the 2006 AMA PPIS mean
expenses for these costs. We further
divided this cost share into Wages &
Salaries and Benefits using 2006 BLS
Employer Costs for Employee
Compensation (ECEC) data for the
Health Care and Social Assistance
(private industry). Although this survey
does not contain data specifically for
offices of physicians, data are available
to help determine the shares associated
with wages & salaries and benefits for
private industry health care and social
assistance services (which include
hospitals, nursing homes, offices of
physicians, and offices of dentists). We
believe these data provide a reasonable
estimate of the split between wages and
benefits for employees in physicians’
offices. Data for 2006 in the ECEC for
Health Care and Social Assistance
indicate that wages and benefits are 71.8
percent and 28.2 percent of
compensation, respectively. The 2000based MEI included a wage and benefit
split of 74.0 percent and 26.0 percent of
compensation.
As in the 2000-based MEI, we are
proposing to use 2006 Current
Population Survey (CPS) data and 2006
BLS Occupational Employment
Statistics (OES) data to develop cost
weights for wages for nonphysician
occupational groups. We determined
total annual earnings for offices of
physicians using employment data from
the CPS and mean annual earnings from
the OES. To arrive at a distribution for
these separate categories, we
determined annual earnings for each of
the four categories (which are
Professional & Technical workers,
Managers, Clerical workers, and Service
workers), using the Standard
Occupational Classification (SOC)
system. We then determined the overall
share of the total for each. The proposed
distribution, as well as the distribution
from the 2000-based MEI are presented
in Table 25.
TABLE 25—PERCENT DISTRIBUTION OF NONPHYSICIAN PAYROLL EXPENSE BY OCCUPATIONAL GROUP: 2006 AND 2000
2006
Expenditure
shares
BLS Occupational Group
2000
Expenditure
shares
Total .................................................................................................................................................................
100.000
100.000
Professional & Technical Workers ...........................................................................................................
Managers ..................................................................................................................................................
Clerical Workers .......................................................................................................................................
Service Workers .......................................................................................................................................
43.671
10.517
32.477
13.336
42.635
24.138
28.187
5.040
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Values may not sum to 100 due to rounding.
The decrease in the Management
expenditure share is directly related to
a decrease in the total number of
employees in Management occupations
in physicians’ offices, in particular,
‘‘Medical and health service managers.’’
The decrease in expenditure share may
also be due, in part to the methods used
in this rebasing. That is, for the 2006based MEI, we are using data limited to
‘‘Offices of physicians.’’ In the 2000based version of the index, the only data
that were available to inform these
estimates were inclusive of physician
offices and clinics (‘‘Offices of
physicians and clinics’’). An
examination of 2006 CPS and OES data
comparing ‘‘Outpatient care centers’’ to
‘‘Offices of physicians’’ indicates that
there is a higher share of management
occupations in the ‘‘Outpatient care
centers’’ than in ‘‘Offices of physicians.’’
The increase in the Service Workers
expenditures share is attributable to a
substantive increase in the number of
employees in service occupations,
particularly, ‘‘Medical assistants and
other health care support occupations’’.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(B) Office Expenses
The aggregate Office Expenses cost
weight was derived using the 2006
AMA PPIS and is explained in more
detail below in this section. This
calculation resulted in a 20.035 percent
share of total costs in 2006 compared to
a 12.209 percent share in the 2000-based
index.
For the 2006-based MEI, we propose
to further disaggregate the Office
Expenses into more detailed cost
categories using the BEA 2002–
Benchmark I/O data for Offices of
physicians, dentists, and other health
practitioners (NAICS 621A00). We used
this data to develop the nine detailed
2002 costs weights as a percent of total
office expenses, as measured by the BEA
I/O data. The total Office Expenses cost
category was calculated by matching the
BEA I/O data as closely as possible to
the AMA survey data, the latter of
which defined office expenses as ‘‘office
(non-medical) equipment and office
(non-medical) supplies, as well as rent,
mortgage, interest, maintenance,
refrigeration, storage, security, janitorial,
depreciation on medical buildings used
in your practice, utilities, or other office
computer systems (including
PO 00000
Frm 00052
Fmt 4701
Sfmt 4702
information management systems/
electronic medical record systems) and
telephone.’’
We then aged the 2002 weights
forward to 2006 to derive the 2006
detailed office expense cost weights as
a percent of total Office Expenses. The
methodology we used to age the data
forward involved applying the annual
price changes from each respective price
proxy to the appropriate cost categories.
We repeated this practice for each year
of the interval. We then applied the
resulting 2006 distributions to the
aggregate 2006 AMA Office Expenses
weight to yield the detailed 2006 Office
Expenses’ weights as a percent of total
expenses.
We are proposing to introduce these
new, more detailed weights for the
2006-based index based on our intent to
derive an increased level of precision
while maintaining appropriate levels of
aggregation in the market basket. The
proposed proxies are described in
section X. of this proposed rule. The
following is a description of what is
included in each of the detailed cost
categories.
• Utilities: The Utilities cost weight
includes expenses classified in the fuel,
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
oil and gas, water and sewage, and
electricity industries. The proposed cost
weight for utilities is 1.139 percent.
• Paper: The Paper cost weight
includes expenses classified in the
paper (including but not limited to
paper, paperboard, and sanitary paper
products) and printing industries. The
proposed cost weight for paper is 0.616
percent.
• Chemicals: The Chemicals cost
weight includes expenses classified in
the basic organic and inorganic
chemical manufacturing industry
(accounting for about 45 percent of the
chemical expenses), as well as other
chemical industries including but not
limited to industrial gas manufacturing
and all other chemical product
manufacturing. The proposed cost
weight for chemicals is 0.679 percent.
• Rubber and Plastics: The Rubber
and Plastics cost weight includes
expenses classified in the rubber and
plastic industries, including but not
limited to, urethane and other foam
product manufacturing and other plastic
and rubber manufacturing industries.
The proposed cost weight for Rubber
and Plastics is 0.563 percent.
• Telephone: The telephone cost
weight includes expenses classified in
the telecommunications (accounting for
the majority of the telephone expenses)
and cable industries. The proposed cost
weight for Telephone services is 1.415
percent.
• Postage: The Postage cost weight
includes postal service expenses. The
proposed cost weight for Postage is
0.661 percent.
• All Other Services: The All Other
Services cost weight includes other
service expenses including, but not
limited to, nonresidential maintenance
and repair, machinery repair, janitorial,
and security services. This cost weight
does not include expenses associated
with professional services such as
accounting, billing, legal and marketing
which are included in the All Other
Expenses cost weight derived using the
AMA PPIS survey. The proposed cost
weight for All Other Services is 4.718
percent.
• Fixed Capital: The Fixed Capital
cost weight includes expenses for
building leases and depreciation. The
proposed cost weight for Fixed Capital
is 8.410 percent.
• Moveable Capital: The Moveable
Capital cost weight includes expenses
for non-medical equipment including
but not limited to, computer equipment
and software, as well as the rental and
leasing of automotive and industrial
machinery equipment. The proposed
cost weight for Moveable Capital is
1.834 percent.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(C) Professional Liability Insurance (PLI)
Expense
The weight for PLI expense was
derived from the 2006 AMA survey and
was calculated as the mean PLI expense
expressed as a percentage of total
expenses. This calculation resulted in a
4.513 percent share of total costs in
2006 compared to a 3.865 percent share
in the 2000-based index. The increase in
the weight for PLI reflects the current
prices of premiums, as well as an
update to the level of coverage
purchased by physicians in 2006
compared to 2000.
(D) Medical Equipment Expenses
The proposed weight for Medical
Equipment was calculated using the
2006 AMA PPIS mean expense data.
This calculation resulted in a 1.978
percent share of total costs in 2006
compared to a 2.055 percent share in the
2000-based index. By definition, this
category includes the expenses related
to depreciation, maintenance contracts,
leases/rental of medical equipment used
in diagnosis or treatment of patients.
The category would also include the
tax-deductible portion of the purchase
price or replacement value of medical
equipment, if not leased.
(E) Medical Supplies Expenses
The proposed weight for Medical
Supplies was calculated using the 2006
AMA PPIS mean expense data. This
calculation resulted in a 1.760 percent
share of total costs in 2006 compared to
a 2.011 percent share in the 2000-based
index. By definition, this category
includes the expenses related to medical
supplies such as sterile gloves, needles,
bandages, specimen containers, and
catheters. Additionally, we are
proposing to exclude the expenses
related to separately billable supplies as
these expenses are not paid for under
the PFS. The Medical Supply cost
category does not include expenses
related to drugs.
(F) All Other Professional Expenses
The proposed weight for All Other
Professional expenses was calculated
using the 2006 AMA PPIS mean
expense data. This calculation resulted
in a 4.513 percent share of total costs in
2006 compared to a 6.433 percent share
in the 2000-based index. By definition,
this category includes the expenses
related to tax-deductible expenses for
any other expenses not reported in
another category from the PPIS. These
expenses would include fees related to
legal, marketing, accounting, billing,
office management services,
professional association memberships,
maintenance of certification or
PO 00000
Frm 00053
Fmt 4701
Sfmt 4702
40091
licensure, journals and continuing
education, professional car upkeep and
depreciation, and any other professional
expenses not reported elsewhere on the
PPIS.
d. Selection of Price Proxies for Use in
the MEI
After the proposed 2006 cost weights
for the rebased and revised MEI were
developed, we reviewed all of the price
proxies to evaluate their
appropriateness. As was the case in the
development of the 2000-based MEI (68
FR 63239), most of the proxy measures
we considered are based on BLS data
and are grouped into one of the
following five categories:
• Producer Price Indices (PPIs): PPIs
measure price changes for goods sold in
markets other than retail markets. These
fixed-weight indexes are a measure of
price change at the intermediate or final
stage of production. They are the
preferred proxies for physician
purchases as these prices appropriately
reflect the product’s first commercial
transaction.
• Consumer Price Indices (CPIs): CPIs
measure change in the prices of final
goods and services bought by
consumers. Like the PPIs, they are fixedweight indexes. Since they may not
represent the price changes faced by
producers, CPIs are used if there are no
appropriate PPIs or if the particular
expenditure category is likely to contain
purchases made at the final point of
sale.
• Average Hourly Earnings (AHEs):
AHEs are available for production and
nonsupervisory workers for specific
industries, as well as for the nonfarm
business economy. They are calculated
by dividing gross payrolls for wages &
salaries by total hours. The series
reflects shifts in employment mix and,
thus, is representative of actual changes
in hourly earnings for industries or for
the nonfarm business economy.
• ECIs for Wages & Salaries: These
ECIs measure the rate of change in
employee wage rates per hour worked.
These fixed-weight indexes are not
affected by employment shifts among
industries or occupations and thus,
measure only the pure rate of change in
wages.
• ECIs for Employee Benefits: These
ECIs measure the rate of change in
employer costs of employee benefits,
such as the employer’s share of Social
Security taxes, pension and other
retirement plans, insurance benefits
(life, health, disability, and accident),
and paid leave. Like ECIs for wages &
salaries, the ECIs for employee benefits
are not affected by employment shifts
among industries or occupations.
E:\FR\FM\13JYP2.SGM
13JYP2
40092
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
When choosing wage and price
proxies for each expense category, we
evaluate the strengths and weaknesses
of each proxy variable using the
following four criteria.
• Relevance: The price proxy should
appropriately represent price changes
for specific goods or services within the
expense category. Relevance may
encompass judgments about relative
efficiency of the market generating the
price and wage increases.
• Reliability: If the potential proxy
demonstrates a high sampling
variability, or inexplicable erratic
patterns over time, its viability as an
appropriate price proxy is greatly
diminished. Notably, low sampling
variability can conflict with relevance—
since the more specifically a price
variable is defined (in terms of service,
commodity, or geographic area), the
higher the possibility of high sampling
variability. A well-established time
series is also preferred.
• Timeliness of actual published
data: For greater granularity and the
need to be as timely as possible, we
prefer monthly and quarterly data to
annual data.
• Public availability: For
transparency, we prefer to use data
sources that are publicly available.
The BLS price proxy categories
previously described meet the criteria of
relevance, reliability, timeliness, and
public availability. Below we discuss
the proposed price-wage proxies for the
rebased and revised MEI (as shown in
Table 23).
(1) Expense Categories in the MEI
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(A) Physician’s Own Time (Physician
Compensation)
In the proposed revised and rebased
MEI, we are using the AHE for the
private nonfarm economy as the proxy
for the Physician Wages & Salaries
component (BLS series code:
CEU0500000008).
As discussed extensively in the
November 2, 1998 final rule (63 FR
58848), and again in the December 31,
2002 final rule (67 FR 80019), we
believe that this price proxy represents
the most appropriate proxy for use in
the MEI. The AHE for the nonfarm
business economy reflects the impacts
of supply, demand, and economy-wide
productivity for the average worker in
the economy. As such, use of this proxy
is consistent with the original legislative
intent that the change in the physicians’
earnings portion of the MEI follow the
change in general earnings for the
economy. Since earnings are expressed
per hour, a constant quantity of labor
input per unit of time is reflected.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Finally, the use of the AHE data is also
consistent with our using the BLS
economy-wide private nonfarm business
sector multifactor productivity measures
since economy-wide wage increases
reflect economy-wide productivity
increases.
The current 2000-based MEI uses the
ECI for Total Benefits (BLS series code:
CIU2030000000000I) for total private
industry as the price proxy for
Physician Benefits. We are proposing to
use the same proxy for the 2006-based
MEI. This means that both the wage and
benefit proxies for physician earnings
are derived from the private nonfarm
business sector and are computed on a
per-hour basis.
(B) Nonphysician Employee
Compensation
For the 2006-based MEI, we are
proposing to use Current Population
Survey (CPS) data on employment by
occupation and earnings from the BLS
Occupational Employment Statistics for
NAICS 6211, Office of Physicians, to
develop labor cost shares for the
nonphysician occupational groups
shown in Table 23. The 2000-based MEI
was based on CPS data for the Standard
Industrial Classification 801 and 803,
which included both office of
physicians and outpatient care centers.
Beginning in 2003, BLS began
publishing CPS data on a NAICS basis
which provided data for office of
physicians (NAICS 6211)and outpatient
care centers (NAICS 6214) separately.
We believe using data for office of
physicians is appropriate for the 2006based MEI. The BLS maintains an ECI
for each selected industry group. We
propose to use these ECIs as price
proxies for nonphysician employee
wages in the same manner they are used
in the current MEI.
As described in the CY 2008 PFS
proposed rule (72 FR 38190), as a result
of the discontinuation of the White
Collar Benefit ECI for private workers,
we are currently using a composite ECI
benefit index. We are proposing to
continue to use the composite ECI for
nonphysician employees in the
proposed rebased and revised MEI;
however, we are proposing to revise the
weights within that blend in order to
reflect the more recent 2006 data. Table
26 lists the four ECI series and
corresponding weights used to construct
the 2006 composite benefit index.
PO 00000
Frm 00054
Fmt 4701
Sfmt 4702
TABLE 26—CMS COMPOSITE PRICE
INDEX FOR NONPHYSICIAN EMPLOYEE BENEFITS
ECI series
Benefits, Private, Professional &
Related ......................................
Benefits, Private, Management,
Business, Financial ...................
Benefits, Private, Office & Administrative Support ........................
Benefits, Private, Service Occupations ...........................................
2006
Weight
(%)
44
11
32
13
(C) Utilities
For the 2006-based MEI, we are
proposing to use the CPI for Fuel and
Utilities (BLS series code
#CUUR0000SAH2) to measure the price
growth of this cost category. This cost
category was not broken-out separately
in the 2000-based MEI.
(D) Chemicals
For the 2006-based MEI, we are
proposing to use the PPI for Other Basic
Organic Chemical Manufacturing (BLS
series code #PCU32519–32519) to
measure the price changes of this cost
category. We are proposing this
industry-based PPI because BEA’s 2002
benchmark I/O data show that the
majority of the office of physicians’
chemical expenses are attributable to
Other Basic Organic Chemical
Manufacturing (NAICS 32519). This cost
category was not broken-out separately
in the 2000-based MEI.
(E) Paper
For the 2006-based MEI, we are
proposing to use the PPI for Converted
Paper and Paperboard (BLS series code
#WPU0915) to measure the price growth
of this cost category. This cost category
was not broken-out separately in the
2000-based MEI.
(F) Rubber and Plastics
For the 2006-based MEI, we are
proposing to use the PPI for Rubber and
Plastic Products (BLS series code
#WPU07) to measure the price growth of
this cost category. This cost category
was not broken-out separately in the
2000-based MEI.
(G) Telephone
For the 2006-based MEI, we are
proposing to use the CPI for Telephone
Services (BLS series code
#CUUR0000SEED) to measure the price
growth of this cost category. This cost
category was not broken-out separately
in the 2000-based MEI.
E:\FR\FM\13JYP2.SGM
13JYP2
40093
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(H) Postage
For the 2006-based MEI, we are
proposing to use CPI for Postage (BLS
series code #CUUR0000SEEC01) to
measure the price growth of this cost
category. This cost category was not
broken-out separately in the 2000-based
MEI.
(I) All Other Services
For the 2006-based MEI, we are
proposing to use the ECI for
Compensation for Service Occupations
(private industry) (BLS series code
#CIU2010000300000I) to measure the
price growth of this cost category. This
cost category was not broken-out
separately in the 2000-based MEI.
(J) Fixed Capital
For the 2006-based MEI, we are
proposing to use the CPI for Owner’s
Equivalent Rent (BLS series code
#CUUS0000SEHC) to measure the price
growth of this cost category. This price
index represents about 50 percent of the
CPI for Housing which was used to in
the 2000-based MEI to proxy total office
expenses.
(K) Moveable Capital
For the 2006-based MEI, we are
proposing to use the PPI for Machinery
and Equipment (series code #WPU11) to
measure the price growth of this cost
category. This cost category was not
broken-out separately in the 2000-based
MEI.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(L) Professional Liability Insurance
In order to accurately reflect the price
changes associated with PLI, each year,
we solicit PLI premium data for
physicians from a sample of commercial
carriers. This information is not
collected through a survey form, but
instead is requested directly from, and
provided by (on a voluntary basis),
several national commercial carriers. As
we require for our other price proxies,
the professional liability price proxy is
intended to reflect the pure price change
associated with this particular cost
category. Thus, it does not include
changes in the mix or level of liability
coverage. To accomplish this result, we
obtain premium information from a
sample of commercial carriers for a
fixed level of coverage, currently $1
million per occurrence and a $3 million
annual limit. This information is
collected for every State by physician
specialty and risk class. Finally, the
State-level, physician-specialty data are
aggregated by effective premium date to
compute a national total, using counts
of physicians by State and specialty as
provided in the AMA publication,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Physician Characteristics and
Distribution in the U.S.
The resulting data provide a quarterly
time series, indexed to a base year
consistent with the MEI, and reflect the
national trend in the average
professional liability premium for a
given level of coverage, generally $1
million/$3 million of claims-made
mature policies. From this series,
quarterly and annual percent changes in
PLI are estimated for inclusion in the
MEI.
The most comprehensive data on
professional liability costs are held by
the State insurance commissioners, but
these data are available only with a
substantial time lag and hence, the data
currently incorporated into the MEI are
much timelier. We believe that, given
the limited data available on
professional liability premiums, the
information and methodology described
above adequately reflect the PLI price
trends facing physicians.
(M) Medical Equipment
The Medical Equipment cost category
includes depreciation, leases, and rent
on medical equipment. We are
proposing to use the PPI for Medical
Instruments and Equipment (BLS series
code: WPU1562) as the price proxy for
this category, consistent with the price
proxy used in the 2000-based MEI and
other CMS input price indexes.
(N) Medical Materials and Supplies
As is used in the 2000-based MEI, we
are proposing to use a blended index
comprised of 50/50 blend of the PPI
Surgical Appliances (BLS series code:
WPU156301) and the CPI–U for Medical
Equipment and Supplies (BLS series
code: CUUR0000SEMG). We believe
physicians purchase the types of
supplies contained within these proxies,
including such items as bandages,
dressings, catheters, I.V. equipment,
syringes, and other general disposable
medical supplies, via wholesale
purchase, as well as at the retail level.
Consequently, we are proposing to
combine the two aforementioned
indexes to reflect those modes of
purchase.
(O) Other Professional Expenses
This category includes the residual
subcategory of other professional
expenses such as accounting services,
legal services, office management
services, continuing education,
professional association memberships,
journals, professional car expenses, and
other professional expenses. Given this
heterogeneous mix of goods and
services, we are proposing to use the
CPI–U for All Items Less Food and
PO 00000
Frm 00055
Fmt 4701
Sfmt 4702
Energy, consistent with the price proxy
used in the 1996 and 2000-based MEI.
(2) Productivity Adjustment to the MEI
The MEI has been adjusted for
changes in productivity since its
inception. In the CY 2003 PFS final rule
(67 FR 80019), we implemented a
change in the way the MEI was adjusted
to account for those changes in
productivity The MEI used for the 2003
physician payment update incorporated
changes in the 10-year moving average
of private nonfarm business (economywide) multifactor productivity that were
applied to the entire index. Previously,
the index incorporated changes in
productivity by adjusting the labor
portions of the index by the 10-year
moving average of economy-wide
private nonfarm business labor
productivity.
We are proposing to continue to use
the current method for adjusting the full
MEI for multifactor productivity in the
rebased and revised MEI.
As described in the CY 2003 PFS final
rule, we believe this adjustment is
appropriate because it explicitly reflects
the productivity gains associated with
all inputs (both labor and non-labor).
We believe that using the 10-year
moving average percent change in
economy-wide multifactor productivity
is appropriate for deriving a stable
measure that helps alleviate the
influence that the peak (or a trough) of
a business cycle may have on the
measure. The adjustment will be based
on the latest available historical
economy-wide nonfarm business
multifactor productivity data as
measured and published by BLS.
e. Results of Rebasing
Table 27 illustrates the results of
updating the MEI from the following
changes to the weights for the Physician
Compensation, Practice Expenses
(excluding PLI), and PLI.
TABLE 27—PERCENT DISTRIBUTION OF
SELECTED PHYSICIAN EXPENSES
USED TO CALIBRATE RVUS: CYS
2006 AND 2000
CY 2006
weight
(%)
Physician Compensation (Own Time) ....
Practice Expenses
(less PLI) ...............
PLI ............................
CY 2000
weight
(%)
48.266
52.466
47.439
4.295
43.669
3.865
The rebased and revised MEI has
several differences as compared to the
2000-based MEI; these changes have
been discussed in detail in prior
E:\FR\FM\13JYP2.SGM
13JYP2
40094
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
sections of this rule. Table 28 shows the
average calendar year percent change
from CY 2004 to CY 2011 for both the
2000- and 2006-based MEIs. The 2006based MEI annual percent changes differ
from the 2000-based MEI annual percent
changes by 0.0 to 0.8 percentage point.
In the 5 most recent years (CYs 2007–
2011), the annual percent change in the
rebased and revised MEI was within 0.3
percentage point of the percent change
in the 2000-based MEI. In the earlier
years, there were bigger differences
between the annual percent change in
the rebased and revised MEI and the
2000-based MEI. The majority of these
differences can be attributed to the
lower benefit cost weight, as measured
by the 2006 AMA data, and the
exclusion of the drug cost weight. The
remaining differences are attributable to
the higher cost weight for PLI, as
measured by the 2006 AMA data.
TABLE 28—ANNUAL PERCENT CHANGE IN THE CURRENT AND PROPOSED REVISED AND REBASED MEI
Proposed
2006-based
MEI
Update year A
CY 2004 ...................................................................................................................................................................
CY 2005 ...................................................................................................................................................................
CY 2006 ...................................................................................................................................................................
CY 2007 ...................................................................................................................................................................
CY 2008 ...................................................................................................................................................................
CY 2009 ...................................................................................................................................................................
CY 2010 ...................................................................................................................................................................
CY 2011 B ................................................................................................................................................................
Avg. Change for CYs 2004–2011 ...........................................................................................................................
Current
2000-based
MEI
2.4
2.1
2.0
1.7
1.9
1.7
1.4
0.3
1.7
2.7
2.9
2.5
2.0
1.8
1.7
1.2
0.3
1.9
A Update year based on historical data through the second quarter of the prior calendar year. For example, the 2010 update is based on historical data through the second quarter 2009.
B Based on the 1st quarter 2010 forecast by HIS Global Insight. With historical data through the 4th quarter 2009.
As shown in Table 29, the projection
of the proposed rebased and revised
MEI for the CY 2011 PFS proposed rule
is an increase of 0.3 percent, identical
to the projected increase using the 2000based MEI. In the CY 2011 PFS final
rule, we will incorporate historical data
through the second quarter of 2010;
therefore, the current estimated increase
of 0.3 percent for 2011 may differ in the
final rule.
TABLE 29—FORECASTED ANNUAL PERCENT CHANGE IN THE CURRENT AND PROPOSED REVISED AND REBASED MEI FOR
CY 2011
Proposed
2006-based
MEI
CY 2011 ...................................................................................................................................................................
2000-based
MEI
0.3
0.3
TABLE 30—FORECASTED ANNUAL PERCENT CHANGE IN THE PROPOSED REVISED AND REBASED MEI CY 2011, ALL
CATEGORIES 1
2006 Weight 2
(%)
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Cost categories
MEI Total, productivity adjusted ..............................................................................................................................
Productivity: 10-year moving average of MFP ........................................................................................................
MEI Total, without productivity adjustment ..............................................................................................................
Physician Compensation (Own Time) 3 ............................................................................................................
Wages and Salaries ..................................................................................................................................
Benefits ......................................................................................................................................................
Practice Expenses ............................................................................................................................................
Nonphysician Compensation .....................................................................................................................
Nonphysician Wages .........................................................................................................................
P&T .............................................................................................................................................
Management ...............................................................................................................................
Clerical ........................................................................................................................................
Services ......................................................................................................................................
Nonphysician Benefits ........................................................................................................................
Other Practice Expenses ..........................................................................................................................
Office Expenses .................................................................................................................................
Utilities .........................................................................................................................................
Chemicals ...................................................................................................................................
Paper ...........................................................................................................................................
Rubber & Plastics .......................................................................................................................
Telephone ...................................................................................................................................
Postage .......................................................................................................................................
All Other Services .......................................................................................................................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00056
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
100.000
N/A
100.000
48.266
43.880
4.386
51.734
19.153
13.752
6.006
1.446
4.466
1.834
5.401
26.308
20.035
1.139
0.679
0.616
0.563
1.415
0.661
4.718
Projected
CY 2011
percent
changes
0.3
1.3
1.6
2.4
2.5
1.5
0.9
1.5
1.5
1.2
1.0
1.8
2.0
1.4
0.4
0.8
¥3.0
¥1.1
¥1.0
¥0.7
1.1
5.5
2.0
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40095
TABLE 30—FORECASTED ANNUAL PERCENT CHANGE IN THE PROPOSED REVISED AND REBASED MEI CY 2011, ALL
CATEGORIES 1—Continued
2006 Weight 2
(%)
Cost categories
Fixed Capital ...............................................................................................................................
Moveable Capital ........................................................................................................................
PLI 4 ....................................................................................................................................................
Medical Equipment .............................................................................................................................
Medical supplies .................................................................................................................................
All Other Expenses ...................................................................................................................................
8.410
1.834
4.295
1.978
1.760
4.513
Projected
CY 2011
percent
changes
0.9
¥0.1
¥2.2
0.8
0.5
1.4
1 The
forecasts are based upon the latest available Bureau of Labor Statistics data as of December 2009.
weights shown for the MEI components are the 2006 base-year weights, which may not sum to subtotals or totals because of rounding.
The MEI is a fixed-weight, Laspeyres-type input price index whose category weights indicate the distribution of expenditures among the inputs to
physicians’ services for CY 2006. To determine the MEI level for a given year, the price proxy level for each component is multiplied by its 2006
weight. The sum of these products (weights multiplied by the price index levels) overall cost categories yields the composite MEI level for a given
year. The annual percent change in the MEI levels is an estimate of price change over time for a fixed market basket of inputs to physicians’
services.
3 The measures of productivity, average hourly earnings, Employment Cost Indexes, as well as the various Producer and Consumer Price Indexes can be found on the Bureau of Labor Statistics Web site at https://stats.bls.gov.
4 Derived from a CMS survey of several major commercial insurers N/A Productivity is factored into the MEI categories as an adjustment to the
price variables; therefore, no explicit weight exists for productivity in the MEI.
2 The
In addition to the proposed revisions
to the MEI mentioned earlier in this
section, we are also proposing to
convene a technical advisory panel later
this year to review all aspects of the
MEI, including the inputs, input
weights, price-measurement proxies,
and productivity adjustment. We will
ask the panel to assess the relevance and
accuracy of these inputs to current
physician practices. The panel’s
analysis and recommendations will be
considered in future rule making to
ensure that the MEI accurately and
appropriately meets its intended
statutory purpose. We are requesting
comments from the physician
community and other interested
members of the public on any other
specific issues that should be
considered by the technical panel.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
f. Adjustments to the RVU Shares To
Match the Proposed Rebased MEI
Weights
As described in the previous section,
we are proposing to rebase the MEI for
CY 2011 based on the most current data
and establish new weights for physician
work, PE, and malpractice under the
MEI. As stated in the previous section,
the MEI was rebased to a CY 1996 base
year beginning with the CY 1999 MEI
(63 FR 58845), and to a CY 2000 base
year beginning with the CY 2004 MEI
(68 FR 63239). For both the CY 1999
and CY 2004 rebasing, we made
adjustments to ensure that our estimates
of aggregate PFS payments for work, PE,
and malpractice were in proportion to
the weights for these categories in the
rebased MEI (63 FR 58829 and 69 FR
1095).
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Consistent with our past practice
when the MEI has been rebased, we are
proposing to make adjustments to
ensure that estimates of aggregate CY
2011 PFS payments for work, PE, and
malpractice are in proportion to the
weights for these categories in the
rebased CY 2011 MEI.
Our proposal would necessitate
increasing the proportion of aggregate
CY 2011 PFS payments for PE and
malpractice and decreasing the
proportion for work. This could be
accomplished by applying adjustments
directly to the work, PE, and
malpractice RVUs. However, we are
cognizant of the public comments made
during prior rulemaking on issues
related to scaling the work RVUs. Many
commenters have indicated a preference
for the work RVUs to remain stable over
time and for any necessary adjustments
that would otherwise be made broadly
to the work RVUs to be accomplished in
an alternative manner. For example, in
past 5-Year Reviews of the work RVUs,
many commenters have cited stability in
the work RVUs, among other reasons, in
their requests that any required budget
neutrality adjustments not be made
directly to the work RVUs. Given these
prior comments, we are proposing to
make the necessary MEI rebasing
adjustments without adjusting the work
RVUs. Instead, we are proposing to
increase the PE RVUs by an adjustment
factor of 1.168 and the malpractice
RVUs by an adjustment factor of 1.413.
The RVUs in Addendum B to this
proposed rule reflect the application of
these adjustment factors. We note that
an application of the 1.413 adjustment
factor to the malpractice RVUs for
services with malpractice RVUs of 0.01
PO 00000
Frm 00057
Fmt 4701
Sfmt 4702
will, due to rounding, result in
malpractice RVUs of 0.01.
Section 1848(c)(2)(B)(ii)(II) of the Act
requires that changes to RVUs cannot
cause the amount of expenditures for a
year to differ by more than $20 million
from what expenditures would have
been in the absence of the changes.
Therefore, as required by section
1848(c)(2)(B)(ii) of the Act, we are
proposing to make an adjustment of
0.921 to the CY 2011 conversion factor
to ensure that the 1.168 adjustment to
the PE RVUs and the 1.413 adjustment
to the malpractice RVUs do not cause an
increase in CY 2011 PFS expenditures.
The current law estimate of the CY 2011
CF is $26.6574.
III. Code-Specific Issues for the PFS
A. Therapy Services
1. Outpatient Therapy Caps for CY 2011
Section 1833(g) of the Act applies an
annual, per beneficiary combined cap
on expenses incurred for outpatient
physical therapy and speech-language
pathology services under Medicare Part
B. A similar separate cap for outpatient
occupational therapy services under
Medicare Part B also applies. The caps
do not apply to expenses incurred for
therapy services furnished in an
outpatient hospital setting. The caps
were in effect during 1999, from
September 1, 2003 through December 7,
2003, and beginning January 1, 2006.
The caps are a permanent provision,
that is, there is no end date specified in
the statute for therapy caps. Beginning
January 1, 2006, the Deficit Reduction
Act (Pub. L. 109–171) (DRA) provided
for exceptions to the therapy caps until
December 31, 2006. The exceptions
E:\FR\FM\13JYP2.SGM
13JYP2
40096
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
process for therapy caps has been
extended through December 31, 2009
pursuant to three subsequent
amendments (in MEIA–TRHCA,
MMSEA, and MIPPA).
Section 1833(g)(5) of the Act (as
amended by section 3103 of the ACA)
extended the exceptions process for
therapy caps through December 31,
2010. We will announce the amount of
the therapy cap for CY 2011 in the CY
2011 PFS final rule with comment
period. The annual change in the
therapy cap is computed by multiplying
the cap amount for CY 2010, which is
$1,860, by the MEI for CY 2011, and
rounding to the nearest $10. This
amount is added to the CY 2010 cap to
obtain the CY 2011 cap. The agency’s
authority to provide for exceptions to
therapy caps (independent of the
outpatient hospital exception) will
expire on December 31, 2010, unless the
Congress acts to extend it. If the current
exceptions process expires, the caps
will be applicable in accordance with
the statute, except for services furnished
and billed by outpatient hospitals.
2. Alternatives to Therapy Caps
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Background
In section 4541 of the Balanced
Budget Act of 1997 (Pub. L. 105–33)
(BBA), the Congress enacted the
financial limitations on outpatient
therapy services (the ‘‘therapy caps’’
discussed above for physical therapy,
occupational therapy, and speechlanguage pathology). At the same time,
the Congress requested that the
Secretary submit a Report to Congress
that included recommendations on the
establishment of a revised coverage
policy for outpatient physical therapy
services and outpatient occupational
therapy services under the statute. The
Balanced Budget Refinement Act of
1999 (Pub. L. 106–113) (BBRA) placed
the first of a series of moratoria on
implementation of the limits. In
addition, it required focused medical
review of claims and revised the report
requirements in section 4541(d)(2) of
the BBA to request a report that
included recommendations on the
following: (A) The establishment of a
mechanism for assuring appropriate
utilization of outpatient physical
therapy services, outpatient
occupational therapy services, and
speech-language pathology services; and
(B) the establishment of an alternative
payment policy for such services based
on classification of individuals by
diagnostic category, functional status,
prior use of services (in both inpatient
and outpatient settings), and such other
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
criteria as the Secretary determines
appropriate, in place of the limits.
In 1999, therapy services were not
defined, but services documented as
therapy were billed and reported when
furnished by a variety of individuals in
many different settings. These services
were not identified in a way that would
allow analysis of utilization or
development of alternative payment
policies.
We have studied therapy services
with the assistance of a number of
contractors over the past 11 years.
Reports of these projects are available
on the CMS Web site at https://
www.cms.gov/TherapyServices/. On
November 9, 2004, we delivered the
Report to Congress, Number 137953,
‘‘Medicare Financial Limitations on
Outpatient Therapy Services’’ that
referenced two utilization analyses. We
periodically updated the utilization
analyses and posted other contracted
reports in order to further respond to the
requirements of the BBRA. Subsequent
reports highlighted the expected effects
of limiting services in various ways and
presented plans to collect data about
patient condition using available tools.
The general belief was that if patient
condition could be reliably determined,
an objective payment policy could be
developed that would ensure
appropriate payment for appropriately
utilized services.
Over the past decade, significant
progress has been made in identifying
the outpatient therapy services that are
billed to Medicare, the demographics of
the beneficiaries who utilize those
services, the types of services, the
HCPCS codes used to bill the services,
the allowed and paid amounts of the
services, and the settings, geographic
locations, and provider types where
services are furnished.
Some of the information that is
necessary to ensure appropriate
utilization and develop objective and
equitable payment alternatives to
therapy caps based on patient condition
has proven difficult to develop. The
influence of prior use of inpatient
services on outpatient use of therapy
services was not accessible due to
systems issues and differences in the
policies, billing, and reporting practices
for inpatient and outpatient therapy
services. The weakness of the ICD–9–
CM diagnostic codes in describing the
condition of the rehabilitation patient
obscured analyses of claims to assess
the need for therapy services. The
primary diagnosis on the claim is a poor
predictor for the type and duration of
therapy services required, which
complicates assignment of patient
cohorts for analysis. Although changes
PO 00000
Frm 00058
Fmt 4701
Sfmt 4702
to the guidance in the Medicare Benefit
Policy Manual (Pub. 100–02) on
documentation of therapy services in
2005 improved the consistency of
records and facilitated chart review, it
became increasingly obvious that
neither claims analysis nor chart review
could serve as a reliable and valid
method to determine a patient’s need for
services or to form the basis for
equitable payment. We concluded that
in order to develop alternative payment
approaches to the therapy caps, we
needed a method to identify patients
with similar risk-adjusted conditions
(cohorts) and then we would identify
the therapy services that are necessary
for the patients to attain the best
outcomes with the most efficient use of
resources.
While we studied therapy utilization,
a number of proprietary tools were
developed by researchers in the
professional community to assess the
outcomes of therapy. Some tool
sponsors collected sufficient
information to predict with good
reliability the amount or length of
treatment that would result in the best
expected outcomes. We encouraged the
use of these proprietary tools in manual
instructions, but proprietary tools do
not serve CMS’ purposes because
modification of proprietary tools may
only be done by the tool sponsor. There
now are some versions of the tools in
the public domain and they are being
utilized widely to identify patient
conditions and, by some insurers, to pay
for efficient and effective treatment.
Examples of such tools including the
National Outcomes Measurement
System (NOMS) by the American
Speech-Language Hearing Association
and Patient Inquiry by Focus On
Therapeutic Outcomes, Inc. (FOTO).
In 2006, Focus on Therapeutic
Outcomes, Inc. delivered to CMS a
report titled, ‘‘Pay for Performance for
Physical Therapy and Occupational
Therapy,’’ which is also available on the
CMS Web site at https://www.cms.gov/
TherapyServices. The purpose of this
project was to simulate a pay-forperformance implementation, designed
to align financial incentives with the
achievement of better clinical outcomes
from services that were delivered
efficiently. The project, funded by HHS/
CMS Grant #18–P–93066/9–01,
demonstrated the predictive validity of
the risk-adjusted pay-for-performance
model and the feasibility of reducing
payments without affecting services to
beneficiaries who need them.
b. Current Activities
The Tax Relief and Health Care Act of
2006 (TRHCA) extended the therapy cap
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
exceptions process through December
31, 2007 and provided funds used for
two CMS projects related to developing
alternative payment approaches for
therapy services that are based on
beneficiary needs. A 5-year project titled
‘‘Development of Outpatient Therapy
Alternatives’’ (DOTPA), awarded to RTI
International, was initiated in order to
develop a comprehensive and uniform
therapy-related data collection
instrument, assess its feasibility, and
determine the subset of the measures
that we could routinely and reliably
collect in support of payment
alternatives. While DOTPA will identify
measurement items relevant to payment,
the project will not deliver a
standardized measurement tool. We
may either develop a tool or allow other
tools to be used for payment purposes
when they include those items that
identify the following: (a) Beneficiary
need; and (b) outcomes (that is
effectiveness of therapy services). In
addition to therapy caps, the DOTPA
project addresses our interest in valuebased purchasing by identifying
components of value, including
beneficiary need and the effectiveness of
therapy services.
The DOTPA project reports are
available on the contractor’s Web site at
https://optherapy.rti.org/. The data
collection design and instrument
development have been completed, and
a Paperwork Reduction Act (PRA)
package was submitted for approval of
the data collection forms by the Office
of Management and Budget (OMB). The
Federal Register notice for the second
round of public comment on this
package was published on April 23,
2010 (75 FR 21296). Once the PRA
package is approved, the contractor will
begin data collection. While approval is
pending, the contractor is recruiting
potential participants in the data
collection, developing training materials
for participants, and updating the
project web site. We are not seeking
public comments on the DOTPA project
in this proposed rule.
The TRCHA also funded the 2-year
project contracted to Computer Sciences
Corporation (CSC) titled ‘‘Short Term
Alternatives for Therapy Services’’
(STATS). STATS will provide
recommendations regarding alternative
payment approaches to therapy caps
that could be considered before
completion of the DOTPA project. The
STATS project draws upon the
analytical and clinical expertise of
contractors and stakeholders to consider
policies, measurement tools, and claims
data that are currently available to
provide further information about
patient condition and the outcomes of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
therapy services. The final report, due
in the fall of CY 2010, will include
recommended actions we could take
within 2 or 3 calendar years to replace
the current cap limits on therapy
services with a policy that pays
appropriately for necessary therapy
services.
c. Potential Short-Term Approaches to
Therapy Caps
On June 30, 2009, we received a draft
of the CSC report titled ‘‘STATS
Outpatient Therapy Practice
Guidelines,’’ a summary of expert
workgroup discussions, and several
short-term payment alternatives for
consideration. CSC discussed options
based on the assumption that short-term
policy changes should facilitate the
development of adequate function and/
or outcomes reporting tools. In the longterm, CSC recommended that payment
be based on function or quality
measurements that adequately perform
risk adjustment for episode-based
payment purposes.
Based on the draft report, additional
stakeholder input, and subsequent
communications with the contractor, in
this proposed rule we are discussing
several potential alternatives to the
therapy caps that could lead to more
appropriate payment for medically
necessary and effective therapy services
that are furnished efficiently. We are
soliciting public comments on this
proposed rule regarding all aspects of
these alternatives, including the
potential associated benefits or
problems, clinical concerns, practitioner
administrative burden, consistency with
other Medicare and private payer
payment policies, and claims processing
considerations. We are not proposing
either short-term or long-term payment
alternatives to the therapy caps at this
time. However, we refer readers to
section II.C.4.(c) of this proposed rule
for our CY 2011 proposal to expand the
MPPR policy to ‘‘always therapy’’
services furnished in a single session in
order to pay more appropriately for
therapy services, taking into
consideration the expected efficiencies
when services are furnished together.
While we are not proposing the
adoption of an MPPR policy for therapy
services specifically as an alternative to
the therapy caps, we acknowledge that
by paying more appropriately for
combinations of therapy services that
are commonly furnished in a single
session, practitioners would be able to
furnish more medically necessary
therapy services to a given beneficiary
before surpassing the caps. This
proposed policy would have the
potential to reduce the number of
PO 00000
Frm 00059
Fmt 4701
Sfmt 4702
40097
beneficiaries impacted by the therapy
caps in a given year.
The three specific short-term options
that we are discussing in this proposed
rule would not require statutory
changes. Some would require moderate
reporting changes that would yield more
detailed information about patient
function and progress to inform future
payment approaches and facilitate the
medical review of services above the
therapy caps at the present time. Others
require new coding and bundled persession payment that would be a first
step toward episode-based payment.
They are not necessarily independent of
each other. Under each of these
alternatives, administrative
simplification with respect to current
policies, such as HCPCS code edits and
‘‘ICD–9–CM to HCPCS code’’ crosswalk
edits that serve to limit utilization
without regard to the patient’s clinical
presentation, could be pursued in the
context of these options.
The first option would modify the
current therapy caps exceptions process
to capture additional clinical
information regarding therapy patient
severity and complexity in order to
facilitate medical review. This approach
would complement the DOTPA project,
which is identifying items to measure
patient condition and outcomes. We
believe the first option may have the
greatest potential for rapid
implementation that could yield useful
information in the short-term. We are
especially interested in detailed public
comments on this option that could
inform a potential proposal to adopt
such an alternative through future
rulemaking. The second option would
involve introducing additional claims
edits regarding medical necessity, in
order to reduce overutilization. The
third option would be to adopt a persession bundled payment that would
vary based on patient characteristics
and the complexity of evaluation and
treatment services furnished in the
session. Each option would require
significant provider and contractor
education, and all would necessitate
major claims processing systems
changes. Moreover, some of the options
may affect beneficiaries by changing the
type or amount of services covered by
Medicare or the beneficiary’s cost
sharing obligations.
Option (1): Revise therapy caps
exceptions process by requiring the
reporting of new patient functionrelated Level II HCPCS codes and
severity modifiers.
This option would require that
clinicians submit beneficiary functionrelated nonpayable HCPCS codes to
replace the –KX modifier (Specific
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40098
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
required documentation on file). Codes
would not be submitted on every claim,
but at episode onset and at periodic
intervals (for example, progress report
intervals of 12 sessions or 30 days—
whichever is less). Codes would be
submitted for all patients in order for
the claims to be paid and not only those
claims approaching or surpassing the
therapy caps. The current –KX modifier
is not useful to identify claims
exceeding therapy caps, because it is
used for services both before and after
the caps are exceeded, and it must be
used on the entire claim for facilities.
New codes also would not identify
claims above the cap, but they would
perform the same function as the
current –KX modifier to signal that
documentation in the medical record
supported medical necessity that should
lead to an exception to the therapy caps.
The codes would also provide more
information for medical review.
Six Level II HCPCS G-codes
representing functions addressed in the
plan of care and 5 (or 7) modifiers
representing severity/complexity would
be utilized to report information on the
claim.
Examples of six new function-related
G-codes:
• GXXXU—Impairments to body
functions and/or structures—current.
• GXXXV—Impairments to body
functions and/or structures—goal.
• GXXXW—Activity limitations and/
or participation restrictions—current.
• GXXXX—Activity limitations and/
or participation restrictions—goal.
• GXXXY—Environmental barriers—
current.
• GXXXZ—Environmental barriers—
goal.
Two potential severity/complexity
scales have been suggested that would
require the adoption of 5 or 7 new
severity modifiers, respectively. Under
one scenario, modifiers based on the
International Classification of Function
could identify severity as follows:
• None (0 to 4 percent);
• MILD (5 to 24 percent);
• MODERATE (25 to 49 percent);
• SEVERE (50 to 95 percent); or
• COMPLETE (96 to 100 percent).
Alternatively, a proportional severity/
complexity scale would use 7 modifiers
to describe impairments, limitations, or
barriers:
• 0 percent;
• 1 to 19 percent;
• 20 to 39 percent;
• 40 to 59 percent;
• 50 to 79 percent;
• 80 to 99 percent; or
• 100 percent.
Implementation of this general
approach would require 6 months to 2
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
years to modify claims processing for
the current therapy caps and exceptions
processing of claims, and to develop,
pilot test, and refine coding before
applying the approach nationally. While
therapists initially would need to learn
the new codes and update their billing
systems, ultimately their reporting
burden would be reduced because the
–KX modifier would not be required on
each claim line for patients with
expenditures approaching or exceeding
the therapy caps. This option could
potentially result in a small reduction in
outpatient therapy expenditures due to
increased Medicare contractor scrutiny
of episodes where functional severity
scores did not change over time, or to
other atypical reporting patterns
associated with the new codes.
In the long-term, these codes and
modifiers could be mapped to reliable
and validated measurement tools (either
currently available tools in the public
domain or newly developed tools from
items on the DOTPA instrument or the
Continuity Assessment Record and
Evaluation (CARE) tool). When
statistically robust patient condition
information has been collected from
claims data, it may be possible to
develop Medicare payment approaches
for outpatient therapy services that
would pay appropriately and similarly
for efficient and effective services
furnished to beneficiaries with similar
conditions who have good potential to
benefit from the services furnished. At
a minimum, the new codes would allow
contractors to more easily identify and
limit the claims for beneficiaries that
show no improvement over reasonable
periods of time.
Option (2): Enhance existing therapy
caps exceptions process by applying
medical necessity edits when perbeneficiary expenditures reach a
predetermined value.
The existing automatic process for
exceptions, and the revised exceptions
process described in Option 1 above,
pay practitioners indefinitely for
services if they attest on the claim by
appending a specific modifier to therapy
HCPCS codes that the services being
furnished are medically necessary and
that supporting documentation is
included in the medical record. Unless
the contractor uses claims edits or does
post payment review, these processes do
not identify or limit unusually high
annual per-beneficiary utilization. High
utilization is not limited to beneficiaries
with multiple or complex conditions.
We could use existing therapy
utilization data to develop annual perbeneficiary medical necessity payment
edits, such as limits to the number of
services per session, per episode, or per
PO 00000
Frm 00060
Fmt 4701
Sfmt 4702
diagnostic grouping, for exceptions to
the therapy caps which could be set at
benchmark payment levels that only a
small percentage of beneficiaries would
surpass in a single year. Once these
levels were reached, additional claims
would be denied and practitioners
would need to appeal those denials if
they wished to challenge Medicare’s
nonpayment.
This alternative would require 1 to 2
years to implement as an expansion of
existing policy, and its effects could be
anticipated by analysis of the current
utilization of therapy services.
Additional practitioner burden would
be incurred in the small number of cases
exceeding the per-beneficiary
expenditure edits when the practitioner
chooses to appeal the medical necessity
denial.
Option (3): Introduce per-session
‘‘Evaluation/Assessment and
Intervention’’ (E&I) codes to bundle
payment for groups of current therapy
HCPCS codes into a single per-session
payment.
As discussed in section II.C.4.(c) of
this proposed rule, multiple therapy
services are often furnished in a single
session, and we are proposing to expand
the MPPR policy to ‘‘always therapy’’
services in CY 2011 in order to take into
consideration the efficiencies that occur
when multiple services (the typical
therapy scenario) are furnished in one
session to a beneficiary. Furthermore,
we note that section 1848(c)(2)(K) of the
Act (as added by section 3134 of the
ACA) regarding potentially misvalued
codes under the PFS specifies that the
Secretary may make appropriate coding
changes, which may include
consolidation of individual services into
bundled codes for payment under the
PFS, as part of her review and
adjustment of the relative values for
services identified as potentially
misvalued.
This option would require that
practitioners submit a single new Level
II HCPCS code to represent all the
therapy services currently reported and
paid separately for an outpatient
therapy session. Payment for the HCPCS
code would be based on patient
characteristics (as identified through
prior CMS contractor analyses) and the
complexity of the evaluation/assessment
and intervention services furnished
during the session. The new coding
requirements would not disrupt the
current exceptions process or the
revised exceptions process described in
Option (1) above. Approximately 12 E&I
codes would be needed, taking into
consideration the basic algorithm shown
in Table 31.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40099
TABLE 31—EVALUATION/ASSESSMENT & INTERVENTION LEVEL II HCPCS CODES
Evaluation/Assessment complexity
Minimal
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Intervention Level:
None ................................................................
Minimal ............................................................
Moderate ..........................................................
Significant ........................................................
We would need to develop and test
operational definitions for each E&I
code so that practitioners would be able
to properly report services and
appropriate relative values could be
established for each per-session code.
We believe that a pilot study might
reveal that the different practice
patterns for the three therapy
professions (physical therapy,
occupational therapy, and speechlanguage pathology) could necessitate
separate relative value determinations
for each E&I code by type of therapy
service furnished. As a result, up to 36
total new Level II HCPCS codes could
be needed (12 per discipline).
We anticipate that the definitions of
E&I codes 1 through 3 and 7 through 12
would describe services that may only
be furnished by a ‘‘clinician’’ (therapist,
physician, or nonphysician
practitioner). E&I codes 1 through 3
would be reported for sessions that
consisted only of evaluations. In
addition, the definitions of E&I codes 4
through 6 would describe services that
could be furnished by or under the
permissible supervision of all qualified
outpatient therapy professionals. Based
upon historical therapy utilization
patterns, the vast majority of E&I codes
submitted would likely fall in the 4
through 9 code range. We would expect
the RVUs under the PFS for all E&I
codes to take into consideration the
efficiencies when multiple services
(those that would be currently reported
under multiple CPT codes) are
furnished.
This option would require 2 to 4 years
to add new codes and conduct a shortterm pilot study to refine coding and
value the 12 new HCPCS codes (or 36
if they are specific to each therapy
discipline). There would be significant
initial practitioner administrative
burden to learn new codes and update
billing systems. However, ultimately,
with elimination of the practitioner’s
reporting of 76 different codes and
many of the associated claims
processing edits, the administrative
burden of reporting therapy services to
Medicare would be minimized. This
bundled approach to reporting and
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
E&I
E&I
E&I
E&I
Code
Code
Code
Code
#1
#4
#7
#10
Moderate
E&I
E&I
E&I
E&I
Code
Code
Code
Code
#2
#5
#8
#11
Significant
E&I
E&I
E&I
E&I
Code
Code
Code
Code
payment could result in more
appropriate valuation of therapy
services that reflects efficiencies when
individually reported services are
furnished in the same session. As a
result, it could lead to reduced therapy
expenditures, as well as a reduction in
the number of beneficiaries affected by
the therapy caps in a given year.
In conclusion, we emphasize that we
continue to be committed to developing
alternatives to the therapy caps that
would provide appropriate payment for
medically necessary and effective
therapy services furnished to Medicare
beneficiaries based on patient needs,
rather than the current therapy caps
which establish financial limitations on
Medicare payment for therapy services
in some settings regardless of medical
necessity. The Congress has repeatedly
intervened to allow exceptions to these
caps for certain time periods, and the
current exceptions are automatically
processed based on a practitioner’s
attestation that medical necessity is
documented in the chart for an
individual patient. We believe that,
ultimately, payment for therapy services
should incentivize the most effective
and efficient care, consistent with
Medicare’s focus on value in its
purchasing.
Therefore, we are soliciting public
comments on potential alternatives to
the therapy caps, including those
discussed in this section of this
proposed rule. The STATS contractor
has worked closely with a broad variety
of clinicians, administrators, scientists,
researchers, and other contractors to
develop the 3 alternatives presented this
discussion. We welcome all public
comments on this propose rule from
interested stakeholders, including
individual therapists from both facility
and nonfacility settings treating Part B
(outpatient) beneficiaries. Among the
topics of interest to us are the following:
• Recommendations for alternative
payment policies (options discussed in
this proposed rule or others) that
address patient needs, while
minimizing payment for inefficient
services or those of limited patient
benefit;
PO 00000
Frm 00061
Fmt 4701
Sfmt 4702
#3.
#6.
#9.
#12.
• Assessment of the practitioner
burden associated with the
recommended policies;
• Likelihood that recommended
changes would minimize fraud, abuse,
and waste;
• Whether the recommendations
could assist CMS in obtaining
meaningful information on patient
function and how that information
could be utilized;
• Whether measurement tools
relevant to assessing the need for
therapy services exist in the public
domain and how they might be utilized;
• What function information should
be collected and how it could be
utilized to ensure necessary care, while
minimizing payment for inefficient
services or those of limited patient
benefit; and
• How therapist behavior, plans of
care, or patient scheduling would be
affected by the recommended
alternatives.
We are committed to finding
alternatives to the current therapy cap
limitations on expenditures for
outpatient therapy services that will
ensure that beneficiaries continue to
receive those medically necessary
therapy services that maximize their
health outcomes. We continue to
dedicate our resources to identifying
alternatives that would encourage the
most efficient and cost-effective
treatments. We believe motivated
therapists, with attention to the most
cost-effective practices, can incorporate
practice efficiencies that benefit patients
by achieving the best possible results at
the lowest cost.
Our STATS and DOTPA projects,
which are currently engaged in data
collection and analysis to inform shortterm and long-term alternatives to the
therapy caps, respectively, lay the
foundation for future payment
alternatives for outpatient therapy
services. We are optimistic that the
STATS project will identify short-term,
feasible alternatives that may be tested
in the future. The DOTPA project will
create a tool and test its use to collect
patient condition information that can
then be applied to identify patient need
E:\FR\FM\13JYP2.SGM
13JYP2
40100
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
for therapy services. Together, these
projects may provide the basis for a
long-term plan to reshape Medicare’s
payment policy for outpatient therapy
services to align with the value-based
purchasing principles that are now
guiding principles of the Medicare
program. We encourage the public to
provide comments so that we may
consider all perspectives as we continue
our work in this important area.
B. Diabetes Self-Management Training
(DSMT) Services (HCPCS Codes G0108
and G0109)
1. Background
Section 4105(a) of BBA provided
coverage for DSMT in outpatient
settings without limiting this coverage
to hospital outpatient departments.
DSMT services consist of educational
and training services furnished to an
individual with diabetes by a certified
provider in an outpatient setting.
Section 4105(a) of the BBA stipulated
that training would be furnished by a
‘‘certified provider’’ which is a physician
or other individual or entity that also
provides other items or services for
which payment may be made under
Medicare. This program is intended to
educate beneficiaries in the successful
self-management of diabetes. The
program includes instructions in selfmonitoring of blood glucose; education
about diet and exercise; an insulin
treatment plan developed specifically
for the patient who is insulindependent; and motivation for patients
to use the skills for self-management.
DSMT services are reported under
HCPCS codes G0108 (Diabetes
outpatient self-management training
services, individual, per 30 minutes)
and G0109 (Diabetes outpatient selfmanagement training services, group
session (2 or more), per 30 minutes).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2. Proposed Payment for DSMT Services
In accordance with section 4105(a) of
the BBA, Medicare payment for
outpatient DSMT services is made
under the PFS as specified in § 414.1
through § 414.48. When we created
HCPCS codes G0108 and G0109, the
only direct costs included in the PE
were registered nurse labor. Section
410.144(a)(4)(a) states that the DSMT
team includes at least a registered
dietitian and a certified diabetes
educator. We did not establish work
RVUs for DSMT services because we
believed training would typically be
performed by individuals other than a
physician, such as a registered nurse (65
FR 83130). However, since that time, we
have received requests from a number of
stakeholders, including the American
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Association of Clinical Endocrinologists
(AACE), the American Association of
Diabetes Educators (AADE), and the
Juvenile Diabetes Research Foundation,
to include physician work in valuing
DSMT services that is similar to the
physician work that has been included
in medical nutrition therapy (MNT)
services since CY 2007 and kidney
disease education (KDE) services since
CY 2010. The stakeholders argued that
because physicians coordinate DSMT
programs, provide patient instruction,
and communicate with referring
physicians, physician work should be
included in the RVUs for DSMT
services. The stakeholders also
requested that we reconsider the direct
PE inputs for DMST services and
include clinical labor for diabetes
educators at a higher hourly rate instead
of registered nurse labor. In addition,
they stated that the supplies and
equipment in the PE for DSMT services
should be the same as for KDE services,
with additional direct PE inputs for a
diabetic educator curriculum, data
tracking software, and DSMT program
accreditation.
For CY 2011, we are proposing to
assign physician work RVUs to DSMT
services that are comparable, as adjusted
for the service times of the HCPCS
codes, to the work RVUs for MNT
services. We are proposing that HCPCS
G0108 for 30 minutes of individual
DSMT services would be crosswalked to
CPT code 97803 (Medical nutrition
therapy; re-assessment and intervention,
individual, face-to-face with the patient,
each 15 minutes) for purposes of
assigning work RVUs, with the
physician work RVUs for CPT code
97803 multiplied by two to account for
the greater time associated with HCPCS
code G0108 (that is, 30 minutes). We are
also proposing that HCPCS G0109 for 30
minutes of group DSMT services would
be crosswalked to CPT code 97804
(Medical nutrition therapy; group (2 or
more individuals(s)), each 30 minutes)
for purposes of assigning work RVUs.
The rationale for the proposed work
RVUs for the DSMT HCPCS G-codes is
based on the similarity of DSMT
services to MNT services in the
individual (CPT code 97803) and group
(CPT code 97804) setting.
For CY 2011, we are also proposing to
modify the PE inputs for DSMT services
to reflect the current equipment and
supplies for the KDE HCPCS G-codes
implemented in the CY 2010 PFS final
rule with comment period (74 FR
61901) (that is, HCPCS codes G0420
(Face-to-face educational services
related to the care of chronic kidney
disease; individual, per session, per one
hour) and G0421 (Face-to-face
PO 00000
Frm 00062
Fmt 4701
Sfmt 4702
educational services related to the care
of chronic kidney disease; group, per
session, per one hour)), based on the
similarity in the equipment and
supplies necessary for DSMT and KDE
services. We have made adjustments to
some of the equipment times for the 30
minute DSMT individual and group
services as compared to the 1 hour
individual and group KDE services. We
are also including a diabetic educator
curriculum and data tracking software
in the PE inputs for DSMT services, but
it is our general practice not to include
program accreditation costs in those PE
inputs. With respect to clinical labor,
rather than changing the current labor
type for DSMT services, we are
proposing to utilize the same approach
as we adopted for MNT services when
we provided physician work RVUs for
those services in CY 2007 (71 FR
69645). Specifically, we are removing
all of the clinical labor from the group
DSMT code and most of the clinical
labor from the individual DSMT code,
given that we are proposing work RVUs
for both DSMT codes for CY 2011.
We believe these proposals would
value DSMT services more consistently
with other similar services that are paid
under the PFS. As a result of our
proposed CY 2011 changes, the
proposed work RVUs for HCPCS codes
G0108 and G0109 are 0.90 and 0.25,
respectively. As described above, we are
also proposing to modify the direct PE
inputs for these codes for CY 2011.
C. End-Stage Renal Disease Related
Services for Home Dialysis (CPT Codes
90963, 90964, 90965, and 90966)
1. End-Stage Renal Disease Home
Dialysis Monthly Capitation Payment
Services (CPT Codes 90963, 90964,
90965, and 90966)
In the CY 2004 PFS final rule with
comment period (68 FR 63216), we
established new Level II HCPCS G-codes
for end-stage renal disease (ESRD)
monthly capitation payment (MCP)
services. For center-based patients,
payment for the G-codes varied based
on the age of the beneficiary and the
number of face-to-face visits furnished
each month (for example, 1 visit, 2–3
visits and 4 or more visits). Under the
MCP methodology, the lowest payment
applied when a physician provided one
visit per month; a higher payment was
provided for two to three visits per
month. To receive the highest payment,
a physician would have to provide at
least four ESRD-related visits per
month. However, payment for home
dialysis MCP services only varied by the
age of beneficiary. Although we did not
initially specify a frequency of required
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
visits for home dialysis MCP services,
we stated that we ‘‘expect physicians to
provide clinically appropriate care to
manage the home dialysis patient’’ (68
FR 63219).
Effective January 1, 2009, the CPT
Editorial Panel created new CPT codes
to replace the G-codes for monthly
ESRD-related services, and we accepted
the new codes for use under the PFS in
CY 2009. The CPT codes for monthly
ESRD-related services for home dialysis
patients include the following, as
displayed in Table 32: 90963, 90964,
90965, and 90966. In addition, the
clinical vignettes used for the valuation
of CPT codes 90963, 90964, 90965, and
90966 include scheduled (and
unscheduled) examinations of the ESRD
patient.
Given that we pay for a physician (or
practitioner) to evaluate the ESRD
patient over the course of an entire
month under the MCP, we believe that
it is clinically appropriate for the
physician (or practitioner) to have at
least one in-person, face-to-face
encounter with the patient per month.
Therefore, we are proposing to require
the MCP physician (or practitioner) to
furnish at least one in-person patient
visit per month for home dialysis MCP
services (as described by CPT codes
90963 through 90966). This requirement
would be effective for home dialysis
MCP services beginning January 1, 2011.
40101
We believe this requirement reflects
appropriate, high quality medical care
for ESRD patients being dialyzed at
home and generally would be consistent
with the current standards of medical
practice.
2. Daily and Monthly ESRD–Related
Services (CPT Codes 90951 through
90970)
In CY 2008, the AMA RUC submitted
recommendations for valuing the new
CY 2009 CPT codes displayed in Table
32 that replaced the MCP HCPCS Gcodes for monthly ESRD-related
services. We accepted these codes for
use under the PFS.
TABLE 32—MCP CODES RECOGNIZED UNDER THE PFS
MCP code
Long descriptor
90951 ................
End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for
the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face
physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for
the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2–3 face-to-face physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients younger than 2 years of age to include monitoring for
the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face physician
visit per month.
End-stage renal disease (ESRD) related services monthly, for patients 2–11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients 2–11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2–3 face-to-face physician visits
per month.
End-stage renal disease (ESRD) related services monthly, for patients 2–11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face physician visit
per month.
End-stage renal disease (ESRD) related services monthly, for patients 12–19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 4 or more face-to-face physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients 12–19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 2–3 face-to-face physician visits
per month.
End-stage renal disease (ESRD) related services monthly, for patients 12–19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents; with 1 face-to-face physician visit
per month.
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face
physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2–3 face-to-face physician visits per month.
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face physician visit per month.
End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to
include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2–11 years of age to include
monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12–19 years of age to include
monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older.
90952 ................
90953 ................
90954 ................
90955 ................
90956 ................
90957 ................
90958 ................
90959 ................
90960 ................
90961 ................
90962 ................
90963 ................
90964 ................
90965 ................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
90966 ................
There are four additional CPT codes
for ESRD-related services that are
reported on a per-day basis. These daily
CPT codes are: 90967 (End-stage renal
disease (ESRD) related services for
dialysis less than a full month of
service, per day; for patients younger
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
than 2 years of age); 90968 (End-stage
renal disease (ESRD) related services for
dialysis less than a full month of
service, per day; for patients 2–11 years
of age); 90969 (End-stage renal disease
(ESRD) related services for dialysis less
than a full month of service, per day; for
PO 00000
Frm 00063
Fmt 4701
Sfmt 4702
patients 12–19 years of age); and 90970
(End-stage renal disease (ESRD) related
services for dialysis less than a full
month of service, per day; for patients
20 years of age and older).
For the MCP codes displayed in Table
32, the AMA RUC initially
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40102
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
recommended 36 minutes of clinical
labor time for the pre-service period.
They also recommended an additional 6
minutes in the post-period for CPT
codes 90960, 90961, 90962, and 90966.
For the four codes describing daily
services (CPT codes 90967 through
90970), the AMA RUC recommended
including 1.2 minutes of clinical labor
per day, which is the prorated amount
of pre-service clinical labor included in
the monthly codes. The AMA RUC also
recommended that CPT codes 90952
and 90953 be contractor-priced.
In the CY 2009 PFS final rule with
comment period (73 FR 69898), we
asked the AMA RUC to reconsider their
recommended PE inputs in the interest
of making certain that they accurately
reflected the typical direct PE resources
required for these services. In addition,
we asked the AMA RUC to review the
physician times for CPT codes 90960
and 90961 that are used in the
calculation of the PE RVUs. We
accepted the work values for the new
CPT codes for ESRD-related services
that were recommended by the AMA
RUC.
Since CY 2009, we have continued to
calculate the PE RVUs for the entire
series of MCP codes displayed in Table
32 by using the direct PE inputs from
the predecessor HCPCS G-codes, except
for CPT codes 90952 and 90953 which
are contractor-priced. We have also
continued to use the physician time
associated with the predecessor HCPCS
G-codes for CPT codes 90960 and 90961
for purposes of calculating the PE RVUs.
In CY 2009, the AMA RUC submitted
new recommendations for CPT codes
90951 and 90954 through 90970. For
each of the MCP codes (CPT code 90951
and CPT codes 90954 through 90966),
the AMA RUC recommended an
increased pre-service clinical staff time
of 60 minutes. For each of the daily
dialysis service codes (CPT codes 90967
through 90970), the AMA RUC
recommended an increased clinical
labor time of two minutes, which is the
prorated amount of clinical labor
included in the monthly codes. The
AMA RUC also recommended an
additional 38 minutes of physician time
for CPT codes 90960 and 90961. This
resulted in a total physician time of 128
minutes and 113 minutes, respectively,
for these codes. The AMA RUC
continued to recommend that CPT
codes 90952 and 90953 be contractorpriced.
For CY 2011, we are proposing to
accept these AMA RUC
recommendations as more accurate
reflections of the typical direct PE
resources required for these services.
Therefore, we are proposing to develop
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
the PE RVUs for CPT code 90951 and
CPT codes 90954 through 90970 using
the direct PE inputs as recommended by
the AMA RUC and reflected in the
proposed CY 2011 PE database, which
is available on the CMS Web site under
the supporting data files for the CY 2011
PFS proposed rule at: https://
www.cms.gov/PhysicianFeeSched/. We
are also proposing to use the AMA RUCrecommended physician times for CPT
codes 90960 and 90961. Consistent with
the AMA RUC’s recommendations, we
are proposing to continue to contractorprice CPT codes 90952 and 90953.
D. Portable X-Ray Set-Up (HCPCS Code
Q0092)
When a portable x-ray is furnished to
a single patient, as many as four
component HCPCS codes may be billed
and paid for the service, including the
portable x-ray transportation (HCPCS
code R0070 (Transportation of portable
x-ray equipment and personnel to home
or nursing home, per trip to facility or
location, one patient seen)); the portable
x-ray set-up (HCPCS code Q0092 (Setup of portable x-ray equipment)); and
the professional and technical
components of the x-ray service itself
(CPT 70000 series). Currently, the direct
PE database contains x-ray equipment in
both the radiology codes in the 70000
series of CPT and HCPCS code Q0092,
the code for the set-up of a portable xray. In the technical component of the
x-ray service is the direct PE input of a
radiology room which contains x-ray
equipment for the various radiology
codes in the 70000 series of CPT. In
addition, portable x-ray equipment is
included as a direct PE input for HCPCS
code Q0092. Thus, x-ray equipment
currently is recognized within the direct
PE values for two of the HCPCS codes
that would be reported for the portable
x-ray service, resulting in an
overvaluation of the comprehensive
portable x-ray service.
Therefore, for CY 2011 we are
proposing to remove portable x-ray
equipment as a direct PE input for
HCPCS code Q0092, in order to pay
more appropriately for the x-ray
equipment used to furnish a portable xray service. We believe the resulting
payment for the comprehensive portable
x-ray service would more appropriately
reflect the resources used to furnish
portable x-ray services by providing
payment for the x-ray equipment solely
through payment for the technical
component of the x-ray service that is
furnished.
PO 00000
Frm 00064
Fmt 4701
Sfmt 4702
E. Pulmonary Rehabilitation Services
(HCPCS Code G0424)
In the CY 2010 PFS proposed rule (74
FR 33614), we proposed to create new
HCPCS G-code G0424 (Pulmonary
rehabilitation, including aerobic
exercise (includes monitoring), per
session, per day) to describe the services
of a pulmonary rehabilitation (PR)
program as specified in section 144(a) of
the Medicare Improvements for Patients
and Providers Act of 2008 (MIPPA).
Using CPT code 93797 (Cardiac rehab
without telemetry) as a reference code,
we proposed to assign 0.18 work RVUs
and 0.01 malpractice RVUs to G0424. To
establish PE RVUs, we reviewed the PE
inputs of similar services, particularly
those of the respiratory therapy HCPCS
codes G0237 (Therapeutic procedures to
increase strength or endurance or
respiratory muscles, face to face, one on
one, each 15 minutes (includes
monitoring)) and G0238 (Therapeutic
procedures to improve respiratory
function, other than described by
G0237, one on one, face to face, per 15
minutes (includes monitoring)), as well
as the cardiac rehabilitation codes, CPT
codes 93797 and 93798 (Physician
services for outpatient cardiac
rehabilitation; with continuous ECG
monitoring (per session)). In the CY
2010 PFS final rule with comment
period (74 FR 61886), we finalized our
proposal with modifications to the code
descriptor and PE inputs, as
recommended by some commenters.
Based on commenters’
recommendations from the CY 2010 PFS
final rule with comment period and
further information furnished by
stakeholders, we are proposing to
increase the work RVUs for HCPCS code
G0424 to 0.28 for CY 2011 to be
comparable to the work RVUs for
cardiac rehabilitation with monitoring
(CPT code 93798) in view of the
monitoring required for HCPCS code
G0424.
In addition, we are also proposing to
increase the clinical labor time for the
respiratory therapist from 15 minutes to
30 minutes and to crosswalk the PE
equipment inputs for HCPCS code
G0424 to those for respiratory treatment
services (HCPCS code G0238), which
include a 1-channel ECG and a pulse
oximeter. We would retain the treadmill
currently assigned to HCPCS code
G0424 and adjust the equipment time to
45 minutes. While several public
commenters recommended this
equipment, these commenters also
requested a full 60 minutes of
respiratory therapist time be included in
the PE for HCPCS code G0424,
comparable to the 15 minutes of
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
respiratory therapist time included in
the one-on-one codes for 15 minutes of
respiratory treatment services (HCPCS
codes G0237 and G0238). However,
because PR services reported under
HCPCS code G0424 can be furnished
either individually or in groups, we
believe that 30 minutes of respiratory
therapist time would be more
appropriate for valuing the typical PR
service.
F. Application of Tissue-Cultured Skin
Substitutes to Lower Extremities
(HCPCS Codes GXXX1 and GXXX2)
There are currently two biological
products, Apligraf and Dermagraft,
which are FDA-approved for the
treatment of diabetic foot ulcers. While
commonly used by podiatrists for this
purpose, these products are also used by
other specialists in the treatment of
other clinical conditions, such as burns.
Many Medicare contractors have
established local coverage
determinations specifying the
circumstances under which these
services are covered. In the case of
diabetic foot ulcers, clinical studies of
Apligraf weekly application were based
on up to 5 treatments over a 12-week
period. In contrast, Dermagraft was
applied weekly, up to 8 treatments over
a 12-week period.
The skin substitute CPT codes were
reviewed and new codes were last
created by the CPT Editorial Panel for
CY 2006. There are currently 2 skin
repair CPT codes that describe Apligraf
application, one primary code, CPT
code 15340 (Tissue cultured allogeneic
skin substitute; first 25 sq cm or less)
and one add-on code, CPT code 15341
(Tissue cultured allogeneic skin
substitute; each additional 25 sq cm, or
part thereof (List separately in addition
to code for primary procedure)) and 4
codes that describe Dermagraft
application, two initial codes based on
body area, CPT codes 15360 (Tissue
cultured allogeneic dermal substitute,
trunk, arms, legs; first 100 sq cm or less,
or 1 percent of body area of infants and
children) and 15365 (Tissue cultured
allogeneic dermal substitute, face, scalp,
eyelids, mouth, neck, ears, orbits,
genitalia, hands, feet, and/or multiple
digits; first 100 sq cm or less, or 1
percent of body area of infants and
children) and two add-on codes, CPT
codes 15361 (Tissue cultured allogeneic
dermal substitute, trunk, arms, legs;
each additional 100 sq cm, or each
additional 1 percent of body area of
infants and children, or part thereof
(List separately in addition to code for
primary procedure)) and 15366 (Tissue
cultured allogeneic dermal substitute,
face, scalp, eyelids, mouth, neck, ears,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
orbits, genitalia, hands, feet, and/or
multiple digits; each additional 100 sq
cm, or each additional 1 percent of body
area of infants and children, or part
thereof (List separately in addition to
code for primary procedure)).
Several stakeholders have expressed
concern about the appropriateness and
equity of the coding and payment for
these services, given their similar uses
and the office resources required when
the products are applied repeatedly over
a number of weeks for treatment of
lower extremity ulcers. They are
concerned that current coding, with the
associated payment policies and relative
values, does not provide for appropriate
payment for the services based on how
they are furnished. In addition, some
stakeholders believe that the current
coding and payment provides a
financial incentive for the selection of
one tissue-cultured product over
another, rather than facilitating clinical
decisionmaking based solely on the
most clinically appropriate product for
the patient’s case. For example, the
Dermagraft and Apligraf application
codes have 90-day and 10-day global
periods, respectively, and their current
values include several follow-up office
visits. When patients are treated
periodically with repeated applications
of the products over several weeks, the
patients may be seen in follow-up by the
physician. However, those encounters
would not be evaluation and
management visits but, instead, would
be procedural encounters that would
typically be valued differently under the
PFS than the follow-up office visits
currently included in the values for the
Dermagraft and Apligraf application
codes. Furthermore, while different
stakeholders have indicated that
debridement and site preparation are
variably performed when these products
are applied, the CPT codes for
Dermagraft application allow separate
reporting of these preparation services
when they are performed, while the
Apligraf application codes bundle these
services. Since CY 2006, the PFS has
accepted the RUC work and PE
recommendations for the Dermagraft
and Apligraf application codes and has
paid accordingly.
With respect to Medicare payment
policy, some Medicare contractors allow
the use of modifier -58 (Staged or
related procedure or service by the same
physician during the postoperative
period) to be reported with the skin
substitute application codes and
provide full payment for the service
each time it is performed, even if the
subsequent application(s) is within the
global period of the service. Other
contractors do not allow the use of
PO 00000
Frm 00065
Fmt 4701
Sfmt 4702
40103
modifier -58, and therefore, provide a
single payment for a series of
applications over 90 days or 10 days, as
applicable to the particular code
reported for the product’s initial
application.
Because of the current inconsistencies
in valuing similar skin substitute
application services and the common
clinical scenarios for their use for
Medicare beneficiaries, we believe that
it would be appropriate to temporarily
create Level II HCPCS G-codes to report
application of tissue-cultured skin
substitutes applied to the lower
extremities in order to provide
appropriate and consistent payment for
the services as they are commonly
furnished. Therefore, we are proposing
to create two new HCPCS G-codes for
CY 2011, GXXX1 (Application of tissue
cultured allogeneic skin substitute or
dermal substitute; for use on lower limb,
includes the site preparation and
debridement if performed; first 25 sq cm
or less) and GXXX2 (Application of
tissue cultured allogeneic skin or
dermal substitute; for use on lower limb,
includes the site preparation and
debridement if performed; each
additional 25 sq cm), that would be
recognized for payment under the PFS
for the application of Apligraf or
Dermagraft to the lower limb. These
codes would not allow separate
reporting of CPT codes for site
preparation or debridement. We
emphasize that we would expect that
the use of these HCPCS G-codes for
payment under Medicare would be
temporary, while stakeholders work
through the usual channels to establish
appropriate coding for these services
that reflects the current common
clinical scenarios in which the skin
substitutes are applied. Furthermore, we
would expect to receive
recommendations from the AMA RUC
for appropriate work values and direct
practice expense inputs for the
applicable codes, according to the usual
process for new or revised codes.
Under the PFS, as a temporary
measure, the HCPCS G-codes would be
assigned a 0-day global period so
payment would be made each a time a
covered service was furnished. We are
proposing to base payment on the
physician work relative values and the
direct PE inputs for the existing CPT
codes for Apligraf application, with
adjustments for the global period
differences because the HCPCS G-codes
and the Apligraf application CPT codes.
These CPT codes resemble the new
HCPCS G-codes in terms of wound size
description and the inclusion of site
preparation and debridement in their
current values so we believe they
E:\FR\FM\13JYP2.SGM
13JYP2
40104
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
appropriately represent the physician
work involved in the proposed HPCPCS
G-codes. However, we would adjust the
work RVUs of the Apligraf application
codes to derive the HCPCS G-code
proposed CY 2011 work values by
extracting the values for any office visits
and discharge day management services
because the HCPCS G-codes have a 0day global period. In addition, we
would adjust the direct PE inputs of the
Apligraf application codes to develop
the proposed CY 2011 direct PE inputs
of the HPCPS G-codes that have a 0-day
global period.
Our crosswalks and adjustments
result in proposed CY 2011 work RVUs
of 2.22 for HPCPCS code GXXX1 and
0.50 for HCPCPS GXXX2. The proposed
direct PE inputs for HCPCS codes
GXXX1 and GXXX2 are included in the
direct PE database for the CY 2011
proposed rule that is posted on the CMS
Web site at https://www.cms.gov/
PhysicianFeeSched/PFSFRN/list.asp.
We note that many Medicare
contractors currently have local
coverage policies that specify the
circumstances under which Medicare
covers the application of skin
substitutes. The local coverage policies
may include diagnostic or prior
treatment requirements, as well as
frequency limitations on the number
and periodicity of treatments. We expect
that these policies would be updated in
the context of the temporary new
HCPCS G-codes that we are proposing
for use in CY 2011 to report the
application of tissue cultured allogeneic
skin or dermal substitutes. We are
proposing to establish the HCPCS Gcodes for temporary use in CY 2011 in
order to improve the consistency and
resource-based nature of PFS payments
for skin substitute application services
that require similar resources. However,
we note our continued interest in
ensuring that skin substitutes are
properly utilized for Medicare
beneficiaries who will benefit from that
treatment. We will continue to monitor
the utilization of these services and plan
to identify any concerning trends in
utilization that contractors may want to
examine further through medical review
or other approaches.
G. Canalith Repositioning (CPT Code
95992)
For CY 2009, CPT created a new code
for canalith repositioning, specifically
CPT code 95992 (Canalith repositioning
procedure(s) (e.g., Epley maneuver,
Semont maneuver), per day). This
service may be furnished by both
physicians and therapists. Although we
accepted the RUC-recommended work
RVUs and PE inputs, we initially
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
bundled this procedure on an interim
basis in the CY 2009 PFS final rule with
comment period (73 FR 69896),
indicating that we believed it would be
paid through the E/M service that it
would accompany. Subsequently, in
view of concerns from therapists who
cannot furnish E/M services, we
clarified that therapists could report one
of the generally defined therapy CPT
codes when canalith repositioning was
furnished. In the CY 2010 PFS final rule
with comment period (74 FR 61766), we
changed the code’s status under the PFS
to ‘‘not recognized for payment under
Medicare,’’ consistent with our
expectation that another payable code
would be reported when the service was
furnished.
Based on further information from
stakeholders regarding the distinct and
separate nature of this procedure from
an E/M service and their request that we
recognize this CPT code for payment,
similar to our separate payment for most
other procedures commonly furnished
in association with an E/M service, we
are proposing to recognize CPT code
95992 for payment under the CY 2011
PFS, consistent with our typical
treatment of most other codes for minor
procedures. In doing so, we are
proposing to change the code’s status to
‘‘A’’ and utilize the CY 2009 RUC
recommendations for work RVUs (0.75)
and PE inputs for establishing its
payment in CY 2011. (That is, status ‘‘A’’
means Active code. These codes are
separately payable under the PFS if
covered.) Because canalith repositioning
(CPT code 95992) can be furnished by
physicians or therapists as therapy
services under a therapy plan of care or
by physicians as physicians’ services
outside of a therapy plan of care, we
would add CPT code 95992 to the
‘‘sometimes therapy’’ list on the therapy
code abstract file.
H. Intranasal/Oral Immunization Codes
(CPT Codes 90467, 90468, 90473, and
90474)
To ensure that the PE RVUs are
consistent between the intranasal/oral
and injectable immunization
administration CPT codes that describe
services that utilize similar PE
resources, we are proposing to
crosswalk the PE values for CPT code
90471 (Immunization administration
(includes percutaneous, intradermal,
subcutaneous, or intramuscular
injections); one vaccine (single or
combination vaccine/toxoid)) to CPT
codes 90467 (Immunization
administration younger than age 8 years
(includes intranasal or oral routes of
administration) when the physician
counsels the patient/family; first
PO 00000
Frm 00066
Fmt 4701
Sfmt 4702
administration (single or combination
vaccine/toxoid), per day) and 90473
(Immunization administration by
intranasal or oral route; one vaccine
(single or combination vaccine/toxoid)).
Similarly, we are also proposing to
crosswalk the PE values for CPT code
90472 (Immunization administration
(includes percutaneous, intradermal,
subcutaneous, or intramuscular
injections); each additional vaccine
(single or combination vaccine/toxoid)
(List separately in addition to code for
primary procedure)) to CPT codes 90468
(Immunization administration younger
than age 8 years (includes intranasal or
oral routes of administration) when the
physician counsels the patient/family;
each additional administration (single
or combination vaccine/toxoid), per day
(List separately in addition to code for
primary procedure)) and 90474
(Immunization administration by
intranasal or oral route; each additional
vaccine (single or combination vaccine/
toxoid) (List separately in addition to
code for primary procedure)).
I. Refinement Panel Process
As discussed in the November 25,
1992 PFS final rule (57 FR 55938), we
adopted a refinement panel process to
assist us in reviewing the public
comments on interim physician work
RVUs for CPT codes with that status in
each year and developing final work
values for the subsequent year. Our
decision to convene multispecialty
panels of physicians was based on our
need to balance the interests of those
who commented on the work RVUs
against the budgetary and redistributive
effects that could occur if we accepted
extensive increases in work RVUs across
a broad range of services. The
refinement panel reviews and discusses
the work involved in each procedure
and then each member individually
rates the work of the procedure. Since
1992, the refinement panels’
recommendation to change a work value
or to retain the interim value has hinged
solely on the outcome of a statistical test
on the ratings (an F-test).
Depending on the number and range
of codes that public commenters,
typically specialty societies, request be
subject to refinement, we establish
refinement panels with representatives
from 4 groups of physicians: Clinicians
representing the specialty most
identified with the procedures in
question; physicians with practices in
related specialties; primary care
physicians; and contractor medical
directors (CMDs). Typically the
refinement panels meet in the summer
prior to the promulgation of the final
rule finalizing the RVUs for the codes.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Typical panels have included 8 to 10
physicians across the 4 groups. Over
time, the statistical test used to evaluate
the RVU ratings of individual panel
members have become less reliable as
the physicians in each group have
tended to select a previously discussed
value, rather than independently
evaluating the work. In addition, the
resulting RVUs have occasionally
exhibited rank order anomalies (that is,
a more complex procedure is assigned
lower RVUs than a less complex
procedure).
Most recently, section 1848(c)(2)(K) of
the Act (as added by section 3134 of the
ACA) authorizes the Secretary to review
potentially misvalued codes and make
appropriate adjustments to the relative
values. In addition, MedPAC has
encouraged CMS to critically review the
values assigned to the services under
the PFS. MedPAC has stated its belief
that CMS has historically relied too
heavily on specialty societies to identify
services that are misvalued by accepting
so many recommendations of the RUC.
We believe the refinement panel
process continues to provide
stakeholders with a meaningful
opportunity for review and discussion
of the interim work RVUs with a
clinically diverse group of experts that
then provides informed
recommendations to CMS. Therefore,
we would like to continue the
refinement process, including the
established composition that includes
representatives from the 4 groups of
physicians, but with administrative
modification and clarification.
Specifically, for refinement panels
beginning in CY 2011 (that is, for those
codes with CY 2011 interim values that
would be subject to refinement during
CY 2011), we are proposing to eliminate
the use of the F-test and instead base
revised RVUs on the median work value
of the panel members’ ratings. We
believe this approach will simplify the
refinement process administratively,
while resulting in a final panel
recommendation that reflects the
summary opinion of the panel members
based on a commonly used measure of
central tendency that is not significantly
affected by outlier values. In addition,
we are clarifying that we have the final
authority to set the RVUs, and therefore,
may make adjustments to the work
RVUs resulting from refinement if
policy concerns warrant their
modification.
J. Remote Cardiac Monitoring Services
(CPT Codes 93012, 93229, 93268, and
93271)
In the CY 2010 PFS final rule with
comment period (74 FR 61755), we
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
indicated that we continued to have
concerns about the issue of developing
PE RVUs for services that are utilized 24
hours a day, 7 days a week (24/7), such
as those that require certain monitoring
system equipment. The PE equipment
methodology was developed for
equipment that is in use during
standard physician’s office business
hours and not this type of 24/7
equipment. We stated that we would
conduct further analysis of this issue.
Services that were contractor-priced in
CY 2009 remained contractor-priced in
CY 2010. We also indicated that any
proposed changes will be
communicated through future
rulemaking.
Since publication of the CY 2010 PFS
final rule with comment period, we
have focused our additional analysis on
four of the CPT codes that commenters
have brought to our attention because
they involve concurrent, remote, 24/7
attended monitoring of multiple
patients from a central location: CPT
code 93012 (Telephonic transmission of
post-symptom electrocardiogram
rhythm strip(s); 24-hour attended
monitoring, per 30 day period of time;
tracing only); CPT code 93229
(Wearable mobile cardiovascular
telemetry with electrocardiographic
recording, concurrent computerized real
time data analysis and greater than 24
hours of accessible ECG data storage
(retrievable with query) with ECG
triggered and patient selected events
transmitted to a remote attended
surveillance center for up to 30 days;
technical support for connection and
patient instructions for use, attended
surveillance, analysis and physician
prescribed transmission of daily and
emergent data reports); CPT code 93268
(Wearable patient activated
electrocardiographic rhythm derived
event recording with presymptom
memory loop, 24-hour attended
monitoring, per 30 day period of time;
includes transmission, physician review
and interpretation); and CPT 93271 code
(Wearable patient activated
electrocardiographic rhythm derived
event recording with presymptom
memory loop, 24-hour attended
monitoring, per 30 day period of time;
monitoring, receipt of transmissions,
and analysis).
Of these four codes, CPT code 93229
is currently contractor-priced in CY
2010, meaning that the local Medicare
contractors determine payment rates for
the service within the PFS geographic
areas in their jurisdiction. The three
services that are currently nationallypriced on the PFS are in the first year
of a 4-year transition to lower payment
rates based on the use of the PPIS data
PO 00000
Frm 00067
Fmt 4701
Sfmt 4702
40105
adopted in the CY 2010 PFS final rule
with comment period. We refer readers
to section II.A.2. of this proposed rule
for a description of the general PFS PE
methodology that is the basis for the
following discussion of approaches to
establishing PE RVUs for these four CPT
codes.
We examined several alternative
methods for developing PE RVUS upon
which PFS payment rates for these four
CPT codes could be based. Each of these
services involves transmission of
information from multiple patients who
wear individual monitoring devices that
transmit patient-specific information to
centralized equipment that is
simultaneously in use for multiple
patients. We believe it would be most
consistent with the principles
underlying the PFS PE methodology to
classify the centralized monitoring
equipment as an indirect cost since it is
servicing multiple patients at the same
time. After classifying this equipment as
an indirect cost, we used our standard
methodology to calculate an indirect
practice cost index value for each code
based on the PE/HR survey data of the
historical mix of specialties providing
these services. Establishing payment
rates for these codes based on this
approach would result in decreases in
the payment rates for these services,
including the typical contractor’s price
for CPT code 93229. For the three
services that are nationally priced, these
decreases would be relative to the lower
payment rates based on the use of the
PPIS data after the 4-year transition.
We also received PE/HR data from the
Remote Cardiac Services Provider
Group (RCSPG), a group of IDTF
suppliers of these types of services. For
sensitivity analysis purposes, we
substituted these data for the PE/HR
data of the specialties performing these
services, while continuing to treat the
centralized monitoring equipment as an
indirect cost. We found that establishing
payment rates for these codes based on
the approach of using the submitted
RCSPG PE/HR data would again result
in decreases in the payment rates for
these services, including the typical
contractor’s price for CPT code 93229.
As in the prior alternative, the decreases
for the nationally priced codes would be
relative to the payment rates reflecting
the 4-year transition to the PPIS data.
Although we believe that it would be
most consistent with the principles
underlying the PE methodology to
classify the centralized monitoring
equipment as an indirect cost, we also
performed a sensitivity analysis of the
payment rates if the centralized
monitoring equipment were classified as
a direct cost. In this simulation, we
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40106
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
assumed that the centralized monitoring
equipment was in year-round use, 7
days per week for 24 hours per day. We
found that establishing payment rates
for these codes based on the approach
of classifying the centralized monitoring
equipment as a direct cost would again
result in decreases in the payment rates
for the nationally priced services
relative to their payment rates after the
4-year transition to the use of the PPIS
data, as well as to the typical current
contractor’s price for CPT code 93229.
Finally, we considered proposing
contractor-pricing for all four of these
services for CY 2011. However, we are
cognizant of past public comments on
this issue that have requested that all of
these services be priced nationally on
the PFS, including the one service (CPT
code 93229) that is currently contractorpriced.
We also considered that the services
currently priced nationally on the PFS
are scheduled to receive lower payment
rates under the 4-year transition to the
PPIS data and that the contractor’s price
for CPT 93229 was recently reduced in
the area where the majority of the
billings for this service currently occur.
After taking all these factors into
consideration, we are not proposing CY
2011 methodological or direct cost input
changes for CPT codes 93012, 93268, or
93271—the services that are currently
nationally priced under the PFS. We are
also proposing to continue contractorpricing for CPT 93229 for CY 2011. We
continue to be interested in public
comments on this issue, including
responses to our analysis of alternative
approaches to establishing PE RVUs for
24/7 services, and further discussion of
the issues we have identified in our
alternative pricing methodologies. In
addition, while we have focused the 24/
7 services analysis to date on
developing the PE RVUs for remote
cardiac monitoring services, there may
be 24/7 services in other areas of
medicine, either currently paid under
the PFS or in development for the
future. Therefore, we are also interested
in public comments on these current or
emerging 24/7 services, including
descriptions of the similarities or
differences between these other services
and remote cardiac monitoring services,
particularly with respect to the issues
we have identified in our analysis of
alternative approaches to establishing
PE RVUs for remote cardiac monitoring
services under the PFS.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
IV. Medicare Telehealth Services for
the Physician Fee Schedule
A. Billing and Payment for Telehealth
Services
1. History
Prior to January 1, 1999, Medicare
coverage for services delivered via a
telecommunications system was limited
to services that did not require a faceto-face encounter under the traditional
model of medical care. Examples of
these services included interpretation of
an x-ray or electrocardiogram or
electroencephalogram tracing, and
cardiac pacemaker analysis.
Section 4206 of the BBA provided for
coverage of, and payment for,
consultation services delivered via a
telecommunications system to Medicare
beneficiaries residing in rural health
professional shortage areas (HPSAs) as
defined by the Public Health Service
Act. Additionally, the BBA required that
a Medicare practitioner (telepresenter)
be with the patient at the time of a
teleconsultation. Further, the BBA
specified that payment for a
teleconsultation had to be shared
between the consulting practitioner and
the referring practitioner and could not
exceed the fee schedule payment which
would have been made to the consultant
for the service provided. The BBA
prohibited payment for any telephone
line charges or facility fees associated
with the teleconsultation. We
implemented this provision in the CY
1999 PFS final rule with comment
period (63 FR 58814).
Effective October 1, 2001, section 223
of the Medicare, Medicaid and SCHIP
Benefits Improvement Protection Act of
2000 (Pub. L. 106–554) (BIPA) added a
new section 1834(m) to the Act which
significantly expanded Medicare
telehealth services. Section
1834(m)(4)(F)(i) of the Act defines
Medicare telehealth services to include
consultations, office visits, office
psychiatry services, and any additional
service specified by the Secretary, when
delivered via a telecommunications
system. We first implemented this
provision in the CY 2002 PFS final rule
with comment period (66 FR 55246).
Section 1834(m)(4)(F)(ii) required the
Secretary to establish a process that
provides for annual updates to the list
of Medicare telehealth services. We
established this process in the CY 2003
PFS final rule with comment period (67
FR 79988).
As specified in regulations at
§ 410.78(b), we generally require that a
telehealth service be furnished via an
interactive telecommunications system.
Under § 410.78(a)(3), an interactive
PO 00000
Frm 00068
Fmt 4701
Sfmt 4702
telecommunications system is defined
as multimedia communications
equipment that includes, at a minimum,
audio and video equipment permitting
two-way, real-time interactive
communication between the patient and
the practitioner at the distant site.
Telephones, facsimile machines, and
electronic mail systems do not meet the
definition of an interactive
telecommunications system. An
interactive telecommunications system
is generally required as a condition of
payment; however, section 1834(m)(1)
of the statute does allow the use of
asynchronous ‘‘store-and-forward’’
technology in delivering these services
when the originating site is a Federal
telemedicine demonstration program in
Alaska or Hawaii. As specified in
regulations at § 410.78(a)(1), store and
forward means the asynchronous
transmission of medical information
from an originating site to be reviewed
at a later time by the practitioner at the
distant site.
Medicare telehealth services may be
provided to an eligible telehealth
individual notwithstanding the fact that
the individual practitioner providing
the telehealth service is not at the same
location as the beneficiary. An eligible
telehealth individual means an
individual enrolled under Part B who
receives a telehealth service furnished at
an originating site. As specified in BIPA,
originating sites are limited under
section 1834(m)(3)(C) of the statute to
specified medical facilities located in
specific geographic areas. The initial list
of telehealth originating sites included
the office of a practitioner, a critical
access hospital (CAH), a rural health
clinic (RHC), a federally qualified health
center (FQHC) and a hospital. More
recently, section 149 of the Medicare
Improvements for Patients and
Providers Act of 2008 (Pub. L. 110–275)
(MIPPA) expanded the list of telehealth
originating sites to include hospitalbased renal dialysis centers, skilled
nursing facilities (SNFs), and
community mental health centers
(CMHCs). In order to serve as a
telehealth originating site, these sites
must be located in an area designated as
a rural health professional shortage area
(HPSA), in a county that is not in a
metropolitan statistical area (MSA), or
must be an entity that participates in a
Federal telemedicine demonstration
project that has been approved by (or
receives funding from) the Secretary of
Health and Human Services as of
December 31, 2000. Finally, section
1834(m) of the statute does not require
the eligible telehealth individual to be
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
presented by a practitioner at the
originating site.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2. Current Telehealth Billing and
Payment Policies
As noted above, Medicare telehealth
services can only be furnished to an
eligible telehealth beneficiary in an
originating site. An originating site is
defined as one of the specified sites
where an eligible telehealth individual
is located at the time the service is being
furnished via a telecommunications
system. In general, originating sites
must be located in a rural HPSA or in
a county outside of an MSA. The
originating sites authorized by the
statute are as follows:
• Offices of a physician or practitioner
• Hospitals
• CAHs
• RHCs
• FQHCs
• Hospital-Based or Critical Access
Hospital-Based Renal Dialysis Centers
(including Satellites)
• SNFs
• CMHCs
Currently approved Medicare
telehealth services include the
following:
• Initial inpatient consultations
• Follow-up inpatient consultations
• Office or other outpatient visits
• Individual psychotherapy
• Pharmacologic management
• Psychiatric diagnostic interview
examination
• End Stage Renal Disease (ESRD)
related services
• Individual medical nutrition therapy
(MNT)
• Neurobehavioral status exam
• Individual health and behavior
assessment and intervention (HBAI)
In general, the practitioner at the
distant site may be any of the following,
provided that the practitioner is
licensed under State law to furnish the
service being furnished via a
telecommunications system:
• Physician
• Physician assistant (PA)
• Nurse practitioner (NP)
• Clinical nurse specialist (CNS)
• Nurse midwife
• Clinical psychologist
• Clinical social worker
• Registered dietitian or nutrition
professional
Practitioners furnishing Medicare
telehealth services are located at a
distant site, and they submit claims for
telehealth services to the Medicare
contractors that process claims for the
service area where their distant site is
located. Section 1834(m)(2)(A) of the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Act requires that a practitioner who
furnishes a telehealth service to an
eligible telehealth individual be paid an
amount equal to the amount that the
practitioner would have been paid if the
service had been furnished without the
use of a telecommunications system.
Distant site practitioners must submit
the appropriate HCPCS procedure code
for a covered professional telehealth
service, appended with the –GT (Via
interactive audio and video
telecommunications system) or –GQ
(Via asynchronous telecommunications
system) modifier. By reporting the –GT
or –GQ modifier with a covered
telehealth procedure code, the distant
site practitioner certifies that the
beneficiary was present at a telehealth
originating site when the telehealth
service was furnished. The usual
Medicare deductible and coinsurance
policies apply to the telehealth services
reported by distant site practitioners.
Section 1834(m)(2)(B) of the Act
provides for payment of a facility fee to
the originating site. To be paid the
originating site facility fee, the provider
or supplier where the eligible telehealth
individual is located must submit a
claim with HCPCS code Q3014
(Telehealth originating site facility fee),
and the provider or supplier is paid
according to the applicable payment
methodology for that facility or location.
The usual Medicare deductible and
coinsurance policies apply to HCPCS
code Q3014. By submitting HCPCS code
Q3014, the originating site authenticates
that it is located in either a rural HPSA
or non-MSA county or is an entity that
participates in a Federal telemedicine
demonstration project that has been
approved by (or receives funding from)
the Secretary of Health and Human
Services as of December 31, 2000 as
specified in section 1834(m)(4)(C)(i)(III)
of the Act.
As described above, certain
professional services that are commonly
furnished remotely using
telecommunications technology, but
that do not require the patient to be
present in-person with the practitioner
when they are furnished, are covered
and paid in the same way as services
delivered without the use of
telecommunications technology when
the practitioner is in-person at the
medical facility furnishing care to the
patient. Such services typically involve
circumstances where a practitioner is
able to visualize some aspect of the
patient’s condition without the patient
being present and without the
interposition of a third person’s
judgment. Visualization by the
practitioner can be possible by means of
x-rays, electrocardiogram or
PO 00000
Frm 00069
Fmt 4701
Sfmt 4702
40107
electroencephalogram tracings, tissue
samples, etc. For example, the
interpretation by a physician of an
actual electrocardiogram or
electroencephalogram tracing that has
been transmitted via telephone (that is,
electronically, rather than by means of
a verbal description) is a covered
physician’s service. These remote
services are not Medicare telehealth
services as defined under section
1834(m). Rather, these remote services
that utilize telecommunications
technology are considered physicians’
services in the same way as services that
are furnished in-person without the use
of telecommunications technology; they
are paid under the same conditions as
in-person physicians’ services (with no
requirements regarding permissible
originating sites), and should be
reported in the same way (that is,
without the –GT or –GQ modifier
appended).
B. Requests for Adding Services to the
List of Medicare Telehealth Services
As noted above, in the December 31,
2002 Federal Register (67 FR 79988), we
established a process for adding services
to or deleting services from the list of
Medicare telehealth services. This
process provides the public with an
ongoing opportunity to submit requests
for adding services. We assign any
request to make additions to the list of
Medicare telehealth services to one of
the following categories:
• Category 1: Services that are similar
to professional consultations, office
visits, and office psychiatry services. In
reviewing these requests, we look for
similarities between the requested and
existing telehealth services for the roles
of, and interactions among, the
beneficiary, the physician (or other
practitioner) at the distant site and, if
necessary, the telepresenter. We also
look for similarities in the
telecommunications system used to
deliver the proposed service, for
example, the use of interactive audio
and video equipment.
• Category 2: Services that are not
similar to the current list of telehealth
services. Our review of these requests
includes an assessment of whether the
use of a telecommunications system to
deliver the service produces similar
diagnostic findings or therapeutic
interventions as compared with the inperson delivery of the same service.
Requestors should submit evidence
showing that the use of a
telecommunications system does not
affect the diagnosis or treatment plan as
compared to in-person delivery of the
requested service.
E:\FR\FM\13JYP2.SGM
13JYP2
40108
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Since establishing the process to add
or remove services from the list of
approved telehealth services, we have
added the following to the list of
Medicare telehealth services: Individual
HBAI services; psychiatric diagnostic
interview examination; ESRD services
with 2 to 3 visits per month and 4 or
more visits per month (although we
require at least 1 visit a month to be
furnished in-person by a physician,
CNS, NP, or PA in order to examine the
vascular access site); individual MNT;
neurobehavioral status exam; and initial
and follow-up inpatient telehealth
consultations for beneficiaries in
hospitals and skilled nursing facilities
(SNFs).
Requests to add services to the list of
Medicare telehealth services must be
submitted and received no later than
December 31 of each calendar year to be
considered for the next rulemaking
cycle. For example, requests submitted
before the end of CY 2010 are
considered for the CY 2012 proposed
rule. Each request for adding a service
to the list of Medicare telehealth
services must include any supporting
documentation the requester wishes us
to consider as we review the request.
Because we use the annual PFS
rulemaking process as a vehicle for
making changes to the list of Medicare
telehealth services, requestors should be
advised that any information submitted
is subject to public disclosure for this
purpose. For more information on
submitting a request for an addition to
the list of Medicare telehealth services,
including where to mail these requests,
we refer readers to the CMS Web site at
https://www.cms.gov/telehealth/.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
C. Submitted Requests for Addition to
the List of Telehealth Services for CY
2011
We received requests in CY 2009 to
add the following services as Medicare
telehealth services effective for CY 2011:
(1) Individual kidney disease education
(KDE) services; (2) individual diabetes
self-management training (DSMT)
services; (3) group KDE, DSMT, MNT,
and HBAI services; (4) initial,
subsequent, and discharge day
management hospital care services; (5)
initial, subsequent, discharge day
management, and other nursing facility
care services; (6) neuropsychological
testing services; (7) speech-language
pathology services; and (8) home wound
care services. The following presents a
discussion of these requests, including
our proposals for additions to the CY
2011 telehealth list.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
1. Individual KDE Services
The American Society of Nephrology,
Dialysis Patient Citizens, AMGEN, and
Kidney Care Partners submitted requests
to add individual KDE services,
reported by HCPCS code G0420 (Faceto-face educational services related to
the care of chronic kidney disease;
individual, per session, per one hour),
to the list of approved telehealth
services for CY 2011 on a category 1
basis.
Individual KDE services, covered
under the new Medicare KDE benefit
effective for services furnished
beginning in CY 2010, are defined as
face-to-face educational services
provided to a patient with stage IV
chronic kidney disease (CKD). We
believe the interaction between a
practitioner and a beneficiary receiving
individual KDE services is similar to the
education, assessment, and counseling
elements of individual MNT services,
reported by HCPCS code G0270
(Medical nutrition therapy;
reassessment and subsequent
intervention(s) following second referral
in same year for change in diagnosis,
medical condition or treatment regimen
(including additional hours needed for
renal disease), individual, face to face
with the patient, each 15 minutes); CPT
code 97802 (Medical nutrition therapy;
initial assessment and intervention,
individual, face-to-face with the patient,
each 15 minutes); and CPT code 97803
(Medical nutrition therapy; reassessment and intervention,
individual, face-to-face with the patient,
each 15 minutes), all services that are
currently on the telehealth list.
Therefore, we are proposing to add
HCPCS code G0420 to the list of
telehealth services for CY 2011 on a
category 1 basis. Consistent with this
proposal, we are also proposing to
revise our regulations at § 410.78(b) and
§ 414.65(a)(1) to include individual KDE
as a Medicare telehealth service.
2. Individual DSMT Services
The Tahoe Forest Health System and
the Marshfield Clinic submitted
requests to add individual DSMT
services, reported by HCPCS code
G0108 (Diabetes outpatient selfmanagement training services,
individual, per 30 minutes), to the list
of telehealth services for CY 2011 on a
category 1 basis. In the CY 2009 PFS
final rule with comment period (73 FR
69743), we stated that we believe
individual DSMT services are not
analogous to individual MNT services
because of the element of skill-based
training that is encompassed within
individual DSMT services that is not an
PO 00000
Frm 00070
Fmt 4701
Sfmt 4702
aspect of individual MNT services (or
any other services currently approved
for telehealth). Due to the statutory
requirement that DSMT services include
teaching beneficiaries the skills
necessary for the self-administration of
injectable drugs, we have stated our
belief that DSMT, whether provided to
an individual or a group, must be
evaluated as a category 2 service as
specified in the CY 2009 PFS proposed
rule (73 FR 38516). We have considered
several previous requests to add DSMT
to the list of Medicare telehealth
services. We have not added individual
DSMT to the list of telehealth services
because we believe that skill-based
training, such as teaching patients how
to inject insulin, would be difficult to
accomplish effectively without the
physical presence of the teaching
practitioner (70 FR 45787 and 70157,
and 73 FR 38516 and 69743).
In considering the new request to add
individual DSMT services to the list of
telehealth services in CY 2011, we have
taken into account requestors’ argument
that individual DSMT services are
highly similar to individual MNT
services and that injection training
constitutes just a small proportion of
DSMT services. Except for the
component of individual DSMT services
that involves instruction in selfadministration of injectable drugs for
eligible beneficiaries, we agree with the
requestors that individual DSMT
services are similar to individual MNT
services, which are currently on the list
of Medicare telehealth services. We note
that Medicare coverage of DSMT
services was initially authorized in the
Balanced Budget Act of 1997. After
more than a decade of Medicare
coverage, the most recent information
shows that DSMT continues to be
significantly underutilized in the
context of the eligible population of
Medicare beneficiaries. While we are
uncertain to what extent geographic
barriers to care contribute to this
underutilization, given the morbidity
associated with poorly managed
diabetes and the growing evidence-base
regarding effective DSMT services, we
believe it is very important to facilitate
Medicare beneficiary access to these
underutilized services. While we have
previously been concerned about
treating the components of DSMT
services differently in the context of
considering DSMT services for the
telehealth list, we believe that our
concern regarding the skill-based
injection training component of DSMT
services can be addressed by imposing
a requirement that a minimum portion
of the training be furnished in-person.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
We note that for beneficiaries who meet
the coverage criteria, Medicare covers
10 hours of DSMT services in the year
following the initial training, as
described in the Medicare Benefit Policy
Manual (Pub. 100–02, Chapter 15,
Section 300.3). Taking into
consideration the initial year coverage
of DSMT services, we are proposing that
a minimum of 1 hour of instruction in
injection training must be furnished inperson during the year following the
initial DSMT service. Imposing this
condition would allow us to expand
access to DSMT services by adding
individual DSMT services to the list of
telehealth services, while ensuring
effective injection training for
beneficiaries.
Therefore, we are proposing to add
HCPCS code G0108 to the list of
telehealth services beginning in CY
2011. We are also proposing that, as a
condition of payment for individual
DSMT services furnished as telehealth
services to an eligible telehealth
individual, a minimum of 1 hour of inperson instruction in the selfadministration of injectable drugs must
be furnished to the individual during
the year following the initial DSMT
service. The injection training may be
furnished through either individual or
group DSMT services. By reporting the
–GT or –GQ modifier with HCPCS code
G0108 as a telehealth service, the
distant site practitioner would certify
that the beneficiary has received or will
receive 1 hour of in-person DSMT
services for purposes of injection
training during the year following the
initial DSMT service. Consistent with
this proposal, we are proposing to revise
our regulations at § 410.78(b) and
§ 414.65(a)(1) to include individual
DSMT services as a Medicare telehealth
service, with the exception of 1 hour of
in-person instruction in selfadministration of injectable drugs which
must be furnished to the eligible
telehealth individual as individual or
group DSMT services during the year
following the initial DSMT service.
We note that, as specified in
§ 410.141(e), individual DSMT services
may be furnished by a physician,
individual, or entity that furnishes other
services for which direct Medicare
payment may be made and that submits
necessary documentation to, and is
accredited by, an accreditation
organization approved by CMS.
However, consistent with the statutory
requirements of section 1834(m)(1) of
the Act and as provided in
§ 410.78(b)(1) and (b)(2) of our
regulations, Medicare telehealth
services, including individual DSMT
furnished as a telehealth service, could
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
only be furnished by a licensed PA, NP,
CNS, certified nurse-midwife, clinical
psychologist, clinical social worker, or
registered dietitian or nutrition
professional.
3. Group KDE, MNT, DSMT, and HBAI
Services
The American Society of Nephrology,
Dialysis Patient Citizens, AMGEN,
Tahoe Forest Health Systems, Kidney
Care Partners, the American
Telemedicine Association, and the
Marshfield Clinic submitted requests to
add one or more of the following group
services to the telehealth list for CY
2011:
• Group KDE services, reported by
HCPCS code G0421 (Face-to-face
educational services related to the care
of chronic kidney disease; group, per
session, per one hour);
• Group MNT services, reported by
CPT code 97804 (Medical nutrition
therapy; group (2 or more individual(s)),
each 30 minutes);
• Group DSMT services, reported by
HCPCS code G0109 (Diabetes outpatient
self-management training services,
group session (2 or more), per 30
minutes); and/or
• Group HBAI services, reported by
CPT code 96153 (Health and behavior
intervention, each 15 minutes, face-toface; group (2 or more patients)) and
96154 (Health and behavior
intervention, each 15 minutes, face-toface; family (with the patient present)).
When furnished as individual
services, HBAI and MNT services are
currently on the list of Medicare
telehealth services. Furthermore, we are
proposing to add individual KDE and
DSMT services to the list of Medicare
telehealth services beginning in CY
2011 as described above.
In the CY 2007 and CY 2010 PFS
rulemaking cycles (70 FR 45787 and
70157, and 74 FR 33543 and 61764), we
stated that we did not believe that group
services could be appropriately
delivered through telehealth. We have
observed that currently there are no
group services approved as Medicare
telehealth services and that there is a
different interactive dynamic between
the practitioner and his or her patients
in group services as compared to
individual services. We previously have
considered requests to add various
group services to the list of Medicare
telehealth services on a category 2 basis
because we have believed that,
especially given the interactive dynamic
between practitioners and their patients,
group services are not similar to other
services on the list of Medicare
telehealth services. Therefore, we have
maintained that it is necessary to
PO 00000
Frm 00071
Fmt 4701
Sfmt 4702
40109
evaluate the addition of group services
by comparing diagnostic findings or
therapeutic interventions when services
are furnished via telehealth versus when
services are furnished in-person.
We continue to believe that the group
dynamic may be a critical and defining
element for certain services, and that
this characteristic precludes many
group services from being considered on
a category 1 basis for addition to the list
of Medicare telehealth services. For
example, we believe that due to the
therapeutic nature of the group dynamic
that is integral to group psychotherapy,
group psychotherapy is fundamentally
different from other Medicare telehealth
services and, therefore, could not be
considered on a category 1 basis for
addition to the telehealth services list.
For the same reason, in the absence of
evidence to the contrary, we do not
believe group psychotherapy services
could be appropriately delivered
through telehealth.
However, upon further consideration,
with regard to the particular group
education and training services for
which we received requests for addition
to the Medicare telehealth services list,
we believe the group dynamic is not
central to the core education and
training components of these particular
services, specifically DSMT, MNT, KDE,
and HBAI services. We believe that
these group services are sufficiently
similar to the individual, related
services that are already on the
telehealth services list or are proposed
for addition beginning in CY 2011.
Specifically, we believe that for these
group services, which consist
principally of an information exchange
for the purpose of education and
training, the roles of, and interactions
between, the patients and the
practitioner are sufficiently similar to
the related individual education and
training services that the services can be
furnished appropriately as a telehealth
service.
Therefore, we are proposing to add
HCPCS code G0421 for group KDE
services, CPT code 97804 for group
MNT services, HCPCS code G0109 for
group DSMT services, and CPT codes
96153 and 96154 for group HBAI
services to the Medicare telehealth
services list on a category 1 basis.
Furthermore, because the concerns we
raised above regarding adequate
injection training with the addition of
individual DSMT are also present for
group DSMT, we are proposing to
require the same minimum of 1 hour of
in-person instruction for injection
training within the year following the
initial DSMT service for any beneficiary
that receives DSMT services via
E:\FR\FM\13JYP2.SGM
13JYP2
40110
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
telehealth. By reporting the –GT or –GQ
modifier with HCPCS code G0109, the
distant site practitioner would certify
that the beneficiary has received or will
receive 1 hour of in-person DSMT
services for purposes of injection
training during the year following the
initial DSMT service. Consistent with
this proposal to add these group
education and training services, we are
also proposing to revise our regulations
at § 410.78(b) and § 414.65(a)(1) to
include group KDE, MNT, DSMT, and
HBAI services as Medicare telehealth
services, with the exception of 1 hour of
in-person instruction of individual or
group DSMT services in the year
following the initial DSMT service.
As described above for individual
DSMT services, we note that group
DSMT services may be furnished by a
physician, individual, or entity that
furnishes other services for which direct
Medicare payment may be made and
that submits necessary documentation
to, and is accredited by, an accreditation
organization approved by CMS, as
specified in § 410.141(e) for DSMT
services. However, consistent with the
statutory requirements of section
1834(m)(1) of the Act and as provided
in § 410.78(b)(1) and (b)(2) of our
regulations, Medicare telehealth
services, including group DSMT
furnished as a telehealth service, could
only be furnished by a licensed PA, NP,
CNS, certified nurse-midwife, clinical
psychologist, clinical social worker, or
registered dietitian or nutrition
professional.
4. Initial, Subsequent, and Discharge
Day Management Hospital Care Services
The University of Louisville School of
Medicine, the American Telemedicine
Association, and Mille Lacs Health
System submitted various requests to
add initial hospital care services
(reported by CPT codes 99221 (Level 1
initial hospital care), 99222 (Level 2
initial hospital care), and 99223 (Level
3 initial hospital care)); subsequent
hospital care services (reported by CPT
codes 99231 (Level 1 subsequent
hospital care), 99232 (Level 2
subsequent hospital care), and 99233
(Level 3 subsequent hospital care)); and/
or hospital discharge day management
services (reported by CPT codes 99238
(Hospital discharge day management; 30
minutes or less) and 99239 (Hospital
discharge day management; more than
30 minutes) to the Medicare telehealth
services list beginning in CY 2011,
generally on a category 1 basis. Some of
the requestors also recommended that
we limit the delivery of these services
through telehealth to the provision of
services to patients with a psychiatric
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
diagnosis or to those treated in a
psychiatric hospital or licensed
psychiatric bed.
We appreciate the recommendations
of the requestors to substantially expand
the list of Medicare telehealth services.
The requestors submitted a number of
studies regarding the outcomes of
telehealth services in caring for patients
with psychiatric diagnoses. However,
we note that the CPT codes for hospital
care services are used to report care for
hospitalized patients with a variety of
diagnoses, including psychiatric
diagnoses. We do not believe it would
be appropriate to add services to the
telehealth list only for certain diagnoses
because the service described by a
HCPCS code is essentially the same
service, regardless of the patient’s
diagnosis. When evaluating the addition
of services for telehealth on a category
1 basis, our focus is on the roles of, and
interactions among, the beneficiary, the
physician or practitioner, and the
telepresenter (if applicable), which
generally are similar across diagnoses
for services that may be reported with
the same HCPCS codes. Even in the
unique case of certain ESRD services,
we limited additions to the list of
Medicare telehealth services based on
the appropriateness of certain specific
codes, taking into consideration the full
service descriptions (69 FR 47511).
Therefore, we continue to believe that it
is most appropriate to consider
additions to the list of telehealth
services based on the overall suitability
of the services described by the relevant
HCPCS codes to delivery through
telehealth.
In the CY 2005, CY 2008, and CY
2009 PFS rulemakings (69 FR 47510 and
66276, 72 FR 38144 and 66250, and 73
FR 38517 and 69745, respectively), we
did not add initial, subsequent, or
discharge day management hospital care
services to the list of approved
telehealth services because of our
concern regarding the use of telehealth
for the ongoing evaluation and
management (E/M) for the generally
high acuity of hospital inpatients. While
we continue to have some concern in
this area, we also share the requestors’
interest in improving access for
hospitalized patients to care furnished
by treating practitioners. Therefore, we
have reevaluated these services in the
context of the CY 2011 requests,
including considering the possibility
that these services could be added on a
category 1 basis based on their
resemblance to services currently on the
telehealth list, such as initial and
follow-up inpatient telehealth
consultations. The following presents a
discussion of our review of the
PO 00000
Frm 00072
Fmt 4701
Sfmt 4702
subcategories of hospital care services
included in these requests.
Currently, one of the three codes for
an initial hospital care service
(specifically CPT codes 99221, 99222, or
99223) is reported for the first hospital
inpatient E/M visit to the patient by the
admitting or a consulting practitioner
when that visit is furnished in-person.
In addition, we note that currently there
are several HCPCS G-codes on the
Medicare telehealth services list that
may be reported for initial and followup inpatient consultations through
telehealth, specifically HCPCS codes
G0406 (Follow-up inpatient telehealth
consultation, limited, physicians
typically spend 15 minutes
communicating with the patient via
telehealth); G0407 (Follow-up inpatient
telehealth consultation, intermediate,
physicians typically spend 25 minutes
communicating with the patient via
telehealth); G0408 (Follow-up inpatient
telehealth consultation, complex,
physicians typically spend 35 minutes
or more communicating with the patient
via telehealth); G0425 (Initial inpatient
telehealth consultation, typically 30
minutes communicating with the
patient via telehealth); G0426 (Initial
inpatient telehealth consultation,
typically 50 minutes communicating
with the patient via telehealth); and
G0427 (Initial inpatient telehealth
consultation, typically 70 minutes or
more communicating with the patient
via telehealth).
While initial inpatient consultation
services are currently on the list of
approved telehealth services, there are
no services on the current list of
telehealth services that resemble initial
hospital care for an acutely ill patient by
the admitting practitioner who has
ongoing responsibility for the patient’s
treatment during the hospital course.
Therefore, we are unable to consider
initial hospital care services on a
category 1 basis for the telehealth list.
We have reviewed the documentation
submitted in support of adding the
initial hospital care codes to the
Medicare telehealth services list as
category 2 requests. Most of the studies
provided by the requestors were specific
to the treatment of patients with
particular diagnoses. Additionally, the
studies were not specific to initial
hospital care visits by admitting
practitioners. Finally, most of the
studies concluded that more research
was required in order to establish
medical equivalence between telehealth
and in-person services. Therefore, we
received no information that provides
robust support for the addition of initial
hospital care services to the approved
telehealth list on a category 2 basis. The
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
initial hospital care codes describe the
first visit to the hospitalized patient by
the admitting practitioner who may or
may not have seen the patient in the
decision-making phase regarding
hospitalization. We believe it is critical
that the initial hospital visit by the
admitting practitioner be conducted inperson to ensure that the practitioner
with ongoing treatment responsibility
comprehensively assesses the patient’s
condition upon admission to the
hospital through a thorough in-person
examination. Therefore, we are not
proposing to add initial hospital care
services to the Medicare telehealth
services list for CY 2011.
We have again considered adding
subsequent hospital care services
reported by CPT codes 99231 through
99233 to the telehealth list for CY 2011
on a category 1 basis. In the CY 2005
and CY 2008 PFS proposed rules (69 FR
47511 and 72 FR 38155), we stated that
the potential acuity of patients in the
hospital setting precludes consideration
of subsequent hospital visits as similar
to existing telehealth services. However,
as stated earlier, we also note that
HCPCS codes for initial and follow-up
inpatient consultation services are on
the list of telehealth services. These E/
M services are furnished to high acuity
hospitalized patients, although not by
the admitting practitioner himself or
herself. However, in light of the
increasingly prevalent care model that
entails multidisciplinary team care for
patients with complex medical illnesses
that involve multiple body systems,
consulting practitioners may often play
a key, intensive, and ongoing role in
caring for hospitalized patients.
Therefore, we believe that subsequent
hospital care visits by a patient’s
admitting practitioner may sufficiently
resemble follow-up inpatient
consultation services to consider these
subsequent hospital care services on a
category 1 basis for the telehealth list.
While we still believe the potential
acuity of hospital inpatients is greater
than those patients likely to receive
currently approved Medicare telehealth
services, we also believe that it would
be appropriate to permit some
subsequent hospital care services to be
furnished through telehealth in order to
ensure that hospitalized patients have
frequent encounters with their
admitting practitioner. However, we
also continue to believe that the
majority of these visits should be inperson to facilitate the comprehensive,
coordinated, and personal care that
medically volatile, acutely ill patients
require on an ongoing basis.
Therefore, we are proposing that
subsequent hospital care services,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
specifically CPT codes 99231, 99232,
and 99233, be added to the list of
telehealth services on a category 1 basis
for CY 2011, but with some limitations
on the frequency that these services may
be furnished through telehealth.
Because of our concerns regarding the
potential acuity of hospital inpatients,
we are proposing to limit the provision
of subsequent hospital care services
through telehealth to once every 3 days.
We are confident that admitting
practitioners will continue to make
appropriate in-person visits to all
patients who need such care during
their hospitalization. Consulting
practitioners should continue to use the
inpatient telehealth consultation HCPCS
G-codes, specifically G0406, G0407,
G0408, G0425, G0426, or G0427 when
reporting consultations furnished to
inpatients via telehealth.
Consistent with this proposal, we are
proposing to revise § 410.78(b) and
§ 414.65(a)(1) to include subsequent
hospital care services as Medicare
telehealth services, with the limitation
of one telehealth subsequent hospital
care service every 3 days.
We also considered adding hospital
discharge day management services to
the list of telehealth services. These
services, reported by CPT codes 99238
and 99239, include the final
examination of the patient, discussion
of the hospital stay, instructions for
continuing care to all relevant
caregivers, and preparation of discharge
records, prescriptions, and referral
forms. These services are furnished
when a practitioner deems it medically
reasonable and necessary to assess a
patient’s readiness for discharge and to
prepare a patient for discharge from an
acute care environment to a less
intensive setting. There are no services
on the current list of telehealth services
that resemble such preparation of a
patient for discharge. We believe it is
especially important that, if a
practitioner furnishes a discharge day
management service, the service be
furnished in-person in order to allow
the practitioner to comprehensively
assess the patient’s status in preparation
for discharge so that the patient will
have a higher likelihood of making a
successful transition to the less
intensive setting. Therefore, we are not
considering hospital discharge day
management services for addition to the
Medicare telehealth services list on a
category 1 basis.
We have reviewed the documentation
submitted by requestors in support of
adding these codes to the Medicare
telehealth services list on a category 2
basis. Most of the submitted studies
were specific to the treatment of
PO 00000
Frm 00073
Fmt 4701
Sfmt 4702
40111
patients with specific diagnoses and
were not specific to discharge services.
Additionally, most of the studies
concluded that more research was
required in order to establish medical
equivalence between telehealth and inperson services. The submitted
documentation did not provide the
necessary evidence to alter our previous
conclusion that hospital discharge day
management services should be
provided in-person in light of the acuity
of hospitalized patients, their typically
complex post-hospitalization care
needs, and the importance of patient
education by the admitting practitioner
who had ongoing responsibility for the
patient’s treatment during the hospital
stay. Therefore, we are not proposing to
add hospital discharge day management
services to the list of telehealth services
for CY 2011.
5. Initial, Subsequent, Discharge Day
Management, and Other Nursing
Facility Care Services
The American Telemedicine
Association and the Marshfield Clinic
submitted requests to add nursing
facility care codes, covering the
spectrum of initial (reported by CPT
codes 99304 (Level 1 initial nursing
facility care), 99305 (Level 2 initial
nursing facility care) and 99306 (Level
3 initial nursing facility care));
subsequent (reported by CPT codes
99307 (Level 1 subsequent nursing
facility care), 99308 (Level 2 subsequent
nursing facility care), 99309 (Level 3
subsequent nursing facility care), and
99310 (Level 4 subsequent nursing
facility care)); discharge day
management (reported by CPT codes
99315 (Nursing facility discharge day
management; 30 minutes or less) and
99316 (Nursing facility discharge day
management; more than 30 minutes));
and other (reported by CPT code 99318
(Evaluation and management of a
patient involving an annual nursing
facility assessment)) services, to the
Medicare telehealth services list
beginning in CY 2011. The requests for
the addition of these services expressed
concerns regarding limited access to
care if we do not allow these services to
be furnished through telehealth, and
requested that CMS acknowledge the
recent Congressional inclusion of
nursing facilities as telehealth
originating sites by adding these codes
to the list of Medicare telehealth
services.
In the CY 2010 PFS proposed and
final rules (74 FR 33544 and 74 FR
61762), we discussed concerns about
potential disparities in patient acuity
between nursing facility services and
the current list of Medicare telehealth
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40112
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
services. We have also declined to add
HCPCS codes to the Medicare telehealth
services list that are used exclusively to
describe Federally-mandated nursing
facility visits. As discussed in the CY
2010 PFS proposed rule (74 FR 33543),
the long-term care regulations at
§ 483.40(c) require that residents of
SNFs receive initial and periodic
personal visits. These regulations ensure
that at least a minimal degree of
personal contact between a practitioner
and a SNF resident is maintained, both
at the point of admission to the facility
and periodically during the course of
the resident’s stay. We continue to
believe that these federally-mandated
visits should be conducted in-person,
and not as Medicare telehealth services.
Therefore, in the CY 2010 PFS final rule
with comment period, we revised
§ 410.78 to preclude physicians and
other practitioners from furnishing the
physician visits required under
§ 483.40(c) through telehealth.
We reviewed the use of telehealth for
each of the subcategories of nursing
facility services included in the requests
for CY 2011. We identified the E/M
services that fulfill Federal requirements
for personal visits under § 483.40(c),
and we are not proposing for CY 2011
to add any HCPCS codes to the
Medicare telehealth services list that are
used exclusively to describe these
Federally-mandated visits. These codes
include the CPT codes for initial
nursing facility care (CPT codes 99304
through 99306) that are used to report
the initial E/M visit that fulfills
Federally-mandated requirements under
§ 483.40(c) and other nursing facility
service (CPT code 99318) that is only
payable by Medicare if the visit is
substituted for a federally-mandated
visit under § 483.40(c).
The nursing facility discharge day
management services reported under
CPT code 99315 and 99316 are E/M
visits that prepare a nursing facility
resident for discharge from the facility.
There are no Medicare requirements
that such a service be furnished. If a
practitioner chooses to furnish this
service, we continue to believe that an
in-person visit is most appropriate in
order to ensure the resident is prepared
for discharge from the nursing facility.
These services are furnished when a
practitioner deems it medically
reasonable and necessary to assess a
patient’s readiness for and to prepare a
patient being discharged from the
monitored nursing facility environment
to another typically less intensive
setting. There are no services on the
current list of telehealth services that
resemble such preparation of a patient
for discharge. As in the case of hospital
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
discharge day management services, we
believe it is especially important that, if
a practitioner furnishes a nursing
facility discharge day management
service, the service be furnished inperson. The practitioner must be able to
comprehensively assess the patient’s
status in preparation for discharge so
that the patient will have a higher
likelihood of making a successful
transition from the nursing facility to
another setting. Therefore, we are not
considering nursing facility discharge
day management services for addition to
the Medicare telehealth services list on
a category 1 basis. When we considered
the addition of these services under
category 2, we had no evidence that
nursing facility discharge services
furnished through telehealth are
equivalent to in-person discharge
services. Therefore, we are not
proposing to add nursing facility
discharge day management services to
the CY 2011 telehealth list.
Subsequent nursing facility services,
reported by CPT codes 99307 through
99310, may be used to report either a
federally-mandated periodic visit under
§ 483.40(c) or another E/M visit, prior to
or after the initial nursing facility care
visit, as long as the subsequent nursing
facility care visit is medically
reasonable and necessary for the
resident’s care. While we continue to
believe that many SNF residents have
complex medical care needs, we believe
that it is appropriate to consider the
addition of these codes to the telehealth
list on a category 1 basis. As we state
above in the context of our discussion
of subsequent hospital care services, the
HCPCS codes for initial and follow-up
inpatient consultation services for
nursing facility patients are on the list
of Medicare telehealth services, and
subsequent nursing facility services are
similar to those services. These E/M
services are furnished to high acuity,
complex SNF patients, although not by
the admitting practitioner himself or
herself. Therefore, we believe that
subsequent nursing facility visits by a
patient’s admitting practitioner
sufficiently resemble follow-up
inpatient consultation services to
consider them on a category 1 basis for
the telehealth list. We have concluded
that it would be appropriate to permit
some subsequent nursing facility care
services to be furnished through
telehealth to ensure that complex
nursing facility patients have frequent
encounters with their admitting
practitioner, although we continue to
believe that the federally-mandated
visits should be in-person to facilitate
the comprehensive, coordinated, and
PO 00000
Frm 00074
Fmt 4701
Sfmt 4702
personal care that these complex
patients require on an ongoing basis.
Therefore, we are proposing that
subsequent nursing facility care
services, specifically CPT codes 99307,
99308, 99309 and 99310, be added to
the list of Medicare telehealth services
on a category 1 basis beginning in CY
2011, with some limitations on
furnishing these services through
telehealth. Because of our concerns
regarding the potential acuity and
complexity of SNF inpatients, we are
proposing to limit the provision of
subsequent nursing facility care services
furnished through telehealth to once
every 30 days. We are especially
interested in public comments,
including any evidence regarding
patterns of high quality care and clinical
outcomes, regarding this proposal to
limit the provision of subsequent
nursing facility care services furnished
through telehealth to once every 30
days. We remain committed to ensuring
that SNF inpatients receive appropriate
in-person visits and that Medicare pays
only for medically reasonable and
necessary care. Currently and
continuing in CY 2011, an unlimited
number of initial and follow-up
consultation services may be furnished
through telehealth to these patients so
we believe that only a limited number
of subsequent nursing facility care
services by the admitting practitioner
would be appropriate for SNF
inpatients. Finally, we are specifying
that subsequent nursing facility care
services reported for a Federallymandated periodic visit under
§ 483.40(c) may not be furnished
through telehealth. In light of this
proposal for CY 2011, we remain
confident that admitting practitioners
will continue to make appropriate inperson visits to all patients who need
such care during their SNF stay.
Consistent with this proposal, we are
proposing to revise § 410.78(b) and
§ 414.65(a)(1) to include subsequent
nursing facility care services as
Medicare telehealth services, with the
limitation of one telehealth subsequent
nursing facility care service every 30
days. Federally-mandated periodic
visits may not be furnished through
telehealth, as specified currently in
§ 410.78(e)(2).
6. Neuropsychological Testing
The American Telemedicine
Association submitted a request to add
neuropsychological testing services,
described by CPT codes 96119
(Neuropsychological testing (e.g.,
Halstead-Reitan Neuropsychological
Battery, Wechsler Memory Scales and
Wisconsin Card Sorting Test), per hour
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
of the psychologist’s or physician’s
time, both face-to-face time
administering tests to the patient and
time interpreting these test results and
preparing the report); and 96119
(Neuropsychological testing (e.g.,
Halstead-Reitan Neuropsychological
Battery, Wechsler Memory scales and
Wisconsin Card Sorting Test), with
qualified health care professional
interpretation and report, administered
by technician, per hour of technician
time, face-to-face), to the list of
telehealth services for CY 2011 based on
their similarity to other telehealth
services.
In the CY 2008 PFS final rule with
comment period (72 FR 66251), we
stated that we have received conflicting
comments and data regarding the
appropriateness of furnishing
neuropsychological testing via
telehealth. While we appreciate the
recent request for addition of these same
services to the Medicare telehealth
services list, we do not believe that
these services are similar to services
currently on the Medicare telehealth
services list and, therefore, we conclude
that they would not be appropriate for
consideration or addition under
category 1. In this year’s request for the
addition of the these services, we
received no information to indicate that
the diagnostic findings of
neuropsychological testing through
telehealth are similar to those based
upon in-person testing, and therefore,
that testing through telehealth does not
affect the patient’s diagnosis. Therefore,
we are not proposing to add
neuropsychological testing services to
the list of approved Medicare telehealth
services for CY 2011.
7. Speech-Language Pathology Services
The Marshfield Clinic submitted a
request to add various speech-language
pathology services to the list of
approved telehealth services for CY
2011. Speech-language pathologists are
not permitted under section
1842(b)(18)(C) of the Act to furnish and
receive payment for Medicare telehealth
services. Therefore, we are not
proposing to add any speech-language
pathology services to the list of
Medicare telehealth services for CY
2011. For further discussion of these
services in the context of telehealth, we
refer readers to the CY 2005 and CY
2007 PFS proposed and final rules with
comment period (69 FR 47512 and
66276, and 71 FR 48995 and 69657).
8. Home Wound Care Services
Wound Care Associates, LLC,
submitted a request to add wound care
in the home setting to the list of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Medicare telehealth services. A patient’s
home is not permitted under current
statute to serve as an originating site for
Medicare telehealth services. Therefore,
we are not proposing to add home
wound care services to the list of
Medicare telehealth services for CY
2011.
D. Summary of CY 2011 Telehealth
Proposals
In summary, we are proposing to add
the following requested services to the
list of Medicare telehealth services for
CY 2011:
• Individual and group KDE services
(HCPCS codes G0420 and G0421,
respectively);
• Individual and group DSMT
services, with a minimum of 1 hour of
in-person instruction to be furnished in
the year following the initial DSMT
service to ensure effective injection
training (HCPCS codes G0108 and
G0109, respectively);
• Group MNT and HBAI services
(CPT codes 97804, and 96153 and
96154, respectively);
• Subsequent hospital care services,
with the limitation for the patient’s
admitting practitioner of one telehealth
visit every 3 days (CPT codes 99231,
99232, and 99233); and
• Subsequent nursing facility care
services, with the limitation for the
patient’s admitting practitioner of one
telehealth visit every 30 days (CPT
codes 99307, 99308, 99309, and 99310).
Furthermore, we are proposing to
revise § 410.78(b) and § 414.65(a)(1)
accordingly. Specifically, we are
proposing to add individual and group
KDE services, individual and group
DSMT services, group MNT services,
group HBAI services, and subsequent
hospital care and nursing facility care
services to the list of telehealth services
for which payment will be made at the
applicable PFS payment amount for the
service of the practitioner. In addition,
we have reordered the listing of services
in these two sections and removed
‘‘initial and follow-up inpatient
telehealth consultations furnished to
beneficiaries in hospitals and SNFs’’ in
§ 410.78(b) because these are described
by the more general term ‘‘professional
consultations’’ that is in the same
section. Finally, we are continuing to
specify that the physician visits
required under § 483.40(c) may not be
furnished as telehealth services.
V. Provisions of the Patient Protection
and Affordable Care Act of 2010
The following section addresses
certain provisions of the Patient
Protection and Affordable Care Act
(Pub. L. 111–148), enacted on March 23,
PO 00000
Frm 00075
Fmt 4701
Sfmt 4702
40113
2010, as amended by the Health Care
and Education Reconciliation Act of
2010 (Pub. L. 111–152) enacted on
March 30, 2010 (collectively known as
the Affordable Care Act (ACA)).
A. Section 3002: Improvements to the
Physician Quality Reporting System
Section 3002 of ACA makes a number
of changes to the Physician Quality
Reporting Initiative (PQRI), including
authorizing incentive payments through
2014, and requiring a penalty beginning
in 2015, for eligible professionals who
do not satisfactorily submit quality data.
For a more detailed discussion of the
provisions of section 3002 of the ACA,
please refer to section VI.G.1. of this
proposed rule.
B. Section 3003: Improvements to the
Physician Feedback Program and
Section 3007: Value-based Payment
Modifier Under the Physician Fee
Schedule
1. Background
As required under section 1848(n) of
the Act, as added by section 131(c) of
MIPPA, we established and
implemented by January 1, 2009, the
Physician Resource Use Measurement &
Reporting (RUR) Program for purposes
of providing confidential reports to
physicians that measure the resources
involved in furnishing care to Medicare
beneficiaries. Section 1848(n) of the Act
also authorizes CMS to include
information on the quality of care
furnished to Medicare beneficiaries by a
physician or group of physicians.
We are continuing a phased
implementation of the program. Phase I
was discussed in the CY 2010 proposed
and final rules (74 FR 33589, and 74 FR
61844, respectively), and has been
completed. Phase I consisted of several
activities including extensive data
analysis to inform decisions about
topics such as measures, attribution,
and risk adjustment and formative
testing of report design with practicing
physicians. We concluded Phase I by
sending to individual practicing
physicians in 12 geographic areas 1
several hundred reports that contained
per capita and episode-based cost
information.
Phase I of the Program focused on
providing confidential feedback on
resource use measures. Section
1848(n)(1)(A)(iii) of the Act states that
the Secretary may also include
information on the quality of care
1 The 12 geographic areas are: Boston, MA,
Syracuse, NY, Northern New Jersey, Greenville, SC,
Miami, FL, Little Rock, AR, Indianapolis, IN,
Cleveland, OH, Lansing, MI, Phoenix, AZ, Seattle,
WA, and Orange County, CA.
E:\FR\FM\13JYP2.SGM
13JYP2
40114
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
furnished to Medicare beneficiaries by
physicians (or groups of physicians) in
the feedback reports. We believe that
providing physicians with feedback on
both quality and cost is consistent with
the direction of other CMS value based
purchasing (VBP) initiatives. As a result,
we decided to include quality measures
in Phase II of the program and, in
particular, we considered measures
used in PQRI and claims-based
measures such as GEM measures (74 FR
61846).
Section 1848(n)(1)(A)(ii) also states
that the Secretary may provide reports
at the physician group level.
Accordingly, as part of Phase II of the
program, we will also include reporting
to group practices, defined as more than
one physician practicing medicine
together (74 FR 61846). In addition, we
noted that the definition applies to the
following types of physician groups: (1)
Formally established single or multispecialty group practices; (2) physicians
practicing in defined geographic
regions; and (3) physicians practicing
within facilities or larger systems of care
(74 FR 61846). As we continue with
Phase II, we plan to report to both
physician group practices and their
affiliated practitioners, recognizing that
many physicians practice in
arrangements other than solo practices.
We believe that using both group and
individual level reporting will also
allow us to gain experience with the
sample size issues that arise when
individual physicians have too few
Medicare beneficiaries with specific
conditions to generate reliable
information. (See the CY 2010 final rule
with comment period (74 FR 61844) for
a detailed discussion of plans for Phase
II.)
2. Effect of the ACA of 2010 on the
Program
The ACA contains two provisions
relevant to the RUR program. Section
3003 continues the confidential
feedback program and requires the
Secretary, beginning in 2012, to provide
reports that compare patterns of
resource use of individual physicians to
other physicians. In addition, section
3007 of the ACA requires the Secretary
to apply a separate, budget-neutral
payment modifier to the Fee-For-Service
physician fee schedule payment
formula. The payment modifier, which
will be phased in beginning January 1,
2015 through January 1, 2017, will
provide for differential payment under
the fee schedule to a physician or
groups of physicians, and later, possibly
to other eligible professionals, based
upon the relative quality and cost of
care of their Medicare beneficiaries.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Accordingly, our goal is to have
Medicare physicians receive a
confidential feedback report prior to
implementation of the payment
modifier. We view these two provisions
as complementary, as we expect the
work done for the confidential feedback
program under section 3003 of the ACA
will inform our implementation of the
payment modifier under section 3007 of
the ACA. The approach used in the
confidential feedback reports will serve
as the foundation for implementing the
payment modifier. Specifically,
throughout future phases of reports
under the RUR program, we will
continue to enhance our measures and
methods and improve the content of the
reports based on both our research and
the feedback of stakeholders before the
payment modifier begins to affect
physician payments in 2015.
We plan to engage in a large-scale
effort to garner widespread stakeholder
involvement with regard to how we
continue to build and expand the
confidential feedback program and
transition to implementation of the
payment modifier. We recognize that
such a payment modifier may have an
impact on the delivery of care to
Medicare beneficiaries. Reports that will
be produced in the future based on
changes as a result of section 3003 of the
ACA will contain both cost and quality
data, and work done to improve these
reports with regard to fair and
actionable measures in each of these
domains will aid our decision making in
how to apply the payment modifier. We
intend to seek stakeholder input on
various aspects of program design,
including cost and quality measures,
methodologies for compositing
measures, and feedback report content
and delivery. Such feedback may be
gathered through rulemaking, open door
forums, or other mechanisms.
3. Phase II Proposed Changes
We anticipate that reports in Phase II
of the RUR Program will be distributed
in the fall of 2010. We are proposing,
however, several changes to the program
parameters for Phase II that were
finalized in prior rules. First, we plan to
discontinue our use of commerciallyavailable proprietary episode grouping
software. In particular, section 3003 of
the ACA requires that the Secretary
develop a Medicare-specific episode
grouper by January 1, 2012, the details
of which must be made public. This
grouper will address the limitations
found in the proprietary software.
We recognize that episode-specific
cost information is meaningful and
actionable for physicians, and we plan
to provide such information in feedback
PO 00000
Frm 00076
Fmt 4701
Sfmt 4702
reports after the public grouper software
is developed. Prior to that, we may
consider other potential interim options
for grouping to provide such
information. We believe that our use of
proprietary episode grouping software
in previous phases of the program had
limitations. These software products
were not intended for use with
Medicare claims data, and we
discovered several problems with the
data outputs. Specifically, the groupers
do not work well to create episodes for
beneficiaries with multiple chronic
conditions, which is a significant
portion of Medicare beneficiaries.
For example, when a beneficiary with
a chronic disease is hospitalized for an
acute condition, that beneficiary most
likely also receives treatments unrelated
to the condition for which he or she is
hospitalized, but related to the chronic
disease. The groupers, which are
proprietary and often referred to as
‘‘black boxes,’’ do not enable users to
understand the coding to determine
how to accomodate these issues.
Therefore, CMS had to make several
decisions about how to pre-process the
claims data so that the groupers could
recognize and attempt to deal with these
issues in the clinical grouping logic.
After report production in Phase I, we
discovered several problems with the
pre-processing, which resulted in
inaccurate episode cost information
being disseminated.
Until a Medicare-specific episode
grouping software is developed, we plan
to produce reports for Phase II that
contain per capita cost information.
More specifically, instead of episodespecific cost information, we plan to
provide overall per capita cost
information, as well as per capita cost
information for those beneficiaries with
five common chronic diseases: (1)
Diabetes, (2) congestive heart failure, (3)
coronary artery disease, (4) chronic
obstructive pulmonary disease, and (5)
prostate cancer. This information will
not be specific to the cost of treating the
disease itself, but will provide total Part
A/B per capita cost information, as well
as service category breakdowns, for
treating the subset of attributed
beneficiaries with that disease.
Second, while commenters have been
generally supportive of including PQRI
measures in the reports, we propose not
including data from PQRI in the reports.
The current support contractor for this
program has only 2007 PQRI data. This
was the first year of PQRI, and
participation was still quite low.
Because of the low number of
physicians reporting under PQRI, and
because providers have the flexibility to
choose which measures to report under
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
PQRI, we believe it would be difficult to
make meaningful peer comparisons for
purposes of these reports. Instead, for
Phase II, we propose using the claimsbased measures developed by CMS in
the Generating Medicare Physician
Quality Performance Measurement
Results (GEM) project.2 This is a core set
of 12 process quality measures that can
be calculated using only administrative
claims data. However, in future phases
of the program, we intend to explore the
possibility of linking this program to the
HITECH incentive program for
meaningful use of electronic health
records, and the group practice
reporting option in PQRI. Both of these
programs offer measures and measure
sets, as well as methods of reporting
data which may be more conducive to
meaningful peer comparisons among
physicians.
Third, we propose to distribute
reports electronically in Phase II, by
leveraging the infrastructure used to
distribute PQRI feedback reports. This
infrastructure will enable groups to
utilize an electronic portal to download
their Phase II reports. Individual
practitioners will be able to contact their
MACs/fiscal intermediaries to receive
an e-mailed copy of their reports. We
have received feedback from physicians
that the reports distributed in Phase I
were too long and cumbersome to
manage in hard copy. Our intent is a
condensed report with electronic
dissemination that allows for easier
navigation. We are seeking public
comment on the above proposals.
4. Implementation of Sections 3003 and
3007 of the ACA
The Affordable Care Act provisions
that we mention above contain several
important implementation dates. In
addition to developing an episode
grouper by January 1, 2012, we are
required to publish the cost and quality
measures we intend to use in
determining the payment modifier to be
effective on January 1, 2012. We are also
required to begin implementing the
program parameters through rulemaking
in 2013. The payment modifier is
effective on January 1, 2015, with a
phased implementation so that all
physicians paid under the physician fee
schedule will be subject to the modifier
by January 1, 2017. On or after January
1, 2017, we have the authority to also
apply the payment modifier to other
eligible professionals.
In anticipation of implementing
sections 3003 and 3007 of the ACA, we
intend to perform extensive data
analysis and research, and to seek
2
https://www.cms.gov/GEM.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
stakeholder input on issues related to
cost and quality measures so that we
can be prepared to publish, by January
1, 2012, those measures we intend to
use for the payment modifier. We intend
for the work done in determining
measures for use in the payment
modifier to inform the continued
dissemination of confidential feedback
reports to both individual physicians
and physician groups. Specifically, the
measures chosen for use in the payment
modifier will be candidates for
inclusion in future phases of the
confidential feedback reports.
As mentioned above, Phase I included
reports to several hundred physicians.
In Phase II we anticipate disseminating
reports to about 40 large physician
groups and the approximately 2,000
physicians affiliated with those groups.
We anticipate future phases of the
reports to include additional
dissemination to increasing numbers of
practitioners and groups such that
virtually every applicable Medicare
practitioner receives a report prior to
implementation of the payment
modifier.
5. Comments Sought on Specific
Statistical Issues Related to the ACA
Sections 3003 and 3007
We recognize that there are many
important decisions to be made when
implementing a program that compares
physicians to their peers, especially
when such information can lead to
differential payment. Since the
inception of the RUR program, all data
have been price standardized which
includes accounting for geographic
adjustments. We have identified
important statistical issues in previous
rules, and as we have done in previous
rules, CMS seeks input on several of
these topics as they relate to future
phases of reports. These include, but are
not limited to: risk adjustment;
attribution; benchmarking; peer groups;
minimum case sizes; cost and quality
measures; and compositing methods. To
date, the public comments we have
received have not led us to a single
methodology to propose for dealing
with any of these issues. Therefore, we
do not make formal proposals in this
proposed rule. Specific parameters of
the RUR program are based on the most
current information we have available to
us. These parameters will continue to
evolve and we will continue to evaluate
them as the state of the art in these areas
continues to improve. Therefore, we
seek public comment on these issues.
a. Risk Adjustment
The cost data used in Phase I will be
risk adjusted. For the per capita costs,
PO 00000
Frm 00077
Fmt 4701
Sfmt 4702
40115
we used the Hierarchical Condition
Categories (HCC) model developed for
risk adjustment in Medicare Advantage
plans. This model takes into account
beneficiary characteristics such as age,
sex, and Medicaid status, and then
predicts costs for beneficiaries based on
their unique mix of health conditions.
Several other socioeconomic factors,
such as the median income per capita in
the county where the physician
practices, were used. For the episode
costs, we used the risk adjustment/
severity levels in the proprietary
grouper software.
The cost data in Phase II are risk
adjusted using the HCC model, but
excluding the additional socioeconomic
factors such as the median income per
capita in the county where the
physician practices, as mentioned
above. Regression analyses indicated
that these additional socioeconomic
factors did little to improve the fit of the
model, so we will not include them.
And since there are no episode-based
costs in Phase II—only annual per
capita costs—the HCC model will be the
only method used. Other methods of
risk adjustment exist that we have not
used, such as the CC (complications and
comorbidities) and MCC (major
complications and comorbidities)
indicators implemented in the 2008
MS–DRG system.
The quality data included in Phase II
will not be risk adjusted because the
GEM measures are all clinical process
measures, and it is generally accepted
that such measures need not be risk
adjusted. Beneficiaries should receive
the indicated preventive services (for
example, breast cancer screening)
regardless of their demographic
characteristics or presence or absence of
health conditions.
We seek comment on the appropriate
method for risk adjusting cost data, as
well as our reasoning for not risk
adjusting clinical process quality
measures.
b. Attribution
Deciding which physician(s) is/are
responsible for the care of which
beneficiaries is an important aspect of
measurement. CMS must strike a
balance between only attributing cost
information to physicians for the
services they personally delivered, and
attributing costs to physicians based on
a more encompassing view of the
services provided to each beneficiary so
as to encourage better care coordination
and accountability for patient outcomes.
There are several methods that are
generally used for attributing
beneficiaries’ costs to physicians for the
purposes of measuring and comparing
E:\FR\FM\13JYP2.SGM
13JYP2
40116
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
performance. In Phase I, we used two
different attribution methodologies. Half
of the reports used the ‘‘multipleproportional’’ attribution, in which a
beneficiary’s costs were summed, and
then divided among the physicians who
treated that beneficiary in the same
proportion as their share of evaluation
and management (E&M) services
provided. The other half of the reports
used the ‘‘plurality-minimum’’ method,
in which a beneficiary’s entire cost
(either for the episode or for the year)
was attributed to the physician who
performed the plurality of the E&M
services, subject to a minimum
percentage (in that case, 10 percent).
In Phase II reports, we plan to use the
‘‘plurality-minimum’’ method with a
minimum percentage threshold of E&M
services of 20 percent for individual
physicians and a minimum percentage
threshold of E&M services of 30 percent
of the E&M services for physician group
level reports. These minimum threshold
determinations were based on our
analysis of the claims data. We
recognize that other attribution methods
exist, which may be either more or less
appropriate given the aspect of care one
is measuring. For example, it may be
desirable to attribute the entire cost of
a surgical episode to the performing
surgeon. Another method for attributing
costs is referred to as ‘‘multiple-even,’’ in
which the entire beneficiary’s cost is
attributed to multiple physicians who
treated the beneficiary.
We seek comment on the topic of
attribution methodologies, including
both of those we have already used in
the program, as well as others that may
or may not be mentioned here.
c. Benchmarking and Peer Groups
Determining the relevant comparisons
to make among physicians is also an
important policy aspect of the program.
CMS’ research conducted in Phase I of
the program indicated that physicians
prefer to be compared only to those
physicians most like them (that is, the
narrowest peer group). We recognize the
importance of fair comparison, but are
also faced with the challenge that very
narrow peer groups are most often not
large enough to make statistically
significant comparisons.
The individual-level reports in both
phases of the program have contained,
or will contain, two peer group
comparisons: (1) Physicians in the same
specialty in the same geographic area;
and (2) physicians in the same specialty
across all 12 geographic areas. In each
of these peer groups, a physician is
shown where he or she falls on a
distribution that specifically identified
the 10th, 50th, and 90th percentiles.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
These benchmarks were finalized on an
interim basis in the CY 2010 proposed
rule (74 FR 33589).
In determining applicability for
episode measures in Phase I, we used a
statistical reliability test. For per capita
measures in Phase I, a physician had to
have 20 or more beneficiaries to be
measured and compared. There was no
minimum peer group size requirement.
The original MIPPA mandate requires
CMS to make comparisons among
physicians on cost, and gives the
Secretary the authority to include
comparisons on quality. The use of
quality measures in the program was
finalized in the CY 2010 final rule (74
FR 61846). In Phase II, comparisons
with appropriate peer groups will be
made for both cost and quality. Phase II
reports will be provided only to those
physicians that have 30 or more patients
for each of the cost measures. For the
quality measures, we plan to use the
measure specifications in the GEM
project to define minimum case sizes,
which are at least 11 beneficiaries. We
also plan to impose a minimum peer
group size of 30 in Phase II for both the
cost and quality measures. A minimum
sample size of 30 is generally accepted
in the research community as the
minimum sample size to represent a
group and make comparisons.
We seek comment on the most
appropriate and relevant peer groups for
comparison, including the appropriate
minimum case sizes and minimum peer
group sizes. We are also interested in
methodologies that can account for
small case sizes.
d. Cost and Quality Measures and
Compositing Methods
As mentioned above, and in previous
rules, section 1848(n)(1)(A)(ii) of the Act
gives the Secretary the authority to
include both cost and quality
information in the feedback reports. In
Phase I, we chose to use only cost
information, and used both per capita
and episode cost measurements. As
mentioned above, we previously
finalized the use of quality measures in
Phase II (74 FR 61846), but propose to
discontinue our use of episode cost
measurements. We have yet to include
any composite measures of cost or
quality in the feedback reports.
Section 3007 of the ACA requires
CMS to pay physicians differentially
based on a modifier derived with
composites of both quality and cost
measures. Accordingly, we will need to
devise a methodology in the future for
compositing cost measures and quality
measures, including considering, among
other things, possible methodologies to
develop a single score. In the future,
PO 00000
Frm 00078
Fmt 4701
Sfmt 4702
episode-based cost measures developed
using the public Medicare-specific
episode grouper software also may be
considered in developing a composite
score. Other domains of measures that
may be considered include patient-level
utilization statistics (for example,
emergency department visits per 1,000
patients) and structural measures such
as whether a provider has adopted an
electronic health record. We recognize
that measure composites are
methodologically and operationally
complex and, therefore, we are seeking
comment on this topic.
We plan to continue a phased
approach in the future. Although we
will continue to move from phase-tophase, any substantive changes to the
RUR program will be implemented
through rulemaking. We also anticipate
continuing to gather feedback from
stakeholders about the important datadriven policy topics that affect the
feedback reports.
C. Section 3102: Extension of the Work
Geographic Index Floor and Revisions
to the Practice Expense Geographic
Adjustment Under the Medicare
Physician Fee Schedule, and Protections
for Frontier States as Amended by
Section 10324
Section 1848(e)(1)(E) of the Act (as
amended by section 3102(a) of the ACA)
extends application of the 1.0 work
GPCI floor for services furnished
through December 31, 2010. In addition,
section 1848(e)(1) of the Act (as
amended by section 3102(b) of the ACA)
specifies that for CY 2010 and CY 2011,
the employee wage and rent portions of
the PE GPCI must reflect only one-half
of the relative cost differences for each
locality compared to the national
average and includes a ‘‘hold harmless’’
provision for any PFS locality that
would receive a reduction to its PE GPCI
resulting from the limited recognition of
cost differences. Section 1848(e)(1) of
the Act (as amended by section 3102(b)
of the ACA) also requires an analysis of
the current methods and data sources
used to determine the relative cost
differences in office rent and employee
wages compared to the national average
and the cost share weights assigned to
each PE GPCI component: Employee
wages, office rent, and supplies. Finally,
section 1848(e)(1) of the Act (as
amended by section 3102(b) of the ACA)
requires the Secretary to make
appropriate adjustments to the PE GPCI
by no later than January 1, 2012. In
addition, section 1848(e)(1) of the Act
(as amended by section 10324(c) of the
ACA) establishes a 1.0 PE GPCI floor for
services furnished in frontier states
effective January 1, 2011. The
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
provisions of the ACA related to the
GPCIs are discussed in detail in section
II.D. of this proposed rule.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
D. Section 3103: Extension of
Exceptions Process for Medicare
Therapy Caps
Section 1833(g)(5) of the Act (as
amended by section 3103 of the ACA)
extends the exceptions process for
therapy caps through December 31,
2010. Therapy caps are discussed in
detail in section III.A. of this proposed
rule.
E. Section 3104: Extension of Payment
for Technical Component of Certain
Physician Pathology Services
Section 542(c) of the Medicare,
Medicaid, and SCHIP Benefits
Improvement and Protection Act of
2000 (BIPA) (Pub. L. 106–554), as
amended by section 732 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) (Pub.
L. 108–173), section 104 of division B of
the Tax Relief and Health Care Act of
2006 (MIEA–TRHCA) (Pub. L. 109–432),
section 104 of the Medicare, Medicaid,
and SCHIP Extension Act of 2007
(MMSEA) (Pub. L. 110–173), and
section 136 of the Medicare
Improvements for Patients and
Providers Act of 2008 (MIPPA) (Pub. L.
110–275) is amended by section 3104 of
the ACA to continue payment to
independent laboratories for the TC of
physician pathology services for fee-forservice Medicare beneficiaries who are
inpatients or outpatients of a covered
hospital through CY 2010. The technical
component (TC) of physician pathology
services refers to the preparation of the
slide involving tissue or cells that a
pathologist interprets. The professional
component (PC) of physician pathology
services refers to the pathologist’s
interpretation of the slide.
When the hospital pathologist
furnishes the PC service for a hospital
patient, the PC service is separately
billable by the pathologist. When an
independent laboratory’s pathologist
furnishes the PC service, the PC service
is usually billed with the TC service as
a combined service.
Historically, any independent
laboratory could bill the Medicare
contractor under the PFS for the TC of
physician pathology services for
hospital patients even though the
payment for the costs of furnishing the
pathology service (but not its
interpretation) was already included in
the bundled inpatient stay payment to
the hospital. In the CY 2000 PFS final
rule with comment period (64 FR 59408
through 59409), we stated that this
policy has contributed to the Medicare
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
program paying twice for the TC service:
(1) To the hospital, through the
inpatient prospective payment rate,
when the patient is an inpatient; and (2)
to the independent laboratory that bills
the Medicare contractor, instead of the
hospital, for the TC service. While the
policy also permits the independent
laboratory to bill for the TC of physician
pathology services for hospital
outpatients, in this case, there generally
would not be duplicate payment
because we would expect the hospital to
not also bill for the pathology service,
which would be paid separately to the
hospital only if the hospital were to
specifically bill for it. We further
indicated that we would implement a
policy to pay only the hospital for the
TC of physician pathology services
furnished to its inpatients.
Therefore, in the CY 2000 PFS final
rule with comment period, we revised
§ 415.130(c) to state that for physician
pathology services furnished on or after
January 1, 2001 by an independent
laboratory, payment is made only to the
hospital for the TC furnished to a
hospital inpatient. Ordinarily, the
provisions in the PFS final rule with
comment period are implemented in the
following year. However, the change to
§ 415.130 was delayed 1 year (until
January 1, 2001), at the request of the
industry, to allow independent
laboratories and hospitals sufficient
time to negotiate arrangements.
Full implementation of § 415.130 was
further delayed by section 542 of the
BIPA and section 732 of the MMA,
which directed us to continue payment
to independent laboratories for the TC
of physician pathology services for
hospital patients for a 2-year period
beginning on January 1, 2001 and for
CYs 2005 and 2006, respectively.
In the CY 2007 MPFS final rule with
comment period (71 FR 69624 and
69788), we amended § 415.130 to
provide that, for services furnished after
December 31, 2006, an independent
laboratory may not bill the carrier for
the TC of physician pathology services
furnished to a hospital inpatient or
outpatient. However, section 104 of the
MIEA–TRHCA continued payment to
independent laboratories for the TC of
physician pathology services for
hospital patients through CY 2007, and
section 104 of the MMSEA further
extended such payment through the first
six months of CY 2008.
Section 136 of the MIPPA extended
the payment through CY 2009. Most
recently, section 3104 of the ACA
amended the prior legislation to extend
the payment through CY 2010.
Consistent with this legislative
change, we are proposing to revise
PO 00000
Frm 00079
Fmt 4701
Sfmt 4702
40117
§ 415.130(d) to: (1) Amend the effective
date of our payment policy to reflect
that for services furnished after
December 31, 2010, an independent
laboratory may not bill the Medicare
contractor for the TC of physician
pathology services furnished to a
hospital inpatient or outpatient; and (2)
reformat this subsection into
subparagraphs.
F. Sections 3105 and 10311: Extension
of Ambulance Add-Ons
1. Amendment to Section 1834(l)(13) of
the Act
Section 146(a) of the MIPPA amended
section 1834(l)(13)(A) of the Act to
specify that, effective for ground
ambulance services furnished on or after
July 1, 2008 and before January 1, 2010,
the ambulance fee schedule amounts for
ground ambulance services shall be
increased as follows:
• For covered ground ambulance
transports which originate in a rural
area or in a rural census tract of a
metropolitan statistical area, the fee
schedule amounts shall be increased by
3 percent.
• For covered ground ambulance
transports which do not originate in a
rural area or in a rural census tract of
a metropolitan statistical area, the fee
schedule amounts shall be increased by
2 percent.
Sections 3105(a) and 10311(a) of the
ACA further amend section
1834(l)(13)(A) of the Act to extend the
payment add-ons described above for an
additional year, such that these add-ons
also apply to covered ground ambulance
transports furnished on or after January
1, 2010 and before January 1, 2011. We
are revising § 414.610(c)(1)(i) to conform
the regulations to this statutory
requirement. This statutory requirement
is self-implementing. A plain reading of
the statute requires only a ministerial
application of the mandated rate
increase, and does not require any
substantive exercise of discretion on the
part of the Secretary. For further
information regarding the extension of
these payment add-ons, please see
Transmittal 706 (Change Request 6972)
dated May 21, 2010.
2. Amendment to Section 146(b)(1) of
MIPPA
Section 146(b)(1) of the MIPPA
amended the designation of rural areas
for payment of air ambulance services.
The statute specified that any area that
was designated as a rural area for
purposes of making payments under the
ambulance fee schedule for air
ambulance services furnished on
December 31, 2006, shall continue to be
E:\FR\FM\13JYP2.SGM
13JYP2
40118
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
treated as a rural area for purposes of
making payments under the ambulance
fee schedule for air ambulance services
furnished during the period July 1, 2008
through December 31, 2009. Sections
3105(b) and 10311(b) of the ACA amend
section 146(b)(1) of MIPPA to extend
this provision for an additional year,
through December 31, 2010.
Accordingly, for areas that were
designated as rural on December 31,
2006, and were subsequently redesignated as urban, we have reestablished the ‘‘rural’’ indicator on the
ZIP Code file for air ambulance services,
effective January 1, 2010 through
December 31, 2010. We are revising
§ 414.610(h) to conform the regulations
to this statutory requirement. This
statutory requirement is selfimplementing. A plain reading of the
statute requires only a ministerial
application of a rural indicator, and
does not require any substantive
exercise of discretion on the part of the
Secretary. For further information
regarding the extension of this MIPPA
provision, please see Transmittal 706
(Change Request 6972) dated May 21,
2010.
3. Amendment to Section 1834(l)(12) of
the Act
Section 414 of the MMA added
paragraph (12) to section 1834(l) of the
Act, which specified that in the case of
ground ambulance services furnished on
or after July 1, 2004, and before January
1, 2010, for which transportation
originates in a qualified rural area (as
described in the statute), the Secretary
shall provide for a percent increase in
the base rate of the fee schedule for such
transports. The statute requires this
percent increase to be based on the
Secretary’s estimate of the average cost
per trip for such services (not taking
into account mileage) in the lowest
quartile of all rural county populations
as compared to the average cost per trip
for such services (not taking into
account mileage) in the highest quartile
of rural county populations. Using the
methodology specified in the July 1,
2004 interim final rule (69 FR 40288),
we determined that this percent
increase was equal to 22.6 percent. As
required by the MMA, this payment
increase was applied to ground
ambulance transports that originated in
a ‘‘qualified rural area’’; that is, to
transports that originated in a rural area
included in those areas comprising the
lowest 25th percentile of all rural
populations arrayed by population
density. For this purpose, rural areas
included Goldsmith areas (a type of
rural census tract). Sections 3105(c) and
10311(c) of the ACA amend section
1834(l)(12)(A) of the Act to extend this
rural bonus for an additional year
through December 31, 2010. Therefore,
as directed by the ACA, we are
continuing to apply the rural bonus
described above (in the same manner as
in previous years), to ground ambulance
services with dates of service on or after
January 1, 2010 and before January 1,
2011 where transportation originates in
a qualified rural area.
We are revising § 414.610(c)(5)(ii) to
conform the regulations to this statutory
requirement. This statutory requirement
is self-implementing. The statute
requires a one-year extension of the
rural bonus (which was previously
established by the Secretary), and does
not require any substantive exercise of
discretion on the part of the Secretary.
For further information regarding the
extension of this rural bonus, please see
Transmittal 706 (Change Request 6972)
dated May 21, 2010.
G. Section 3107: Extension of Physician
Fee Schedule Mental Health Add-On
Section 3107 of the ACA amends
section 138(a)(1) of the MIPPA to
continue the 5 percent increase in
Medicare payment for specified mental
health services through December 31,
2010. This payment increase was
originally authorized under section 138
of the MIPPA from July 1, 2008 until
December 31, 2009. Accordingly,
payment for the 24 psychiatry CPT
codes in Table 33, representing
‘‘specified services,’’ remains increased
by 5 percent until December 31, 2010.
TABLE 33—SPECIFIED MENTAL HEALTH SERVICES SUBJECT TO THE FIVE PERCENT INCREASE IN MEDICARE PAYMENT
THROUGH DECEMBER 31, 2010
Office or Other Outpatient Facility
Insight Oriented, Behavior Modifying and/or Supportive Psychotherapy
90804 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
30 minutes face-to-face with the patient).
90805 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
30 minutes face-to-face with the patient; with medical evaluation and management services).
90806 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
50 minutes face-to-face with the patient).
90807 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
50 minutes face-to-face with the patient; with medical evaluation and management services).
90808 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
80 minutes face-to-face with the patient).
90809 (Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an
80 minutes face-to-face with the patient; with medical evaluation and management services).
office or outpatient facility, approximately 20 to
office or outpatient facility, approximately 20 to
office or outpatient facility, approximately 45 to
office or outpatient facility, approximately 45 to
office or outpatient facility, approximately 75 to
office or outpatient facility, approximately 75 to
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Interactive Psychotherapy
90810 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient).
90811 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and
management services).
90812 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient).
90813 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and
management services).
90814 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient).
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00080
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40119
TABLE 33—SPECIFIED MENTAL HEALTH SERVICES SUBJECT TO THE FIVE PERCENT INCREASE IN MEDICARE PAYMENT
THROUGH DECEMBER 31, 2010—Continued
90815 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an office or outpatient facility, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and
management services).
Inpatient Hospital, Partial Hospital or Residential Care Facility
Insight Oriented, Behavior Modifying and/or Supportive Psychotherapy
90816
care
90817
care
90818
care
90819
care
90821
care
90822
care
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 20 to 30 minutes face-to-face with the patient).
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services).
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 45 to 50 minutes face-to-face with the patient).
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services).
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 75 to 80 minutes face-to-face with the patient).
(Individual psychotherapy, insight oriented, behavior modifying and/or supportive, in an inpatient hospital, partial hospital
setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services).
or residential
or residential
or residential
or residential
or residential
or residential
Interactive Psychotherapy
90823 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient).
90824 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 20 to 30 minutes face-to-face with the patient; with medical evaluation and management services).
90826 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient).
90827 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 45 to 50 minutes face-to-face with the patient; with medical evaluation and management services).
90828 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient).
90829 (Individual psychotherapy, interactive, using play equipment, physical devices, language interpreter, or other mechanisms of non-verbal
communication, in an inpatient hospital, partial hospital or residential care setting, approximately 75 to 80 minutes face-to-face with the patient; with medical evaluation and management services).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
H. Section 3108: Permitting Physician
Assistants To Order Post-Hospital
Extended Care Services
The ACA included a selfimplementing provision relating to
SNFs. Section 3108 adds physician
assistants (PAs) to the list of
practitioners (that is, physicians, nurse
practitioners (NPs), and clinical nurse
specialists) that can perform the
required initial certification and
periodic recertifications under section
1814(a)(2)(B) of the Act with respect to
the SNF level of care. Accordingly, we
are proposing to make appropriate
revisions to include PAs in
§ 424.20(e)(2), in which we refer to NPs,
clinical nurse specialists, and PAs
collectively as ‘‘physician extenders.’’
I. Section 3111: Payment for Bone
Density Tests
Section 1848(b) of the Act (as
amended by section 3111 of the ACA)
changes the payment calculation for
dual-energy X-ray absorptiometry (DXA)
services described by two specified
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
DXA CPT codes for CYs 2010 and 2011.
This provision requires payment for
these services at 70 percent of the
product of the CY 2006 RVUs for these
DXA codes, the CY 2006 conversion
factor (CF), and the geographic
adjustment for the relevant payment
year.
Effective January 1, 2007, the CPT
codes for DXA services were revised.
The former DXA CPT codes 76075 (Dual
energy X-ray absorptiometry (DXA),
bone density study, one or more sites;
axial skeleton (e.g., hips, pelvis, spine));
76076 (Dual energy X-ray
absorptiometry (DXA), bone density
study, one or more sites; appendicular
skeleton (peripheral) (e.g., radius, wrist,
heel)); and 76077 (Dual energy X-ray
absorptiometry (DXA), bone density
study, one or more sites; vertebral
fracture assessment) were deleted and
replaced with new CPT codes 77080,
77081, and 77082 that have the same
respective code descriptors as the
predecessor codes. Section 1848(b) of
the Act (as amended by section 3111 of
PO 00000
Frm 00081
Fmt 4701
Sfmt 4702
the ACA) specifies that the revised
payment applies to two of the
predecessor codes (CPT codes 76075
and 76077) and ‘‘any succeeding codes,’’
which are, in this case, CPT codes
77080 and 77082.
Section 1848(b) (as amended by
section 3111 of the ACA) revises the
payment for CPT codes 77080 and
77082 during CY 2010 and CY 2011. We
have provided payment in CY 2010
under the PFS for CPT codes 77080 and
77082 at the specified rates. We note
that the RVUs included in Addendum B
to this proposed rule reflect the RVUs
that result from application of this
statutory provision and the proposed CY
2011 conversion factor. Because the
statute specifies a payment amount for
these services as described previously,
we imputed RVUs for CY 2011 to
include in Addendum B that would
provide the specified payment amount
for these services when multiplied by
the CY 2011 CF. Specifically, we
divided the payment amount based on
the statutory requirements by the CY
E:\FR\FM\13JYP2.SGM
13JYP2
40120
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2011 CF for this proposed rule, and
distributed the imputed total RVUs
across the work, PE, and malpractice
components proportionately to their CY
2006 distribution. Therefore, these
imputed RVUs for CPT codes 77080 and
77082 are displayed in Addendum B to
this proposed rule.
J. Section 3114: Improved Access for
Certified Nurse-Midwife Services
Section 1833(a)(1)(K) of the Act (as
amended by section 3114 of the ACA)
increases the amount of Medicare
payment made under the PFS for
certified nurse-midwife (CNM) services.
Currently, section 1833(a)(1)(K) of the
Act specifies that the payment amount
for CNM services is 80 percent of the
lesser of the actual charge or 65 percent
of the PFS amount. Under section
1833(a)(1)(K) of the Act (as amended by
section 3114 of the ACA), effective for
services furnished on or after January 1,
2011, Medicare payment for CNM
services is increased to 100 percent of
the PFS amount (or 80 percent of the
actual charge if that is less). We are
proposing to revise our regulations at
§ 414.54 (Payment for certified nursemidwives’ services) accordingly to
reflect the increased payment for CNM
services effective for services furnished
on or after January 1, 2011.
Although CNMs are currently paid
under Medicare Part B for their
professional services, there is no
mention of CNMs under the regulatory
provision that lists the providers and
suppliers of services to whom payment
is made under the Medicare Part B
program. Accordingly, we are proposing
to make a technical revision to § 410.150
(To whom payment is made) to specify
that Medicare Part B pays CNMs for
professional services in all settings, as
well as services and supplies furnished
incident to those services.
CNMs are authorized under the
statute to be paid directly for services
that they are legally authorized to
furnish under State law and that are of
the type that would otherwise be
covered if furnished by a physician or
incident to a physician’s services.
Additionally, there is no requirement
under the CNM benefit for physician
oversight or supervision. Accordingly,
CNMs are authorized to personally
furnish diagnostic tests that fall under
their State scope of practice without
regard to the levels of physician
supervision required under the
diagnostic tests benefit. Therefore, we
are amending § 410.32(b)(2) (Exceptions
to the levels of physician supervision
required for diagnostic tests) to include
CNMs who furnish diagnostic tests that
fall within their State scope of practice.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
K. Section 3122: Extension of Medicare
Reasonable Costs Payments for Certain
Clinical Diagnostic Laboratory Tests
Furnished to Hospital Patients in
Certain Rural Areas
Section 416 of the MMA established
a reasonable cost payment for outpatient
clinical diagnostic laboratory tests
furnished by hospitals with fewer than
50 beds that are located in qualified
rural areas for cost reporting periods
beginning during the 2-year period
beginning on July 1, 2004.
Section 105 of the Tax Relief and
Health Care Act of 2006 (Pub. L. 109–
432) (TRHCA) extended the 2-year
period in section 416(b) of the MMA for
an additional cost-reporting year.
Section 107 of the Medicare,
Medicaid, and SCHIP Extension Act of
2007 (Pub. L. 110–173) (MMSEA)
extended the time period for cost
reporting periods beginning on July 1,
2004, and ending on June 30, 2008. For
some hospitals with cost reports that
began as late as June 30, 2008, this
extension affected services performed as
late as June 29, 2009, because this was
the date those cost reports would have
closed.
Section 3122 of the ACA reinstitutes
reasonable cost payment for clinical
diagnostic laboratory tests performed by
hospitals with fewer than 50 beds that
are located in qualified rural areas as
part of their outpatient services for cost
reporting periods beginning on or after
July 1, 2010, through June 30, 2011. For
some hospitals with cost reports that
begin as late as June 30, 2011, this
reinstitution of reasonable cost payment
could affect services performed as late
as June 29, 2012, because this is the date
those cost reports will close.
L. Section 3134: Misvalued Codes Under
the Physician Fee Schedule
Section 1848(c)(2)(K) of the Act (as
added by section 3134 of the ACA)
requires the Secretary to periodically
review and identify potentially
misvalued codes and make appropriate
adjustments to the relative values of
those services identified as being
potentially misvalued. Section
1848(c)(2)(K) of the Act (as added by
section 3134 of the ACA) further
specifies that the Secretary may use
existing processes to receive
recommendations on the review and
appropriate adjustment of potentially
misvalued services, as well as conduct
surveys or implement other data
collection activities, studies, or other
analyses as the Secretary determines to
be appropriate to facilitate the review
and appropriate adjustment of the
relative values of potentially misvalued
PO 00000
Frm 00082
Fmt 4701
Sfmt 4702
codes. Finally, section 1848(c)(2)(L) of
the Act (as added by section 3134 of the
ACA) provides that the Secretary shall
establish a process to validate relative
value units under the PFS.
We note that over the past several
years, we have been working with the
AMA RUC to identify approaches to
addressing the issue of potentially
misvalued services. Our proposed CY
2011 approaches to categories of
potentially misvalued codes are
discussed in section II.C. of this
proposed rule.
M. Section 3135: Modification of
Equipment Utilization Factor for
Advanced Imaging Services
1. Adjustment in Practice Expense To
Reflect Higher Presumed Utilization
Section 1848(b)(4)(C) of the Act (as
added by section 3135(a) of the ACA)
adjusts the utilization rate for expensive
diagnostic imaging equipment to 75
percent in the methodology for
establishing the PE of the associated
procedures. As discussed further in
section II.A.3.a. of this proposed rule,
effective January 1, 2011, we are
proposing to assign a 75 percent
equipment utilization rate assumption
to expensive diagnostic imaging
equipment used in services described by
the HCPCS codes displayed in Table 4.
In the CY 2010 PFS final rule with
comment period (74 FR 61755), we
finalized a policy to increase the
utilization rate to 90 percent for
expensive diagnostic equipment priced
at more than $1 million (CT and MRI
scanners), providing for a 4-year
transition to the 90 percent utilization
rate from the CY 2009 utilization rate of
50 percent. Therefore, in CY 2010 we
were transitioning to a 90 percent
equipment utilization rate assumption,
applying a 25/75 blend of the new and
old PE RVUs, respectively, for the
associated procedures. Section
1848(b)(4)(C) of the Act (as added by
section 3135(a) of the ACA) does not
provide for any further transition and,
therefore, we are assigning a 75 percent
equipment utilization rate assumption
to CT and MRI scanners, effective
January 1, 2011. Under section
1848(b)(4) of the Act (as amended by
section 3135(a) of the ACA), this change
in the equipment utilization rate
assumption from CY 2010 to CY 2011 is
not budget neutral under the PFS. The
equipment utilization rate assumption
remains at 50 percent for all other
equipment included in the PFS PE
methodology.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
2. Adjustment in Technical Component
‘‘Discount’’ on Single-Session Imaging to
Consecutive Body Parts
Section 1848(b)(4)(D) of the Act (as
added by section 3135(a) of the ACA)
increases the established PFS multiple
procedure payment reduction (MPPR)
for the technical component (TC) of
certain single-session imaging services
to consecutive body areas from 25 to 50
percent, effective July 1, 2010, and
section 1848(c)(2)(B)(v)(VI) of the Act
(as added by section 3135(b) of the
ACA) exempts this change from the PFS
budget neutrality provision. This policy
is discussed in detail in section II.C.4 of
this proposed rule.
Effective January 1, 2006, we adopted
an MPPR of 25 percent for the technical
component (TC) of certain diagnostic
imaging procedures, applied to the
second and subsequent services when
more than one service in one of 11
imaging families, defined by imaging
modality and contiguous body area, is
furnished in a single session (70 FR
70261 through 70263). The established
imaging MPPR applies to TC-only
services and to the TC of global services.
It does not apply to professional
component (PC) services. Under this
policy, full payment was made for the
TC of the highest priced procedure,
while payment was made at 75 percent
of the TC for each additional procedure.
As of July 1, 2010, and continuing in CY
2011, payment is made at 50 percent of
the TC for each additional procedure,
consistent with the statutory provision.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
N. Section 3136: Revision for Payment
for Power-Driven Wheelchairs
1. Payment Rules for Power Wheelchairs
Durable medical equipment (DME) is
defined at section 1861(n) of the Act
and includes wheelchairs necessary for
use in the patient’s home. Section
1861(n) provides that wheelchairs
included in the definition of DME ‘‘may
include a power-operated vehicle that
may be appropriately used as a
wheelchair, but only where the use of
such a vehicle is determined to be
necessary on the basis of the
individual’s medical and physical
condition.’’ The general Medicare
payment rules for DME are set forth in
section 1834(a) of the Act and 42 CFR
part 414, subpart D of our regulations.
Section 1834(a)(1) of the Act and
§ 414.210(a) of our regulations establish
that the Medicare payment for a DME
item is generally equal to 80 percent of
either the lower of the actual charge or
the fee schedule amount for the item.
The beneficiary coinsurance is generally
equal to 20 percent of either the lower
of the actual charge or the fee schedule
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
amount for the item once the deductible
is met.
For Medicare payment purposes,
power wheelchairs or power-driven
wheelchairs are classified under various
codes in the Healthcare Common
Procedure Coding System (HCPCS)
based on the level of performance and
functional characteristics of each power
wheelchair that accommodate the
specific needs of patients. Power
wheelchairs classified under
performance Groups 1 through 3 are
covered under Medicare for use in the
patient’s home. Power wheelchair
groups were established in 2006 with
the release of the Power Mobility Device
Coding Guidelines published by the
Durable Medical Equipment Regional
Carriers (DMERCs) currently called the
Durable Medical Equipment Medicare
Administrative Contractors (DME
MACs). The DMEPOS quality standards
define certain power wheelchairs falling
as ‘‘complex, rehabilitative’’ power
wheelchairs, and these ‘‘complex,
rehabilitative’’ power wheelchairs are
treated as a separate product category
for the purpose of implementing the
DMEPOS Competitive Bidding Program
(CBP) mandated by section 1847(a) of
the Act. In both the quality standards
and the DMEPOS competitive bidding
program, complex, rehabilitative power
wheelchairs are defined or identified as
power wheelchairs classified as Group 2
power wheelchairs with power options
that can accommodate rehabilitative
features (for example, tilt in space) or
Group 3 power wheelchairs.
With the exception of power
wheelchairs furnished during calendar
year 1990, power wheelchairs have been
paid under the capped rental category of
DME since January 1, 1989. The
payment rules for capped rental DME
are provided at section 1834(a)(7) of the
Act and § 414.229 of our regulations.
Payment for these items is generally on
a monthly rental basis, with rental
payments capped at 13 months. After a
13-month period of continuous use
during which rental payments are made,
the statute and regulations require that
the supplier transfer title to the
wheelchair to the beneficiary. In
addition, effective for power
wheelchairs furnished on or after
January 1, 1***, section 1834(a)(7) of
the Act, as amended by section
4152(c)(2) (D) of the Omnibus Budget
Reconciliation Act of 1990 (Pub. L. 101–
508), mandates that the supplier of the
power wheelchair offer the patient the
option to purchase rather than rent the
item. Since 1991, over 95 percent of
Medicare beneficiaries have exercised
this lump-sum purchase option for
power wheelchairs.
PO 00000
Frm 00083
Fmt 4701
Sfmt 4702
40121
Consistent with payment for other
DMEPOS items, § 414.210(f)(1) permits
payment for replacement of capped
rental DME if the item has been in
continuous use for the equipment’s
reasonable useful lifetime or is lost,
stolen, or irreparably damaged. Section
414.210(f)(1) states the reasonable useful
lifetime for equipment is determined
through program instructions. In the
absence of CMS program instructions,
the carrier may determine the
reasonable useful lifetime for
equipment, but in no case can it be less
than 5 years. Computation is based on
when the equipment is delivered to the
beneficiary, not the age of the
equipment. If the beneficiary elects to
obtain a new capped rental item after
the reasonable useful lifetime, a new 13month rental payment period would
begin for the new equipment in
accordance with the requirements of
§ 414.229.
Section 1834(a)(7)(A) of the Act,
§ 414.229(b) and (c) set forth the current
fee schedule amounts for capped rental
items. Pursuant to section
1834(a)(7)(A)(i)(II) of the Act and
§ 414.229(b), the current rental fee
schedule amounts for months 1 thru 3
of the 13-month capped rental period
are calculated to pay 10 percent of the
average of allowed purchase price for
the item. The rental fee schedule
amounts for months 4 thru 13 of the 13month capped rental period are
calculated to pay 7.5 percent of the
average of allowed purchase price for
the item. The purchase price is
determined consistent with section
1834(a)(8) of the Act and § 414.229(c)
and § 414.220(e) and (f) and is updated
by the covered item update, as required
by section 1834(a)(14) of the Act and
§ 414.229(d). The current purchase price
amount for power wheelchairs acquired
on a lump sum purchase basis is 100
percent of the purchase price calculated
for the item when rented, as discussed
above.
2. Revision of Payment Amounts for
Power Wheelchairs
Section 3136(a) of the ACA made
several changes to section 1834(a)(7)(A)
of the Act. Section 3136(a)(1) of the
ACA amends section 1834(a)(7)(A) of
the Act by adding a new subclause (III)
to section 1834(a)(7)(A)(i) of the Act.
Subclause (III) revises the capped rental
fee schedule amounts for all power
wheelchairs, modifying the current
payment structure of 10 percent of the
purchase price for months 1 thru 3 and
7.5 percent of that purchase price for
months 4 through 13 that was discussed
above. The rental fee schedule amount
for months 1 thru 3 of the 13-month
E:\FR\FM\13JYP2.SGM
13JYP2
40122
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
capped rental period for power
wheelchairs is revised to 15 percent of
the purchase price for the item. The
rental fee schedule amounts for months
4 thru 13 of the 13-month capped rental
period for power wheelchairs is revised
to 6 percent of the purchase price for the
item. The statutory provision does not
change the methodologies used to
calculate and subsequently update of
the purchase price of power
wheelchairs. Therefore, the
methodology described above for
determining the purchase price amounts
will continue to apply.
Pursuant to section 3136(c) of the
ACA, the changes made by section
3136(a) of the ACA apply to powerdriven wheelchairs furnished on or after
January 1, 2011.
Furthermore, as discussed above,
section 3136(c)(2) of the ACA states that
the changes made by section 3136(a),
including the new payment structure for
power wheelchairs, do not apply to
payment made for items and services
furnished pursuant to contracts entered
into under section 1847 of the Act for
the DMEPOS CBP prior to January 1,
2011 which applies to the
implementation of the first round of the
DMEPOS CBP. As a result, contract
suppliers furnishing power wheelchairs
in competitive bidding areas (CBA)
pursuant to contracts entered into prior
to January 1, 2011 as part of Round 1 of
the DMEPOS CBP will continue to be
paid based under the current regulations
using 10 percent of the purchase price
for months 1 through 3 and 7.5 percent
for each of the remaining months. As a
result, we are proposing to make
changes to §§ 414.202, 414.229 and
414.408 to reflect these statutory
requirements.
3. Elimination of Lump Sum Payment
for Standard Power Wheelchairs
Section 3136(a)(2) of the ACA further
amends section 1834(a)(7)(A)(iii) by
inserting the term ‘‘complex
rehabilitative’’ before the term ‘‘powerdriven wheelchairs.’’ As a result, section
1834(a)(7)(A)(iii) of the Act now extends
the lump sum purchase option only to
complex rehabilitative power
wheelchairs. As discussed above,
‘‘complex rehabilitative power
wheelchairs are power wheelchairs that
are classified as: (1) Group 2 power
wheelchairs with power options that
can accommodate rehabilitative features
(for example, tilt in space), or (2) Group
3 power wheelchairs. We consider all
other power wheelchairs to be standard
power wheelchairs. Therefore, we
propose to interpret the language
‘‘complex rehabilitative’’ in section
1834(a)(7)(A) of the Act consistent with
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
this longstanding classification. As a
result, the changes made by section
3136 to section 1834(a)(7)(A)(iii)
eliminate the lump sum purchase
option for standard power wheelchairs.
Pursuant to section 3136(c) of the
ACA, the changes made to section
1834(a)(7)(A)(iii) of the Act apply to
power-driven wheelchairs furnished on
or after January 1, 2011. The lump sum
purchase payment option will no longer
extend to standard power driven
wheelchairs furnished on or after
January 1, 2011.
Furthermore, section 3136(c)(2) of the
ACA states that the changes made by
section 3136(a), including the limitation
of the lump sum purchase payment
option to complex, rehabilitative power
wheelchairs, do not apply to payment
made for items and services furnished
pursuant to contracts entered into under
section 1847 of the Act for the DMEPOS
CBP prior to January 1, 2011 pursuant
to the implementation of the first round
of the DMEPOS CBP. As a result,
contract suppliers furnishing power
wheelchairs in CBAs pursuant to
contracts entered into prior to January 1,
2011 as part of Round 1 of the DMEPOS
CBP must continue to offer beneficiaries
the lump sum purchase option for all
power wheelchairs.
We are proposing changes to
§§ 414.229 and 414.408 to reflect our
interpretation of these statutory
requirements.
O. Section 3139: Payment for Biosimilar
Biological Products
Section 3139 of the ACA amends
section 1847A of the Act to provide for
Medicare payment of biosimilar
biological products using the average
sale price (ASP) methodology.
Section 1847A of the Act, as amended
by the ACA, defines a biosimilar
biological product as a biological
product approved under an abbreviated
application for a license of a biological
product that relies in part on data or
information in an application for
another biological product licensed
under section 351 of the Public Health
Service Act (PHSA). The reference
biological product for a biosimilar
biological product is defined by the
statute as the biological product
licensed under such section 351 of the
PHSA that is referred to in the
application of the biosimilar biological
product.
The ACAct also amends section
1847A of the Act to specify that the
payment amount for a biosimilar
biological product will be the sum of the
following two amounts: the ASP of all
NDCs assigned to the biosimilar
biological drug product determined
PO 00000
Frm 00084
Fmt 4701
Sfmt 4702
using the methodology in section
1847A(b)(6) of the Act, and 6 percent of
the payment amount determined using
the methodology in section 1847A(b)(4)
of the Act for the corresponding
reference biological product. Sections
7001 to 7003 of the ACA also
established a licensing pathway for
biosimilar biological products, and in
accordance with the statute, the
effective date for Medicare ASP
statutory provisions is July 1, 2010. We
are proposing conforming regulation
text changes at § 414.902 and § 414.904
and we welcome comments on these
conforming changes.
We anticipate that as biosimilar
biological drug products are approved,
we will receive ASP sales data through
the ASP data submission process and
publish national payment amounts in a
manner that is consistent with our
current approach to other drugs and
biologicals that are paid under section
1847A of the Act and set forth in 42 CFR
part 414 subpart J. Until we have
collected sufficient sales data, as
reported by manufacturers, payment
limits will be determined in accordance
with the provisions in section
1847A(c)(4) of the Act. If no
manufacturer data is collected, prices
will be determined by local contractors
using any available pricing information,
including provider invoices. More
information about the ASP payment
methodology and the data submission
process may be found on the CMS Web
site at https://www.cms.gov/
McrPartBDrugAvgSalesPrice/
01_overview.asp and in this rule, in the
section VI.A.1. of this proposed rule,
‘‘Carry Over’’ ASP.
P. Section 3401: Revision of Certain
Market Basket Updates and
Incorporation of Productivity
Improvements Into Market Basket
Updates That Do Not Already
Incorporate Such Improvements.
1. ESRD Market Basket Discussion
Section 3401(h) of the ACA amended
section 1881(b)(14)(F) of the Act and
directs the Secretary to annually
increase payment amounts established
under the ESRD market basket. Please
see section VI.E. of this proposed rule
for a detailed description of these
provisions.
2. Productivity Adjustment Regarding
Ambulatory Surgical Center,
Ambulance, Clinical Laboratory and
DMEPOS Fee Schedules
Section 3401 of the ACA requires that
the update factor under certain payment
systems be annually adjusted by
changes in economy-wide productivity.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
The year that the productivity
adjustment is effective varies by
payment system. Specifically, section
3401 of the ACA requires that in CY
2011 (and in subsequent years) update
factors under the ambulatory surgical
center (ASC) payment system, the
ambulance fee schedule (AFS), and the
clinical laboratory fee schedule (CLFS)
be adjusted by changes in economywide productivity. Section 3401(a)
amends section 1886(b)(3)(B) of the Act
to add clause (xi)(II) which sets forth the
definition of this productivity
adjustment. The statute defines the
productivity adjustment to be equal to
the 10-year moving average of changes
in annual economy-wide private
nonfarm business multifactor
productivity (MFP) (as projected by the
Secretary for the 10-year period ending
with the applicable fiscal year, year,
cost reporting period, or other annual
period) (the ‘‘MFP adjustment’’). Please
see https://www.bls.gov/mfp for more
information on MFP. This is the link to
the Bureau of Labor Statistics (BLS)
historical published data on the
measure of MFP.
The projection of MFP will be
produced by an economic forecasting
firm, currently HIS Global Insight (IGI).
In order to generate a forecast of MFP,
IGI would replicate the MFP measure
40123
calculated by the BLS using a series of
proxy variables derived from the IGI US
Macro-economic models. These models
take into account a very broad range of
factors that influence the total US
economy. IGI forecasts the underlying
proxy components such as Gross
Domestic Product (GDP), capital, and
labor inputs required to estimate MFP,
and will combine those projections
according to the BLS methodology. For
more information on the BLS measure of
MFP, including technical notes, visit:
https://www.bls.gov/mfp/. Table 34 lists
the MFP component series employed by
the BLS and the corresponding concepts
estimated by IGI.
TABLE 34—MULTIFACTOR PRODUCTIVITY COMPONENT SERIES EMPLOYED BY THE BUREAU OF LABOR STATISTICS AND
HIS GLOBAL INSIGHT
IGI Series
Real value-added output, constant 2000 dollars .....................................
Private non-farm business sector labor input; 2000=100.00 ...................
Aggregate capital inputs; 2000=100.00 ....................................................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
BLS Series
Real gross non-farm value added output, chained 2005 dollar billions.
Hours of all persons-private nonfarm business sector; 1992=1.0.
Real effective capital stock used for full employment GDP, chained
2005 dollar billions.
To identify the appropriate proxy
variables, IGI compared the historical
growth rates of the BLS and IGI
components listed above and found they
were consistent across all series and
therefore suitable proxies for calculating
MFP. IGI would use the growth rates of
the forecasted IGI concepts to project
BLS’ components of MFP, and derive
the MFP adjustment that would be used
under section 3401 to adjust the updates
for the ASC payment system, the AFS,
and the CLFS.
As discussed below, for each of these
payment systems, the update factor is
the percentage increase (or percentage
decrease for the CLFS) in the consumer
price index for all urban consumers
(CPI–U) (referred to as the ‘‘CPI–U
update factor’’).
The statute for all three payment
systems generally states that the
Secretary shall reduce the CPI–U
adjustment by the MFP adjustment. In
order to calculate the MFP-adjusted
updates to these payment systems, the
MFP percentage adjustment would be
subtracted from the CPI–U update factor
(for the most recent 12-month period
beginning with July 1 of the previous
year and ending with June 30 of the
current year). For example, if the update
factor (CPI–U) is 4.0 percent, and the
projected MFP is 1.3 percent, the MFP–
Adjusted update factor (or MFP–
Adjusted CPI–U for these payment
systems) would be a 2.7 percent
increase.
The period on which the CPI–U is
calculated is for the most recent 12-
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
month period beginning with July 1 of
the previous year and ending with June
30 of the current year, and we propose
that the end of the 10-year moving
average of changes in the MFP should
coincide with the end of this CPI–U
timeframe. Since the CPI–U update
factor is reduced by the MFP adjustment
to determine the annual update for these
payment systems, we believe it is
appropriate for the numbers associated
with both parts of the calculation to be
projected as of the same end date (in
this case, the end date of the time frame
for both estimates would be June 30th
of the year preceding the update year
itself). In this way, changes in market
conditions are aligned. We will round
the final annual adjustment to the onetenth of one percentage point level up
or down as applicable according to
conventional rounding rules (that is, if
the number we are rounding is followed
by 5, 6, 7, 8, or 9, we will round the
number up; if the number we are
rounding is followed by 0, 1, 2, 3, or 4,
we will round the number down).
Below, we provide more information
on the statutory requirements and
proposals for each of the three payment
systems. The statutory requirements for
the ASC payment system will also be
addressed in the CY 2011 OPPS/ASC
proposed rule. We note that, in this
proposed rule, we are describing the
legislative provision and outlining the
methodology we propose to use to
calculate and apply the MFP adjustment
to determine the annual updates for
ASCs, the AFS, and the CLFS for CY
PO 00000
Frm 00085
Fmt 4701
Sfmt 4702
2011 and each subsequent year. We will
set forth the final MFP adjustment for
CY 2011 in the CY 2011 PFS final rule.
Once we finalize the methodology for
determining and applying the MFP
adjustment to the CPI–U update factors
for these payment systems, for
subsequent calendar years, as we have
done in the past, we intend to notify the
general public of the annual update to
the AFS and CLFS via CMS instruction
and on the CMS Web site. These
notifications would set forth both the
CPI–U percentage increase or decrease
and the MFP adjustment for the
applicable year. For ASCs, for
subsequent calendar years, as we have
done in the past, we would continue to
notify the general public of the annual
update to the ASC payment amount via
OPPS/ASC rulemaking.
We welcome comments on these
proposals.
a. Ambulatory Surgical Centers (ASCs)
Section 1833(i)(2)(C) of the Act
requires that, if the Secretary has not
updated the ASC payment amounts in a
calendar year, the payment amounts
shall be increased by the percentage
increase in the CPI–U as estimated by
the Secretary for the 12-month period
ending with the midpoint of the year
involved. Because the Secretary does
update the ASC payment amounts
annually, we adopted a policy, which
we codified at § 416.171(a)(2)(ii), to
update the ASC conversion factor using
the CPI–U for CY 2010 and subsequent
calendar years. Therefore, the annual
E:\FR\FM\13JYP2.SGM
13JYP2
40124
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
update to the ASC payment system is
the CPI–U (referred to as the CPI–U
update factor). Section 3401(k) of the
ACA amends section 1833(i)(2)(D) of the
Act by adding a new clause (v) which
requires that ‘‘any annual update under
[the ASC payment] system for the year
* * * shall be reduced by the
productivity adjustment described in
section 1886(b)(3)(B)(xi)(II)’’ (which we
refer to as the MFP adjustment) effective
with the calendar year beginning
January 1, 2011. Section 3401(k) of the
ACA states that application of the MFP
adjustment to the ASC payment system
may result in the update to the ASC
payment system being less than zero for
a year and may result in payment rates
under the ASC payment system for a
year being less than such payment rates
for the preceding year.
In accordance with section
1833(i)(2)(C)(i) of the Act, before
applying the MFP adjustment, the
Secretary first determines the
‘‘percentage increase’’ in the CPI–U,
which we interpret cannot be a negative
number. Thus, in the instance where the
percentage change in the CPI–U for a
year is negative, we propose to hold the
CPI–U update factor for the ASC
payment system to zero. Section
1833(i)(2)(D)(v) of the Act, as added by
section 3401(k) of the ACA, then
requires that the Secretary reduce the
CPI–U update factor (which would be
held to zero if the CPI–U percentage
change is negative) by the MFP
adjustment, and states that application
of the MFP adjustment may reduce this
percentage change below zero. If the
application of the MFP adjustment to
the CPI–U percentage increase would
result in a MFP-adjusted CPI–U update
factor that is less than zero, then the
annual update to the ASC payment rates
would be negative and payments would
decrease relative to the prior year.
Table 35 provides illustrative
examples of how the MFP would be
applied to the ASC payment system.
1886(b)(3)(B)(xi)(II) (as discussed
above). Section 3401(j) further amends
section 1834(l)(3) to state that the
application of subparagraph (C) (that is,
the reduction of the CPI–U percentage
increase by the MFP adjustment) may
result in that percentage increase being
less than zero for a year, and may result
in payment rates for a year being less
than such payment rates for the
preceding year.
In accordance with section 1834(l)(3)
of the Act as amended by section 3401(j)
of the ACA, before applying the MFP
adjustment, the Secretary first
determines the ‘‘percentage increase’’ in
the CPI–U, which we interpret cannot
be a negative number. Thus, in the
instance where the percentage change in
TABLE 35—MULTIFACTOR PRODUC- the CPI–U for a year is negative, we
TIVITY ADJUSTED PAYMENT UPDATE: propose to hold the AIF to zero. The
ILLUSTRATIVE EXAMPLE
statute then requires that the Secretary
reduce the CPI–U percentage increase
MFP–Adjusted (which would be held to zero if the CPI–
CPI–U
MFP
CPI–U update U percentage change is negative) by the
(percent)
(percent)
factor
MFP adjustment, and states that
(percent)
application of the MFP adjustment may
4.0
1.3
2.7 reduce this percentage increase below
4.0
4.7
¥0.7 zero. If the application of the MFP
0.0
0.2
¥0.2 adjustment to the CPI–U percentage
increase would result in an MFPb. Ambulance Fee Schedule (AFS)
adjusted AIF that is less than zero, then
the annual update to the AFS would be
In accordance with section
negative and payments would decrease
1834(l)(3)(B) of the Act, the AFS is
relative to the prior year.
required to be increased each year by
the percentage increase in the CPI–U
Table 36 provides illustrative
(U.S. city average) for the 12-month
examples of how the MFP would be
period ending with June of the previous applied to the AFS. Finally, we propose
year. We refer to this update as the
to revise § 414.610(f) to require that the
Ambulance Inflation Factor (AIF).
AIF be reduced by the MFP adjustment
Section 3401(j) of the ACA amends
as required by the statute in determining
section 1834(l)(3) of the Act to add a
the annual update under the ambulance
new subparagraph (C) which states that, fee schedule for CY 2011 and each
for CY 2011 and each subsequent year,
subsequent year, and to revise § 414.620
after determining the percentage
to state that changes in payment rates
increase under section 1834(l)(3)(B)
resulting from the incorporation of the
(that is, the CPI–U percentage increase,
AIF and the MFP adjustment will be
or AIF), the Secretary shall reduce such
announced by CMS by instruction and
percentage increase by the MFP
on the CMS Web site, as we discussed
adjustment described in section
above.
These examples show the implication of
a positive CPI–U update factor with a
smaller MFP, a positive CPI–U update
factor with a large MFP, and a CPI–U
update factor of 0. We discuss the
application of the MFP to the CPI–U
update factor for the ASC payment
system under the OPPS/ASC CY 2001
proposed rule (1504–P), which will be
published around the same time as this
proposed rule. Comments on the
specific mathematical calculation of the
MFP should be made to this PFS
proposed rule. Comments on the
application of the MFP to the CPI–U
update factor under the ASC payment
system should be made to the OPPS/
ASC CY 2011 proposed rule (1504–P).
TABLE 36—EXAMPLES OF THE APPLICATION OF THE MULTIFACTOR PRODUCTIVITY ADJUSTMENT TO THE AMBULANCE FEE
SCHEDULE
B
C
D
CPI–UA
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
A
AIF
MFP
Final update rounded
2.0%
0.0%
¥2.0%
1.0%
2.0%
0.0%
0.0%
1.0%
1.3%
1.3%
1.3%
1.3%
0.7%
¥1.3%
¥1.3%
¥0.3%
c. Clinical Laboratory Fee Schedule
Section 1833(h)(2)(A)(i) of the Act, as
amended by section 3401(l) of the ACA,
requires the Secretary to annually adjust
VerDate Mar<15>2010
00:05 Jul 13, 2010
Jkt 220001
the CLFS ‘‘by a percentage increase or
decrease equal to the percentage
increase or decrease in the Consumer
Price Index for All Urban Consumers
PO 00000
Frm 00086
Fmt 4701
Sfmt 4702
(United States city average minus, for
each of the years 2009 through 2010, 0.5
percentage points.’’ Therefore, the
E:\FR\FM\13JYP2.SGM
13JYP2
40125
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
adjustment to the fee schedule can be an
increase or a decrease.
Section 3401(l) of the ACA also adds
new clause (iv) that applies in CY 2011
and each subsequent year. This clause
requires the Secretary to reduce the
adjustment in clause (i): (1) By the MFP
adjustment described in section
1886(b)(3)(B)(xi)(II) for 2011 and each
subsequent year and (2) by 1.75
percentage points for each of 2011
through 2015 (the ‘‘percentage
adjustment’’). However, section 3401(l)
of the ACA states that the MFP
adjustment will not apply in a year
where the adjustment to the fee
schedule determined under clause (i) is
zero or a percentage decrease for a year.
Further, the application of the MFP
adjustment may not result in an
adjustment to the fee schedule under
clause (i) of less than zero for a year.
Therefore, we are proposing to apply
the MFP adjustment as follows:
• If the CPI–U update factor is
positive, it would be reduced by the
MFP. However, if application of the
MFP would result in a negative update,
the update would be held to zero.
• If the CPI–U update factor is zero or
negative, the MFP adjustment would not
be applied.
Section 3401(l) of the ACA also states
that the application of the percentage
adjustment may result in an adjustment
to the fee schedule under clause (i)
being less than zero for a year and may
result in payment rates for a year being
less than such payment rates for the
preceding year. Therefore, we are
proposing to apply the percentage
reduction of 1.75 percentage points to
any adjustment to the fee schedule
under the CLFS as directed by Section
3401(l) of the ACA.
Table 37 provides illustrative
examples of how these adjustments
would be applied to fees under the
CLFS.
TABLE 37—EXAMPLES OF THE APPLICATION OF THE MULTIFACTOR PRODUCTIVITY ADJUSTMENT TO THE CLINICAL LAB FEE
SCHEDULE
Productivity adjusted
update
CPI–U
MFP
Greater of 0.0% or
(Col.A)¥(Col.B)
Resultant change to CLFS
(¥1.75%)
Percentage point reduction
Col.C¥Col.D
B
C
D
E
2.0%
0.0%
¥2.0%
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
A
1.3%
N/A
N/A
0.7%
0.0%
0.0%
¥1.75%
¥1.75%
¥1.75%
¥1.05%
¥1.75%
¥1.75%
d. DMEPOS Fee Schedule
Sections 1834(a)(14), 1834(h)(4), and
1842(s)(1) of the Act mandate annual
updates to the fee schedule amounts
established in accordance with these
respective sections for covered items of
durable medical equipment defined in
section 1834(a)(13) of the Act, prosthetic
devices, orthotics, and prosthetics
defined in section 1834(h)(4)(B) and (C)
of the Act, and parenteral and enteral
nutrients, equipment, and supplies
described in section 1842(s)(2)(D) of the
Act. The annual updates for 2011 for
these sections are based on the
percentage increase in the CPI–U for the
12-month period ending with June 2010.
The annual updates for years
subsequent to 2011 are based on the
percentage increase in the CPI–U for the
12-month period ending with June of
the previous year (that is, June 2011 for
2012, June 2011 for 2013, etc.). Since
1990 for durable medical equipment,
prosthetic devices, orthotics, and
prosthetics and 2003 for parenteral and
enteral nutrients, equipment, and
supplies, these annual fee schedule
updates have been implemented on an
annual basis through program
instructions.
Section 3401(m) of the ACA amends
section 1834(a)(14) of the Act to add a
new subparagraph (L) which provides
that, for CY 2011 and each subsequent
year, the fee schedule update factor
VerDate Mar<15>2010
23:56 Jul 12, 2010
Jkt 220001
based on the CPI–U for the 12-month
period ending with June of the previous
year is to be reduced by the MFP
adjustment described in section
1886(b)(3)(B)(xi)(II) of the Act (as
discussed above). Section 3401(m) of
the ACA further amends section
1834(a)(14) of the Act to state that the
application of subparagraph (L) (that is,
the reduction of the CPI–U percentage
increase by the MFP adjustment) may
result in that percentage increase being
less than zero for a year, and may result
in payment rates for a year being less
than such payment rates for the
preceding year.
Section 3401(n) of ACA amends
section 1834(h)(4)(A) of the Act to add
a new clause (xi) which provides that,
for CY 2011 and each subsequent year,
the fee schedule update factor based on
the CPI–U for the 12-month period
ending with June of the previous year is
to be reduced by the MFP adjustment
described in section 1886(b)(3)(B)(xi)(II)
of the Act (as discussed above). Section
3401(n) of the ACA further amends
section 1834(h)(4) of the Act to state that
the application of subparagraph (A)(xi)
(that is, the reduction of the CPI–U
percentage increase by the MFP
adjustment) may result in that
percentage increase being less than zero
for a year, and may result in payment
rates for a year being less than such
payment rates for the preceding year.
PO 00000
Frm 00087
Fmt 4701
Sfmt 4702
Section 3401(o) of ACA amends
section 1842(s)(1) of the Act to add a
new subparagraph (B) and clause (ii)
which provides that, for CY 2011 and
each subsequent year, the fee schedule
update factor based on the CPI–U for the
12-month period ending with June of
the previous year is to be reduced by the
MFP adjustment described in section
1886(b)(3)(B)(xi)(II) (as discussed
above). Section 3401(o) further amends
section 1842(s)(1) to state that the
application of subparagraph (B)(ii) (that
is, the reduction of the CPI–U
percentage increase by the MFP
adjustment) may result in that
percentage increase being less than zero
for a year, and may result in payment
rates for a year being less than such
payment rates for the preceding year.
The MFP adjustments to the CPI–U
percentage increases used in calculating
the fee schedule adjustment factors for
these DMEPOS items and services as
mandated by sections 3401(m), (n), and
(o) of ACA are simple mathematical
calculations and are ministerial in
nature. Therefore, we plan to implement
these adjustments for 2011 and
subsequent years as part of the annual
program instructions related to the
DMEPOS fees schedule updates.
E:\FR\FM\13JYP2.SGM
13JYP2
40126
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Q. Section 4103: Medicare Coverage of
Annual Wellness Visit Providing a
Personalized Prevention Plan
1. Background
a. Medicare Coverage of Preventive
Physical Examinations and Routine
Checkups
Section 1862(a)(7) of the Act
explicitly prohibits Medicare payment
for routine physical checkups with
certain exceptions. One exception is for
the Initial Preventive Physical Exam
(also referred to as the ‘‘Welcome to
Medicare’’ exam) established for new
beneficiaries effective for services
furnished on or after January 1, 2005.
Section 4103 of the ACA has provided
another exception to section 1862(a)(7).
Congress has expanded Medicare
coverage under part B to include an
Annual Wellness Visit Providing
Personalized Prevention Plan Services
(hereinafter referred to as the annual
wellness visit) in sections 1861(s)(2)(FF)
and 1861(hhh) of the Act. This
expanded benefit will be effective on
January 1, 2011. Preventive care has
become an increasing focus of the
Medicare program. For instance, section
101 of the MIPPA expanded Medicare’s
authority to establish coverage for
preventive services that meet specified
criteria. Among other things, the annual
wellness visit will encourage
beneficiaries to obtain the preventive
services already covered by Medicare,
and that are appropriate for each
individual beneficiary.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
b. Requirements for Coverage of an
Annual Wellness Visit
Section 4103 of the ACA provides for
coverage of an annual wellness visit,
which includes and/or takes into
account a health risk assessment (HRA),
and creates a personalized prevention
plan for beneficiaries, subject to certain
eligibility and other limitations. Section
4103 of the ACA also requires the
identification of elements that must be
provided to a beneficiary as part of the
first visit for personalized prevention
plan services and requires the
establishment of a yearly schedule for
appropriate provision of such elements
thereafter.
The Affordable Care Act specifies
elements that may be included in a
personalized prevention plan, including
establishment of, or update to, the
individual’s medical and family history,
a list of the individual’s current
providers and suppliers and
medications prescribed for the
individual; measurement of height,
weight, body-mass index (BMI) or waist
circumference, and blood pressure;
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
detection of any cognitive impairment;
establishment or update of an
appropriate screening schedule for the
next 5 to 10 years; establishment or
update of a list of risk factors and
conditions (including any mental health
conditions) for which interventions are
recommended or underway; and
furnishing of personalized health advice
and referral, as appropriate, to health
education or preventive counseling
services or programs. The Affordable
Care Act also permits the Secretary to
add other elements to the annual
wellness visit determined to be
appropriate.
2. Proposed Revisions
a. Proposed Revisions to § 411.15,
Particular Services Excluded From
Coverage
To conform the regulations to the
statutory requirements of the ACA, we
are proposing to revise § 411.15 by
specifying an exception to the routine
physical checkups exclusion from
coverage in § 411.15(a)(1) and modifying
§ 411.15(k)(15). We would add a
provision to permit coverage of annual
wellness visits that meet the eligibility
limitation and the conditions for
coverage we are specifying in § 410.15
(Annual Wellness Visit Providing
Personalized Prevention Plan Services).
Coverage of the annual wellness visit is
furnished under Medicare Part B only.
As provided in the statute, this new
coverage allows payment for an annual
wellness visit if provided after January
1, 2011 for an individual who is no
longer within 12 months after the
effective date of his or her first Medicare
Part B coverage period, and has not
received either an IPPE or an annual
wellness visit within the past 12
months.
b. Proposed Revisions to Part 410,
Subpart B—Medical and Other Health
Services
We propose to add § 410.15(a),
Condition for Coverage of Annual
Wellness Visits Providing Personalized
Prevention Plan Services, and
§ 410.15(b), Limitation on Coverage of
Annual Wellness Visits Providing
Personalized Prevention Plan Services,
to codify the coverage of the annual
wellness visit providing personalized
prevention plan services.
We are proposing to define several
terms in § 410.15. These include the
following terms: (1) Detection of any
cognitive impairment; (2) Review of the
individual’s functional ability and level
of safety; (3) Health professional; (4)
Establishment of, or update to the
individual’s medical and family history;
PO 00000
Frm 00088
Fmt 4701
Sfmt 4702
(5) Eligible beneficiary; (6) First annual
wellness visit providing personalized
prevention plan services; and (7)
Subsequent annual wellness visit
providing personalized prevention plan
services.
Further, the ACA allows the addition
of any other element determined
appropriate by the Secretary for
inclusion in an annual wellness visit.
We reviewed the relevant medical
literature, current clinical practice
guidelines, and the recommendations of
the United States Preventive Services
Task Force (USPSTF). Pursuant to that
review, we propose to add depression
screening and functional status
screening as elements of the first annual
wellness visit only. In their December
2009 Recommendation Statement, the
U.S. Preventive Services Task Force
(USPSTF) recommends screening adults
for depression when staff-assisted
depression care supports are in place to
assure accurate diagnosis, effective
treatment and follow-up (Grade: B
recommendation). That is, the USPSTF
recommends the service; and there is
high certainty that the net benefit is
moderate or there is moderate certainty
that the net benefit is moderate to
substantial.
The USPSTF is currently updating its
1996 recommendation regarding
screening for hearing impairment in
older adults as well as its
recommendation on falls in the elderly.
Until those recommendations can be
published, functional status screening
(including assessment of hearing
impairment, ability to successfully
perform activities of daily living, fall
risk and home safety) appears
supportable by evidence only for the
first annual wellness visit.
We also are proposing that the
definition of the term ‘‘Establishment of,
or an update to the individual’s medical
and family history’’ include more than a
list of all of an individual’s prescribed
medications as provided in the statute,
but also supplements such as vitamins
and calcium that an individual may use
or be exposed to. Supplements such as
these are commonly used by many
beneficiaries and the medical literature
supports that their use be closely
monitored by health professionals
because they can interact with
prescribed medications and may result
in unintended medical problems in
individual cases. The statute expressly
permits the Secretary to add other
elements such as this to the annual
wellness visits.
(1) Definitions
We are proposing to add the following
definitions to § 410.15:
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• Detection of any cognitive
impairment, for purposes of this section,
means assessment of an individual’s
cognitive function by direct observation,
with due consideration of information
obtained by way of patient report,
concerns raised by family members,
friends, caretakers, or others.
• Review of the individual’s
functional ability and level of safety, for
purposes of this section includes, at a
minimum, assessment of the following
topics:
++ Hearing impairment;
++ Ability to successfully perform
activities of daily living;
++ Fall risk;
++ Home safety.
• Health professional, for purposes of
this section means:
++ A physician who is a doctor of
medicine or osteopathy (as defined in
section 1861(r)(1) of the Act); or
++ A practitioner as described in clause
(i) of section 1842(b)(18)(C) of the Act,
that is, a physician assistant, nurse
practitioner, or clinical nurse
specialist (as defined in section
1861(aa)(5) of the Social Security
Act); or
++ A medical professional (including a
health educator, registered dietitian,
or nutritionist) or a team of medical
professionals, who are working under
the supervision of a physician as
defined in this definition.
• Establishment of, or an update to
the individual’s medical and family
history, for purposes of this section,
means at a minimum the collection and
documentation of the following:
++ Past medical and surgical history,
including experiences with illnesses,
hospital stays, operations, allergies,
injuries, and treatments.
++ Use or exposure to medications and
supplements, including calcium and
vitamins.
++ Medical events experienced by the
beneficiary’s parents and any siblings
and children, including diseases that
may be hereditary or place the
individual at increased risk.
• Eligible beneficiary, for purposes of
this section, means an individual who is
no longer within 12 months after the
effective date of his or her first Medicare
Part B coverage period, and has not
received either an initial preventive
physical examination or an annual
wellness visit providing a personalized
prevention plan within the past 12
months.
(2) Requirements of the First Visit for
Personalized Prevention Plan Services
We are proposing that the first annual
wellness visit for purposes of this
benefit include the following:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
• Establishment of the individual’s
medical and family history;
• Establishment of a list of current
providers and suppliers that are
regularly involved in providing medical
care to the individual;
• Measurement of the individual’s
height, weight, body mass index (or
waist circumference, if appropriate),
blood pressure, and other routine
measurements as deemed appropriate,
based on the individual’s medical and
family history;
• Detection of any cognitive
impairment that the individual may
have;
• Review of the individual’s potential
(risk factors) for depression, including
current or past experiences with
depression or other mood disorders,
based on the use of an appropriate
screening instrument for persons
without a current diagnosis of
depression, which the health
professional as defined in this section
may select from various available
screening questions or standardized
questionnaires designed for this purpose
and recognized by national professional
medical organizations;
• Review of the individual’s
functional ability and level of safety,
based on direct observation or the use
of appropriate screening questions or a
screening questionnaire, which the
health professional as defined in this
section may select from various
available screening questions or
standardized questionnaires designed
for this purpose and recognized by
national professional medical
organizations;
• Establishment of the following:
++ A written screening schedule, such
as a checklist, for the next 5 to 10
years as appropriate, based on
recommendations of the USPSTF and
the Advisory Committee on
Immunization Practices, and the
individual’s health status, screening
history, and age-appropriate
preventive services covered by
Medicare; and
++ A list of risk factors and conditions
for which primary, secondary or
tertiary interventions are
recommended or are underway,
including any mental health
conditions or any such risk factors or
conditions that have been identified
through an initial preventive physical
examination (as described under
§ 410.16), and a list of treatment
options and their associated risks and
benefits;
• Furnishing of personalized health
advice and a referral, as appropriate, to
health education or preventive
PO 00000
Frm 00089
Fmt 4701
Sfmt 4702
40127
counseling services or programs aimed
at reducing identified risk factors and
improving self management, or
community-based lifestyle interventions
to reduce health risks and promote selfmanagement and wellness, including
weight loss, physical activity, smoking
cessation, fall prevention, and nutrition;
and
• Any other element determined
appropriate by the Secretary through the
National Coverage Determination
process.
(3) Requirements of Subsequent Visits
for Personalized Prevention Plan
Services
We are proposing that subsequent
annual wellness visits providing
personalized prevention plan services
for purposes of this benefit include the
following:
• An update of the individual’s
medical and family history;
• An update of the list of current
providers and suppliers that are
regularly involved in providing medical
care to the individual, as that list was
developed for the first annual wellness
visit providing personalized prevention
plan services;
• Measurement of an individual’s
weight, blood pressure, and other
routine measurements as deemed
appropriate, based on the individual’s
medical and family history;
• Detection of any cognitive
impairment, as that term is defined in
this section, that the individual may
have;
• An update to the following:
++ The written screening schedule for
the individual as that schedule was
developed at the first annual wellness
visit providing personalized
prevention plan services; and
++ The list of risk factors and
conditions for which primary,
secondary or tertiary interventions are
recommended or are underway for the
individual as that list was developed
at the first annual wellness visit
providing personalized prevention
plan services;
• Furnishing of personalized health
advice to the individual and a referral,
as appropriate, to health education or
preventive counseling services or
programs as that advice and related
services are defined in paragraph (a) of
this section;
• Any other element determined
appropriate by the Secretary through the
National Coverage Determination
process. Body-mass index (BMI) should
be calculated at the first annual
wellness visit and may be recalculated
at subsequent visits, if indicated. Given
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40128
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
the general stability of adult height, we
would not expect the BMI to
meaningfully change in the absence of
significant weight change. We have not
in the definition of the subsequent
annual visit required measurement of
the individual’s height.
We are proposing to add two distinct
elements to the definition of the first
annual wellness visit only: depression
screening and functional status
assessment. Our review of the medical
literature and the USPSTF
recommendations indicates that the
optimum frequency for those services is
unknown. Thus we believe it would be
premature and beyond the current
evidence to require that they be
included in the definition of subsequent
visits, but they may be performed at
these visits, if indicated.
In addition, to facilitate future
consideration of coverage of additional
elements in the definitions of the first
and subsequent annual wellness visits
in § 410.15(a), we are proposing that the
determination of other required
elements for those purposes will be
made through the National Coverage
Determination (NCD) process. The NCD
process is evidence based, transparent
and furnishes the opportunity for public
comment, and is described in sections
1862(l) of the Act.
While section 4103 of the ACA
ultimately requires that an HRA be
included in the new annual wellness
visit benefit beginning January 1, 2011,
the HRA guidelines (with standards for
interactive telephonic and web-based
HRAs) and the model HRA tool also
required by section 4103 are not yet
available. As a result, we have not
included requirements related to the
HRA in this proposed rule. When HRA
guidelines and standards have been
established, and a model HRA
instrument is available and determined
by the Secretary to be appropriate for
the Medicare population, we will revise
these regulations to include the HRA as
an element in the definition of the
annual wellness visit.
We are requesting public comments
on the components of both the first and
subsequent annual wellness visits, as
well as the definitions of related terms
in the document. We ask that
commenters making specific
recommendations on this or any related
issue provide documentation from the
medical literature, current clinical
practice guidelines, or the USPSTF or
Advisory Committee on Immunization
Practices recommendations.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
3. Payment for the Annual Wellness
Visit Providing Personalized Prevention
Plan Services (PPPS)
Section 4103 of the ACA created a
new benefit for the ‘‘annual wellness
visit’’ with personalized prevention plan
services. The Affordable Care Act
amends section 1861(s)(2) of the Act by
adding a new subsection (FF) to provide
for coverage of the annual wellness visit
beginning January 1, 2011. Section 4103
also adds new subsection (hhh) to
section 1861 of the Act to define
‘‘personalized prevention plan services’’
and to specify who may furnish these
services. Finally, section 4103 amends
section 1848(j)(3) of the Act to provide
for payment of annual wellness visits
under the PFS, and specifically
excludes the annual wellness visit from
the hospital outpatient prospective
payment system (OPPS). Therefore, a
single payment under the PFS will be
made when an annual wellness visit is
furnished by a physician, physician
assistant, nurse practitioner, or clinical
nurse specialist, or by a medical
professional or team of medical
professionals, as determined
appropriate by the Secretary, under the
supervision of a physician.
To allow for Medicare reporting and
payment of the annual wellness visit,
we are proposing to create two new
HCPCS G-codes for reporting the first
wellness visit and creation of the PPPS
and the subsequent visits available to
the beneficiary every 12 months.
Specifically, we are proposing to
establish the following two new HCPCS
codes for CY 2011: GXXXA (Annual
wellness visit; includes a personalized
prevention plan of service (PPPS), first
visit) and GXXXB (Annual wellness
visit; includes a personalized
prevention plan of service (PPPS),
subsequent visit). A beneficiary’s first
annual wellness visit to a practitioner
would be reported to Medicare under
HCPCS code GXXXA, even if the
beneficiary had previously received an
initial preventive physical examination
(IPPE) that was covered by Medicare.
Beneficiaries, in their first 12 months of
Part B coverage, will continue to be
eligible only for an IPPE. After the first
12 months of Part B coverage, on and
after January 1, 2011, beneficiaries will
be eligible for an annual wellness visit
described by HCPCS code GXXXA or
GXXXB, provided that the beneficiary
has not received an IPPE or annual
wellness visit within the preceding 12month period.
A beneficiary would be eligible for
one initial annual wellness visit covered
by Medicare that must include all of the
required elements that we are proposing
PO 00000
Frm 00090
Fmt 4701
Sfmt 4702
for the first visit as described in the
preceding section. All other annual
wellness visits that would include the
required elements for those visits would
be reported as subsequent visits, even if
a different practitioner furnished the
subsequent annual wellness visit. We
would expect there to be continuity and
communication among the practitioners
caring for beneficiaries over time with
respect to the PPPS, and that would
include the case where a different
practitioner furnishing a subsequent
annual wellness visit would update the
information in the patient’s medical
record based on the patient’s interval
history since the previous annual
wellness visit.
The first wellness visit described by
HCPCS code GXXXA is similar to the
IPPE that is currently reported with
HCPCS code G0402 (Initial preventive
physical examination; face-to-face visit,
services limited to new beneficiary
during the first 12 months of Medicare
enrollment). We believe that the
physician work and nonfacility PE of
the IPPE and the first annual wellness
visit are very similar, given that both
represent an initial beneficiary visit
focused on prevention. In the CY 2010
PFS final rule with comment period
discussion of payment for the IPPE (74
FR 61767), we noted that in the context
of physician work and intensity, HCPCS
code G0402 was most equivalent to CPT
code 99204 (Level 4 new patient office
or other outpatient visit). Therefore, for
CY 2011, we are proposing to crosswalk
the same physician work RVUs of 2.43
from CPT code 99204 to HCPCS codes
G0402 and GXXXA. Similarly, we
believe the direct PE inputs for all of
these services are similar and, therefore,
we are proposing to assign the same
direct PE inputs to HCPCS codes G0402
and GXXXA as are included for CPT
code 99204. We note that currently, the
direct PE inputs for HCPCS code G0402
also include preventive assessment
forms, and we are proposing to add this
supply to the PE for HCPCS code
GXXXA as well because we believe it
would be used in the first wellness visit.
The proposed CY 2011 PE and
malpractice RVUs for HCPCS code
GXXXA are displayed in Addendum B
to this proposed rule. We also note that
we are proposing no facility PE RVUs
for HCPCS code GXXXA because only a
single payment will be made under the
PFS when this service is furnished.
There is no separate facility payment for
GXXXA when a practitioner furnishes
this service in the facility setting.
Moreover, we believe that a
subsequent annual wellness visit
described by HCPCS code GXXXB is
most similar, from the perspectives of
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
physician work and PE, to CPT code
99214 (Level 4 established patient office
or other outpatient visit). The
subsequent annual wellness visit is a
patient visit for PPPS that includes
certain required elements, such as
updating information regarding the
patient’s history, risk factors, and
regular medical care providers and
suppliers since the prior annual visit,
and obtaining routine measurements.
We believe the physician work and
direct PE of a subsequent annual
wellness visit are similar, in terms of
evaluation and management (E/M) visit
level, to the first wellness visit, which
we are proposing to value like a level 4
new patient office or other outpatient
visit, as we have previously valued the
IPPE. However, the subsequent annual
wellness visit would typically be for an
established patient and, as described
earlier in this section, we are proposing
that certain wellness visit elements only
must be furnished in the first wellness
visit. As a result, we believe it would be
most appropriate to value the
subsequent annual wellness visit based
upon an E/M visit for an established
patient. Therefore, for CY 2011 we are
proposing to crosswalk the same
physician work RVUs of 1.50 from CPT
code 99214 to HCPCS code GXXXB.
Furthermore, we believe the direct PE
inputs for these two services are also
similar and, therefore, we are proposing
to assign the same direct PE inputs to
HCPCS code GXXXB as are assigned to
CPT code 99214. We note that we are
also proposing to add the same
preventive assessment forms to the PE
for HCPCS code GXXXB as we are
proposing to add for HCPCS code
GXXXA because we believe this supply
would be used in both the first and
subsequent annual wellness visits. The
proposed CY 2011 PE and malpractice
RVUs for HCPCS code GXXXB are
displayed in Addendum B to this
proposed rule. Similar to our treatment
of HCPCS code GXXXA for the first
wellness visit, we are proposing no
facility PE RVUs for HCPCS code
GXXXB as only a single payment will be
made under the PFS when this service
is furnished. There is no separate
facility payment for GXXXB when a
practitioner furnishes this service in the
facility setting.
While we believe there could be
overlap in the direct PE, malpractice
expense, and physician work in both
history taking and examination of the
patient in the context of the initial or
subsequent wellness visit and another
E/M service, we are not proposing to
limit the level of a medically necessary
E/M visit when furnished and billed
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
with a wellness visit. As we stated in
the CY 2005 PFS final rule with
comment period with respect to the
IPPE (69 FR 66289 through 66290), we
do not want to prohibit the reporting of
an appropriate level of service when it
is necessary to evaluate and treat the
beneficiary for acute and chronic
conditions. However, at the same time,
we believe the practitioner is better able
to discuss health promotion, disease
prevention, and the educational
opportunities available with
beneficiaries when their health status
has been stabilized and the beneficiary
is physically receptive. Therefore,
depending on the clinical
circumstances, a CPT code for a
medically necessary E/M visit may be
reported and appended with CPT
modifier -25 (significant, separately
identifiable evaluation and management
service by the same physician on the
same day of the procedure or other
service) to designate the E/M visit as a
separately identifiable service from the
initial or subsequent wellness visit.
However, we believe this scenario
would be uncommon, and we expect
that no components of an encounter
attributable to the annual wellness visit
would be used in determining the level
of a separate E/M visit that would also
be reported.
With respect to beneficiary costsharing, section 4103(c) of the ACA
amends section 1833(a)(1) of the Act by
adding subparagraph (X), referring to
the PPPS to state that the amount paid
shall be 100 percent of the lesser of the
actual charge for the services or the
amount determined under the payment
basis determined under section 1848 of
the Act, thereby eliminating
coinsurance for the annual wellness
visit. Finally, section 4103(b)(4) of the
ACA amends section 1833(b) of the Act
to specify that the Part B deductible
does not apply to the annual wellness
visit. We expect that practitioners will
work to ensure that this valuable new
Medicare benefit is furnished to the
beneficiaries that they care for in their
practices, effective January 1, 2011.
R. Section 4104: Removal of Barriers to
Preventive Services in Medicare
1. Definition of ‘‘Preventive Services’’
Section 4104 of the ACA revises
section 1861(ddd) of the Act to add
paragraph (3), which defines the term
‘‘preventive services’’ as follows:
• The specific services currently
listed in section 1861(ww)(2) of the Act
with the explicit exclusion of
electrocardiograms (as specified in
section 1861(ww)(2)(M) of the Act);
PO 00000
Frm 00091
Fmt 4701
Sfmt 4702
40129
• The initial preventive physical
examination (IPPE) established by
section 611 of the MMA and defined in
section 1861(ww)(1) of the Act; and
• The annual wellness visit, as
specified by section 1861(hhh) of the
Act as added by section 4103 of the
ACA. We refer readers to section V.Q. of
this proposed rule for the proposed
provisions related to the coverage of and
payment for the annual wellness visit.
The regulations regarding coverage of
the IPPE are specified in § 410.16 and
remain unchanged by the ACA.
The specific preventive services
included in the definition of ‘‘preventive
services’’ in section 1861(ddd)(3)(A) of
the Act as cross-referenced to section
1861(ww)(2) of the Act, excluding
electrocardiograms, include the
following:
• Pneumococcal, influenza, and
hepatitis B vaccine and administration.
• Screening mammography.
• Screening pap smear and screening
pelvic exam.
• Prostate cancer screening tests.
• Colorectal cancer screening tests.
• Outpatient diabetes selfmanagement training (DSMT).
• Bone mass measurement.
• Screening for glaucoma.
• Medical nutrition therapy (MNT)
services.
• Cardiovascular screening blood
tests.
• Diabetes screening tests.
• Ultrasound screening for abdominal
aortic aneurysm (AAA).
• Additional preventive services
identified for coverage through the
national coverage determination (NCD)
process.
We note that currently the only
additional preventive service identified
for coverage through the NCD process is
HIV testing. A proposed NCD for
smoking cessation services for
asymptomatic patients was released in
May 2010 on the CMS Web site at:
https://www.cms.gov/mcd/
index_list.asp?list_type=nca. We will
address the applicability of section
1861(ddd)(3)(A) of the Act (as added by
section 4104 of the ACA) to these
services if an NCD establishing them as
additional preventive services is
finalized.
We are proposing to add the
definition of ‘‘preventive services’’ in
§ 410.2 to implement the provisions of
section 1861(ddd)(3) of the Act (as
amended by section 4104 of the ACA).
2. Deductible and Coinsurance for
Preventive Services
Section 4104(b)(4) of the ACA amends
section 1833(a)(1) of the Act by
requiring 100 percent Medicare
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40130
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
payment for the IPPE and for those
preventive services recommended by
the United States Preventive Services
Task Force (USPSTF) with a grade of A
or B for any indication or population
and that are appropriate for the
individual. This provision waives any
coinsurance that would otherwise be
applicable under section 1833(a)(1) of
the Act for those items and services
listed in section 1861(ww)(2) of the Act
(excluding electrocardiograms) to which
the USPSTF has given a grade of A or
B. In addition, section 4103(c)(1) of the
ACA amends section 1833(c)(1) of the
Act to waive the coinsurance for the
annual wellness visit. The coinsurance
represents the beneficiary’s share of the
payment to the provider or supplier for
furnished services. Coinsurance
generally refers to a percentage (for
example, 20 percent) of the Medicare
payment rate for which the beneficiary
is liable and is applicable under the
PFS, while copayment generally refers
to an established amount that the
beneficiary must pay that is not
necessarily related to a particular
percentage of the Medicare payment,
and is applicable under the hospital
Outpatient Prospective Payment System
(OPPS). We refer readers to the CY 2011
OPPS/ASC proposed rule for proposed
provisions related to payment for
preventive services, including waiver of
the deductible and copayment, under
the OPPS.
Section 4104(c) of the ACA amends
section 1833(b)(1) of the Act to waive
the Part B deductible for preventive
services described in subparagraph (A)
of section 1861(ddd)(3) of the Act that
have a grade of A or B from the
USPSTF. In addition, section 1833(b)(1)
of the Act (as amended by section
4103(c)(4) of the ACA) waives the Part
B deductible for the annual wellness
visit. These provisions are effective for
services furnished on and after January
1, 2011. Section 101(b)(2) of the MIPPA
amended section 1833(b) of the Act to
waive the deductible for the IPPE
effective January 1, 2009.
Not all preventive services described
in subparagraph (A) of section
1861(ddd)(3) are recommended by the
USPSTF with a grade of A or B and,
therefore, some of the preventive
services do not meet the criteria in
sections 1833(a)(1) and (b)(1) of the Act
for the waiver of the deductible and
coinsurance. However, with certain
exceptions noted below, the changes
made by section 4104 of the ACA do not
affect most of the preexisting specific
provisions in sections 1833(a) and
1833(b) of the Act (that are codified in
regulations in § 410.160(b) and
§ 410.152) that waive the deductible and
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
coinsurance for specific services. For
example, section 1833(a)(1)(D) of the
Act already waives the coinsurance and
section 1833(b)(3) of the Act waives the
deductible for clinical laboratory tests
(including tests furnished for screening
purposes). Section 4104 of the ACA
does not change this provision and,
therefore, the waiver of both the
deductible and coinsurance remains in
place for all laboratory tests, regardless
of whether the particular clinical
laboratory test meets the USPSTF
grading criteria specified in sections
1833(a)(1) and 1833(b)(1) of the Act (as
amended by section 4104 of the ACA)
for waiver of the deductible and
coinsurance as a preventive service.
The following preventive services
listed in section 1833(ddd)(3)(A) of the
Act are not recommended by the
USPSTF with a grade of A or B for any
indication or population: digital rectal
examination furnished as a prostate
cancer screening service; glaucoma
screening; DSMT services; and barium
enema furnished as a colorectal cancer
screening service.
Specifically, HCPCS code G0102
(Prostate cancer screening; digital rectal
exam), which does not have a grade of
A or B from the USPSTF for any
indication or population, will continue
to be subject to the deductible and
coinsurance as there is no statutory
provision to the contrary. However, the
deductible and coinsurance for HCPCS
code G0103 (Prostate cancer screening;
prostate specific antigen test (PSA)) will
continue to be waived in accordance
with section 1833(a)(1)(D) of the Act,
even though this service also does not
have a grade of A or B from the
USPSTF.
Glaucoma screening services,
described by HCPCS codes G0117
(Glaucoma screening for high risk
patients furnished by an optometrist or
ophthalmologist) and G0118 (Glaucoma
screening for high risk patient furnished
under the direct supervision of an
optometrist or ophthalmologist), will
continue to be subject to the deductible
and coinsurance because these services
are not recommended with a grade of A
or B by the USPSTF for any indication
or population and there is no other
statutory provision to except them.
Similarly, DSMT services are currently
not rated by the USPSTF, and there is
no other statutory provision to except
them from applicability of the
deductible and coinsurance. Therefore
the deductible and coinsurance
requirements will continue to apply.
Barium enemas furnished as
colorectal cancer screening tests,
described by HCPCS codes G0106
(Colorectal cancer screening; alternative
PO 00000
Frm 00092
Fmt 4701
Sfmt 4702
to G0104, screening sigmoidoscopy,
barium enema) and G0120 (Colorectal
cancer screening; alternative to G0105,
screening colonoscopy, barium enema),
do not have a grade of A or B from the
USPSTF for any indication or
population. However, the deductible
does not apply to barium enemas
furnished as colorectal cancer screening
tests, because colorectal cancer
screening tests are explicitly excluded
from the deductible in section
1833(b)(8) of the Act. However, there is
no specific exclusion of barium enemas
from the coinsurance requirement in
section 1833(b)(1) of the Act and,
therefore, this requirement, as
applicable, continues to apply to barium
enemas. We note that the USPSTF has
given a grade of A to screening
colonoscopy, screening flexible
sigmoidoscopy, and fecal occult blood
screening tests, and that, as a result,
these colorectal cancer screening tests
are subject to the statutory waiver of
both the deductible and coinsurance.
We note also that the USPSTF ceased
to make recommendations with regard
to vaccines and vaccine administration
after CY 1996, so as not to conflict with
the recommendations of the Centers for
Disease Control and Prevention’s
Advisory Committee on Immunization
Practices. However, the USPSTF’s most
recent vaccine recommendations gave a
grade of B to influenza and
pneumococcal vaccines and their
administration and a grade of A to
hepatitis B vaccine and its
administration. While sections
1833(a)(1) and 1833(b)(1) of the Act
require that the preventive services
receive a grade of A or B from the
USPSTF for the coinsurance and
deductible to be waived, the statute
does not specify that the recommended
grade must be furnished by the USPSTF
within any given timeframe. The
USPSTF grades for these preventive
services are the most current USPSTF
grade and have never been withdrawn.
Therefore, we believe that these
preventive services meet the
requirements of the statute for the
waiver of the deductible and
coinsurance. We also note that the
Centers for Disease Control and
Prevention’s Advisory Committee on
Immunization Practices currently
recommends influenza, pneumococcal,
and hepatitis B vaccines.
We are proposing to update
§ 410.160(b), which lists the services for
which expenses incurred are not subject
to the Part B annual deductible and do
not count toward meeting that
deductible. Specifically, we are
proposing to revise § 410.160(b)(2) to
include influenza and hepatitis B
E:\FR\FM\13JYP2.SGM
13JYP2
40131
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
vaccines and their administration, in
addition to pneumococcal vaccine and
its administration. In addition, in
§ 410.160(b), we are also proposing to
add exceptions for bone mass
measurement, MNT services, and the
annual wellness visit.
In § 410.152, we are proposing to
revise paragraph (l) to establish the
amount of payment under the
applicable payment system for
providers and suppliers of the services
listed in the paragraph and displayed in
Table 38. Table 38 displays the HCPCS
codes that we are proposing as
‘‘preventive services’’ under section
1861(ddd)(3)(A) of the Act and
identifies the HCPCS codes for the IPPE
and the annual wellness visit. Table 38
also indicates the most recent USPSTF
grade, if any, that is the basis for our
proposed policy with regard to waiver
of the deductible and coinsurance, as
applicable, and the Medicare payment
system under which the HCPCS code
would be paid when furnished outside
of the facility setting. We note that the
changes made by section 4104 of the
ACA with respect to the deductible and
coinsurance apply in all settings in
which the services are furnished.
In developing recommendations
regarding preventive services, we
recognize that the USPSTF may make
recommendations that are specific to an
indication or population, at times
including characteristics such as gender
and age in its recommendations. While
we are proposing to waive the
deductible and coinsurance for any
Medicare covered preventive service
recommended with a grade of A or B for
any indication or population, with no
limits on the indication or population as
long as the USPSTF has recommended
the preventive service for at least one
indication and/or population with a
grade of A or B, we note that all existing
Medicare coverage policies for such
services, including any limitations
based on indication or population,
continue to apply. In some cases,
national coverage policies may currently
limit Medicare coverage based on the
indication or population, consistent
with the USPSTF recommendations
with a grade of A or B for the indication
or population. In other cases where
Medicare does not explicitly noncover
preventive services for a specific
population or indication, we would
expect that, particularly in those cases
where the USPSTF recommendation
grade is a D (that is, the USPSTF
recommends against the service because
there is moderate or high certainty that
the service has no net benefit or that the
harms outweigh the benefits),
practitioners would only order those
preventive services that are clinically
appropriate for the beneficiary. If we
have concerns in the future about the
appropriateness of preventive services
for an indication or population in light
of the USPSTF’s recommendations, we
may consider using our authority under
section 1834(n)(1) of the Act (as added
by section 4105 of the ACA) to modify
Medicare coverage of any preventive
service to be consistent with the
recommendations of the USPSTF.
Section 10501(i)(2) of the ACA
amended the definition of Federally
Qualified Health Center (FQHC) services
as defined in section 1861(aa)(3)(A) of
the Act by replacing the specific
references to services provided under
section 1861(qq) and (vv) of the Act
(diabetes outpatient self-management
training services and medical nutrition
therapy services, respectively) with
preventive services as defined in section
1861(ddd)(3) of the Act, as established
by section 4014(a)(3) of the ACA. These
changes are effective for services
provided on or after January 1, 2011.
Accordingly, we are proposing to
conform the regulations to the new
statutory requirement by adding a new
section § 405.2449 which would add the
new preventive services definition to
the definition of FQHC services effective
for services provided on or after January
1, 2011.
Section 1861(ddd)(3) of the Act
defines ‘‘preventive services’’ as
consisting of the following three
components:
• Screening and preventive services
described in section 1861(ww)(2) of the
Act (other than electrocardiograms
described in subparagraph (M) of that
same subsection).
• An initial preventive physical
examination, as defined in section
1861(ww) of the Act.
• Personalized prevention plan
services as defined in section
1861(hhh)(1) of the Act.
We are proposing to add each of these
three components into the new
Medicare FQHC preventive services
definition in a new § 405.2449.
Section 4104(b)(1) of the ACA, as
amended by section 10406 of the same
Act, waives coinsurance for preventive
services by adding section 1833(a)(1)(Y)
to the Act to require, essentially, waiver
of coinsurance for preventive services
that are recommended with a grade of
A or B by the USPSTF for any
indication or population. This provision
is specifically designed to remove
barriers to affording and obtaining such
preventive services under Medicare.
In addition, section 10501(i)(3)(B)(ii)
of the ACA added section 1833(a)(1)(Z)
to the Act to require a 20-percent copay
on all FQHC services after
implementation of the FQHC
prospective payment system. We believe
we can give both section 1833(a)(1)(Y)
and (Z) of the Act, and the definition of
FQHC services (revised to include the
broader scope of preventive services)
their best effect by permitting a 100
percent reimbursement rate for
preventive services as defined at section
1861 (ddd)(3) of Act, effective January 1,
2011.
Section 1833(b)(4) of the Act
stipulates that the Medicare Part B
deductible shall not apply to Federally
qualified health center services. The
ACA makes no change to this provision,
therefore Medicare shall continue to
waive the Part B deductible for all
federally qualified health center
services, including preventive services
added by the ACA.
TABLE 38—PROPOSED CY 2011 DEDUCTIBLE AND COINSURANCE FOR PREVENTIVE SERVICES UNDER SECTION
1861(ddd)(3)(A) OF THE ACT (INCLUDES THE IPPE AND THE ANNUAL WELLNESS VISIT)
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Preventive
service
Initial Preventive Physical
Examination, IPPE.
CPT/
HCPCS
Code
G0402
G0403
VerDate Mar<15>2010
USPSTF
rating 1
Long descriptor
Initial preventive physical examination;
face to face visits, services limited to
new beneficiary during the first 12
months of Medicare enrollment.
Electrocardiogram, routine ECG with 12
leads; performed as a screening for the
initial preventive physical examination
with interpretation and report.
23:56 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00093
Fmt 4701
Payment
method
CY 2010 coins./
deductible
CY 2011 coins./
deductible
* Not
Rated.
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
..................
PFS ..........
Not Waived .............
Not Waived.
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40132
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 38—PROPOSED CY 2011 DEDUCTIBLE AND COINSURANCE FOR PREVENTIVE SERVICES UNDER SECTION
1861(ddd)(3)(A) OF THE ACT (INCLUDES THE IPPE AND THE ANNUAL WELLNESS VISIT)—Continued
Preventive
service
CPT/
HCPCS
Code
G0404
G0405
Ultrasound
Screening
for Abdominal Aortic
Aneurysm
(AAA).
Cardiovascular
Disease
Screening.
G0389
Long descriptor
USPSTF
rating 1
Payment
method
CY 2010 coins./
deductible
CY 2011 coins./
deductible
Electrocardiogram, routine ECG with 12
leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination.
Electrocardiogram, routine ECG with 12
leads; interpretation and report only,
performed as a screening for the initial
preventive physical examination.
Ultrasound, B-scan and/or real time with
image documentation; for abdominal
aortic aneurysm (AAA) ultrasound
screening.
..................
PFS ..........
Not Waived .............
Not Waived.
..................
PFS ..........
Not Waived .............
Not Waived.
B ..............
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
Lipid panel ................................................
A ..............
CLFS .......
WAIVED ..................
WAIVED.
82465
83718
Diabetes
Screening
Tests.
80061
Cholesterol, serum or whole blood, total ..
Lipoprotein, direct measurement; high
density cholesterol (hdl cholesterol).
Triglycerides ..............................................
Glucose; quantitative, blood (except reagent strip).
..................
..................
CLFS .......
CLFS .......
WAIVED ..................
WAIVED ..................
WAIVED.
WAIVED.
..................
B ..............
CLFS .......
CLFS .......
WAIVED ..................
WAIVED ..................
WAIVED.
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
* Not
Rated.
* Not
Rated.
CLFS .......
WAIVED ..................
WAIVED.
PFS ..........
Not Waived .............
Not Waived.
..................
PFS ..........
Not Waived .............
Not Waived.
B ..............
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
B ..............
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
84478
82947
82950
82951
Diabetes SelfManagement Training Services.
(DSMT) ..........
G0108
G0109
Medical Nutrition Therapy
(MNT) Services.
97802
97803
97804
G0270
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
G0271
VerDate Mar<15>2010
Glucose; post glucose dose (includes glucose).
Glucose; tolerance test (gtt), three specimens (includes glucose).
Diabetes outpatient self-management
training services, individual, per 30
minutes.
Diabetes outpatient self-management
training services, group session (2 or
more), per 30 minutes.
Medical nutrition therapy; initial assessment and intervention, individual, faceto-face with the patient, each 15 minutes.
Medical nutrition therapy; re-assessment
and intervention, individual, face-toface with the patient, each 15 minutes.
Medical nutrition therapy; group (2 or
more individual(s)), each 30 minutes.
Medical nutrition therapy; reassessment
and subsequent intervention(s) following second referral in same year for
change in diagnosis, medical condition
or treatment regimen (including additional hours needed for renal disease),
individual, face to face with the patient,
each 15 minutes.
Medical nutrition therapy, reassessment
and subsequent intervention(s) following second referral in same year for
change in diagnosis, medical condition,
or treatment regimen (including additional hours needed for renal disease),
group (2 or more individuals), each 30
minutes.
00:05 Jul 13, 2010
Jkt 220001
PO 00000
Frm 00094
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40133
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 38—PROPOSED CY 2011 DEDUCTIBLE AND COINSURANCE FOR PREVENTIVE SERVICES UNDER SECTION
1861(ddd)(3)(A) OF THE ACT (INCLUDES THE IPPE AND THE ANNUAL WELLNESS VISIT)—Continued
Preventive
service
Screening Pap
Test.
CPT/
HCPCS
Code
G0123
G0124
G0141
G0143
G0144
G0145
G0147
G0148
P3000
P3001
Q0091
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Screening Pelvic Exam.
Screening
Mammography.
G0101
77052
77057
G0202
Bone Mass
Measurement.
VerDate Mar<15>2010
G0130
Long descriptor
USPSTF
rating 1
Payment
method
CY 2010 coins./
deductible
Screening cytopathology, cervical or vaginal (any reporting system), collected in
preservative fluid, automated thin layer
preparation,
screening
by
cytotechnologist under physician supervision.
Screening cytopathology, cervical or vaginal (any reporting system), collected in
preservative fluid, automated thin layer
preparation, requiring interpretation by
physician.
Screening cytopathology smears, cervical
or vaginal, performed by automated
system, with manual rescreening, requiring interpretation by physician.
Screening cytopathology, cervical or vaginal (any reporting system), collected in
preservative fluid, automated thin layer
preparation, with manual screening and
rescreening by cytotechnologist under
physician supervision.
Screening cytopathology, cervical or vaginal (any reporting system), collected in
preservative fluid, automated thin layer
preparation, with screening by automated system, under physician supervision.
Screening cytopathology, cervical or vaginal (any reporting system), collected in
preservative fluid, automated thin layer
preparation, with screening by automated system and manual rescreening
under physician supervision.
Screening cytopathology smears, cervical
or vaginal, performed by automated
system under physician supervision.
Screening cytopathology smears, cervical
or vaginal, performed by automated
system with manual rescreening.
Screening papanicolaou smear, cervical
or vaginal, up to three smears, by technician under physician supervision.
Screening papanicolaou smear, cervical
or vaginal, up to three smears, requiring interpretation by physician.
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory.
Cervical or vaginal cancer screening; pelvic and clinical breast examination.
Computer-aided detection (computer algorithm analysis of digital image data
for lesion detection) with further physician review for interpretation, with or
without digitization of film radiographic
images; screening mammography (list
separately in addition to code for primary procedure).
Screening mammography, bilateral (2view film study of each breast).
Screening mammography, producing direct digital image, bilateral, all views.
Single energy x-ray absorptiometry (sexa)
bone density study, one or more sites;
appendicular
skeleton
(peripheral)
(e.g., radius, wrist, heel).
A ..............
CLFS .......
WAIVED ..................
WAIVED.
..................
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
A ..............
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
A ..............
CLFS .......
WAIVED ..................
WAIVED.
A ..............
CLFS .......
WAIVED ..................
WAIVED.
A ..............
CLFS .......
WAIVED ..................
WAIVED.
A ..............
CLFS .......
WAIVED ..................
WAIVED.
A ..............
CLFS .......
WAIVED ..................
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
..................
PFS ..........
Coins. applies &
ded. is waived.
WAIVED.
..................
PFS ..........
Coins. applies &
ded. is waived.
WAIVED.
A ..............
PFS ..........
WAIVED.
B ..............
PFS ..........
Coins. applies and
ded. is waived.
Coins. applies and
ded. is waived.
B ..............
PFS ..........
WAIVED.
..................
PFS ..........
B ..............
PFS ..........
Coins. applies and
ded. is waived.
Coins. applies &
ded. is waived.
Not Waived .............
23:56 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00095
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
CY 2011 coins./
deductible
WAIVED.
WAIVED.
WAIVED.
40134
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 38—PROPOSED CY 2011 DEDUCTIBLE AND COINSURANCE FOR PREVENTIVE SERVICES UNDER SECTION
1861(ddd)(3)(A) OF THE ACT (INCLUDES THE IPPE AND THE ANNUAL WELLNESS VISIT)—Continued
Preventive
service
CPT/
HCPCS
Code
77078
77079
77080
77081
77083
76977
Colorectal
Cancer
Screening.
G0104
G0105
G0106
G0120
G0121
82270
G0328
Prostate Cancer Screening.
G0102
G0103
Glaucoma
Screening.
G0117
G0118
Influenza
Virus Vaccine.
90655
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
90656
90657
90658
90660
VerDate Mar<15>2010
Long descriptor
USPSTF
rating 1
Payment
method
CY 2010 coins./
deductible
Computed tomography, bone mineral
density study, 1 or more sites; axial
skeleton (e.g., hips, pelvis, spine).
Computed tomography, bone mineral
density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel).
Dual-energy x-ray absorptiometry (dxa),
bone density study, 1 or more sites;
axial skeleton (e.g., hips, pelvis, spine).
Dual-energy x-ray absorptiometry (dxa),
bone density study, 1 or more sites;
appendicular
skeleton
(peripheral)
(e.g., radius, wrist, heel).
Radiographic
absorptiometry
(e.g.,
photodensitometry, radiogrammetry), 1
or more sites.
Ultrasound bone density measurement
and interpretation, peripheral site(s),
any method.
Colorectal cancer screening; flexible
sigmoidoscopy.
..................
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
..................
PFS ..........
Not Waived .............
WAIVED.
B ..............
PFS ..........
Not Waived .............
WAIVED.
A ..............
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
..................
PFS ..........
WAIVED.
* Not
Rated.
PFS ..........
Coins. applies and;
ded. is waived.
Coins. applies and
ded. is waived.
..................
PFS ..........
Coins. applies and
ded. is waived.
Coins. applies and
ded. is waived.
A ..............
PFS ..........
Coins. applies and
ded. is waived.
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
..................
CLFS .......
Coins. applies and
ded. is waived.
WAIVED.
D ..............
PFS ..........
Not Waived .............
Not Waived.
..................
CLFS .......
WAIVED ..................
WAIVED.
I ................
PFS ..........
Not Waived .............
Not Waived.
..................
PFS ..........
Not Waived .............
Not Waived.
B ..............
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
Drug Pricing File.
WAIVED ..................
WAIVED.
Colorectal cancer screening; colonoscopy
on individual at high risk.
Colorectal cancer screening; alternative
to G0104, screening sigmoidoscopy,
barium enema.
Colorectal cancer screening; alternative
to G0105, screening colonoscopy, barium enema..
Colorectal cancer screening; colonoscopy
on individual not meeting criteria for
high risk.
Blood, occult, by peroxidase activity (e.g.,
guaiac), qualitative; feces, consecutive.
Colorectal cancer screening; fecal occult
blood test, immunoassay, 1–3 simultaneous.
Prostate cancer screening; digital rectal
examination.
Prostate cancer screening; prostate specific antigen test (PSA).
Glaucoma screening for high risk patients
furnished by an optometrist or ophthalmologist.
Glaucoma screening for high risk patient
furnished under the direct supervision
of an optometrist or ophthalmologist.
Influenza virus vaccine, split virus, preservative free, when administered to
children 6–35 months of age, for
intramuscular use.
Influenza virus vaccine, split virus, preservative free, when administered to individuals 3 years and older, for
intramuscular use.
Influenza virus vaccine, split virus, when
administered to children 6–35 months
of age, for intramuscular use.
Influenza virus vaccine, split virus, when
administered to individuals 3 years of
age and older, for intramuscular use.
Influenza virus vaccine, live, for intranasal
use.
23:56 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00096
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
CY 2011 coins./
deductible
Coins. applies and
ded. is waived.
40135
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 38—PROPOSED CY 2011 DEDUCTIBLE AND COINSURANCE FOR PREVENTIVE SERVICES UNDER SECTION
1861(ddd)(3)(A) OF THE ACT (INCLUDES THE IPPE AND THE ANNUAL WELLNESS VISIT)—Continued
Preventive
service
CPT/
HCPCS
Code
90662
G0008
G9141
G9142
Pneumococcal
Vaccine.
90669
90670
90732
Hepatitis B
Vaccine.
G0009
90740
90743
90744
90746
90747
HIV Screening
G0010
86689
G0432
G0433
G0435
Annual
Wellness
Visit.
GXXXA
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
GXXXB
Long descriptor
USPSTF
rating 1
Payment
method
CY 2010 coins./
deductible
Influenza virus vaccine, split virus, preservative
free,
enhanced
immunogenicity via increased antigen
content, for intramuscular use.
Administration of influenza virus vaccine
Influenza A (H1N1) immunization administration (includes the physician counseling the patient/family).
Influenza A (H1N1) vaccine, any route of
administration.
..................
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
..................
PFS ..........
PFS ..........
WAIVED ..................
WAIVED ..................
WAIVED.
WAIVED.
..................
WAIVED ..................
WAIVED.
Pneumococcal conjugate vaccine, polyvalent, when administered to children
younger than 5 years, for intramuscular
use.
Pneumococcal conjugate vaccine, 13 valent, for intramuscular use..
Pneumococcal polysaccharide vaccine,
23-valent, adult or immunosuppressed
patient dosage, when administered to
individuals 2 years or older, for subcutaneous or intramuscular use.
Administration of pneumococcal vaccine
Hepatitis
B
vaccine,
dialysis
or
immunosuppressed patient dosage (3
dose schedule), for intramuscular use.
Hepatitis B vaccine, adolescent (2 dose
schedule), for intramuscular use.
Hepatitis B vaccine, pediatric/adolescent
dosage (3 dose schedule), for
intramuscular use.
Hepatitis B vaccine, adult dosage, for
intramuscular use.
Hepatitis
B
vaccine,
dialysis
or
immunosuppressed patient dosage (4
dose schedule), for intramuscular use.
Administration of hepatitis B vaccine .......
HTLV or HIV antibody, confirmatory test
(e.g., Western Blot).
Infectious agent antigen detection by enzyme immunoassay (EIA) technique,
qualitative or semi-qualitative, multiplestep method, HIV–1 or HIV–2, screening.
Infectious agent antigen detection by enzyme-linked immunosorbent assay
(ELISA) technique, antibody, HIV–1 or
HIV–2, screening.
Infectious agent antigen detection by
rapid antibody test of oral mucosa
transudate, HIV–1 or HIV–2, screening.
Annual wellness visit, including PPPS,
first visit.
B ..............
Drug Pricing File
(if not
supplied
at no
cost).
Drug Pricing File.
WAIVED ..................
WAIVED.
WAIVED ..................
WAIVED.
..................
Drug Pricing File.
Drug Pricing File.
WAIVED ..................
WAIVED.
..................
A ..............
PFS ..........
Drug Pricing File.
WAIVED ..................
Not Waived .............
WAIVED.
WAIVED.
..................
Drug Pricing File.
Drug Pricing File.
Not Waived .............
WAIVED.
Not Waived .............
WAIVED.
Not Waived .............
WAIVED.
..................
Drug Pricing File.
Drug Pricing File.
Not Waived .............
WAIVED.
A ..............
A ..............
PFS ..........
CLFS .......
Not Waived .............
WAIVED ..................
WAIVED.
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
..................
CLFS .......
WAIVED ..................
WAIVED.
* Not
Rated.
PFS ..........
N/A ..........................
WAIVED.
Annual wellness visit, including PPPS,
subsequent visit.
..................
PFS ..........
N/A ..........................
WAIVED.
..................
..................
..................
1 U.S.
CY 2011 coins./
deductible
Preventive Services Task Force Recommendations.
A—The USPSTF strongly recommends that clinicians routinely provide [the service] to eligible patients. (The USPSTF found good evidence
that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms.)
B—The USPSTF recommends that clinicians routinely provide [the service] to eligible patients. (The USPSTF found at least fair evidence that
[the service] improves important health outcomes and concludes that benefits outweigh harms.)
C—The USPSTF makes no recommendation for or against routine provision of [the service]. (The USPSTF found at least fair evidence that
[the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation.)
D—The USPSTF recommends against routinely providing [the service] to asymptomatic patients. (The USPSTF found at least fair evidence
that [the service] is ineffective or that harms outweigh benefits.)
VerDate Mar<15>2010
23:56 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00097
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40136
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
I—The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. (Evidence that [the
service] is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined.)
4. Extension of Waiver of Deductible to
Services Furnished in Connection With
or in Relation to a Colorectal Cancer
Screening Test That Becomes Diagnostic
or Therapeutic
Section 4104(c) of the ACA amends
section 1833(b) of the Act to waive the
Part B deductible for colorectal cancer
screening tests that become diagnostic.
Specifically, section 1833(b)(1) of the
Act (as amended by section 4104(c)(2) of
the ACA) waives the deductible with
respect to a colorectal cancer screening
test regardless of the code that is billed
for the establishment of a diagnosis as
a result of the test, or for the removal of
tissue or other matter or other procedure
that is furnished in connection with, as
a result of, and in the same clinical
encounter as a screening test. We are
proposing that all surgical services
furnished on the same date as a planned
screening colonoscopy, planned flexible
sigmoidoscopy, or barium enema be
considered to be furnished in
connection with, as a result of, and in
the same clinical encounter as the
screening test. In the event of a
legislative change to this policy (for
example, a statutory change that would
waive the coinsurance for these related
services in addition to the deductible),
we would reassess the appropriateness
of this proposed definition of services
that are furnished in connection with, as
a result of, and in the same clinical
encounter as the colorectal cancer
screening test that becomes diagnostic.
We also note that the beneficiary’s
annual deductible would likely be met
when any surgical procedure (related or
not) is furnished on the same day as the
scheduled screening test.
We are proposing to implement this
provision by creating a HCPCS modifier
that providers and practitioners would
append to the diagnostic procedure
code that is reported instead of the
screening colonoscopy or screening
flexible sigmoidoscopy HCPCS code or
as a result of the barium enema when
the screening test becomes a diagnostic
service. The claims processing system
would respond to the modifier by
waiving the deductible for all surgical
services on the same date as the
diagnostic test. Coinsurance would
continue to apply to the diagnostic test
and to other services furnished in
connection with, as a result of, and in
the same clinical encounter as the
screening test.
S. Section 5501: Expanding Access to
Primary Care Services and General
Surgery Services
1. Section 5501(a): Incentive Payment
Program for Primary Care Services
a. Background
Section 5501(a) of the ACA revises
section 1833 of the Act by adding a new
paragraph (x), ‘‘Incentive Payments for
Primary Care Services.’’ Section 1833(x)
of the Act states that in the case of
primary care services furnished on or
after January 1, 2011 and before
January 1, 2016 by a primary care
practitioner, there shall also be paid on
a monthly or quarterly basis an amount
equal to 10 percent of the payment
amount for such services under Part B.
Section 1833(x)(2)(A) of the Act (as
added by section 5501(a) of the ACA)
defines a primary care practitioner as:
(1) A physician, as described in section
1861(r)(1) of the Act, who has a primary
specialty designation of family
medicine, internal medicine, geriatric
medicine, or pediatric medicine; or (2)
a nurse practitioner, clinical nurse
specialist, or physician assistant as
defined in section 1861(aa)(5) of the
Act, and in all cases, for whom primary
care services accounted for at least 60
percent of the allowed charges under
Part B for the practitioner in a prior
period as determined appropriate by the
Secretary.
Section 1833(x)(2)(B) (as added by
section 5501(a)(2)(B) of the ACA)
defines primary care services as those
services identified by the following
HCPCS codes as of January 1, 2009 (and
as subsequently modified by the
Secretary, as applicable):
• 99201 through 99215 for new and
established patient office or other
outpatient evaluation and management
(E/M) visits;
• 99304 through 99340 for initial,
subsequent, discharge, and other
nursing facility E/M services; new and
established patient domiciliary, rest
home (e.g., boarding home), or custodial
care E/M services; and domiciliary, rest
home (e.g., assisted living facility), or
home care plan oversight services; and
• 99341 through 99350 for new and
established patient home E/M visits.
These codes are displayed in Table
39. All of these codes remain active in
CY 2010 and there are no other codes
used to describe these services.
TABLE 39—PRIMARY CARE SERVICES ELIGIBLE FOR PRIMARY CARE INCENTIVE PAYMENTS IN CY 2011
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
CPT codes
99201
99202
99203
99204
99205
99211
99212
99214
99215
99304
99305
99306
99307
99308
99309
99310
99315
99316
99318
99324
Description
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
................
VerDate Mar<15>2010
Level 1 new patient office or other outpatient visit.
Level 2 new patient office or other outpatient visit.
Level 3 new patient office or other outpatient visit.
Level 4 new patient office or other outpatient visit.
Level 5 new patient office or other outpatient visit.
Level 1 established patient office or other outpatient visit.
Level 2 established patient office or other outpatient visit.
Level 4 established patient office or other outpatient visit.
Level 5 established patient office or other outpatient visit.
Level 1 initial nursing facility care.
Level 2 initial nursing facility care.
Level 3 initial nursing facility care.
Level 1 subsequent nursing facility care.
Level 2 subsequent nursing facility care.
Level 3 subsequent nursing facility care.
Level 4 subsequent nursing facility care.
Nursing facility discharge day management;. 30 minutes.
Nursing facility discharge day management; more than 30 minutes.
Other nursing facility services; evaluation and management of a patient involving an annual nursing facility assessment.
Level 1 new patient domiciliary, rest home, or custodial care visit.
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00098
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40137
TABLE 39—PRIMARY CARE SERVICES ELIGIBLE FOR PRIMARY CARE INCENTIVE PAYMENTS IN CY 2011—Continued
CPT codes
99325
99326
99327
99328
99334
99335
99336
99337
99339
Description
................
................
................
................
................
................
................
................
................
99340 ................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
99341
99342
99343
99344
99345
99347
99348
99349
99350
................
................
................
................
................
................
................
................
................
Level 2 new patient domiciliary, rest home, or custodial care visit.
Level 3 new patient domiciliary, rest home, or custodial care visit.
Level 4 new patient domiciliary, rest home, or custodial care visit.
Level 5 new patient domiciliary, rest home, or custodial care visit.
Level 1 established patient domiciliary, rest home, or custodial care visit.
Level 2 established patient domiciliary, rest home, or custodial care visit.
Level 3 established patient domiciliary, rest home, or custodial care visit.
Level 4 established patient domiciliary, rest home, or custodial care visit.
Individual physician supervision of a patient in home, domiciliary or rest home recurring complex and multidisciplinary care
modalities; 30 minutes.
Individual physician supervision of a patient in home, domiciliary or rest home recurring complex and multidisciplinary care
modalities; 30 minutes or more.
Level 1 new patient home visit.
Level 2 new patient home visit.
Level 3 new patient home visit.
Level 4 new patient home visit.
Level 5 new patient home visit.
Level 1 established patient home visit.
Level 2 established patient home visit.
Level 3 established patient home visit.
Level 4 established patient home visit.
b. Proposed Primary Care Incentive
Payment Program (PCIP)
For primary care services furnished
on or after January 1, 2011 and before
January 1, 2016, we are proposing to
provide a 10 percent incentive payment
to primary care practitioners, identified
as the following: (1) In the case of
physicians, enrolled in Medicare with a
primary specialty designation of 08—
family practice, 11—internal medicine,
37—pediatrics, or 38—geriatrics; or (2)
in the case of nonphysician
practitioners (NPPs), enrolled in
Medicare with a primary care specialty
designation of 50—nurse practitioner,
89—certified clinical nurse specialist, or
97—physician assistant; and (3) for
whom the primary care services
displayed in Table 39 accounted for at
least 60 percent of the allowed charges
under Part B for such practitioner
during the time period that is specified
by the Secretary, and proposed in this
section.
We are proposing to use the most
current full year of claims data to
identify primary care practitioners
eligible for the PCIP for a CY based on
the practitioner’s primary specialty (as
identified on claims) and the
practitioner’s percentage of all allowed
charges for the primary care services
displayed in Table 39. We commonly
use the most recent full year of claims
data for purposes of establishing annual
payment amounts under a number of
Medicare’s fee-for-service programs. A
practitioner with a primary care
specialty designation would be eligible
for the PCIP in a CY if the percentage
of his or her allowed charges for
primary care services (identified in
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Table 39) on claims where the
practitioner is identified as one of the
primary care specialties described above
meets or exceeds the 60 percent
threshold. We note that the
practitioner’s specialty is applied to the
claim by the claims processing system
and reflects the physician’s primary
specialty designation for purposes of
Medicare enrollment on the date the
claim is processed, which would
usually be close to the date on which
the service was actually furnished to the
beneficiary. We would identify primary
care practitioners eligible for the PCIP
for a year by the individual physician/
practitioner national provider identifier
(NPI) number using the most current
full year of claims data available.
Therefore, for determining PCIP
practitioner eligibility for CY 2011, we
would use CY 2009 PFS claims data,
processed through June 30, 2010. This
would ensure analysis of about 99
percent of CY 2009 claims to determine
practitioner eligibility for PCIP payment
beginning January 2011. We note that
the MMA changed the requirements for
critical access hospital (CAH) billing for
practitioners’ professional services and,
therefore, modifications were made to
the Medicare claims processing system
to require CAHs to identify the
practitioner furnishing a service on the
CAH claim for that professional service.
However, because the rendering
practitioner has only been identified on
CAH claims since July 1, 2009, for the
first year of the PCIP we are proposing
to identify eligible practitioners using
only 6 months of CAH data for those
CAHs paid under the optional method.
Thereafter, we would update the list of
PO 00000
Frm 00099
Fmt 4701
Sfmt 4702
practitioners eligible for the PCIP
annually based on the most recent
available full year of PFS and CAH
claims data.
To the extent practitioners were paid
under the PFS during the historical
claims data year for some primary
services and, for other services, CAHs
were paid under the optional method
for those same practitioners’
professional services, we would
aggregate the historical claims data from
all settings by the practitioner’s NPI in
order to determine whether the
practitioner is eligible for PCIP
payments. We note that for all
practitioners (both practitioners paid
under the PFS and practitioners for
whose professional services CAHs are
paid under the optional method), the
period of claims data used for the
annual determination of the primary
care service percentage of allowed
charges with a practitioner specialty of
primary care would lag the PCIP
payment year by 2 years (for example,
CY 2010 claims data would be used for
the CY 2012 PCIP). This 2-year lag is
consistent with other areas of the
Medicare program where we rely on
information from claims data to inform
payment in a future year, such as the
use of CY 2009 PFS utilization data in
the establishment of certain aspects of
CY 2011 PFS payment rates.
Under the proposed PCIP eligibility
determination method, it would be
necessary to revise the list of eligible
practitioners based on updated claims
data regarding primary specialty
designation and the percentage of a
practitioner’s allowed charges for
primary care services each year. The
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40138
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
revised list of practitioners developed
prior to the beginning of the next CY
would establish a practitioner’s
eligibility for PCIP payments for the full
next CY. That is, once eligible for the
PCIP for a given CY, the practitioner
would receive PCIP payments for
primary care services furnished
throughout that full CY until we
reassess the practitioner’s PCIP
eligibility for the next year’s payments.
As a result, a practitioner newly
enrolling in Medicare during a CY
would not be eligible for the PCIP until
Medicare claims data reflecting the
practitioner’s primary care specialty and
a percentage of allowed charges for
primary care services that equals or
exceeds the 60 percent threshold were
available to establish the practitioner’s
eligibility for the next PCIP year.
Similarly, an enrolled practitioner’s
change in primary specialty designation
(either to or from a primary care
specialty) would not affect that
practitioner’s eligibility for the PCIP
until the practitioner’s claims reflecting
the change were available for analysis in
preparation for the next applicable CY
PCIP. Given the statutory requirement
that a practitioner’s primary care
services account for at least 60 percent
of the allowed charges under Part B for
the practitioner in a prior period as
determined by the Secretary, we see no
clear alternative methodologies that
would allow PCIP payments to be made
to those practitioners newly enrolling in
Medicare without the 2-year lag in
eligibility determination that was
described previously. However, given
our general interest in supporting
primary care practitioners and entry
into primary care practice by new
physicians and NPPs in order to ensure
that Medicare beneficiaries have access
to these important services, we are
seeking public comments on alternative
approaches for establishing PCIP
eligibility for newly enrolled
practitioners that would be consistent
with the statutory requirement.
We plan to monitor changes in the
primary specialties of enrolled
practitioners over time and would
expect not to see significant changes in
the specialties of currently enrolled
practitioners as a result of the PCIP
payments. We would expect that
physicians changing their primary
specialty to one of the primary care
specialties of family medicine, internal
medicine, geriatric medicine, or
pediatric medicine and who would be
newly eligible for the PCIP would be
furnishing primary care services to the
patients in their practices. Consistent
with our past policies, we would expect
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
that physicians changing their primary
specialty designation under Medicare
would make such changes only so that
their primary specialty designation is
fully consistent with the specific or
unique type of medicine they practice.
If we find that physicians are changing
their specialty designations (for
example, cardiologists who designate
their primary specialty as internal
medicine, although they practice
cardiology) in order to take advantage of
the PCIP payments, we would
considering making future revisions to
eliminate such an outcome.
Consistent with the established
Medicare HPSA physician bonus
program (Medicare Claims Processing
Manual, Pub. 100–04, Chapter 12,
Section 90.4.4) and the proposed Health
Professional Shortage Area Surgical
Incentive Payment Program (HSIP)
described in section III.S.2. of this
proposed rule, we are proposing that
PCIP payments would be calculated by
the Medicare contractors and made
quarterly on behalf of the eligible
primary care practitioner for the
primary care services furnished by the
practitioner in that quarter. The primary
care practitioners’ professional services
may be paid under the PFS based on a
claim for professional services or, where
the practitioner has reassigned his or
her benefits to a CAH paid under the
optional method, to the CAH based on
an institutional claim.
As discussed above, eligible primary
care practitioners would be identified
on a claim based on the NPI of the
rendering practitioner. If the claim is
submitted by a practitioner’s group
practice or a CAH, the rendering
practitioner’s NPI must be included on
the line-item for the primary care
service (identified in Table 39 above) in
order for a determination to be made
regarding whether or not the service is
eligible for payment of the PCIP. We
note that, in order to be eligible for the
PCIP, physician assistants, clinical
nurse specialists, and nurse
practitioners must be billing for their
services under their own NPI and not
furnishing services incident to
physicians’ services. Regardless of the
specialty area in which they may be
practicing, these specific NPPs would be
eligible for the PCIP based on their
specialty if their historical percentage of
allowed charges for primary care
services equals or exceeds the 60
percent threshold.
We note that section 1833(x)(4) of the
Act (as added by section 5501(a) of the
ACA) specifies ‘‘there shall be no
administrative or judicial review under
section 1869, 1878, or otherwise,
respecting the identification of primary
PO 00000
Frm 00100
Fmt 4701
Sfmt 4702
care practitioners.’’ We believe that the
inclusion of this language is intended to
provide a means for the practical
implementation of this provision. That
is, because we must develop a process
and identify primary care practitioners
before we can make payment under the
PCIP to the eligible primary care
practitioners, the statute gives CMS the
authority to make final determinations
of eligible primary care practitioners
that are not subject to appeal through
the various channels normally available
to practitioners, in order for the timely
payments under the PCIP to occur. In
contrast, if the determinations that CMS
must make under this provision were
subject to appeal, the timely
implementation of this provision could
be jeopardized and payments under the
PCIP could be significantly delayed.
However, we do not believe that the ‘‘no
administrative or judicial review’’ clause
precludes CMS from correcting errors
resulting from clerical or mathematical
mistakes. Therefore, we note that
practitioners would have the
opportunity to notify CMS of clerical or
mathematical errors that may have
occurred during the process of
identifying eligible primary care
practitioners for PCIP payment, and
which could result in a mistaken
eligibility determination for the PCIP.
In summary, under the PCIP
beginning in CY 2011, we are proposing
to identify primary care practitioners
based on their primary specialty and
percentage of allowed charges for
primary care services that equals or
exceeds the 60 percent threshold based
upon the most current full year of
Medicare claims data, which would be
the claims data for 2 years prior to the
incentive payment year (for example,
CY 2009 claims data processed through
June 2010 would be used to identify
primary care practitioners for the CY
2011 PCIP). Practitioners identified as
eligible for the PCIP immediately prior
to the PCIP payment year would then
receive quarterly incentive payments
during the PCIP year equal to 10 percent
of the payment amount for their primary
care services under Part B, in addition
to the amount the primary care
practitioner would otherwise be paid for
their professional services under Part B
for furnishing the primary care services.
For example, primary care practitioners
identified in late CY 2010 for the CY
2011 PCIP would receive quarterly PCIP
payments in CY 2011 that equal 10
percent of the Part B payment for the
primary care services those practitioners
furnish during CY 2011.
We further note that section
1833(x)(3) of the Act (as added by
section 5501(a) of the ACA) authorizes
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
payment under the PCIP as an
additional payment amount for
specified primary care services without
regard to any additional payment for the
service under section 1833(m) of the
Act. Therefore, an eligible primary care
physician furnishing a primary care
service in a HPSA may receive both a
HPSA physician bonus payment under
the established program and a PCIP
payment under the new program
beginning in CY 2011, but the PCIP
payment is made without regarding to
the HPSA physician bonus payment
amount. In addition, payments for
outpatient CAH services under section
1834(g)(2)(B) of the Act (as amended by
section 5501(a) of the ACA) are not
affected by the PCIP payment amounts
made to the CAH on behalf of the
primary care practitioner.
Accordingly, for CY 2011, we are
proposing to add a new § 414.80 to our
regulations to specify the requirements
of the PCIP. Proposed § 414.80(a) would
define primary care practitioners and
primary care services. Proposed
§ 414.80(b) would provide eligible
primary care practitioners a 10 percent
incentive payment with respect to
primary care services, in addition to the
amount that would otherwise be paid
for their professional services under Part
B. Quarterly PCIP payments would be
made to eligible practitioners or to
CAHs paid under the optional method
that are billing on behalf of practitioners
for their professional services for
identified primary care services.
2. Section 5501(b): Incentive Payment
Program for Major Surgical Procedures
Furnished in Health Professional
Shortage Areas
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Background
Section 1833(m) of the Act provides
for an additional 10 percent incentive
payment for physicians’ services
furnished to a covered individual in an
area that is designated as a geographic
Health Professional Shortage Area
(HPSA) as identified by the Secretary
prior to the beginning of such year.
Section 5501(b) of the ACA revises
section 1833 of the Act by adding the
new subparagraph (y), ‘‘Incentive
Payments for Major Surgical Procedures
Furnished in Health Professional
Shortage Areas.’’
In the case of major surgical
procedures furnished by a general
surgeon on or after January 1, 2011 and
before January 1, 2016, in an area
designated under section 332(a)(1)(A) of
the Public Health Service Act as a
geographic HPSA, there shall be paid on
a monthly or quarterly basis, an amount
equal to 10 percent of the payment
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
amount for eligible services under Part
B. Section 1833(y)(2)(A) of the Act (as
added by section 5501(b) of the ACA)
defines a general surgeon as a physician
who is described in section 1861(r)(1) of
the Act and who has designated a CMS
specialty code of 02—General Surgery
as his or her primary specialty code in
the physician enrollment under section
1866(j) of the Act.
Section 1833(y)(2)(B) of the Act (as
added by section 5501(b) of the ACA)
defines major surgical procedures as
surgical procedures for which a 10-day
or 90-day global period is used for
payment under the PFS in section
1848(b) of the Act. In Addendum B to
the CY 2010 PFS final rule with
comment period (74 FR 62017 through
62143), as corrected in the correction
notice (74 FR 65455 through 65457), we
identified 489 10-day global procedure
codes and 3,796 90-day global
procedure codes for a total of 4,285
surgical procedure codes that would
have met the surgical procedure criteria
for the incentive payment if it were
applicable in CY 2010.
b. Proposed HPSA Surgical Incentive
Payment Program (HSIP)
For services furnished on or after
January 1, 2011 and before January 1,
2016, we are proposing to provide a 10
percent incentive payment to general
surgeons, identified by their enrollment
in Medicare with a primary specialty
code of 02—general surgery, in addition
to the amount they would otherwise be
paid for their professional services
under Part B, when they furnish a major
surgical procedure in a location that was
defined by the Secretary as of December
31 of the prior year as a geographic
HPSA. As with the PCIP described
above, we do not believe that surgeons
will change their Medicare specialty
designation in order to take advantage of
the HSIP payments. However, we will
monitor the specialty designations of
enrolled physicians, and if we find that
surgeons are changing their primary
specialty designation to general surgery
in order to take advantage of the HSIP
payments, we would consider making
future revisions to eliminate such an
outcome.
Consistent with the established
Medicare HPSA physician bonus
program, we are proposing that these
HSIP payments would be calculated by
the Medicare contractors based on the
criteria for payment that we have
established as discussed earlier in this
section, and payments would be made
quarterly on behalf of the qualifying
general surgeon for the qualifying major
surgical procedures. The surgeons’
professional services may be paid under
PO 00000
Frm 00101
Fmt 4701
Sfmt 4702
40139
the PFS based on a claim for
professional services or, where the
physician has reassigned his or her
benefits to a critical access hospital
(CAH) paid under the optional method,
to the CAH based on an institutional
claim.
Qualifying general surgeons would be
identified on a claim for a major surgical
procedure based on the primary
specialty of the rendering physician,
identified by his or her NPI, of 02—
general surgery. If the claim is
submitted by a physician’s group
practice or a CAH, the rendering
physician’s NPI must be included on the
line-item for the major surgical
procedure in order for a determination
to be made regarding whether or not the
procedure is eligible for payment under
the HSIP.
For HSIP payment to be applicable,
the major surgical procedure must be
furnished in an area designated by the
Secretary as of December 31 of the prior
year as a geographic HPSA. We would
provide HSIP payments for major
surgical procedures furnished by
general surgeons in the same HPSAs as
we currently recognize for purposes of
payment of all physicians under the
established Medicare HPSA physician
bonus program under section 1833(m) of
the Act.
Each year, we publish a list of zip
codes eligible for automatic payment of
the HPSA physician bonus payment at:
https://www.cms.gov/
hpsapsaphysicianbonuses/
01_overview.asp. We are proposing to
use the same list of zip codes for
automatic payment of the bonus for
eligible services furnished by general
surgeons. We are also proposing to
create a new HCPCS code modifier to
identify circumstances when general
surgeons furnish services in areas that
are designated as HPSAs as of December
31 of the prior year, but that are not on
the list of zip codes eligible for
automatic payment. The new modifier
would be appended to the major
surgical procedure on claims submitted
for payment, similar to the current
process for payment of the Medicare
HPSA physician bonus when the
geographic HPSA is not a HPSA
identified for automatic payment.
Consistent with the statutory
requirement, we are proposing to define
major surgical procedures as those for
which a 10-day or 90-day global period
is used for payment under the PFS. For
CY 2011, approximately 4,300 10-day
and 90-day global surgical procedures
codes are identified in Addendum B to
this proposed rule under the far right
column labeled ‘‘Global’’ and designated
with ‘‘010’’ or ‘‘090,’’ respectively.
E:\FR\FM\13JYP2.SGM
13JYP2
40140
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
We further note that section
1833(y)(3) of the Act (as added by
section 5501(b)(1) of the ACA)
authorizes payment under the HSIP as
an additional payment amount for
specified surgical services without
regard to any additional payment for the
service under section 1833(m) of the
Act. Therefore, a general surgeon may
receive both a HPSA physician bonus
payment under the established
Medicare HPSA physician bonus
program and an HSIP payment under
the new program beginning in CY 2011,
but the HSIP payment is made without
regarding to the HPSA physician bonus
payment amount. In addition, payments
for outpatient CAH services under
section 1834(g)(2)(B) of the Act (as
amended by section 5501(b) of the ACA)
are not affected by the HSIP payment
amounts made to the CAH on behalf of
the general surgeon.
Accordingly, for CY 2011, we are
proposing to amend § 414.2 by adding
the definitions of ‘‘HPSA’’ and ‘‘major
surgical procedure.’’ We are also
proposing to revise § 414.67 to move the
existing provisions to paragraph (a) to
be grouped as the ‘‘Health Professional
Shortage Area (HPSA) physician bonus
program’’ and adding a new paragraph
(b) for the ‘‘HPSA surgical incentive
payment program’’ provisions. Proposed
§ 414.67(b) would state that general
surgeons who furnish identified 10-day
and 90-day global period surgical
procedures in an area designated by the
Secretary as of December 31 of the prior
year as a geographic HPSA that is
recognized by Medicare for the HPSA
physician bonus program as specified
under renumbered § 414.67(a)(1) would
receive a 10 percent incentive payment
in addition to the amount that would
otherwise be paid for their professional
services under Part B. Physicians
furnishing services in areas that are
designated as geographic HPSAs prior to
the beginning of the year but not
included on the published list of zip
codes for which automated HPSA
surgical bonus payments are made
should report a specified HCPCS code
modifier to receive the HSIP payment.
Quarterly incentive payments would be
made to physicians or to CAHs paid
under the optional method that are
billing on behalf of physicians for their
professional services.
3. Sections 5501(a) and (b) of the ACA
and Payment for Critical Access
Hospital Professional Services Under
the Optional Method
Section 1834(g) of the Act establishes
the payment rules for outpatient
services furnished by a CAH. In 1999,
section 403(d) of the Balanced Budget
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Refinement Act of 1999 (Pub. L. 106–
113) (BBRA) amended section 1834(g) of
the Act to provide for two methods of
payment for outpatient services
furnished by a CAH. Specifically,
section 1834(g)(1) of the Act, as
amended by the BBRA, specifies that
the amount of payment for outpatient
services furnished by a CAH is equal to
the reasonable costs of the CAH in
furnishing such services. (The physician
or other practitioner furnishing the
professional service receives payment
under the PFS.) In the alternative, the
CAH may make an election, under
section 1834(g)(2) of the Act, to receive
amounts that are equal to ‘‘the
reasonable costs’’ of the CAH for facility
services plus, with respect to the
professional services, the amount
otherwise paid for professional services
under Medicare, less the applicable
Medicare deductible and coinsurance
amount. The election made under
section 1834(g)(2) of the Act is
sometimes referred to as ‘‘method II’’ or
‘‘the optional method.’’ Throughout this
section of this preamble, we refer to this
election as ‘‘the optional method.’’
In 2000, section 202 of the Medicare,
Medicaid and SCHIP Benefits
Improvement and Protection Act of
2000) (Pub. L. 106–554) (BIPA)
amended section 1834(g)(2)(B) of the
Act to increase the payment for
professional services under the optional
method to 115 percent of the amount
otherwise paid for professional services
under Medicare. In addition, in 2003
section 405(a)(1) of the MMA amended
section 1834(g)(l) of the Act by inserting
the phrase ‘‘equal to 101 percent of’’
before the phrase ‘‘the reasonable costs.’’
However, section 405 of the MMA did
not make a corresponding change to
section 1834(g)(2)(A) of the Act
regarding the amount of payment for
facility services under the optional
method. In 2010, Section 3128 of the
ACA amended section 1834(g)(2)(A) of
the Act by inserting the phrase ‘‘101
percent of’’ before ‘‘the reasonable costs.’’
Section 5501(a) of the ACA amends
section 1833 of the Act by adding a new
paragraph (x), ‘‘Incentive Payments for
Primary Care Services,’’ that authorizes
additional Part B payments to primary
care practitioners for primary care
services. Section 5501(b) of the ACA
further amends section 1833 of the Act
by adding new paragraph (y), ‘‘Incentive
Payments for Major Surgical Procedures
Furnished in Health Professional
Shortage Areas,’’ that authorizes
additional Part B payments for major
surgical procedures furnished by
general surgeons in HPSAs. Sections
5501(a)(3) and 5501(b)(3) of the ACA
make conforming amendments to
PO 00000
Frm 00102
Fmt 4701
Sfmt 4702
section 1834(g)(2)(B) of the Act, which
refers to payment to the CAH for
professional services under the optional
method, by adding at the end of section
1834(g)(2)(B) the following phrase,
‘‘Subsections (x) and (y) of 1833 shall
not be taken into account in
determining the amounts that would
otherwise be paid pursuant to the
preceding sentence.’’ As such, section
1834(g)(2)(B) of the Act (as amended by
sections 5501(a)(2) and 5501(b)(2) of the
ACA) requires that under the optional
method, the 115 percent adjustment
payment to the CAH for professional
services is calculated without
considering the incentive payments for
primary care services furnished by
primary care practitioners and major
surgical procedures furnished by
general surgeons in HPSAs as these
terms are defined under sections
1833(x) and (y) of the Act.
The regulations implementing section
1834(g)(2)(B) of the Act, payment to the
CAH for professional services under the
optional method, are in
§ 413.70(b)(3)(ii)(B). In order to
implement the amendments to section
1834(g)(2)(B) of the Act as specified by
sections 5501(a)(2) and 5501(b)(2) of the
ACA, we are proposing to amend the
regulations in § 413.70(b)(3)(ii)(B) to
state that, effective for primary care
services furnished by primary care
practitioners and major surgical
procedures furnished by general
surgeons in HPSAs on or after January
1, 2011 and before January 1, 2016, the
additional incentive payment amounts
as specified in § 414.67 and § 414.80 are
not included in the determination of the
payment for professional services made
to the CAH under the optional method.
Accordingly, we are proposing that
payment for professional services to the
CAH at 115 percent of the PFS amount
under the optional method would not
take into account the additional Part B
incentive payments for primary services
furnished by primary care practitioners
and major surgical procedures furnished
by general surgeons in HPSAs as
provided in § 414.67 and § 414.80.
T. Section 6003: Disclosure
Requirements for In-Office Ancillary
Services Exception to the Prohibition on
Physician Self-Referral for Certain
Imaging Services
1. Background
Section 1877 of the Act also known as
the physician self-referral law: (1)
Prohibits a physician from making
referrals for certain ‘‘designated health
services’’ (DHS) payable by Medicare to
an entity with which he or she (or an
immediate family member) has a
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
financial relationship (ownership or
compensation), unless an exception
applies; and (2) prohibits the entity from
filing claims with Medicare (or billing
another individual, entity, or third party
payer) for those DHS rendered as a
result of a prohibited referral. The
statute establishes a number of specific
exceptions and grants the Secretary the
authority to create regulatory exceptions
that pose no risk of program or patient
abuse.
Section 1877(b)(2) of the Act, entitled
‘‘In-office Ancillary Services’’ sets forth
the exception that permits a physician
in a solo or group practice to order and
provide designated health services
(DHS), other than most durable medical
equipment and pretrial and enteral
nutrients, in the office of the physician
or group practice, provided that certain
specific criteria are met. Under this
exception, the statute limits who can
furnish the service, designates where
the service must be performed, and
limits who can bill for the service. As
explained at the end of the statutory
exception, the service may also be
subject to ‘‘such other requirements as
the Secretary may impose by regulation
as needed to protect against program or
patient abuse.’’ The in-office ancillary
services exception is interpreted at
§ 411.355(b).
Section 6003 of the ACA amends
section 1877(b)(2) of the Act by creating
a new disclosure requirement for the inoffice ancillary services exception to the
prohibition on physician self-referral.
Specifically, section 6003 provides that,
with respect to referrals for magnetic
resonance imaging (MRI), computed
topography (CT), positron emission
topography (PET), and any other DHS
specified under section 1877(h)(6)(D)
that the Secretary determines
appropriate, we must promulgate a
requirement that the referring physician
inform a patient in writing at the time
of the referral that the patient may
obtain the service from a person other
than the referring physician or someone
in the physician’s group practice and
provide the patient with a list of
suppliers who furnish the service in the
area in which the patient resides.
2. Proposed Disclosure Requirement
We are proposing to implement
section 6003 of the ACA by amending
§ 411.355(b) to add new paragraph
(b)(7). We describe below our proposal
for the new disclosure requirement.
a. Services That Trigger the Disclosure
Requirement
Section 6003(a) of the ACA requires
that the new disclosure requirement
apply to MRI, CT, and PET services as
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
well as such other radiology or imaging
services included in the DHS category
specified in section 1877(h)(6)(D) of the
Act that the Secretary determines
appropriate. We are considering
whether to expand this disclosure
requirement to other radiology and
imaging services. We are not inclined to
expand the disclosure requirement but
we solicit comments regarding whether
other radiology or imaging services that
fall under section 1877(h)(6)(D) of the
Act should be included in this
requirement, and if so, which services,
and the purpose served by extending the
disclosure requirement to additional
radiology or imaging services.
b. General Disclosure Requirements
In § 411.355(b)(7), we are proposing
that the disclosure notice should be
written in a manner sufficient to be
reasonably understood by all patients
and must, as the ACA requires, be given
to the patient at the time of the referral.
This notice must indicate to the patient
that the services may be obtained from
a person other than the referring
physician or his or her group practice
and include a list of other suppliers who
provide the service being referred (MRI,
CT, or PET).
We believe one purpose of the
disclosure requirement is to inform a
patient’s decision-making regarding his
or her own care. The list of suppliers
provided to the patient by the physician
is meant to serve as a resource for the
patient. Nothing on the disclosure
notice or list of suppliers may indicate
to the patient that he or she must
receive imaging from a supplier on the
list if not receiving the service from the
referring physician. The patient may
receive the imaging service from the
referring physician, from a supplier
identified on the notice, or from another
supplier of the patient’s choice. The
patient is free to choose the supplier of
the service.
c. List of Alternate Suppliers
Section 6003(a) of the ACA specifies
that the referring physician must
provide a written list of ‘‘suppliers (as
defined in section 1861(d)).’’ Section
1861(d) of the Act defines supplier as ‘‘a
physician or other practitioner, a
facility, or other entity (other than a
provider of services) that furnishes
items or services under this title.’’ We
are proposing that only suppliers be
included on the written list. We are not
proposing to permit or require the list to
include ‘‘providers of services’’, which is
defined in section 1861(u) of the Act to
include hospitals and critical access
hospitals, among other facilities. We are
soliciting comments regarding whether
PO 00000
Frm 00103
Fmt 4701
Sfmt 4702
40141
inclusion of providers of services on the
written notice would benefit patients in
choosing an alternate entity for an
imaging service by providing more, and
varied, options.
Section 6003(a) of the ACA also
requires that the alternate suppliers
specified in the notice provided to the
patient must furnish the relevant
services ‘‘in the area in which [the
patient] resides.’’ We are aware that a
patient may travel outside the area in
which he or she resides in order to
receive medical care. We believe that
requiring an original written notice for
each patient based upon a certain
distance from the patient’s residence
could place a significant administrative
burden on physicians practicing in a
solo or group practice. It would be
impractical for a physician to prepare a
separate list for every area in which his
or her patients reside. Additionally, we
believe that if a patient has traveled to
see the referring physician, the
physician is located in an area
convenient to the patient and therefore,
a referral within a certain distance of
this location would also be convenient
for the patient.
In order to ease the administrative
burden of creating multiple lists while
still implementing the requirements of
the statute, we are proposing that the
suppliers included in this notice should
be located within a 25-mile radius of the
physician’s office location at the time of
the referral. We believe that a 25-mile
radius is large enough in most areas to
generate a list of suppliers that will be
useful to patients. We note that we have
used a 25-mile radius in other physician
self-referral exceptions, including the
intra-family rural referrals exception
(§ 411.355(j)) and the physician
recruitment exception (§ 411.357(e)).
Even if a patient resides more than 25
miles away, we are proposing that it
will be sufficient to provide a list of
suppliers located within a 25-mile
radius of the physician’s office location
at the time the referral is made. As
discussed above, we believe that
measuring the distance from the
physician’s office location will better
serve patients who have perhaps
traveled from long distances to receive
specialized treatment.
We are soliciting comments regarding
the proposed 25-mile radius
requirement. In attempting to minimize
confusion and burden related to
implementing this provision, we have
proposed the same standard for both
urban and rural areas. We realize that in
some areas 25 miles may be too small
to generate a sufficient list of other
suppliers. We are interested in hearing
whether an alternative distance may be
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40142
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
more effective for urban or rural areas as
well as what other criteria should be
considered in finalizing regulations for
physicians in both urban and rural
areas.
In order to help a patient make an
informed decision regarding other
options for the recommended imaging
services, we propose that the written
notice include no fewer than 10 other
suppliers. We considered proposing that
the list include the 10 closest suppliers,
but we want to allow physicians some
flexibility in drafting the list of
suppliers. On the other hand, we are
concerned that physicians located in
large metropolitan areas will draft a list
that includes suppliers located mostly at
the edges of the 25-mile radius, thereby
increasing the chances that the patient
will choose to receive imaging services
from the referring physician’s practice.
We are soliciting comments regarding
whether providing a list of 10 suppliers
is sufficient or too burdensome or
susceptible to abuse and whether there
are alternate criteria we should use that
would result in an adequate list of
convenient suppliers that does not
impose an undue burden on physician
practices or a risk of abuse.
We recognize that there may be fewer
than 10 other suppliers within a 25-mile
radius of the referring physician’s office
location. We propose that, under these
circumstances, the physician shall list
all of the other suppliers of the
particular imaging service that are
present within a 25-mile radius of the
referring physician’s office location,
including up to 10 suppliers as required
by these regulations. If no other
suppliers of the imaging services
ordered exist within the 25-mile radius
of the physician’s office location, the
physician need not provide a list of
alternative suppliers, but must still
disclose to his or her patients that the
patients may receive the imaging
services from another supplier. In this
last situation, simply providing this
disclosure statement will satisfy the
disclosure requirement of this provision
even though alternative suppliers are
not listed. The physician must maintain
documentation of the disclosure.
We are proposing that the written
notice be required to include certain
information about the listed suppliers in
order to satisfy this disclosure
requirement. The list must include the
name, address, phone number, and
distance from the physician’s office
location at the time of the referral. We
propose to require inclusion of the
distance from the physician’s location to
the other suppliers in order to
emphasize to the patient the relative
convenience of the listed suppliers.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
We are not proposing an exception to
the disclosure requirement for MRI, CT,
or PET services furnished on an
emergency or time-sensitive basis. We
are soliciting comments related to
whether there are other procedures or
circumstances in which it may be
difficult or impractical to provide the
written disclosure prior to provision of
the imaging services.
This proposal sets forth criteria that
apply to the disclosure requirement and
list of alternative suppliers. These
criteria are intended to provide clear
guidance as to how physicians may
comply with the new requirement of the
in-office ancillary services exception.
We understand that there may be
alternative ways to implement these
statutory requirements. One possible
alternative is to only require a
‘‘reasonable’’ list of other suppliers with
general requirements for the disclosure
to patients, while providing that if the
physician meets the more specific
requirements set forth in this proposal,
he or she will be deemed to have a
‘‘reasonable’’ disclosure. We seek
comments on this specific alternative
and any other alternative methods of
compliance that still satisfy the
statutory requirements.
d. Documentation of Disclosure
In order to document that this
disclosure requirement has been
satisfied, we propose that a record of the
patient’s signature on the disclosure
notification must be maintained as an
element of the patient’s medical record.
We are soliciting comments regarding
the burden of this recordkeeping
requirement. We are also interested in
comments that suggest alternative
means of recording that the disclosure
was made to the patient at the time of
referral.
e. Effective Date
As discussed above, section 6003(a) of
the ACA amends section 1877(b)(2) of
the Act by instructing that the new
disclosure requirement be added as one
of the additional requirements of the inoffice ancillary services exception. The
last sentence of the statutory exception
preceding this amendment authorizes
the Secretary to impose ‘‘such other
requirements * * * by regulation as
needed to protect against program or
patient abuse’’ (emphasis added). The
amendment specifies that ‘‘[s]uch
requirements shall * * * include a
[disclosure] requirement * * *’’ In
reading the last sentence of section
1877(b)(2) together with the
amendment, we do not believe that the
amendment is self-effectuating. Instead,
the new disclosure requirement of
PO 00000
Frm 00104
Fmt 4701
Sfmt 4702
section 6003 must be promulgated by
regulation. Therefore, we believe that a
correct reading of section 6003(a) is that
this amendment shall not be effective
until the Secretary promulgates a final
regulation implementing this new
requirement and the regulation becomes
effective.
We considered whether, pursuant to
section 6003 of the ACA, the final rule
setting forth the disclosure requirement
should apply retroactively to all services
furnished on or after January 1, 2010.
Given the structure of the amended inoffice ancillary services exception and
the statute as a whole, however, we
believe that retroactive rulemaking is
not required. Therefore, we are
proposing that the new disclosure
requirement shall apply only to services
furnished on or after the effective date
of the final regulation implementing
section 6003 of the ACA. We are
proposing an effective date of January 1,
2011 for the regulation implementing
this provision.
U. Section 6404: Maximum Period for
Submission of Medicare Claims
Reduced to Not More Than 12 Months
1. Background
Sections 1814(a)(1), 1835(a), and
1842(b)(3)(B) of the Act establish time
limits for filing Medicare Part A and B
claims. Prior to the enactment of the
ACA, under sections 1814(a)(1) and
1835(a) of the Act, providers could file
for Part A and Part B claims,
respectively, ‘‘* * * no later than the
close of the period of 3 calendar years
following the year in which such
services are furnished (deeming any
services furnished in the last 3 calendar
months of any calendar year to have
been furnished in the succeeding
calendar year) except that, where the
Secretary deems that efficient
administration so requires, such period
may be reduced to not less than 1
calendar year * * *’’. Prior to the
enactment of the ACA, CMS was
authorized to establish a minimum time
limit for provider-submitted Part A and
Part B claims of at least 1 calendar year
from the date of service, and a
maximum time limit not to exceed 4
years and 3 months after the date of
service.
Additionally, prior to the enactment
of the ACA, under section 1842(b)(3)(B)
of the Act, Part B claims for physician
and other supplier services could be
filed with Medicare ‘‘* * * no later than
the close of the calendar year following
the year in which such service is
furnished (deeming any service
furnished in the last 3 months of any
calendar year to have been furnished in
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
the succeeding calendar year) * * *’’.
Therefore, prior to the enactment of the
ACA, CMS was authorized to establish
a minimum time limit for filing Part B
claims of 15 months and a potential
maximum of 27 months after the service
was furnished, depending on what
month of the year the service was
furnished.
Section 424.44 implements sections
1814(a)(1), 1835(a), and 1842(b)(3)(B) of
the Act. In order to effectively
administer the Medicare Program, CMS,
through regulations, modified the
potential minimum and maximum time
periods for filing Part A claims so that
Part A claims would have the same time
limits as Part B claims. At § 424.44(a),
CMS adopted the minimum time limit
of 15 months and potential maximum of
27 months after the service was
furnished that was permitted under
section 1842(b)(3)(B) of the Act for Part
B claims and uniformly applied that 15
to 27 month time limit to both Part A
and B claims. Also, under § 424.44(b),
CMS allowed providers and suppliers
the opportunity to file claims after the
15 to 27 month deadline for filing
claims expired when the failure to file
‘‘* * * was caused by error or
misrepresentation of an employee,
intermediary, carrier, or agent of the
Department that was performing
Medicare functions and acting within
the scope of its authority.’’
2. Provisions of the ACA
Section 6404 of the ACA amended
sections 1814(a)(1), 1835(a), and
1842(b)(3)(B) of the Act regarding
Medicare fee-for-service (FFS) claims for
services furnished on or after January 1,
2010. Under section 6404(b)(1) of the
ACA, all claims for services furnished
on or after January 1, 2010 must be filed
within 1 calendar year after the date of
service. The provisions of the ACA did
not amend these sections of the Act for
services furnished before January 1,
2010. However, section 6404(b)(2) of the
ACA created a new requirement that
claims for services furnished before
January 1, 2010 must be filed on or
before December 31, 2010. Thus, the
statutory provisions prior to the
enactment of the ACA remain in effect
for pre-2010 services, subject to this
new requirement. The practical effect of
this change is that any claims for
services furnished before October 1,
2009 will follow the current existing
regulations. But for any services
furnished during the last three months
of 2009, those claims must be filed no
later than December 31, 2010. For
services furnished between October 1,
2009 and December 31, 2009, providers
and suppliers will only have 12–15
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
months to file a claim, whereas before
the ACA amendments, they would have
had an additional year to file their
claims, or 24 to 27 months. Therefore,
in order to effectuate the changes made
by the ACA, we are proposing to amend
§ 424.44 so that it is consistent with the
amended statutory provisions.
We are proposing to amend
§ 424.44(a) by replacing the current text
with the requirement that claims for
services provided on or after January 1,
2010 must be submitted no later than
the close of the period ending 1
calendar year after the date of service.
As noted above, any services furnished
before January 1, 2010 will still be
subject to the pre-existing statutory
provisions. Therefore, we are proposing
that for pre-2010 services, the preexisting regulatory structure will
continue to apply. For those services
furnished before January 1, 2010, claims
must be filed on or before December 31
of the following year for services that
were furnished during the first 9 months
of a calendar year, and on or before
December 31st of the second following
year for services that were furnished
during the last 3 months of the calendar
year. However, for those services
provided in the last three months of
2009, we propose that all claims for
those services must be filed no later
than December 31, 2010.
Section 6404 of the ACA also gives
the Secretary authority to create
exceptions to the 1 year timely filing
period. In addition to the existing
exception to the timely filing
requirement due to error or
misrepresentation by CMS, our
contractors or agents, we propose to
create two new exceptions. First, we are
proposing to create an exception for
those situations where a beneficiary
becomes retroactively entitled to
Medicare benefits, but was not entitled
at the time the services were furnished.
Second, we are proposing to permit
providers and suppliers to file claims
after the time limit for filing claims has
expired in limited dual eligible
Medicare/Medicaid beneficiary
situations.
The first new proposed exception at
§ 424.44(b)(2) will permit providers and
suppliers to file claims after the time
limit for filing claims expires when
CMS or our contractors determines that
the following conditions have been met:
• At the time the service was
furnished the beneficiary was not
entitled to Medicare; and
• The beneficiary subsequently
received notification of Medicare
entitlement effective retroactively to or
before the date of the furnished service.
PO 00000
Frm 00105
Fmt 4701
Sfmt 4702
40143
In these situations, if CMS or one of
our contractors determines that both of
the conditions in § 424.44(b)(2) are met,
then the time to file a claim will be
extended through the last day of the 6th
calendar month following the month in
which the beneficiary received
notification of Medicare entitlement
effective retroactively to or before the
date of the furnished service. Therefore,
instead of the beneficiary having to pay
out of his or her own pocket for the
service or instead of the beneficiary’s
other insurance or some other payer that
is secondary to Medicare having to pay
primary for the service, Medicare may
pay primary (or secondary or tertiary)
for the service since the beneficiary was
entitled to Medicare (although
retroactively) at the time the service was
furnished. All of Medicare’s payment
rules including Medicare’s Secondary
Payer rules still apply in these
retroactive entitlement situations.
The second proposed new exception
at § 424.44(b)(3) will permit providers
and suppliers to file claims for duallyeligible beneficiaries after the time limit
for filing claims expires when CMS or
our contractors determine that all of the
following conditions have been met:
• At the time the service was
furnished the beneficiary was not
entitled to Medicare;
• The beneficiary subsequently
received notification of Medicare
entitlement effective retroactively to or
before the date of the furnished service;
and
• A State Medicaid agency recovered
the Medicaid payment for the furnished
service from the provider or supplier 11
months or more after the date of service.
This proposed exception applies to
situations where a provider or supplier
bills (and receives payment from)
Medicaid for the services that a dual
eligible Medicare/Medicaid beneficiary
receives from the provider or supplier.
However, at the time the services were
furnished, the patient was not a dual
eligible Medicare/Medicaid beneficiary
yet because Medicare entitlement was
granted to the individual retroactively
after the service was actually furnished
to the individual. In addition, after the
State Medicaid Program discovers that
the individual was granted Medicare
entitlement retroactively, the State
Medicaid Program recovers its payments
from the provider or supplier for that
individual’s services instructing the
provider or supplier that Medicare
should be billed for the services (not
Medicaid). If all three of the conditions
outlined above occur within 11 months
of the date the service was furnished,
then the provider or supplier will have
enough time to bill Medicare for the
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40144
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
service. However, if Medicaid recovers
their incorrect payment 11 months or
more after the date the service was
furnished, then the provider or supplier
will not have enough time to file a claim
with Medicare for the covered services
because the time limit for filing claims
expires 1 calendar year after the date of
service. In these situations, if CMS or
one of our contractors determines that
all of the conditions at § 424.44(b)(3) are
met, then the time to file a claim will
be extended through the last day of the
6th calendar month following the month
in which the State Medicaid agency
recovered the Medicaid payment for the
furnished service from the provider or
supplier. Therefore, we are proposing
that this exception along with the
aforementioned retroactive entitlement
exception be added to § 424.44.
We are proposing that for the one
existing exception due to error or
misrepresentation by CMS, our
contractors or agents (see § 424.44(b)(1))
that no extension of time will be granted
beyond 4 years from the date of service.
Limiting the exception for this timely
filing extension is consistent with
current CMS policy. Moreover, we
believe that limiting this exception to 4
years after the date of service strikes an
appropriate balance between fairness
and equity for providers, suppliers, and
beneficiaries and administrative finality
for the Medicare program. We recognize
that limiting the exceptions process
could have potential impacts on those
that wish to avail themselves of this
exception. Therefore, we are soliciting
comments on how this proposed four
year limitation on the exception at
§ 424.44(b)(1) will impact providers,
suppliers and beneficiaries and the
frequency of such occurrences. In
addition, we are soliciting comments on
whether the proposed four year
limitation for this particular exception
is appropriate, or what changes, if any,
should be made to the limitation on the
exceptions process, including a
rationale or justification for an
alternative time limitation.
CMS is not proposing a definition of
the term ‘‘date of service’’ in this
regulation. Yet we recognize that the
definition of this term is very important
to providers, suppliers, and
beneficiaries because the ‘‘date of
service’’ will ultimately determine when
the claim has to be filed in order to meet
the new 1 calendar year requirement. In
most cases the ‘‘date of service’’ will be
the date that the item or service is
actually furnished to the beneficiary;
however, we recognize that for many
Part A and B services it is difficult to
craft a uniform rule that will apply a
consistent date of service standard. It is
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
our intention to provide sub-regulatory
guidance on what constitutes the date of
service for different Part A and B
services. We are soliciting comments
regarding whether CMS should provide
a regulatory definition of ‘‘date of
service’’ and, if so, how should it define
this term.
We are also clarifying the exception
that appears at § 424.44(e). We are
making clear that this regulation does
not supersede the restriction on
retrospective billing that appears in
§§ 424.520 and 424.521. Under these
provisions certain newly-enrolled
suppliers, such as physicians, nonphysician practitioners, physician or
non-physician practitioner
organizations and IDTFs, have only a
limited ability to submit claims for
items or services furnished prior to the
effective date of their Medicare billing
privileges even if these claims would
otherwise be considered timely. In
addition, we want to make clear that the
one calendar year timely filing limit in
section 424.44(a) does apply to any
retrospective claims permitted by
sections 424.520 and 424.521 and to
claims for items or services furnished
after the effective date of the supplier’s
billing privileges.
V. Section 6410 and MIPPA:
Adjustments to the Metropolitan
Statistical Areas (MSA) for Medicare
Durable Medical Equipment,
Prosthetics, Orthotics, and Supplies
Competitive Acquisition Program
We are proposing a number of
revisions to the DMEPOS CBP as a
result of changes to the statute made by
both the Medicare Improvements for
Patients and Provider Act of 2008
(MIPPA) and the ACA. Since both
MIPPA and the ACA specify
requirements for MSA selection for
round 2 and beyond we are outlining
our proposals for implementing the
statutory requirements related to MSA
selection in both MIPPA and the ACA
in this section. First, we propose to use
the authority provided by the statute at
section 1847(a)(1)(D)(ii) of the Act, as
amended by MIPPA to subdivide
Metropolitan Statistical Areas (MSAs)
with populations of greater than
8,000,000 under Round 2 of the
DMEPOS CBP. Second, we propose to
exclude certain areas from competitive
bidding after round 2 as mandated by
section 1847(a)(1)(D)(iii) of the Act, as
amended by MIPPA. Third, we propose
to implement the requirement of section
6410 of the ACA to expand Round 2 of
the program by adding 21 of the largest
MSAs based on total population to the
original 70 already selected for round 2.
PO 00000
Frm 00106
Fmt 4701
Sfmt 4702
1. Background
Section VI.H of this proposed rule
provides background on the DMEPOS
CBP, including a description of many of
the changes made to the program by
section 154 of MIPPA. In this section,
we provide additional information
regarding changes made by both MIPPA
and Section 6410 of the ACA. In
addition to the changes discussed
previously in this proposed rule, MIPPA
also added subparagraph (D) to section
1847(a)(1) of the Act. Section
1847(a)(1)(D)(ii), as added by MIPPA,
addresses Round 2 of the DMEPOS CBP,
and section 1847(a)(1)(D)(iii) addresses
subsequent rounds of the Program.
Section 1847(a)(1)(D)(ii)(II) of the Act
specifies that the Secretary shall
implement DMEPOS competitive
bidding in the areas previously selected
for round 2 of the program and also
allows the Secretary, in implementing
round 2 of the program, to subdivide
metropolitan statistical areas (MSAs)
with populations of greater than
8,000,000 into separate CBAs.
Previously, we believe the statute could
have been interpreted to allow CMS to
subdivide large MSAs but MIPPA gave
CMS the explicit authority to subdivide
large MSAs. Section 1847(a)(1)(D)(iii)
imposes new requirements on the
Secretary for competitions occurring
before 2015 in subsequent rounds of the
program. For such competitions (other
than national mail order), the following
areas are to be excluded from the
program: (I) Rural areas; (II) MSAs not
selected under Round 1 or 2 with a
population of less than 250,000; and (III)
certain areas with low population
density within a selected MSA. These
requirements do not apply to a national
mail order program.
Finally, MIPPA required that we
implement Round 2 of the DMEPOS
CBP in the same MSAs that were
designated as of June 1, 2008. In 2010,
section 6410(a) of the ACA amended
sections 1847(a)(1)(B)(i)(II) and (D)(ii) of
the Act to expand Round 2 of the
program from 70 MSAs to 91 MSAs by
adding the next 21 largest MSAs by total
population not already selected for
Rounds 1 or 2.
2. Subdividing Large MSAs Under
Round 2
We have selected MSAs for Round 1
and for Round 2 consistent with
MIPPA’s requirement. For round 1
CBAs generally were comparable to
MSAs, however, for round 2 we are
proposing to subdivide MSAs of
8,000,000 or more in population. The
authority to subdivide MSAs into
separate areas for competitive bidding
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
purposes is set forth in section
1847(a)(1)(D)(ii)(II) of the Act which
states, ‘‘[t]he Secretary may subdivide
metropolitan statistical areas with
populations (based upon the most
recent data from the Census Bureau) of
at least 8,000,000 into separate areas for
competitive acquisition purposes.’’ We
have identified three MSAs which,
based on the 2009 estimate from the
Census Bureau data, could be
subdivided under section
1847(a)(1)(D)(ii)(II): (1) ChicagoNaperville-Joliet, Illinois-IndianaWisconsin (IL-IN-WI) MSA with a
population of 9,569,624; (2) Los
Angeles-Long Beach-Santa Ana,
California (CA) MSA with a population
of 12,872,808; and (2) New YorkNorthern New Jersey-Long Island, New
York-New Jersey-Pennsylvania (NY-NJPA) MSA with a population of
19,006,798. We are proposing to divide
these MSAs into separate CBAs because
we believe this approach would create
more manageable CBAs for contract
suppliers to serve and allow more small
suppliers to be considered for
participation in the program.
We considered certain factors when
considering whether to propose
subdividing the MSAs with populations
of at least 8,000,000. We considered the
geographic, social, and economic
integration of each of the MSAs. We
apply all of these factors when grouping
counties into CBAs considered at a
county level in each MSA and we
believe it is also appropriate to use these
factors to determine: (1) Whether or not
to subdivide an MSA into separate
CBAs, and (2) once the decision is made
to subdivide the MSA, how to subdivide
the MSA. We considered the following
factors, generally in the order in which
they are listed:
• Geographic size of the MSA and the
location of the counties within each
MSA compared to neighboring counties;
• The driving distances from north to
south and east to west within each MSA
and county;
• The total population and the
population of FFS Medicare
beneficiaries using DMEPOS items
subject to competitive bidding;
• The DMPOS allowed charges for
items subject to competitive bidding;
• Comparably sized Round 1 and
Round 2 MSAs based on beneficiary
counts and allowed charges for
competitive bid items;
• The interstate highway
infrastructures of the MSAs; and
• The current service patterns of
suppliers in each county of the MSA.
We used each of the factors to the
extent practical to develop initial
proposals for reasonable and workable
subdivisions of these highly and
densely populated MSAs. We believe
consideration of these factors will help
us meet our goal of subdividing large
and densely populated MSAs and
creating CBAs that are attractive to
suppliers and incentivize them to bid
competitively for a contract. With this
goal in mind, we are trying to establish
40145
CBAs that provide for a good volume of
DMEPOS business for winning bidders,
avoid obvious geographic obstacles,
mimic existing supplier service
patterns, and, to the extent possible, do
not cross State lines. We believe the
factors we have selected will achieve
those objectives.
We found that counties clearly
delineate areas within a MSA, and as we
have done for Round 1 by identifying
CBAs by counties and zip codes, we are
proposing to subdivide the MSAs at a
county level. Since the Office of
Management and Budget (OMB) defines
the MSAs by counties and county-based
subdivisions are stable, we use counties
to subdivide CBAs. When subdividing
an MSA into counties, we consider
counties that share social, economic and
geographic integration. The ChicagoNaperville-Joliet IL-IN-WI MSA
comprises 14 counties within 3 States:
Illinois, Indiana, and Wisconsin. This
MSA has 207,106 beneficiaries and
$218,161,562 of DMEPOS allowed
charges subject to the DMEPOS CBP.
Using the factors that we indentified, we
would subdivide the ChicagoNaperville-Joliet, IL-IN-WI MSA into
four separate CBAs: Indiana-Chicago
Metro CBA; South-West-Chicago-Metro
CBA; Central-Chicago Metro CBA; and
Northern-Chicago Metro CBA. The
counties, DMEPOS allowed charges, and
the number of beneficiaries subject to
competitive bidding, and the general
population that comprise each of these
proposed CBAs are shown in Table 40.
TABLE 40—CHICAGO-NAPERVILLE-JOLIET, IL-IN-WI
DMEPOS
allowed Charles*
CBA name/County
DMEPOS
beneficiary count
subject to
competitive
bidding*
General
population **
$18,600,917
1,238,119
580,842
4,856,838
16,637
1,191
393
4,526
493,800
32,544
13,933
162,181
CBA TOTAL ..........................................................................................
25,276,716
22,747
702,458
South-West-Chicago-Metro CBA:
Will, IL ...........................................................................................................
Grundy, IL .....................................................................................................
Kendall, IL .....................................................................................................
DeKalb, IL .....................................................................................................
Kane, IL ........................................................................................................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Indiana-Chicago Metro CBA:
Lake, IN ........................................................................................................
Jasper, IN .....................................................................................................
Newton, IN ....................................................................................................
Porter, IN ......................................................................................................
13,523,185
1,417,511
978,215
2,358,319
9,273,504
12,522
1,405
1,052
2,323
9,082
681,097
47,958
103,460
106,321
507,579
CBA TOTAL ..........................................................................................
27,550,734
26,384
1,446,415
Central-Chicago Metro CBA:
Cook, IL ........................................................................................................
DuPage, IL ....................................................................................................
124,854,279
16,945,135
116,360
18,492
5,294,664
930,528
CBA TOTAL ..........................................................................................
141,799,414
134,852
6,225,192
Northern-Chicago Metro CBA:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00107
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40146
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 40—CHICAGO-NAPERVILLE-JOLIET, IL-IN-WI—Continued
DMEPOS
allowed Charles*
CBA name/County
DMEPOS
beneficiary count
subject to
competitive
bidding*
General
population **
Lake, IL .........................................................................................................
McHenry, IL ..................................................................................................
Kenosha, WI .................................................................................................
12,352,802
7,020,768
4,161,128
12,482
6,852
3,789
712,453
318,641
164,465
CBA TOTAL ..........................................................................................
23,534,698
23,123
1,195,559
MSA TOTAL ..........................................................................................
218,161,562
207,106
9,569,624
* Source: Medicare claims from 10/1/08 to 9/30/09 for items subject to competitive bidding.
** Source: U.S. Census Bureau 2009 population estimates.
Figure 1 shows the boundaries of each
proposed CBA.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
BILLING CODE 4120–01–P
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00108
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40147
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00109
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.452
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
BILLING CODE 4120–01–C
40148
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
The Indiana-Chicago Metro CBA
would include all four of the Indiana
counties that are part of the MSA. The
other CBAs in the MSA would be as
follows:
• The South-West-Chicago Metro
CBA would include counties in Illinois
located to the south and west of the
Central-Chicago Metro CBA.
• The Central-Chicago Metro CBA
would include the city of Chicago
covering both Cook and DuPage
counties.
• The Northern-Chicago Metro CBA
which is north of the Central-Chicago
Metro CBA subdivision that
encompasses the city of Chicago.
The Los Angeles-Long Beach-Santa
Ana, CA MSA comprises two counties:
Los Angeles County and Orange County.
The MSA has 173,631 fee-for-service
beneficiaries receiving DMEPOS subject
to competitive bidding and
$244,523,957 in DMEPOS allowed
charges subject to the DMEPOS CBP. We
propose to subdivide the Los AngelesLong Beach-Santa Ana, CA MSA into
two CBAs: Los Angeles County CBA and
Orange County CBA. The DMEPOS
allowed amount and beneficiary count
subject to competitive bidding, and the
general population that comprises these
two proposed CBAs are shown in Table
41.
TABLE 41—LOS ANGELES-LONG BEACH-SANTA ANA, CA
DMEPOS
allowed amount *
CBA name
DMEPOS
beneficiary
count *
General
population **
Los Angeles County CBA ................................................................................................
$201,244,121
137,408
9,862,049
CBA Total .................................................................................................................
201,244,121
137,408
* 9,862,049
Orange County CBA ........................................................................................................
43,279,836
36,223
3,010,759
CBA Total .................................................................................................................
43,279,836
36,223
3,010,759
MSA Total ..........................................................................................................
244,523,957
173,631
12,872,808
*Source: Medicare claims from 10/1/08 to 9/30/09 for items subject to competitive bidding.
**Source: U.S. Census Bureau 2009 population estimates.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Figure 2 shows the boundaries of each
proposed CBA.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00110
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
As mentioned earlier, we propose to
subdivide MSAs using counties, and
since the Los Angeles-Long Beach-Santa
Ana, CA MSA only has two counties, it
offers only one subdivision along the
county lines. Hence, we have proposed
to divide the MSA by the two counties
creating two CBAs.
We also propose to use the authority
in section 1847(a)(3)(A) of the Act to
exclude certain areas within the Los
Angeles-Long Beach-Santa Ana, CA
MSA. We believe these areas meet the
requirement of section 1847(a)(3)(A);
they are rural areas with a low
population density within an urban area
that are not competitive. In the final rule
CMS–1270 F § 414.410(c) published in
April 2007, we defined the factors we
consider when determining an area is
considered a low population density
VerDate Mar<15>2010
23:56 Jul 12, 2010
Jkt 220001
area or an area that would not be
competitive. Based on our review of the
County Subdivision Population from the
2000 Census from the U.S. Census
Bureau, and using the factors set forth
in the April 2007 proposed rule, we
propose to exclude the area of Los
Angeles County north of the San Gabriel
mountains. This large geographic area
has a population of about 357,000,
which is only 4 percent of the total
population of Los Angeles County, and
is separated from the rest of the county
by the San Gabriel Mountains. The area
north of the San Gabriel Mountains has
one major road and many terrains which
make this area remote. The majority of
the population in LA County lives south
of the San Gabriel Mountains.
We believe that excluding this area
will create a more manageable CBA that
PO 00000
Frm 00111
Fmt 4701
Sfmt 4702
40149
still provides sufficient volume of
DMEPOS items while avoiding the
geographic obstacle of the mountains.
We believe including this area in the
DMEPOS CBP would result in fewer
small suppliers being considered for
participation under the program,
because we would not expect small
suppliers to have the resources to serve
these more remote areas. As a result, we
expect that if this proposal is finalized
it will increase the number of bids
submitted for the CBAs within the Los
Angeles-Long Beach-Santa Ana, CA
MSA.
The Los Angeles County includes the
two islands of Santa Catalina and San
Clemente off the west coast. We are
proposing that the two islands be
included as a part of the Los Angeles
County CBA in order to ensure that
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.002
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40150
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
beneficiaries presently residing on these
islands or who move to these islands in
the future are ensured access to
competitively bid items by contract
suppliers. San Clemente Island is a
military base with a current population
of zero, and therefore, the inclusion of
this area in the CBA would not result in
an increase in the supplier service area
at this time.
We also propose to subdivide the New
York-Northern New Jersey-Long Island,
NY–NJ–PA MSA into five CBAs. This
MSA comprises 23 counties in three
States: New York, New Jersey and
Pennsylvania. The MSA has 344,879
FFS beneficiaries receiving DMEPOS
subject to the DMEPOS CBP and
$350,449,795 in allowed charges for
DMEPOS items subject to competitive
bidding. The counties, DMEPOS
allowed amount and beneficiary count
subject to competitive bidding and the
general populations that comprise each
of these proposed CBAs are shown in
Table 42.
TABLE 42—NEW YORK-NORTHERN NEW JERSEY-LONG ISLAND, NY-NJ-PA
DMEPOS
allowed amount *
CBA name/County
DMEPOS
beneficiary count *
General
population **
Nassau-Brooklyn-Queens County Metro CBA:
Nassau, NY ..................................................................................................
Kings, NY ......................................................................................................
Queens, NY ..................................................................................................
$30,888,889
47,044,915
33,406,236
29,857
44,893
32,798
1,351,625
2,556,598
2,293,007
CBA TOTAL ..........................................................................................
111,340,040
107,548
6,201,230
Suffolk County CBA:
Suffolk, NY ....................................................................................................
31,950,806
31,476
1,512,224
CBA TOTAL ..........................................................................................
31,950,806
31,476
1,512,224
Bronx-Manhattan NY CBA:
Bronx, NY .....................................................................................................
New York, NY ...............................................................................................
19,791,646
26,483,792
17,002
26,414
1,391,903
1,634,795
CBA TOTAL ..........................................................................................
46,275,438
43,416
3,026,698
North-West NY Metro CBA:
Hudson, NJ ...................................................................................................
Bergen, NJ ....................................................................................................
Passaic, NJ ...................................................................................................
Putnam, NY ..................................................................................................
Rockland, NY ................................................................................................
Essex, NJ .....................................................................................................
Morris, NJ .....................................................................................................
Sussex, NJ ...................................................................................................
Pike, PA ........................................................................................................
Westchester, NY ...........................................................................................
13,622,910
19,948,837
10,266,137
1,997,668
6,421,317
1,392,770
9,094,758
2,905,240
1,393,003
16,971,210
12,644
20,278
10,233
1,876
6,265
1,379
9,830
2,819
1,475
17,220
595,419
894,840
490,948
99,244
298,545
770,675
487,548
150,909
59,664
953,943
CBA TOTAL ..........................................................................................
84,013,850
84,019
4,801,735
Southern NY Metro CBA:
Hunterdon, NJ ..............................................................................................
Richmond, NY ..............................................................................................
Union, NJ ......................................................................................................
Middlesex, NJ ...............................................................................................
Monmouth. NJ ..............................................................................................
Ocean, NJ .....................................................................................................
Somerset, NJ ................................................................................................
2,709,880
7,054,863
10,466,838
15,803,473
14,979,747
20,913,022
4,941,838
2,356
6,626
10,654
16,649
15,110
21,600
5,425
129,031
487,407
523,249
789,102
642,448
569,111
324,563
CBA TOTAL ..........................................................................................
76,869,661
78,420
3,464,911
MSA TOTAL ..........................................................................................
350,449,795
344,879
19,006,798
* Source: Medicare claims from 10/1/08 to 9/30/09 for items subject to competitive bidding.
** Source: U.S. Census Bureau 2009 population estimates.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Figure 3 shows the boundaries of each
proposed CBA.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00112
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
The Nassau-Brooklyn-Queens CBA
would be contiguous to Suffolk County
and would consist of the western part of
Long Island and extend to the eastern
part of New York City. The Suffolk
County CBA would consist of the
eastern part of Long Island and would
encompass most of Long Island. The
Bronx-Manhattan NY CBA would
include the entire area of Manhattan
and the Bronx. The North-West NY
Metro CBA would be situated north and
west of New York City and would
extend into New Jersey and
Pennsylvania. The Southern NY Metro
CBA would include Staten Island and
would extend south to Ocean County,
New Jersey.
At the March 17, 2010 meeting of the
Program Advisory and Oversight
Committee (PAOC), we presented these
proposals for subdividing these three
large MSAs. Various members of the
PAOC had the following suggestions for
subdividing these MSAs:
• Draw the boundaries of CBAs using
the interstate highways rather than the
divisions by County;
• Determine the current servicing
areas of suppliers by MSA and product
category by using a scatter plot;
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
• Use the Hudson River to divide the
CBAs for the New York MSA;
• Carve out Pike and Putnam
Counties from the New York MSA due
to their location and their low
population density;
• Include Manhattan as a separate
CBA, due to its unique nature as a self
contained area;
• Consider State licensure
requirements when we divide the MSAs
into CBAs;
• In the LA County CBA, exclude the
area north of the San Gabriel Mountains
from the CBA; and
• Consider traffic patterns when
dividing the Los Angeles MSAs into
CBAs.
We are considering the PAOC’s advice
and recommendations and invite further
comments on the proposed subdivisions
and PAOC’s advice of these three MSAs.
3. Exclusions of Certain Areas After
Round 2 and Prior to 2015
The MIPPA amended the statute by
requiring that competition under Round
2 takes place in 2011 and by adding
section 1847(a)(1)(D)(iii) that requires
CMS to exclude the following areas
from the competitive bid program for
PO 00000
Frm 00113
Fmt 4701
Sfmt 4702
40151
competitions after Round 2 of the
program and before 2015:
• Rural Areas;
• Metropolitan Statistical Areas not
selected under Round 1 or Round 2 with
a population of less than 250,000; and
• Areas with a low population
density within a MSA that is otherwise
selected consistent with section
1847(a)(3)(A).
We propose to incorporate these
requirements and timeframes in
proposed § 414.410(c).
4. Expansion of Round 2
Section 6410(a) of the ACA expanded
the areas to be included in Round 2 of
the program. As amended by section
6410(a) of the ACA, section
1847(a)(1)(B)(i)(II) requires that the
competition for Round 2 of the program
occur in 91 of the largest MSAs in 2011.
Prior to this change, Round 2 was to
include 70 MSAs. Section
1847(a)(1)(D)(ii)(II), as added by section
6410(a), specifies that the additional 21
MSAs to be included in Round 2
‘‘include the next 21 largest
metropolitan statistical areas by total
population’’ (after those already selected
Round 2). The 2009 annual population
estimates from the U.S. Census Bureau
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.003
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40152
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
are the most recent estimates of
population that will be available prior to
the Round 2 competition mandated to
take place in 2011. We therefore
propose to use these estimates to
determine the additional 21 MSAs to be
included in Round 2 of the program.
Table 43 is a list of the additional 21
MSAs added to Round 2.
TABLE 43—ADDITIONAL 21 MSAS ADDED TO ROUND 2
2009 Total
population
21 Additional MSAs
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD ..............................................................................................................................
Washington-Arlington-Alexandria, DC-VA-MD-WV .............................................................................................................................
Boston-Cambridge-Quincy, MA-NH .....................................................................................................................................................
Phoenix-Mesa-Scottsdale, AZ .............................................................................................................................................................
Seattle-Tacoma-Bellevue, WA .............................................................................................................................................................
St. Louis, MO-IL ...................................................................................................................................................................................
Baltimore-Towson, MD ........................................................................................................................................................................
Portland-Vancouver-Beaverton, OR-WA .............................................................................................................................................
Providence-New Bedford-Fall River, RI-MA ........................................................................................................................................
Buffalo-Niagara Falls, NY ....................................................................................................................................................................
Rochester, NY .....................................................................................................................................................................................
Tucson, AZ ..........................................................................................................................................................................................
Honolulu, HI .........................................................................................................................................................................................
Albany-Schenectady-Troy, NY ............................................................................................................................................................
Worcester, MA .....................................................................................................................................................................................
Oxnard-Thousand Oaks-Ventura, CA .................................................................................................................................................
Springfield, MA ....................................................................................................................................................................................
Bradenton-Sarasota-Venice, FL ..........................................................................................................................................................
Poughkeepsie-Newburgh-Middletown, NY ..........................................................................................................................................
Stockton, CA ........................................................................................................................................................................................
Boise City-Nampa, ID ..........................................................................................................................................................................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
W. Section 10501(i)(3)—Proposed
Collection of HCPCS Data for
Development and Implementation of a
Prospective Payment System for the
Medicare Federally Qualified Health
Center Program
The Omnibus Budget Reconciliation
Act (OBRA) of 1989 amended the Social
Security Act by creating new FQHC
benefit programs under both Medicare
and Medicaid. The Medicare FQHC
benefit provides coverage for a full
range of primary care services,
including physician and certain
nonphysician services (PAs, NPs),
clinical social worker, psychologist
services, and preventive services.
FQHCs are ‘‘safety net’’ providers (for
example, community health centers and
programs serving migrants, the
homeless, public housing centers, and
tribal groups). The main purpose of the
FQHC program is to enhance the
provision of primary care services in
underserved urban and rural
communities. FQHCs typically enhance
the availability of care to vulnerable
populations, including Medicare,
Medicaid, SCHIP, and the uninsured.
Most of these health centers receive
HRSA grants for services to the
uninsured.
Medicare pays FQHCs on the basis of
reasonable cost, subject to an upper
payment limit on the reasonableness of
incurred cost. Actual Medicare
reasonable cost is determined based
upon a Medicare cost report filed by the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
FQHC after the end of its fiscal year.
Prior to the start of the year, an interim
all-inclusive per-visit payment amount,
based upon an estimate of Medicare
reasonable costs, is calculated for each
Medicare FQHC. During the year, this
interim all-inclusive per-visit payment
amount is paid for each covered visit
between a Medicare beneficiary and an
FQHC health professional. After the end
of the Medicare FQHC’s cost reporting
year, interim per-visit payments are
reconciled to actual Medicare
reasonable costs based upon the
Medicare cost report filed by the FQHC.
Section 10501(i)(3) of the ACA now
amends this current Medicare FQHC
payment policy with an entirely
different payment system, effective with
cost reporting periods beginning on or
after October 1, 2014.
Section 10501(i)(3)(A) of the ACA
amended section 1834 of the Act by
adding a new subsection (o),
Development and Implementation of
Prospective Payment System. This
subsection provides the statutory
framework for development and
implementation of a prospective
payment system for Medicare FQHCs.
Section 1834(o)(1)(B) of the Act, as
established by the ACA, addresses
collection of data necessary to develop
and implement the new Medicare FQHC
prospective payment system.
Specifically, section 1834(o)(1)(B) of the
Act, Collection of Data and Evaluation,
grants the Secretary of HHS the
authority to require FQHCs to submit
PO 00000
Frm 00114
Fmt 4701
Sfmt 4702
5,968,252
5,476,241
4,588,680
4,364,094
3,407,848
2,828,990
2,690,886
2,241,841
1,600,642
1,123,804
1,035,566
1,020,200
907,574
857,592
803,701
802,983
698,903
688,126
677,094
674,860
606,376
such information as may be required in
order to develop and implement the
Medicare FQHC prospective payment
system, including the reporting of
services using HCPCS codes. Section
1834(o)(1)(B) of the Act requires that the
Secretary impose this data collection
submission requirement no later than
January 1, 2011. Accordingly, we are
proposing to add a new paragraph (d) to
§ 405.2470 to require Medicare FQHCs
to begin reporting all services furnished
and using HCPCS codes for these
services starting January 1, 2011.
Beginning January 1, 2011, the Medicare
FQHC would be required to report on
Medicare FQHC claims all pertinent
service(s) provided for each Medicare
FQHC visit (defined in § 405.2463). This
additional reporting would include the
information needed to develop and
implement a PPS for FQHCs. For
example, corresponding HCPCS code(s)
would be required to be reported along
with the presently required Medicare
revenue code(s) for the Medicare FQHC
visit(s). CMS’ Medicare FQHC claims
processing system would be revised to
accept the addition of the new reporting
requirements effective January 1, 2011.
The proposed new data collection effort
would be for informational and data
gathering purposes only, and would not
be utilized to determine Medicare
payment to the FQHC. Until the FQHC
prospective payment system is
implemented in 2014 and the Medicare
claims processing system is revised to
reflect such a system, Medicare FQHC
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
payment would continue in the current
manner (utilizing revenue codes and the
interim per-visit payment rate
methodology).
We further note that Medicare FQHCs
would be required to adhere to the
information collection requirements in
accordance with the content and terms
of their Medicare agreement as
stipulated at § 405.2434. Failure to do so
could result in the termination of the
FQHC’s Medicare agreement in
accordance with § 405.2436 of the
Medicare FQHC regulations.
At this time, we do not foresee
additional claims or other information
collection needs beyond collection of
HCPCS codes. Accordingly, we are not
proposing additional information
collection requirements at this time.
However, we invite public comment on
any additional information FQHCs
believe may be necessary in order to
develop and implement a prospective
payment system for Medicare FQHCs.
VI. Other Provisions of the Proposed
Regulation
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
A. Part B Drug Payment: Average Sales
Price (ASP) Issues
1. ‘‘Carry Over’’ ASP
The ASP payment methodology is
authorized under section 303(c) of the
MMA which amends Title XVIII of the
Act by adding section 1847A of the Act.
This section establishes the use of the
ASP methodology for payment for drugs
and biologicals described in section
1842(o)(1)(C) of the Act furnished on or
after January 1, 2005. For purposes of
this part, the term ‘‘drugs’’ will hereafter
refer to both drugs and biologicals. The
ASP methodology applies to most drugs
furnished incident to a physician’s
service, drugs furnished under the
durable medical equipment (DME)
benefit, certain oral anti-cancer drugs,
and oral immunosuppressive drugs.
Sections 1847A and 1927(b) of the Act
specify quarterly ASP data reporting
requirements for manufacturers.
Specific ASP reporting requirements are
set forth in section 1927(b) of the Act.
Although delays in reporting have been
uncommon, they create a risk that:
(1) Could result in the publication of
payment limits which do not reflect
prices for drug products, and (2) could
result in inaccurate payments, the need
for correction of files and unintentional
ASP payment limit variability.
As a result of these concerns, we are
seeking to establish a process for
addressing situations where
manufacturers fail to report
manufacturer ASP data in a timely
fashion. This proposal is intended to
allow us to calculate and report ASP
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
payment limits for a given quarter
within the existing timelines and does
not affect the CMS or OIG’s authority to
assess civil monetary penalties
associated with untimely or false ASP
reporting. Manufacturers who
misrepresent or fail to report
manufacturer ASP data will remain
subject to civil monetary penalties, as
applicable and described in sections
1847A and 1927(b) of the Act.
For the purposes of reporting under
section 1847A of the Act, the term
manufacturer is defined in section
1927(k)(5) of the Act and means any
entity engaged in the following:
production, preparation, propagation,
compounding, conversion or processing
of prescription drug product, either
directly or indirectly by extraction from
substances of natural origin, or
independently by means of chemical
synthesis, or by a combination of
extraction and chemical synthesis; or
packaging, repackaging, labeling,
relabeling, or distribution of
prescription drug products. The term
manufacturer does not include a
wholesale distributor of drugs or a retail
pharmacy licensed under State law.
However, manufacturers that also
engage in certain wholesaler activities
are required to report ASP data for those
drugs that they manufacture. Note that
the definition of manufacturers for the
purposes of ASP data reporting includes
repackagers.
In accordance with section 1847A of
the Act, manufacturers are required to
report data on the NDC level, which
include the following elements: the
manufacturer ASP for drugs; the
Wholesale Acquisition Cost (WAC) in
effect on the last day of the reporting
period; the number of ASP units sold;
and the NDC. Currently, when
manufacturer ASP data or specific data
elements are not available, we calculate
an ASP price for a billing code based on
other applicable and available pricing
data from manufacturers for that drug.
This includes WAC prices from
compendia if manufacturer data are not
available for a billing code. WAC prices
tend to be higher than manufacturer
ASP prices.
Although problems with reporting
have been uncommon, we have recently
encountered situations where delays in
manufacturer ASP reporting could have
led to significant ASP payment limit
fluctuations for highly utilized HCPCS
codes. The greatest potential impact
occurs when data for high volume drug
products within a HCPCS code that is
represented by a limited number of
NDCs have not been reported and
cannot be included in the ASP volume
weighted calculations described in
PO 00000
Frm 00115
Fmt 4701
Sfmt 4702
40153
section 1847A(b) of the Act. For
multisource drugs, such a situation is
likely to artificially increase or decrease
Medicare ASP payment limits, which in
turn would affect beneficiary cost
sharing amounts. Such artificial
fluctuations of the ASP payment limit
could provide the appearance of
instability unrelated to market forces
and could also create access issues for
providers and beneficiaries and
confusion that could ultimately affect
product demand in the marketplace.
In order to minimize the possibility of
ASP payment limit fluctuations due to
missing data, we are proposing a
process, consistent with our authority in
section 1847A(c)(5)(B), to update ASPs,
based on the manufacturer’s ASP
calculated for the most recent quarter
for which data is available. Specifically,
we are proposing to carry over the
previously reported manufacturer ASP
for an NDC(s) when missing
manufacturer ASP and/or WAC data
could cause significant changes or
fluctuations in ASP payment limits, and
efforts by us to obtain manufacturer
reported ASP before Medicare ASP
payment limits publication deadlines
have not been successful. For example,
the most recently reported manufacturer
ASP prices for products on the market
would be carried over to the next
quarter if an entire manufacturer’s
submission was not received,
manufacturer ASP price data for specific
NDCs has not been reported, or only
WAC data has been reported; however,
NDCs that have zero sales or are no
longer being manufactured will not be
subjected to this process. Also, we are
proposing to apply the carryover
process only in cases where missing
data results in a 10 percent or greater
change in the ASP payment limit
compared to the previous quarter. Based
on experience with ASP methodology
since 2006, we believe that this
percentage threshold meets the
definition of significant. We are
specifically seeking comments on our
use of 10 percent as the threshold
amount. In order to better represent
actual market trends, that is actual
increases or decreases in manufacturer
reported ASP for the group of NDCs that
represent the HCPCS code, we are
proposing that the manufacturer ASP
payment amounts for the individual
NDCs that are carried over will be
adjusted by the weighted average of the
change in the manufacturer ASP for the
NDCs that were reported during both
the most recently available quarter and
the current quarter. We would
appreciate comments about whether
other methods to account for
E:\FR\FM\13JYP2.SGM
13JYP2
40154
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
marketplace price trends to the carried
over NDCs could be a better substitute
for applying the weighted average
change. The previous quarter’s sales
volumes will be carried over. An
example of the proposed process
appears in Table 44.
We propose to apply this process to
both single source drugs and multiple
source drugs. However, we are
concerned that including single source
drugs in the carry over process could
create an incentive for non-reporting in
situations where ASP prices for a single
source drug are falling and the
manufacturer stops reporting ASP in an
effort to preserve a higher payment
amount despite the risk of significant
statutory penalties for such an action.
Therefore, we are specifically requesting
comments on this option and the effect
of limiting this proposal to multiple
source drugs only. We will consider
these comments carefully before
including both single source and
multisource drugs in this process.
TABLE 44—PROPOSED ASP CARRYOVER EXAMPLE FOR NDCS IN A SPECIFIC HCPCS CODE
Previous
Qtr reported volume
Previous quarter reported NDCs
Previous
Qtr ASP
price
Current Qtr
reported
NDCs
Current Qtr
reported
volume
12345–6789–10 ........................................................
2000
$1.000
12345–6789–11 ........................................................
3000
1.000
12345–6789–12 ........................................................
5000
1.000
45678–1234–90 ........................................................
9000
1.100
12345–6789–
10
12345–6789–
11
12345–6789–
12
(**)
45678–1234–99 ........................................................
27000
1.100
(**)
Current Qtr
ASP price
Current Qtr
NDCs for calculation
Current Qtr
volume for
calculation
Current Qtr
price for
calculation
2500
$0.980
2500
$0.980
1700
0.980
1700
0.980
5500
0.980
5500
0.980
(**)
(**)
9000
* 1.078
(**)
(**)
12345–6789–
10
12345–6789–
11
12345–6789–
12
45678–1234–
90
45678–1234–
99
27000
* 1.078
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
* This result is obtained by calculating the weighted average price change in NDCs available (that is, 12345–6789–10 thru 12345–6789–12) in both the previous
and current quarters, which is ¥2% [(0.98–1.00)*100], and applying that change to the previous quarter’s manufacturer ASP for the missing NDCs (that is, 45678–
1234–90 and 45678–1234–99). The last two columns on the right would be used to calculate the weighted ASP and payment limits for the 5 NDCs as a HCPCS code
and accounts for missing prices for two high volume NDCs that represent most of the units sold within the HCPCS code and therefore heavily influence the price calculation for the HCPCS code.
** Missing.
Our proposed approach is intended to
establish a straightforward and
transparent solution that minimizes the
effect of missing manufacturer ASP data
on Medicare ASP payment limits. We
believe that the availability of a
mechanism to minimize non-market
related price fluctuations is desirable
when efforts to obtain manufacturer’s
ASP data by deadlines have not been
successful. Our proposed mechanism is
not intended to alter or adjust reported
prices and will not be used to do so, but
instead is intended to more accurately
represent prices in the marketplace if
manufacturer ASP data for particular
drug product(s) is missing. Based on our
experience with ASP reporting since
2004, we do not believe that this process
will be used frequently. However, as we
stated previously, recent concerns with
delays in reporting of manufacturer ASP
data have led to this proposal.
We also remind manufacturers that
significant civil monetary penalties for
not reporting or misrepresenting
manufacturer ASP data are authorized
under sections 1847A(d)(4) and
1927(b)(3)(C) of the Act and codified in
regulations at § 414.806. This proposal
should not be interpreted to mean that
CMS and the OIG will refrain from
collecting such penalties for ASP
reporting violations. Late or missing
reports will not be tolerated. This
proposed policy would be implemented
regardless of any efforts by the OIG to
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
enforce Civil Monetary Penalties for
non-reporting.
We would also like to remind
manufacturers that additional specific
information about reporting ASP data to
us is available. (See for example.: 69 FR
17936, 69 FR 66299, 70 FR 70215, 71 FR
69665, 72 FR 66256, 73 FR 69751, and
74 FR 61904.) Also, Frequently Asked
Questions are posted in the Related
Links Inside CMS Section of the ASP
Overview Web page at https://
www.cms.hhs.gov/
McrPartBDrugAvgSalesPrice/
01_overview.asp#TopOfPage, and the
Downloads section of the same webpage
contains a link to the ASP Data Form
(addendum A), which includes
examples of how ASP data must be
reported and formatted for submission.
In particular, we would like to remind
manufacturers to report sales volume in
quantities of NDC units sold (not vials
or other units of sale), and to use a zero
(that is the character ‘‘0’’) instead of a
blank when reporting items that did not
have any sales in a particular quarter. In
addition, manufacturers should report
both the ASP and the WAC for each
NDC, the expiration date for the last lot
sold, if applicable, and the date of first
sale for an NDC.
In summary, in situations where any
current quarter’s manufacturer ASP data
is unavailable, we are proposing,
consistent with our authority in section
1847A(c)(5)(B), to use the most recent
data available in the ASP payment limit
calculation for single source and
PO 00000
Frm 00116
Fmt 4701
Sfmt 4702
multiple source drugs. We look forward
to comments on this proposal and the
proposed changes to § 414.904(i).
2. Partial Quarter ASP Data
Section 1847A(c)(4) of the Act states
that ‘‘In the case of a drug or biological
during an initial period (not to exceed
a full calendar quarter) in which data on
the prices for sales for the drug or
biological is not sufficiently available
from the manufacturer to compute an
average sales price for the drug or
biological, the Secretary may determine
the amount payable under this section
for the drug or biological based on—(A)
the wholesale acquisition cost; or
(B) the methodologies in effect under
this part on November 1, 2003, to
determine payment amounts for drugs
or biological.’’
When a new drug product enters the
market, the first date of sale rarely
coincides with the beginning of a
calendar quarter. Therefore, the ASP
data for many new drug products falls
into partial quarter status during the
first quarter of sales. We are taking this
opportunity to describe our policy
regarding how reported data is used in
the calculation of ASP payment limits
during the first quarter of sales for single
source and multiple source drugs.
In accordance with section
1847A(c)(4)(A) of the Act, it has been
our policy to price new single source
drugs at WAC for the first quarter
(unless the date of first sale is on the
first day of the quarter), and to add new
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
NDCs for multi source drugs and
product line expansions of single source
drugs to the ASP calculation for a
quarter as soon as these products are
reported.
We believe that the approaches for
both single source and multi source
drugs are consistent with the statute,
particularly section 1847A(c)(4) of the
Act, and we intend to continue this
policy.
3. Determining the Payment Amount for
Drugs and Biological Which Include
Intentional Overfill
The methodology for developing
Medicare drug payment allowances
based on the manufacturers’ submitted
ASP data is specified in 42 CFR part
414, subpart K. We initially established
this regulatory text in the CY 2005 PFS
final rule with comment period (69 FR
66424). We further described the
formula we use to calculate the payment
amount for each HCPCS billing code in
the CY 2006 PFS proposed rule (70 FR
45844) and final rule with comment
period (70 FR 70217). With the
enactment of the Medicare, Medicaid
and SCHIP Extension Act (MMSEA)
(Pub. L. 110–173), the formula we use
changed beginning April 1, 2008.
Section 112(a) of the MMSEA requires
us to calculate payment amounts using
a specified volume-weighting
methodology. In addition, section 112(b)
of the MMSEA sets forth a special rule
for determining the payment amount for
certain drugs and biological. We
addressed these changes in the CY 2009
PFS proposed and final rules (73 FR
38520 and 69571, respectively). For
each billing code, we calculate a
volume-weighted, ASP-based payment
amount using the ASP data submitted
by manufacturers. Manufacturers submit
ASP data to us at the 11-digit National
Drug Code (NDC) level, including the
number of units of the 11-digit NDC
sold and the ASP for those units. We
determine the number of billing units in
an NDC based on the amount of drug in
the package.
For example: A manufacturer sells a
box of 4 vials of a drug. Each vial
contains 20 milligrams (mg); the billing
code is per 10 MG. The number of
billing units in this NDC for this billing
code is (4 vials × 20mg)/10mg = 8
billable units.
Beginning April 1, 2008, we use a
two-step formula to calculate the
payment amount for each billing code.
We sum the product of the
manufacturer’s ASP and the number of
units of the 11-digit NDC sold for each
NDC assigned to the billing and
payment code, and then divide this total
by the sum of the product of the number
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
of units of the 11-digit NDC sold and the
number of billing units in that NDC for
each NDC assigned to the billing and
payment code.
The provisions in section 112 of the
MMSEA were self-implementing for
services on and after April 1, 2008.
Because of the limited time between
enactment and the implementation date,
it was not practical to undertake and
complete rulemaking on this issue prior
to implementing the required changes.
As a result of the legislation, we revised
§ 414.904 to codify the changes to the
determination of payment amounts
consistent with section 112 of the
MMSEA.
Since that time, we have become
aware of situations where
manufacturers, by design, include a
small amount of ‘‘intentional overfill’’ in
containers of drugs. We understand that
this ‘‘intentional overfill’’ is intended to
compensate for loss of product when a
dose is prepared and administered
properly. For instance, a hypothetical
drug is intended to be delivered at a 0.5
mg dose which must be drawn into a
syringe from a vial labeled for single use
only. The vial is labeled to contain 0.5
mg of product but actually contains 1.5
mg of product. The additional 1.0 mg of
product is included, by design, and is
intended to be available to the provider
so as to ensure a full 0.5 mg dose is
administered to the patient.
Our ASP payment calculations are
based on data reported to us by
manufacturers. This data includes the
‘‘volume per item.’’ In our ‘‘Appendix
A—Average Sales Price Reporting Data
Elements’’ available on our Web site at
https://www.cms.gov/
McrPartBDrugAvgSalesPrice/, we define
‘‘volume per item’’ as ‘‘The amount in
one item. (ex., 10 ml in one vial, or 500
tablets in one bottle) Enter ‘‘1’’ for
certain forms of drugs (for example,
powders and sheets) when ‘‘Strength of
the Product’’ indicates the amount of the
product per item.’’ In order to accurately
calculate Medicare ASP payment limits
under section 1847A, we interpret ‘‘the
amount in one item’’ to be the amount
of product in the vial or other container
as indicated on the FDA-approved label.
It has been longstanding Medicare
policy that in order to meet the general
requirements for coverage under the
‘‘incident to’’ provision, services or
supplies should represent an expense
incurred by the physician or entity
billing for the services or supplies (See
Medicare Benefit Policy Manual
(Publication #100–02), Chapter 15,
Sections 50.3, 60.1.A). Such physicians’
services and supplies include drugs and
biological under section 1861(s)(2)(A).
In accordance with this policy,
PO 00000
Frm 00117
Fmt 4701
Sfmt 4702
40155
providers may only bill for the amount
of drug product actually purchased and
that the cost of the product must
represent an expense to the physician.
We further understand that when a
provider purchases a vial or container of
product, the provider is purchasing an
amount of drug defined by the product
packaging or label. Any excess, free
product (that is, overfill) is provided
without charge to the provider. In
accordance with our policy, providers
may not bill Medicare for overfill
harvested from containers, including
overfill amounts pooled from more than
one container, because that overfill does
not represent a cost to the provider.
Claims for drugs and biological that do
not represent a cost to the provider are
not reimbursable, and providers who
submit such claims may be subject to
scrutiny and follow up action by CMS,
its contractors, and OIG.
Because such overfill is not included
in the calculation of payment limits
under the methodology in section
1847A of the Act and does not represent
an incurred cost to a provider, we are
proposing to update our regulations at
42 CFR part 414 subpart J to clearly state
that Medicare ASP payment limits are
based on the amount of product in the
vial or container as reflected on the
FDA-approved label. We are also
proposing to update our regulations to
clearly state that payment for amounts
of free product, or product in excess of
the amount reflected on the FDAapproved label, will not be made under
Medicare.
4. WAMP/AMP
Section 1847A(d)(1) of the Act states
that ‘‘the Inspector General of HHS shall
conduct studies, which may include
surveys to determine the widely
available market prices (WAMP) of
drugs and biologicals to which this
section applies, as the Inspector
General, in consultation with the
Secretary, determines to be
appropriate.’’ Section 1847A (d)(2) of the
Act states that, ‘‘Based upon such
studies and other data for drugs and
biologicals, the Inspector General shall
compare the ASP under this section for
drugs and biologicals with—
• The widely available market price
(WAMP) for these drugs and biologicals
(if any); and
• The average manufacturer price
(AMP) (as determined under section
1927(k)(1) of the Act) for such drugs and
biologicals.’’
Section 1847A(d)(3)(A) of the Act
states that, ‘‘The Secretary may disregard
the ASP for a drug or biological that
exceeds the WAMP or the AMP for such
drug or biological by the applicable
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40156
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
threshold percentage (as defined in
subparagraph (B)).’’ Section
1847A(d)(3)(C) of the Act states that if
the OIG finds that the ASP for a drug or
biological is found to have exceeded the
WAMP or AMP by this threshold
percentage, the OIG ‘‘shall inform the
Secretary (at such times as the Secretary
may specify to carry out this
subparagraph) and the Secretary shall,
effective as of the next quarter,
substitute for the amount of payment
otherwise determined under this section
for such drug or biological, the lesser
of—(i) the widely available market price
for the drug or biological (if any); or (ii)
103 percent of the average manufacturer
price * * *.’’
The applicable threshold percentage
is specified in section 1847A(d)(3)(B)(i)
of the Act as 5 percent for CY 2005. For
CY 2006 and subsequent years, section
1847A(d)(3)(B)(ii) of the Act establishes
that the applicable threshold percentage
is ‘‘the percentage applied under this
subparagraph subject to such
adjustment as the Secretary may specify
for the WAMP or the AMP, or both.’’ In
the CY 2006 (70 FR 70222), CY 2007 (71
FR 69680), CY 2008 (72 FR 66258), CY
2009 (73 FR 69752), and CY 2010 (74 FR
61904) PFS final rules with comment
period, we specified an applicable
threshold percentage of 5 percent for
both the WAMP and AMP. We based
this decision on the fact that data was
too limited to support an adjustment to
the current applicable threshold
percentage.
For CY 2011, we are proposing to
specify two separate adjustments to the
applicable threshold percentages. When
making comparisons to the WAMP, we
propose the applicable threshold
percentage to remain at 5 percent. The
applicable threshold percentage for the
AMP is addressed below in this section
of the preamble. Although the latest
WAMP comparison was published in
2008, the OIG is continuing to perform
studies comparing ASP to WAMP.
Based on available OIG reports that have
been published comparing WAMP to
ASP, we do not have sufficient
information to determine that the 5
percent threshold percentage is
inappropriate. As a result, we believe
that continuing the 5 percent applicable
threshold percentage for the WAMP is
appropriate for CY 2011. Therefore we
are proposing to revise § 414.904(d)(3)
to include the CY 2011 date.
As we noted in the CY 2010 PFS final
rule with comment period (74 FR
61904), we understand that there are
complicated operational issues
associated with this policy. We continue
to proceed cautiously in this area. We
remain committed to providing
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
stakeholders, including providers and
manufacturers of drugs impacted by
potential price substitutions with
adequate notice of our intentions
regarding such, including the
opportunity to provide input with
regard to the processes for substituting
the WAMP for the ASP.
We welcome comments on our
proposal to continue the applicable
threshold percentage at 5 percent for the
WAMP for 2011.
5. AMP Threshold and Price
Substitutions
a. AMP Threshold
As mentioned elsewhere in this
proposal, when making comparisons of
ASP to AMP, the applicable threshold
percentage for CY 2005 was specified in
statute as 5 percent. Section 1847A(d)(3)
of the Act allows the Secretary to
specify adjustments to this threshold
percentage for years subsequent to 2005,
and to specify the timing for any price
substitution. For CY 2006 (70 FR
70222), CY 2007 (71 FR 69680), CY 2008
(72 FR 66258), CY 2009 (73 FR 69752),
and CY 2010 (74 FR 61904), the
Secretary made no adjustments to the
threshold percentage; it remained at 5
percent.
For CY 2011, we are proposing with
respect to AMP substitution to apply the
applicable percentage subject to certain
adjustment such that comparisons of
ASP to AMP will only be made when
the ASP exceeds the AMP by 5 percent
in two consecutive quarters
immediately prior to the current pricing
quarter, or three of the previous four
quarters immediately prior to the
current quarter.
In general, the ASP methodology
reflects average market prices for Part B
drugs for a quarter. The ASP is based,
in part, on the average sales price to all
purchasers for a calendar quarter; the
AMP, in turn, represents the average
price paid by certain wholesalers.
Accordingly, while the ASP payment
amount for a billing code may exceed its
AMP for that billing code for any given
quarter, this may only reflect a
temporary fluctuation in market prices
that would be otherwise corrected in a
subsequent quarter. We believe this
fluctuation is demonstrated by how few
billing codes exceed the applicable
threshold percentage over multiple
quarters. For example, in the Inspector
General’s report ‘‘Comparison of
Average Sales Prices and Average
manufacturer Prices: An Overview of
2008’’, only 33 of 482 examined billing
codes exceeded the applicable threshold
percentage over multiple quarters. This
figure also included billing codes that
PO 00000
Frm 00118
Fmt 4701
Sfmt 4702
exceeded the threshold based on partial
price comparisons (OEI–03–09–00350).
We are concerned that comparisons of a
single quarter’s ASP to AMP will not
adequately account for these temporary
fluctuations and underlying market
trends. We believe that applying this
threshold percentage adjusted to reflect
data from multiple quarters will account
for continuing differences between ASP
and AMP, and allow us to better
identify those drugs that consistently
trigger the substitution threshold.
We further propose to apply the
applicable AMP threshold percentage
only for those situations where AMP
and ASP comparisons are based on the
same set of NDCs for a billing code (that
is, ‘‘complete’’ AMP data). Prior to 2008,
the OIG calculated a volume-weighted
AMP and made ASP and AMP
comparisons for only billing codes with
such ‘‘complete’’ AMP data. In such
comparisons, a volume-weighted AMP
for a billing code was calculated when
NDC-level AMP data was available for
the same NDCs used by us to calculate
the volume-weighted ASP. Beginning in
the first quarter of 2008, the OIG also
began to make ASP and AMP
comparisons based on ‘‘partial’’ AMP
data (that is, AMP data for some, but not
all NDCs in a billing code). For these
comparisons, the volume-weighted
AMP for a billing code is calculated
even when only such limited AMP data
is available. That is, the volumeweighted AMP calculated by the
Inspector General is based on fewer
NDCs than the volume-weighted ASP
calculated by CMS. Moreover, volumeweighted ASPs are not adjusted by the
Inspector General to reflect the fewer
number of NDCs in the volumeweighted AMP.
Because the OIG’s partial AMP data
comparison does not reflect all the
NDCs used in our volume-weighted ASP
calculations, we have some concerns
using the volume-weighted AMP. We
believe that such AMP data may not
adequately account for market-related
drug price changes and may lead to the
substitution of incomplete and
inaccurate volume-weighted prices.
Such substitutions may impact
physician and beneficiary access to
drugs. Therefore, in accordance with
our authority as set forth in section
1847A(d)(1) and (3) of the Act, we are
proposing the substitution of 103
percent of AMP for 106 percent of ASP
should be limited to only those drugs
with ASP and AMP comparisons based
on the same set of NDCs. We are
proposing to revise § 414.904(d)(3) to
reflect corresponding regulatory text
changes, and we welcome comments on
all aspects of this proposal.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
b. AMP Price Substitution
(1) Inspector General Studies
Section 1847A(d) of the Act requires
the Inspector General to conduct studies
of the widely available market price for
drugs and biological to which section
1847A of the Act applies. However, it
does not specify the frequency of when
such studies should be conducted. The
Inspector General has conducted studies
comparing AMP to ASP for essentially
each quarter since the ASP system has
been implemented. Since 2005, the OIG
40157
has published 18 reports pertaining to
the price substitution issue (see Table
45), of which 16 have identified billing
codes with volume-weighted ASPs that
have exceeded their volume-weighted
AMPs by the applicable threshold
percentage.
TABLE 45—PUBLISHED OIG REPORTS ON PRICE SUBSTITUTIONS
Date
Report title
7/2008 ...............
6/2006 ...............
4/2010 ...............
A Comparison of Average Sales Price to Widely Available Market Prices for Inhalation Drugs (OEI–03–07–00190).
A Comparison of Average Sales Price to Widely Available Market Prices: Fourth Quarter 2005 (OEI–03–05–00430).
Comparison of Third-Quarter 2009 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2010 (OEI–03–10–00150).
Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2008 (OEI–03–09–00350).
Comparison of Second-Quarter 2009 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2009 (OEI–03–09–00640).
Comparison of First-Quarter 2009 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2009 (OEI–03–09–00490).
Comparison of Fourth-Quarter 2008 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2009 (OEI–03–09–00340).
Comparison of Third-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2009 (OEI–03–09–00150).
Comparison of Second-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2008 (OEI–03–09–00050).
Comparison of First-Quarter 2008 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2008 (OEI–03–08–00530).
Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2007 (OEI–03–08–00450).
Comparison of Fourth-Quarter 2007 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2008 (OEI–03–08–00340).
Comparison of Third-Quarter 2007 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2008 (OEI–03–08–00130).
Comparison of Second-Quarter 2007 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2007 (OEI–03–08–00010).
Comparison of First-Quarter 2007 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2007 (OEI–03–07–00530).
Comparison of Third-Quarter 2006 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2007 (OEI–03–07–00140).
Comparison of Fourth-Quarter 2005 Average Sales Price and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2006 (OEI–03–06–00370).
Monitoring Medicare Part B Drug Prices: A Comparison of Average Sales Price to Average Manufacturer Prices (OEI–03–04–
00430).
2/2010 ...............
1/2010 ...............
8/2009 ...............
8/2009 ...............
4/2009 ...............
2/2009 ...............
12/2008 .............
12/2008 .............
8/2008 ...............
5/2008 ...............
12/2007 .............
9/2007 ...............
7/2007 ...............
7/2006 ...............
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
4/2006 ...............
For example, in their latest report
comparing AMP to ASP entitled
‘‘Comparison of Third-Quarter 2009
Average Sales Price and Average
Manufacturer Prices: Impact on
Medicare Reimbursement for First
Quarter 2010’’ (OEI–03–10–00150), the
Inspector General found that of 356
billing codes with complete AMP data
in the third quarter of 2009, 16 met the
5 percent threshold, that is, ASP
exceeded AMP by at least 5 percent.
Eight of these 16 billing codes were also
eligible for price adjustments in one or
more of the previous four quarters, with
three drugs meeting the 5-percent
threshold in all five quarters under
review. This Inspector General report
further indicates that, ‘‘If reimbursement
amounts for all 16 drugs had been based
on 103 percent of the AMPs, we
estimate that Medicare expenditures
would have been reduced by over half
a million dollars in the first quarter of
2010.’’ These drugs and the savings
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
found by the Inspector General
constitute potential savings for the
Medicare program and beneficiaries.
(2) Regulatory, Judicial, and Legislative
Changes
Since 2005, regulatory and legislative
changes, as well as litigation, have had
a direct impact on this price
substitution issue. In 2007, we
published a final rule that, in
accordance with section 6001(c) of the
Deficit Reduction Act, was designed to
clarify the definition of AMP (72 FR
39142). On December 19, 2007, the
United States District Court for the
District of Columbia issued a
preliminary injunction in National
Association of Chain Drug Stores et al.
v. Health and Human Services, Civil
Action No. 1:07-cv-02017(RCL) that
enjoins CMS, in part, from posting any
AMP data on a public Web site or
otherwise disclosing any AMP data to
certain individuals or entities,
including, but not limited to, States or
PO 00000
Frm 00119
Fmt 4701
Sfmt 4702
their representatives. (For additional
information on this injunction, please
see our Web site at https://
www.cms.hhs.gov/DeficitReductionAct/
Downloads/AMPPIOrder.pdf).
In 2010, section 2503 of ACA
amended the definition of AMP, in part,
to reflect the average price paid for
covered outpatient drugs: (1) By
wholesalers for drugs distributed to
retail community pharmacies; and (2) by
retail community pharmacies that
purchase drugs directly from the
manufacturer. The statute defines retail
community pharmacies, in part, as
independent, chain, and supermarket
pharmacies.
(3) Proposal
Overall, we are cognizant that any
policy must reflect market-related
pricing changes. Additionally, we
continue to recognize the need, in light
of the statute, to implement a price
substitution policy.
E:\FR\FM\13JYP2.SGM
13JYP2
40158
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
As discussed previously, section
1847A(d)(3) of the Act provides
authority for us to determine the
applicable percentage subject to ‘‘such
adjustment as the Secretary may specify
for the widely available market price or
the average manufacturer price, or
both.’’ We also have authority to specify
the timing of any ASP substitution.
Consistent with this authority, we are
proposing a policy to substitute 103
percent of AMP for 106 percent of ASP
where the applicable percentage has
been satisfied for a number of calendar
quarters, as discussed elsewhere in this
rule. This policy would apply to both
single source and multiple source drugs
and biologicals as defined respectively
at section 1847A(c)(6)(C) and (D) of the
Act.
We acknowledge the limitation of the
preliminary injunction on our ability to
publicly disclose AMP data and until
that injunction is modified, we will not
implement this price substitution
policy.
Because of the lack of data regarding
WAMP to ASP comparisons, we are
explicitly excluding WAMP from this
price substitution proposal though we
are proposing to maintain the WAMP
threshold at 5 percent for CY 2011 in a
separate section of this rule. Overall, we
are interested in implementing a price
substitution policy that reflects marketrelated pricing changes and which
focuses on those drugs that consistently
exceed the price substitution threshold
over multiple quarters. Unlike the OIG’s
AMP studies, the published WAMP
studies have recommended price
substitutions based on specific
timeframes that do not illustrate
whether such pricing discrepancies are
singular or consistent across multiple
quarters. We will reconsider proposing
a policy for the substitution of WAMP
at a later date.
(4) Timeframe for and Duration of Price
Substitutions
As stated in § 414.804(a)(5), a
manufacturer’s average sales price must
be submitted to CMS within 30 days of
the close of the quarter. We then
calculate an ASP for each billing code
as per the process outlined at § 414.904.
Then, as per our CY 2005 PFS final rule
(69 FR 66300), we implement these new
prices through program instructions or
otherwise at the first opportunity after
we receive the data, which is the
calendar quarter after receipt.
Section 1847A(d)(3)(C) of the Act
indicates that a price substitution would
be implemented ‘‘effective as of the next
quarter’’ after the OIG has informed us
that the ASP for a drug or biological
exceeds its AMP by the applicable
percentage threshold. The OIG does not
receive new ASP prices for a given
quarter until after we have finalized
them. Also, the results of their pricing
comparisons are not available until after
the ASP prices for a given quarter have
gone into effect. Therefore, we
anticipate that there will be a three
quarter lag for substituted prices from
the quarter in which manufacturer sales
occurred, though this will depend in
great part upon the timeframe in which
we obtain comparison data from the
OIG. Table 46 provides an example of
this timeframe.
TABLE 46—EXAMPLE PRICE SUBSTITUTION TIMEFRAME
Q2–10
Q3–10
Q4–10
CMS publishes Q4–10 payment
limits.
Manufacturer
sells drug.
.............................
...........................
Manufacturer submits Q2–10
pricing data. CMS calculates
ASP payment limits for Q4–10.
......................................................
OIG Process .......
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
ASP Process .......
...........................
......................................................
Given this lag in time, the ASP price
for a billing code may have decreased
since the OIG’s comparison. Therefore,
consistent with our authorities in
section 1847A(d)(3) of the Act and our
desire to provide accurate payments
consistent with these provisions, we
believe that the timing of any
substitution policy should permit a final
comparison between the OIG’s volumeweighted 103 percent AMP for a billing
code (calculated from the prior quarter’s
data) and the billing code’s volumeweighted 106 percent ASP, as calculated
by CMS, for the current quarter. This
final comparison would assure the
Secretary that the 106 percent ASP
payment limit continues to exceed 103
percent of the OIG’s calculated AMP in
order to avoid a situation in which the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
CMS calculates ASP payment
limits for Q1–11. Compares
calculated payment limits to
OIG substitute prices. Publishes Q1–11 prices that may
include OIG substitute prices.
OIG receives Q4–10 pricing from
CMS and compares it to Q2–
10 volume-weighted AMP data.
Notifies
CMS
of
eligible
HCPCS for substitution.
Secretary would inadvertently raise the
Medicare payment limit through this
price substitution policy. We
specifically request comments on this
proposal.
ASP payment limits are calculated on
a quarterly basis as per section
1847A(c)(5)(A) of the Act, and we are
particularly mindful that the ASP-based
payment allowance for a billing code
may change from quarter to quarter. As
such, we propose that any price
substitution would last for one quarter.
Overall, we believe that our proposal
as outlined above to substitute 103
percent of AMP for 106 percent of ASP
provides us with a viable mechanism for
generating savings for the Medicare
program and its beneficiaries since it
will allow Medicare to pay based off
lower market prices for those drugs and
PO 00000
Frm 00120
Fmt 4701
Q1–11
Sfmt 4702
biologicals that consistently exceed the
applicable threshold percentage.
Moreover, it will enable us to address a
programmatic vulnerability identified
by the OIG. We welcome comments on
all aspects of our proposal.
We are also seeking comment on other
issues related to the comparison
between ASP and AMP, such as—
• Any effect of definitional
differences between AMP and ASP,
particularly in light of the revised
definition of AMP per ACA;
• The impact of any differences in
AMP and ASP reporting by
manufacturers on price substitution
comparisons; and
• Whether and/or how general
differences and similarities between
AMP and manufacturer’s ASP would
affect comparisons between these two.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
B. Ambulance Fee Schedule Issue:
Policy for Reporting Units When Billing
for Ambulance Fractional Mileage
Under the ambulance fee schedule,
the Medicare program pays for
transportation services for Medicare
beneficiaries when other means of
transportation are contraindicated and
all other applicable medical necessity
requirements are met. Ambulance
services are classified into different
levels of ground (including water) and
air ambulance services based on the
medically necessary treatment provided
during transport. These services include
the following levels of service:
• For Ground—
++ Basic Life Support (BLS)
(emergency and nonemergency).
++ Advanced Life Support, Level 1
(ALS1) (emergency and nonemergency).
++ Advanced Life Support, Level 2
(ALS2).
++ Specialty Care Transport (SCT).
++ Paramedic ALS Intercept (PI).
• For Air—
++ Fixed Wing Air Ambulance (FW).
++ Rotary Wing Air Ambulance
(RW).
1. History of Medicare Ambulance
Services
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Statutory Coverage of Ambulance
Services
Under sections 1834(l) and 1861(s)(7)
of the Act, Medicare Part B
(Supplementary Medical Insurance)
covers and pays for ambulance services,
to the extent prescribed in regulations,
when the use of other methods of
transportation would be contraindicated
by the beneficiary’s medical condition.
The House Ways and Means Committee
and Senate Finance Committee Reports
that accompanied the 1965 Social
Security Amendments suggest that the
Congress intended that—
• The ambulance benefit cover
transportation services only if other
means of transportation are
contraindicated by the beneficiary’s
medical condition; and
• Only ambulance service to local
facilities be covered unless necessary
services are not available locally, in
which case, transportation to the nearest
facility furnishing those services is
covered (H.R. Rep. No. 213, 89th Cong.,
1st Sess. 37 and Rep. No. 404, 89th
Cong., 1st Sess. Pt 1, 43 (1965)).
The reports indicate that
transportation may also be provided
from one hospital to another, to the
beneficiary’s home, or to an extended
care facility.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
b. Medicare Regulations for Ambulance
Services
Our regulations relating to ambulance
services are set forth at 42 CFR part 410,
subpart B, and 42 CFR part 414, subpart
H. Section 410.10(i) lists ambulance
services as one of the covered medical
and other health services under
Medicare Part B. Therefore, ambulance
services are subject to basic conditions
and limitations set forth at § 410.12 and
to specific conditions and limitations as
specified in § 410.40 and § 410.41. Part
414, subpart H, describes how payment
is made for ambulance services covered
by Medicare.
2. Mileage Reporting
a. Background and Current Process for
Reporting Ambulance Mileage
Historically, the Medicare fee-forservice (FFS) claims processing system
lacked the capability to accept and
process fractional unit amounts reported
in any claim format. Therefore, the
standard for reporting units for
ambulance mileage was to bill in whole
number increments. Thus, if the total
units of service for ambulance mileage
included a fractional amount, providers
and suppliers of ambulance services
(hereafter referred to collectively as
‘‘providers and suppliers’’) were
instructed to round the fraction up to
the next whole number. Claims billed
with fractional units of service were, at
that time, returned as unprocessable as
CMS’ claims processing systems could
not accept nor adjudicate fractional unit
amounts properly.
Consequently, in Change Request (CR)
1281 (Transmittal AB–00–88, issued on
September 18, 2000), we instituted an
operational procedure requiring wholeunit reporting of mileage on ambulance
claims. Specifically, we instructed
providers and suppliers that ‘‘If mileage
is billed, the miles must be whole
numbers. If a trip has a fraction of a
mile, round up to the nearest whole
number.’’ Our instructions also stated
that ‘‘1’’ should be reported for trips
totaling less than a single mile. This was
an operational instruction based on
Medicare’s FFS system limitations and
capabilities at the time, as our claims
processing systems were not capable of
accepting and processing claims
submitted with fractional units of
service. Since then, our claims
processing system functionality has
evolved to the point where this
rounding process is no longer necessary
for most ambulance transports, as it is
now possible for our FFS systems to
capture and accurately process
fractional units on both paper and
electronic forms.
PO 00000
Frm 00121
Fmt 4701
Sfmt 4702
40159
Under our current instructions,
providers and suppliers continue to
report loaded mileage as whole-number
units on both paper and electronic
claims. Providers and suppliers utilize
the appropriate Healthcare Common
Procedure Coding System (HCPCS) code
for ambulance mileage to report the
number of miles traveled during a
Medicare-covered trip rounded up to
the nearest whole mile at a minimum of
1 unit for the purpose of determining
payment for mileage. Transmittal AB–
00–88 established a list of HCPCS codes
accepted by Medicare for the purpose of
billing mileage. Providers and suppliers
were instructed to use these specific
HCPCS codes and enter the total
number of covered miles in the ‘‘units’’
field of the claim form. For example, if
a covered trip from the point of pickup
(POP) to the Medicare-approved
destination (see § 414.40 for a list of
approved destinations) totaled 9.1
miles, the provider would enter the
appropriate HCPCS code for covered
mileage and a ‘‘10’’ in the units field.
Providers and suppliers billing for trips
totaling, for example, 0.5 covered miles,
would enter ‘‘1’’ in the units field along
with the appropriate HCPCS code for
mileage.
b. Concerns Regarding the Potential for
Inaccuracies in Reporting Units and
Associated Considerations
Often an ambulance provider will
transport a distance that is either not an
exact whole number of miles or less
than one whole mile during a covered
trip. Currently, providers and suppliers
billing for ambulance services must
round up the total billable mileage to
the nearest whole mile for trips that
include a fraction of a mile or less than
one whole mile. Under our current
instructions, a provider or supplier is
required to bill as much as .9 of a mile
more than what was actually traveled.
We have been contacted by suppliers
on several occasions with concerns
regarding our current instructions for
reporting ambulance mileage. Certain
suppliers believe that our instructions
require them to bill inaccurately. One
company in particular stated that they
routinely need to bill for trips totaling
less than 1 mile. The beneficiaries that
are being transported by this company
live in the immediate vicinity of the
facility to which they are being
transported, and therefore, the number
of loaded miles for each trip totals
approximately one half of a mile. The
company was concerned that since
Medicare requires that they enter a ‘‘1’’
in the units field of their claims for
mileage, they are being overpaid by
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40160
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Medicare for mileage based on the
service they actually provided.
However, the company’s main
concern revolved around the risk of
creating an appearance of impropriety.
Although our instructions clearly state
that providers and suppliers should, as
a matter of procedure, round up
fractional mileage amounts to the
nearest whole mile, some providers and
suppliers indicated that they wanted to
bill as accurately as possible and that
they only wanted to be paid for the
service they actually provided. We
thoroughly considered these concerns
while reevaluating the procedure for
reporting units for fractional mileage
amounts.
Our first priority in considering the
issues raised by ambulance providers
and suppliers was to ascertain the basis
for the current mileage reporting
instructions. As previously discussed,
the original instructions for reporting
fractional mileage were published in
Transmittal AB–00–88, issued on
September 18, 2000. We instructed
providers and suppliers to round
fractional mileage amounts ‘‘up to the
nearest whole mile’’ and to enter ‘‘1’’ for
fractional mileage totaling less than one
mile. This particular process had also
been in place prior to issuance of the
transmittal. The reason for the
procedure was that our claims
processing systems were not capable of
accepting and processing claims
submitted with fractional units of
service—even if the service was
commonly measured in fractional
amounts, as with ambulance mileage.
We then explored whether a change
in our procedure would be: (a)
Appropriate, (b) possible considering
our current system capabilities and
industry standards of measurement, and
(c) applicable to any service other than
ambulance mileage. As to the
appropriateness of changing the
procedure for reporting units of service
on provider claims for fractional
ambulance mileage, we believe that we
should make every effort to create and
implement policies and processes that
create the best opportunity for accuracy
in billing. It is not our intention to put
providers and suppliers in a position
where they are required to bill
inaccurately for the service they
provide. We continue to strive toward
ensuring that providers and suppliers
bill and are paid only for services
actually provided. We believe that
changing our current procedure for
reporting units of service to require
reporting of fractional mileage will help
to ensure that providers and suppliers
can submit claims that more precisely
reflect actual mileage, and are
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
reimbursed more accurately for the
services they actually provided. We
originally instituted a policy of
accepting and processing only whole
units because at that time, system
limitations prevented us from accepting
and processing fractional ambulance
mileage.
Second, we considered whether it is
currently possible for our claims
processing systems to accept and
process fractional unit amounts on both
paper and electronic claims. Upon
reevaluating our system capabilities, we
found that technological advancements
in Optical Character Recognition (OCR)
and electronic claim submission have
made it possible for our FFS systems to
capture and accurately process
fractional units on both paper and
electronic claims. We note that our
systems currently have the capability to
accept fractional units with accuracy up
to as much as one thousandth of a unit
(that is, to 3 decimal places).
We also considered whether
ambulance providers and suppliers have
the capability to measure fractional
mileage. This was an important point
because if providers and suppliers are
not able to measure mileage with any
more specificity than the nearest whole
number mile, then there would be no
need to modify the current procedure
for billing fractional mileage. In that
case, providers and suppliers would
continue to report mileage as whole
numbers since they could measure no
more accurately than that. However,
both analog and digital motor vehicle
odometers are designed to measure
mileage accurately to within a minimum
of a tenth of a mile. While we found that
some vehicle odometers measure
mileage more accurately than a tenth of
a mile, most odometers are accurate to
the nearest tenth of a mile. Additionally,
aircraft geographic positioning system
(GPS) technology provides the means to
accurately determine billable mileage to
the tenth of a mile.
Third, we considered whether a
policy of billing fractional units would
be applicable to any other service
besides ambulance mileage. The units of
service field on both the electronic and
paper claim is used to report the
quantity of services or supplies
provided to Medicare beneficiaries and
is used to report a wide range of services
and supplies including, but not limited
to: Number of office visits; anesthesia
minutes; quantity of drugs
administered; covered miles. Although
Medicare currently makes payment
based on fractional units for some
services (for example, calculation of
payment after conversion of anesthesia
time reported in minutes to time units),
PO 00000
Frm 00122
Fmt 4701
Sfmt 4702
there is currently no requirement that
providers bill fractional units on the
claim. If we were to implement a policy
of requiring reporting of fractional units
for other types of services or supplies
we would first need to evaluate whether
it is possible to do so considering
industry standards of measurement. As
previously discussed, providers and
suppliers of ambulance services have
the capability to determine fractional
mileage using standard onboard
equipment, that is, an odometer, GPS,
and/or other similar equipment used to
measure distance traveled. This would
enable us to readily implement a
fractional unit billing policy for
ambulance mileage; whereas
applicability to other areas (such as
anesthesia, drugs, etc.) would require
more analysis to determine whether a
fractional unit billing policy is feasible,
efficacious, and cost effective.
Additionally, this issue was first raised
by ambulance suppliers who were
concerned about overbilling and being
overpaid by Medicare. Therefore, we
believe it is most reasonable to first
address the area where concerns have
been raised (that is, ambulance mileage)
and consider applicability of this
procedure to other types of services and
items in the future.
Finally, and perhaps most
importantly, we considered that our
claims processing system should be
configured to process claims as
accurately as possible so as to provide
for more accurate payments and to
safeguard Medicare dollars. As
previously discussed, ambulance
providers and suppliers currently have
the capability to measure mileage
accurately to within a minimum of a
tenth of a mile using devices (for
example, odometers, GPS technology,
etc.) already equipped onboard their
vehicles. We believe that requiring
ambulance providers and suppliers to
round (and report) fractional ambulance
mileage up to the next tenth of a mile
strikes a proper balance between
ensuring that the claims processing
system adjudicates a claim as accurately
as the system will permit without
unduly burdening the ambulance
community.
Based on all of the above
considerations, we have decided that
our claims processing instructions for
submission of claims for ambulance
mileage should be revised to reflect the
current functionality of our claims
processing systems so as to maximize
the accuracy of claims payment, as
further discussed below in this section.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
c. Billing of Fractional Units for Mileage
It is both reasonable and prudent that,
in order to ensure accuracy of payment,
we facilitate and allow submission of
the most accurate information on all
Medicare ambulance claims.
Furthermore, since our claims
processing systems are currently
capable of accepting and processing
fractional units of service, we believe
that ambulance mileage should be billed
to and paid by Medicare in fractional
amounts to enhance payment accuracy.
Based on all the considerations
discussed above, we are proposing to
require that claims for mileage
submitted by ambulance providers and
suppliers for an ambulance transport
(ground and air) be billed in fractional
units, by rounding up to the nearest
tenth of a mile (with the exception
discussed below). As discussed above,
we believe that requiring ambulance
providers and suppliers to round (and
report) fractional mileage up to the next
tenth of a mile would allow us to
provide for more accurate claims
payment without unduly burdening the
ambulance community.
Therefore, we are proposing that,
effective for claims with dates of service
on and after January 1, 2011, ambulance
providers and suppliers would be
required to report mileage rounded up
to the nearest tenth of a mile for all
claims for mileage totaling up to 100
covered miles. Providers and suppliers
would submit fractional mileage using a
decimal in the appropriate place (for
example, 99.9). Since standard vehicle
mileage (analog, digital, and GPS) is or
can be calculated accurately to the
nearest tenth of a mile, we are proposing
that the mileage billed to Medicare by
ambulance providers and suppliers be
reported by rounding up to the next
tenth of a mile.
Although the electronic claim formats
can accommodate fractional mileage
when mileage is equal to or greater than
100 covered miles (for example, 100.0),
the paper claim cannot. Because the
Form CMS–1500 paper claim currently
only supports four characters (including
the decimal point) in the units field
(Item 24G), we also propose that mileage
equal to or greater than 100 covered
miles continue to be reported in whole
number miles on both paper and
electronic claims. We propose that
providers and suppliers would round
up fractional mileage to the next whole
number for mileage that exceeds 100
covered miles and report the resulting
whole number in the units’ field. We
would revise the instructions set forth
in our Claims Processing Manual to
reflect the revised procedures for
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
submitting and paying claims for
fractional ambulance.
C. Clinical Laboratory Fee Schedule:
Signature on Requisition
In the March 10, 2000 Federal
Register, we published the ‘‘Medicare
Program; Negotiated Rulemaking:
Coverage and Administrative Policies
for Clinical Diagnostic Laboratory
Services’’ proposed rule (65 FR 13082)
announcing and soliciting comments on
the results of our negotiated rulemaking
committee tasked to establish national
coverage and administrative policies for
clinical diagnostic laboratory tests
under Part B of Medicare. In our final
rule published in the November 23,
2001 Federal Register (66 FR 58788), we
explained our policy on ordering
clinical diagnostic laboratory services
and amended § 410.32 to make our
policy more explicit. Our regulation at
§ 410.32(a) states the requirement that
‘‘[a]ll diagnostic x-ray tests, diagnostic
laboratory tests, and other diagnostic
tests must be ordered by the physician
who is treating the beneficiary.’’ In the
November 23, 2001 final rule, we added
paragraph (d)(2) to § 410.32 to require
that the physician or qualified
nonphysician practitioner (NPP) (that is,
clinical nurse specialists, clinical
psychologists, clinical social workers,
nurse-midwives, nurse practitioners
(NPs), and physician assistants (PAs))
who orders the service must maintain
documentation of medical necessity in
the beneficiary’s medical record (66 FR
58809). In the preamble discussions to
the March 10, 2000 proposed rule and
November 23, 2001 final rule (65 FR
13089 and 66 FR 58802, respectively),
we noted that ‘‘[w]hile the signature of
a physician on a requisition is one way
of documenting that the treating
physician ordered the test, it is not the
only permissible way of documenting
that the test has been ordered.’’ In those
preambles, we described the policy of
not requiring physician signatures on
requisitions for clinical diagnostic
laboratory tests, but implicitly left in
place the existing requirements for a
written order to be signed by the
ordering physician or NPP for clinical
diagnostic laboratory tests, as well as
other types of diagnostic tests. We
further stated in the preambles of the
proposed and final rules that we would
publish an instruction to Medicare
contractors clarifying that the signature
of the ordering physician is not required
for Medicare purposes on a requisition
for a clinical diagnostic laboratory test
(65 FR 13089 and 66 FR 58802).
On March 5, 2002, we published a
program transmittal implementing the
administrative policies set forth in the
PO 00000
Frm 00123
Fmt 4701
Sfmt 4702
40161
final rule, including the following
instruction: ‘‘Medicare does not require
the signature of the ordering physician
on a laboratory service requisition.
While the signature of a physician on a
requisition is one way of documenting
that the treating physician ordered the
service, it is not the only permissible
way of documenting that the service has
been ordered. For example, the
physician may document the ordering of
specific services in the patient’s medical
record.’’ (Transmittal AB–02–030,
Change Request 1998, dated March 5,
2002).
On January 24, 2003, we published a
program transmittal in order to
manualize the March 5, 2002
Transmittal. (Transmittal 1787, Change
Request 2410, dated January 24, 2003).
The cover note to the transmittal states,
‘‘Section 15021, Ordering Diagnostic
Tests, manualizes Transmittal AB–02–
030, dated March 5, 2002. In accordance
with negotiated rulemaking for
outpatient clinical diagnostic laboratory
services, no signature is required for the
ordering of such services or for
physician pathology services.’’ In the
manual instructions in that transmittal
in a note, we stated: ‘‘No signature is
required on orders for clinical
diagnostic services paid on the basis of
the physician fee schedule or for
physician pathology services.’’ The
manual instructions did not explicitly
reference clinical diagnostic laboratory
tests as the cover note did. Rather, the
transmittal seemed to extend the policy
set forth in the Federal Register (that no
signature is required on requisitions for
clinical diagnostic laboratory tests paid
under the Clinical Laboratory Fee
Schedule (CLFS)) to also apply to
clinical diagnostic tests paid on the
basis of the Physician Fee Schedule
(PFS) and physician pathology services.
In addition, the manual instructions
used the term ‘‘order’’ instead of
‘‘requisition,’’ which some members of
the industry have asserted caused
confusion.
When we transitioned from paper
manuals to the current electronic
Internet Only Manual system, these
manual instructions were inadvertently
omitted from the new Benefit Policy
Manual (BPM).
In August 2008, we issued a program
transmittal (Transmittal 94, Change
Request 6100, dated August 29, 2008) to
update the BPM to incorporate language
that was previously contained in section
15021 of the Medicare Carriers Manual.
The reissued language states, ‘‘No
signature is required on orders for
clinical diagnostic tests paid on the
basis of the clinical laboratory fee
schedule, the physician fee schedule, or
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40162
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
for physician pathology services.’’ Based
on further review, we have determined
that there are no clinical diagnostic
laboratory tests paid under the PFS.
After Transmittal 94 was published, we
received numerous inquiries from
laboratory, diagnostic testing, and
hospital representatives who had
questions about whether the provision
applied to all diagnostic services,
including x-rays, MRIs, and other
nonclinical laboratory fee schedule
diagnostic services.
To resolve any existing confusion
surrounding the implementation of the
policy in 2001 and subsequent
transmittals, we restated and solicited
public comments on our policy in the
CY 2010 PFS proposed rule (74 FR
33641). Our current policy is that a
physician’s signature is not required on
a requisition for clinical diagnostic
laboratory tests paid on the basis of the
CLFS; however, it must be evident, in
accordance with our regulations at
§ 410.32(d)(2) and (3), that the physician
ordered the services.
We note that we solicited and
received comments on this signature
requirement during the notice and
comment period for the March 10, 2000
proposed rule in the context of our
proposal to add paragraph (d)(2)(i) to
§ 410.32 to require that the practitioner
who orders a diagnostic laboratory test
must maintain documentation of
medical necessity in the beneficiary’s
medical record. The majority of
comments supported the adoption of a
policy that the signature of the
practitioner on a requisition for a
clinical diagnostic laboratory test paid
under the CLFS is not the only way of
documenting that the test has been
ordered and, thus, should not be
required provided such documentation
exists in an alternate form.
This policy regarding requisitions for
clinical diagnostic laboratory tests does
not supersede other applicable Medicare
requirements (such as those related to
hospital Conditions of Participation
(CoPs)) which require the medical
record to include an order signed by the
physician who is treating the
beneficiary. Nor do we believe that
anything in our policy regarding
signatures on requisitions for clinical
diagnostic laboratory tests supersedes
other requirements mandated by
professional standards of practice or
obligations regarding orders and
medical records promulgated by
Medicare, the Joint Commission, or
State law; nor do we believe the policy
would require providers to change their
business practices.
We also restated and solicited public
comment on our long-standing policy
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
consistent with the principle in
§ 410.32(a) that a written order for
diagnostic tests including those paid
under the CLFS and those that are not
paid under the CLFS (for example, that
are paid under the PFS or under the
OPPS), such as X-rays, MRIs, and the TC
of physician pathology services, must be
signed by the ordering physician or
NPP. That is, the policy that signatures
are not required on requisitions for
clinical diagnostic laboratory tests paid
based on the CLFS applies only to
requisitions (as opposed to written
orders) (74 FR 33642).
Additionally, we solicited public
comments about the distinction between
an order and a requisition (74 FR
33642). We note that an ‘‘order’’ as
defined in our IOM, 100–02, Chapter 15,
Section 80.6.1, is a communication from
the treating physician/practitioner
requesting that a diagnostic test be
performed for a beneficiary. The order
may conditionally request an additional
diagnostic test for a particular
beneficiary if the result of the initial
diagnostic test ordered yields to a
certain value determined by the treating
physician/practitioner (for example, if
test X is negative, then perform test Y).
As set forth in the CY 2010 MPFS final
rule (FR 74 61930), an order may be
delivered via any of the following forms
of communication:
• A written document signed by the
treating physician/practitioner, which is
hand-delivered, mailed, or faxed to the
testing facility.
• A telephone call by the treating
physician/practitioner or his or her
office to the testing facility.
• An electronic mail, or other
electronic means, by the treating
physician/practitioner or his or her
office to the testing facility.
If the order is communicated via
telephone, both the treating physician/
practitioner, or his or her office, and the
testing facility must document the
telephone call in their respective copies
of the beneficiary’s medical records.
In the proposed rule (74 FR 33642),
we defined a ‘‘requisition’’ as the actual
paperwork, such as a form, which is
provided to a clinical diagnostic
laboratory that identifies the test or tests
to be performed for a patient. It may
contain patient information, ordering
physician information, referring
institution information, information
about where to send reports, billing
information, specimen information,
shipping addresses for specimens or
tissue samples, and checkboxes for test
selection. We believe it is ministerial in
nature, assisting laboratories with
billing and handling of results, and
serves as an administrative convenience
PO 00000
Frm 00124
Fmt 4701
Sfmt 4702
to providers and patients. We believe
that a written order, which may be part
of the medical record, and the
requisition are two different documents,
although a requisition that is signed
may serve as an order. We welcomed
comments from the public about the
distinction between requisitions and
orders.
During the proposed and final
rulemaking process for CY 2010, we
received numerous comments on these
issues, including, among others:
Expressions of continued confusion
over the difference between an ‘‘order’’
and a ‘‘requisition’’; requests that CMS
develop a single policy for all outpatient
laboratory services, without the
distinction for those paid under the
CLFS or the PFS; and concerns about
reference laboratory technicians who
felt compelled to perform a test in order
to protect the viability of the specimen
although they did not have the proper
documentation. See 74 FR 61930–32 for
a complete discussion of the comments
received and responses to these issues.
In the CY 2010 PFS final rule with
comment period (74 FR 61931), we
stated that, in light of the issues and
concerns raised during the comment
period, and our desire to create policy
that will address the concerns in a
meaningful, clear and thoughtful way,
we would continue to carefully consider
the issues of physician signatures on
requisitions and orders and that we plan
to revisit these issues in the future
paying particular attention to the
definitions of order and requisition.
Since the publication of the CY 2010
PFS final rule with comment period, we
have considered an approach that
would address the concerns raised. We
are proposing to require a physician’s or
NPP’s signature on requisitions for
clinical diagnostic laboratory tests paid
on the basis of the CLFS.
We believe that this policy would
result in a less confusing process. We
believe that it would be less confusing
because a physician’s signature would
then be required for all requisitions and
orders, eliminating uncertainty over
whether the documentation is a
requisition or an order, whether the type
of test being ordered requires a
signature, or which payment system
does or does not require a physician or
NPP signature. We also believe that it
would not increase the burden on
physicians because it is our
understanding that, in most instances,
physicians are annotating the patient’s
medical record with either a signature
or an initial (the ‘‘order’’), as well as
providing a signature on the paperwork
that is provided to the clinical
diagnostic laboratory that identifies the
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
test or tests to be performed for a patient
(the ‘‘requisition’’) as a matter of course.
Further, this policy would make it
easier for the reference laboratory
technicians to know whether a test is
appropriately requested, and potential
compliance problems would be
minimized for laboratories during the
course of a subsequent Medicare audit
because a signature would be
consistently required. As already
discussed, this minimizes confusion
and provides a straightforward directive
for laboratories to meet.
We welcome comments on this
proposal.
D. Discussion of Chiropractic Services
Demonstration
Section 651 of MMA requires the
Secretary to conduct a 2-year
demonstration to evaluate the feasibility
and advisability of expanding coverage
for chiropractic services under
Medicare. Medicare coverage for
chiropractic services is limited to
manual manipulation of the spine to
correct a subluxation described in
section 1861(r)(5) of the Act. The
demonstration expanded current
Medicare coverage to include ‘‘care for
neuromusculoskeletal conditions
typical among eligible beneficiaries and
diagnostic and other services that a
chiropractor is legally authorized to
perform by the State or jurisdiction in
which such treatment is provided’’ and
was conducted in four geographically
diverse sites, two rural and two urban
regions, with each type including a
Health Professional Shortage Area
(HPSA). The two urban sites were 26
counties in Illinois and Scott County,
Iowa, and 17 counties in Virginia. The
two rural sites were the States of Maine
and New Mexico. The demonstration,
which ended on March 31, 2007, was
required to be budget neutral as section
651(f)(1)(B) of MMA mandates the
Secretary to ensure that ‘‘the aggregate
payments made by the Secretary under
the Medicare program do not exceed the
amount which the Secretary would have
paid under the Medicare program if the
demonstration projects under this
section were not implemented.’’
In the CY 2006, 2007, and 2008 PFS
final rules with comment period (70 FR
70266, 71 FR 69707, 72 FR 66325,
respectively), we included a discussion
of the strategy that would be used to
assess budget neutrality (BN) and the
method for adjusting chiropractor fees
in the event the demonstration resulted
in costs higher than those that would
occur in the absence of the
demonstration. We stated BN would be
assessed by determining the change in
costs based on a pre-post comparison of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Medicare costs for beneficiaries in the
demonstration and their counterparts in
the control groups and the rate of
change for specific diagnoses that are
treated by chiropractors and physicians
in the demonstration sites and control
sites. We also stated that our analysis
would not be limited to only review of
chiropractor claims because the costs of
the expanded chiropractor services may
have an impact on other Medicare costs.
In the CY 2010 PFS final rule with
comment period (74 FR 61926), we
discussed the evaluation of this
demonstration conducted by Brandeis
University and the two sets of analyses
used to evaluate budget neutrality. In
the ‘‘All Neuromusculoskeletal
Analysis,’’ which compared the
Medicare costs of all beneficiaries who
received services for a
neuromusculoskeletal condition in the
demonstration areas with those of
beneficiaries with similar characteristics
from similar geographic areas that did
not participate in the demonstration, the
total effect of the demonstration to
Medicare was $114 million. In the
‘‘Chiropractic User Analysis,’’ which
compared the Medicare costs of
beneficiaries who used expanded
chiropractic services to treat a
neuromusculoskeletal condition in the
demonstration areas, with those of
beneficiaries with similar characteristics
who used chiropractic services as
currently covered by Medicare to treat a
neuromusculoskeletal condition from
similar geographic areas that did not
participate in the demonstration, the
total effect of the demonstration to
Medicare was $50 million.
As explained in the CY 2010 PFS final
rule, we based the BN estimate on the
‘‘Chiropractic User Analysis’’ because of
its focus on users of chiropractic
services rather than all Medicare
beneficiaries with neuromusculoskeletal
conditions, including those who did not
use chiropractic services and who
would not have become users of
chiropractic services even with
expanded coverage for them (74 FR
61926 through 61927). Users of
chiropractic services are most likely to
have been affected by the expanded
coverage provided by this
demonstration. Cost increases and
offsets, such as reductions in
hospitalizations or other types of
ambulatory care, are more likely to be
observed in this group.
As explained in the CY 2010 PFS final
rule (74 FR 61927), because the costs of
this demonstration were higher than
expected and we did not anticipate a
reduction to the PFS of greater than 2
percent per year, we finalized a policy
to recoup $50 million in expenditures
PO 00000
Frm 00125
Fmt 4701
Sfmt 4702
40163
from this demonstration over a 5-year
period, that is, CYs 2010 through 2014
(74 FR 61927). Specifically, we are
recouping $10 million for each such
year through adjustments to the
chiropractic CPT codes. Payment under
the PFS for these codes will be reduced
by approximately 2 percent. We believe
that spreading this adjustment over a
longer period of time will minimize its
potential negative impact on
chiropractic practices.
We are continuing the
implementation of the required budget
neutrality adjustment by recouping $10
million in CY 2011. Our Office of the
Actuary estimates chiropractic
expenditures in CY 2011 to be
approximately $524 million based on
actual Medicare spending for
chiropractic services for the most recent
available year. To recoup $10 million in
CY 2011, the payment amount under the
PFS for the chiropractic CPT codes (that
is, CPT codes 98940, 98941, and 98942)
will be reduced by approximately 2
percent. We are reflecting this reduction
only in the payment files used by the
Medicare contractors to process
Medicare claims rather than through
adjusting the RVUs. Avoiding an
adjustment to the RVUs would preserve
the integrity of the PFS, particularly
since many private payers also base
payment on the RVUs.
E. Provisions Related to Payment for
Renal Dialysis Services Furnished by
End-Stage Renal Disease (ESRD)
Facilities
Since August 1, 1983, payment for
dialysis services furnished by ESRD
facilities has been based on a composite
rate payment system that provides a
fixed, prospectively determined amount
per dialysis treatment, adjusted for
geographic differences in area wage
levels. The composite rate is designed to
cover a package of goods and services
needed to furnish dialysis treatments
that include, but not be limited to,
certain routinely provided drugs,
laboratory tests, supplies, and
equipment. Unless specifically included
in the composite rate, other injectable
drugs and laboratory tests medically
necessary for the care of patients on
dialysis are separately billable.
Other than periodic updates, there
were no significant changes to the
composite rate payment system until the
implementation of the basic case-mix
adjusted composite rate payment system
beginning January 1, 2005. The Congress
has enacted a number of adjustments to
the composite rate since that time. As a
result of the July 15, 2008 enactment of
MIPPA, we are required to implement
an end-stage renal disease (ESRD)
E:\FR\FM\13JYP2.SGM
13JYP2
40164
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
bundled prospective payment system
effective January 1, 2011 (referred to as
the ‘‘ESRD PPS’’). Below we briefly
discuss the ESRD PPS, the basic casemix composite payment system, as well
as our proposed updates to the
composite rate portion of the blended
payment for CY 2011.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. MIPPA—The ESRD PPS
On September 29, 2009, we published
in the Federal Register a proposed rule
entitled ‘‘End-Stage Renal Disease
Prospective Payment System’’ (74 FR
49922). In that rule, we proposed to
implement a case-mix adjusted bundled
PPS for renal dialysis services beginning
January 1, 2011, in accordance with the
statutory provisions set forth in section
153(b) of MIPPA. The ESRD PPS would
replace the current basic case-mix
adjusted composite payment system and
the methodologies for the
reimbursement of separately billable
outpatient ESRD services.
As explained in the ESRD PPS
proposed rule (74 FR 50019), section
1881(b)(14)(E)(i) of the Act requires a 4year transition (phase-in) from the
current composite payment system to
the ESRD PPS, and section
1881(b)(14)(E)(ii) of the Act allows
ESRD facilities to make a one-time
election to be excluded from the
transition. Electing to be excluded from
the 4-year transition means that the
ESRD facility receives payment for renal
dialysis services based on 100 percent of
the payment rate established under the
ESRD PPS, rather than a blended rate
under each year of the transition based
in part on the payment rate under the
current payment system and in part on
the payment rate under the ESRD PPS.
As of January 1, 2011, ESRD facilities
that elect to go through the transition
would be paid in the first year a blended
amount that will consist of 75 percent
of the basic case-mix adjusted
composite payment system and the
remaining 25 percent would be based on
the ESRD PPS payment. Thus, we must
continue to update the basic case-mix
composite payment system for purposes
of determining the composite rate
portion of the blended payment amount
during the ESRD PPS 4-year transition
(CYs 2011 through 2013.) Accordingly,
in this proposed rule, we are proposing
the composite rate portion of the blend,
which includes an update to the drug
add-on and the application of the wage
index, as well as the payment amount
for the first-year (CY 2011) of the ESRD
PPS transition. We anticipate that the
final rule for the ESRD PPS will be
published this summer.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
b. Medicare Modernization Act
(MMA)—The Basic Case-Mix Adjusted
Composite Payment System
Section 623 of the MMA amended
section 1881 of the Act to require
changes to the composite rate payment
methodology, as well as to the pricing
methodology for separately billable
drugs and biologicals furnished by
ESRD facilities. Section 1881(b)(12) of
the Act, as added by section 623(d) of
the MMA, requires the establishment of
a basic case-mix adjusted composite
payment system that includes services
comprising the composite rate and an
add-on to the composite rate component
to account for the difference between
current payments for separately billed
drugs and the revised drug pricing
specified in the statute. In addition,
section 1881(b)(12)(A) of the Act
requires that the composite rate be
adjusted for a number of patient
characteristics (case-mix) and section
1881(b)(12)(D) of the Act gives the
Secretary discretion to revise the wage
indices and the urban and rural
definitions used to develop them.
Finally, section 1881(b)(12)(E) of the Act
imposed a budget neutrality (BN)
requirement, so that aggregate payments
under the basic case-mix adjusted
composite payment system equal the
aggregate payments for the same period
if section 1881(b)(12) of the Act did not
apply.
1. CY 2005 Revisions
In the CY 2005 PFS final rule with
comment period (69 FR 66319 through
66334), we implemented section
1881(b)(12) of the Act, as added by
section 623 of the MMA, and revised
payments to ESRD facilities. These
revisions that were effective January 1,
2005, included an update of 1.6 percent
to the composite rate component of the
payment system; a drug add-on
adjustment of 8.7 percent to the
composite rate to account for the
difference between pre-MMA payments
for separately billable drugs and
payments based on revised drug pricing
for 2005 which used acquisition costs.
Also, to implement section
1881(b)(13) of the Act, we revised
payments for drugs billed separately by
independent ESRD facilities, paying for
the top 10 ESRD drugs based on
acquisition costs (as determined by the
OIG) and for other separately billed
drugs at the average sales price +6
percent (ASP+6).
In addition, effective April 1, 2005,
we implemented the case-mix
adjustments to the composite rate for
certain patient characteristics (that is,
age, low body mass index, and body
PO 00000
Frm 00126
Fmt 4701
Sfmt 4702
surface area). For further explanation of
the development of the basic case-mix
adjusted composite payment system, see
the CY 2005 PFS final rule with
comment period (69 FR 66319 through
66334).
2. CY 2006 Revisions
In the CY 2006 PFS final rule with
comment, we implemented additional
revisions to payments to ESRD facilities
required under section 623 of the MMA.
We revised the drug payment
methodology applicable to drugs
furnished by ESRD facilities. Effective
January 1, 2006, all separately billed
drugs and biologicals furnished by both
hospital-based and independent ESRD
facilities were paid based on ASP+6
percent. The drug add-on adjustment
was updated to 14.5 percent to reflect
the expected growth in expenditures for
separately billable drugs in CY 2006.
We also implemented a revised
geographic adjustment authorized by
section 1881(b)(12)(D) of the Act. This
adjustment revised the labor market
areas to incorporate the Core-Based
Statistical Area (CBSA) designations
established by the Office of Management
and Budget (OMB) by providing a 4-year
transition from the previous wageadjusted composite rates. Effective
January 1, 2006, 25 percent of the
payment was based on the revised
geographic adjustments, and the
remaining 75 percent of payment was
based on the metropolitan statistical
area-based (MSA-based) adjustments.
Other adjustments included the
elimination of the wage index ceiling,
and reducing the wage index floor to
0.8500, as well as a revised labor
portion of the composite rate to which
the geographic adjustment is applied.
In addition, section 5106 of the DRA
(Pub. L. 109–171) provided for a 1.6
percent update to the composite rate
component of the basic case-mix
adjusted composite payment system,
effective January 1, 2006. For further
explanation of the revisions to the basic
case-mix adjusted composite payment
system, see the CY 2006 PFS final rule
with comment period (70 FR 70161
through 70771).
3. CY 2007 Revisions
In the CY 2007 PFS final rule with
comment period, we implemented a
method to annually calculate the growth
update to the drug add-on adjustment
required by section 1881(b)(12) of the
Act, as well as a growth update of 0.5
percent to the drug add-on adjustment.
Also, section 103 of the MIEA–TRHCA
(Pub. L. 109–432) established a 1.6
percent update to the composite rate
portion of the payment system, effective
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
April 1, 2007. The effect of this increase
in the composite rate was a reduction in
the drug add-on adjustment to 14.9
percent, effective April 1, 2007. As a
result, the drug add-on adjustment to
the composite rate increased from 14.5
to 15.1 percent. Since we compute the
drug add-on adjustment as a percentage
of the weighted average base composite
rate, increases in the composite rate
portion of the payment reduce the drug
add-on percentage.
We provided an update to the wage
index adjustments to reflect the latest
hospital wage data, including a BN
adjustment factor. We also implemented
the second year of the transition to the
CBSA-based wage index, where 50
percent of the payment was based on
the CBSA-based geographic
adjustments, and the remaining 50
percent of payment was based on the
MSA-based adjustments. In addition, we
reduced the wage index floor 0.85 to
0.80.
For further explanation of the
development of the basic case-mix
adjusted composite payment system, see
the CY 2007 PFS final rule with
comment period (71 FR 69681 through
69688).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
4. CY 2008 Revisions
In the CY 2008 PFS final rule with
comment period (72 FR 66280), we
implemented a growth update to the
drug add-on adjustment of 0.5 percent.
As a result, the drug add-on adjustment
to the composite payment rate increased
from 14.9 percent to 15.5 percent. In
addition, we updated the wage index
adjustments to reflect the latest hospital
wage data, including a wage index BN
adjustment of 1.055473 to the wage
index for CY 2008, and finally, for CY
2008, we implemented the third year of
the transition to the CBSA-based wage
index, where 75 percent of the payment
was based on the the CBSA-based
adjustments and the remaining 25
percent of payment was based on the
MSA-based adjustments. In addition, we
reduced the wage index floor from 0.80
to 0.75.
5. CY 2009 Revisions
For CY 2009, section 153(a) of the
MIPPA updated sections 1881(b)(12)(G)
and 1881(b)(12)(A) of the Act to revise
payments to ESRD facilities effective for
services furnished on or after January 1,
2009 and January 1, 2010. The revisions
included an update of 1 percent to the
composite rate, and the establishment of
a site neutral composite rate to both
hospital-based and independent dialysis
facilities that reflects the labor share
applicable to independent dialysis
facilities (53.711). The 1 percent
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
increase to the independent dialysis
facility’s CY 2008 composite rate of
$132.49 resulted in a CY 2009 base
composite rate for hospital-based and
independent dialysis facilities of
$133.81. The one percent increase in the
composite rate portion of the payment
system effective January 1, 2009,
reduced the drug add-on adjustment
from 15.5 to 15.2 percent.
Also, we updated the wage index
adjustments to reflect the latest
available wage data, including a wage
index BN adjustment of 1.056672 to the
wage index for CY 2009. Finally, we
completed the 4-year transition to the
CBSA-based geographic adjustments
and reduced the wage index floor from
0.7500 to 0.700. For further detail,
regarding the ESRD provisions, see the
2008 PFS final rule with comment
period (73 FR 61921 through 61926).
6. CY 2010 Revisions
For CY 2010, we updated the casemix adjusted composite rate payment
system by updating the drug add-on
component of the composite rate
system, as well as the wage index values
used to adjust the labor component of
the composite rate. Specifically, to
update the drug add-on adjustment, we
conducted a trend analysis of CY 2006
through 2008, we implemented a zero
growth update to the drug add-on
adjustment to the composite rates for
2010 required by section 1881(b)(12)(F)
of the Act.
Also, section 1881(b)(12)(G)(iv) of the
Act, as added by section 153(a)(1) of the
MIPPA, increased the composite rate by
1.0 percent for ESRD services furnished
on or after January 1, 2010. The 1.0
percent increase resulted in a base
composite rate of $135.15 per treatment
and reduced the drug add-on
adjustment from 15.2 to 15.0 percent.
Lastly, we updated the wage index to
reflect the latest available wage data,
including a revised BN adjustment
factor of 1.057888. We applied a
reduction to the wage index floor from
0.700 to 0.6500.
For further detail, regarding the ESRD
provisions, see the 2009 final rule with
comment period (74 FR 33634 through
33639).
7. CY 2011 Proposals
For purposes of establishing the
composite rate portion of the blended
payments under the ESRD PPS for those
facilities electing to go through the
transition in CY 2011, CMS is proposing
the following:
• An update to the drug add-on
adjustment to the composite rate, using
a refined methodology for projecting
growth in drug expenditures; and
PO 00000
Frm 00127
Fmt 4701
Sfmt 4702
40165
• An update to the wage index
adjustment to reflect the latest available
wage data, including a revised BN
adjustment.
• A reduction in the ESRD wage
index floor from 0.6500 to 0.600.
8. The Affordable Care Act
Section 1881(b)(14)(F) of the Act, as
added by section 153(b) of MIPPA and
amended by section 3401(h) of ACA,
governs the ESRD market basket
increase factor (that is, the ESRD market
basket). As explained in the ESRD PPS
proposed rule (74 FR 4997), we
described how the ESRD Bundled
market basket would be used to update
the composite rate portion of the ESRD
payments during the PPS transition.
Ordinarily in updating the composite
payment system, we discuss any
updates to the composite rate. However,
beginning in 2011, the composite
payment would be used as part of the
blended payments during the ESRD PPS
transition. Since the publication of the
ESRD PPS proposed rule, and as
explained in the ESRD PPS final rule,
which we anticipate will be published
this summer, we interpret this provision
as requiring that the composite rate
portion of the blended payment amount
be increased in CY 2011 by the ESRD
market basket percentage increase factor
(the ‘‘ESRD market basket’’).
For purposes of this proposed rule, for
CY 2011, we anticipate an estimate of a
2.5 percent increase to the ESRD
composite rate portion of the blended
payment amount, resulting in a CY 2011
composite rate of $138.53
($135.15*1.025). This 2.5 percent
increase does not apply to the drug addon adjustment to the composite rate.
Also, we note that the drug add-on
percentage would be reduced from 15.0
to 14.7 as a result of the proposed
increase to the composite rate in CY
2011. (A detailed explanation of the
reduction to the drug add-on adjustment
is discussed below).
9. Proposed Update to the Drug Add-on
Adjustment to the Composite Rate
a. Estimating Growth in Expenditures
for Drugs and Biologicals in CY 2011
Section 1881(b)(12)(F) of the Act
specifies that the drug add-on increase
must reflect ‘‘the estimated growth in
expenditures for drugs and biologicals
(including erythropoietin) that are
separately billable * * *.’’ By referring
to ‘‘expenditures,’’ we believe the statute
contemplates that the update would
account for both increases in drug
prices, as well as increases in utilization
of those drugs.
Since we now have 4 years of drug
expenditure data based on ASP pricing,
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40166
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
we propose to continue estimating
growth in drug expenditures based on
the trends in available data. Therefore,
for CY 2011, we are proposing to use
trend analysis from drug expenditure
data to update the per treatment drug
add-on adjustment. We then removed
growth in enrollment for the same time
period from the expenditure growth so
that the residual reflects per patient
expenditure growth (which includes
price and utilization combined).
We further propose to use the per
patient growth update to the drug addon adjustment for CY 2011. To estimate
drug expenditure growth using trend
analysis, we looked at the average
annual growth in total drug
expenditures between 2006 and 2009.
First, we estimated the total drug
expenditures for all ESRD facilities in
CY 2009. For this proposed rule, we
used the final CY 2006, through CY
2008 ESRD claims data and the latest
available CY 2009 ESRD facility claims,
updated through December 31, 2009
(that is, claims with dates of service
from January 1 through December 31,
2009, that were received, processed,
paid, and passed to the National Claims
History File as of December 31, 2009).
For the CY 2011 PFS final rule, we plan
to use additional updated CY 2009
claims with dates of service for the same
timeframe. This updated CY 2009 data
file will include claims received,
processed, paid, and passed to the
National Claims History File as of June
30, 2010.
While the CY 2009 claims file used in
this proposed rule is the most current
available, we recognize that it does not
reflect a complete year, as claims with
dates of service towards the end of the
year have not all been processed. To
more accurately estimate the update to
the drug add-on, aggregate drug
expenditures are required. Based on an
analysis of the 2008 claims data, we are
proposing to inflate the CY 2009 drug
expenditures to estimate the June 30,
2010 update of the 2009 claims file. We
used the relationship between the
December 2008 and the June 2009
versions of 2008 claims to estimate the
more complete 2009 claims that will be
available in June 2010 and applied that
ratio to the 2009 claims data from the
December 2009 claims file. The net
adjustment to the CY 2009 claims data
is an increase of 12.22 percent to the
2009 expenditure data. This adjustment
allows us to more accurately compare
the 2008 and 2009 drug expenditure
data to estimate per patient growth. As
stated earlier in this section, we plan to
use additional updated CY 2009 claims
in the CY 2011 PFS final rule.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Using the full-year 2009 drug
expenditure figure, we calculated the
average annual change in drug
expenditures from 2006 through 2009.
This average annual change showed an
increase of 2.1 percent for this
timeframe. We propose to use this 2.1
percent increase to project drug
expenditures for both 2010 and 2011.
b. Estimating Per Patient Growth
Once we had the projected growth in
drug expenditures from 2010 to 2011,
which is what we believe that section
1881(b)(12)(F) of the Act requires us to
use to update the drug add-on
adjustment. To calculate the per patient
growth between CYs 2010 and 2011, we
removed the enrollment component by
using the estimated growth in
enrollment data between CY 2010 and
CY 2011. This was approximately 3.6
percent. To do this, we divided the total
drug expenditure change between 2010
and 2011 (1.021) by enrollment growth
of 3.6 percent (1.036) for the same
timeframe. The result is a per patient
growth factor equal to 0.986 (1.021/
1.036 = 0.986). Thus, we are projecting
a 1.4 percent decrease in per patient
growth in drug expenditures between
2010 and 2011.
c. Applying the Proposed Growth
Update to the Drug Add-On Adjustment
In CY 2006, we applied the projected
growth update percentage to the total
amount of drug add-on dollars
established for CY 2005 to establish a
dollar amount for the CY 2006 growth
update. In addition, we projected the
growth in dialysis treatments for CY
2006 based on the projected growth in
ESRD enrollment. We divided the
projected total dollar amount of the CY
2006 growth by the projected growth in
total dialysis treatments to develop the
per treatment growth update amount.
This growth update amount, combined
with the CY 2005 per treatment drug
add-on amount, resulted in an average
drug add-on amount per treatment of
$18.88 (or a 14.5 percent adjustment to
the composite rate) for CY 2006.
In the CY 2007 PFS final rule with
comment period (71 FR 69684), we
revised our update methodology by
applying the growth update to the per
treatment drug add-on amount. That is,
for CY 2007, we applied the growth
update factor of 4.03 percent to the
$18.88 per treatment drug add-on
amount for an updated amount of
$19.64 per treatment (71 FR 69684). For
CY 2008, the per treatment drug add-on
amount was updated to $20.33. In the
CY 2009 and 2010 PFS final rule with
comment period (73 FR 69755 through
69757 and 74 FR 61923), we applied a
PO 00000
Frm 00128
Fmt 4701
Sfmt 4702
zero update to per treatment drug addon amount which left it at $20.33. As
discussed in detail below, for CY 2011,
we are again proposing no update to the
per treatment drug add-on amount of
$20.33 established in CY 2008.
d. Proposed Update to the Drug Add-On
Adjustment
As discussed previously in this
section, we estimate a 2.1 percent
increase in drug expenditures between
CY 2010 and CY 2011. Combining this
reduction with a 3.6 percent increase in
enrollment, as described above, we are
projecting a 1.4 percent decrease in per
patient growth of drug expenditures
between CY 2010 and CY 2011.
Therefore, we are projecting that the
combined growth in per patient
utilization and pricing for CY 2011
would result in a negative update equal
to 0.2 percent. However, similar to last
year and as indicated above, we are
proposing a zero update to the drug addon adjustment. We believe this
approach is consistent with the
language under section 1881(b)(12)(F) of
the Act which states in part that ‘‘the
Secretary shall annually increase’’ the
drug add-on amount based on the
growth in expenditures for separately
billed ESRD drugs. Our understanding
of the statute contemplates ‘‘annually
increase’’ to mean a positive or zero
update to the drug add-on. Therefore,
we propose to apply a zero update, and
to maintain the $20.33 per treatment
drug add-on amount for CY 2011.
e. Proposed Update to the Geographic
Adjustments to the Composite Rate
The purpose of the wage index is to
adjust the composite rates for differing
wage levels covering the areas in which
ESRD facilities are located. The wage
indexes are calculated for each urban
and rural area.
In addition, we generally have
followed wage index policies related to
these definitions as used under the
inpatient hospital prospective payment
system (IPPS), but without regard to any
approved geographic reclassification
authorized under sections 1886(d)(8)
and (d)(10) of the Act or other
provisions that only apply to hospitals
paid under the IPPS (70 FR 70167). For
purposes of the ESRD wage index
methodology, the hospital wage data we
use is pre-classified, pre-floor hospital
data and unadjusted for occupational
mix.
f. Proposed Updates to Core-Based
Statistical Area (CBSA) Definitions
In the CY 2006 PFS final rule with
comment period (70 FR 70167), we
announced our adoption of the OMB’s
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
CBSA-based geographic area
designations to develop revised urban/
rural definitions and corresponding
wage index values for purposes of
calculating ESRD composite rates. The
CBSA-based geographic area
designations are described in OMB
Bulletin 03–04, originally issued June 6,
2003, and is available online at https://
www.whitehouse.gov/omb/bulletins/
b03-04.html. In addition, OMB has
published subsequent bulletins
regarding CBSA changes, including
changes in CBSA numbers and titles.
We wish to point out that this and all
subsequent ESRD rules and notices are
considered to incorporate the CBSA
changes published in the most recent
OMB bulletin that applies to the
hospital wage index used to determine
the current ESRD wage index. The OMB
bulletins may be accessed online at
https://www.whitehouse.gov/omb/
bulletins/.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
g. Updated Wage Index Values
In the CY 2007 PFS final rule with
comment period (71 FR 69685), we
stated that we intended to update the
ESRD wage index values annually. The
ESRD wage index values for CY 2011
were developed from FY 2007 wage and
employment data obtained from the
Medicare hospital cost reports. As we
indicated, the ESRD wage index values
are calculated without regard to
geographic classifications authorized
under sections 1886(d)(8) and (d)(10) of
the Act and utilize pre-floor hospital
data that is unadjusted for occupational
mix. We propose to use the same
methodology for CY 2011, with the
exception that FY 2007 hospital data
would be used to develop the CY 2011
wage index values. For a detailed
description of the development of the
proposed CY 2011 wage index values
based on FY 2007 hospital data, see the
FY 2011 IPPS proposed rule (75 FR
23944). Section III.G, of the preamble to
the FY 2011 IPPS proposed rule,
‘‘Method for Computing the Proposed
FY 2011 Unadjusted Wage Index,’’
describes the cost report schedules, line
items, data elements, adjustments, and
wage index computations. The wage
index data affecting the ESRD composite
rate for each urban and rural locale may
also be accessed on the CMS Web site
at https://www.cms.hhs.gov/
AcuteInpatientPPS/WIFN/list.asp. The
wage data are located in the section
entitled, ‘‘FY 2011 Proposed Rule
Occupational Mix Adjusted and
Unadjusted Average Hourly Wage and
Pre-reclassified Wage Index by CBSA.’’
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
i. Reduction to the ESRD Wage Index
Floor
In the CY 2010 PFS final rule with
comment period, we stated our
intention to continue to reassess the
need for a wage index floor (74 FR
61924). We also stated that a gradual
reduction in the floor is needed to
support continuing patient access to
dialysis in areas that have low wage
index values, especially in Puerto Rico
where the wage index values are below
the current wage index floor.
In the ESRD PPS proposed rule (74 FR
49968), we stated our intent to continue
to reduce the wage index floor to the
composite rate during the transition. For
CY 2011, we propose that the ESRD
wage index floor would be reduced from
0.65 to 0.60.
j. Proposed Wage Index Values for Areas
With No Hospital Data
As discussed in the CY 2010 PFS final
rule (74 FR 61925), and the ESRD PPS
proposed rule (74 FR 49969) we have a
methodology for identifying the small
number of ESRD facilities in both urban
and rural geographic areas where there
are no hospital wage data from which to
calculate ESRD wage index values. At
that time those rules were published,
the affected areas were rural Puerto
Rico, and the urban area Hinesville-Fort
Stewart, GA (CBSA 25980), and rural
Massachusetts.
In the case of Massachusetts, the
entire rural area consists of Dukes and
Nantucket Counties. We determined
that the borders of Dukes and Nantucket
counties are contiguous with CBSA
12700, Barnstable Town, MA, and CBSA
39300, Providence-New Bedford-Fall
River, RI–MA. We intend to use the
same methodology for CY 2011. Under
this methodology, this results in a
proposed CY 2011 wage index value of
1.3577 for the composite rate portion of
the blend, and a wage index value of
1.2844 for the ESRD PPS portion of the
blend for Barnstable Town, MA (CBSA
12700) and also results in a proposed
CY 2011 wage index value of 1.1343 for
the composite rate portion of the blend,
and a wage index value of 1.0731 for the
ESRD PPS portion of the blend for
(Providence-New Bedford-Fall River,
RI–MA (CBSA 39300). These averages
result in an imputed proposed wage
index value of 1.2460 for rural
Massachusetts in CY 2011, for the
composite rate portion of the blend, and
a wage index value of 1.1788 for the
ESRD PPS portion of the blend.
For Hinesville-Fort Stewart, GA
(CBSA 25980), which is an urban area
without specific hospital wage data, we
propose to apply the same methodology
PO 00000
Frm 00129
Fmt 4701
Sfmt 4702
40167
used to impute a wage index value that
we used in CYs 2006 through 2010.
Specifically, we compute the average
wage index value of all urban areas
within the State of Georgia. This results
in a CY 2011 wage index value of 0.9465
for the composite rate portion of the
blend, and a wage index value of 0.8954
for the ESRD PPS portion of the blend
for Hinesville-Fort Stewart, GA (CBSA
25980).
For CY 2011, there is an additional
urban area—Anderson, SC—with no
hospital data. For this urban area,
Anderson, SC (CBSA 11340), we
propose to use the same methodology
we have used for the other urban area
with no hospital data, that is,
Hinesville-Fort Stewart, GA (CBSA
25980). Under the methodology used for
that area, we compute the average of all
urban areas within the State of South
Carolina. This approach would result in
a CY 2011 wage index value of 0.9480
for the composite rate portion of the
blend, and a wage index value of 0.8839
for the ESRD PPS portion of the blend
for the Anderson, SC CBSA (CBSA
11340).
For Puerto Rico, because all
geographic areas in Puerto Rico were
subject to the wage index floor in CYs
2006 through 2010, we applied the
ESRD wage index floor to rural Puerto
Rico as well. Therefore, for CY 2011, all
urban areas in Puerto Rico that have a
wage index are eligible for the ESRD
wage index floor of 0.60. Currently there
are no ESRD facilities located in rural
Puerto Rico, however, should any
facilities open in rural Puerto Rico, we
intend to apply the CY 2011 proposed
wage index floor of 0.60 to facilities that
are located in rural Puerto Rico. The
proposed reduction to the wage index
floor of 0.60 remains higher than the
actual wage index values for ESRD
facilities located in Puerto Rico, which
currently range from 0.3674 to 0.4828.
Also, in the CY 2010 PFS final rule with
comment period (74 FR 61925), we
stated that we would continue to
evaluate existing hospital wage data and
possibly wage data from other sources
such as the Bureau of Labor Statistics,
to determine if other methodologies
might be appropriate for imputing wage
index values for areas without hospital
wage data for CY 2011 and subsequent
years. To date, no data from other
sources, superior to that currently used
in connection with the IPPS wage index
has emerged. For ESRD purposes, we
continue to believe this is an
appropriate policy.
Finally, for CY 2011, we are
proposing to use the FY 2011 wage
index data (collected from cost reports
submitted by hospitals for cost reporting
E:\FR\FM\13JYP2.SGM
13JYP2
40168
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
periods beginning FY 2007) to compute
the ESRD composite payment rates
effective beginning January 1, 2011.
k. Budget Neutrality Adjustment
We have previously interpreted the
statute as requiring that the geographic
adjustment be made in a budget neutral
manner. Given our application of the
ESRD wage index, this means that
aggregate payments to ESRD facilities in
CY 2011 would be the same as aggregate
payments that would have been made if
we had not made any changes to the
geographic adjusters. We note that this
BN adjustment only addresses the
impact of changes in the geographic
adjustments. A separate BN adjustment
was developed for the case-mix
adjustments required by the MMA.
As we are not proposing any changes
to the case-mix measures for CY 2011,
the current case-mix BN adjustment of
0.9116 would remain in effect for CY
2011. Consistent with prior rulemaking,
For CY 2011, we propose to apply the
wage-index BN adjustment factor of
1.057057 directly to the ESRD wage
index values to the composite rate
portion of the blend. Because the ESRD
wage index is only applied to the laborrelated portion of the composite rate, we
computed the BN adjustment factor
based on that proportion (53.711
percent).
To compute the proposed CY 2011
wage index BN adjustment factor
(1.057057), we used the FY 2007 prefloor, pre-reclassified, non-occupational
mix-adjusted hospital data to compute
the wage index values, 2009 outpatient
claims (paid and processed as of
December 31, 2009), and geographic
location information for each facility
which may be found through Dialysis
Facility Compare Web page on the CMS
Web site at
https://www.cms.hhs.gov/
DialysisFacilityCompare/. The FY 2011
hospital wage index data for each urban
and rural locale by CBSA may also be
accessed on the CMS Web site at https://
www.cms.hhs.gov/AcuteInpatientPPS/
WIFN/list.asp. The wage index data are
located in the section entitled, ‘‘FY 2011
Proposed Rule Occupational Mix
Adjusted and Unadjusted Average
Hourly Wage and Pre-Reclassified Wage
Index by CBSA.’’
Using treatment counts from the 2009
claims and facility-specific CY 2010
composite rates, we computed the
estimated total dollar amount each
ESRD provider would have received in
CY 2010. The total of these payments
became the target amount of
expenditures for all ESRD facilities for
CY 2011. Next, we computed the
estimated dollar amount that would
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
have been paid for the same ESRD
facilities using the proposed ESRD wage
index for CY 2011. The total of these
payments becomes the new CY 2011
amount of wage-adjusted composite rate
expenditures for all ESRD facilities.
After comparing these two dollar
amounts (target amount divided by the
new CY 2011 amount), we calculated an
adjustment factor that, when multiplied
by the applicable CY 2011 ESRD wage
index value, would result in aggregate
payments to ESRD facilities that would
remain within the target amount of
composite rate expenditures. When
making this calculation, the ESRD wage
index floor value of 0.6000 is applied
whenever appropriate. The proposed
wage BN adjustment factor for CY 2011
is 1.057057.
To ensure BN, we also must apply the
BN adjustment factor to the wage index
floor of 1.057057 which results in an
adjusted wage index floor of 0.6343
(0.6000 x 1.057057) for CY 2011. This
budget neutrality factor is not applied to
the wage index values for the ESRD PPS
portion of the blend.
l. ESRD Wage Index Tables
The CY 2011 ESRD proposed wage
index tables are located in Addenda K
and L of this proposed rule. The wage
index tables lists two separate columns
of wage index values. The first column
lists the wage index values will be
applied under the composite rate
portion and includes the budget
neutrality adjustment of 1057057. The
second column lists the wage index
values that will be applied under the
ESRD PPS.
F. Issues Related to the Medicare
Improvements for Patients and
Providers Act of 2008 (MIPPA)
1. Section 131: Physician Payment,
Efficiency, and Quality Improvements—
Physician Quality Reporting Initiative
(PQRI)
a. Program Background and Statutory
Authority
The Physician Quality Reporting
Initiative (PQRI) is a voluntary reporting
program, first implemented in 2007, that
provides an incentive payment to
identified EPs (EPs) who satisfactorily
report data on quality measures for
covered professional services furnished
during a specified reporting period. We
propose to add § 414.90 to title 42 of the
Code of Federal Regulations to
implement the provisions of the PQRI
discussed in this section of the
proposed rule.
Under section 1848(k)(3)(B) of the
Act, the term ‘‘EP’’ means any of the
following: (1) A physician; (2) a
PO 00000
Frm 00130
Fmt 4701
Sfmt 4702
practitioner described in section
1842(b)(18)(C); (3) a physical or
occupational therapist or a qualified
speech-language pathologist; or (4) a
qualified audiologist. The PQRI was first
implemented in 2007 as a result of
section 101 of Division B of the Tax
Relief and Health Care Act of 2006—the
Medicare Improvements and Extension
Act of 2006 (Pub.L. 109–432) (MIEA–
TRHCA), which was enacted on
December 20, 2006. The PQRI was
extended and further enhanced as a
result of the Medicare, Medicaid, and
SCHIP Extension Act of 2007 (Pub. L.
110–173) (MMSEA), which was enacted
on December 29, 2007, and the MIPPA,
which was enacted on July 15, 2008.
Changes to the PQRI as a result of these
laws, as well as information about the
PQRI in 2007, 2008, 2009, and 2010 are
discussed in detail in the CY 2008 PFS
proposed and final rules (72 FR 38196
through 38204 and 72 FR 66336 through
66353, respectively), CY 2009 PFS
proposed and final rules (73 FR 38558
through 38575 and 73 FR 69817 through
69847, respectively), and CY 2010 PFS
proposed and final rules (74 FR 33559
through 33600 and 74 FR 61788 through
61861, respectively). Further detailed
information, about the PQRI program,
related laws, and help desk resources, is
available on the CMS Web site at
https://www.cms.gov/PQRI.
The ACA makes a number of changes
to the PQRI, including authorizing
incentive payments through 2014, and
requiring a penalty beginning in 2015
for EPs who do not satisfactorily report
data on quality measures in the
applicable reporting period for the year.
The various provisions of the ACA, with
respect to PQRI, are further discussed in
sections VI.F.1.b., VI.F.1.k., and VI.F.1.l.
of this proposed rule.
Prior to the enactment of the ACA,
PQRI incentive payments were only
authorized through 2010. As discussed
further in sections VI.F.1.b. and VI.F.1.l.
below, under section 1848(m)(1)(A) of
the Act, as amended by section 3002(a)
of the ACA, PQRI incentive payments
are extended through 2014 for EPs that
satisfactorily report data on PQRI
quality measures for the applicable
reporting period. Section 1848(m)(1)(B)
of the Act, as amended by section
3002(a) of the ACA, authorizes a 1.0
percent incentive payment for program
year 2011 and a 0.5 percent incentive
payment for program years 2012
through 2014 for qualified EPs who
satisfactorily submit PQRI quality
measures data. Beginning in 2015, an
incentive payment adjustment will be
implemented for EPs who do not
satisfactorily report quality measures as
required by section 1848(a)(8) of the Act
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
and added by section 3002(b) of the
ACA.
Section 3002(e) of the ACA amends
section 1848(m)(5) of the Act to require
the Secretary to provide timely feedback
to EPs on the performance of the EP
with respect to satisfactorily submitting
data on quality measures. This is
discussed further in section VI.F.1.l.(4)
below.
Section 3002(f)(2) amends section
1848(m)(5) of the Act by adding a
requirement with respect to an informal
appeals process. Specifically, section
1848(m)(5)(I) of the Act, as discussed
further in section VI.F.1.l.(5) below,
requries that the Secretary establish and
have in place an informal process by
January 1, 2011, whereby EPs may seek
a review of the determination that an EP
did not satisfactorily submit data on
quality measures for purposes of
qualifying for a PQRI incentive
payment.
Section 1848(m)(7) of the Act
(‘‘Additional Incentive Payment’’), as
added by section 10327(a) of the ACA,
provides that for years 2011 through
2014, the applicable quality percent
under PQRI for EPs satisfactorily
reporting PQRI quality measures data
will be increased by 0.5 percentage
points, if the EP also meets certain
requirements, including satisfactorily
reporting data on quality measures for a
year and having such data submitted on
their behalf through a Maintenance of
Certification Program (MOCP) (as
defined under section 1848(m)(7) of the
Act) and participating in an MOCP
practice assessment more frequently
than is required to qualify for or
maintain board certification status.
Section 1848(m)(7) of the Act
(‘‘Additional Incentive Payment’’) is
discussed in more detail in section
VI.F.1.l.(2). Furthermore, section
3002(c) of the ACA, as amended by
section 10327(b) of the ACA authorizes
the Secretary to incorporate
participation and successful completion
in an MOCP and successful completion
of a qualified MOCP practice assessment
into the composite of measures of
quality of care furnished under the PFS
payment modifier.
Also discussed further in section
VI.F.1.k. below, section 10331 of the
ACA requires the Secretary to develop
a Physician Compare Internet web site
by January 1, 2011, on which
information on physicians enrolled in
the Medicare program and other EPs
who participate in the PQRI program
would be posted. With respect to
measures collected under the PQRI
program, to the extent practicable, the
Secretary will implement a plan by
January 1, 2013, to report 2012 PQRI
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
information on the Physician Compare
Web site.
Finally, section 1848(m)(7) of the Act
(‘‘Integration of Physician Quality
Reporting and EHR Reporting’’), as
added by section 3002 of the ACA
requires that not later than January 1,
2012, the Secretary shall develop a plan
to integrate reporting on quality
measures under subsection (o) relating
to the meaningful use of electronic
health records (EHRs), as discussed
further in section VI.F.1.l.(3) below.
b. Incentive Payments for the 2011 PQRI
As stated above, for years 2011
through 2014, section 3002(a) of the
ACA extends the opportunity for EPs to
earn a PQRI incentive payment for
satisfactorily reporting PQRI quality
measures. For 2011 PQRI, section
1848(m)(2)(B) of the Act, as amended by
section 3002(a) of the ACA, authorizes
a 1.0 percent incentive, and for 2012
through 2014, a 0.5 percent incentive,
for qualified EPs who satisfactorily
submit PQRI quality measures data.
Regardless of the reporting mechanism,
and/or the associated reporting period
(both discussed in detail below) an EP
chooses to report quality data for
purposes of PQRI, if the EP meets the
respective criteria for satisfactory
reporting, the EP may receive a 1.0
percent incentive.
The PQRI incentive payment amount
is calculated using estimated Medicare
Part B PFS allowed charges for all
covered professional services, not just
those charges associated with the
reported quality measures. ‘‘Allowed
charges’’ refers to total charges,
including the beneficiary deductible
and coinsurance, and is not limited to
the 80 percent paid by Medicare or the
portion covered by Medicare where
Medicare is secondary payer. Amounts
billed above the PFS amounts for
assigned and non-assigned claims will
not be included in the calculation of the
incentive payment amount. In addition,
since, by definition under section
1848(k)(3)(A) of the Act, ‘‘covered
professional services’’ are limited to
services for which payment is made
under, or is based on, the PFS and
which are furnished by an EP, other Part
B services and items that may be billed
by EPs, but are not paid under or based
upon the Medicare Part B PFS, are not
included in the calculation of the
incentive payment amount.
As mentioned above, we are
proposing a number of reporting
mechanisms that EPs may choose in
order to participate in PQRI. Our
proposals for claims-based reporting,
registry-based reporting, and EHR-based
reporting are discussed below with
PO 00000
Frm 00131
Fmt 4701
Sfmt 4702
40169
respect to the opportunity for individual
EPs to participate in PQRI. For
satisfactory reporting at the individual
level in 2011, 1.0 percent of qualified
charges would be paid at the TIN/NPI
level. These proposed reporting
mechanisms are addressed in section
G.1.d. below. Our proposed criteria for
satisfactorily reporting using the various
reporting mechanisms are discussed in
further detail in sections VI.F.1.e. and
VI.F.1.f. below. Our proposals with
respect to the reporting mechanisms and
criteria for satisfactorily reporting for
group practices are also addressed
below, in section VI.F.1.g. Those group
practices that satisfactorily report will
also be paid a 1.0 percent incentive
payment based upon the qualified
charges for the group practice TIN.
c. Proposed 2011 Reporting Periods for
Individual EPs
Under section 1848(m)(6)(C) of the
Act, the ‘‘reporting period’’ for the 2008
PQRI and subsequent years is defined to
be the entire year, but the Secretary is
authorized to revise the reporting period
for years after 2009 if the Secretary
determines such revision is appropriate,
produces valid results on measures
reported, and is consistent with the
goals of maximizing scientific validity
and reducing administrative burden. For
the 2011 PQRI, we propose the
following reporting periods: (1) 12month reporting period for claims-based
reporting and registry-based reporting
(that is, January 1, 2011 through
December 31, 2011); (2) 12-month
reporting period for EHR-based
reporting (that is, January 1, 2011
through December 31, 2011; and (3) 6month reporting period for claims-based
reporting and registry-based reporting
(that is, July 1, 2011 through December
31, 2011). Additionally, as discussed
further below in their respective
sections, we propose the 12-month
reporting period for the group practice
reporting option (GPRO) for both PQRI
and the eRx Prescribing Incentive
Program (January 1, 2011 through
December 31, 2011).
The proposed 2011 PQRI reporting
periods are consistent with the 2010
reporting periods. In addition, in prior
program years, we received input from
stakeholders in support of partial year
reporting for all reporting mechanisms,
to give more EPs the opportunity to
begin reporting later in the year. We
agree that having the same reporting
periods for all mechanisms may be less
complex, and may facilitate
participation in 2011 PQRI for certain
EPs. In an effort to be consistent with
prior program years, and move in the
direction of maintaining program
E:\FR\FM\13JYP2.SGM
13JYP2
40170
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
stability and continuing program
flexibility, while increasing successful
reporting of 2011 PQRI measures, we
propose to retain 2010 PQRI reporting
periods as described above. We invite
comments on the proposed reporting
periods for 2011 PQRI.
d. Proposed 2011 PQRI Reporting
Mechanisms for Individual EPs
When the PQRI was first implemented
in 2007, there was only 1 reporting
mechanism available to submit data on
PQRI quality measures. For the 2007
PQRI, EPs had to submit quality data
codes (QDCs) on Medicare Part B claims
(claims-based reporting). QDCs are
Current Procedural Terminology (CPT)
Category II codes or G-codes (where CPT
Category II codes are not yet available).
CPT Category II codes and G-codes are
Healthcare Common Procedure Coding
System (HCPCS) codes for reporting
quality data. For the 2008 PQRI, we
added registry-based reporting as an
alternative reporting mechanism as
required by section 1848(k)(4) of the
Act. Under this option, EPs may submit
data on PQRI quality measures to a
qualified PQRI registry and request the
registry to submit PQRI quality
measures results and numerator and
denominator data on the 2008 PQRI
quality measures or measures groups.
For the 2009 PQRI, we retained the 2
reporting mechanisms used in the 2008
PQRI (that is, claims-based reporting
and registry-based reporting) for
reporting individual PQRI quality
measures and for reporting measures
groups.
Finally, to promote the adoption of
EHRs, and to facilitate quality measure
data reporting, we sought to establish an
EHR reporting option by conducting
limited testing of EHR reporting for the
2008 and 2009 PQRI. This involved the
submission of clinical quality data
extracted from an EHR, or the EHRbased reporting mechanism. No
incentive payment was available to
those EPs who participated in testing
the EHR-based reporting mechanism.
For the 2010 PQRI, we retained the
claims-based reporting mechanism, the
registry-based reporting mechanism,
and established EHR reporting for a
limited subset of the 2010 PQRI quality
measures, as identified in Table 14 of
the CY 2010 PFS final rule with
comment period (74 FR 61831),
contingent upon the successful
completion of our 2009 EHR data
submission testing process and a
determination based on that testing
process that accepting data from EHRs
on quality measures for the 2010 PQRI
was practical and feasible. In the 2010
PQRI, following the successful
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
completion of the 2009 EHR data
submission testing process, it was
determined that it is practical and
feasible to accept data from EHRs on
quality measures for the 2010 PQRI.
For the 2011 PQRI, we are proposing
to retain the claims-based reporting
mechanism and the registry-based
reporting mechanism. We also propose
to retain the 2010 EHR-based reporting
mechanism, by which we will continue
to accept quality measures data
extracted from a qualified EHR product
for a limited subset of the proposed
2011 PQRI quality measures, as
identified in Tables 55 and 56. Under
the 2011 PQRI, we propose that the EHR
submission is optional.
For the 2011 PQRI, we are not
proposing to offer additional reporting
options for individual EPs beyond those
discussed above. In contrast to prior
program years (2008 PQRI, 2009 PQRI,
and 2010 PQRI), we believe that other
options would not facilitate reporting of
quality data for PQRI by EPs. However,
we seek public comment on these
proposals and invite suggestions as to
other options that could be included in
the PQRI.
We recognize that there continues to
be a number of limitations associated
with claims-based reporting since the
claims processing system was
developed for billing purposes and not
for the submission of quality data.
Claims submission, however, is
available to all EPs. We have observed
that only about half of those EPs who
participated in PQRI via the claimsbased reporting mechanism satisfied the
criteria for satisfactory reporting (that is,
reported at least 3 PQRI measures or
1–2 measures if there were fewer than
3 applicable measures, for at least 80
percent of the EP’s Medicare Part B FFS
patients for whom services were
furnished during the reporting period to
which the measure applies) and
qualified for the incentive. We have also
found that measures with complex
specifications, such as those that require
multiple diagnosis codes are not as
conducive to claims-based reporting and
may be associated with a greater number
of invalidly reported QDCs. Similarly,
when multiple measures share the same
codes it may be difficult to determine
which measure(s) the EP intended to
report through claims. Finally, for
pragmatic efficiency it is not practical to
allow resubmission of claims for the
sole purpose of adding QDCs. This
means that claims-based reporting must
be concurrent with billing.
By contrast, our experience with the
registry-based reporting mechanism
continues to be a favorable option, as
the drawbacks discussed above do not
PO 00000
Frm 00132
Fmt 4701
Sfmt 4702
apply. Data has shown that not only
have the participation rates for registrybased reporting increased, but also
satisfactory reporting, resulting in an
incentive payment for EPs, has also
increased. Furthermore, the available
number of qualified registries has also
increased since 2008, and we expect
additional registries to become qualified
in future years. For these reasons, we
maintain that the registry-based
reporting option remains viable, and
furthermore, we anticipate continuing to
expand this option in future years.
We also believe that EHR-based
reporting continues to be a viable option
for overcoming the limitations
associated with claims-based reporting
of quality measures, as clinical quality
data is extracted from the EHR for
submission. We believe further that
retaining the EHR-based reporting
mechanism for 2011 PQRI will continue
to promote the adoption and use of
EHRs and further align with the
provision in the ACA related to the
integration of PQRI EHR measures and
the EHR incentive program measures in
years after 2011, which is discussed in
further detail in section VI.F.1.l.(3)
below.
In summary, we propose that for
2011, an EP may choose to report data
on PQRI quality measures through
claims, a qualified registry (for the
proposed qualification requirements for
registries, see section VI.F.1.d.(4) of this
proposed rule), or through a qualified
EHR product (for the proposed
qualification requirements for the EHR
vendors and their products, see section
VI.F.1.d.(5) of this proposed rule). As in
previous years, depending on which
PQRI individual quality measures or
measures groups an EP selects, one or
more of the proposed reporting
mechanisms may not be available for
reporting a particular 2011 PQRI
individual quality measure or measures
group. For example, the EHR reporting
mechanism currently is not available for
reporting measures groups and
specifications for the electronic
transmission of a measure via an EHR
are not available for all of the individual
PQRI measures. In addition, as
discussed previously the specifications
for some measures are too complex for
claims-based reporting. The proposed
2011 reporting mechanisms through
which each proposed 2011 PQRI
individual quality measure and
measures group could be reported are
identified in Tables 47 and 48. We
invite comments on our proposal for the
2011 reporting mechanisms.
While we propose to retain the
claims-based reporting mechanism for
2011, we note that we continue to
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
consider significantly limiting the
claims-based mechanism of reporting
clinical quality measures in future
program years. This limitation
continues to be contingent upon there
being an adequate number and variety
of registries available and/or the
continuation and/or expansion of the
EHR reporting option. Potentially, we
would continue to retain claims-based
reporting in years after 2011 principally
for the reporting of structural measures,
such as Measure #124 Health
Information Technology (HIT):
Adoption/Use of Electronic Health
Records (EHR), and in circumstances
where claims-based reporting is the only
available mechanism for certain
categories of EPs to report on PQRI
quality measures.
Continuing to reduce our reliance on
the claims-based reporting mechanism
after 2011 would allow us and EPs to
continue to devote available resources
towards maximizing the potential of
registries and EHRs for quality
measurement reporting. Both
mechanisms hold the promise of more
sophisticated and timely reporting of
clinical quality measures. Clinical data
registries allow the collection of more
detailed data, including outcomes,
without the necessity of a single
submission contemporaneously with
claims billing, which overcomes some
of the limitations of the claims-based
reporting mechanism. Registries can
also provide feedback and quality
improvement information based on
reported data. Finally, clinical data
registries can also receive data from
EHRs, and therefore, serve as an
alternative means to reporting clinical
quality data extracted from an EHR. As
we continue to qualify additional
registries (qualified registries are listed
on the CMS PQRI Web site https://
www.cms.gov/PQRI/20_Alternative
ReportingMechanisms.asp#TopOfPage),
we believe there may be a sufficient
number of registries by 2012 to make it
possible to reduce the claims-based
reporting mechanism for many
measures after 2011. We again invite
comments on our intent to lessen our
reliance on the claims-based reporting
mechanism for the PQRI program
beyond 2011.
As in previous years, regardless of the
reporting mechanism chosen by an EP,
there is no requirement for the EP to
sign up or register to participate in the
PQRI. However, there may be some
requirements for participation through a
specific reporting mechanism that are
unique to that particular reporting
mechanism. In addition to the proposed
criteria for satisfactory reporting of
individual measures and measures
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
groups described in section VI.F.1.e.
and section VI.F.1.f., respectively, of
this proposed rule, EPs must ensure that
they meet all requirements for their
chosen reporting mechanism for 2011.
(1) Proposed Requirements for
Individual EPs Who Choose the ClaimsBased Reporting Mechanism
For EPs who choose to participate in
the 2011 PQRI by submitting data on
individual quality measures or measures
groups through the claims-based
reporting mechanism, we propose the
EP would be required to submit the
appropriate PQRI QDCs on the
professionals’ Medicare Part B claims.
QDCs for the EP’s selected individual
PQRI quality measures or measures
group may be submitted to CMS at any
time during 2011. Please note, however,
that as required by section
1848(m)(1)(A) of the Act, all claims for
services furnished between January 1,
2011 and December 31, 2011, would
need to be processed by no later than
February 28, 2012, to be included in the
2011 PQRI analysis.
(2) Proposed Requirements for
Individual EPs Who Choose the
Registry-Based Reporting Mechanism
We propose that in order to report
quality data on the 2011 PQRI
individual quality measures, or
measures groups, through a qualified
clinical registry, an EP must enter into
and maintain an appropriate legal
arrangement with a qualified 2011 PQRI
registry. Such arrangements would
provide for the registry’s receipt of
patient-specific data from the EP and
the registry’s disclosure of quality
measures results and numerator and
denominator data on PQRI quality
measures or measures groups on behalf
of the EP to CMS. Thus, the registry
would act as a Health Insurance
Portability and Accountability Act of
1996 (Pub. L. 104–191) (HIPAA)
Business Associate and agent of the EP.
Such agents are referred to as ‘‘data
submission vendors.’’ The ‘‘data
submission vendors’’ would have the
requisite legal authority to provide
clinical quality measures results and
numerator and denominator data on
individual quality measures or measures
groups on behalf of the EP for the PQRI.
We propose that the registry, acting as
a data submission vendor, would submit
CMS-defined registry-derived measures
information to our designated database
for the PQRI, using a CMS-specified
record layout, which would be provided
to the registry by CMS.
To maintain compliance with
applicable statutes and regulations, our
program and our data system must
PO 00000
Frm 00133
Fmt 4701
Sfmt 4702
40171
maintain compliance with the HIPAA
requirements for requesting, processing,
storing, and transmitting data. EPs that
conduct HIPAA covered transactions
also would need to maintain
compliance with the HIPAA
requirements.
We propose that EPs choosing to
participate in PQRI through the registrybased reporting mechanism for 2011
would need to select a qualified PQRI
registry and submit information on
PQRI individual quality measures or
measures groups to the selected registry
in the form and manner and by the
deadline specified by the registry.
We propose to post on the PQRI
section of the CMS Web site at https://
www.cms.gov a list of qualified
registries for the 2011 PQRI, including
the registry name, contact information,
and the 2011 measure(s) and/or
measures group(s) and eRx reporting (if
qualified) for which the registry is
qualified and intends to report. As in
the 2010 PQRI, we propose for the 2011
PQRI to post the names of the 2011
PQRI qualified registries in 3 phases,
which are discussed below. In any
event, even though a registry is listed as
‘‘qualified,’’ we cannot guarantee or
assume responsibility for the registry’s
successful submission of the required
PQRI quality measures results or
measures group results or required data
elements submitted on behalf of a given
EP.
In the first phase, we propose to post,
by December 31, 2010, a list of those
registries qualified for the 2011 PQRI
based on the following: (1) Being a
qualified registry for a prior PQRI
program year that successfully
submitted 2008 and/or 2009 PQRI
quality measures results and numerator
and denominator data on the quality
measures; (2) having received a letter
indicating their continued interest in
being a PQRI registry for 2011 by
October 31, 2010; and (3) the registry’s
compliance with the 2011 PQRI registry
requirements. This list may be modified
if any given registry fails to meet any
new requirement(s) proposed for 2011.
The testing of any additional
requirements will be completed as soon
as possible but by the end of the first
quarter of 2011 at the latest. By posting
this first list of qualified registries for
the 2011 PQRI, we seek to make
available the names of registries that can
be used at the start of the 2011 reporting
period.
We propose in the second phase, to
add the names of the registries that were
initially qualified in 2010 and submitted
actual quality data on behalf of their EPs
to CMS for the first time in early 2011.
Successful submission of data to CMS
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40172
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
for the year in which a registry is
qualified is the final step in the
qualification process and a necessary
requirement if the registry desires to
continue to participate in PQRI in
subsequent years. We propose that these
registries also must meet any new 2011
requirements and will also undergo
testing, which will be completed by the
end of the first quarter of 2011 at the
latest.
In the third phase, we propose to
complete posting of the list of qualified
2011 registries as soon as we have
completed vetting the additional
registries interested in and capable of
participating in the 2011 PQRI. We
anticipate this will be completed no
later than the summer of 2011. An EP’s
ability to report PQRI quality measures
data and numerator and denominator
data on PQRI quality measures or
measures groups using the registrybased reporting mechanism should not
be impacted by the complete list of
qualified registries for the 2011 PQRI
being made available after the start of
the reporting period. First, registries
would not begin submitting EPs’ PQRI
quality measures results and numerator
and denominator data on the quality
measures or measures groups to CMS
until 2012. Second, if an EP decides that
he or she is no longer interested in
submitting quality measures data and
numerator and denominator data on
PQRI individual quality measures or
measures group through the registrybased reporting mechanism after the
complete list of qualified registries
becomes available, this would not
preclude the EP from attempting to meet
the criteria for satisfactory reporting
through another 2011 PQRI reporting
mechanism, such as claims or EHRbased data submission.
In addition to meeting the above
proposed requirements specific to
registry-based reporting, we propose
that EPs who choose to participate in
PQRI through the registry-based
reporting mechanism would need to
meet the relevant criteria proposed for
satisfactory reporting of individual
measures or measures groups that all
EPs must meet in order to satisfactorily
report for PQRI 2011. However, in 2011,
we propose not to count measures that
are reported through a registry or EHR
that have a zero percent performance
rate. That is, if the recommended
clinical quality action is not performed
on at least 1 patient for a particular
measure or measures group reported by
the EP via a registry or EHR, we will not
count the measure (or measures groups)
as a measure (or measures group)
reported by an EP. We propose to
disregard measures (or measures groups)
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
that are reported through a registry or
EHR that have a zero percent
performance rate in the 2011 PQRI
because we are assuming that the
measure was not applicable to the EP
and was likely reported from EHRderived data (or from data mining) and
was unintentionally submitted from the
registry or EHR to CMS. We also seek to
avoid the possibility of intentional
submission of spurious data solely for
the purpose of receiving an incentive
payment for reporting.
(3) Proposed Requirements for
Individual EPs Who Choose the EHRBased Reporting Mechanism
For 2011, in addition to meeting the
criteria for satisfactory reporting of at
least 3 individual measures, we propose
the following requirements associated
with EHR-based reporting: (1) Selection
of a PQRI qualified EHR product; and
(2) submission of clinical quality data
extracted from the EHR to a CMS
clinical data warehouse in the CMSspecified manner and format. These
proposed requirements are identical to
the 2010 requirements for individual
EPs who choose the EHR-based
requirements. We are proposing to
retain the 2010 requirements because
results from 2010 EHR data submission
will not be available until 2011. A test
of quality data submission from EPs
who wish to report 2010 quality
measure data directly from their
qualified EHR product will be required
and occur in early 2011 immediately
followed by the submission of the EP’s
actual 2010 PQRI data. This entire final
test/production 2010 data submission
timeframe is expected to be January
2011 through March 2011. As discussed
in the CY 2010 PFS final rule with
comment period (74 FR 61800),
throughout most of 2010, we will
continue to vet newly self-nominated
EHR vendor products for possible
qualification for the 2011 PQRI program
year. We expect to list any additional
PQRI qualified EHR products by January
2011. It is expected that these newly
qualified products would be able to
submit 2011 PQRI data in early 2012.
Measures group reporting is not an
option for EHR based quality measure
reporting for 2010. We propose to
continue this policy for 2011 and
therefore, propose not to include
measures group reporting via EHRs for
the 2011 PQRI. We will receive 2010
production data in early 2011 and since
this will be the first time we have an
opportunity to receive direct EHR data
submission for quality reporting and to
calculate the results, we believe it is
best not to add another reporting option
using EHRs at this time. We propose
PO 00000
Frm 00134
Fmt 4701
Sfmt 4702
that EPs who choose the EHR-based
reporting mechanism for the 2011 PQRI
would be required to (in addition to
meeting the criteria for satisfactory
reporting of individual measures)—
• Have a qualified EHR product;
• Have an active Individuals
Authorized Access to CMS Computer
Services (IACS) user account with a data
submission role or be able to use the
surrogate data submission method (if
one exists) that will be used to submit
clinical quality data extracted from the
EHR to a CMS clinical data warehouse
or another CMS approved means of
securely transmitting the quality
measures data to CMS such as a CMS/
OCSQ approved HIE (health information
exchange) if we are able to collect data
from HIEs in 2012 using the NHIN
(national health information network) or
NHIN direct network;
• Submit a test file containing real or
test clinical quality data extracted from
the EHR to a CMS clinical data
warehouse via an approved data
submission method such as IACS, an
HIE, or the NHIN between July 1, 2011
and September 30, 2011 (if technically
feasible); and
• Submit a file containing the EP’s
2011 PQRI clinical quality data
extracted from the EHR for the entire
reporting period (that is January 1, 2011
through December 31, 2011) via IACS or
an acceptable surrogate (if technically
feasible) between January 1, 2012,
through February 28, 2012.
However, as stated above, the 2010
EHR Testing Program is still ongoing.
Since we are proposing that only EHR
vendors that self-nominated to
participate in the 2011 EHR Testing
Program and successfully complete the
2011 EHR Testing Program would be
considered qualified EHR vendors for
the 2011 PQRI, there is no guarantee
that there will be any additionally
qualified EHR vendors available for the
2011 PQRI. In addition, as we complete
the 2010 EHR Testing Program and are
better able to determine what is
technically feasible, the actual dates on
which EPs are required to submit their
test files and/or to begin submitting
their actual 2011 PQRI data are subject
to change.
We cannot assume responsibility for
the successful submission of data from
an EP’s EHR. Any EP who chooses to
submit PQRI data extracted from an
EHR should contact the EHR product’s
vendor to determine if the product is
qualified and has been updated to
facilitate PQRI quality measures data
submission. Such professionals also
should begin attempting submission
soon after the opening of the clinical
data warehouse in order to assure the
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
professional has a reasonable period of
time to work with his or her EHR and/
or its vendor to correct any problems
that may preclude successful quality
measures data submission through that
EHR. As we indicated above, we are
proposing that data submission for the
2011 PQRI would need to be completed
by February 28, 2012.
The specifications for the electronic
transmission of the 2011 PQRI
measures, identified in Tables 55 and 56
of this proposed rule as being available
for EHR-based reporting in 2011, will be
posted on the Alternative Reporting
Mechanisms page of the PQRI section of
the CMS Web site during the summer of
2010.
(4) Proposed Qualification
Requirements for Registries
In order to be ‘‘qualified’’ to submit
quality measures results and numerator
and denominator data on PQRI quality
measures and measures groups on
behalf of EPs pursuing a PQRI incentive
for the 2008, 2009, and 2010 PQRI, we
required registries to complete a selfnomination process and to meet certain
technical and other requirements. For
the 2010 PQRI, registries that were
qualified for 2009 did not need to be ‘‘requalified’’ for 2010 unless they were
unsuccessful at submitting 2009 PQRI
data (that is, failed to submit 2009 PQRI
data per the 2009 PQRI registry
requirements). Registries that were
‘‘qualified’’ for 2009 and wished to
continue to participate in 2010 were
only required to communicate their
desire to continue participation for 2010
by submitting a letter to CMS indicating
their continued interest in being a PQRI
registry for 2010 and their compliance
with the 2010 PQRI registry
requirements by March 31, 2010.
For the 2011 PQRI, we are proposing
to require a self-nomination process for
registries wishing to submit 2011 PQRI
quality measures or measures groups on
behalf of EPs for services furnished
during the applicable reporting periods
in 2011. We propose that the registry
self-nomination process for the 2011
PQRI would be based on a registry
meeting specific technical and other
requirements, as discussed below.
To be considered a qualified registry
for purposes of submitting individual
quality measures and measures groups
on behalf of EPs who choose to report
using this reporting mechanism under
the 2011 PQRI, we propose that all
registries (new to PQRI and those
previously qualified) must:
• Be in existence as of January 1,
2011;
• Have at least 25 participants by
January 1, 2011;
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
• Provide at least 1 feedback report
per year to participating EPs;
• Not be owned and managed by an
individual locally-owned singlespecialty group (in other words, singlespecialty practices with only 1 practice
location or solo practitioner practices
would be prohibited from selfnominating to become a qualified PQRI
registry);
• Participate in ongoing 2011 PQRI
mandatory support conference calls
hosted by CMS (approximately 1 call
per month), including an in-person
registry kick-off meeting to be held at
CMS headquarters in Baltimore, MD.
Registries that miss more than one
meeting will be precluded from
submitting PQRI data for the reporting
year (2011);
• Be able to collect all needed data
elements and transmit to CMS the data
at the TIN/NPI level for at least 3
measures in the 2011 PQRI program
(according to the posted 2011 PQRI
Measure Specifications);
• Be able to calculate and submit
measure-level reporting rates or the data
elements needed to calculate the
reporting rates by TIN/NPI;
• Be able to calculate and submit, by
TIN/NPI, a performance rate (that is, the
percentage of a defined population who
receive a particular process of care or
achieve a particular outcome) for each
measure on which the TIN/NPI reports
or the data elements needed to calculate
the reporting rates;
• Be able to separate out and report
on Medicare Part B FFS patients;
• Provide the name of the registry;
• Provide the reporting period start
date the registry will cover;
• Provide the reporting period end
date the registry will cover;
• Provide the measure numbers for
the PQRI quality measures on which the
registry is reporting;
• Provide the measure title for the
PQRI quality measures on which the
registry is reporting;
• Report the number of eligible
instances (reporting denominator);
• Report the number of instances of
quality service performed (numerator);
• Report the number of performance
exclusions;
• Report the number of reported
instances, performance not met (EP
receives credit for reporting, not for
performance);
• Be able to transmit this data in a
CMS-approved XML format. We expect
that this CMS-specified record layout
will be substantially the same as for the
2008, 2009, and 2010 PQRI if aggregate
level data is continued but will likely
change if individual data elements are
required, as discussed below. This
PO 00000
Frm 00135
Fmt 4701
Sfmt 4702
40173
layout will be provided to registries in
2011;
• Comply with a CMS-specified
secure method for data submission,
such as submitting the registry’s data in
an XML file through an IACS user
account or another approved method
such as over the NHIN (national health
information network) if technically
feasible;
• Submit an acceptable ‘‘validation
strategy’’ to CMS by March 31, 2011. A
validation strategy ascertains whether
EPs have submitted accurately and on at
least the minimum number (80 percent)
of their eligible patients, visits,
procedures, or episodes for a given
measure. Acceptable validation
strategies often include such provisions
as the registry being able to conduct
random sampling of their participant’s
data, but may also be based on other
credible means of verifying the accuracy
of data content and completeness of
reporting or adherence to a required
sampling method;
• Perform the validation outlined in
the strategy and send the results to CMS
by June 30, 2012 for the 2011 reporting
year’s data;
• Enter into and maintain with its
participating professionals an
appropriate Business Associate
agreement that provides for the
registry’s receipt of patient-specific data
from the EPs, as well as the registry’s
disclosure of quality measure results
and numerator and denominator data on
behalf of EPs who wish to participate in
the PQRI program;
• Obtain and keep on file signed
documentation that each holder of an
NPI whose data are submitted to the
registry has authorized the registry to
submit quality measures and numerator
and denominator data to CMS for the
purpose of PQRI participation. This
documentation must be obtained at the
time the EP signs up with the registry
to submit PQRI quality measures data to
the registry and must meet any
applicable laws, regulations, and
contractual business associate
agreements;
• Provide CMS access (if requested
for validation purposes) to review the
Medicare beneficiary data on which
2011 PQRI registry-based submissions
are founded or provide to CMS a copy
of the actual data (if requested);
• Provide the reporting option
(reporting period and reporting criteria)
that the EP has satisfied or chosen;
• Provide CMS a signed, written
attestation statement via mail or e-mail
which states that the quality measure
results and any and all data including
numerator and denominator data
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40174
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
provided to CMS are accurate and
complete;
• Indicate the reporting period
chosen for each EP who chooses to
submit data on measures groups;
• Base reported information on
measures groups only on patients to
whom services were furnished during
the 12-month reporting period of
January through December 2011 or the
6-month reporting period of July 1, 2011
through December 31, 2011;
• Agree that the registry’s data may be
inspected or a copy requested by CMS
and provided to CMS under our
oversight authority;
• Be able to report data on all
applicable measures in a given measures
group on either 30 or more Medicare
Part B FFS patients from January 1, 2011
through December 31, 2011, or on 80
percent of applicable Medicare Part B
FFS patients for each EP (with a
minimum of 15 patients during the
January 1, 2011, through December 31,
2011, reporting period or a minimum of
8 patients during the July 1, 2011,
through December 31, 2011, reporting
period).
These proposed qualification
requirements for 2011 registries are
similar to the PQRI qualification
requirements for registries for previous
years. However, we note, that registries
would no longer be permitted to include
non-Medicare patients for measures
group reporting (see section VI.F.1.f. of
this proposed rule for further discussion
of the criteria for satisfactory reporting
of measures groups by individual EPs).
In addition, in prior years registries
were permitted to develop their own
algorithms to calculate measure results
(that is, reporting and performance
rates) from the data provided to them
from their EP members. For the 2011
PQRI, we propose that all current and
future registries would have to meet the
following new requirements proposed
for 2011:
• Use PQRI measure specifications
and the CMS provided measure
calculation algorithm to calculate
reporting rates or performance rates
unless otherwise stated if aggregated
measures data is continued for 2011
PQRI registry reporting. CMS will
provide registries a calculation
algorithm for each measure and/or
measures group they intend to report in
2011.
• Provide a calculated result using
the CMS supplied algorithm and XML
file for each measure that the registry
intends to calculate (as described
below). This applies to all registries;
those that are new to the program, and
those that were previously qualified.
The registries will be required to show
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
that they can calculate the proper
measure results (that is, reporting and
performance rates) using the CMSsupplied algorithm and send the
calculated data back to CMS in the
specified format.
• Provide us the individual data
elements used to calculate the measures
if so requested by CMS for validation
purposes, if aggregated data submission
is still the selected method of data
collection. Registries that are subject to
validation will be asked to send discrete
data elements for a measure (determined
by CMS) in the required data format for
us to recalculate the registries’ reported
results. Validation will be conducted for
several measures at a randomly selected
sample of registries in order to validate
their data submissions.
While registries allow EPs to collect
data over a broader timeframe enabling
us to implement more sophisticated
measures in PQRI and despite their
apparent success as a vehicle for quality
reporting (over 90.0 percent of EPs who
participated in the 2008 PQRI through
registry-based reporting were incentive
eligible), registry data results have been
inconsistent when we have validated
the registry data against claims. Even
though qualified registries go through a
thorough vetting and testing process, we
have found differences in measure
results (that is, performance rates)
reported by the registries when
compared to measure results calculated
from claims data for the same EP. This
makes it difficult for EPs to analyze
their performance results for practice
improvement in that the information
may not be reliable and reproducible
from registry to registry. This also makes
possible physician comparison difficult
and inconsistent. We believe there are
likely several reasons for these
inconsistencies, including the fact that
some registries are getting their data
from an EP’s EHR, the use of nonMedicare patients by registries for
measures groups, and the use of
different algorithms by registries to
calculate measures. We believe the
proposed new requirements for
registries discussed above will help us
in validating the registry data we receive
by addressing some of the reasons
leading to the inconsistencies. The
proposal for 2011 to retain many of the
2010 requirements while introducing
some new requirements is intended to
improve the registry-based reporting
mechanism by capitalizing on some of
the registry’s existing quality
improvement functions, maximizing the
registry’s ability to successfully submit
EP’s quality measure results and
numerator and denominator data on
PQRI individual quality measures or
PO 00000
Frm 00136
Fmt 4701
Sfmt 4702
measures groups to CMS, and
discouraging small physicians’ offices or
an individual EP from self-nominating
to become a qualified registry. We
continue to be concerned that an
individual EP or a small practice does
not have either the resources, or the
capabilities, to successfully submit
quality measures results and numerator
and denominator data on PQRI
individual measures or measures groups
through the registry data submission
process. We invite comments on the
process and requirements that we
propose to use to determine whether a
registry is qualified to submit quality
measures results (performance rates and
reporting rates) and numerator and
denominator data on PQRI quality
measures or measures groups on an EP’s
behalf.
As stated previously, registries
currently calculate the measure results
(that is reporting and performance rates)
from the data submitted to them by their
EP members and send us the measure
results for each participating EP, which
are aggregated, nonpatient identifiable
data. An advantage of this approach is
that less data will need to be transmitted
to CMS (since we only receive
aggregated data), which means there is
less data for CMS to analyze.
Another option that we considered
was changing the requirements with
respect to the type of data that registries
send us. For 2011, we considered
requiring registries, instead, to send
discrete data elements for a measure (as
determined by CMS) in the required
data format for us to calculate the EP’s
measure results. Thus, the registry
would be required to send CMS
beneficiary-level data provided to the
registry by the EP and CMS would use
the data to calculate the EP’s measure
results (that is, reporting and
performance rates). This approach is
similar to the approach that was
contemplated when registry data
submission began in 2008 and was
referred to as ‘‘Option 2’’ in the CY 2008
PFS proposed rule (72 FR 38203). An
advantage of this approach is that it
allows us to calculate the measure
results and reduces the variation that
occurs when registries try to aggregate
their data and calculate the measure
results themselves. Reducing the
variation would facilitate comparison of
EPs’ results should we move towards
public reporting of performance results
in the future. Also, if the measure
specifications change from year to year,
this approach would require the registry
to make fewer systems changes. The
registry would not need to update the
algorithms used to calculate the
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
measure’s results. We invite comments
on this alternative that was considered.
We propose to post the final 2011
PQRI registry requirements, including
the exact date by which registries that
wish to qualify for 2011 must submit a
self-nomination letter and instructions
for submitting the self-nomination
letter, on the PQRI section of the CMS
Web site at https://www.cms.gov/PQRI by
November 15, 2010. We anticipate that
new registries that wish to self-nominate
for 2011 would be required to do so by
January 31, 2011.
Similar to 2010 PQRI, we propose that
registries that were ‘‘qualified’’ for 2010
and wish to continue to participate in
2011 will not need to be ‘‘re-qualified’’
for 2011 except to the extent that the
requirements change for 2011 (as
proposed above). If this occurs, we
propose that all previously qualified
registries would need to demonstrate
that they can meet the new 2011 data
submission requirements. Additionally,
we propose that registries that are
unsuccessful submitting 2010 PQRI data
(that is, fail to submit 2010 PQRI data
per the 2010 PQRI registry
requirements) will need to go through a
full self-nomination vetting process for
2011. Successful 2010 PQRI registries
that choose to report on new or different
2011 PQRI measures would also need to
qualify for these additional measures
and/or methods. We also propose that
registries that are ‘‘qualified’’ for 2010,
who were successful in submitting 2010
PQRI data, and wish to continue to
participate in 2011 would need to
indicate their desire to continue
participation for 2011 by submitting a
letter to CMS indicating their continued
interest in being a PQRI registry for 2011
and their compliance with the 2011
PQRI registry requirements by no later
than October 31, 2010. Instructions
regarding the procedures for submitting
this letter will be provided to qualified
2010 PQRI registries on the 2010 PQRI
registry support conference calls.
Similar to 2010 PQRI, we propose that
if a qualified 2010 PQRI registry fails to
submit 2010 PQRI data per the 2010
PQRI registry requirements, the registry
would be considered unsuccessful at
submitting 2010 PQRI data and would
need to go through the full selfnomination process again to participate
in the 2011 PQRI. By March 31, 2011,
registries that are unsuccessful at
submitting quality measures results and
numerator and denominator data for
2010 would need to be able to meet the
2011 PQRI registry requirements and go
through the full vetting process again.
This would include CMS receiving the
registry’s self-nomination by March 31,
2011. As discussed further under
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
section VI.F.2. of this proposed rule, we
propose that the above registry
requirements would apply not only for
the purpose of a registry qualifying to
report 2011 PQRI quality measure
results and numerator and denominator
data on PQRI individual quality
measures or measures groups, but also
for the purpose of a registry qualifying
to submit the proposed electronic
prescribing measure for the 2011
Electronic Prescribing Incentive
Program. We invite comments on the
proposed qualification requirements for
registries for the 2011 PQRI.
(5) Proposed Qualification
Requirements for EHR Vendors and
Their Products
In 2010 PQRI, EHR products were
listed on the PQRI section of the CMS
Web site at https://www.cms.hhs.gov/
PQRI as a ‘‘qualified’’ EHR product (that
is, the name of the vendor software
product and the version that was
qualified), and were available for the
product’s users to submit quality data
on Medicare beneficiaries to CMS
directly from their system for the 2010
PQRI. This list of qualified EHR vendors
and products was posted upon
completion of the 2009 EHR Testing
Program in January 2010.
Vendors’ EHR products that were
listed as ‘‘qualified’’ products for the
2010 PQRI were selected because the
vendor self-nominated to participate in
the 2009 EHR Testing Program and
demonstrated that their products met
the ‘‘Requirements for Electronic Health
Record (EHR) Vendors to Participate in
the 2009 PQRI EHR Testing Program’’
that were posted on the Alternative
Reporting Mechanisms page of the PQRI
section of the CMS Web site at https://
www.cms.gov/PQRI/20_Alternative
ReportingMechanisms.asp#TopOfPage
on December 31, 2008. Additionally, a
vendor’s EHR system was required to be
updated according to the Final 2010
EHR specifications, which were posted
in January 2010 on the Alternative
Reporting Mechanisms page of the PQRI
section of the CMS Web site in order for
an EHR vendor and its product to be
qualified to submit information on 2010
PQRI measures.
The EHR vendor qualification process
for the 2011 PQRI was finalized in the
2010 PFS final rule with comment
period (74 FR 61800 through 61802) and
is currently underway. We anticipate
the EHR vendor vetting process for the
2011 PQRI will be complete in early
2011. At the conclusion of the 2011
PQRI EHR vendor vetting process, those
EHR products that meet all of the 2011
EHR vendor requirements will be listed
on the PQRI section of the CMS Web
PO 00000
Frm 00137
Fmt 4701
Sfmt 4702
40175
site as a ‘‘qualified’’ PQRI EHR product,
which indicates that the product’s users
may submit quality data to CMS for the
2011 PQRI. We continue to caution
there is no guarantee that there will be
any qualified EHR vendors available for
the 2011 PQRI. However, since seven
EHR vendors and their programs were
‘‘qualified’’ to submit quality data to
CMS directly from their EPs for 2010
PQRI reporting, we are optimistic that
for 2011 PQRI and subsequent years
there will continue to be multiple
‘‘qualified’’ EHR vendors available for
EPs.
During 2011, we propose to use the
same self-nomination process described
in the ‘‘Requirements for Electronic
Health Record (EHR) Vendors to
Participate in the 2011 PQRI EHR
Testing Program’’ posted on the PQRI
section of the CMS Web site at https://
www.cms.gov/PQRI/20_
AlternativeReporting
Mechanisms.asp#TopOfPage, to qualify
additional EHR vendors and their EHR
products to submit quality data
extracted from their EHR products to the
CMS clinical quality data warehouse for
2012 PQRI. We propose that any EHR
vendor interested in having one or more
of their EHR products ‘‘qualified’’ to
submit quality data extracted from their
EHR products to the CMS clinical
quality data warehouse for 2012 and
subsequent years will be required to
submit their self-nomination letter by
January 31, 2011. Instructions for
submitting the self-nomination letter
will be provided in the 2012 EHR
vendor requirements, which we expect
to post in the 4th quarter of CY 2010.
Specifically, for the 2012 PQRI, we
propose that only EHR vendors that selfnominate to participate in the 2012 EHR
Test Program will be considered
qualified EHR vendors for the 2012
PQRI. We propose that the 2011 PQRI
EHR test vendors, who, if their testing
is successful, may report 2012 PQRI
data to CMS, must meet the following
requirements:
• Be able to collect and transmit all
required data elements according to the
2012 EHR Specifications.
• Be able to separate out and report
on Medicare Part B FFS patients only.
• Be able to include TIN/NPI
information submitted with an EP’s
quality data.
• Be able to transmit this data in the
CMS-approved format.
• Comply with a secure method for
data submission.
• Not be in a beta test form.
• Have at least 25 active users.
Additionally, we propose that
previously qualified PQRI EHR vendors
and 2012 EHR test vendors must also
E:\FR\FM\13JYP2.SGM
13JYP2
40176
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
participate in ongoing PQRI mandatory
support conference calls hosted by CMS
(approximately one call per month).
These requirements would apply not
only for the purpose of a vendor’s EHR
product being qualified so that the
product’s users may submit data
extracted from the EHR for the 2012
PQRI in 2013, but also for the purpose
of a vendor’s EHR product being
qualified so that the product’s users may
electronically submit data extracted
from the EHR for the electronic
prescribing measure for the 2012 eRx
Incentive Program in 2013. We propose
that if a vendor misses more than one
mandatory support call or meeting, the
vendor and their product would be
disqualified for the PQRI reporting year,
which is covered by the call.
We propose that previously qualified
vendors and new vendors will need to
incorporate any new EHR measures
(measures electronically-specified)
added to PQRI for the reporting year
they wish to maintain their PQRI
qualification, as well as update their
electronic measure specifications and
data transmission schema should either
or both change. This proposed
requirement ensures that all PQRI
qualified EHR products can be used by
EPs to report any PQRI EHR measure.
We invite comments on the proposed
qualification requirements for EHR
Vendors and their products for the 2012
PQRI.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
e. Proposed Criteria for Satisfactory
Reporting of Individual Quality
Measures for Individual EPs
Section 1848(m)(3)(A) of the Act
established the criteria for satisfactorily
submitting data on individual quality
measures as at least 3 measures in at
least 80 percent of the cases in which
the measure is applicable. If fewer than
3 measures are applicable to the services
of the professional, the professional may
meet the criteria by submitting data on
1 or 2 measures for at least 80 percent
of applicable cases where the measures
are reportable. This section establishes
the presumption that if an EP submits
quality data codes for a particular
measure the measure applies to the EP.
For years after 2009, section
1848(m)(3)(D) of the Act provides
additional authority to the Secretary, in
consultation with stakeholders and
experts, to revise the criteria for
satisfactorily reporting data on quality
measures. Based on this authority and
the input we have previously received
from stakeholders, we propose, for 2011,
the following 2 criteria for claims-based
reporting of individual measures by
individual EPs:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
• Report on at least 3 measures that
apply to the services furnished by the
professional; and
• Report each measure for at least 50
percent of the EP’s Medicare Part B FFS
patients for whom services were
furnished during the reporting period to
which the measure applies.
To the extent that an EP has fewer
than 3 PQRI measures that apply to the
EP’s services, then we propose the EP
would be able to meet the criteria for
satisfactorily reporting data on
individual quality measures by meeting
the following 2 criteria:
• Report on all measures that apply to
the services furnished by the
professional (that is 1 to 2 measures);
and
• Report each measure for at least 50
percent of the EP’s Medicare Part B FFS
patients for whom services were
furnished during the reporting period to
which the measure applies.
We also propose for 2011 the
requirement that an EP who reports on
fewer than 3 measures through the
claims-based reporting mechanism may
be subject to the Measure Applicability
Validation (MAV) process, which would
allow us to determine whether an EP
should have reported quality data codes
for additional measures. This process
was applied in prior years. Under the
proposed MAV process, when an EP
reports on fewer than 3 measures, we
propose to review whether there are
other closely related measures (such as
those that share a common diagnosis or
those that are representative of services
typically provided by a particular type
of EP). We further propose that if an EP
who reports on fewer than 3 measures
in 2011 reports on a measure that is part
of an identified cluster of closely related
measures and did not report on any
other measure that is part of that
identified cluster of closely related
measures, then the EP would not qualify
as a satisfactory reporter in 2011 PQRI
or earn an incentive payment. In 2011,
we propose that these criteria for
satisfactorily reporting data on fewer
than 3 individual quality measures
would apply for the claims-based
reporting mechanism only.
We note that the proposed 2011
criteria for satisfactory reporting of
individual quality measures through
claims submission are different from the
2010 criteria, which required reporting
on at least 80 percent of the EP’s
Medicare Part B FFS patients for whom
services were furnished during the
reporting period to which the measure
applies.
The rationale for an 80 percent
reporting rate is that this sample size
would prevent selective reporting to
PO 00000
Frm 00138
Fmt 4701
Sfmt 4702
achieve higher performance rates.
However, we now have experience with
claims based reporting, which has
proved challenging for EPs, as discussed
above. In 2007, approximately half of
PQRI participants (defined as
submitting at least one QDC), qualified
for the PQRI incentive payment.
Following the 2007 program
completion, we performed an extensive
review and made a number of analytic
changes that we detailed in our 2007
PQRI Experience Report. For 2008, the
analytic changes that we made
following the completion of the 2007
program resulted in substantial
increases in valid QDC reporting and
the number of professionals qualifying
for an incentive payment. However, the
number who qualified for the incentive
for the 2008 program year remained at
about half of those who participated. A
major reason for this was reporting at
less than the required 80 percent
reporting requirement. As a result of our
review of the 2007 and 2008 program
results, we believe that we can reduce
the reporting sample requirement to 50
percent for claims-based submission
without increasing the likelihood that
professionals will selectively report
based on whether the performance
expectation of a measure is met for that
particular patient. Inasmuch as we do
not allow resubmission of a claim solely
for the purpose of resubmission of a
QDC, EPs will still need to submit QDCs
contemporaneously with the claim.
Therefore, we believe that even at a 50
percent reporting it would be difficult to
selectively report for the purpose of
better performance. Based on our
review, we further believe that by
reducing the reporting sample, there
will be substantial increases in the
portion of participating professionals
who qualify for the PQRI incentive.
Thus, we believe we can encourage
significantly broader participation
which otherwise might be deterred if
physicians and other EPs do not believe
that they are likely to qualify for the
incentive.
As previously stated, we propose that
the 50 percent reporting sample would
apply only to the 2011 PQRI claimsbased reporting mechanism available for
reporting individual PQRI quality
measures and not registry-based
reporting or EHR-based reporting.
For the 2011 PQRI, we propose the
following 2 criteria for satisfactory
reporting of data on individual PQRI
quality measures for registry-based and
EHR-based reporting:
• Report on at least 3 measures that
apply to the services furnished by the
professional; and
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• Report each measure for at least 80
percent of the EP’s Medicare Part B FFS
patients for whom services were
furnished during the reporting period to
which the measure applies.
We do not believe that reducing the
reporting sample to 50 percent for
registry-based reporting or EHR-based
reporting would substantially impact
the portion of participating
professionals who qualify for the PQRI
incentive. As stated previously, over
90.0 percent of EPs submitting data
through registries were incentive
eligible.
The proposed 2011 criteria for
satisfactory reporting of data on
individual PQRI quality measures are
summarized in Table 47 and are
arranged by reporting mechanism and
reporting period. We seek public
comment on these proposed reporting
criteria. We are particularly interested
in receiving comments on our proposal
to lower the reporting criteria for
claims-based reporting of individual
40177
measures from 80 percent to 50 percent.
We seek input on whether 50 percent is
an appropriate threshold or if another
threshold would be more appropriate.
We had considered lowering the
reporting criteria to a higher threshold
(such as 60 percent or 75 percent) but
we found that differences in the
performance rates at 50 percent and 80
percent reporting were not substantial
while differences in the proportion of
EPs satisfactorily reporting at the two
different thresholds were substantial.
TABLE 47—PROPOSED 2011 CRITERIA FOR SATISFACTORY REPORTING OF DATA ON INDIVIDUAL PQRI QUALITY
MEASURES, BY REPORTING MECHANISM AND REPORTING PERIOD
Reporting mechanism
Reporting criteria
Claims-based reporting ..............................
• Report at least 3 PQRI measures, or 1–2 measures if
less than 3 measures apply to the EP; and
• Report each measure for at least 50% of the EP’s
Medicare Part B FFS patients seen during the reporting period to which the measure applies.
• Report at least 3 PQRI measures, or 1–2 measures if
less than 3 measures apply to the EP; and
• Report each measure for at least 50% of the EP’s
Medicare Part B FFS patients seen during the reporting period to which the measure applies.
• Report at least 3 PQRI measures; and
• Report each measure for at least 80% of the EP’s
Medicare Part B FFS patients seen during the reporting period to which the measure applies.
• Report at least 3 PQRI measures; and
• Report each measure for at least 80% of the EP’s
Medicare Part B FFS patients seen during the reporting period to which the measure applies.
• Report at least 3 PQRI measures; and
• Report each measure for at least 80% of the EP’s
Medicare Part B FFS patients seen during the reporting period to which the measure applies.
Claims-based reporting ..............................
Registry-based reporting ............................
Registry-based reporting ............................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
EHR-based reporting ..................................
Table 47 illustrates that there are a
total of 5 proposed reporting options for
2011, or ways in which an EP may meet
the criteria for satisfactorily reporting on
individual quality measures for the 2011
PQRI. Each proposed reporting option
consists of the criteria for satisfactorily
reporting such data and results on
individual quality measures relevant to
a given reporting mechanism and
reporting period. EPs may potentially
qualify for an incentive as satisfactorily
reporting individual quality measures
under more than one of the proposed
reporting criteria, proposed reporting
mechanism, and or for more than one
proposed reporting period; however,
only one incentive payment will be
made to an EP based on the longest
reporting period for which the EP
satisfactorily reports.
f. Proposed Criteria for Satisfactory
Reporting Measures Groups for
Individual EPs
We also propose that individual EPs
have the option to report measures
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Reporting period
groups instead of individual quality
measures to qualify for the 2011 PQRI
incentive, using claims or registries. As
stated previously, we do not propose to
make the EHR-based reporting
mechanism available for reporting on
measures groups in 2011. The criteria
that we propose for 2011 for satisfactory
reporting of measures groups through
claims-based or registry-based reporting
for either the 12-month or 6-month
reporting period are as follows: (1) For
claims-based reporting, the reporting of
at least 1 measures group for at least 50
percent of patients to whom the
measures group applies, during the
reporting period; or (2) for registrybased reporting, the reporting of at least
1 measures group for at least 80 percent
of patients to whom the measures group
applies during the reporting period. EPs,
for both claims-based and registry-based
reporting under these criteria, would be
required to submit data on a minimum
of 15 unique Medicare Part B FFS
patients for the 12-month reporting
period and a minimum of 8 Medicare
PO 00000
Frm 00139
Fmt 4701
Sfmt 4702
January 1, 2011–December 31, 2011.
July 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
July 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
Part B FFS patients for the 6-month
reporting period. We note that the
proposed criteria for 2011 are the same
criteria as for 2010 PQRI reporting on
measures groups, with the exception of
our reducing the reporting sample from
80 percent to 50 percent for claimsbased submission of measures groups.
We propose to reduce the reporting
sample requirement for claims-based
submission of measures groups for the
same reasons discussed in section
VI.F.1.e. of this proposed rule for
claims-based submission of individual
measures. In other words, we believe
that reducing the reporting sample from
80 percent to 50 percent will
substantially increase the portion of
participating EPs who qualify for a 2011
PQRI incentive without encouraging EPs
to selectively report only those cases
that will increase their performance
rates. Additionally for 2011, we propose
to retain the criteria, available only for
the 12-month reporting period, based on
reporting on at least 1 measures group
for at least 30 patients for whom
E:\FR\FM\13JYP2.SGM
13JYP2
40178
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
services were furnished between
January 1, 2011, and December 31, 2011,
to whom the measures group applies.
We also propose that the 30 patients on
which an EP would need to report a
measures group for 2011 would not
need to be consecutive patients. We
propose that the EP may report on any
30 unique patients seen during the
reporting period to which the measures
group applies. As in previous years, we
propose that for 2011, the patients, for
claims-based reporting, would be
limited to Medicare Part B FFS patients.
Finally, for registry-based reporting in
2011, in contrast to prior program years,
we propose to require that the minimum
patient numbers or percentages must be
met by Medicare Part B FFS patients
exclusively and not non-Medicare Part
B FFS patients. The reason for this is the
difficulty of analyzing data we receive
from registries, where patients other
than Medicare Part B FFS patients are
included. For example, under our
proposal we would be able to compare
claims data with registry submitted data
to compare patients in the denominator
of the measure for validation. The
proposed 2011 criteria for satisfactory
reporting of data on measures groups are
summarized in Table 48 and are
arranged by reporting mechanism and
reporting period.
TABLE 48—PROPOSED 2011 CRITERIA FOR SATISFACTORY REPORTING ON MEASURES GROUPS, BY REPORTING
MECHANISM AND REPORTING PERIOD
Reporting mechanism
Reporting criteria
Claims-based reporting ..............................
• Report at least 1 PQRI measures group;
• Report each measures group for at least 30 Medicare Part B FFS patients.
• Report at least 1 PQRI measures group;
• Report each measures group for at least 50% of the
EP’s Medicare Part B FFS patients seen during the
reporting period to whom the measures group applies; and
• Report each measures group on at least 15 Medicare
Part B FFS patients seen during the reporting period
to which the measures group applies.
• Report at least 1 PQRI measures group;
• Report each measures group for at least 50% of the
EP’s Medicare Part B FFS patients seen during the
reporting period to whom the measures group applies; and
• Report each measures group on at least 8 Medicare
Part B FFS patients seen during the reporting period
to which the measures group applies.
• Report at least 1 PQRI measures group;
• Report each measures group for at least 30 Medicare Part B FFS patients.
• Report at least 1 PQRI measures group;
• Report each measures group for at least 80% of the
EP’s Medicare Part B FFS patients seen during the
reporting period to whom the measures group applies; and
• Report each measures group on at least 15 Medicare
Part B FFS patients seen during the reporting period
to which the measures group applies.
• Report at least 1 PQRI measures group;
• Report each measures group for at least 80% of the
EP’s Medicare Part B FFS patients seen during the
reporting period to whom the measures group applies; and
• Report each measures group on at least 8 Medicare
Part B FFS patients seen during the reporting period
to which the measures group applies.
Claims-based reporting ..............................
Claims-based reporting ..............................
Registry-based reporting ............................
Registry-based reporting ............................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Registry-based reporting ............................
As illustrated in Table 48, there are a
total of 6 proposed reporting options, or
ways in which EPs may meet the criteria
for satisfactory reporting of measures
groups for the 2011 PQRI. Each
proposed reporting option consists of
the criteria for satisfactory reporting
relevant to a given reporting mechanism
and reporting period. As stated
previously, EPs may potentially qualify
as satisfactorily reporting for 2011 PQRI
on measures groups under more than
one of the reporting criteria, reporting
mechanisms, and/or for more than one
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Reporting period
reporting period; however, only one
incentive payment will be made to an
EP based on the longest reporting period
for which the EP satisfactorily reports.
Similarly, an EP could also potentially
qualify for the PQRI incentive payment
by satisfactorily reporting both
individual measures and measures
groups. However, only one incentive
payment will be made to the EP based
on the longest reporting period for
which the EP satisfactorily reports. We
invite comments on the proposed
PO 00000
Frm 00140
Fmt 4701
Sfmt 4702
January 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
January 1, 2011–December 31, 2011.
criteria for satisfactory reporting
measures groups for individual EPs.
g. Proposed Reporting Option for
Satisfactory Reporting on Quality
Measures by Group Practices
(1) Background and Authority
Section 1848(m)(3)(C)(i) of the Act
requires the Secretary to establish and
have in place a process by January 1,
2010 under which EPs in a group
practice (as defined by the Secretary)
shall be treated as satisfactorily
submitting data on quality measures
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
the PGP demonstration while
concurrently expanding the availability
of the GPRO to more group practices.
Since the PGP demonstration is a
demonstration program for large group
practices, one of the requirements for
group practices participating in the PGP
demonstration is for each practice to
have 200 or more members. To be
consistent with the PGP demonstration,
we propose one GPRO process, which
we refer to as ‘‘GPRO I’’ that would be
available only to similar large group
practices. For group practices that have
fewer than 200 members, we propose, if
technically feasible, an alternative
GPRO process which we refer to as
‘‘GPRO II’’. We invite comments on the
proposed definition of ‘‘group practice’’
and our proposal to expand the
definition of group practice to include
groups with 2 or more members.
In order to participate in the 2011
PQRI through the GPRO, we propose to
require group practices to complete a
self-nomination process and to meet
certain technical and other
requirements. The proposed selfnomination process and participation
requirements for GPRO I and GPRO II
are separately discussed below.
As discussed further in section VI.F.2.
of this proposed rule, participation in
the Electronic Prescribing (eRx)
Incentive Program is voluntary for group
practices selected to participate in the
PQRI group practice reporting option.
However, for 2011, we propose that
group practices must participate in the
PQRI group practice reporting option in
order to be eligible to participate in the
eRx group practice reporting option for
2011 PQRI. This is the current
requirement under the 2010 PQRI and
ERx Incentive programs. Therefore, we
(2) Definition of ‘‘Group Practice’’
propose that a group practice that
As stated above, section
wishes to participate in both the PQRI
1848(m)(3)(C)(i) of the Act authorizes
group practice reporting option and the
the Secretary to define ‘‘group practice.’’ electronic prescribing group practice
For purposes of determining whether a
reporting option must notify CMS of its
group practice satisfactorily submits
desire to do so at the time that it selfPQRI quality measures data, we propose nominates to participate in the PQRI
that for the 2011 PQRI a ‘‘group practice’’ group practice reporting option.
In addition, we propose that group
would consist of a physician group
practices that are participating in
practice, as defined by a TIN, with 2 or
more individual EPs (or, as identified by Medicare demonstration projects, as
approved by the Secretary, would also
NPIs) who have reassigned their billing
be considered group practices for
rights to the TIN. This proposed
definition for group practice is different purposes of the 2011 PQRI GPRO.
Specifically, for the 2011 PQRI we
from the 2010 PQRI definition of group
propose to deem group practices
practice in that we propose to change
participating in the PGP, Medicare Care
the minimum group size from 200 to 2
Management Performance (MCMP), and
to enable more group practices to
EHR demonstrations to be participating
participate in the PQRI GPRO in 2011.
in the PQRI GPRO since many of the
Generally, our intent continues to be
to build on an existing quality reporting measures being reported under these
demonstration programs are similar to
program that group practices may
PQRI measures. As a result, such
already be familiar with by modeling
some aspects of the the PQRI GPRO after practices do not need to separately self-
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
under PQRI if, in lieu of reporting
measures under PQRI, the group
practice reports measures determined
appropriate by the Secretary, such as
measures that target high-cost chronic
conditions and preventive care, in a
form and manner, and at a time
specified by the Secretary. Section
1848(m)(3)(C)(ii) of the Act requires that
this process provide for the use of a
statistical sampling model to submit
data on measures, such as the model
used under the Medicare Physician
Group Practice (PGP) demonstration
project under section 1866A of the Act.
A group practice reporting option
(GPRO) was established for the 2010
PQRI in the CY 2010 PFS final rule with
comment period (74 FR 61807 through
61811).
In addition, payments to a group
practice under section 1848(m) of the
Act by reason of the process proposed
herein shall be in lieu of the PQRI
incentive payments that would
otherwise be made to EPs in the group
practice for satisfactorily submitting
data on quality measures (that is,
prohibits double payments). Therefore,
for the 2011 PQRI, we propose to
continue to allow a group practice, as a
whole (that is, for the TIN(s)), to
participate in 2011 PQRI and to submit
PQRI quality measures for 2011 and
qualify to earn an incentive. If, however,
an individual EP is affiliated with a
group practice participating in the
GPRO and the group practice
satisfactorily reports under the GPRO,
the EP will be considered as
satisfactorily reporting PQRI quality
measures data at the individual level
under that same TIN(s) (that is, for the
same TIN/NPI combination).
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00141
Fmt 4701
Sfmt 4702
40179
nominate to participate in the PQRI
GPRO, although it would be necessary
for such groups to meet the
requirements for incentive qualification
under their respective approved
demonstration project. For example, the
MCMP demonstration sites would be
required to meet the requirements for
earning a PQRI incentive specified
under the MCMP demonstration.
For purposes of the 2011 eRx
Incentive Program, however, we
propose that group practices
participating in CMS-approved
demonstration projects discussed above
would be required to meet the proposed
2011 eRx Incentive Program GPRO
requirements or the proposed 2011 eRx
Incentive Program requirements for
individual EPs in order to qualify for a
2011 eRx incentive. Such group
practices would not be able to qualify
for a 2011 eRx incentive via
participation in an approved
demonstration project since there is no
eRx requirement under these
demonstrations.
(3) Proposed Process for Physician
Group Practices To Participate as Group
Practices and Criteria for Satisfactory
Reporting
(i) Group Practice Reporting Option for
Physician Group Practices With 200 or
More NPIs–GPRO I
As stated above, we propose that
group practices interested in
participating in GPRO I must selfnominate to do so. Specifically, we
propose that the 2011 PQRI selfnomination letter for group practices
interested in participating in the 2011
PQRI through the GPRO I must be
accompanied by an electronic file
submitted in a format specified by CMS
(such as, a Microsoft Excel file) that
includes the group practice’s TIN(s) and
name of the group practice, the name
and e-mail address of a single point of
contact for handling administrative
issues, as well as the name and e-mail
address of a single point of contact for
technical support purposes. This
information was also required as part of
the self-nomination process for the 2010
PQRI GPRO.
One change that we propose from the
2010 PQRI GPRO is that we propose for
2011 PQRI GPRO I to validate that the
group practice consists of a minimum of
200 NPIs and we will supply group
practices with this list. We invite
comment on this proposed change for
self nomination criteria. In addition, we
propose that the self-nomination letter
must also indicate the group practice’s
compliance with the following
requirements:
• Have an active IACS user account;
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40180
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• Agree to attend and participate in
all mandatory GPRO training sessions;
and
• Have billed Medicare Part B on or
after January 1, 2010 and prior to
October 29, 2010.
We propose to post the final 2011
PQRI participation requirements for
group practices, including instructions
for submitting the self-nomination letter
and other requested information, on the
PQRI section of the CMS Web site at
https://www.cms.gov/PQRI by November
15, 2010. Group practices that wish to
self-nominate for 2011 would be
required to do so by January 31, 2011.
Upon receipt of the self-nomination
letters we propose to assess whether the
participation requirements were met by
each self-nominated group practice
using 2010 Medicare claims data. We do
not propose to preclude a group practice
from participating in the GPRO I if we
discover, from analysis of the 2010
Medicare claims data, that there are
some EPs (identified by NPIs) that are
not established Medicare providers (that
is, have not billed Medicare Part B on
or after January 1, 2010 and prior to
October 29, 2010) as long as the group
has at least 200 established Medicare
providers. NPIs who are not established
Medicare providers, however, would
not be included in our incentive
payment calculations. We propose that
group practices that were selected to
participate in the 2010 PQRI GPRO
would automatically be qualified to
participate in the 2011 PQRI GPRO I
and would not need to complete the
2011 PQRI GPRO I self-nomination
process.
For physician groups selected to
participate in the PQRI GPRO I for 2011,
we propose to retain the existing 12month reporting period beginning
January 1, 2011. We propose that group
practices participating in GPRO I submit
information on these measures using a
data collection tool based on the GPRO
Tool used in 2010 PQRI GPRO by 36
participating group practices to report
quality measures under PQRI. The 2010
PQRI GPRO Tool will be updated as
needed to include the 2011 PQRI GPRO
I measures. We believe that use of the
GPRO data collection tool allows group
practices the opportunity to calculate
their own performance rates for
reporting quality measures. We propose
that physician groups selected to
participate in the 2011 PQRI through the
GPRO I report on a proposed common
set of 26 NQF-endorsed quality
measures that are based on measures
currently used for 2010 PQRI GPRO. We
believe these measures target high-cost
chronic conditions and preventive care.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
The proposed quality measures are
identified in Table 71.
The proposed 2011 PQRI GPRO I
quality measures are based on a subset
of the Doctor’s Office Quality (DOQ)
quality measures set developed under
the direction of CMS and were used in
the PGP and/or MCMP demonstration
programs, and have subsequently been
used in 2010 PQRI GPRO. Contributors
to the development of the DOQ
measures set included the American
Medical Association’s Physician
Consortium for Performances
Improvement (AMA–PCPI), the
American College of Cardiology (ACC),
the American Heart Association (AHA),
the National Diabetes Quality
Improvement Alliance, the National
Committee for Quality Assurance
(NCQA), and the Veterans Health
Administration (VA). In most instances,
these measures overlap with the
proposed 2011 PQRI measures for
reporting by individual EPs, however,
there are some measures proposed for
GPRO I that are not proposed for
individual EPs.
These quality measures are grouped
into four disease modules: coronary
artery disease; diabetes; heart failure;
and preventive care services. On
February 2, 2010, we hosted a 2011
PQRI listening session to solicit input
on a number of aspects of the PQRI,
including measures for the 2011 PQRI
GPRO. Since we received no suggestions
for additional disease modules for the
GPRO I from this listening session, we
are not proposing any additional
measures for the 2011 PQRI GPRO I. We
invite comments on our proposal to use
the 26 measures identified in Table 71
for inclusion in 2011 PQRI GPRO I. We
specifically request comments on
whether these measures can and/or
should be expanded for the group
practice reporting option for future
program years. Disease modules and
measures should address high cost
conditions and/or a gap in care. Further
detail on criteria for measure selection
can be found in section VI.F.1.h. below.
The proposed process that group
practices will be required to use to
report data on quality measures for the
2011 PQRI GPRO I and the proposed
associated criteria for satisfactory
reporting of data on quality measures by
group practices, are summarized in
Table 49. Under our proposed 2011
program, group practices participating
in PQRI GPRO I as a group practice
would be required to report on all of the
measures listed in Table 71.
As part of the data submission process
for 2011 GPRO I, we propose that during
2012, each group practice would be
required to report quality measures with
PO 00000
Frm 00142
Fmt 4701
Sfmt 4702
respect to services furnished during the
2011 reporting period (that is, January 1,
2011, through December 31, 2011) on an
assigned sample of Medicare
beneficiaries. We propose to analyze the
January 1, 2011 through October 31,
2011 (that is, the last business day of
October 2011) National Claims History
(NCH) file to assign Medicare
beneficiaries to each physician group
practice using a patient assignment
methodology modeled after the patient
assignment methodology used in the
PGP demonstration. Based on our desire
to model the PQRI GPRO I after the PGP
demonstration, we will also consider
applying any refinements made to the
patient assignment methodology used in
the PGP demonstration prior to January
1, 2011 to the 2011 PQRI GPRO I.
Assigned beneficiaries would be limited
to those Medicare FFS beneficiaries
with Medicare Parts A and B for whom
Medicare is the primary payer. Assigned
beneficiaries would not include
Medicare Advantage enrollees. A
beneficiary would be assigned to the
physician group that provides the
plurality of a beneficiary’s office or
other outpatient evaluation and
management allowed charges (based on
Medicare Part B claims submitted for
the beneficiary for dates of services
between January 1, 2011, and October
31, 2011). Beneficiaries with only 1 visit
to the group practice between January 1,
2011 and October 31, 2011, would be
eliminated from the group practice’s
assigned patient sample for purposes of
2011 PQRI GPRO I. For inclusion in the
sample, assigned beneficiaries would be
required to have at least 2 visits to the
group practice between January 1, 2011,
and October 31, 2011.
Once the beneficiary assignment has
been made for each physician group
during the fourth quarter of 2011, we
propose to provide each physician
group selected to participate in the PQRI
GPRO I with access to a database (that
is, a data collection tool) that will
include the group’s assigned beneficiary
samples and the quality measures listed
in Table 71. We propose to pre-populate
the data collection tool with the
assigned beneficiaries’ demographic and
utilization information based on all of
their Medicare claims data. We intend
to provide the selected physician groups
with access to this pre-populated
database by no later than the first
quarter of 2012. The physician group
would be required to populate the
remaining data fields necessary for
capturing quality measure information
on each of the assigned beneficiaries.
Numerators for each of the quality
measures would include all
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
beneficiaries in the denominator
population who also satisfy the quality
performance criteria for that measure.
Denominators for each quality measure
would include a sample of the assigned
beneficiaries who meet the eligibility
criteria for that disease module or each
preventive care quality measure. All of
the assigned patients’ inpatient,
outpatient, and physician claims would
be used in determining clinical
eligibility for each module, regardless if
they were submitted by the group
practice or other providers. Identical to
the sampling method used in the PGP
demonstration, we propose that the
random sample must consist of at least
411 assigned beneficiaries. If the pool of
eligible assigned beneficiaries is less
than 411, then the group practice must
report on 100 percent, or all, of the
assigned beneficiaries to satisfactorily
participate in the group practice
reporting option. For each disease
module or preventive care measure, the
physician group would be required to
40181
report information on the assigned
patients in the order in which they
appear in the group’s sample (that is,
consecutively). These proposed
reporting criteria are identical to the
reporting criteria used in the PGP
demonstration and in the 2010 PQRI
GPRO. By building on an existing
demonstration program that large group
practices may already have experience
with, we hope to minimize burden on
both group practices and CMS.
TABLE 49—2011 PROPOSED PROCESS FOR PHYSICIAN GROUP PRACTICES TO PARTICIPATE AS GROUP PRACTICES AND
CRITERIA FOR SATISFACTORY REPORTING OF DATA ON QUALITY MEASURES BY GROUP PRACTICES FOR GPRO I
Reporting criteria
A pre-populated data collection tool provided by CMS.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Reporting mechanism
• Report on all measures included in the data collection tool (26 measures); and
• Complete the tool for the first 411 consecutively
ranked and assigned beneficiaries in the order in
which they appear in the group’s sample for each
disease module or preventive care measure. If the
pool of eligible assigned beneficiaries is less than
411, then report on 100% of assigned beneficiaries.
For 2011, we propose an exclusive
reporting mechanism for EPs identified
as part of the group practice with
respect to the group as identified by the
TIN. However, EPs who are part of the
group practice, and who separately
practice with respect to another TIN to
which the EP has reassigned benefits,
could separately qualify as individual
EPs with respect to the other practice
(TIN). As discussed above, we propose
that each physician group selected to
participate in the PQRI GPRO I would
have access to a data base (that is a data
collection tool) that would include the
assigned beneficiary sample and the
quality measures. This data collection
tool was originally developed for use in
the PGP demonstration, updated for use
in the MCMP demonstration, and will
continue to be updated as needed for
use in the PQRI. The assigned
beneficiaries’ demographic and
utilization information is pre-populated
based on claims data. We anticipate
being able to provide the selected
physician groups with access to this
pre-populated database by the first
quarter of 2012. The physician group
would be required to populate the
remaining data fields necessary for
capturing quality measure information
on each of the assigned beneficiaries.
Numerators for each of the quality
measures would include all
beneficiaries in the denominator
population who also satisfy the quality
performance criteria for that measure.
Denominators for each quality measure
would include a sample of the assigned
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Reporting period
beneficiaries who meet the eligibility
criteria for that quality measure module
or preventive care measure.
We expect that use of the PQRI GPRO
I data collection tool allows group
practices the opportunity to calculate
their own performance rates for
reporting quality measures. This
provides group practices with the
chance to preview their information
prior to the public posting of
performance data should we choose to
do so in future program years.
We invite comment on our proposal
for 2011 to retain 200 as the number of
NPIs for a TIN required for each group
practice under the GPRO I. We also
invite comment on our proposal to
allow those ‘‘qualified’’ for 2010 GPRO
to be rolled over for automatic
qualification for 2011 GPRO I.
(ii) Group Practice Reporting Option for
Group Practices of 2—199 NPIs—
GPRO–II
As discussed previously, section
1848(m)(3)(C) of the Act authorizes us to
define the term ‘‘group practice’’ and
requires us to establish a process under
which EPs in group practices shall be
treated as satisfactorily submitting data
on PQRI quality measures, but is not
prescriptive with regard to the
characteristics of this process. Although
for 2010 we did not provide a process
for groups of less than 200 NPIs to
report under the GPRO, we believe that
there are significant potential benefits to
allowing reporting at the group level
generally. At present, for example,
PO 00000
Frm 00143
Fmt 4701
Sfmt 4702
January 1, 2011–December 31, 2011.
where more than one individual
professional sees the same patient, each
may have to report separately with
respect to the patient even for processes
of care that do not need to be repeated
at each visit. Thus, there is significant
duplication of reporting. Additionally,
while we are not proposing to report
performance information with respect to
the 2011 PQRI GPRO, the public
reporting of performance information at
the group level raises substantially
fewer issues, such as privacy, and the
potential adverse impact of public
reporting on the individual physician,
and the lack of sufficient numbers of
patients for any one physician to
meaningfully differentiate performance
results. Finally, we believe that many
process-of-care measures depend on
general functioning of the practice, such
as in coordinating and tracking care, as
opposed to a quality of a particular
professional in the group, particularly
for measures related to prevention and
care of chronic illnesses.
As a result, based on our authority
under section 1848(m)(3)(C) of the Act
to establish a process for group practices
and our discretion to define ‘‘group
practice’’ under this section we are
proposing multiple processes for
reporting at the group level for groups
of EPs of all sizes for purposes of
qualifying for a PQRI incentive
payment. The proposed process for
groups of 200 or more EPs, known as
GPRO I, was discussed above. If
technically feasible, we propose a new
group practice reporting option (GPRO
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40182
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
II) for groups of 2–199 NPIs in a TIN for
2011. For GPRO II in 2011, we propose
to require groups of EPs who decide to
report as a group to self-nominate. The
self-nomination process would consist
of sending a letter with the name of the
group, the TIN, an e-mail address of the
contact person, and the names and NPIs
of all of the EPs practicing under that
group’s TIN. We do not propose to
preclude a group practice from
participating in the GPRO II if we
discover, from analysis of the 2010
Medicare claims data, that there are
some EPs (identified by NPIs) that are
not established Medicare providers (that
is, have not billed Medicare Part B on
or after January 1, 2010 and prior to
October 29, 2010) as long as the group
has at least 2 established Medicare
providers. NPIs who are not established
Medicare providers, however, would
not be included in our incentive
payment calculations.
We also propose that self-nominating
groups would need to indicate in this
letter if the group intends to report as a
group for the eRx Incentive Program and
the reporting mechanism the group
intends to use to report as a group for
the eRx Incentive Program. We would
require that this information be sent to:
GPRO II, c/o CMS, 7500 Security Blvd.,
Mail Stop S3–02–01, Baltimore, MD
21244, and must be postmarked by
January 31, 2011, for consideration in
the program.
Since GPRO II would be a new
process available to groups in 2011, we
propose to initially pilot the GPRO II
process with a limited number of
groups. We propose to select the first
500 groups that meet the proposed
eligibility requirements to participate in
the 2011 GPRO II. We propose to use the
postmark to determine the order in
which groups self-nominated for GPRO
II. We propose to consider only selfnomination letters postmarked between
January 3, 2011 and January 31, 2011.
We do not propose to consider letters
postmarked prior to January 3, 2011 to
prevent groups from self-nominating
before the GPRO II requirements are
finalized and to discourage groups from
self-nominating for GPRO II prior to
reviewing the final GPRO II
requirements.
For purposes of quality data
submission, we propose, for the GPRO
II, to allow EPs to submit their data
through claims or through a qualified
GPRO registry to the extent registries are
technically capable of collecting,
calculating and transmitting the
required data to CMS and that we are
able to accept such data from registries.
For GPRO II, as discussed in greater
detail below, we propose that in
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
addition to reporting a specific number
of individual measures, the group
would have to report one or more
proposed 2011 PQRI measures groups
identified in Tables 57 through 70 of
this proposed rule depending on the
size of the group practice. In this way
we seek to address a concern expressed
regarding PQRI for individual reporting
that EPs are able to select any three of
a large array of measures making
comparison data difficult whether for
the same individual or among
professionals. We believe that by having
a smaller set of measures to choose
from, we hope to focus on topics of
major significance, and make the
information obtained with respect to
quality more meaningful.
For purposes of satisfying the
requirements under section
1848(m)(3)(C)(i) of the Act for groups of
2–199 NPIs, we propose that in order to
be treated as satisfactorily reporting
under GPRO II, the group practice
would be required to report on 50
percent or more (if submitting through
claims) of all Medicare Part B patients
who fit into the measures group
denominator or 80 percent or more of
Medicare patients if using a registry to
report.
Additionally, to earn a PQRI incentive
payment for all allowed Medicare Part
B services that are provided by the TIN,
we propose that a group practice must
report on three to six individual 2011
PQRI measures, depending on the size
of the group. We propose that the group
practice may select from among any of
the 2011 PQRI measures on which to
submit data, provided the measures
selected are not duplicated in the
measures group(s) reported.
We propose that, to satisfactorily
report individual PQRI measures, a
group must report each measure at the
same rate (percentage) as determined by
the method of submission as individual
EPs. For example, if reporting via
claims, to satisfactorily report
individual measures, each measure
would need to be reported on at least 50
percent of eligible Medicare Part B FFS
patients.
An alternative which we considered
was to require that the individual
measures be selected from a more
limited set of measures, such as
measures closely linked to improved
population health, or other measures
perceived to address the greatest
potential benefit from improved
performance. While there are potential
benefits to this approach of encouraging
broad reporting of a more limited set of
measures, we are concerned that any
limited measures set may not be
applicable to all groups, such as single
PO 00000
Frm 00144
Fmt 4701
Sfmt 4702
specialty groups. Further we are
concerned that this would diminish an
important strength of the overall PQRI
measures set, which is its broad
applicability. We invite comments on
the potential benefits of a core measures
set, as opposed to allowing groups to
select from among the array of PQRI
measures, what measures should be
included in that set, whether there are
any PQRI measures that all
professionals in group practices should
report, where the measure applies to
patients of the group.
A second alternative that we
considered was to require group
practices, as part of the self-nomination
process, to designate whether they were
a multispecialty group with primary
care, a multispecialty group without
primary care, or a single specialty
group, and if so, the specialty.
Depending on what type of specialty the
group is, we would identify a set of
PQRI measures pertaining to the group’s
specialty and require the group practice
to report on the identified set of
specialty-specific PQRI measures. We
invite comments on the potential
benefits of this approach as opposed to
allowing groups to select from among
the array of PQRI measures or requiring
all groups, regardless of specialty, to
report on the same core set of measures.
Table 50 sets forth the proposed
criteria for satisfactory reporting under
the 2011 PQRI GPRO II and
requirements for each group based on
their respective group size (number of
EPs).
If a group does not satisfactorily
report as a GPRO II group, we propose
to analyze the individual professional’s
data to see if they satisfactorily reported
at the individual TIN/NPI level. If the
EP satisfactorily reported at the
individual level, he or she would
receive a PQRI incentive, which is
calculated using the EP’s TIN/NPI
Medicare Part B allowed charges.
If a group practice participating in the
2011 PQRI GPRO II wants to also
participate in the 2011 eRx Incentive
Program as a small group, we propose
that the group would need to indicate
that preference in their self-nomination
letter and would need to report on the
number of unique encounters based on
their group size as listed in Table 50
below. For the 2011 eRx reporting for
GPRO II, we propose the following
reporting mechanisms: claims, a GPRO
eRx qualified registry or a GPRO
qualified EHR. As with the 2011 eRx
Incentive Program for individual EPs
and the 2011 eRx GPRO I, at least 10
percent of a GPRO II group’s charges
would need to be comprised of codes in
the denominator of the electronic
E:\FR\FM\13JYP2.SGM
13JYP2
40183
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
prescribing measure and the group
would need to use an electronic
prescribing system that meets the
requirements of the 2011 eRx measure.
Similar to proposed GPRO I, if a GPRO
II group self-nominates to report the eRx
measure as a group, we propose that all
members of the group practicing under
the group’s TIN would be ineligible to
report as an individual electronic
prescriber.
TABLE 50—2011 PROPOSED PROCESS FOR PHYSICIAN GROUP PRACTICES TO PARTICIPATE AS GROUP PRACTICES AND
CRITERIA FOR SATISFACTORY REPORTING OF DATA ON QUALITY MEASURES BY GROUP PRACTICES FOR GPRO II
Group size (number of
EPs)
Number of MGs
required to be reported
Percent of Medicare Pt B patients in denominator for successful reporting
via claims
Percent of Medicare Pt B patients in denominator for successful reporting
via registries
Minimum number
of patients in
each measures
group
Number of required individual
measures to report
Required number
of unique visits
where an e-prescription was
generated to be
a successful
electronic prescriber
1
1
2
3
4
50%
50%
50%
50%
50%
80%
80%
80%
80%
80%
35
50
50
60
100
3
3
4
5
6
75
225
475
925
1875
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2–10 .................................
11–25 ...............................
26–50 ...............................
51–100 .............................
101–199 ...........................
The required number of unique visits
where an electronic prescription was
generated to be a successful electronic
prescriber was determined by taking the
midpoint of the group size range and
multiplying the number by 12.5 and
then rounding this number to the
nearest multiple of 5. This is consistent
with how the 2010 eRx GPRO
requirements, which requires that the
group practice report that at least 1
prescription during an encounter was
generated and transmitted using a
qualified electronic prescribing system
in at least 2,500 instances during the
reporting period, were derived. For the
2010 eRx Incentive Program, we
assumed that half the members of an
average sized-group (which we assumed
to be 200 EPs) do not furnish the
services represented by the electronic
prescribing measure’s denominator
codes, and thus, would not have an
opportunity to report the electronic
prescribing measure. For the remaining
EPs within the group who do have an
opportunity to report the electronic
prescribing measure, we sought to hold
those EPs to the same standard as
individual EPs. Thus, for an average 200
EP group, each of the 100 EPs with an
opportunity to report the electronic
prescribing measure would be expected
to have 25 unique electronic prescribing
events for a total of 2,500 unique
electronic prescribing events for the
group.
We propose posting the information
required by section 1848(m)(5)(G) of the
Act for those group practices that are
selected to participate in the 2011 PQRI
under the GPRO II. That is, we propose
to post the names of group practices that
satisfactorily report under GPRO II as
we propose to do for group practices
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
that satisfactorily report under the 2011
PQRI GPRO I.
We invite comment on our proposal
to add this second option (GPRO II) for
group practices to report PQRI quality
data measures and the GPRO II process.
We also invite comments regarding our
proposal to publicly report GPRO II
information with respect to satisfactory
PQRI participation.
(iii) Alternatives Considered for
Expanding the GPRO in 2011
In addition to the GPRO II, another
option that we considered for expanding
the GPRO for 2011 was to expand GPRO
I to include smaller group practices.
Specifically, we considered allowing
groups of 100 or more EPs to participate
in the PQRI under GPRO using the same
reporting mechanism and reporting
criteria required under the 2010 PQRI
GPRO and proposed for the 2011 PQRI
GPRO I. We also considered modifying
the definition of ‘‘group practice’’ to
include groups that have and use
multiple TINs. We invite comments on
these alternatives.
h. Statutory Requirements and Other
Considerations for 2011 PQRI Measures
(1) Statutory Requirements for 2011
PQRI Measures
Under section 1848(k)(2)(C)(i) of the
Act, the PQRI quality measures shall be
such measures selected by the Secretary
from measures that have been endorsed
by the entity with a contract with the
Secretary under subsection 1890(a) of
the Act (that is, the National Quality
Forum, or NQF). However, in the case
of a specified area or medical topic
determined appropriate by the Secretary
for which a feasible and practical
measure has not been endorsed by the
NQF, section 1848(k)(2)(C)(ii) of the Act
PO 00000
Frm 00145
Fmt 4701
Sfmt 4702
authorizes the Secretary to specify a
measure that is not so endorsed as long
as due consideration is given to
measures that have been endorsed or
adopted by a consensus organization
identified by the Secretary, such as the
AQA alliance. In light of these statutory
requirements, we believe that, except in
the circumstances specified in the
statute, each proposed 2011 PQRI
quality measure would need to be
endorsed by the NQF. The NQF
endorsement status of each of the
proposed measures is identified for each
measure. The basis for including certain
measures that are not endorsed by NQF
is discussed further below.
Additionally, section 1848(k)(2)(D) of
the Act requires that for each 2011 PQRI
quality measure, ‘‘the Secretary shall
ensure that EPs have the opportunity to
provide input during the development,
endorsement, or selection of measures
applicable to services they furnish.’’ We
believe that this requirement is met for
all proposed measures in several ways.
Measure developers generally include a
public comment phase in their measure
development process. As part of the
measures development process,
measures developers typically solicit
public comments on measures that they
are testing in order to determine
whether additional refinement of the
measure(s) is needed prior to
submission for consensus endorsement.
For example, information on the
measure development process,
employed by us when CMS or our
contractor is the measure developer, is
available in the ‘‘Measures Management
System Blueprint’’ found on the CMS
Web site at https://www.cms.gov/apps/
QMIS/mmsBlueprint.asp. EPs also have
the opportunity to provide input on a
measure as the measure is being vetted
E:\FR\FM\13JYP2.SGM
13JYP2
40184
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
through the NQF consensus
endorsement process. The NQF employs
a public comment period for measures
vetted through its consensus
endorsement process (and previously,
for the AQA consensus adoption
process). Additionally, we have invited
suggestions for measures during the last
3 years, including most recently via the
Listening Session held at CMS on
February 2, 2010. The goal of the
Listening Session was to discuss and
solicit feedback on suggestions received
on individual quality measures and
measures groups for possible inclusion
in the proposed set of quality measures
for use in the 2011 PQRI program.
Finally, as in previous program years,
EPs also have an opportunity to provide
input on the measures proposed for
inclusion in the 2011 PQRI through this
proposed rule, which provides a 60-day
comment period. Accordingly, with
regard to the 2011 PQRI, we believe we
have satisfied this requirement in
multiple ways.
The statutory requirements under
section 1848(k)(2)(C) of the Act, subject
to the exception noted above, require
only that the measures be selected from
measures that have been endorsed by
the entity with a contract with the
Secretary under section 1890(a) (that is,
the NQF) and are silent with respect to
how the measures that are submitted to
the NQF for endorsement were
developed. The basic steps for
developing measures applicable to
physicians and other EPs prior to
submission of the measures for
endorsement may be carried out by a
variety of different organizations. We do
not believe there needs to be any special
restrictions on the type or make up of
the organizations carrying out this basic
development of physician measures,
such as restricting the initial
development to physician-controlled
organizations. Any such restriction
would unduly limit the basic
development of quality measures and
the scope and utility of measures that
may be considered for endorsement as
voluntary consensus standards.
(2) Other Considerations for Measures
Proposed for Inclusion in the 2011 PQRI
As stated previously, in addition to
reviewing the 2010 PQRI measures for
purposes of developing the proposed
2011 PQRI measures, we reviewed and
considered measure suggestions
including comments received in
response to the CY 2010 PFS proposed
rule and final rule with comment
period. Additionally, suggestions and
input received through other venues,
such as an invitation for measures
suggestions via the Listening Session
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
held February 2, 2010, were also
reviewed and considered for purposes
of our development of the list of
proposed 2011 PQRI quality measures.
A summary of the measures suggestions
received via the Listening Session is
included in the background paper that
was provided to Listening Session
participants. The Listening Session
background paper is posted on CMS
Sponsored Calls page of the PQRI
section of the CMS Web site at: https://
www.cms.gov/PQRI/04_
CMSSponsoredCalls.asp#TopOfPage.
With respect to the selection of new
measures (that is, measures that have
never been selected as part of a PQRI
quality measure set for 2010 or any prior
year), we propose to apply the following
considerations, which include many of
the same considerations applied to the
selection of 2009 and 2010 PQRI quality
measures for inclusion in the 2011 PQRI
quality measure set described above:
• High Impact on Healthcare.
++ Measures that are high impact and
support CMS and HHS priorities for
improved quality and efficiency of
care for Medicare beneficiaries. These
current and long-term priority topics
include the following: Prevention;
chronic conditions; high cost and
high volume conditions; elimination
of health disparities; healthcareassociated infections and other
conditions; improved care
coordination; improved outcomes;
improved efficiency; improved
patient and family experience of care;
improved end-of-life/palliative care;
effective management of acute and
chronic episodes of care; reduced
unwarranted geographic variation in
quality and efficiency; and adoption
and use of interoperable HIT.
• Measures that are included in, or
facilitate alignment with, other
Medicare, Medicaid, and CHIP programs
in furtherance of overarching healthcare
goals.
• NQF Endorsement.
++ Measures must be NQF-endorsed by
June 1, 2010, in order to be
considered for inclusion in the 2011
PQRI quality measure set except as
provided under section
1848(k)(2)(C)(ii) of the Act.
++ Section 1848(k)(2)(C)(ii) of the Act
provides an exception to the
requirement that the Secretary select
measures that have been endorsed by
the entity with a contract under
section 1890(a) of the Act (that is, the
NQF). As long as an area or medical
topic for which a feasible and
practical NQF-endorsed measure is
not available has been identified and
due consideration has been given to
PO 00000
Frm 00146
Fmt 4701
Sfmt 4702
measures that have been adopted by
the AQA or other consensus
organization identified by Secretary.
As discussed above, we anticipate not
including measures which only have
AQA adoption for future program
years.
++ The statutory requirements under
section 1848(k)(2)(C) of the Act,
subject to the exception noted above,
require only that the measures be
selected from measures that have been
endorsed by the entity with a contract
with the Secretary under section
1890(a) (that is, the NQF) and are
silent with respect to how the
measures that are submitted to the
NQF for endorsement are developed.
The basic steps for developing
measures applicable to physicians
and other EPs prior to submission of
the measures for endorsement may be
carried out by a variety of different
organizations. We do not believe there
needs to be any special restrictions on
the type or makeup of the
organizations carrying out this basic
development of physician measures,
such as restricting the initial
development to physician-controlled
organizations. Any such restriction
would unduly limit the basic
development of quality measures and
the scope and utility of measures that
may be considered for endorsement as
voluntary consensus standards. The
requirements under section
1848(k)(2)(C) of the Act pertain only
to the selection of measures and not
to the development of measures.
• Address Gaps in PQRI Measure Set.
++ Measures that increase the scope of
applicability of the PQRI measures to
services furnished to Medicare
beneficiaries and expand
opportunities for EPs to participate in
PQRI. We continue to seek the broad
ability to assess the quality of care
furnished to Medicare beneficiaries,
and ultimately to compare
performance among professionals. We
seek to increase the circumstances
where EPs have at least three
measures applicable to their practice
and measures that help expand the
number of measures groups with at
least four measures in a group.
• Measures of various aspects of
clinical quality including outcome
measures, where appropriate and
feasible, process measures, structural
measures, efficiency measures, and
measures of patient experience of care.
Other considerations that we propose
to apply to the selection of measures for
2011, regardless of whether the measure
was a 2010 PQRI measure or not, were:
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
• Measures that are functional, which
is to say measures that can be
technically implemented within the
capacity of the CMS infrastructure for
data collection, analysis, and
calculation of reporting and
performance rates. This leads to
preference for measures that reflect
readiness for implementation, such as
those that are currently in the 2010
PQRI program or have been through
testing. The purpose of measure testing
is to reveal the measure’s strengths and
weaknesses so that the limitations can
be addressed and the measure refined
and strengthened prior to
implementation. For any new measures
considered for 2011 PQRI, preference is
given to those that can be most
efficiently implemented for data
collection and submission. Therefore,
any measures that have previously been
found to be technically impractical to
report because they are analytically
challenging due to any number of
factors, including those that are claimsbased, will again not been included for
2011 PQRI. For example, in some cases,
we are proposing to replace existing
2010 PQRI measures with updated and
improved measures that are less
technically challenging to report. For
example, we are proposing to replace
existing 2010 PQRI measures #114 and
#115 with updated and improved
measure #TBD (Preventive Care and
Screening: Tobacco Use: Screening and
Cessation Intervention), which is less
technically challenging to report.
• In 2011 PQRI, as in 2010 PQRI, for
some measures that are useful, but
where data submission is not feasible
through all otherwise available PQRI
reporting mechanisms, a measure may
be included for reporting solely through
specific reporting mechanism(s) in
which its submission is feasible. For the
2011 PQRI, we propose to retain those
measures that had previously been
available for claims-based reporting and
registry-based reporting, which were
changed for 2010 PQRI to registry-based
reporting only because they were
technically challenging to report and/or
analyze through the claims-based
reporting mechanism.
We welcome comments on the
implication of including or excluding
any given measure or measures for our
proposed 2011 PQRI quality measure
set, as well as feedback relative to our
proposed approach in selecting
measures. We recognize that some
commenters may also wish to
recommend additional measures for
inclusion in the 2011 PQRI measures
that we are not proposing. While we
welcome all constructive comments and
suggestions, and may consider such
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
recommended measures for inclusion in
future measure sets for PQRI and/or
other programs to which such measures
may be relevant, we will not be able to
consider such additional measures for
inclusion in the final 2011 measure set.
As discussed above, section
1848(k)(2)(D) of the Act requires that the
public have the opportunity to provide
input during the selection of measures.
We also are required by other applicable
statutes to provide opportunity for
public comment on provisions of policy
or regulation that are established via
notice and comment rulemaking.
Measures that were not included in this
proposed rule for inclusion in the 2011
PQRI that are recommended to CMS via
comments on this proposed rule cannot
be included in the 2011 measure set.
As discussed above, section
1848(k)(2)(D) of the Act requires that the
public have the opportunity to provide
input during the selection of measures.
We also are required by other applicable
statutes to provide opportunity for
public comment on provisions of policy
or regulation that are established via
notice and comment rulemaking.
Measures that were not included in this
proposed rule for inclusion in the 2011
PQRI that are recommended to CMS via
comments on this proposed rule have
not been placed before the public to
comment on the selection of those
measures within the rulemaking
process. Even when measures have been
published in the Federal Register, but
in other contexts and not specifically
proposed as PQRI measures, such
publication does not provide true
opportunity for public comment on
those measures’ potential inclusion in
PQRI. Thus, such additional measures
recommended for selection for the 2011
PQRI via comments on this proposed
rule cannot be included in the 2011
measure set. However, as discussed
above, we will consider comments and
recommendations for measures, which
may not be applicable to the final set of
2011 PQRI measures, for purposes of
identifying measures for possible use in
future years’ PQRI or other initiatives to
which those measures may be pertinent.
In addition, as in prior years, we again
note that we do not use notice and
comment rulemaking as a means to
update or modify measure
specifications. Quality measures that
have completed the consensus process
have a designated party (usually, the
measure developer/owner) who has
accepted responsibility for maintaining
the measure. In general, it is the role of
the measure owner, developer, or
maintainer to make changes to a
measure. Therefore, comments
requesting changes to a specific
PO 00000
Frm 00147
Fmt 4701
Sfmt 4702
40185
proposed PQRI measure’s title,
definition, and detailed specifications or
coding should be directed to the
measure developer identified in Tables
52 through 70. Contact information for
the 2010 PQRI measure developers is
listed in the ‘‘2010 PQRI Quality
Measures List,’’ which is available on
the PQRI section of the CMS Web site
at https://www.cms.gov/PQRI.
However, we stress that inclusion of
measures that are not NQF endorsed or
AQA adopted is an exception to the
requirement under section
1848(k)(2)(C)(i) of the Act that measures
be endorsed by the NQF. We may
exercise this exception authority in a
specified area or medical topic for
which a feasible and practical measure
has not been endorsed by NQF, so long
as due consideration is given to
measures that have been endorsed by
the NQF.
i. Proposed 2011 PQRI Quality Measures
for Individual EPs
As in 2010 PQRI, individual EPs have
the choice of reporting PQRI quality
measures data on either individual
quality measures or on measures groups
for 2011 PQRI.
Consistent with statutory
requirements for identifying and
including measures for 2011 PQRI, the
individual quality measures identified
for use in the 2011 PQRI will be selected
from those we propose in this rule and
will ultimately be finalized as of the
date the CY 2011 PFS final rule with
comment period is available for public
inspection at the Office of the Federal
Register. No changes (that is, additions
or deletions of measures) will be made
after publication of the CY 2011 PFS
final rule with comment period.
However, as was the case in previous
program years, we may make
modifications or refinements, such as
revisions to measures titles and code
additions, corrections, or revisions to
the detailed specifications for the 2011
measures until the beginning of the
reporting period. The 2011 measures
specifications for individual quality
measures will be available on the PQRI
section of the CMS Web site at https://
www.cms.gov/PQRI when they are
sufficiently developed or finalized. We
are targeting finalization and
publication of the detailed
specifications for all 2011 PQRI
measures on the PQRI section of the
CMS Web site by November 15, 2010
and will, in no event, publish these
specifications later than December 31,
2010. The detailed specifications will
include instructions for reporting and
will identify the circumstances in which
each measure is applicable. For 2011,
E:\FR\FM\13JYP2.SGM
13JYP2
40186
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
we are proposing that for the most part,
final PQRI quality measures will be
selected from the 2010 PQRI measures.
In response to the February 2, 2010
Listening Session, CMS received 146
individual measure suggestions and 9
measures groups suggestions, one of
which included modifications to an
existing measures group, for possible
inclusion in the 2011 PQRI.
We propose to include a total of 198
measures (this includes both individual
measures and measures that are part of
a proposed 2011 measures group) on
which individual EPs can report for the
2011 PQRI. The individual PQRI quality
measures proposed for the 2011 PQRI
are listed in Tables 52 through 56 and
fall into four broad categories as set
forth below. The four categories are the
following:
• Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Claims-Based Reporting and RegistryBased Reporting;
• Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Registry-Based Reporting Only;
• New Individual Quality Measures
Proposed for 2011; and
• Proposed 2011 Measures Available
for EHR-Based Reporting.
In addition, we are also proposing the
inclusion of 1 new measures group for
2011 PQRI. The measures proposed for
2011 measures groups are listed in
Tables 57 through 70. Please note Table
51 includes 2010 PQRI measures that
are not proposed for inclusion in 2011
PQRI.
TABLE 51—2010 PQRI QUALITY MEASURES NOT PROPOSED FOR INCLUSION IN THE 2011 PQRI
Measure No.
114
115
135
136
139
Measure title
.............................
.............................
.............................
.............................
.............................
Preventive Care and Screening: Inquiry Regarding Tobacco Use.
Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit.
Chronic Kidney Disease (CKD): Influenza Immunization.
Melanoma: Follow-Up Aspects of Care.
Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement.
After careful consideration of 2010
PQRI measures, we propose to retire
these 5 measures because they did not
meet one or more of the considerations
for selection of proposed 2011 measures
discussed in section VI.F.1.h. above.
Specifically, we are proposing to retire
PQRI measures #135, #136, and #139,
for 2011 because they have been
considered by NQF for possible
endorsement but ultimately were not
NQF-endorsed. In addition we propose
to replace existing 2010 PQRI measures
#114 and #115 with an updated and
improved measure (#TBD ‘‘Preventive
Care and Screening: Tobacco Use:
Screening and Cessation Intervention’’),
which is less technically challenging to
report. We invite comments on our
proposal to retire the 2010 measures
listed in Table 51 for the 2011 PQRI.
(1) Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Claims-Based Reporting and RegistryBased Reporting
For 2011, we propose to retain 170
measures currently used in the 2010
PQRI. These 170 proposed measures
include 45 registry-only measures
currently used in the 2010 PQRI, but do
not include any measures that are
proposed to be included as part of the
2011 Back Pain measures group (see
section VI.F.1.i.(5) of this proposed
rule). Similar to the 2010 PQRI, for
2011, we propose that any 2011 PQRI
measures that are included in the Back
Pain measures group would not be
reportable as individual measures
through claims-based reporting or
registry-based reporting.
The 125 individual 2010 PQRI
measures proposed for inclusion in the
2011 PQRI quality measure set as
individual quality measures for either
claims-based reporting or registry-based
reporting are listed by their Measure
Number and Title in Table 52, along
with the name of the measure’s
developer/owner, and the NQF measure
number, if applicable. The PQRI
Measure Number is a unique identifier
assigned by CMS to all measures in the
PQRI measure set. Once a PQRI Measure
Number is assigned to a measure, it will
not be used again to identify a different
measure, even if the original measure to
which the number was assigned is
subsequently retired from the PQRI
measure set. A description of the
measures listed in Table 52 can be
found in the ‘‘2010 PQRI Quality
Measures List,’’ which is available on
the Measures and Codes page of the
PQRI section of the CMS Web site at
https://cms.gov/PQRI.
The 2010 measures that are proposed
to be available for registry-based
reporting only for the 2011 PQRI are
discussed and identified in section
VI.F.1.i.(2) of this proposed rule.
TABLE 52—PROPOSED 2011 MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
EITHER CLAIMS-BASED REPORTING OR REGISTRY-BASED REPORTING
Measure No.
Measure title
Measure developer
1 .........................
Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes
Mellitus.
Diabetes Mellitus: Low Density Lipoprotein (LDL–C) Control
in Diabetes Mellitus.
Diabetes Mellitus: High Blood Pressure Control in Diabetes
Mellitus.
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy
Prescribed for Patients with CAD.
Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD.
Stroke and Stroke Rehabilitation: Computed Tomography
(CT) or Magnetic Resonance Imaging (MRI) Reports.
NCQA .....................................
0059.
NCQA .....................................
0064.
NCQA .....................................
0061.
AMA–PCPI .............................
0067.
NCQA .....................................
0105.
AMA–PCPI/NCQA .................
0246.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
2 .........................
3 .........................
6 .........................
9 .........................
10 .......................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00148
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
NQF Measure No.
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40187
TABLE 52—PROPOSED 2011 MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
EITHER CLAIMS-BASED REPORTING OR REGISTRY-BASED REPORTING—Continued
Measure No.
Measure title
Measure developer
12 .......................
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation.
Age-Related Macular Degeneration (AMD): Dilated Macular
Examination.
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy.
Diabetic Retinopathy: Communication with the Physician
Managing On-Going Diabetes Care.
Perioperative Care: Timing of Antibiotic Prophylaxis—Ordering Physician.
Perioperative Care: Selection of Prophylactic Antibiotic—
First OR Second Generation Cephalosporin.
Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures).
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients).
Osteoporosis: Communication with the Physician Managing
On-Going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older.
Aspirin at Arrival for Acute Myocardial Infarction (AMI) .........
Perioperative Care: Timely Administration of Prophylactic
Parenteral Antibiotics.
Stroke and Stroke Rehabilitation: Deep Vein Thrombosis
Prophylaxis (DVT) for Ischemic Stroke or Intracranial
Hemorrhage.
Stroke and Stroke Rehabilitation: Discharged on Antiplatelet
Therapy.
Stroke and Stroke Rehabilitation: Screening for Dysphagia
Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services.
Screening or Therapy for Osteoporosis for Women Aged 65
Years and Older.
Osteoporosis: Management Following Fracture of Hip,
Spine or Distal Radius for Men and Women Aged 50
Years and Older.
Osteoporosis: Pharmacologic Therapy for Men and Women
Aged 50 Years and Older.
Coronary Artery Bypass Graft (CABG): Use of Internal
Mammary Artery (IMA) in Patients with Isolated CABG
Surgery.
Coronary Artery Bypass Graft (CABG): Preoperative BetaBlocker in Patients with Isolated CABG Surgery.
Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures).
Medication Reconciliation: Reconciliation After Discharge
From an Inpatient Facility.
Advance Care Plan ................................................................
Urinary Incontinence: Assessment of Presence or Absence
of Urinary Incontinence in Women Aged 65 Years and
Older.
Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older.
Urinary Incontinence: Plan of Care for Urinary Incontinence
in Women Aged 65 Years and Older.
Chronic
Obstructive
Pulmonary
Disease
(COPD):
Spirometry Evaluation.
Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy.
Asthma: Pharmacologic Therapy ...........................................
12–Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain.
12–Lead Electrocardiogram (ECG) Performed for Syncope
Community-Acquired Pneumonia (CAP): Vital Signs ............
Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation.
Community-Acquired Pneumonia (CAP): Assessment of
Mental Status.
Community-Acquired Pneumonia (CAP): Empiric Antibiotic ..
Asthma: Asthma Assessment ................................................
AMA–PCPI/NCQA .................
0086.
AMA–PCPI/NCQA .................
0087.
AMA–PCPI/NCQA .................
0088.
AMA–PCPI/NCQA .................
0089.
AMA–PCPI/NCQA .................
0270.
AMA–PCPI/NCQA .................
0268.
AMA–PCPI/NCQA .................
0271.
AMA–PCPI/NCQA .................
0239.
AMA–PCPI/NCQA .................
0045.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0092.
0270.
AMA–PCPI/NCQA .................
0240
AMA–PCPI/NCQA .................
0325.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0243.
0244.
AMA–PCPI/NCQA .................
0046.
AMA–PCPI/NCQA .................
0045.
AMA–PCPI/NCQA .................
0049.
Society of Thoracic Surgeons
(STS).
0516 or 0134.
STS ........................................
0127 or 0236.
AMA–PCPI/NCQA .................
0637.
AMA–PCPI/NCQA .................
0097.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0326.
0098.
AMA–PCPI/NCQA .................
0099.
AMA–PCPI/NCQA .................
0100.
AMA–PCPI .............................
0091.
AMA–PCPI .............................
0102.
AMA–PCPI .............................
AMA–PCPI/NCQA .................
0047.
0090.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0093.
0232
0094.
AMA–PCPI/NCQA .................
0234.
AMA–PCPI/NCQA .................
AMA–PCPI .............................
0096.
0001.
14 .......................
18 .......................
19 .......................
20 .......................
21 .......................
22 .......................
23 .......................
24 .......................
28 .......................
30 .......................
31 .......................
32 .......................
35 .......................
36 .......................
39 .......................
40 .......................
41 .......................
43 .......................
44 .......................
45 .......................
46 .......................
47 .......................
48 .......................
49 .......................
50 .......................
51 .......................
52 .......................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
53 .......................
54 .......................
55 .......................
56 .......................
57 .......................
58 .......................
59 .......................
64 .......................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00149
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
NQF Measure No.
40188
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 52—PROPOSED 2011 MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
EITHER CLAIMS-BASED REPORTING OR REGISTRY-BASED REPORTING—Continued
Measure No.
Measure title
Measure developer
65 .......................
Treatment for Children With Upper Respiratory Infection
(URI): Avoidance of Inappropriate Use.
Appropriate Testing for Children With Pharyngitis .................
Myelodysplastic Syndrome (MDS) and Acute Leukemias:
Baseline Cytogenetic Testing Performed on Bone Marrow.
Myelodysplastic Syndrome (MDS): Documentation of Iron
Stores in Patients Receiving Erythropoietin Therapy.
Multiple Myeloma: Treatment With Bisphosphonates ............
Chronic Lymphocytic Leukemia (CLL): Baseline Flow
Cytometry.
Breast Cancer: Hormonal Therapy for Stage IC–IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive
Breast Cancer.
NCQA .....................................
0069.
NCQA .....................................
AMA–PCPI/American Society
of Hematology (ASH).
AMA–PCPI/ASH ....................
0002.
0377.
AMA–PCPI/ASH ....................
AMA–PCPI/ASH ....................
0380.
0379.
AMA–PCPI/American Society
of Clinical Oncology
(ASCO)/National Comprehensive Cancer Network
(NCCN).
AMA–PCPI/ASCO/NCCN ......
0387.
AMA–PCPI .............................
0464.
AMA–PCPI .............................
0227.
AMA–PCPI .............................
0395.
AMA–PCPI .............................
AMA–PCPI .............................
AMA–PCPI .............................
0396.
0397.
0398.
AMA–PCPI .............................
0401.
AMA–PCPI .............................
0394.
AMA–PCPI .............................
AQA adopted Currently
NQF review.
AQA adopted Currently
NQF review.
AQA adopted Currently
NQF review.
AQA adopted Currently
NQF review.
0391.
66 .......................
67 .......................
68 .......................
69 .......................
70 .......................
71 .......................
72 .......................
91 .......................
Colon Cancer: Chemotherapy for Stage III Colon Cancer
Patients.
Prevention of Catheter-Related Bloodstream Infections
(CRBSI): Central Venous Catheter (CVC) Insertion Protocol.
End-Stage Renal Disease (ESRD): Influenza Immunization
in Patients with ESRD.
Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating
Treatment.
Hepatitis C: HCV Genotype Testing Prior to Treatment ........
Hepatitis C: Antiviral Treatment Prescribed ...........................
Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week
12 of Treatment.
Hepatitis C: Counseling Regarding Risk of Alcohol Consumption.
Hepatitis C: Counseling Regarding Use of Contraception
Prior to Antiviral Therapy.
Acute Otitis Externa (ACE): Topical Therapy ........................
92 .......................
Acute Otitis Externa (ACE): Pain Assessment ......................
AMA–PCPI .............................
93 .......................
Acute Otitis Externa (ACE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use.
Otitis Media with Effusion (OME): Diagnostic Evaluation—
Assessment of Tympanic Membrane Mobility.
Breast Cancer Resection Pathology Reporting: pT Category
(Primary Tumor) and pN Category (Regional Lymph
Nodes) With Histologic Grade.
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional
Lymph Nodes) With Histologic Grace.
Prostate Cancer: Avoidance of Overuse of Bone Scan for
Staging Low-Risk Prostate Cancer Patients.
Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk
Prostate Cancer Patients.
Prostate Cancer: Three-Dimensional (3D) Radiotherapy ......
Major Depressive Disorder (MDD): Diagnostic Evaluation ....
Major Depressive Disorder (MDD): Suicide Risk Assessment.
Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy.
Osteoarthritis: Function and Pain Assessment ......................
Preventive Care and Screening: Influenza Immunization for
Patients ≥ 50 Years Old.
Preventive Care and Screening: Pneumonia Vaccination for
Patients 65 Years and Older.
Preventive Care and Screening: Screening Mammography
Preventive Care and Screening: Colorectal Cancer Screening.
Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use.
Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient ......
Diabetes Mellitus: Urine Screening for Microalbumin or
Medical Attention for Nephropathy in Diabetic Patients.
AMA–PCPI .............................
76 .......................
79 .......................
84 .......................
85 .......................
86 .......................
87 .......................
89 .......................
90 .......................
94 .......................
99 .......................
100 .....................
102 .....................
104 .....................
105 .....................
106 .....................
107 .....................
108 .....................
109 .....................
110 .....................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
111 .....................
112 .....................
113 .....................
116 .....................
117 .....................
119 .....................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00150
Fmt 4701
Sfmt 4702
AMA–PCPI .............................
AMA–PCPI/College of American Pathologists (CAP).
NQF Measure No.
0378.
0385.
AMA–PCPI/CAP ....................
0392.
AMA–PCPI .............................
0389.
AMA–PCPI .............................
0390.
AMA–PCPI .............................
AMA–PCPI .............................
AMA–PCPI .............................
0388.
0103.
0104.
NCQA .....................................
0054.
AMA–PCPI .............................
AMA–PCPI .............................
0050.
0041.
NCQA .....................................
0043.
NCQA .....................................
NCQA .....................................
0031.
0034.
NCQA .....................................
0058.
NCQA .....................................
NCQA .....................................
0055.
0062.
E:\FR\FM\13JYP2.SGM
13JYP2
under
under
under
under
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40189
TABLE 52—PROPOSED 2011 MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
EITHER CLAIMS-BASED REPORTING OR REGISTRY-BASED REPORTING—Continued
Measure No.
Measure title
Measure developer
NQF Measure No.
121 .....................
Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorous, Intact Parathyroid Hormone (iPTH)
and Lipid Profile).
Chronic Kidney Disease (CKD): Blood Pressure Management.
Chronic Kidney Disease (CKD): Plan of Care—Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA).
Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR).
Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral
Neuropathy—Neurological Evaluation.
Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention—Evaluation of Footwear.
Preventive Care and Screening: Body Mass Index (BMI)
Screening and Follow-Up.
Documentation and Verification of Current Medications in
the Medical Record.
Pain Assessment Prior to Initiation of Patient Therapy and
Follow-Up.
Screening for Clinical Depression and Follow-Up Plan .........
Age-Related Macular Degeneration (AMD): Counseling on
Antioxidant Supplement.
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of Plan
of Care.
Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications.
Radiology: Exposure Time Reported for Procedures Using
Fluoroscopy.
Radiology: Inappropriate Use of ‘‘Probably Benign’’ Assessment Category in Mammography Screening.
Nuclear Medicine: Correlation With Existing Imaging Studies
for All Patients Undergoing Bone Scintigraphy.
Chronic Kidney Disease (CKD): Referral for Arteriovenous
(AV) Fistula.
Falls: Risk Assessment ..........................................................
Falls: Plan of Care .................................................................
Oncology: Radiation Dose Limits to Normal Tissues ............
Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection.
Carotid Endarterectomy: Use of Patch During Conventional
Carotid Endarterectomy.
Diabetes Mellitus: Foot Exam ................................................
Hemodialysis Vascular Access Decision-Making by Surgeon
To Maximize Placement of Autogenous Arterial Venous
(AV) Fistula.
Preventive Care and Screening: Unhealthy Alcohol Use—
Screening.
Pediatric End-Stage Renal Disease (ESRD): Influenza Immunization.
Rheumatoid Arthritis (RA): Tuberculosis Screening ..............
Rheumatoid Arthritis (RA): Periodic Assessment of Disease
Activity.
Rheumatoid Arthritis (RA): Functional Status Assessment ...
Rheumatoid Arthritis (RA): Assessment and Classification of
Disease Prognosis.
Rheumatoid Arthritis (RA): Glucocorticoid Management .......
Elder Maltreatment Screen and Follow-Up Plan ...................
Functional Outcome Assessment in Chiropractic Care .........
Hepatitis C: Hepatitis A Vaccination in Patients with HCV ....
Hepatitis C: Hepatitis B Vaccination in Patients with HCV ....
Endoscopy & Polyp Surveillance: Colonoscopy Interval for
Patients With a History of Adenomatous Polyps—Avoidance of Inappropriate Use.
Wound Care: Use of Compression System in Patients With
Venous Ulcers.
Referral for Otologic Evaluation for Patient With Congenital
or Traumatic Deformity of the Ear.
AMA–PCPI .............................
Combined: 0570, 0571, 0572,
0626.
AMA–PCPI .............................
AQA adopted.
AMA–PCPI .............................
AQA adopted.
CMS/Quality Insights of Pennsylvania (QIP).
American Podiatric Medical
Association (APMA).
APMA .....................................
0488.
CMS/QIP ................................
0421.
CMS/QIP ................................
0419.
CMS/QIP ................................
0420.
CMS/QIP ................................
AMA–PCPI/NCQA .................
0418.
0566.
AMA–PCPI/NCQA .................
0563.
AMA–PCPI .............................
0051.
AMA–PCPI/NCQA .................
0510.
AMA–PCPI/NCQA .................
0508.
AMA–PCPI .............................
0511.
AMA–PCPI .............................
AQA adopted.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AMA–PCPI .............................
STS ........................................
AQA adopted.
AQA adopted.
0382
0455.
Society of Vascular Surgeons
(SVS).
NCQA .....................................
SVS ........................................
0466.
AMA–PCPI .............................
AQA adopted.
AMA–PCPI .............................
AQA adopted.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AQA adopted.
AQA adopted.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AQA adopted.
AQA adopted.
AMA–PCPI/NCQA .................
CMS/QIP ................................
CMS/QIP ................................
AMA–PCPI .............................
AMA–PCPI .............................
AMA–PCPI/NCQA .................
AQA adopted.
AQA adopted.
AQA adopted.
0399.
0400.
AQA adopted Currently under
NQF review.
AMA–PCPI/NCQA .................
AQA adopted.
Audiology Quality Consortium
(AQC).
Not applicable.
122 .....................
123 .....................
124 .....................
126 .....................
127 .....................
128 .....................
130 .....................
131 .....................
134 .....................
140 .....................
141 .....................
142 .....................
145 .....................
146 .....................
147 .....................
153 .....................
154
155
156
157
.....................
.....................
.....................
.....................
158 .....................
163 .....................
172 .....................
173 .....................
175 .....................
176 .....................
177 .....................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
178 .....................
179 .....................
180
181
182
183
184
185
.....................
.....................
.....................
.....................
.....................
.....................
186 .....................
188 .....................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00151
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
0417.
0416.
0056.
0259.
40190
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 52—PROPOSED 2011 MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
EITHER CLAIMS-BASED REPORTING OR REGISTRY-BASED REPORTING—Continued
Measure No.
Measure title
Measure developer
189 .....................
Referral for Otologic Evaluation for Patient With History of
Active Drainage From the Ear Within the Previous 90
days.
Referral for Otologic Evaluation for Patient With a History of
Sudden or Rapidly Progessive Hearing Loss.
Perioperative Temperature Management ..............................
Oncology: Cancer Stage Documented ..................................
Stenosis Measurement in Carotid Imaging Studies ...............
Ischemic Vascular Disease (IVD): Blood Pressure Management Control.
Ischemic Vascular Disease (IVD): Complete Lipid Profile .....
Ischemic Vascular Disease (IVD): Low Density Lipoprotein
(LDL–C) Control.
Ischemic Vascular Disease (IVD): Use of Aspirin or Another
Anti-thrombotic.
AQC .......................................
Not applicable.
AQC .......................................
Not applicable.
AMA–PCPI .............................
AMA–PCPI/ASCO ..................
AMA–PCPI/NCQA .................
NCQA .....................................
0454.
0386.
0507.
0084.
NCQA .....................................
NCQA .....................................
0073.
0075.
NCQA .....................................
0068
190 .....................
193
194
195
201
.....................
.....................
.....................
.....................
202 .....................
203 .....................
204 .....................
It is our understanding that measures
#188, #189, and #190 were considered
by NQF for possible endorsement but
were not ultimately NQF-endorsed.
However, since we are not aware of any
other NQF-endorsed measures that are
available to audiologists, we propose to
exercise our exception authority under
section 1848(k)(2)(C)(ii) of the Act.
Therefore, we propose to use measures
#188, #189, and #190 for the 2011 PQRI
despite the fact that they are neither
NQF-endorsed nor AQA adopted.
Please note that detailed measure
specifications, including the measure’s
title, for 2010 individual PQRI quality
measures may have been updated or
modified during the NQF endorsement
process or for other reasons prior to
2011. The 2011 PQRI quality measure
specifications for any given individual
quality measure may, therefore, be
different from specifications for the
same quality measure used for 2010.
Specifications for all 2011 individual
PQRI quality measures, whether or not
included in the 2010 PQRI program,
must be obtained from the specifications
document for 2011 individual PQRI
quality measures, which will be
available on the PQRI section of the
CMS Web site on or before December
31, 2010.
(2) Proposed 2011 Individual Quality
Measures Selected From the 2010 PQRI
Quality Measures Set Available for
Registry-Based Reporting Only
For the 2011 PQRI, we propose to
include 45 registry-only individual
measures from the 2010 PQRI. As in
2010 PQRI, we are proposing to
designate these measures as registryonly measures for 2011 to relieve
ongoing analytical difficulties
encountered with claims-based
reporting of these measures in prior
program years. We encourage comments
on our proposal to designate these 45
2010 measures as registry-only measures
for the 2011 PQRI.
Although we are proposing to
designate certain measures as registryonly measures for 2011, we cannot
NQF Measure No.
guarantee that there will be a registry
qualified to submit each registry-only
measure for 2011. We rely on registries
to self-nominate and identify the types
of measures for which they would like
to be qualified to submit quality
measures results and numerator and
denominator data on quality measures.
If no registry self-nominates to submit
measure results and numerator and
denominator data on a particular type of
measure for 2011, then an EP would not
be able to report that particular measure
type via a registry. The Measure Number
and Measure Title for these proposed
registry-only measures are listed in
Table 53 along with the NQF measure
number, if applicable, and the name of
the measure’s developer/owner. As
mentioned above, a description of the
measures listed in Table 53 can be
found in the ‘‘2010 PQRI Quality
Measures List,’’ which is available on
the Measures and Codes page of the
PQRI section of the CMS Web site at
https://www.cms.gov/PQRI.
TABLE 53: 2011 PROPOSED MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
REGISTRY-BASED REPORTING ONLY
Measure No.
Measure title
Measure developer
5 .........................
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
Left Ventricular Systolic Dysfunction (LVSD).
Coronary Artery Disease (CAD): Beta-Blocker Therapy for
CAD Patients With Prior Myocardial Infarction (MI).
Heart Failure: Beta-Blocker Therapy for Left Ventricular
Systolic Dysfunction (LVSD).
Stroke and Stroke Rehabilitation: Anticoagulant Therapy
Prescribed for Atrial Fibrillation at Discharge.
End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients.
End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis.
Hepatitis C: Testing for Chronic Hepatitis C—Confirmation
of Hepatitis C Viremia.
AMA–PCPI .............................
0081.
AMA–PCPI .............................
0070.
AMA–PCPI .............................
0083.
AMA–PCPI/NCQA .................
0241.
AMA–PCPI .............................
0323.
AMA–PCPI .............................
0321
AMA–PCPI .............................
0393.
7 .........................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
8 .........................
33 .......................
81 .......................
82 .......................
83 .......................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00152
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
NQF Measure No.
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40191
TABLE 53: 2011 PROPOSED MEASURES SELECTED FROM THE 2010 PQRI QUALITY MEASURE SET AVAILABLE FOR
REGISTRY-BASED REPORTING ONLY—Continued
Measure No.
Measure title
Measure developer
118 .....................
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker
(ARB) Therapy for Patients With CAD and Diabetes and/
or Left Ventricular Systolic Dysfunction (LSVD).
Melanoma: Continuity of Care—Recall System .....................
Melanoma: Coordination of Care ...........................................
Oncology: Medical and Radiation—Pain Intensity Quantified
Oncology: Medical and Radiation—Plan of Care for Pain ....
HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ................
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis.
HIV/AIDS: Adolescent and Adult Patients With HIV/AIDS
Who Are Prescribed Potent Antiretroviral Therapy.
HIV/AIDS: HIV RNA Control After Six Months of Potent
Antiretroviral Therapy.
Coronary Artery Bypass Graft (CABG): Prolonged Intubation
(Ventilation).
Coronary Artery Bypass Graft (CABG): Deep Sternal
Wound Infection Rate.
Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA).
Coronary Artery Bypass Graft (CABG): Postoperative Renal
Insufficiency.
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration.
Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge.
Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge.
Coronary Artery Bypass Graft (CABG): Lipid Management
and Counseling.
Pediatric End-Stage Renal Disease (ESRD): Plan of Care
for Inadequate Hemodialysis.
Stroke and Stroke Rehabilitation: Thrombolytic Therapy ......
AMA–PCPI .............................
0066.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AMA–PCPI .............................
AMA–PCPI .............................
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0650.
0561.
0384.
0383.
0404.
0405.
AMA–PCPI/NCQA .................
0406.
AMA–PCPI/NCQA .................
0407.
STS ........................................
0129.
STS ........................................
0130.
STS ........................................
0131.
STS ........................................
0114.
STS ........................................
0115.
STS ........................................
0116.
STS ........................................
0117.
STS ........................................
0118.
AMA–PCPI .............................
AQA adopted Currently under
NQF review.
0437.
137
138
143
144
159
160
.....................
.....................
.....................
.....................
.....................
.....................
161 .....................
162 .....................
164 .....................
165 .....................
166 .....................
167 .....................
168 .....................
169 .....................
170 .....................
171 .....................
174 .....................
187 .....................
191 .....................
192 .....................
196 .....................
197 .....................
198 .....................
199 .....................
200 .....................
205 .....................
206 .....................
207 .....................
208 .....................
209 .....................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
210
211
212
213
214
.....................
.....................
.....................
.....................
.....................
215 .....................
216 .....................
Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery.
Cataracts: Complications Within 30 Days Following Cataract
Surgery Requiring Additional Surgical Procedures.
Coronary Artery Disease (CAD): Symptom and Activity Assessment.
Coronary Artery Disease (CAD): Drug Therapy for Lowering
LDL–Cholesterol.
Heart Failure: Left Ventricular Function (LVF) Assessment ..
Heart Failure: Patient Education ............................................
Heart Failure: Warfarin Therapy Patients With Atrial Fibrillation.
HIV/AIDS: Sexually Transmitted Disease Screening for
Chlamydia and Gonorrhea.
HIV/AIDS: Screening for High Risk Sexual Behaviors ..........
HIV/AIDS: Screening for Injection Drug Use .........................
HIV/AIDS: Sexually Transmitted Disease Screening for
Syphilis.
Functional Communication Measure—Spoken Language
Comprehension.
Functional Communication Measure—Attention ....................
Functional Communication Measure—Memory .....................
Functional Communication Measure—Motor Speech ...........
Functional Communication Measure—Reading .....................
Functional Communication Measure—Spoken Language
Expression.
Functional Communication Measure—Writing .......................
Functional Communication Measure—Swallowing ................
Please note, as previously discussed
above, detailed measure specifications,
including a measure’s title, for 2010
PQRI quality measures may be updated
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
AHA/ASA/ ..............................
TJC ........................................
AMA–PCPI/NCQA .................
Frm 00153
Fmt 4701
Sfmt 4702
0565.
AMA–PCPI/NCQA .................
0564.
AMA–PCPI .............................
0065.
AMA–PCPI .............................
0074.
AMA–PCPI .............................
AMA–PCPI .............................
AMA–PCPI .............................
0079.
0082.
0084.
AMA–PCPI/NCQA .................
0409.
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
AMA–PCPI/NCQA .................
0413.
0415.
0410.
American Speech Language
Haring Association (ASHA).
ASHA .....................................
...........................................
ASHA .....................................
ASHA .....................................
ASHA .....................................
0445.
0449.
0448.
0447.
0446.
0444.
ASHA .....................................
ASHA .....................................
0442.
0443.
or modified during the NQF
endorsement process or for other
reasons during 2010. Therefore, the
2011 PQRI quality measure
PO 00000
NQF Measure No.
specifications for any given quality
measure may be different from
specifications for the same quality
measure used for 2010. Specifications
E:\FR\FM\13JYP2.SGM
13JYP2
40192
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
for all 2011 individual PQRI quality
measures, whether or not included in
the 2010 PQRI program, must be
obtained from the specifications
document for 2011 individual PQRI
quality measures, which will be
available on the PQRI section of the
CMS Web site on or before December
31, 2010.
(3) New Individual Quality Measures
Proposed for 2011
We propose to include in the 2011
PQRI quality measure set 20 measures
that were not included in the 2010 PQRI
quality measures set provided that each
measure obtains NQF endorsement by
June 1, 2010 and its detailed
specifications are completed and ready
for implementation in PQRI by August
15, 2010. Besides having NQF
endorsement, we again propose that the
development of a measure is considered
complete for the purposes of the 2011
PQRI if by August 15, 2010: (1) The
final, detailed specifications for use in
data collection for PQRI have been
completed and are ready for
implementation, and (2) all of the
Category II Current Procedural
Terminology (CPT II) codes required for
the measure have been established and
will be effective for CMS claims data
submission on or before January 1, 2011.
The titles of these proposed additional,
or new, measures are listed in Table 54
along with the name of the measure
developer and the proposed reporting
mechanism (that is, whether the
measure is proposed to be reportable
using claims, registries, or both). For
these 20 proposed measures, a PQRI
Measure Number will be assigned to a
measure if and when the measure is
included in the final set of 2011 PQRI
measures.
Due to the complexity of their
measure specifications, we propose that
8 of these 20 measures would be
available as registry-only measures for
the 2011 PQRI. The remaining 15
measures are proposed to be available
for reporting through either claimsbased reporting or registry-based
reporting.
TABLE 54—NEW INDIVIDUAL QUALITY MEASURES PROPOSED FOR 2011
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Measure title
NQF Measure number
Measure
developer
Change in Risk-Adjusted Functional Status for Patients
With Knee Impairments.
Change in Risk-Adjusted Functional Status for Patients
With Hip Impairments.
Change in Risk-Adjusted Functional Status for Patients
With Lower Leg, Foot or Ankle Impairments.
Change in Risk-Adjusted Functional Status for Patients
With Lumbar Spine Impairments.
Change in Risk-Adjusted Functional Status for Patients
With Shoulder Impairments.
Change in Risk-Adjusted Functional Status for Patients
With Elbow, Wrist or Hand Impairments.
Change in Risk-Adjusted Functional Status for Patients
With a Functional Deficit of the Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic
Impairment.
Care Transitions: Reconciled Medication List Received by
Discharged Patients (Inpatient Discharges to Home/Self
Care or Any Other Site of Care).
Care Transitions: Transition Record with Specified Elements Received by Discharged Patients (Inpatient Discharges to Home/Self Care or Any Other Site of Care).
Care Transitions: Timely Transmission of Transition Record
(Inpatient Discharges to Home/Self Care or Any Other
Site of Care).
Care Transitions: Transition Record with Specified Elements Received by Discharged Patients (Emergency Department Discharges to Ambulatory Care [Home/Self
Care] or Home Health Care).
Hypertension (HTN): Plan of Care .......................................
Heart Failure (HF): Left Ventricular Function (LVF) Testing
Melanoma: Overutilization of Imaging Studies in Stage 0–
IA Melanoma.
Radiology: Reminder System for Mammograms ..................
Asthma: Assessment of Asthma Risk—Emergency Department/Inpatient Setting.
Asthma: Discharge Plan—Emergency Department/Inpatient
Setting.
Preventive Care and Screening: Tobacco Use: Screening
and Cessation Intervention.
Recording of Performance Status Prior to Lung or Esophageal Cancer Resection.
Pulmonary Function Tests Before Major Anatomic Lung
Resection.
0422 ......................................
FOTO ....................................
Registry.
0423 ......................................
FOTO ....................................
Registry.
0424 ......................................
FOTO ....................................
Registry.
0425 ......................................
FOTO ....................................
Registry.
0426 ......................................
FOTO ....................................
Registry.
0427 ......................................
FOTO ....................................
Registry.
0428 ......................................
FOTO ....................................
Registry.
Currently under NQF review
Society of Hospital Medicine
(SMH) AMA–PCPI/NCQA.
Claims, Registry.
Currently under NQF review
Society of Hospital Medicine
(SMH) AMA–PCPI/NCQA.
Claims, Registry.
Currently under NQF review
Society of Hospital Medicine
(SMH) AMA–PCPI/NCQA.
Claims, Registry.
Currently under NQF review
Society of Hospital Medicine
(SMH) AMA–PCPI/NCQA.
Claims, Registry.
0017 ......................................
79 ..........................................
0562 ......................................
AMA–PCPI ............................
CMS ......................................
AMA–PCPI ............................
Claims, Registry.
Registry.
Claims, Registry.
0509 ......................................
Currently under NQF review
AMA–PCPI ............................
AMA–PCPI ............................
Claims, Registry.
Claims, Registry.
Currently under NQF review
AMA–PCPI ............................
Claims, Registry.
0028 ......................................
AMA–PCPI ............................
Claims, Registry.
0457 ......................................
Society of Thoracic Surgery
(STS).
Society of Thoracic Surgery
(STS).
Claims, Registry.
These measures are being proposed for
the 2011 PQRI because they meet one or
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
0458 ......................................
more of the considerations for measure
PO 00000
Frm 00154
Fmt 4701
Sfmt 4702
Reporting
mechanism(s)
Claims, Registry.
selection discussed in section VI.F.1.h.
of this proposed rule.
E:\FR\FM\13JYP2.SGM
13JYP2
40193
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(4) Proposed 2011 Measures Available
for EHR-Based Reporting
For 2011, we propose to again accept
PQRI data from EHRs for a limited
subset of the proposed 2011 PQRI
quality measures, contingent upon the
successful completion of our 2010 EHR
data submission process and a
determination that accepting data from
EHRs on quality measures for the 2011
PQRI continues to be practical and
feasible.
We propose to make a total of 22
measures available for EHR-based
reporting in the 2010 PQRI. These
include the 10 measures available for
EHR-based reporting in the 2010 PQRI,
which are identified in Table 55 and 12
additional measures identified in Table
56 that overlap with the clinical quality
measures used in the EHR incentive
program established by the American
Recovery and Reinvestment Act
(ARRA). Again, this year, we propose to
make these measures available for
electronic submission via an EHR
because these measures target
preventive care or common chronic and
high-cost conditions.
TABLE 55—PROPOSED 2011 MEASURES AVAILABLE FOR EHR-BASED REPORTING FROM 2010 PQRI
Measure No.
Measure title
Measure
developer
1 ........................
Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes
Mellitus.
Diabetes Mellitus: Low Density Lipoprotein (LDL–C) Control in Diabetes Mellitus.
Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or
Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular
Systolic Dysfunction (LVSD).
Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD
Patients with Prior Myocardial Infarction (MI).
Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old.
Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older.
Preventive Care and Screening: Screening Mammography .............
Preventive Care and Screening: Colorectal Cancer Screening ........
Health Information Technology (HIT): Adoption/Use of Electronic
Health Records (EHR).
NCQA ...........................................
0059.
NCQA ...........................................
0064.
NCQA ...........................................
AMA–PCPI ...................................
0061.
0081.
AMA–PCPI ...................................
0070.
AMA–PCPI ...................................
0041.
NCQA ...........................................
0043.
NCQA ...........................................
NCQA ...........................................
CMS/QIP ......................................
0031.
0034.
0488.
2 ........................
3 ........................
5 ........................
7 ........................
110 ....................
111 ....................
112 ....................
113 ....................
124 ....................
NQF Measure No.
TABLE 56: PROPOSED 2011 MEDICARE ARRA—HITECH MEASURES AVAILABLE FOR EHR-BASED REPORTING
Measure No.
Measure title
Measure
developer
TBD ...................
128 ....................
Hypertension (HTN): Blood Pressure Measurement .........................
Preventive Care and Screening: Body Mass Index (BMI) Screening
and Follow-Up.
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
Childhood Immunization Status .........................................................
Body Mass Index (BMI) 2 Through 18 Years of Age ........................
AMA–PCPI ...................................
CMS/Quality Insights of Pennsylvania.
AMA–PCPI ...................................
0013.
0421.
NCQA ...........................................
National Initiative for Children’s
Healtcare Quality.
AMA–PCPI/NCQA .......................
0038.
0024.
AMA–PCPI/NCQA .......................
AMA–PCPI/NCQA .......................
0326.
0098.
AMA–PCPI ...................................
NCQA ...........................................
......................................................
AQA Adopted.
0022.
0049.
AMA–PCPI ...................................
0051.
TBD ...................
TBD ...................
TBD ...................
39 ......................
47 ......................
48 ......................
173 ....................
TBD ...................
41 ......................
142 ....................
Screening or Therapy for Osteoporosis for Women Aged 65 Years
and Older.
Advance Care Plan ............................................................................
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older.
Preventive Care & Screening: Unhealthy Alcohol Use—Screening ..
Drugs To Be Avoided in the Elderly ..................................................
Osteoporosis: Pharmacologic Therapy for Men and Women Aged
50 Years and Older.
Osteoarthritis: Assessment of Use of Anti-Inflammatory or Analgesic OTC Meds.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(5) Measures Proposed for Inclusion in
2011 Measures Groups
We propose to retain the following 13
2010 PQRI measures groups for the 2011
PQRI: (1) Diabetes Mellitus; (2) CKD; (3)
Preventive Care; (4) CABG; (5)
Rheumatoid Arthritis; (6) Perioperative
Care; (7) Back Pain; (8) CAD; (9) Heart
Failure; (10) IVD; (11) Hepatitis C; (12)
HIV/AIDS; and (13) CAP. We are
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
proposing to include these measures
groups in 2011 PQRI because they each
contain at least 4 PQRI quality measures
that share a common denominator
definition.
For 2011, we propose that the CABG,
CAD, Heart Failure, HIV/AIDS measures
groups continue to be reportable
through the registry-based reporting
mechanism only, while the remaining
Diabetes Mellitus, CKD, Preventive
PO 00000
Frm 00155
Fmt 4701
Sfmt 4702
NQF Measure No.
0028.
0046.
Care, Rheumatoid Arthritis,
Perioperative Care, Back Pain, IVD,
Hepatitis C, and CAP measures groups
will continue to be reportable through
either claims-based reporting or registrybased reporting for the 2011 PQRI. The
4 2011 proposed measures groups
reportable via registry-based reporting
only are identified with an asterisk (*)
below.
E:\FR\FM\13JYP2.SGM
13JYP2
40194
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
For 2010, the 13 measures groups that
we propose to retain in the 2011 PQRI,
combined with the one additional
measures group we are proposing for
2011, makes a total of 14 measures
groups for the 2011 PQRI. The 1
additional measures group we propose
for the 2011 PQRI, identified in Table
70, is an Asthma Measures Group. The
Asthma Measures Group is proposed to
be reportable through either claimsbased reporting or registry-based
reporting.
We believe that the measure groups
proposed for the 2011 PQRI address
gaps in quality reporting and are those
that have a high impact on HHS and
CMS priority topics for improved
quality and efficiency for Medicare
beneficiaries (such as prevention,
chronic conditions, improved care
coordination, improved efficiency,
improved patient and family experience
of care, and effective management of
acute and chronic episodes).
Finally, as in previous program years,
for 2011, we continue to propose that
except for the measures included in the
Back Pain measures group, the measures
included in any proposed 2011
measures group be reportable either as
individual measures or as part of a
measures group. For 2011, we propose
that the measures proposed for
inclusion in the Back Pain measures
group will continue to be reportable
only as part of a measures group and not
as individual measures in 2011. We
propose that measures selected for
inclusion in all 2011 PQRI measures
groups (except for the Back Pain
measures group) are reportable either as
individual measures or as part of a
measures group.
The measures proposed for inclusion
in each of the 2011 measures groups are
identified in Tables 57 through 70. As
stated previously, the PQRI Measure
Number is a unique identifier assigned
by CMS to all measures in the PQRI
measure set. Once a PQRI Measure
Number is assigned to a measure, it will
not be used again, even if the measure
is subsequently retired from the PQRI
measure set. Measures that are not
preceded by a number (in other words,
those preceded by ‘‘TBD’’) in Tables 57
through 71 were never part of a PQRI
measure set prior to 2011. A number
will be assigned to such measures for
2011, if we finalize inclusion of the
measures in the 2011 PQRI.
As with measures group reporting in
the 2008, 2009, and 2010 PQRI, we
propose that each EP electing to report
a group of measures for 2011 must
report all measures in the group that are
applicable to each patient or encounter
to which the measures group applies at
least up to the minimum number of
patients required by the applicable
reporting criteria.
TABLE 57—MEASURES PROPOSED FOR 2011 DIABETES MELLITUS MEASURES GROUP
Measure No.
Measure Title
NQF Measure No.
1 ........................
Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes
Mellitus.
Diabetes Mellitus: Low Density Lipoprotein (LDL–C) Control in Diabetes Mellitus.
Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient ..................
Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients.
Diabetes Mellitus: Foot Exam ............................................................
0059 .............................................
NCQA.
0064 .............................................
NCQA.
0061 .............................................
0055 .............................................
0062 .............................................
NCQA.
NCQA.
NCQA.
0056 .............................................
NCQA.
2 ........................
3 ........................
117 ....................
119 ....................
163 ....................
Measure developer
TABLE 58—MEASURES PROPOSED FOR 2011 CKD MEASURES GROUP
Measure No.
Measure Title
NQF Measure No.
121 ....................
Chronic Kidney Disease (CKD): Laboratory Testing (Calcium,
Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile).
Chronic Kidney Disease (CKD): Blood Pressure Management ........
Chronic Kidney Disease (CKD): Plan of Care—Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents
(ESA).
Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV)
Fistula.
0570, 0571, 0572, 0626 ..............
AMA–PCPI.
AQA adopted ...............................
AQA adopted ...............................
AMA–PCPI.
AMA–PCPI.
AQA adopted ...............................
AMA–PCPI.
122 ....................
123 ....................
153 ....................
Measure developer
TABLE 59—MEASURES PROPOSED FOR 2011 PREVENTIVE CARE MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
Measure developer
39 ......................
Screening or Therapy for Osteoporosis for Women Aged 65 Years
and Older.
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older.
Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old.
Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older.
Preventive Care and Screening: Screening Mammography .............
Preventive Care and Screening: Colorectal Cancer Screening ........
Preventive Care and Screening: Body Mass Index (BMI) Screening
and Follow-Up.
Preventive Care and Screening: Unhealthy Alcohol Use—Screening.
0046 .............................................
AMA–PCPI/NCQA.
0098 .............................................
AMA–PCPI/NCQA.
0041 .............................................
AMA–PCPI.
0043 .............................................
NCQA.
0031 .............................................
0034 .............................................
0421 .............................................
NCQA.
NCQA.
CMS/QIP.
AQA adopted ...............................
AMA–PCPI.
48 ......................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
110 ....................
111 ....................
112 ....................
113 ....................
128 ....................
173 ....................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00156
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40195
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 59—MEASURES PROPOSED FOR 2011 PREVENTIVE CARE MEASURES GROUP—Continued
Measure No.
Measure title
NQF Measure No.
TBD ...................
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
0028 .............................................
Measure developer
AMA–PCPI.
TABLE 60—MEASURES PROPOSED FOR 2011 CABG MEASURES GROUP *
Measure No.
Measure title
NQF Measure No.
Measure developer
43 ......................
Coronary Artery Bypass Graft (CABG): Use of Internal Mammary
Artery (IMA) in Patients with Isolated CABG Surgery.
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker
in Patients with Isolated CABG Surgery.
Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation).
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate.
Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA).
Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency.
Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ......
Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at
Discharge.
Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered
at Discharge.
Coronary Artery Bypass Graft (CABG): Lipid Management and
Counseling.
0516, 0134 ...................................
0127, 0236 ...................................
Society of Thoracic
Surgeons (STS).
STS.
0129 .............................................
STS.
0130 .............................................
STS.
0131 .............................................
STS.
0114 .............................................
STS.
0115 .............................................
0116 .............................................
STS.
STS.
0117 .............................................
STS.
0118 .............................................
STS.
44 ......................
164 ....................
165 ....................
166 ....................
167 ....................
168 ....................
169 ....................
170 ....................
171 ....................
* This measures group is reportable through registry-based reporting only.
TABLE 61—MEASURES PROPOSED FOR 2011 RHEUMATOID ARTHRITIS MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
108 ....................
Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug
(DMARD) Therapy.
Rheumatoid Arthritis (RA): Tuberculosis Screening ..........................
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
Rheumatoid Arthritis (RA): Functional Status Assessment ...............
Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis.
Rheumatoid Arthritis (RA): Glucocorticoid Management ...................
0054 .............................................
NCQA.
AQA
AQA
AQA
AQA
...............................
...............................
...............................
...............................
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
AQA adopted ...............................
AMA–PCPI/NCQA.
176
177
178
179
....................
....................
....................
....................
180 ....................
adopted
adopted
adopted
adopted
Measure developer
TABLE 62—MEASURES PROPOSED FOR 2011 PERIOPERATIVE CARE MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
Measure developer
20 ......................
Perioperative Care: Timing of Antibiotic Prophylaxis—Ordering
Physician.
Perioperative Care: Selection of Prophylactic Antibiotic—First OR
Second Generation Cephalosporin.
Perioperative Care: Discontinuation of Prophylactic Antibiotics
(Non-Cardiac Procedures).
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis
(When Indicated in ALL Patients).
0270 .............................................
AMA–PCPI/NCQA.
0268 .............................................
AMA–PCPI/NCQA.
0271 .............................................
AMA–PCPI/NCQA.
0239 .............................................
AMA–PCPI/NCQA.
21 ......................
22 ......................
23 ......................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
TABLE 63—MEASURES PROPOSED FOR 2011 BACK PAIN MEASURES GROUP
Measure No.
148
149
150
151
Measure title
....................
....................
....................
....................
VerDate Mar<15>2010
Back
Back
Back
Back
Pain:
Pain:
Pain:
Pain:
20:23 Jul 12, 2010
NQF Measure No.
Initial Visit ........................................................................
Physical Exam .................................................................
Advice for Normal Activities ............................................
Advice Against Bed Rest .................................................
Jkt 220001
PO 00000
Frm 00157
Fmt 4701
Sfmt 4702
0322
0319
0315
0313
.............................................
.............................................
.............................................
.............................................
E:\FR\FM\13JYP2.SGM
13JYP2
Measure developer
NCQA.
NCQA.
NCQA.
NCQA.
40196
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 64—MEASURES PROPOSED FOR 2011 CAD MEASURES GROUP*
Measure No.
Measure title
NQF Measure No.
6 ........................
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD.
Coronary Artery Disease (CAD): Symptom and Activity Assessment
Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL–
Cholesterol.
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
0067 .............................................
AMA–PCPI.
0065 .............................................
0074 .............................................
AMA–PCPI.
AMA–PCPI.
0028 .............................................
AMA–PCPI.
196 ....................
197 ....................
TBD ...................
Measure developer
* This measures group is reportable through registry-based reporting only.
TABLE 65—MEASURES PROPOSED FOR 2011 HEART FAILURE MEASURES GROUP*
Measure No.
Measure title
NQF Measure No.
5 ........................
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or
Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular
Systolic Dysfunction (LVSD).
Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic
Dysfunction (LVSD).
Heart Failure: Left Ventricular Function (LVF) Assessment ..............
Heart Failure: Patient Education ........................................................
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
0081 .............................................
AMA–PCPI.
0083 .............................................
AMA–PCPI.
0079 .............................................
0082 .............................................
0028 .............................................
AMA–PCPI.
AMA–PCPI.
AMA–PCPI.
8 ........................
198 ....................
199 ....................
TBD ...................
Measure developer
* This measures group is reportable through registry-based reporting only.
TABLE 66—MEASURES PROPOSED FOR 2011 IVD MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
201 ....................
Ischemic Vascular Disease (IVD): Blood Pressure Management
Control.
Ischemic Vascular Disease (IVD): Complete Lipid Profile ................
Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL–C)
Control.
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic.
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention.
0073 .............................................
NCQA.
0075 .............................................
0075 .............................................
NCQA.
NCQA.
0068 .............................................
NCQA.
0028 .............................................
AMA–PCPI.
202 ....................
203 ....................
204 ....................
TBD ...................
Measure developer
TABLE 67—MEASURES PROPOSED FOR 2011 HEPATITIS C MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
84 ......................
Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment.
Hepatitis C: HCV Genotype Testing Prior to Treatment ...................
Hepatitis C: Antiviral Treatment Prescribed .......................................
Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of
Treatment.
Hepatitis C: Counseling Regarding Risk of Alcohol Consumption ....
Hepatitis C: Counseling Regarding Use of Contraception Prior to
Antiviral Therapy.
Hepatitis C: Hepatitis A Vaccination in Patients with HCV ...............
Hepatitis C: Hepatitis B Vaccination in Patients with HCV ...............
0395 .............................................
AMA–PCPI.
0396 .............................................
0397 .............................................
0398 .............................................
AMA–PCPI.
AMA–PCPI.
AMA–PCPI.
0401 .............................................
0394 .............................................
AMA–PCPI.
AMA–PCPI.
0399 .............................................
0400 .............................................
AMA–PCPI.
AMA–PCPI.
85 ......................
86 ......................
87 ......................
89 ......................
90 ......................
183 ....................
184 ....................
Measure developer
TABLE 68—MEASURES PROPOSED FOR 2011 HIV/AIDS MEASURES GROUP*
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Measure No.
Measure title
NQF Measure No.
Measure developer
159 ....................
160 ....................
161 ....................
HIV/AIDS: CD4+ Cell Count or CD4+ Percentage ............................
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis ....
HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are
Prescribed Potent Antiretroviral Therapy.
HIV/AIDS: HIV RNA Control After Six Months of Potent
Antiretroviral Therapy.
HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia
and Gonorrhea.
HIV/AIDS: Screening for High Risk Sexual Behaviors ......................
HIV/AIDS: Screening for Injection Drug Use .....................................
0404 .............................................
0405 .............................................
0406 .............................................
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
0407 .............................................
AMA–PCPI/NCQA.
0409 .............................................
AMA–PCPI/NCQA.
0413 .............................................
0415 .............................................
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
162 ....................
205 ....................
206 ....................
207 ....................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00158
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40197
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 68—MEASURES PROPOSED FOR 2011 HIV/AIDS MEASURES GROUP*—Continued
Measure No.
Measure title
NQF Measure No.
Measure developer
208 ....................
HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis .....
0410 .............................................
AMA–PCPI/NCQA.
* This measures group is selected to be reportable through registry-based reporting only.
TABLE 69—MEASURES PROPOSED FOR 2011 CAP MEASURES GROUP
Measure No.
Measure title
56 ......................
57 ......................
58 ......................
59 ......................
Community-Acquired
Community-Acquired
Saturation.
Community-Acquired
Status.
Community-Acquired
NQF Measure No.
Measure developer
Pneumonia (CAP): Vital Signs ........................
Pneumonia (CAP): Assessment of Oxygen
0232 .............................................
0094 .............................................
AMA–PCPI/NCQA.
AMA–PCPI/NCQA.
Pneumonia (CAP): Assessment of Mental
0234 .............................................
AMA–PCPI/NCQA.
Pneumonia (CAP): Empiric Antibiotic .............
0096 .............................................
AMA–PCPI/NCQA.
TABLE 70—MEASURES PROPOSED FOR 2011 ASTHMA MEASURES GROUP
Measure No.
Measure title
NQF Measure No.
53 ......................
64 ......................
TBD ...................
Asthma: Pharmacologic Therapy .......................................................
Asthma: Asthma Assessment ............................................................
Asthma: Assessment of Asthma Risk—Emergency Department/Inpatient Setting.
Asthma: Discharge Plan-Emergency/Inpatient Setting ......................
0047 .............................................
0001 .............................................
Currently under NQF review ........
AMA–PCPI.
AMA–PCPI.
AMA–PCPI.
Currently under NQF review ........
AMA–PCPI.
TBD ...................
We note that the specifications for
measures groups do not necessarily
contain all the specification elements of
each individual measure making up the
measures group. This is based on the
need for a common set of denominator
specifications for all the measures
making up a measures group in order to
define the applicability of the measures
group. Therefore, the specifications and
instructions for measures groups will
again be provided separately from the
specifications and instructions for the
individual 2011 PQRI measures. We
will post the detailed specifications and
specific instructions for reporting
measures groups on the PQRI section of
the CMS Web site at https://
www.cms.gov/PQRI by no later than
December 31, 2010.
Additionally, the detailed measure
specifications and instructions for
submitting data on those 2011 measures
groups that were also included as 2010
PQRI measures groups may be updated
or modified prior to 2011. Therefore, the
2011 PQRI measure specifications for
any given measures group could be
different from specifications and
submission instructions for the same
measures group used for 2010. These
measure specification changes are not
expected to materially impact the
intended meaning of the measures or
the strength of the measures.
j. Proposed 2011 PQRI Quality Measures
for Physician Groups Selected To
Participate in the Group Practice
Reporting Option (GPRO I)
As discussed in section VI.F.1.g.(3).(i)
of this proposed rule, we propose that
physician groups selected to participate
in the 2011 PQRI GPRO I would be
required to report on 26 proposed
measures. We are proposing these
measures because they are NQFendorsed measures currently collected
as part of the PGP and/or MCMP
demonstrations and in the 2010 PQRI
Measure developer
GPRO. These proposed measures are
listed in Table 71. To the extent that a
measure is an existing PQRI measure
available for reporting by individual
EPs, the Measure Title is preceded by
the measure’s PQRI Measure Number. If
there is no number in the PQRI Measure
Number column of the table, then the
measure is not an existing PQRI
measure and will be added to the 2011
PQRI for purposes of the GPRO I.
Measures proposed for GPRO II are
discussed in section VI.F.1.g.(3).(ii) of
this proposed rule.
As in the 2010 PQRI, a separate
measures specifications manual and
other supporting documents will be
available for group practices
participating in the 2011 PQRI GPRO I.
We anticipate that the group practice
measures specifications manual will be
available by November 15, 2010 on the
PQRI section of the CMS Web site at
https://www.cms.gov/PQRI.
TABLE 71—MEASURES FOR PHYSICIAN GROUPS PARTICIPATING IN THE 2011 PQRI GROUP PRACTICE REPORTING
OPTION (GPRO I)
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
PQRI measure
No.
Measure title
Measure
developer
1 ........................
Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes
Mellitus.
Diabetes Mellitus: Low Density Lipoprotein (LDL–C)Control ............
Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or
Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular
Systolic Dysfunction (LVSD).
Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD.
NCQA ...........................................
0059
NCQA ...........................................
NCQA ...........................................
AMA–PCPI ...................................
0064
0061
0081
AMA–PCPI ...................................
0067
2 ........................
3 ........................
5 ........................
6 ........................
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00159
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
NQF No.
40198
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 71—MEASURES FOR PHYSICIAN GROUPS PARTICIPATING IN THE 2011 PQRI GROUP PRACTICE REPORTING
OPTION (GPRO I)—Continued
PQRI measure
No.
Measure title
Measure
developer
7 ........................
Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD
Patients with Prior Myocardial Infarction (MI).
Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic
Dysfunction (LVSD).
Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old.
Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older.
Preventive Care and Screening: Screening Mammography .............
Preventive Care and Screening: Colorectal Cancer Screening ........
Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient ..................
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme
(ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) for Patients with CAD and Diabetes and/or Left Ventricular Systolic
Dysfunction (LVSD).
Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients.
Diabetes Mellitus: Foot Exam ............................................................
Diabetes Mellitus: Hemoglobin A1c Testing ......................................
Diabetes Mellitus: Lipid Profile ...........................................................
Heart Failure: Left Ventricular Function (LVF) Testing ......................
Heart Failure: Left Ventricular Function (LVF) Assessment ..............
Heart Failure: Weight Measurement ..................................................
Heart Failure: Patient Education ........................................................
Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation ..
Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL–
Cholesterol.
Hypertension: Blood Pressure Measurement ....................................
Hypertension (HTN): Blood Pressure Control ...................................
Hypertension (HTN): Plan of Care .....................................................
AMA–PCPI ...................................
0070
AMA–PCPI ...................................
0083
AMA–PCPI ...................................
0041
NCQA ...........................................
0043
NCQA ...........................................
NCQA ...........................................
NCQA ...........................................
AMA–PCPI ...................................
0031
0034
0055
0066
NCQA ...........................................
0062
NCQA ...........................................
NCQA ...........................................
NCQA ...........................................
CMS.
AMA–PCPI ...................................
CMS AMA–PCPI not maintaining
AMA–PCPI ...................................
AMA–PCPI ...................................
AMA–PCPI ...................................
0056
0057
0063
AMA–PCPI ...................................
NCQA ...........................................
AMA–PCPI ...................................
0013
0018
0017
8 ........................
110 ....................
111 ....................
112
113
117
118
....................
....................
....................
....................
119 ....................
163 ....................
GPRO DM–1 .....
GPRO DM–9 .....
GPRO HF–2 ......
198 ....................
GPRO HF–3 ......
199 ....................
200 ....................
197 ....................
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
GPRO HTN–1 ...
GPRO HTN–2 ...
GPRo HTN–3 ....
k. Public Reporting of PQRI Data
Section 1848(m)(5)(G) of the Act
requires the Secretary to post on the
CMS Web site, in an easily
understandable format, a list of the
names of EPs (or group practices) who
satisfactorily submitted data on quality
measures for the PQRI and the names of
the EPs (or group practices) who are
successful electronic prescribers. In
addition, section 10331(a)(1) of the
ACA, requires the Secretary to develop
a Physician Compare Internet Web site
by January 1, 2011, on which
information on physicians enrolled in
the Medicare program and other EPs
who participate in the PQRI program
would be posted.
To meet the ACA deadline of January
1, 2011, with respect to establishing the
Physician Compare Web site, we
propose, for 2011 PQRI, to use the
current Physician and Other Health Care
Professional Directory as a foundation
for the Physician Compare Web site. As
in 2010 PQRI, we propose to continue
to make public the names of EPs and
group practices that satisfactorily
submit quality data for the 2011 PQRI.
Previously, this was posted on the
Physician and Other Health Care
Professionals Directory. Our intent for
the 2011 PQRI is to post the information
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
on the Physician Compare Web site that
must be developed by January 1, 2011.
Specifically, we propose to post the
names of EPs who: (1) Submit data on
the 2011 PQRI quality measures through
one of the reporting mechanisms
available for the 2011 PQRI; (2) meet
one of the proposed satisfactory
reporting criteria of individual measures
or measures groups for the 2011 PQRI as
described above; and (3) qualify to earn
a PQRI incentive payment for covered
professional services furnished during
the applicable 2011 PQRI reporting
period, for purposes of satisfying the
requirements under section
1848(m)(5)(G)(i) of the Act, on the
Physician Compare Web site.
Similarly, for purposes of publicly
reporting the names of group practices,
on the Physician Compare Web site, for
2011, we propose to post the names of
group practices that: (1) Submit data on
the 2011 PQRI quality measures through
one of the proposed group practice
reporting options; (2) meet the proposed
criteria for satisfactory reporting under
the respective group practice reporting
option; and (3) qualify to earn a PQRI
incentive payment for covered
professional services furnished during
the applicable 2011 PQRI reporting
period for purposes of satisfying the
PO 00000
Frm 00160
Fmt 4701
Sfmt 4702
NQF No.
0079
0085
0082
0084
0074
requirements under section
1848(m)(5)(G)(i) of the Act.
We do not propose to require as a
condition of participation in the 2011
PQRI that performance information be
made publicly available at either the
group practice or individual level for
2011 PQRI. However, we note that
section 10331 of the ACA requires that
not later than January 1, 2013, and with
respect to reporting periods that begin
no earlier than January 1, 2012, we
implement a plan for making publicly
available through Physician Compare,
information on physician performance,
including measures collected under
PQRI. Consistent with section 10331 of
the ACA, we expect, in the future, to
publicly report performance information
based on PQRI.
We will be working on a plan to
expand the information that is publicly
posted on the Physician Compare in
future years. This will be further
described in future rulemaking. We
solicit comments on our plan for
implementation of a Physician Compare
Web site for 2011.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
l. Other Relevant ACA Provisions
(1) Section 3002 (b)—Incentive Payment
Adjustment for Quality Reporting
Beginning 2015, a payment
adjustment will apply under the PQRI.
Specifically, under section 1848(a)(8) of
the Act, as added by section 3002(b) of
the ACA, with respect to covered
professional services furnished by an EP
during 2015 or any subsequent year, if
the EP does not satisfactorily submit
data on quality measures for covered
professional services for the quality
reporting period for the year, the fee
schedule amount for services furnished
by such professionals during the year
shall be equal to the applicable percent
of the fee schedule amount that would
otherwise apply to such services. The
applicable percent for 2015 is 98.5
percent and for 2016 and each
subsequent year it is 98.0 percent.
We will address this provision of the
ACA in future notice and comment
rulemaking.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(2) Section 3002(c)—Maintenance of
Certification Programs and Section
10327 Improvements to the Physician
Quality Reporting System
Section 3002(c) of the ACA amends
section 1848(k)(4) of the Act to require
a mechanism whereby an EP may
provide data on quality measures
through an MOCP operated by a
specialty body of the American Board of
Medical Specialties (ABMS). In
addition, section 1848(m)(7)of the Act
(‘‘Additional Incentive Payment’’), as
added by section 10327(a) of the ACA,
provides for an additional 0.5 percent
incentive payment for years 2011
through 2014 if certain requirements are
met. In accordance with section
1848(m)(7)(B) of the Act, in order to
qualify for the additional incentive
payment, an EP must—
• Satisfactorily submit data on quality
measures under PQRI for a year and
have such data submitted—
++ On their behalf through an MOCP
that meets the criteria for a registry
under PQRI (see section VI.F.1.d.(4) of
this proposed rule); or
++ In an alternative form and manner
determined appropriate by the
Secretary; and
• More frequently than is required to
qualify for or maintain board
certification status—
++ Participate in such an MOCP for a
year; and
++ Successfully completes a qualified
MOCP for such year.
Section 1848(m)(7)(C)(i) of the Act
defines ‘‘Maintenance of Certification
Program’’ as a continuous assessment
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
program, such as a qualified ABMS
MOCP, or an equivalent program (as
determined by the Secretary), that
advances quality and the lifelong
learning and self-assessment of board
certified specialty physicians by
focusing on the competencies of patient
care, medical knowledge, practice-based
learning, interpersonal and
communications skills and
professionalism. Such a program shall
require a physician to do the following:
• Maintain a valid, unrestricted
medical license in the United States.
• Participate in educational and selfassessment programs that require an
assessment of what was learned.
• Demonstrate, through a formalized,
secure examination, that the physician
has the fundamental diagnostic skills,
medical knowledge, and clinical
judgment to provide quality care in their
respective specialty.
• Successful completion of a
qualified MOCP practice assessment.
As defined in section
1848(m)(7)(C)(ii) of the Act, a ‘‘qualified
Maintenance of Certification Program
practice assessment’’ means an
assessment of a physician’s practice
that—
(1) Includes an initial assessment of
an EP’s practice that is designed to
demonstrate the physician’s use of
evidence-based medicine;
(2) Includes a survey of patient
experience with care; and
(3) Requires a physician to implement
a quality improvement intervention to
address a practice weakness identified
in the initial assessment and then to
remeasure to assess performance after
such intervention.
To qualify for the additional incentive
payment, section 1848(m)(7)(B)(iii) of
the Act also requires the MOCP Program
to submit to CMS, on behalf of the EP,
information:
(1) In a form and manner specified by
the Secretary, that the EP has
successfully completed a qualified
MOCP practice assessment for such
year;
(2) If requested by the Secretary,
information on the survey of patient
experience with care; and
(3) As the Secretary may require, on
the methods, measures, and data used
under the MOCP and the qualified
MOCP practice assessment.
Section 10327(b) of the ACA amends
section 3002(c) of the ACA further to
specify that the additional 0.5 percent
incentive payment is available only for
years 2011, 2012, 2013, and 2014. For
years after 2014, if the Secretary
determines it to be appropriate, the
Secretary may incorporate participation
in an MOCP and successful completion
PO 00000
Frm 00161
Fmt 4701
Sfmt 4702
40199
of a qualified MOCP practice assessment
into the composite of measures of
quality for care furnished pursuant to
the physician fee schedule payment
modifier.
To implement the provisions under
sections 3002(c) and 10327 of the ACA,
CMS proposes for 2011 to require the
following:
• An EP wishing to be eligible for the
additional PQRI incentive payment of
0.5 percent must meet the proposed
requirements for satisfactory PQRI
reporting, for program year 2011, based
on the 12-month reporting period. We
propose to require that EPs seeking the
additional PQRI incentive payment
satisfactorily report for a 12-month
reporting period rather than only a 6
month reporting period, based on the
statutory language that the EP must
satisfactorily report ‘‘for a year.’’ For
purposes of satisfactory reporting under
PQRI, we propose that the EP may
participate as an individual EP using
either individual PQRI measures or
measures groups and submitting the
PQRI data via claims, a registry, or an
her or participate under one of the
GPRO options (I or II),. Alternatively,
EPs may satisfactorily report under
PQRI based on submission of PQRI data
by an MOCP, provided that the MOCP
has qualified as a PQRI registry for 2011.
As indicated previously, an EP would
not necessarily have to qualify for PQRI
through an MOCP serving as a registry.
Rather, we propose that an EP may
qualify for the additional incentive,
without reqard to the method by which
the EP has met the basic requirement of
satisfactory reporting under PQRI.
• In addition to meeting the proposed
requirements for satisfactory reporting
under PQRI for program year 2011, the
EP must have data submitted on his or
her behalf through an MOCP, for the
MOCP in which the EP participates.
Although the MOCP need not become a
qualified registry for data submission for
PQRI purposes, the MOCP must meet
the criteria for a registry for submission
of the MOCP data as specified below.
• An EP must, more frequently than
is required to qualify for or maintain
board certification, participate in an
MOCP for a year and successfully
complete a qualified MOCP practice
assessment for such year. We believe
that the ‘‘more frequently’’ requirement
applies both to the elements of the
MOCP itself and the requirement to
successfully complete a qualified MOCP
practice assessment. With regard to the
elements other than completing a
qualified MOCP practice assessment, we
propose to require that the MOCP certify
that the EP has ‘‘more frequently’’ than
is required to qualify for or maintain
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40200
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
board certification ‘‘participated in a
MOCP for a year’’ as required by section
10327 of the ACA. We do not propose
to specify with respect to participation
how an EP must meet the more
frequently requirement, but rather that
the MOCP so certify that EP has met this
requirement. We note that we do not
believe that the ‘‘more frequently’’
requirement is applicable to the
licensure requirement, given that one
cannot be licensed ‘‘more frequently’’
than is required. However, we do
believe that the ‘‘more frequently’’
requirement applies to the required
elements under sections
1848(m)(7)(C)(i)(II) and
1848(m)(7)(C)(i)(III) of the Act. In other
words, we believe that the EP must
‘‘more frequently’’ than is required to
qualify for or maintain board
certification, participate in educational
and self-assessment programs that
require an assessment of what was
learned; demonstrate, through a
formalized, secure examination, that the
physician has the fundamental
diagnostic skills, medical knowledge,
and clinical judgment to provide quality
care in their respective specialty; and
successfully complete a qualified MOCP
practice assessment.
With respect to the MOCP practice
assessment, which is specifically
delineated in section 1848(m)(7)(B)(ii)
of the Act as being required more often
than is necessary to qualify for or
maintain board certification, we believe
we need to be more specific regarding
our interpretation of the phrase ‘‘more
frequently.’’ Additionally, we are aware
that some specialty boards have varying
MOCP requirements for physicians to
maintain board certification, based on
the date of original certification. Some,
we believe, may not be required to
participate in an MOCP program at all
in order to maintain board certifications.
Accordingly, we recognize that ‘‘more
often’’ may vary among physicians
certified by the same specialty board.
We interpret the statutory provisions as
requiring participation in and successful
completion of at least one MOCP
practice assessment. Therefore, we
propose, as a basic requirement,
participation in and successful
completion in at least one MOCP
practice assessment. For physicians who
are not required to participate in an
MOCP to maintain board certification,
‘‘more often’’ would be more than 0, and
therefore only once. For physicians,
however, who are otherwise required by
the specialty board to participate in an
MOCP to maintain board certification
status, these physicians would need to
complete the MOCP practice assessment
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
a second time in order to qualify for the
additional incentive payment. If an
MOCP practice assessment were
required more than once during a
particular cycle, the EP would be
required to complete the MOCP practice
assessment a third time in order to
qualify for the additional incentive.
We are also aware that ABMS boards
are at various stages in implementing
the practice assessment modules, and
some may not have such assessment
modules in place. However, inasmuch
as we interpret the statute to require an
MOCP practice assessment at least once
as part of the MOCP, EPs who do not
have available, through their boards or
otherwise, an MOCP practice
assessment are not eligible for the 0.5
percent incentive.
• We believe that the experience of
care survey provides particularly
valuable information and propose that a
qualified MOCP practice assessment
must include a survey of patient
experience with care. The Secretary may
request information on the survey of
patient experience with care, under
section 1848(m)(7)(B)(iii) of the Act. In
view of the importance of this
information, and the lack of readily
available alternative sources, we
propose to require that MOCPs submit
information as to the survey of patient
experience with care for the EP
regarding whom information is being
submitted by the MOCP.
We propose that MOCPs, who wish to
enable their members to be eligible for
an additional PQRI incentive payment
for the 2011 PQRI, will need to go
through a self-nomination process by
January 31, 2011. We propose the board
will need to include all of the following
information in their self-nomination
letter to CMS:
• Provide detailed information
regarding the MOCP with reference to
the statutory requirements for such
program.
• Indicate the organization
sponsoring the MOCP, and whether the
MOCP is sponsored by an ABMS board.
If not an ABMS board, indicate whether
the program is substantially equivalent
to the ABMS MOCP process.
• The frequency of a cycle of MOC for
the specific MOCP of the sponsoring
organization; including what constitutes
‘‘more frequently’’ for the MOCP practice
assessment for the specific MOCP of the
sponsoring organization.
• What was, is, or will be the first
year of availability of the MOCP practice
assessment for completion by an EP.
• What data is collected under the
patient experience of care survey and
how this information would be
provided to CMS.
PO 00000
Frm 00162
Fmt 4701
Sfmt 4702
• How the MOCP monitors that an EP
has implemented a quality improvement
process for their practice.
• Describe the methods, and data
used under the MOCP, and provide a
list of all measures used in the MOCP
for 2010 and to be used for 2011,
including the title and descriptions of
each measure, the owner of the measure,
whether the measure is NQF endorsed,
and a link to a Web site containing the
detailed specifications of the measures,
or an electronic file containing the
detailed specifications of the measures.
We propose that sponsoring
organizations who desire to participate
as an MOCP will need to be able to
provide CMS the following information
in a CMS-specified file format by no
later than the end of the first quarter of
2012:
• The name, NPI and applicable
TIN(s) of the EP who would like to
participate in this process;
• Attestation from the board that the
information provided to CMS is
accurate and complete;
• The board has signed
documentation from the EP that the EP
wishes to have their information
released to CMS; Information from the
experience of care survey;
• Information certifying that the EP
has participated in an MOCP for a year,
more frequently than is required to
qualify for or maintain board
certification status, including the year
that the physician met the board
certification requirements for the
MOCP, and the year the EP participated
in an MOCP ‘‘more frequently’’ than is
required to maintain or qualify for board
certification; and
• Information certifying that the EP
has completed the MOCP practice
assessment one additional time more
than is required to qualify for or
maintain board certification, including
the year of the original MOCP practice
assessment or that an MOCP practice
assessment is not required for the EP,
and the year of the additional MOCP
practice assessment completion.
We propose that specialty boards that
also desire to send PQRI information to
CMS on behalf of their EP should be
able to meet the requirements for
registry data submission proposed in
section VI.F.1.d.(4) of this rule and
should follow the directions for selfnomination to become a qualified
registry. Boards may also participate as
registries for PQRI data provided that
they meet the registry requirements.
As an alternative to requiring boards
to either operate a qualified PQRI
registry or to self-nominate to submit
MOCP data to CMS on behalf of their
members, we also considered having the
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
various boards submit the MOCP data to
the ABMS and having ABMS channel
the information from the various boards
to CMS. We invite comments on the
proposed mechanism for receiving
MOCP data from the specialty boards as
well as on the alternative mechanism
that we considered.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(3) Section 3002(d)—Integration of PQRI
and EHR Reporting
Section 1848(m)(7) of the Act
(‘‘Integration of Physician Quality
Reporting and EHR Reporting), as added
by section 3002(d) of the ACA requires
us to move towards the integration of
EHR measures with respect to the PQRI
program. Section 1848(m)(7) of the Act
specifies that by no later than January 1,
2012, the Secretary shall develop a plan
to integrate reporting on quality
measures under PQRI with reporting
requirements under subsection (o)
relating to the meaningful use of EHRs.
Such integration shall consist of the
following:
(A) The selection of measures, the
reporting of which would both
demonstrate—
(i) Meaningful use of an EHR for
purposes of the EHR incentive program;
and
(ii) Quality of care furnished to an
individual; and
(B) Such other activities as specified
by the Secretary.
In an effort to align PQRI with the
EHR incentive program, we propose to
include many ARRA core clinical
quality measures in the PQRI program,
to demonstrate meaningful use of EHR
and quality of care furnished to
individuals. We propose the selection of
these measures to meet the requirements
of planning the integration of PQRI and
EHR reporting. We are working towards
a plan to integrate reporting on quality
measures to make available by January
1, 2012.
We solicit comments on this approach
to integrate PQRI EHR measures with
the clinical quality measures adopted
for the EHR incentive program.
Specifically, we encourage comments
on how CMS plans to align the
measures, and how the plan for
integration will optimally improve
quality of care for individuals and
provide meaningful use of EHRs.
(4) Section 3002(e)—Feedback
Section 3002 (e) of the ACA amends
section 1848(m)(5) of the Act by adding
subparagraph (H), which requires the
Secretary to provide timely feedback to
EPs on the performance of the EP with
respect to satisfactorily submitting data
on quality measures. Since the
inception of the program in 2007, the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PQRI program has provided EPs who
have reported PQRI data on quality
measures feedback reports at the TIN/
NPI level detailing participation in
PQRI, including reporting rate and
performance rate information. For 2008,
we improved the format and content of
feedback reports based on stakeholder
input. We also developed an alternate
report distribution method whereby
each EP can directly request and receive
a feedback report. We will continue to
provide feedback reports to individuals
and group practices that satisfactorily
submit PQRI quality measure and thus
qualify to earn a PQRI incentive.
We believe that the requirements
under section 1848(m)(5)(H) of the Act,
as added by section 3002(e) of the ACA,
for ‘‘timely’’ feedback reports with
respect to satisfactorily submitting data
on quality measures is met by providing
the feedback reports on or about the
time of issuance of the incentive
payments. Thus, we propose to provide
2011 feedback reports on or about the
time of issuance of the 2011 incentive
payments, consistent with our current
practice.
In addition, we also propose to
provide interim feedback reports for EPs
reporting 2011 measures groups through
the claims-based reporting mechanism.
Specifically, we propose to develop
interim feedback reports that are similar
in content and format to the reports that
we currently provide for such EPs using
claims for dates of service between
January 1, 2011 and February 28, 2011.
We expect that we would be able to
make these interim feedback reports
available to EPs in June 2011. We
believe interim feedback reports would
be particularly valuable to EPs reporting
measures group because, unlike with
individual measures reporting, EPs
would not be required to report on a
certain percentage of eligible cases to
satisfactorily report the 2011 PQRI
measures groups. EPs could just report
on 30 eligible cases to satisfactorily
report using measures groups. Interim
feedback regarding the number of cases
reported as of February 28, 2011 would
be valuable since an EP would know
how many more cases he or she needs
to report to satisfy the criteria for
satisfactory reporting for claims-based
reporting of measures groups.
We also intend to continue to explore
methods to facilitate PQRI feedback
report distribution. Additionally, based
on feedback from the 2011 PQRI
Listening Session that was held on
February 2, 2010, we are considering a
process by which we could respond to
interim feedback report requests at the
individual level for claims-based
submission, based upon first quarter
PO 00000
Frm 00163
Fmt 4701
Sfmt 4702
40201
claims data for the applicable program
year. The goal of this would be to
provide information to EPs as to errors
in claims-based QDC submission while
the reporting period is ongoing and
prior to the start of the 6-month
reporting period. We welcome
comments with respect to our proposal
to provide timely feedback reports for
PQRI.
(5) Section 3002(f)—Appeals
Section 1848(m)(5)(I) of the Act, as
amended and added by section
3002(f)(2) of the ACA, requires an
informal review process. Specifically,
the statute requires that the Secretary
establish and have in place, no later
than January 1, 2011, an informal
process for EPs to seek a review of the
determination that an EP did not
satisfactorily submit data on quality
measures under the PQRI.
We note that except as provided
under the informal process under
section 1848(m)(5)(I) of the Act, section
1848(m)(5)(E) of the Act, as amended by
section 3002(f) of the ACA, specifies
that, with respect to the PQRI, there
shall be no administrative or judicial
review under section 1869, section
1878, or otherwise, of:
(1) The determination of measures
applicable to services furnished by EPs
under PQRI;
(2) The determination of satisfactory
reporting under PQRI; and
(3) The determination of any PQRI
incentive payment and PQRI payment
adjustment.
We propose to base the informal
process on our current inquiry process
whereby an EP can contact the Quality
Net Help Desk (via phone or e-mail) for
general PQRI and eRx Incentive Program
information, information on PQRI
feedback report availability and access,
and/or information on PQRI Portal
password issues. We believe that the
current inquiry process provides a good
basis for an informal review process
because EPs currently can utilize the
inquiry process if they have questions
on whether they qualified for an
incentive. However, the current inquiry
process does not have timelines nor is
it restricted to questions solely on
whether the EP qualified for an
incentive. Thus, for purposes of the
informal process required under section
1848(m)(5)(E) of the Act, we propose the
following process:
• An EP electing to utilize the
informal process must request an
informal review within 90 days of the
release of his or her feedback report.
• An EP can request the informal
review by notifying the Quality Net
Help Desk via e-mail at
E:\FR\FM\13JYP2.SGM
13JYP2
40202
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
qnetsupport@sdps.org. The e-mail
requesting the initiation of the informal
review process should summarize the
concern(s) of the EP and the reason(s)
for requesting an informal review.
• We propose to provide the EP with
a response to his or her request for an
informal review within 60 days of
receiving the original request.
• As this process is informal and the
statute does not require a formal appeals
process, we will not include a hearing
or evidence submission process,
although the EP may submit information
to assist in the review.
• Based on our informal review, we
will provide a written response. Where
we find that the EP did satisfactorily
report, we propose to provide the
applicable incentive payment.
• Given that this is an informal
review process and given the limitations
on review under section 1848(m)(5)(E)
of the Act, decisions based on the
informal review will be final, and there
will be no further review or appeal.
• By December 31, 2011, we propose
to post on the CMS PQRI Web site,
further information regarding the
operational aspects of the informal
review process for 2011 PQRI. We invite
public comment on this proposed
process.
2. Section 132: Incentives for Electronic
Prescribing (eRx)— The Electronic
Prescribing Incentive Program
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Program Background and Statutory
Authority
As defined in § 423.159(a), eRx is the
transmission using electronic media, of
prescription or prescription-related
information between prescriber,
dispenser, pharmacy benefit manager
(PBM), or health plan, either directly or
through an intermediary, including an
eRx network. Included in eRx, but not
limited to, are two-way transmissions
between the point of care and the
dispenser.
Section 1848(m)(2) of the Act
promotes the use of electronic
prescribing by authorizing incentive
payments to EPs or group practices who
are ‘‘successful electronic prescribers.’’
The intention of the 2011 eRx Incentive
Program, which is separate from, and in
addition to, any incentive payment that
EPs may earn through the PQRI
program, is to continue to encourage
significant expansion of the use of
electronic prescribing by authorizing a
combination of financial incentives and
payment adjustments. Individual EPs do
not have to participate in PQRI in order
to participate in the eRx Incentive
Program (and vice versa). We propose to
add § 414.92 to title 42 of the Code of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Federal Regulations to implement the
provisions of the eRx Incentive Program
discussed in this section of the
proposed rule.
For 2011, which is the third year of
the eRx Incentive Program, the Secretary
is authorized to provide successful
electronic prescribers, as defined in
section 1848(m)(3)(B) of the Act and
further discussed below in this section,
an incentive payment equal to 1.0
percent of the total estimated Medicare
Part B PFS allowed charges (based on
claims submitted not later than 2
months after the end of the reporting
period) for all covered professional
services furnished during the 2011
reporting period. Covered professional
services are defined under the statute to
be services for which payment is made
under, or is based on, the PFS and
which are furnished by an EP. The
applicable electronic prescribing
percent (1.0 percent) authorized for the
2011 eRx Incentive Program is different
from that authorized for the 2009 and
2010 eRx Incentive Program.
Under section 1848(m)(2)(C) of the
Act, the incentive payments for
successful electronic prescribers for
future years are authorized as follows:
• 1.0 percent for 2012.
• 0.5 percent for 2013.
However, section 1848(m)(2)(D) of the
Act, as added by section 4101(f)(2)(B) of
Title IV of Division B of the American
Recovery and Reinvestment Act of 2009
(Pub.L. 111–5) (ARRA–HITECH),
specifies that the eRx incentive does not
apply to an EP (or group practice), if, for
the EHR reporting period, the EP (or
group practice) earns an incentive
payment under the Medicare EHR
incentive program. The Medicare EHR
incentive program begins in 2011.
Therefore, EPs who earn an incentive
under the Medicare EHR Incentive
Program, with respect to certified EHR
technology that has eRx capabilities,
will not be eligible to earn a separate
incentive payment for being a successful
electronic prescriber under the eRx
Incentive Program.
For eRx, when reporting any of the Gcodes for purposes of qualifying for the
incentive payment for electronic
prescribing in 2011, we propose that the
professional must have and regularly
use a ‘‘qualified’’ electronic prescribing
system, as defined in the electronic
prescribing measure specifications. If
the professional does not have general
access to an eRx system in the practice
setting, as cited in the hardship
exception as stated by the secretary,
there is nothing to report.
In addition, under section
1848(a)(5)(A) of the Act, a PFS payment
adjustment applies beginning in 2012 to
PO 00000
Frm 00164
Fmt 4701
Sfmt 4702
those who are not successful electronic
prescribers. Specifically, for 2012, 2013,
and 2014, if the EP is not a successful
electronic prescriber for the reporting
period for the year, the PFS amount for
covered professional services furnished
by such professionals during the year as
referenced above shall be less than the
PFS amount that would otherwise apply
over the next several years by:
• 1.0 percent for 2012.
• 1.5 percent for 2013.
• 2.0 percent for 2014.
We believe that the criteria for
determination of successful electronic
prescriber proposed herein for the eRx
incentive payment are not required to be
identical to the criteria that will be used
to determine the applicability of the
payment adjustment that begins in 2012.
Policy considerations underlying the
application of the incentive payment are
not necessarily the same as those in
applying a payment adjustment. In
general, we believe that an incentive
should be broadly available to
encourage the widest possible adoption
of eRx, even for low volume prescribers.
On the other hand, we believe that a
payment adjustment should be applied
primarily to assure that those who have
a large volume of prescribing do so
electronically, without penalizing those
for whom the adoption and use of an
electronic prescribing system may be
impractical given the low volume of
prescribing. The 2011 eRx incentive and
the application of the payment
adjustment for 2012 will be addressed
separately below.
Under section 1848(m)(6)(A) of the
Act, the definition of ‘‘EP’’ for purposes
of eligibility for the eRx Incentive
Program is identical to the definition of
‘‘EP’’ for the PQRI under section
1848(k)(3)(B) of the Act. In other words,
EPs include physicians, other
practitioners as described in section
1842(b)(18)(C) of the Act, physical and
occupational therapists, qualified
speech-language pathologists, and
qualified audiologists. However, as we
have noted in prior years, for purposes
of the eRx Incentive Program, eligibility
is further restricted by scope of practice
to those professionals who have
prescribing authority. Detailed
information about the types of
professionals that are eligible to
participate in the eRx Incentive Program
is available on the Electronic
Prescribing Incentive Program section of
the CMS Web site at https://
www.cms.gov/ERXIncentive.
As in the 2010 eRx Incentive Program,
we propose in 2011 that the eRx
Incentive Program continue to be an
incentive program in which
determination of whether an EP is a
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
successful electronic prescriber will be
made at the individual professional
level, based on the NPI. Inasmuch as
some individuals (identified by NPIs)
may be associated with more than one
practice or TIN, the determination of
whether an EP is a successful electronic
prescriber will be made to the holder of
each unique TIN/NPI combination.
Then, as in previous years, payment
will be made to the applicable holder of
the TIN. For 2011, the determination of
whether an EP is a successful electronic
prescriber will continue to be made for
each unique TIN/NPI combination.
However, section 1848(m)(3)(C) of the
Act required the Secretary by January 1,
2010 to establish and have in place a
process under which EPs in a group
practice (as defined by the Secretary)
would be treated as meeting the
requirements for submitting data on
electronic prescribing quality measures
for covered professional services for a
reporting period (or, for purposes of the
payment adjustment under section
1848(a)(5) of the Act, for a reporting
period for a year) if, in lieu of reporting
the electronic prescribing measure, the
group practice reports measures
determined appropriate by the
Secretary, such as measures that target
high-cost chronic conditions and
preventive care, in a form and manner,
and at a time specified by the Secretary.
Therefore, in addition to making
incentive payments for 2011 to
individual EPs based on separately
analyzing whether the individual EPs
are successful electronic prescribers, we
propose to also make incentive
payments to group practices based on
the determination that the group
practice, as a whole, is a successful
electronic prescriber in accordance with
section 1848(m)(3)(C) of the Act.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
b. The 2011 eRx Incentive
(1) The 2011 Reporting Period for the
eRx Incentive Program
Section 1848(m)(6)(C)(i)(II) of the Act
defines ‘‘reporting period’’ for the 2011
eRx Incentive Program to be the entire
year. Section 1848(m)(6)(C)(ii) of the
Act, however, authorizes the Secretary
to revise the reporting period if the
Secretary determines such revision is
appropriate, produces valid results on
measures reported, and is consistent
with the goals of maximizing scientific
validity and reducing administrative
burden. We propose the 2011 eRx
Incentive Program reporting period to be
the entire calendar year (January 1, 2011
through December 31, 2011) based on
the definition of ‘‘reporting period’’
specified under section
1848(m)(6)(C)(i)(II) of the Act. We
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
believe that keeping the 2011 eRx
Incentive Program reporting period
consistent with 2009 and 2010 eRx
Incentive Program reporting periods
will help to further maintain program
stability and be less confusing for EPs.
Accordingly, we propose that
successful electronic prescribers would
be eligible to receive an incentive
payment equal to 1.0 percent of the total
estimated allowed Medicare Part B
charges (based on claims submitted by
no later than February 28, 2012) for all
covered professional services furnished
January 1, 2011 through December 31,
2011.
(2) Proposed Criteria for Determination
of Successful Electronic Prescriber for
EPs
Under section 1848(m)(3)(B) of the
Act, in order to qualify for the incentive
payment, an EP must be a ‘‘successful
electronic prescriber,’’ which the
Secretary is authorized to identify using
1 of 2 possible criteria. One criterion,
under section 1848(m)(3)(B)(ii) of the
Act, is based on the EP’s reporting, in
at least 50 percent of the reportable
cases, on any electronic prescribing
quality measures that have been
established under the physician
reporting system, under subsection
1848(k) of the Act (which, as noted
previously, we have named ‘‘PQRI’’ for
ease of reference) and are applicable to
services furnished by the EP during a
reporting period. We applied this
criterion in 2009. However, for years
after 2009, section 1848(m)(3)(D) of the
Act permits the Secretary in
consultation with stakeholders and
experts to revise the criteria for
submitting data on electronic
prescribing measures under section
1848(m)(3)(B)(ii) of the Act.
The second criterion, under section
1848(m)(3)(B)(iii) of the Act, is based on
the electronic submission by the EP of
a sufficient number (as determined by
the Secretary) of prescriptions under
Part D during the reporting period. If the
Secretary decides to use the latter
standard, then, in accordance with
section 1848(m)(3)(B)(iv) of the Act, the
Secretary is authorized to use Part D
drug claims data to assess whether a
‘‘sufficient’’ number of prescriptions
have been submitted by EPs. However,
under section 1848(m)(3)(B)(i) of the
Act, if the standard based on a sufficient
number (as determined by the Secretary)
of electronic Part D prescriptions is
applied for a particular reporting period,
then the standard based on the reporting
on electronic prescribing measures
would no longer apply.
For 2011, we propose to continue to
require EPs to report on the electronic
PO 00000
Frm 00165
Fmt 4701
Sfmt 4702
40203
prescribing measure used in the 2009
and 2010 eRx Incentive Program to
determine whether an EP is a successful
electronic prescriber, but we are
proposing to again use modified
measure specifications and to use
modified reporting criteria based on the
authority provided under section
1848(m)(3)(D) of Act, as discussed
below.
As we stated in prior years, we are
still considering the use of a certain
number of Part D prescribing events as
the basis for the incentive payment. We
propose to continue to require EPs to
report on the electronic prescribing
measure used in the 2009 and 2010 eRx
Incentive Program because we believe
that the accuracy and completeness of
the Part D data with respect to whether
a prescription was submitted
electronically is unknown. In 2010,
information on whether a prescription
was submitted electronically by an
individual EP began to be collected on
the Part D claims and/or Prescription
Drug Event (PDE) data. Also, since April
1, 2009, prescription drug plan sponsors
are required to send PDE data with an
individual prescriber’s NPI. We
currently have limited information on
the accuracy and completeness of NPI
data that is submitted with the PDE
data. The NPI is needed in order for
CMS to be able to link an EP’s PDE data
to his or her Medicare Part B claims to
calculate the incentive payment
amount. During 2010, we continue to
evaluate the adequacy of Part D data to
determine the feasibility of its use for
determining whether an EP qualifies as
a successful electronic prescriber. The
use of Part D data for correlation has not
yet shown to be possible due to NPI and
other issues. Part D data is supplied by
the pharmacy and not the EP. We are in
the process of writing and will publish
an evaluation of the PQRI reporting
experience. The experience report will
include an evaluation of the eRx
Incentive Program.
(i) Reporting the Electronic Prescribing
Measure
For 2011, we propose to retain the 3
reporting mechanisms available to
individual EPs to report the electronic
prescribing measure in 2010 to maintain
program stability. First, we propose to
again retain the claims-based reporting
mechanism that is used in the 2009 and
2010 eRx Incentive Program. In
addition, similar to the PQRI, for the
eRx Incentive Program, we propose to
continue the registry-based reporting
mechanism and, we also propose that
the EHR-based reporting mechanism be
available for the electronic prescribing
measure for 2011.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40204
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
We propose that only registries
qualified to submit quality measure
results and numerator and denominator
data on quality measures on behalf of
EPs for the 2011 PQRI would be
qualified to submit measure results and
numerator and denominator data on the
electronic prescribing measure on behalf
of EPs for the 2011 eRx Incentive
Program. As in 2010, not all registries
qualified to submit quality measures on
behalf of EPs for the 2011 PQRI would
be qualified to submit quality measures
results and numerator and denominator
data on the eRx measure. The electronic
prescribing measure is reportable by an
EP any time he or she bills for one of
the procedure codes for Part B services
included in the measure’s denominator.
Some registries who self-nominate to
become a qualified registry for PQRI
may not choose to self-nominate to
become a qualified registry for
submitting measures that require
reporting at each eligible visit. Registries
need to indicate their desire to qualify
to submit measure results and
numerator and denominator data on the
electronic prescribing measure for the
2011 eRx Incentive program at the time
that they submit their self-nomination
letter for the 2011 PQRI. In addition, we
propose that registries that want to be
qualified to submit measure results and
numerator and denominator data on the
electronic prescribing measure for the
2011 eRx Incentive Program would be
required to transmit 2011 eRx measure
results and numerator and denominator
data on the electronic prescribing
measure to CMS in two separate
transmissions. In addition to submitting
2011 measure results and numerator
data on the electronic prescribing
measure in 2012 as described in section
VI.F.1. above, such registries would
need to submit 2011 measure results
and numerator and denominator data on
the electronic prescribing measure
between July 1, 2011 and August 19,
2011 for purposes of the eRx penalty
described in section VI.F.2.c. below.
The self-nomination process and
requirements for registries for the PQRI,
which also would apply to the registries
for the 2011 eRx Incentive Program, are
discussed previously in section VI.F.1.
of this proposed rule. We will post a
final list of qualified registries for the
2011 eRx Incentive Program on the
Electronic Prescribing Incentive
Program section of the CMS Web site at
https://www.cms.gov/ERXIncentive when
we post the final list of qualified
registries for the 2011 PQRI on the PQRI
section of the CMS Web site.
Similarly, we continue to propose that
only EHR products ‘‘qualified’’ to
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
potentially be able to submit clinical
quality data extracted from the EHR to
CMS for the 2011 PQRI would be
considered ‘‘qualified’’ for the purpose
of an EP potentially being able to submit
data on the electronic prescribing
measure for the 2011 eRx Incentive
Program. The self-nomination process
and requirements for EHR vendors for
the PQRI, which would apply to the
EHR vendors for the 2011 eRx Incentive
Program were discussed in the CY 2010
PFS final rule with comment period (74
FR 61801 through 61802). EHR vendors
were required to indicate their desire to
have one or more of their EHR products
qualified for the purpose of an EP
potentially being able to submit data on
the electronic prescribing measure for
the 2011 eRx Incentive Program at the
time that they submitted their selfnomination letter for the 2011 PQRI. A
list of qualified EHR vendors and their
products (including the version that is
qualified) for the 2011 eRx Incentive
Program will be posted on the eRx
Incentive Program section of the CMS
Web site at https://www.cms.gov/
ERXIncentive when we post the list of
qualified EHR products for the 2011
PQRI on the PQRI section of the CMS
Web site. We propose that EPs who
want to use a qualified EHR to submit
the electronic prescribing measure for
the 2011 eRx Incentive Program would
be required to transmit 2011 eRx data to
CMS in two separate transmissions. In
addition to submitting 2011 data on the
electronic prescribing measure in 2012,
as described in section VI.F.1. above,
such EPs would need to submit 2011
data on the electronic prescribing
measure between July 1, 2011 and
August 19, 2011 for purposes of the eRx
penalty described in section VI.F.2.c.
below.
(ii) The Reporting Denominator for the
Electronic Prescribing Measure
The electronic prescribing measure,
similar to the PQRI measures, has 2
basic elements, which include: (1) A
reporting denominator that defines the
circumstances when the measure is
reportable; and (2) a reporting
numerator.
The denominator for the electronic
prescribing measure consists of specific
billing codes for covered professional
services. The measure becomes
reportable when any one of these
procedure codes is billed by an EP for
Part B covered professional services. As
initially required under section
1848(k)(2)(A)(ii) of the Act, and further
established through rulemaking and
under section 1848(m)(2)(B) of the Act,
we may modify the codes making up the
denominator of the electronic
PO 00000
Frm 00166
Fmt 4701
Sfmt 4702
prescribing measure. As such, we
expanded the scope of the denominator
codes for 2010 to covered professional
services outside the professional office
and outpatient setting, such as
professional services furnished in
skilled nursing facilities or the home
care setting.
We propose to retain the following
CPT codes in the denominator of the
electronic prescribing measure for 2011:
90801, 90802, 90804, 90805, 90806,
90807, 90808, 90809, 90862, 92002,
92004, 92012, 92014, 96150, 96151,
96152, 99201, 99202, 99203, 99204,
99205, 99211, 99212, 99213, 99214,
99215, 99304, 99305, 99306, 99307,
99308, 99309, 99310, 99315, 99316,
99324, 99325, 99326, 99327, 99328,
99334, 99335, 99336, 99337, 99341,
99342, 99343, 99344, 99345, 99347,
99348, 99349, 99350, G0101, G0108,
G0109. In 2010, the expansion of the
electronic prescribing measure
denominator was expected to provide
more EPs the opportunity to report the
measure, and thus, provide more
opportunities for EPs to participate in
the eRx Incentive Program. Thus far, our
experience in the 2010 eRx Incentive
Program has been positive and we do
not see a need to change the
denominator codes for 2011. We invite
comments on our proposal to retain the
denominator codes from the 2010
electronic prescribing measure
denominator.
There are no diagnosis codes in the
measure’s denominator and there are no
age/gender requirements in order for a
patient to be included in the measure’s
denominator (that is, reporting of the
electronic prescribing measure is not
further limited to certain ages or a
specific gender). EPs are not required to
report this measure in all cases in which
the measure is reportable. EPs who do
not bill for one of the procedure codes
for Part B covered professional services
included in the measure’s denominator
will have no occasion to report the
electronic prescribing measure.
We further propose that by December
31, 2010, we will post the final
specifications of the measure on the
‘‘eRx Measure’’ page of the eRx Incentive
Program section of the CMS Web site at
https://www.cms.gov/ERXIncentive.
(iii) Qualified Electronic Prescribing
System—Required Functionalities and
Part D eRx Standards
To report the electronic prescribing
measure in 2011, we again propose that
the EP must report one of the measure’s
numerator ‘‘G’’ codes, as will be
discussed below. However, when
reporting any of the G-codes for
purposes of qualifying for the incentive
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
payment for electronic prescribing in
2011, we propose that the professional
must have and regularly use a
‘‘qualified’’ electronic prescribing
system, as defined in the electronic
prescribing measure specifications. If
the professional does not have general
access to an eRx system in the practice
setting, the EP does not have any data
to report for purposes of the incentive
payment.
Required Functionalities for a
‘‘Qualified’’ Electronic Prescriber
System.
For 2011, we propose to retain what
constitutes a ‘‘qualified’’ electronic
prescribing system as a system based
upon certain required functionalities
that the system can perform. We
propose that for 2011, a ‘‘qualified’’
electronic prescribing system would be
one that can—
• Generate a complete active
medication list incorporating electronic
data received from applicable
pharmacies and PBMs, if available.
• Allow EPs to select medications,
print prescriptions, electronically
transmit prescriptions, and conduct
alerts (written or acoustic signals to
warn the prescriber of possible
undesirable or unsafe situations
including potentially inappropriate dose
or route of administration of a drug,
drug-drug interactions, allergy concerns,
or warnings and cautions). This
functionality must be enabled.
• Provide information related to
lower cost, therapeutically appropriate
alternatives (if any). The ability of an
electronic prescribing system to receive
tiered formulary information, if
available, would again suffice for this
requirement for 2011 and until this
function is more widely available in the
marketplace.
• Provide information on formulary
or tiered formulary medications, patient
eligibility, and authorization
requirements received electronically
from the patient’s drug plan (if
available).
Part D Electronic Prescribing
Standards. Section 1848(m)(3)(B)(v) of
the Act specifies that to the extent
practicable, in determining whether an
EP is a successful electronic prescriber,
‘‘the Secretary shall ensure that EPs
utilize electronic prescribing systems in
compliance with standards established
for such systems pursuant to the Part D
Electronic Prescribing Program under
section 1860D–4(e)’’ of the Act. The Part
D standards for electronic prescribing
systems establish which electronic
standards Part D sponsors, providers,
and dispensers must use when they
electronically transmit prescriptions
and certain prescription related
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
information for Part D covered drugs
that are prescribed for Part D eligible
individuals. To be a qualified electronic
prescribing system under the current
eRx Incentive Program, electronic
systems must convey the information
listed above under (a) through (d) using
the standards currently in effect for the
Part D electronic prescribing program.
Additional Part D electronic prescribing
standards were implemented April 1,
2009. These latest Part D electronic
prescribing standards, and those that
had previously been adopted, can be
found on the CMS Web site at https://
www.cms.gov/eprescribing.
To ensure that EPs utilize electronic
prescribing systems that meet these
requirements, the electronic prescribing
measure requires that those
functionalities required for a ‘‘qualified’’
electronic prescribing system utilize the
adopted Part D electronic prescribing
standards. The Part D electronic
prescribing standards relevant to the
four functionalities for a ‘‘qualified’’
system in the electronic prescribing
measure described above and listed as
(a), (b), (c), and (d), currently are as
follows:
(a) Generate medication list—Use the
National Council for Prescription Drug
Programs (NCPDP) Prescriber/
Pharmacist Interface SCRIPT Standard,
Implementation Guide, Version 8,
Release 1, October 2005 (hereinafter
‘‘NCPDP SCRIPT 8.1’’) Medication
History Standard.
(b) Transmit prescriptions
electronically—Use the NCPDP SCRIPT
8.1 for the transactions listed at
§ 423.160(b)(2).
(c) Provide information on lower cost
alternatives—Use the NCPDP Formulary
and Benefits Standard, Implementation
Guide, Version 1, Release 0 (Version
1.0), October 2005 (hereinafter ‘‘NCPDP
Formulary and Benefits 1.0’’).
(d) Provide information on formulary
or tiered formulary medications, patient
eligibility, and authorization
requirements received electronically
from the patient’s drug plan—use—
(1) NCPDP Formulary and Benefits 1.0
for communicating formulary and
benefits information between
prescribers and plans;
(2) Accredited Standards Committee
(ASC) X12N 270/271–Health Care
Eligibility Benefit Inquiry and Response,
Version 4010, May 2000, Washington
Publishing Company, 004010X092 and
Addenda to Health Care Eligibility
Benefit Inquiry and Response, Version
4010A1, October 2002, Washington
Publishing Company, 004010X092A1
for communicating eligibility
information between the plan and
prescribers; and
PO 00000
Frm 00167
Fmt 4701
Sfmt 4702
40205
(3) NCPDP Telecommunication
Standard Specification, Version 5,
Release 1 (Version 5.1), September 1999,
and equivalent NCPDP Batch Standard
Batch Implementation Guide, Version 1,
Release 1 (Version 1.1), January 2000 for
communicating eligibility information
between the plan and dispensers.
However, there are Part D electronic
prescribing standards that are in effect
for functionalities that are not
commonly utilized at this time. Such
functionalities are not currently
required for a ‘‘qualified’’ system under
the eRx Incentive Program. One
example is Rx Fill Notification, which is
discussed in the Part D electronic
prescribing final rule (73 FR 18918,
18926). For purposes of the 2011
Electronic Prescribing Program, we
again are not proposing to require that
an electronic prescribing system contain
all functionalities for which there are
available Part D electronic prescribing
standards. For those required
functionalities described above, we
propose that a ‘‘qualified’’ system must
use the adopted Part D electronic
prescribing standards for electronic
messaging.
There are other aspects of the
functionalities for a ‘‘qualified’’ system
that are not dependent on electronic
messaging and are part of the software
of the electronic prescribing system, for
which Part D standards for electronic
prescribing do not pertain and are not
required for purposes of the eRx
Incentive Program. For example, the
requirements in qualification (b) listed
above that require the system to allow
professionals to select medications,
print prescriptions, and conduct alerts
are functions included in the particular
software, for which Part D standards for
electronic messaging do not apply.
We are aware that there are significant
numbers of EPs who are interested in
participating in the eRx Incentive
Program, but currently do not have an
electronic prescribing system. The
electronic prescribing measure does not
require the use of any particular system
or transmission network; only that the
system be a ‘‘qualified’’ system having
the functionalities described above
based on Part D electronic prescribing
standards. As in 2010, if the
professional does not have general
access to an electronic prescribing
system in the practice setting, the EP
does not have any data to report for
purposes of the incentive payment and
would not be able to participate in the
2011 eRx Incentive Program. If an EP
does not participate in the 2011 eRx
Incentive Program he or she may be
subject to the 2012 eRx penalty
E:\FR\FM\13JYP2.SGM
13JYP2
40206
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
discussed in section VI.F.2.c. of this
proposed rule.
(iv) The Reporting Numerator for the
Electronic Prescribing Measure
The proposed criteria for reporting for
purposes of being a 2011 successful
electronic prescriber are designed to
reward those EPs who demonstrate that
they have adopted a qualified electronic
prescribing system and actually used
the system in a substantial way to
electronically prescribe. In this context,
the reporting of information in
circumstances where a professional did
not electronically prescribe is not
pertinent. Additionally, although it may
be of interest to measure the proportion
of prescribing events that are electronic,
we do not believe such detail at the
individual or group practice level is of
sufficient value to warrant the high
burden of reporting such information.
We do note that in the future the use of
Part D claims data may allow this
information to be collected without the
necessity for professionals to
specifically report such details.
Accordingly, for the 2011 electronic
prescribing measure, we propose to
retain the following numerator G-code
from the 2010 electronic prescribing
measure’s numerator: G8553 (At least 1
prescription created during the
encounter was generated and
transmitted electronically using a
qualified electronic prescribing system.)
We propose to post the final 2011
electronic prescribing measure
specifications on the ‘‘eRx Measure’’
page of the eRx Incentive Program
section of the CMS Web site at https://
www.cms.gov/ERXIncentive. We
propose to post the final 2011 electronic
prescribing measure specifications by
no later than December 31, 2010.
Because the electronic prescribing
quality measure will apply only when
an EP furnishes services indicated by
one of the codes included in the
measure’s denominator, for claimsbased reporting, for example, it will not
be necessary for an EP to report G-codes
for the electronic prescribing measure
on claims not containing one of the
denominator codes. However, if
reporting a G-code, the G-code data
submission will only be considered
valid if it appears on the same Medicare
Part B claim containing one of the
electronic prescribing quality measure’s
denominator codes.
In addition, if the EP submits a
Medicare Part B claim containing one of
the electronic prescribing measure’s
denominator codes, he or she can report
the numerator G-code only when the EP
furnishes services indicated by the Gcode included in the measure’s
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
numerator. That is, only when at least
1 prescription created during the
encounter is generated and transmitted
electronically using a qualified
electronic prescribing system.
(v) Criteria for Successful Reporting of
the Electronic Prescribing Measure
As discussed above, section
1848(m)(3)(D) of the Act authorizes the
Secretary to revise the criteria for
submitting data on the electronic
prescribing measure from the criteria
specified under section 1848(m)(3)(B)(ii)
of the Act, which requires the measure
to be reported in at least 50 percent of
the cases in which the measure is
reportable. In 2010, we revised the
criteria for successful electronic
prescriber such that an EP shall be
treated as a successful electronic
prescriber for a reporting period based
on the EP’s reporting of the electronic
prescribing measure by generating and
reporting one or more prescriptions
associated with a patient visit
electronically, a minimum of 25 unique
visits per year in 2010 of applicable
cases in the denominator of the eRx
measure. For 2011, we again propose to
make the determination of whether an
EP is a successful electronic prescriber
based on a count of the number of times
(minimum threshold of 25) an EP
reports that at least one prescription
created during the encounter is
generated using a qualified electronic
prescribing system (that is, reports the
G8553 code).
As in 2010, we believe these criteria
will bring us closer to our intention to
transition to using a certain number of
electronic Part D prescribing events as
the basis for the incentive payment in
future years. In proposing these criteria
again for 2011 eRx, we continue to
assume that once an EP has invested in
an eRx system, integrated the use of the
eRx system into the practice’s work
flows, and has used the system to some
extent, he or she is likely to continue to
use the eRx system for most of the
prescriptions he or she generates.
For structural measures such as the
electronic prescribing measure, once an
EP has demonstrated that he or she has
integrated use of an eRx system into his
or her practice’s work flow, we believe
that requiring the EP to continue to
report the measure represents an
administrative burden with little added
benefit to the reliability and validity of
the data being reporting. In contrast, for
clinical quality measures, we believe
that the reliability and validity of the
performance rates depends on the
adequacy of the sample. Therefore, we
propose that an EP would be required to
report that at least 1 prescription for a
PO 00000
Frm 00168
Fmt 4701
Sfmt 4702
Medicare Part B FFS patient created
during an encounter that is represented
by 1 of the codes in the denominator of
the electronic prescribing measure was
generated and transmitted electronically
using a qualified eRx system for at least
25 times during the 2011 reporting
period.
The reporting threshold of 25 also
takes into consideration that
prescriptions are not generated with
every Medicare Part B FFS patient
encounter, some prescriptions, such as
narcotics, cannot be prescribed
electronically, and that not all Medicare
Part B FFS encounters are represented
by the electronic prescribing measure’s
denominator codes.
As stated previously, we propose that
by December 31, 2010, we will post the
final specifications of the measure on
the ‘‘eRx Measure’’ page of the eRx
Incentive Program section of the CMS
Web site at https://www.cms.gov/
ERXIncentive.
(3) Determination of the 2011 Incentive
Payment Amount for Individual EPs
Who Are Successful Electronic
Prescribers
Section 1848(m)(2)(B) of the Act
imposes a limitation on the electronic
prescribing incentive payment. The
Secretary is authorized to choose 1 of 2
possible criteria for determining
whether or not the limitation applies to
a successful electronic prescriber. The
first criterion, under section
1848(m)(2)(B)(i) of the Act, is based
upon whether the Medicare Part B
allowed charges for covered
professional services to which the
electronic prescribing quality measure
applies are less than 10 percent of the
total Medicare Part B PFS allowed
charges for all covered professional
services furnished by the EP during the
reporting period. The second criterion,
under section 1848(m)(2)(B)(ii) of the
Act, is based on whether the EP submits
(both electronically and nonelectronically) a sufficient number (as
determined by the Secretary) of
prescriptions under Part D (which can,
again, be assessed using Part D drug
claims data). If the Secretary decides to
use the latter criterion, then, in
accordance with section 1848(m)(2)(B)
of the Act, the criterion based on the
reporting on electronic prescribing
measures would no longer apply. The
statutory limitation also applies with
regard to the application of the payment
adjustment.
Based on our proposal to make the
determination of whether an EP is a
‘‘successful electronic prescriber’’ based
on submission of the electronic
prescribing measure, we propose to
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
again apply the criterion under section
1848(m)(2)(B)(i) of the Act for the
limitation for the 2011 eRx Incentive
Program.
Since, as discussed above, we are
retaining for 2011 our proposal to make
the determination of whether an EP is
a ‘‘successful electronic prescriber’’
based on submission of the electronic
prescribing measure, we also are
proposing to retain the requirement to
analyze the claims submitted by the EP
at the TIN/NPI level to determine
whether the 10 percent threshold is met
in determining the receipt of an
electronic prescribing incentive
payment for 2011 by an EP. This
calculation is expected to take place in
the first quarter of 2012 and will be
performed by dividing the EP’s total
2011 Medicare Part B PFS allowed
charges for all such covered professional
services submitted for the measure’s
denominator codes by the EP’s total
Medicare Part B PFS allowed charges for
all covered professional services (as
assessed at the TIN/NPI level). If the
result is 10 percent or more, then the
statutory limitation will not apply and
a successful electronic prescriber will
qualify to earn the electronic prescribing
incentive payment. If the result is less
than 10 percent, then the statutory
limitation will apply and the EP will not
earn an electronic prescribing incentive
payment even if he or she electronically
prescribes and reports a G-code
indicating that he or she generated and
transmitted a prescription electronically
at least 25 times for those eligible cases
that occur during the 2011 reporting
period. Although an individual EP may
decide to conduct his or her own
assessment of how likely this statutory
limitation is expected to apply to him or
her before deciding whether or not to
report the electronic prescribing
measure, an individual EP may report
the electronic prescribing measure
without regard to the statutory
limitation for the incentive payment.
(4) Proposed Reporting Option for
Satisfactory Reporting of the Electronic
Prescribing Measure by Group Practices
In 2010 eRx Incentive Program, we
were required by section 1848(m)(3)(C)
of the Act to establish a process under
which EPs in a group practice shall be
treated as a successful electronic
prescriber. In addition, section
1848(m)(3)(C)(iii) of the Act requires
that payments to a group practice by
reason of the process established under
section 1848(m)(3)(C)(i) of the Act shall
be in lieu of the payments that would
otherwise be made under this
subsection to EPs in the group practice
for being a successful electronic
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
prescriber. In 2011, we propose to retain
the requirements from 2010 eRx
Incentive Program with respect to
making incentive payments to group
practices based on the determination
that the group practice, as a whole, is a
successful electronic prescriber for
2011. An individual EP who is affiliated
with a group practice participating in
the group practice reporting option that
successfully meets the proposed
requirements for group practices would
not be eligible to earn a separate eRx
incentive payment for 2011 on the basis
of his or her successfully reporting the
electronic prescribing measure at the
individual level.
(i) Definition of ‘‘Group Practice’’
Section 1848(m)(3)(C)(i) of the Act
authorizes the Secretary to define
‘‘group practice.’’ For purposes of
determining whether a group practice is
a successful electronic prescriber for
2011, we propose that consistent with
the definition of group practice
proposed for the PQRI group practice
reporting option (GPRO) discussed in
section VI.F.1. of this proposed rule, a
‘‘group practice’’ would be defined as a
single Taxpayer Identification Number
(TIN) with 2 or more EPs, as identified
by their individual National Provider
Identifier (NPI), who have reassigned
their Medicare billing rights to the TIN.
‘‘Group practice’’ would also include
group practices participating in
Medicare demonstration projects
approved by the Secretary, as described
in section VI.F.1.g.(2) of this proposed
rule.
In addition, we propose to restrict
participation in the 2011 eRx GPRO to
group practices participating in the 2011
PQRI GPRO (either through GPRO I or
GPRO II) or group practices that are
deemed to be participating in the 2011
PQRI GPRO (that is, group practices
participating in a CMS-approved
Medicare demonstration) that have
indicated their desire to participate in
the 2011 eRx GPRO.
Therefore, unlike individual EPs who
are not required to participate in the
PQRI, to be eligible to earn an electronic
prescribing incentive in 2011, group
practices that wish to participate in the
electronic prescribing group practice
reporting option will be required to
participate in the PQRI group practice
reporting option or be deemed to be
participating in the PQRI group practice
reporting option based on the practice’s
participation in an approved Medicare
demonstration project. Participation in
the eRx Incentive Program, including
participation in the electronic
prescribing group practice reporting
option is, however, optional for group
PO 00000
Frm 00169
Fmt 4701
Sfmt 4702
40207
practices that are participating in PQRI
under the group practice reporting
option. If a group practice wishes to
participate in the 2011 eRx Incentive
Program under the group practice
reporting option, it must indicate its
desire to do so at the time that the group
practice self-nominates to participate in
the 2011 PQRI group practice reporting
option. There is no need for group
practices to indicate their intent to
participate in the 2011 eRx Incentive
Program as individual EPs when the
group practice self-nominates to
participate in the 2011 PQRI group
practice reporting option.
Group practices interested in
participating in the 2011 PQRI through
the group practice reporting option will
be required to submit a self-nomination
letter to CMS, requesting to participate
in the 2011 PQRI group practice
reporting option. Instructions for
submitting the self-nomination letter
will be posted on the PQRI section of
the CMS Web site by November 15,
2010. A group practice that wishes to
participate in the eRx Incentive Program
group practice reporting option will be
notified of the selection decision to
participate in the eRx Incentive Program
at the same time that it is notified of the
selection decision for the PQRI group
practice reporting option.
In addition to meeting the proposed
eligibility requirements discussed in
section VI.F.1.g. of this proposed rule,
we propose that a group practice that
wishes to participate in the 2011 eRx
Incentive Program under the group
practice reporting option will also have
to indicate how it intends to report the
electronic prescribing measure. That is,
the group practice will need to indicate
in its self-nomination letter which
reporting mechanism the group practice
intends to use for purposes of
participating in the 2011 eRx Incentive
Program group practice reporting
option.
(2) Process for Group Practices to
Participate as Group Practices and
Criteria for Successful Reporting of the
Electronic Prescribing Measure by
Group Practices
For group practices selected to
participate in the electronic prescribing
group practice reporting option for
2011, we propose the reporting period
would be January 1, 2011, to December
31, 2011.
We propose that physician groups
selected to participate in the 2011 eRx
Incentive Program through the group
practice reporting option would be able
to choose to report the electronic
prescribing measure through the claims-
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40208
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
based, the registry-based, or, the EHRbased reporting mechanism.
In order for a group practice
participating in the PQRI GPRO I to be
considered a successful electronic
prescriber, we propose that the group
practice would have to report that at
least 1 prescription during an encounter
was generated and transmitted
electronically using a qualified
electronic prescribing system in at least
2,500 instances during the reporting
period. In order for a group practice
participating in the PQRI GPRO II to be
considered a successful electronic
prescriber, we propose that the group
practice would have to report that at
least 1 prescription during an encounter
was generated and transmitted
electronically using a qualified
electronic prescribing system for the
number of instances specified in Table
50 (see section VI.F.1.g.(3).(ii). of this
proposed rule). In other words, a group
of 2–10 NPIs would need to report the
2011 electronic prescribing measure for
at least 75 denominator eligible patient
encounters during 2011, 225 instances
for groups of 11–25 NPIs, 475 instances
for groups of 26–50 NPIs, 925 instances
for groups of 51–100, and 1,875
instances for groups of 101–199.
Section 1848(m)(2)(B) of the Act
specifies that the limitation on the
applicability of the electronic
prescribing incentive applies to group
practices as well as individual EPs.
Therefore, in determining whether a
group practice will receive an electronic
prescribing incentive payment for 2011
by meeting the proposed reporting
criteria described above, we would
determine whether the 10 percent
threshold is met based on the claims
submitted by the group practice.
This calculation is expected to take
place in the first quarter of 2012 and
will be determined by dividing the
group practice’s total 2011 Medicare
Part B PFS allowed charges for all
covered professional services submitted
for the measure’s denominator codes by
the group practice’s total Medicare Part
B PFS allowed charges for all covered
professional services. If the result is 10
percent or more, then the statutory
limitation would not apply and a group
practice that is determined to be a
successful electronic prescriber would
qualify to earn the electronic prescribing
incentive payment. If the result is less
than 10 percent, then the statutory
limitation would apply and the group
practice would not qualify to earn the
electronic prescribing incentive
payment.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
c. The 2012 eRx Penalty
As stated previously, section
1848(a)(5) of the Act requires that
beginning with respect to covered
professional services furnished by an EP
in 2012, if the EP is not a successful
electronic prescriber for the reporting
period for the year, the fee schedule
amount for such services furnished by
such professional during 2012 shall be
equal to 99 percent of the fee schedule
amount that would otherwise apply to
such PFS services. As noted previously,
we do not believe that the criteria that
will be used to determine the
applicability of the payment adjustment,
or penalty, for 2012 need to be identical
to the criteria for determination of
successful electronic prescriber.
We note also that although earning an
incentive payment under the EHR
incentive payment program precludes
an EP from earning an eRx incentive
payment, it does not preclude the EP
from being subject to the eRx penalty. In
order to avoid the eRx penalty, an EP
participating in the Medicare EHR
incentive program still must meet the
relevant eRx penalty criteria for being a
successful electronic prescriber.
(1) The eRx Penalty Reporting Period
For purposes of the 2012 eRx penalty,
we propose to make a determination of
whether an EP or a group practice is a
successful electronic prescriber based
on the reporting period that begins
January 1, 2011 through June 30, 2011.
We are proposing a 6-month reporting
period for the 2012 penalty rather than
a 12-month reporting period so that we
may be able to complete the analysis of
2011 data to determine whether an EP
or group practice is a successful
electronic prescriber prior to January 1,
2012. In order to apply the penalty in
2012 concurrently with claims
submission, we will need to make a
determination of whether the penalty
applies sufficiently in advance of 2012.
We believe that establishing a 6-month
reporting period for the first year of the
penalty will provide administrative
efficiencies and avoid the need to apply
a retroactive penalty or to make
retroactive payments based on
application of a penalty.
For EPs and group practices using the
claims-based reporting mechanism, we
propose that all claims for services
furnished between January 1, 2011 and
June 30, 2011 must be processed by no
later than July 31, 2011 for the claim to
be included in our data analysis. This is
in contrast to the incentive, where we
allow 2 months for claims to be
processed. In order to be able to make
a determination of whether the penalty
PO 00000
Frm 00170
Fmt 4701
Sfmt 4702
applies sufficiently in advance of 2012,
we will need to begin our analysis of the
claims shortly after June 30, 2011. We
invite comments on the proposed
reporting period for the 2012 penalty
and our proposal to require claims to be
submitted by no later than 1 month after
the reporting period.
(2) Criteria for Determining
Applicability of the 2012 eRx Penalty to
Individual EPs
Based on the authority under section
1848(m)(3)(D) of the Act, we propose
that the 2012 eRx penalty would apply
to an individual EP unless one of the
following conditions is met:
• The EP is not a physician (includes
MDs, DOs, and podiatrists), nurse
practitioner, or physician assistant as of
June 30, 2011. We believe that it is
appropriate to limit the application of
the penalty to those professionals who
generally have prescribing privileges
nationwide. Other EPs not listed above
may have prescribing privileges in some
states but not others. Therefore, we
propose to exempt EPs who do not
generally have prescribing privileges
from being subject to the penalty.
• The EP does not have at least 100
cases (that is, claims for patient
services) containing an encounter code
that falls within the denominator of the
eRx measure for dates of service
between January 1, 2011 through June
30, 2011. We seek to apply the penalty
only to EPs who have a sufficient
number of cases between January 1,
2011 and June 30, 2011 to meet the
criteria for successful electronic
prescribing for purposes of the penalty.
We believe that, on average, for every 10
eligible cases, there will be at least one
electronic prescribing opportunity,
which provides a sufficient number of
cases to allow EPs to meet the criteria
for being a successful electronic
prescriber. In addition, we seek to
prevent EPs who are new to Medicare
from being subject to the eRx penalty.
• The EP is a successful electronic
prescriber for the January 1, 2011
through June 30, 2011 reporting period.
Specifically, we propose that the EP
must report that at least 1 prescription
for Medicare Part B FFS patients created
during an encounter that is represented
by 1 of the codes in the denominator of
the 2011 electronic prescribing measure
was generated and transmitted
electronically using a qualified eRx
system at least 10 times during the 2012
eRx penalty reporting period (that is,
January 1, 2011 through June 30, 2011).
We propose reporting criteria that are
lower for the 2012 eRx penalty than for
the 2011 eRx incentive because EPs will
only have 6 months to satisfy the
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
criteria for the 2012 penalty but have a
full year to satisfy the criteria for the
2011 incentive.
The limitation with respect to the
electronic prescribing measures
required under section 1848(m)(2)(B)(i)
of the Act also applies to the penalty.
Therefore, we propose that if less than
10 percent of the EP’s estimated total
allowed charges for the January 1, 2011
through June 30,2011 reporting period
are comprised of services which appear
in the denominator of the 2011
electronic prescribing measure, then the
EP would not be subject to the eRx
penalty.
We invite comments on the proposed
conditions under which we would
prospectively apply the 1.0 percent
reduction in PFS charges for services
furnished January 1, 2012 through
December 31, 2012. We specifically
invite comments on our proposals to
exempt certain types of EPs and EPs
who do not have a certain number of
cases from the penalty as well as the
proposed criteria for successful
reporting of the electronic prescribing
measure for individual EPs with respect
to the penalty.
As with the 2011 incentive payment,
we propose that the determination of
whether an EP is subject to the penalty
will be made at the individual
professional level, based on the NPI and
for each unique TIN/NPI combination.
(3) Criteria for Determining
Applicability of the 2012 eRx Penalty to
Group Practices
As required by section 1848(m)(3)(C)
of the Act, we are also required to
establish and have in place a process
under which EPs in a group practice
shall be treated as a successful
electronic prescriber for purposes of the
eRx penalty. Thus, we propose that for
purposes of the 2012 eRx penalty, a
payment adjustment would not be
applied to a a group practice
participating in the 2011 eRx GPRO if
the group practice is participating in
either the 2011 PQRI GPRO I or the 2011
PQRI GPRO II and meets the proposed
2011 criteria for successful electronic
prescribing described in sections
VI.F.2.b.(4).(ii). (with respect to the eRx
requirements for GPRO I participants
who wish to participate in the 2011 eRx
GPRO) and VI.F.1.g.(3).(ii). of the
preamble to this proposed rule (with
respect to the eRx requirements for
GPRO II participants who wish to
participate in the 2011 eRx GPRO) for
the 2011 eRx incentive.
For purposes of the 2012 eRx penalty,
we propose that the proposed 2011
criteria for successful electronic
prescribing would need to be satisfied
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
during the 2012 eRx penalty reporting
period of January 1, 2011 through June
30, 2011 for the same operational
reasons that we are proposing a 6-month
reporting period for the penalty for
individual EPs. Furthermore, we do not
believe that group practices would be
disadvantaged by having to satisfy the
proposed criteria for being a successful
electronic prescriber for the 2011
incentive in 6 months rather than 12
months to avoid the penalty. When
compared to the criteria for individual
EPs, the proposed criteria for being a
successful electronic prescriber for the
2011 eRx incentive payment for group
practices enable group practices, on
average, to earn the incentive by
electronically prescribing a fewer
number of prescriptions per EP than
what individual EPs are required to do.
For purposes of determining whether
the eRx penalty applies to a group
practice, we propose to conduct our
analysis for each unique TIN/NPI
combination so as not to disadvantage
EPs who may have joined the group
practice after January 1, 2011.
In addition, in accordance with
section 1848(m)(2)(B)(i) of the Act, we
also propose that the 2012 eRx penalty
would not apply to an eRx GPRO in
which less than 10 percent of the group
practice’s estimated total allowed
charges for the January 1, 2011 through
June 30, 2011 reporting period are
comprised of services which appear in
the denominator of the 2011 electronic
prescribing measure. To be consistent
with how this limitation is applied to
group practices for purposes of the
incentive, we propose to determine
whether this limitation applies to a
group practice for the penalty at the TIN
level.
For the same reasons that we are
proposing a 6-month reporting period
for the 2012 eRx penalty for group
practices, we also propose that we will
use only claims processed by July 31,
2011 in our analysis. This is consistent
with our proposed approach for
analyzing individual EP claims.
Similarly, we propose that registries
would need to submit eRx data for
services furnished January 1, 2011
through June 30, 2011 to CMS between
July 1, 2011 and August 19, 2011 so that
we may include registry data in our
analysis. We propose also that group
practices participating in the eRx group
practice reporting option via EHR-based
reporting would be required to submit
eRx data for services furnished January
1, 2011 through June 30, 2011 to CMS
between July 1, 2011 and August 19,
2011.
We invite comments on the proposed
criteria for determining applicability of
PO 00000
Frm 00171
Fmt 4701
Sfmt 4702
40209
the 2012 eRx penalty to group practices,
including the proposed criteria for
successful reporting of the electronic
prescribing measure for group practices,
and our proposed analytical approach.
(4) Significant Hardship Exemption
Section 1848(a)(5)(B) of the Act
provides that the Secretary may, on a
case-by-case basis, exempt an EP from
the application of the payment
adjustment, or penalty, if the Secretary
determines, subject to annual renewal,
that compliance with the requirement
for being a successful electronic
prescriber would result in a significant
hardship, such in the case of an EP who
practices in a rural area without
sufficient Internet access. Therefore, we
propose that in addition to meeting the
criteria for successful electronic
prescriber described in sections
VI.F.2.(c).(2) and VI.F.2.(c).(3) of the
preamble to this proposed rule, an EP or
group practice may also be exempt from
application of the 2012 eRx penalty, if
during the 2012 eRx penalty reporting
period (that is, January 1, 2011 through
June 30, 2011), one of the following
circumstances applies to the EP or
group practice:
• The EP or group practice practices
in a rural area with limited high speed
Internet access.
• The EP or group practice practices
in an area with limited available
pharmacies for electronic prescribing.
We propose to add two additional ‘‘G’’
codes to the 2011 electronic prescribing
measure’s specifications describing
these 2 circumstances. EPs or group
practices to whom one or more of these
circumstances apply would be required
to report the appropriate G-code at least
once between January 1, 2011 and June
30, 2011 using their selected 2011 eRx
reporting mechanism. Reporting of one
of these two G-codes prior to June 30,
2011 will indicate to us that the EP or
group practice would like to be
considered for an exemption from the
2012 penalty under the significant
hardship exception. We invite
comments on the proposed process for
the significant hardship exception as
well as comments regarding other
circumstances that should be
considered a significant hardship.
d. The 2013 eRx Penalty
Section 1848(a)(5) of the Act also
requires that with respect to covered
professional services furnished by an EP
in 2013, if the EP is not a successful
electronic prescriber for the reporting
period for the year, the fee schedule
amount for such services furnished by
such professional during 2013 shall be
equal to 98.5 percent of the fee schedule
E:\FR\FM\13JYP2.SGM
13JYP2
40210
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
amount that would otherwise apply to
such PFS services. Under section
1848(m)(3)(C) of the Act, we are also
required to establish and have in place
a process under which EPs in a group
practice shall be treated as a successful
electronic prescriber for purposes of the
eRx penalty.
For purposes of the 2013 eRx penalty,
we propose to use the proposed 2011
criteria for successful electronic
prescriber to determine whether an EP
or a group practice is a successful
electronic prescriber for purposes of the
2013 eRx penalty. In addition, we
propose that the reporting period for the
2013 eRx penalty would be the 2011
eRx incentive reporting period of
January 1, 2011 through December 31,
2011. We believe that matching the
criteria that will be applied for the 2013
penalty with the criteria that will be
applied for the incentive in an earlier
year would be the most effective means
of encouraging EPs and group practices
to adopt and use electronic prescribing
systems since anyone who does not
qualify for an incentive in 2011 would
be subject to a payment adjustment in
2013. We invite comments on this
proposal.
e. Public Reporting of Names of
Successful Electronic Prescribers
Section 1848(m)(5)(G) of the Act
requires the Secretary to post on the
CMS Web site, in an easily
understandable format, a list of the
names of EPs (or group practices) who
satisfactorily submit data on quality
measures for the PQRI and the names of
the EPs (or group practices) who are
successful electronic prescribers. As
required by section 1848(m)(5)(G) of the
Act, we are proposing to make public
the names of EPs and group practices
who are successful electronic
prescribers for the 2011 eRx Incentive
Program on the Physician Compare Web
site that we are required to establish by
January 1, 2011 under section 10331 of
the ACA. As stated under section
VI.F.1.k. of this proposed rule, we plan
to use the existing Physician and Other
Health Care Professionals directory as
the foundation for the Physician
Compare Web site.
We anticipate that the names of
individual EPs and group practices who
are successful electronic prescribers for
the 2011 eRx Incentive Program will be
available in 2012 after the 2011
incentive payments are paid.
To comply with section 1848(m)(5)(G)
of the Act, we specifically propose to
post the names of individual EPs who
report the electronic prescribing
measure at least 25 times during the
2011 reporting period for patient
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
encounters included in the measure’s
denominator, without regard to whether
the limitation under section
1848(m)(2)(B) of the Act applies to the
EP and without regard to whether the
EP actually qualifies to earn an
incentive payment. In addition, since
the PQRI and the eRx Incentive Program
are two separate incentive programs and
individual EPs are not required to
participate in both programs to earn an
incentive under either program, we
point out that it is possible for an EP
who participates in both incentive
programs to be listed both as an
individual EP who satisfactorily submits
data on quality measures for the PQRI
and is a successful electronic prescriber
under the eRx Incentive Program.
Likewise, an individual EP may be
listed as an individual EP who
satisfactorily submits data on quality
measures for the PQRI but not as a
successful electronic prescriber under
the eRx Incentive Program (or vice
versa) even if he or she participated in
both incentive programs.
Similarly, for purposes of publicly
reporting the names of group practices,
on the Physician Compare Web site, we
intend to post the names of group
practices that report the electronic
prescribing measure the required
number of times during the 2011
reporting period for patient encounters
included in the measure’s denominator
without regard to whether the limitation
under section 1848(m)(2)(B) of the Act
applies to the group practice or whether
the group practice actually qualifies to
earn an incentive payment. Although
any group practice participating in the
eRx Incentive Program under the group
practice reporting option would also
have to participate in a PQRI group
practice reporting option, the criteria for
satisfactory reporting of PQRI measures
for group practices are different from the
criteria for successful reporting of the
electronic prescribing measure by group
practices. Therefore, it is possible for a
group practice to be listed as a group
practice that satisfactorily submits data
on quality measures for the PQRI but
not as a successful electronic prescriber
under the eRx Incentive Program, or
vice versa.
G. DMEPOS Provisions
1. Medicare Durable Medical
Equipment, Prosthetics, Orthotics, and
Supplies (DMEPOS) Competitive
Bidding Program (CBP)
a. Legislative and Regulatory History of
DMEPOS CBP
Medicare pays for most DMEPOS
furnished after January 1, 1989 pursuant
to fee schedule methodologies set forth
PO 00000
Frm 00172
Fmt 4701
Sfmt 4702
in section 1834 of the Act, as added by
section 4062 of the Omnibus Budget
Reconciliation Act of 1987 (OBRA ’87)
(Pub. L. 100–203). Specifically, sections
1834(a)(1)(A) and (B), and 1834 (h)(1)(A)
of the Act provide that Medicare
payment for these items is equal to 80
percent of the lesser of the actual charge
for the item or the fee schedule amount
for the item. We implemented this
payment methodology at 42 CFR part
414, subpart D of our regulations.
Sections 1834(a)(2) through (a)(5) and
1834(a)(7) of the Act, and implementing
regulations at § 414.200 through
§ 414.232 (with the exception of
§ 414.228), set forth separate payment
categories of durable medical equipment
(DME) and describe how the fee
schedule for each of the following
categories is established:
• Inexpensive or other routinely
purchased items (section 1834(a)(2) of
the Act and § 414.220 of the
regulations);
• Items requiring frequent and
substantial servicing (sections 1834(a)(3)
of the Act and § 414.222 of the
regulations);
• Customized items (section
1834(a)(4) of the Act and § 414.224 of
the regulations);
• Oxygen and oxygen equipment
(section 1834(a)(5) of the Act and
§ 414.226 of the regulations);
• Other items of DME (section
1834(a)(7) of the Act and § 414.229 of
the regulations).
For a detailed discussion of payment
for DMEPOS under fee schedules, see
the final rule published in the April 10,
2007 Federal Register (72 FR 17992).
Blood glucose testing strips or
diabetic testing strips are covered under
the Medicare DME benefit in accordance
with section 1861(n) of the Act. Other
supplies that are necessary for the
effective use of DME are also covered
under the Medicare DME benefit in
accordance with longstanding program
instructions at section 110.3 of chapter
15 of the Medicare Benefit Policy
Manual.
Section 1847 of the Act, as amended
by section 302(b)(1) of the MMA,
requires the Secretary to establish and
implement a DMEPOS CBP. Under the
DMEPOS CBP, Medicare sets payment
amounts for selected DMEPOS items
and services furnished to beneficiaries
in competitive bidding areas (CBAs)
based on bids submitted by qualified
suppliers and accepted by Medicare. For
competitively bid items, these new
payment amounts, referred to as ‘‘single
payment amounts (SPA),’’ replace the
fee schedule payment methodology.
Section 1847(b)(5) of the Act provides
that Medicare payment for these
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
competitively bid items and services is
made on an assignment-related basis
equal to 80 percent of the applicable
SPA, unless any unmet Part B
deductible described in section 1833(b)
of the Act. Section 1847(b)(2)(A)(iii) of
the Act prohibits the awarding of
contracts to any entity unless the total
amounts to be paid to contractors in a
CBA are expected to be less than the
total amounts that would otherwise be
paid under the fee schedule
methodologies set forth in section
1834(a) of the Act. This requirement
guarantees savings to both the Medicare
program and beneficiaries under the
program. The fee schedule
methodologies will continue to set
payment amounts for noncompetitively
bid DMEPOS items and services. The
program also includes provisions to
ensure beneficiary access to quality
DMEPOS items and services. Section
1847 of the Act limits participation in
the program to suppliers who have met
applicable quality and financial
standards and requires the Secretary to
maintain beneficiary access to multiple
suppliers.
When first enacted by the Congress,
section 1847(a)(1)(B) of the Act required
the Secretary to phase in the DMEPOS
CBP in a manner so that the competition
under the program occurred in 10 of the
largest metropolitan statistical areas
(MSAs) in 2007. The program was to be
expanded into 70 additional MSAs in
2009, and then into additional areas
after 2009.
In the May 1, 2006 Federal Register
(72 FR 25654), we issued a proposed
rule that would implement the DMEPOS
CBP for certain DMEPOS items and
services and solicited public comment
on our proposals. In the April 10, 2007
Federal Register (72 FR 17992), we
issued a final rule addressing the
comments on the proposed rule and
establishing the regulatory framework
for the DMEPOS CBP in accordance
with section 1847 of the Act.
Consistent with the requirements of
section 1847 of the Act and the
competitive bidding regulations, we
began implementation of the program by
conducting the first round of
competition in 10 of the largest MSAs
in 2007. We limited competition during
this first round of the program to
DMEPOS items and services included in
10 selected product categories,
including mail order diabetic supplies.
The bidding window opened on May
15, 2007 and was extended to allow
bidders adequate time to prepare and
submit their bids. We then evaluated
each submission and awarded contracts
consistent with the requirements of
section 1847(b)(2) of the Act and
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
§ 414.414. Following the bid evaluation
process, we awarded over 329 contracts
to qualified suppliers.
The DMEPOS CBP was effective on
July 1, 2008. Beginning on that date,
Medicare coverage for competitively bid
DMEPOS items and services furnished
in the first 10 CBAs was limited to items
and services furnished by contract and
grandfathered suppliers of oxygen and
oxygen equipment and rented DME, and
payment to these suppliers was based
on the SPA, as determined under the
competitive bidding regulations. For
further discussion of the DMEPOS CBP
and the bid evaluation process, see the
final rule published in the April 10,
2007 Federal Register (72 FR 17992).
On July 15, 2008, the MIPPA was
enacted. Section 154 of the MIPPA
amended section 1847 of the Act to
make certain limited changes to the
DMEPOS CBP. Section 154(a) of the
MIPPA delayed competition under the
program and amended section
1847(a)(1)(D)(i) of the Act to terminate
the competitive bidding contracts
effective June 30, 2008 and prohibit
payment based on the contracts.
Section 154(a) of the MIPPA required
the Secretary to conduct a second
competition to select suppliers for
Round 1 in 2009 (‘‘Round 1 Rebid’’). The
Round 1 Rebid includes the ‘‘same items
and services’’ and is to be conducted in
the ‘‘same areas’’ as the 2007 Round 1
competition, with certain limited
exceptions. Specifically, we were
required to exclude the product category
of negative pressure wound therapy
(NPWT) items and services and the San
Juan, Puerto Rico CBA from the Round
1 Rebid. In addition, section 154(a) of
the MIPPA permanently excluded group
3 complex rehabilitative wheelchairs
from the DMEPOS CBP by amending the
definition of ‘‘items and services’’ in
section 1847(a)(2) of the Act. Section
154(a) of the MIPPA delayed
competition for Round 2 of the
DMEPOS CBP from 2009 to 2011, and
subsequent competitions under the
program to after 2011. Finally, section
154(a) of the MIPPA specifically
addresses the phase in of a competition
for national mail order items and
services by specifying that such
competitions may be phased in after
2010.
b. Implementation of a National Mail
Order DMEPOS Competitive Bidding
Program (CBP) for Diabetic Testing
Supplies
We conducted competitions for mail
order diabetic testing supplies in the 10
CBAs selected for Round 1. In the
Round 1 rebid we conducted
competition for mail order diabetic
PO 00000
Frm 00173
Fmt 4701
Sfmt 4702
40211
testing supplies in 9 of the 10 CBAs
selected in Round 1. These competitions
were limited to diabetic testing supplies
furnished by mail order contract
suppliers, as defined in the April 10,
2007 DMEPOS Competitive Bidding
final rule (72 FR 17992) to individuals
located in those CBAs. As defined in the
final rule, a mail order contract supplier
is ‘‘a contract supplier that furnishes
items through the mail to beneficiaries
who maintain a permanent residence in
a CBA’’. We clarified in program
instructions that ‘‘mail order’’ means
items ordered remotely (that is, by
phone, e-mail, Internet, or mail) and
delivered to a beneficiary’s residence by
common carriers (for example, U.S.
Postal Service, Federal Express, United
Parcel Service, or other shipping or
courier service companies) but not items
obtained by beneficiaries from local
retail storefronts.
Due to the inclusion of mail order
diabetic supplies as a product category
in Round 1 of the program, Medicare
beneficiaries in a CBA who obtain
diabetic testing supplies through mail
order must purchase these supplies
from a mail order contract supplier in
order for Medicare to pay for these
items. Payment for these items will be
at the SPA determined consistent with
the program’s regulations. Beneficiaries
who do not obtain their testing supplies
through mail order may purchase these
products from any enrolled Medicare
supplier and Medicare payment for
these items will be at the fee schedule
amount. The home blood glucose
monitor (diabetic testing equipment)
itself is not included in the Round 1
DMEPOS CBP for mail order diabetic
supplies. This allows the beneficiary to
go to any enrolled supplier to obtain the
glucose monitor that the beneficiary and
their clinician believes best meets their
medical needs. The supplier of the
glucose monitor is responsible for
training the beneficiary on how to use
the monitor and for answering all follow
up questions and providing all services
required by the DMEPOS quality
standards and supplier standards, found
in § 424.57, related to the glucose
monitoring system selected by the
beneficiary and their clinician. The
beneficiary then has the choice of
obtaining the replacement diabetic
testing supplies that work with their
purchased monitoring system from any
local, non-mail order supplier (typically
a pharmacy) or from a mail order
supplier whose contract requires them
to ship the replacement diabetic
supplies directly to the beneficiary’s
home. If the beneficiary wants to
continue receiving their replacement
E:\FR\FM\13JYP2.SGM
13JYP2
40212
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
supplies from a local pharmacy because
that is their preference or because they
want to have face-to-face access to a
local pharmacist who, in addition to the
supplier of the glucose monitoring
system, can answer questions about the
use of their system in testing their blood
glucose levels, this choice is preserved.
However, if they choose the
convenience and savings associated
with having their replacement supplies
shipped directly to their home, the
beneficiary can decide to obtain their
supplies from a mail order contract
supplier.
The SPA was on average 43 percent
lower than the fee schedule amount for
diabetic testing supplies during the
Round 1 of DMEPOS CBP. This
reduction in payment would have
resulted in a reduction of the
beneficiary’s co-insurance payment. The
contracts and SPAs for the Round 1
Rebid for mail order diabetic testing
supplies are scheduled to be effective
for diabetic supplies furnished on a mail
order basis to beneficiaries in the 9
CBAs from January 1, 2011, through
December 31, 2012.
(1) National Mail Order DMEPOS CBP
As part of our rulemaking
implementing the DMEPOS CBP, we
established regulations to implement
competitions on a regional or national
level for certain items such as diabetic
testing supplies that are furnished on a
mail order basis. We explained our
rationale for establishing a national
DMEPOS CBP for items furnished on a
mail order basis in the Federal Register
in the May 1, 2006 proposed rule (71 FR
25669) and April 10, 2007 final rule (72
FR 18018). A national mail order
program would generate immediate
national savings at a magnitude that
may not be possible with local
competitions among suppliers that are
not able to obtain the type of volume
purchasing discounts from
manufacturers that are available to large,
national mail order suppliers. In a
September 2004 report (GAO–04–765),
the Government Accountability Office
(GAO) recommended that we consider
using mail delivery for items that can be
provided directly to beneficiaries in the
home as a way to implement a DMEPOS
competitive bidding strategy. In the case
of diabetic supplies and other items
furnished by local neighborhood
pharmacies, establishing a competition
for items furnished on a mail order basis
would exempt local pharmacies from
competing with national mail order
suppliers while preserving the choice of
the beneficiary to go to any local
pharmacy to pick up their diabetic
supplies. Manufacturers and suppliers
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
have stated to CMS at different meetings
on numerous occasions that the choice
for beneficiaries to obtain diabetic
supplies from local pharmacies with
licensed pharmacists in house who can
provide instructions and guidance to
beneficiaries related to their testing
needs is important and needs to be
preserved.
(2) DMEPOS CBP for National Mail
Order Diabetic Supplies
In the January 16, 2009 Federal
Register, we published an interim final
rule (IFC) (74 FR 2873) implementing
certain changes to the DMEPOS CBP.
Specifically, the rule implemented
certain MIPPA provisions that delayed
implementation of Round 1 of the
program; required CMS to conduct a
second Round 1 competition in 2009,
and mandated certain changes for both
the Round 1 Rebid and subsequent
rounds of the program. In the January
16, 2009 IFC preamble, we indicated
that we would be considering
alternatives for competition of diabetic
testing supplies in future notice and
comment rulemaking. We explained
that we believed it was consistent with
section 1847(a) to employ competitive
bidding for diabetic suppliers in both
the mail order and traditional retail
markets, in part due to concerns raised
about the bifurcation of the method of
delivery of diabetic supplies and the
difficulty in defining what constitutes
‘‘mail order’’ for purposes of
competition.
(3) Overview of Proposed Rule
As part of the phase in of the
DMEPOS CBP, we are proposing to
implement a national mail order
DMEPOS CBP for diabetic testing
supplies. Under the proposed mail order
DMEPOS CBP, we would award
contracts to suppliers to furnish these
items across the nation to beneficiaries
who elect to have replacement diabetic
testing supplies delivered to their
residence. Suppliers wishing to furnish
these items through mail order to
Medicare beneficiaries would be
required to submit bids to participate in
any DMEPOS CBP implemented for the
furnishing of mail order items. In
accordance with the DMEPOS CBP final
rule, payment for mail order diabetic
supplies would be based on the SPA
determined from the bids submitted and
accepted for the furnishing of diabetic
testing supplies by mail order
throughout the national CBA.
As part of our proposal to implement
the national mail order DMEPOS CBP,
we are also proposing a revised
definition in regulation of ‘‘mail order’’
so that there would be a clear
PO 00000
Frm 00174
Fmt 4701
Sfmt 4702
distinction between mail order items
and non-mail order items. This revised
definition would apply to all future
competitions for mail order items and
services. We are also proposing to
implement the special rule mandated by
section 1847(b)(10)(A) of the Act for
competitions for diabetic testing strips
following the Round 1 Rebid. Section
1847(b)(10)(A) requires suppliers
bidding in competitions to furnish
diabetic testing strips after the Round 1
Rebid to demonstrate that their bid
covers at least 50 percent of all types of
diabetic testing strips furnished by
suppliers. If the supplier is not able to
satisfy this requirement, the Secretary
must reject that bid. Finally, we are
proposing to include an additional term
in contracts of mail order suppliers of
diabetic testing supplies following the
Round 1 Rebid. The proposed term
would prohibit suppliers from
influencing or incentivizing
beneficiaries to change their brand of
glucose monitor and test strips.
(4) Future Competitions for Diabetic
Testing Supplies
Section 1847(a)(1)(A) of the Act
mandates the establishment of DMEPOS
CBP for items described in section
1847(a)(2)(A) of the Act, including
diabetic testing supplies. Section
1847(a)(1)(B)(ii) of the Act authorizes
the phase in of items and services under
these programs beginning with the
highest cost and highest volume items
and services or those items and services
that are determined to have the largest
savings potential. Current Medicare
claims data from fiscal year 2009 shows
that over 62 percent of beneficiaries
currently receive their replacement
diabetic testing supplies from mail order
suppliers. Mail order diabetic testing
supplies account for approximately one
billion dollars in allowed charges per
year and are therefore high volume
items. We believe that a national mail
order CBP for diabetic testing supplies
would result in large savings as a result
of competition between entities that
would factor into their bids savings
from volume discount purchasing of
quantities of supplies needed on a
national rather than local basis.
Therefore, we believe that implementing
a national mail order DMEPOS CBP for
diabetic testing supplies is the best
option for meeting the requirements of
the statute referenced above as long as
certain refinements discussed below are
made to the program to address
concerns about the mail order/non-mail
order bifurcation.
We have heard from industry groups
and suppliers that furnish diabetic
testing supplies on a national mail order
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
basis of their concerns that national
chain pharmacies that furnish diabetic
testing supplies through both a national
mail order business and local retail
pharmacies will encourage beneficiaries
to obtain these items from local retail
locations by inappropriately offering
certain incentives to Medicare
beneficiaries such as coupons for other
store items. Based on our experience
from Round 1, we believe DMEPOS CBP
for mail order diabetic testing supplies
would be subject to manipulation
without a clearer definition of what we
mean by mail order. We agree with the
industry groups and suppliers that have
indicated that this practice will harm
businesses that only furnish diabetic
testing supplies on a mail order basis. In
order to address these concerns, we are
proposing to add to § 414.402 a
definition of ‘‘National mail order
DMEPOS CBP.’’ We propose to define
that term as a program whereby
contracts are awarded to suppliers for
the furnishing of mail order items across
the nation. We believe that
implementing a national competitive
bidding program for diabetic supplies
would preserve beneficiary choice to
purchase testing supplies in person
from any local pharmacy that is an
enrolled Medicare supplier that
furnishes diabetic supplies, while
clarifying the definition of mail order
will provide significant savings
potential for beneficiaries and the
program. Savings would be generated in
the near future from national SPAs for
supplies furnished on a mail order or
home delivery basis and on a long term
basis for all diabetic supplies as a result
of the requirement of section
1834(a)(1)(F) of the Act to either
competitively bid in all areas or adjust
prices in all areas by January 1, 2016.
We believe that more beneficiaries will
elect to choose the mail order/home
delivery option, thereby further
increasing short term savings under the
program. Even if this is not the case, and
the percentage of beneficiaries choosing
the mail order/home delivery option
remains at the current rate of 62 percent,
savings for the remaining 38 percent
must be achieved by no later than
January 1, 2016, as a result of the
requirements of section 1834(a)(1)(F) of
the Act.
We considered other alternatives for
establishing DMEPOS CBP for diabetic
testing supplies that would eliminate
the mail order/non-mail order
bifurcation and associated concerns.
These alternatives include:
• A national competition among all
types of suppliers for all replacement
diabetic supplies. Under this
alternative, all beneficiaries would
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
receive their replacement diabetic
supplies from contract suppliers
responsible for furnishing diabetic
supplies throughout the nation using
any method of delivery as long as the
supplies are delivered on a timely basis.
• Competitions in regional CBAs
among all types of suppliers for all
replacement diabetic supplies. Under
this alternative, all beneficiaries would
receive their replacement diabetic
supplies from contract suppliers
responsible for furnishing diabetic
supplies throughout a designated region
of the country using any method of
delivery to a beneficiary home as long
as the supplies are delivered on a timely
basis.
• Competitions in local CBAs among
all types of suppliers for all replacement
diabetic supplies. Under this
alternative, all beneficiaries would
receive their replacement diabetic
supplies from contract suppliers
responsible for furnishing diabetic
supplies throughout the local area using
any method of delivery to a beneficiary
as long as the supplies are delivered on
a timely basis.
We believe that the first option to bid
on a national basis for all diabetic
supplies, would result in most
beneficiaries using mail order and might
generate more savings than a national
competition for diabetic supplies
furnished on a mail order basis only.
However, this first option would likely
eliminate the beneficiary choice to
obtain replacement diabetic supplies on
a non-mail order basis from any
enrolled supplier that is a pharmacy or
other local supplier storefront where a
licensed pharmacist is on hand to offer
guidance and consultation to the
beneficiary. We believe the other two
options would also diminish this
choice. In addition, the alternatives of
regional or local competitions are not
likely to result in savings at or above the
level that can be generated from a
national competition for mail order
supplies. Suppliers participating in a
national program may be able to obtain
volume purchasing discounts for the
quantities of supplies needed
nationwide. Therefore, we are not
proposing any of these alternatives at
this time. However, we are specifically
requesting public comments on these
and other alternatives for establishing
DMEPOS CBP for diabetic supplies.
In § 414.411, we are proposing to
establish a national mail order DMEPOS
CBP with competitions taking place
after 2010 for the purpose of awarding
contracts to suppliers to furnish
replacement diabetic testing supplies
across the nation, with additional
program refinements described below.
PO 00000
Frm 00175
Fmt 4701
Sfmt 4702
40213
We note that the decision to proceed
with a national mail order competition
after 2010 does not prevent us from
phasing in competitions for non-mail
order diabetic supplies or from
conducting competitions for diabetic
supplies in general in the future
consistent with section 1847(a)(1) of the
Act.
(5) Definition of Mail Order Item
We are proposing to define ‘‘mail
order item’’ in 42 CFR 414.402 to mean
any item (for example, diabetic testing
supplies) shipped or delivered to the
beneficiary’s home, regardless of the
method of delivery. We are also
proposing to define ‘‘non-mail order
item’’ as any item (for example, diabetic
testing supplies) that a beneficiary or
caregiver picks up in person at a local
pharmacy or supplier storefront.
Therefore, the only items excluded from
the mail order definition and mail order
competition would be those that a
beneficiary or caregiver picks up in
person at a local pharmacy or other
local supplier storefront. These revised
definitions of mail order item and nonmail order item are intended to clearly
identify which items are truly mail
order. In addition, we believe this
definition will preserve the choice of
the beneficiary to obtain replacement
diabetic supplies in person from a local
pharmacy and eliminate the
circumvention of the mail order
program.
As discussed above, for Round 1 and
the Round 1 Rebid of the DMEPOS CBP,
we defined mail order contract supplier
in our regulations at § 414.402 to mean
a contract supplier that furnishes items
through the mail. We further defined
mail order in program instructions to
mean ‘‘items ordered remotely (that is,
by telephone, e-mail, Internet or mail)
and delivered to beneficiary’s residence
by common carriers (for example, U.S.
Postal Service, Federal Express, United
Parcel Service) and does not include
items obtained by beneficiaries from
local storefronts.’’ The intent of the
Round 1 definition was to distinguish
between mail order supplies (supplies
furnished directly to the beneficiary’s
home) and non-mail order supplies
(supplies picked up at a local
pharmacy). Manufacturers and suppliers
of blood glucose monitors and test strips
have expressed on numerous occasions
the importance of maintaining the
patient option of obtaining diabetic
testing supplies from a local pharmacy
that provides full time access to a
licensed pharmacist who can provide
instructions and guidance to the
beneficiary or caregiver related to the
use of the diabetic supplies (the
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40214
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
pharmacy pickup option). This is the
‘‘non-mail order’’ option we attempted to
separate from the mail order option with
the Round 1 definition of mail order.
During implementation of Round 1 of
the program, we discovered that
suppliers that did not successfully
compete and win a contract under the
program tried to adopt certain
approaches to circumvent the mail order
definition. In the first round of
competitive bidding, suppliers that lost
their bid to be a contract supplier for
mail order diabetic testing supplies
considered ways to change their
delivery methods to circumvent the
mail order DMEPOS CBP. For example,
some mail order suppliers considered
purchasing a fleet of cars to deliver
these items to the beneficiary’s home so
as not to be considered a mail order
supplier. Other suppliers attempted to
enter into special ‘‘private’’
arrangements with well known delivery
services and claimed that because of
such arrangements they should not be
considered mail order suppliers. These
alternative home delivery methods do
not provide any benefits to the patient
beyond what the traditional mail order
home delivery method offers. They are
simply ways to continue furnishing
diabetic supplies on a home delivery
basis after submitting a bid for mail
order that does not result in the award
of a contract under the DMEPOS CBP.
Without a clear distinction between
mail order (home delivery option) and
non-mail order (pharmacy pickup
option), suppliers could continue to
attempt to make arrangements as they
did in the initial Round 1 competition
to circumvent the DMEPOS CBP. We
consider these practices to be
inconsistent with the DMEPOS CBP
statute and regulations currently in
effect, and our proposal is intended to
further clarify the existing definition of
mail order. Such arrangements prevent
beneficiaries and the Medicare program
from realizing savings afforded by the
mail order DMEPOS CBP and is unfair
to winning suppliers who bid in good
faith for a contract for furnishing
supplies to the home delivery market.
This proposed definition of mail order
item would not apply to the Round 1
competition because of the specific
requirement of MIPPA to rebid Round 1
in 2009 for the same items and services
included in the initial Round 1
competition. However, for a national
competition, it is imperative that the
new definition of mail order item be in
place because of the implications such
a program would have on the entire
mail order delivery market in the United
States. In these future competitions, we
would continue to emphasize in our
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
educational efforts the basic distinction
between mail order (home delivery) and
non-mail order (pharmacy pickup). In
addition, we will continue to take
appropriate and necessary action against
suppliers that do not comply with the
revised definition.
As mentioned above, an alternative
DMEPOS CBP for replacement diabetic
supplies would be to hold a national
competition among all types of
suppliers for all replacement diabetic
supplies. One benefit to this approach is
that it would eliminate the need to
differentiate between mail order and
non-mail order supplies; however, it
would likely eliminate the pharmacy
pickup choice since most local
pharmacies would not be able to service
the entire CBA if they did not also
operate a national mail order service.
We invite comments on our proposed
definition of ‘‘mail order’’ and its impact
on future rounds of bidding.
(6) Special Rule in Case of Competition
for Diabetic Testing Strips
Following Round 1 of the program,
any competition for diabetic testing
strips, such as the national mail order
program for diabetic testing supplies
proposed in this rule, must include the
special rule set forth in section
1847(b)(10)(A) of the Act. Under that
section, a supplier must demonstrate
that their bid to furnish diabetic testing
strips covers the furnishing of a
sufficient number of different types of
diabetic testing strip products that, in
the aggregate and taking into account
volume for the different products, to
account for at least 50 percent of all
such types of products on the market.
Section 1847(a)(10)(A) also specifies
that the volume for the different
products may be determined in
accordance with data (which may
include market based data) recognized
by the Secretary. When a beneficiary
needs to obtain replacement test strips,
they must obtain the specific brand of
test strips products that work with their
brand and model of blood glucose
monitor. The test strips are not
manufactured in a way that allows use
of different brands of test strips in
different brands of monitors. Therefore,
when replacement test strips are
furnished, the supplier must ensure that
the specific brand and model of test
strips that the patient requires for use
with their purchased monitor is
furnished.
Section 1847(b)(10)(B) of the Act
mandates the Office of Inspector
General (OIG) of the Department to
conduct a study before 2011 to generate
volume data for the various products
that could be used for this purpose.
PO 00000
Frm 00176
Fmt 4701
Sfmt 4702
Under the DMEPOS CBP, bidding
suppliers are required to provide
information on the products they plan
to furnish if awarded a contract. We
propose to use this information and
information on the market share
(volume) of the various diabetic testing
strip products to educate suppliers on
meeting the requirements of this special
rule. In addition, it may be necessary to
obtain additional information from
suppliers such as invoices or purchase
orders to verify that the requirements in
the statute have been met.
We are proposing that suppliers be
required to demonstrate that its bid
covers the minimum 50 percent
threshold provided in the statute, but
we invite comments on whether a
higher threshold should be used. We
have proposed the 50 percent threshold
in part because we believe that all
suppliers have an inherent incentive to
furnish a wide variety of types of
diabetic testing products to generate a
wider customer referral base. The 50
percent threshold would ensure that
beneficiaries have access to mail order
delivery of the top-selling diabetic test
strip products. In addition, as explained
below, we are proposing an ‘‘antiswitching provision’’ that we believe
should obviate the need to establish a
threshold of greater than 50 percent for
the purpose of implementing this
special rule because the contract
suppliers would not be able to carry a
limited variety of products and switch
beneficiaries to those products.
For purposes of implementing the
special rule in section 1847(b)(10)(A),
we are proposing to define ‘‘diabetic
testing strip product’’ as a specific brand
and model of test strip, as that is the
best way to distinguish among different
products. Therefore, we plan to use
market based data for specific brands
and models of diabetic test strips to
determine the relative market share or
volume of the various products on the
market that are available to Medicare
beneficiaries. We plan to review a
variety of data, including but not
limited to data furnished in the OIG
report, to determine the market share of
the various products. The special rule
mandated by section 1847(b)(10)(A) of
the Act applies to all competitions for
diabetic testing strips after the first
round of the DMEPOS CBP. Therefore,
we would apply this rule to non-mail
order competitions and/or local
competitions conducted for diabetic
testing strips after Round 1 of the
DMEPOS CBP.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(7) Anti-Switching Rule in Case of
Competition for Diabetic Test Strips
We do not believe that we can
effectively apply the 50 percent rule, as
required by section 1847(b)(10)(A) of the
Act, if we do not establish an antiswitching rule to prevent suppliers from
influencing beneficiaries to switch
monitors. We have heard concerns from
beneficiary advocacy groups, as well as
industry representatives, that contract
suppliers furnishing diabetic testing
supplies in the first round encouraged
beneficiaries to switch to a different
brand of blood glucose monitor and
testing supplies than they and/or their
physician or clinician previously
selected. Suppliers attempted to switch
beneficiaries to the less expensive
monitor or the monitor that provided
them with the most profit rather than
the monitor that was most suitable for
them. Without the anti-switching rule,
suppliers may offer 50 percent of the
brands on the market but continue to
switch beneficiaries to the least
expensive brands so that the
requirement to offer at least 50 percent
of the brands on the market rather than
a few specific brands becomes
meaningless.
We are proposing to prohibit
suppliers awarded contracts for diabetic
testing supplies from influencing or
incentivizing the beneficiary in any way
to switch the brand of glucose monitor
and testing supplies they are currently
using. We would propose that contract
suppliers continue to furnish the brand
of testing supplies that work with the
monitor currently in use by the
beneficiary. In the case where the
beneficiary is receiving a monitor for the
first time or a replacement monitor, the
contract supplier would be subject to
the requirements of § 414.420 in order to
protect beneficiaries from feeling forced
or incentivized to use a particular type
or brand of monitor We continue to
believe the proper role of the contract
supplier is to furnish diabetic testing
strips and other supplies to
beneficiaries, not to interfere with the
beneficiary’s selection of the type of
monitor and supplies. This requires the
supplier to furnish the brand of testing
supplies that work with the blood
glucose monitor product that the
beneficiary and/or clinician, and not the
supplier of the testing supplies, selects.
If the beneficiary needs a blood glucose
monitor for the first time, or needs to
replace their existing blood glucose
monitor, and neither the beneficiary nor
their physician has determined which
brand or type of monitor to obtain, the
beneficiary may continue to ask for
assistance from the supplier to select a
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
monitor and the supplier should show
them the full range of products.
However, if the beneficiary has already
selected a monitor and simply needs
replacement diabetic testing supplies,
the supplier must furnish the brands of
testing supplies that work with the
brand monitor that the beneficiary has
selected. We believe this proposal
would preserve the integrity of the
clinical decision regarding choice of
glucose monitoring system and would
result in contract suppliers offering a
wide variety of diabetic testing supply
products.
We are proposing to amend § 414.422
to add the anti-switching requirement to
the terms of the contract for a supplier
of diabetic testing supplies. A supplier
would be in breach of their contract and
subject to the sanctions set forth under
§ 414.423(g), including termination, if
they violate this term. We welcome
comments on this proposal.
c. Off-the-Shelf (OTS) Orthotics
Exemption
In the April 10, 2007 final rule (72 FR
17992), we established § 414.404(b)(1),
which sets forth several exemptions to
the DMEPOS CBP. These exceptions are
applicable to providers, physicians, and
treating practitioners that furnish
certain DMEPOS items under Medicare
Part B. The exempted items are limited
to crutches, canes, walkers, folding
manual wheelchairs, blood glucose
monitors, and infusion pumps that are
DME. For an explanation as to why
these items were exempt see the
DMEPOS Competitive Bidding final rule
(CMS–1270–F) published April 10,
2007, (72 FR 17992). For the exemptions
to apply, the items must be furnished by
a physician or treating practitioner to
his or her own patients as part of his or
her professional service. The items are
to be billed under a billing number
assigned to the physician, the treating
practitioner (if possible), or a group
practice to which the physician or
treating practitioner has reassigned the
right to receive Medicare payment.
The April 10, 2007 final rule also
established an exemption for a physical
therapist in private practice (as defined
in § 410.60(c)) or an occupational
therapist in private practice (as defined
in § 410.59(c)) to furnish competitively
bid OTS orthotics without submitting a
bid and being awarded a contract under
the DMEPOS CBP, provided that the
items are furnished only to the
therapist’s own patients as part of a
physical or occupational therapy
service.
Section 154(d) of MIPPA amended
section 1847(a) of the Act by adding
paragraph (7), which expands the
PO 00000
Frm 00177
Fmt 4701
Sfmt 4702
40215
exemptions from the DMEPOS CBP for
certain OTS orthotics to physicians or
other practitioners (as defined by the
Secretary) if furnished to their own
patients as part of their professional
service. Section 1847(a)(7) of the Act, as
added by MIPPA, also expanded the
exemption from the program to
hospitals for certain OTS orthotics,
crutches, canes, walkers, folding manual
wheelchairs, blood glucose monitors,
and infusion pumps if these items are
furnished to the hospital’s own patients
during an admission or on the date of
discharge.
The DMEPOS CBP Round 1 Rebid
interim final rule with comment period
(IFC) included the expanded exemption
for certain DMEPOS items as provided
by MIPPA for hospitals. We noted in the
IFC that we would address the
expanded exemption of OTS orthotics
for hospitals, physicians and other
practitioners in future rulemaking.
In this proposed rule, we are
proposing to revise current provisions at
§ 414.404(b)(1)(i) to incorporate the
provision of section 1847(a)(7)(A)(i) and
(ii) of the Act that exempts from the
program OTS orthotics furnished by
physicians and other practitioners to
their own patients as part of their
professional service or by hospitals to
the hospital’s own patients during an
admission or on the date of discharge.
d. Grandfathering Rules Resulting in
Additional Payments To Contract
Suppliers Under the DMEPOS
Competitive Bidding Program (CBP)
Section 1847(a)(4) of the Act requires
that in the case of rented DME and
oxygen and oxygen equipment, the
Secretary shall establish a
‘‘grandfathering’’ process. This
requirement was implemented through
regulations at § 414.408(j) that were
published in the April 10, 2007 Federal
Register (72 FR 17992). The
grandfathering process allows
beneficiaries who were renting DME
items or receiving oxygen and oxygen
equipment prior to the start of a
DMEPOS CBP from a supplier who did
not win a contract to continue to rent
the equipment from that noncontract
supplier if that supplier chooses to
become a grandfathered supplier. Under
§ 414.408(i)(2), when the beneficiary
decides to use a contract supplier
instead of a grandfathered supplier to
receive their oxygen equipment and
supplies, the contract supplier receives
a minimum of 10 monthly payments for
taking over the furnishing of oxygen and
oxygen equipment. When a beneficiary
decides to use a contract supplier to
furnish capped rental DME, section
§ 414.408(h)(2) restarts the 13-month
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40216
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
capped rental period. These rules were
established, in part, based on advice
from the Program Advisory and
Oversight Committee (PAOC) and are
intended to give bidding suppliers an
assurance that they would be
compensated in these situations and
would not have to factor into their bids
the cost of receiving as few as one
monthly payment for beneficiaries near
the end of the 13-month cap for capped
rental items and 36-month cap for
oxygen equipment.
At the time these rules were
developed, the supplier was mandated
by the statute to transfer title to the
equipment to the beneficiary after the
both the 13-month cap for capped rental
items and the 36-month cap for oxygen
equipment. Section 144(b) of the MIPPA
repealed the transfer of title requirement
for oxygen equipment, as established by
Deficit Reduction Act of 2005, replacing
that requirement with the 36-month
rental cap. Under the revised oxygen
payment provisions, suppliers now get
the equipment back when the
beneficiary no longer needs it. Also, at
the time these rules were developed, the
beneficiary had the option to acquire
standard power wheelchairs on a lump
sum purchase basis, an option which
greater than 95% of the beneficiaries
selected, based upon historic claims
data. Therefore, those items generally
would not be affected by the
grandfathering rules. However, as
discussed in section 3136 of this
proposed rule, section 3136 of the ACA
eliminates the lump sum purchase
option for standard power wheelchairs.
This new policy applies to items
furnished under the DMEPOS CBP
beginning with Round 2 of the program.
Over 200,000 beneficiaries received
standard power wheelchairs nationwide
in 2009, and the Medicare allowed
charges for these wheelchairs was over
$650 million, including both rental and
purchase options. Therefore, this large
volume of capped rental items will be
subject to the grandfathering rules
effective with Round 2 of the DMEPOS
CBP, thus increasing the overall
magnitude of the effect these rules have
on the program and beneficiaries.
In some cases, the grandfathering
rules described above place a financial
burden on beneficiaries who are near
the end of the 13 or 36-month rental cap
periods. If a beneficiary’s existing
supplier chooses not to be a
grandfathered supplier, the beneficiary
will be required to switch to a contract
supplier in order for Medicare to
continue to pay for the furnishing of the
rental equipment. In such cases, the
beneficiary will be responsible for
additional co-insurance amounts. Based
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
on experience from the initial Round 1
competition in 2008, we believe that
most suppliers will choose to
grandfather and therefore these rules
will have no impact on these situations.
However, in those limited situations in
which the beneficiary does not use a
grandfathered supplier and the
beneficiary is near the end of the 13 or
36-month rental cap period, the impact
on the beneficiary could be significant.
As mentioned above, our current
grandfathering rules will result in a
limited number of beneficiaries facing
additional co-insurance payments. To
illustrate the impact some beneficiaries
may face as a result of these rules, a
beneficiary who has already made 12
coinsurance payments for a capped
rental item could make as many as 12
additional copayments as a result of
restarting the capped rental period
when they transition from a noncontract
supplier to a contract supplier at the
beginning of a DMEPOS CBP. In another
example, a beneficiary who has already
made 35 coinsurance payments for
oxygen and oxygen equipment could
make as many as 9 additional
copayments as a result of the rule that
provides a minimum of 10 monthly
payments when they transition from a
noncontract supplier to a contract
supplier at the beginning of a DMEPOS
CBP. As stated above, we expect that
most noncontract suppliers will choose
to become grandfathered suppliers,
therefore limiting the number of
instances where these rules would
apply. However, in light of the
beneficiary impact in the those extreme
cases illustrated above, and in light of
the recent legislative changes by the
MIPPA and the ACA as explained
above, we are reevaluating whether or
not changes to these grandfathering
rules are necessary. As discussed above,
as a result of the MIPPA, suppliers of
oxygen equipment no longer lose title to
the equipment after receiving the 36th
payment and this may warrant
reconsideration of the minimum
number of payments they should
receive as contract suppliers when a
beneficiary transitions to them from a
noncontract supplier at the beginning of
a DMEPOS CBP. In addition, we believe
it is important to reevaluate the policy
that restarts the 13-month capped rental
period in situations where a beneficiary
transitions from a noncontract supplier
to a contract supplier at the beginning
of a DMEPOS CBP. Therefore, we are
soliciting public comments on whether
or not the current rules should be
changed to reduce the number of
payments the contract supplier would
receive in these situations above the 13
PO 00000
Frm 00178
Fmt 4701
Sfmt 4702
and 36-month limits set forth under the
standard payment rules in section
1834(a) of the Act. We also plan to
solicit advice from the PAOC on this
subject at a future committee meeting.
e. Appeals Process
The DMEPOS CBP final rule issued
on April 10, 2007 includes
§ 414.422(g)(1), which states that ‘‘any
deviation from contract requirements,
including a failure to comply with
governmental agency or licensing
organization requirements, constitutes a
breach of contract.’’ In the event we
determine that a contract supplier’s
actions constitute a breach of contract,
§ 414.422(g)(2) authorizes us to take one
or more of the following actions:
• Require the contract supplier to
submit a corrective action plan;
• Suspend the contract supplier’s
contract;
• Terminate the contract;
• Preclude the contract supplier from
participating in the DMEPOS CBP;
• Revoke the supplier number of the
contract supplier; or
• Avail itself of other remedies
allowed by the statute.
Proposed Appeals Process
We are proposing to add a new
§ 414.423 to establish an appeals
process for contracts terminated under
section 1847(a) and (b) of the Act.
Section § 414.423, as proposed in this
rule, would set forth policies and
procedures relating to our
determinations of a breach of contract
and the appeals process for contract
suppliers that are considered to be in
breach of contract. In addition, we are
proposing to add new definitions to
§ 414.402 that are used in the proposed
§ 414.423.
Given the impact that termination has
on a contract supplier, we believe it is
appropriate for contract suppliers whose
contract(s) may be terminated due to a
breach of contract to have access to an
appeal process that will reconsider that
termination. In establishing this process
we reviewed other appeals processes,
such as the appeals process under Part
D located at 42 CFR 423.641 through
423.668, Subpart N—Medicare Contract
Determinations and Appeals, to
consider essential steps to ensure
suppliers have access to an appropriate
review of certain CMS decisions. We
chose to propose a simplified process
that would not result in disruption to
the program by having suppliers going
in and out of the program. For this
reason, we propose a process for review
and reconsideration before the contract
is actually terminated. This proposal
would avoid the necessity to reinstate
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
retroactively suppliers because the
contracts would generally not be
terminated before the full review
process has occurred. This would
protect the supplier because we
generally would not terminate a
supplier until a final decision is made.
Another feature of this process that may
be beneficial to some suppliers is
allowing them to submit a corrective
action plan (CAP) depending upon the
nature of the breach. We believe our
proposal would allow most suppliers to
correct identified deficiencies.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(1) Purpose and Definitions: (§ 414.402)
We are proposing to amend § 414.402
to define the following terms:
• Affected party means a contract
supplier that has been notified that their
DMEPOS CBP contract would be
terminated for a breach of contract.
• Breach of contract means any
deviation from contract requirements,
including a failure to comply with a
governmental agency or licensing
organization requirements.
• Corrective Action Plan (CAP) means
a contract supplier’s written document
with supporting information that
describes the actions the contract
supplier would take within a specified
timeframe to remedy the breach of
contract.
• Competitive Bidding
Implementation Contractor (CBIC)
Hearing Officer (HO) means an
individual, who was not involved with
the CBIC recommendation to terminate
a DMEPOS CBP contract, who is
designated by CMS to review and make
an unbiased and independent
determination from the CBIC’s
recommendation to terminate a
DMEPOS CBP contract.
• Parties to the Hearing means the
DMEPOS contract supplier and CMS.
(2) Applicability
The appeals process proposed in this
regulation would allow contract
suppliers the opportunity for a review of
the following:
• A CMS determination under
§ 414.422(g)(1) that the contract supplier
breached its contract entered into as
part of the DMEPOS CBP; and
• Certain agency actions taken under
§ 414.422(g)(2).
The proposed appeals process would
not apply to any other actions made by
CMS, nor would the existence of other
appeals processes preclude us from
terminating a DMEPOS CBP contract. In
other words, the proposed appeals
process would be in addition to—and
would not replace—existing CMS
regulations regarding other appeals
mechanisms. For example, a contract
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
may be terminated because a supplier’s
National Supplier Clearinghouse (NSC)
number has been revoked or inactivated.
In this case, the supplier would not
appeal the decision to inactive or revoke
its number through this appeals process.
Instead, the supplier would continue to
appeal the inactivation or revocation of
its supplier number through the NSC’s
appeals process, and we would
postpone the termination decision until
the supplier completes the NSC appeals
process.
Under our proposal, when we issue a
termination decision, it would be final
and binding unless a postponement of
the termination decision is allowed by
proposed § 414.423. We welcome
comments on the scope of the proposed
appeals process.
(3) Contract Termination
We are proposing that this appeals
process applies in situations where the
supplier has received a notice that we
have determined that they are in breach
of contract and that their contract is
therefore subject to termination. A
contract may be terminated for any
violation of the terms of the contract.
Examples of violations include, but are
not limited to, situations where the
contract supplier—
• Has committed or participated in
false, fraudulent, or abusive activities
affecting the Medicare program,
including the submission of false or
fraudulent data or claims;
• Experiences financial difficulties so
that they are unable to effectively
provide the necessary services to a
Medicare beneficiary; or
• Fails to meet the nondiscrimination policy and provides
different items to beneficiaries located
in a competitive bidding area (CBA)
than it provides to its non-Medicare
beneficiaries at § 414.422(c).
We welcome comments on our
proposed termination process.
(4) Notice of Termination
Under the proposed rule, the CBIC
would work with suppliers to
informally resolve performance
deficiencies under its DMEPOS CBP
contract prior to sending a
recommendation to CMS that the
supplier’s contract be terminated. If the
CBIC cannot informally resolve the
supplier’s deficiencies and recommends
that we terminate the contract, we
would review the CBIC’s
recommendation to terminate the
supplier’s contract. If we find that a
breach occurred, we would begin the
contract termination process by sending
out a notice of termination to the
supplier.
PO 00000
Frm 00179
Fmt 4701
Sfmt 4702
40217
We also propose requirements for the
notice of termination so that suppliers
are informed of the basis for CMS’s
action as well as their options to
respond to this action. The notice would
explain all actions we plan to take in
response to the supplier’s breach, such
as the ability to submit a CAP or our
determination to preclude a supplier
from participating in future rounds of
competitive bidding if found in breach
of contract. If the supplier decides to
appeal any of these decisions the
supplier would submit an appeal in
response to the notice to terminate. If
we consider a supplier to be in breach
of its contract, either in part or in whole,
we would notify the contract supplier of
the termination by certified mail. The
notice would indicate that the contract
supplier has been found to be in breach
of contract and that the supplier’s
contract would be terminated within 45
calendar days of the date of the
notification of termination. The notice
would be sent by the CBIC using
certified mail on the same date as the
date on the notification of termination.
The date of the notification of
termination is the date that the
notification is signed. The notification
will be mailed on the date that it is
signed. This date will be indicated on
the notification.
The proposed rule requires the notice
to include, at a minimum, the following
information:
• The reasons for the termination in
sufficient detail to allow the contract
supplier to understand the nature of its
breach of contract;
• Depending on the nature of the
breach, whether the supplier may be
allowed to submit a CAP in lieu of
requesting a hearing by the HO;
• The right to request a hearing by the
HO;
• The address to which the written
request for a hearing must be mailed;
• The address to which the CAP must
be mailed; and
• The effective date of the
termination of the contract, if a CAP is
not submitted or if a request for a
hearing has not been filed timely.
We believe that this information
would be sufficient to provide the
supplier with the basis for CMS’s action,
as well as their options in responding to
our decision. We welcome comments on
our proposal regarding the contents of
the notice.
In addition, our proposed rule
requires the notice to indicate any
additional penalties that may result
from the termination, such as not being
eligible to bid in future rounds of
competitive bidding. An appeal of the
termination would include the appeal of
E:\FR\FM\13JYP2.SGM
13JYP2
40218
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
any other results from the termination
that are permissible under § 414.423,
such as preclusion from participation in
future rounds of the DMEPOS CBP. We
believe this information may help the
supplier to decide whether to appeal the
notice of termination.
(5) Corrective Action Plan
We are also proposing a process by
which a contract supplier may be able
to submit a CAP to address the breach
of contract. Depending on the nature of
the breach of contract, we propose that
the notice to the supplier would
indicate whether a contract supplier
would be allowed to provide the CBIC
with a written CAP instead of
submitting a request for a hearing by a
HO. For example, under this proposal
we would not allow a CAP if the
supplier has been excluded, debarred or
convicted of a health care related crime.
We may also not allow a CAP that
would result in negative consequences
to the beneficiaries or the program
caused by delaying the termination of
the contract.
We are proposing timelines related to
the CAP. Under the proposed rule, if the
supplier decides to submit a CAP, the
CAP must be received by the CBIC
within 30 calendar days from the date
on the notice of termination. If the
supplier decides not to submit a CAP,
the supplier retains the right to request
a review by a HO within 30 days from
the date of the notice for termination.
While the CAP is being evaluated, the
termination determination would be
postponed. We believe that 30 days is a
sufficient amount of time for suppliers
to prepare and submit a CAP and this
would also ensure that there are no
unnecessary delays in the appeals
process.
Under the proposed rule, we would
require the CAP to demonstrate that the
contract supplier has a plan to remedy
all of the deficiencies that were
identified in its notice of termination
and must specify the timeframes for
correcting these deficiencies. The CBIC
would review the CAP to ensure that the
contract supplier would be taking the
appropriate measures in a timely
manner to remedy the breach of
contract. What constitutes a timely
manner is dependent on the type of
deficiency that is being corrected. Once
the nature of the deficiency is identified
the CBIC and CMS would make a caseby-case determination concerning what
constitutes a timely manner for
correcting the deficiency. However, we
expect most deficiencies to be corrected
within 90 days or less. Further guidance
of what constitutes a timely manner
would be communicated to the contract
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
supplier by the CBIC as part of the
review process.
As part of the review process, the
CBIC would provide guidance, in
accordance with CMS instructions,
regarding the type of documentation
that the CAP and the follow-up report
must provide to substantiate that the
deficiencies have been corrected. To
make a determination if a CAP would be
considered acceptable, we may discuss
the CAP with the supplier, and as a
result of these discussions, the CBIC
will allow a supplier to make revisions
to its CAP during the review process.
Suppliers may only revise their CAP
one time during the review process. The
timeframe for the review process would
vary upon the circumstances for each
case. If the supplier does not submit an
acceptable CAP during the review
process, the supplier would receive a
new notice that their CAP is not
acceptable or has not been implemented
consistent with the supplier’s original
submission and its contract would be
terminated within 45 calendar days.
Every supplier would have a one time
opportunity to revise their CAP based
upon deficiencies identified by the
CBIC. Failure to develop and implement
an approved CAP would result in a new
notice to the supplier of the termination
of the DMEPOS CBP contract and
provide notice that the supplier may
request a hearing on this termination.
Under the proposed rule, once an
acceptable CAP has been completed the
contract supplier must provide a followup report within 5 days of the agreed
upon date for the completion of the CAP
to verify that all of the deficiencies
identified in the CAP have been
corrected consistent with the
timeframes specified in the CAP, as
approved by the CMS. We believe that
5 days is sufficient time for a supplier
to submit a report to CBIC outlining all
steps that have been completed to
correct the identified deficiencies.
We welcome comments on our
proposals relating to the option for a
CAP.
(6) Right To Request a Hearing by the
CBIC Hearing Officer (HO)
We propose that a contract supplier
that has received a notice that we
consider the supplier in breach of
contract has the right to request a
hearing before a HO who was not
involved with the original breach of
contract determination. We consider
this process to be a reconsideration of
the original decision, and consistent
with other Medicare appeals provisions,
we believe it is important that an
individual not involved in making the
initial recommendation conduct the
PO 00000
Frm 00180
Fmt 4701
Sfmt 4702
reconsideration of the initial decision.
As mentioned previously, the HO would
be an individual who is designated by
CMS to review and to make an unbiased
and independent recommendation of
whether to terminate the supplier’s
DMEPOS CBP contract. The notice to
the contract supplier would also
identify the location to which a request
for hearing must be sent.
Under the proposed rule, a contract
supplier may appeal the notice of
termination by submitting a written
request to the CBIC for a hearing by a
HO. The written request should include
any evidence to support its appeal. The
HO is not required to allow evidence
submitted in addition to the evidence
submitted along with the written
request. The hearing request must be
received by the CBIC within 30 calendar
days from the date of the termination
letter. A request for a hearing must be
sent to the address identified on the
notice. Failure to request a hearing
within the allotted 30 calendar days
would result in a termination of the
supplier’s contract, as of the effective
date of termination identified in the
notice to the supplier. There would be
no extensions to this 30-day timeframe.
We believe suppliers have sufficient
time to decide whether or not to request
a hearing and the deficiencies identified
in the notice may pose a risk to the
DMEPOS CBP. The date the request is
received by the CBIC determines if the
hearing request was timely filed.
We would require that the request for
hearing be filed by a supplier’s
authorized official, because an
authorized official of the company
signed the contract and this ensures the
validity of the request. The authorized
official must be an official of the
company who is identified on the
supplier’s CMS 855–S form as an
authorized official of the supplier. A
supplier may appoint someone other
than the authorized official to be a
representative for them at the hearing.
However, the representative may not be
an individual who has been disqualified
or suspended from acting as a
representative by the Secretary or
otherwise prohibited by law. The
request for a hearing must be filed with
the CBIC at the address identified on the
notice of termination.
We welcome comments on our
proposed process for requesting a
hearing by a HO.
(7) Scheduling of the Hearing
The proposed rule also addresses
scheduling the hearing. We propose that
within 30 calendar days from the receipt
of a supplier’s timely hearing request
the HO would contact the parties to
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
schedule a hearing. The request for a
hearing would result in the
postponement of the date of the contract
termination. The only exception to this
rule is when a supplier has been
excluded, debarred or convicted of a
health care related crime; in that
situation the supplier’s contract would
be terminated immediately. In the
hearing request the contract supplier
may ask for the hearing to be held in
person or by telephone. The HO would
send a notice to the parties to the
hearing indicating the time and place
for the hearing at least 30 days before
the date of the hearing. The HO may, on
his or her own motion, or at the request
of a party, change the time and place for
the hearing, but must give the parties to
the hearing a 30-day notice of the
change.
The proposed rule would require that
the HO’s notice scheduling the hearing
must provide, at a minimum, the
following information:
• Date, time, and location of the
scheduled hearing;
• Description of the hearing
procedure;
• Issues to be resolved;
• Requirement that the contract
supplier bears the burden of proof to
demonstrate that it is not in breach of
contract; and
• Provide an opportunity for the
supplier to submit evidence to support
its appeal. We believe this information
provides the supplier with sufficient
information regarding the hearing date,
time, and matters that would be
addressed at that time. We welcome
comments on the content of this notice
and the procedures for scheduling a
hearing.
(8) Burden of Proof
We propose that the contract supplier
would present to the HO the basis for its
disagreement with the termination
notice and would have the burden of
proof to demonstrate to the HO with
supporting evidence that it is not in
breach of its contract and that the
termination action is not appropriate.
The supplier’s supporting evidence
must be submitted with its request for
a hearing. The supporting evidence and
the request for a hearing must be
submitted together and received by the
HO within 30 calendar days from the
date identified on the notice of
termination. In the absence of good
cause, the HO may not allow evidence
to be submitted in addition to the
evidence submitted along with the
written request. We also have the
opportunity to submit evidence to the
HO within 30 days of receiving the
notice announcing the hearing. The HO
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
will share all evidence submitted, both
from the supplier and CMS, in
preparation for the hearing with all
affected parties within 15 days prior to
the scheduled date of the hearing.
We welcome comments on our
proposal regarding the burden of proof.
(9) Role of the Hearing Officer (HO)
Our proposal requires that the HO
conduct a thorough and independent
review. Such a review requires the
consideration of all information and
documentation relevant to the hearing
and submitted consistent with this
proposal. Consistent with this goal, we
propose that the HO is responsible for
all of the following:
• Sharing all evidence submitted,
both from supplier and CMS, in
preparation for the hearing with all
affected parties within 15 days prior to
the scheduled date of the hearing.
• Conducting the hearing and
deciding the order in which the
evidence and the arguments of the
parties would be presented.
• Determining the rules on
admissibility of the evidence.
• Examining the witnesses, in
addition to the examinations conducted
by CMS and the contract supplier.
• Determining the rules for requesting
documents and other evidence from
other parties.
• Ensuring a complete recording of
the hearing is available and provided to
all parties to the hearing and the CBIC.
• Preparing a file of the record of the
hearing which includes all evidence
submitted as well as any relevant
documents identified by the HO and
considered as part of the hearing.
• Complying with all applicable
provisions of 42 U.S.C. Title 18 and
related provisions of the Act, the
applicable regulations issued by the
Secretary, and manual instructions
issued by CMS.
The HO would make a
recommendation based on the
information presented and submitted.
The HO would issue a written
recommendation to CMS within 30 days
of the close of the hearing, unless the
HO requests an extension from CMS and
demonstrates to CMS that he or she
needs an extension due to complexity of
the matter or heavy work load. The HO’s
recommendation would include the
rationale for his or her recommendation
regarding the termination of the
supplier’s contract and the HO would
submit this recommendation to CMS for
its determination.
We welcome comments on the role of
the CBIC HO in our proposed rule.
PO 00000
Frm 00181
Fmt 4701
Sfmt 4702
40219
(10) CMS’s Final Determination
Under the proposed rule, the HO’s
recommendation is submitted to CMS,
and the agency would make the final
determination regarding whether the
supplier’s contract would be terminated.
Our determination would be based upon
on the record of the hearing, evidence,
and documents considered by the HO as
part of the HO recommendation.
Information submitted after the hearing
would not be considered. Our decision
would be made within 30 days of the
receipt of the HO’s recommendation. If
our decision is to terminate the contract,
the supplier would be notified of the
effective date of termination by certified
mail. Our decision regarding the
termination of the contract is final and
binding.
We welcome comments on our
proposal relating to CMS’s final
determination of a supplier’s contract
termination.
(11) Effective Date of the Contract
Termination
Under the proposed rule, suppliers
who submit a CAP or request a hearing
would have the termination date
identified on the notice delayed. The
only exception to this rule is when a
supplier has been excluded, debarred or
convicted of a health care related crime;
in that situation the contract would be
terminated immediately. For
terminations that do not meet these
exceptions, the effective date of a final
termination would be determined as
follows:
• The termination of a supplier’s
DMEPOS CBP contract is effective on
the date specified in the initial notice of
termination, which will be 45 days from
the date of the notice, unless the
supplier request a hearing with the HO
or the supplier submits an acceptable
CAP.
• After reviewing the HO
recommendation, if we terminate a
supplier’s contract the effective date of
the termination would be the date
specified in the post-hearing notice sent
to the supplier indicating CMS’s final
determination to terminate the contract.
We welcome comments on our
proposals related to the effective date of
contract termination.
(12) Effect of Contract Termination
Under our proposal, once a supplier’s
contract is terminated for breach of
contract under the DMEPOS CBP, the
contract supplier is no longer a
DMEPOS CBP contract supplier for any
DMEPOS CBP product category for
which it was awarded a contract. This
termination applies to all areas and
E:\FR\FM\13JYP2.SGM
13JYP2
40220
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
product categories because there is only
one contract that encompasses all CBAs
and product categories for which the
supplier was awarded a contract. We
would not make payment and would
reject claims for DMEPOS competitive
bid items and services furnished by a
supplier whose contract has been
terminated after the effective date of the
termination for the remainder of the
contract period.
We recognize that a supplier’s
termination would impact beneficiaries
within the CBA. Therefore, we therefore
propose that terminated suppliers must
notify all beneficiaries within the CBA
who are receiving rented competitively
bid items of the termination of their
contract status so that the beneficiaries
can make arrangements to receive
equipment and suppliers through other
contract suppliers. After we have made
our final determination and sent
notification to the supplier, the supplier
must notify beneficiaries within 5 days
of receipt of the contract supplier’s final
notice of termination. This notice must
inform beneficiaries that they would
have to select a new contract supplier to
furnish their DMEPOS items in order for
Medicare to pay for these items. For
beneficiary protection, we also propose
that contract suppliers who fail to give
proper notification to beneficiaries may
be prevented from participating in
future rounds of DMEPOS CBP. We also
propose that rental items may not be
picked up from the beneficiary’s home
until after the last day of the rental
month for which the supplier has
already received payment. We are
proposing both of these policies to
protect the beneficiary and to ensure
that suppliers do not pick up equipment
from a beneficiary for a time period for
which they have already been paid to
provide the service.
2. Changes to Payment Rules for Oxygen
and Oxygen Equipment
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
a. Background
The general Medicare payment rules
for DME are set forth in section 1834(a)
of the Act and 42 CFR part 414, subpart
D of our regulations. Section 1834(a)(1)
of the Act and § 414.210(a) of our
regulations establish the Medicare
payment for a DME item as equal to 80
percent of either the lower of the actual
charge or the fee schedule amount for
the item. The beneficiary coinsurance is
equal to 20 percent of either the lower
of the actual charge or the fee schedule
amount for the item once the deductible
is met.
The specific payment rules for oxygen
and oxygen equipment under the
existing fee schedules are set forth in
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
section 1834(a)(5) of the Act and
§ 414.226 of our regulations. Suppliers
are paid a monthly payment amount for
furnishing medically necessary oxygen
contents (for both stationary and
portable) and stationary oxygen
equipment described under the class
described in § 414.226(c)(1)(i).
Equipment in the stationary class
includes stationary oxygen
concentrators, which concentrate
oxygen from room air; stationary liquid
oxygen systems, which use oxygen
stored as a very cold liquid in cylinders
and tanks; and gaseous oxygen systems,
which administer compressed oxygen
directly from cylinders.
A monthly add-on payment is also
made to suppliers furnishing medically
necessary portable oxygen equipment
falling under one of two classes
described in § 414.226(c)(1)(ii) and (iii).
Equipment in these classes includes
traditional portable equipment, that is,
portable liquid oxygen systems and
portable gaseous oxygen systems, and
oxygen generating portable equipment
(OGPE), that is, portable oxygen
concentrators and oxygen transfilling
equipment used to fill portable tanks or
cylinders in the home. Both the liquid
and gaseous oxygen systems (for
stationary and traditional portable
systems) require on-going delivery of
oxygen contents.
Section 1834(a)(5)(F) of the Act, as
amended by section 144(b) of MIPPA,
limits the monthly rental payments to
suppliers for oxygen equipment to 36
months of continuous use, although
monthly payments for furnishing
gaseous or liquid oxygen contents
continue after the 36-month equipment
rental cap is reached for gaseous or
liquid systems. In the CY 2009 PFS final
rule with comment period (73 FR 69875
through 69876), we discussed section
144(b) of MIPPA and included a
detailed discussion of how section
5101(b) of the Deficit Reduction Act of
2005 (DRA) previously required
suppliers to transfer title to oxygen
equipment to the beneficiary at the end
of the 36-month rental period. Section
144(b) of the MIPPA repealed this
requirement to transfer title to the
oxygen equipment to the beneficiary
and allows suppliers to retain title to the
oxygen equipment after 36 monthly
rental payments are made for the
equipment.
Section 414.210 establishes the
requirements for the replacement of
DME, including oxygen equipment.
Section 414.210(f)(1) states that if an
item of DME, which includes oxygen
equipment, has been in continuous use
by the patient for the equipment’s
reasonable useful lifetime or if the
PO 00000
Frm 00182
Fmt 4701
Sfmt 4702
original equipment is lost, stolen, or
irreparably damaged, the patient may
elect to obtain a new piece of
equipment. In such circumstances,
§ 414.420(f)(2) authorizes payment for
the new oxygen equipment in
accordance with § 414.226(a). Section
414.210(f)(1) states that the reasonable
useful lifetime for DME, which includes
oxygen equipment, is determined
through program instructions. In the
absence of CMS program instructions,
the carrier may determine the
reasonable useful lifetime for
equipment, but in no case can it be less
than 5 years. Computation is based on
when the equipment is delivered to the
beneficiary, not the age of the
equipment. If the beneficiary elects to
obtain new oxygen equipment after the
reasonable useful lifetime, the payment
is made for a new 36-month rental
period in accordance with § 414.226(a).
We are proposing to revise the
payment rule for oxygen and oxygen
equipment at § 414.226(g)(1) to address
situations where beneficiaries relocate
outside the service area of a supplier
during the 36-month rental payment cap
period for the oxygen equipment.
Beneficiaries are experiencing great
difficulties in finding suppliers willing
to furnish oxygen equipment in
situations where only a few months are
left in the 36-month rental payment
period at the time they relocate. For
example, if a beneficiary is in the 30th
rental month, the new supplier would
be entitled to only 6 months of rental
payments and then would have to
continue to furnish the oxygen and
oxygen equipment during any period of
medical need for the remainder of the
reasonable useful lifetime of the
equipment. This creates a financial
disincentive for oxygen suppliers to
furnish oxygen and oxygen equipment
to beneficiaries in these situations.
The proposed changes to the payment
rules for oxygen and oxygen equipment
would apply to oxygen and oxygen
equipment furnished under Part B and
would also apply to oxygen and oxygen
equipment furnished under programs
implemented in accordance with
section 1847(a) of the Act.
b. Furnishing Oxygen Equipment after
the 36-Month Rental Period (Cap)
In the CY 2010 PFS final rule with
comment period (74 FR 61887 through
61890), we finalized § 414.226(g)(1)
which, in accordance with section
1834(a)(5)(F)(ii)(I) of the Act, requires
the supplier that furnishes oxygen
equipment during the 36-month rental
period to continue furnishing the
oxygen equipment after the 36-month
rental period. The supplier is required
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
to continue to furnish the equipment
during any period of medical need for
the remainder of the reasonable useful
lifetime of the equipment. As we noted
when finalizing this rule, section
1834(a)(5)(F)(ii)(I) does not provide any
exceptions to this requirement. If the
beneficiary relocates outside the
supplier’s normal service area at some
time after the 36-month rental period
but before the end of the reasonable
useful lifetime of the equipment, the
supplier must make arrangements for
the beneficiary to continue receiving the
equipment at his or her new place of
residence. This responsibility for
furnishing the equipment does not
transfer to another supplier.
We revised § 414.226(f) to conform
our regulations to this new MIPPA
requirement. We deleted the transfer of
ownership requirement and added the
new requirement that the supplier must
continue furnishing the oxygen
equipment after the 36-month rental
period during any period of medical
need for the remainder of the reasonable
useful lifetime of the equipment. It is
important to note that § 414.226(g)(1)(ii)
does not apply this same requirement in
situations where the beneficiary
relocates outside of the supplier’s
normal service area during the 36month rental period.
c. Furnishing Oxygen Equipment during
the 36-Month Rental Period (Cap)
Section § 414.226(g)(1) contains the
requirement that the supplier that
furnishes oxygen and oxygen equipment
for the first month of the 36th month of
the rental cap period must continue to
furnish the equipment for the entire 36month period of continuous use, with
limited exceptions. One exception at
§ 414.226(g)(1)(ii) applies when a
beneficiary permanently relocates his or
her residence during the 36-month
rental period outside of the current
supplier’s normal service area. This
exception was proposed in the ‘‘Home
Health Prospective Payment System
Rate Update for Calendar Year 2007 and
Deficit Reduction Act of 2005 Changes
to Medicare Payment for Oxygen
Equipment and Capped Rental Durable
Medical Equipment; Proposed Rule’’
published in the August 3, 2006 Federal
Register (71 FR 44094) and was
intended to reduce the burden on the
supplier in these situations. This
approach is also consistent with the
regulations addressing capped rental
items described in § 414.229. We
addressed this issue in the capped
rental context in the July 10, 1995
Federal Register (60 FR 35494) in
response to comments. The discussion
states that since the implementation of
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
the capped rental payment methodology
on January 1, 1989, we received no
reports of beneficiaries having difficulty
obtaining access to capped rental DME
after relocating outside the supplier’s
service area. Since enactment of the
capped rental DME payment category in
section 4062 of the Omnibus Budget
Reconciliation Act of 1987 (Pub. L. 100–
203), representatives of the DME
industry indicated that suppliers would
be able to accommodate beneficiaries in
these situations, and this has proven to
be true for capped rental items. In fact,
we have found this to be the case to this
day.
For this reason, we believed that
beneficiaries would not encounter
problems obtaining access to oxygen
and oxygen equipment in similar
situations, that is, following the 36month cap imposed by section 144(b) of
MIPPA. However, since the changes to
the payment rules for oxygen and
oxygen equipment mandated by the
DRA became effective in 2006 and the
36-month rental cap imposed by MIPPA
was reached for the first time in January
2009, we have received many reports of
beneficiaries relocating prior to the end
of the 36-month rental payment cap
period and having difficulty finding an
oxygen supplier in the new location. We
have learned that many suppliers are
unwilling to provide services in
situations where there are a few number
of months left in the 36-month rental
payment period.
We do not believe that beneficiaries
have encountered similar issues
following the 36-month rental cap,
which most likely is the result of
different statutory requirements for
these two periods (that is, during and
after the 36-month rental period).
Section 1834(a)(5)(F)(ii) of the Act
requires the supplier that furnishes the
oxygen equipment during the 36-month
rental payment period to continue
furnishing the equipment after the 36month rental payment period.
Consistent with this requirement, we
established regulations at § 414.226(f)(1)
that require the supplier to furnish the
equipment or make arrangements for
furnishing the equipment in situations
where the beneficiary relocates outside
the supplier’s normal service area. Since
no such requirement currently applies
in situations where the beneficiary
relocates prior to the end of the 36month rental payment period, and in
fact current regulations at
§ 414.226(g)(1)(ii) absolve the supplier
of the obligation to continue furnishing
oxygen equipment in these situations,
beneficiaries are experiencing
difficulties finding suppliers of oxygen
equipment in their new locations that
PO 00000
Frm 00183
Fmt 4701
Sfmt 4702
40221
are willing to accommodate them. As
noted above, we have not seen this
problem in the capped rental DME
context. The requirement at
§ 414.226(g)(1) to furnish oxygen
equipment for the entire 36 month
rental cap period was established in the
course of implementing section 5101(b)
of the DRA in order to safeguard the
beneficiary from situations where
suppliers might discontinue service and
pick up oxygen equipment prior to the
end of the 36-month rental cap in order
to avoid losing title to the equipment.
As mentioned earlier, the transfer of
title of oxygen and oxygen equipment
after the 36th paid rental month was
repealed. The exception to this rule at
§ 414.226(g)(1)(ii) was established based
on our experience that suppliers of
capped rental DME have accommodated
beneficiaries in these situations, which,
unfortunately, has not been our
experience in the context of oxygen
equipment.
In order to address this vulnerability
facing beneficiaries as a result of
regulations currently in effect, we are
proposing to revise the exception at
§ 414.226(g)(1)(ii) to apply only to
situations where the beneficiary
relocates before the 18th paid rental
month to an area that is outside the
normal service area of the supplier that
initially furnished the equipment. We
are proposing to revise the regulation to
require the supplier that furnishes the
oxygen equipment and receives
payment for month 18 or later to either
furnish the equipment for the remainder
of the 36-month rental payment period
or, in the case where the beneficiary has
relocated outside the service area of the
supplier, make arrangements for
furnishing the oxygen equipment with
another supplier for the remainder of
the 36-month rental payment period.
The supplier that is required to furnish
the equipment on the basis of this
requirement must also furnish the
equipment after the 36-month rental
payment period in accordance with the
requirements of section 1834(a)(5)(F)(ii)
and § 414.226(f).
The proposed revision would mean
that a supplier does not have to
continue to furnish the oxygen
equipment if the beneficiary relocates
outside the normal service area before
the 18th paid rental month during a
period of continuous use. Under the
current rule, a supplier does not have to
furnish the oxygen equipment if the
beneficiary relocated before the 36th
paid rental month during a period of
continuous use. The current rule was
established based on the long term,
demonstrated ability of suppliers of
capped rental DME to accommodate
E:\FR\FM\13JYP2.SGM
13JYP2
40222
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
beneficiaries in situations where they
relocate near the end of a capped rental
payment period. With regard to oxygen
equipment, suppliers in general have
not demonstrated a willingness to
accommodate beneficiaries in similar
situations. Therefore, it is necessary to
revisit this rule in order to protect
beneficiaries in these situations. This
proposal would allow either a new
supplier in the beneficiary’s new service
area or a supplier in the old service area
to receive at least half of the 36 monthly
payments allowed for under the current
statutory payment rule for oxygen
equipment. We believe this approach
would be fair to suppliers in either
scenario since the same minimum
number of payments applies. Based on
current 2010 Medicare allowed fee
schedule amounts for stationary oxygen
equipment, total payments for 18
months is $3,117.06. We believe this
new rule would provide greater
financial incentive to suppliers in areas
where beneficiaries relocate to furnish
oxygen equipment in these situations.
We also believe that this proposal
would not disadvantage suppliers
required to continue furnishing oxygen
equipment or make arrangements for
furnishing oxygen equipment to
beneficiaries that relocate outside their
normal service area since these
suppliers would receive 18 or more
monthly payments. Most of the cases
that have been reported regarding
problems encountered by beneficiaries
in obtaining access to oxygen equipment
after relocating during the 36-month
rental cap period have been situations
where the beneficiary has relocated
during the second half of the 36-month
rental cap period. Therefore, we believe
that this rule would largely address
access problems associated with
relocations during the 36-month rental
cap period because the supplier that
received payments during the first half
of the 36-month rental cap period would
be obligated to continuing furnishing
the equipment during the second half of
the 36-month rental cap period.
H. Provider and Supplier Enrollment
Issue: Air Ambulance Provision
The National Transportation Safety
Board (NTSB) is an independent Federal
agency charged by the Congress with
investigating transportation accidents,
determining their probable cause and
making recommendations to prevent
similar accidents from occurring. Based
on information derived from testimony
provided at the NSTB public hearing
and investigations into recent
Helicopter Emergency Medical Services
(HEMS) accidents, the NTSB made
several specific recommendations to the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Secretary of Health and Human Services
on September 24, 2009.
Specifically, the NTSB recommended
that the Secretary develop minimum
safety accreditation standards for HEMS
operators that augment the operating
standards of 14 CFR part 135 by
including for all fights with medical
personnel on board: (a) Scenario-based
pilot training; (b) implementation of
preflight risk evaluation programs; and
(c) the installation of FAA-approved
terrain awareness warning systems,
night vision imaging systems, flight data
recording systems for monitoring and
autopilots if a second pilot is not used.
In response to the NTSB concerns, the
Secretary noted that the
recommendations to CMS were similar
to those being made to the Federal
Aviation Administration (FAA). While
we have expertise to regulate health and
safety requirements that suppliers and
providers of healthcare should meet, we
do not have the expertise to determine
aircraft safety requirements. The
Secretary stated that, ‘‘we believe the
FAA should determine the minimum
level of safety that HEMS operators
should meet and CMS should adopt
regulations that require any HEMS
operator that enrolls in Medicare to
meet those requirements.’’ The Secretary
also added that, ‘‘while we do not
believe CMS should augment FAA
regulations, we do believe that CMS’
regulations should ensure that only
those HEMS operators that maintain the
minimum level of requirements
established by the FAA through its
regulations are enrolled or maintain
enrollment in the Medicare program.’’
In the April 21, 2006 Federal
Register, we published the
‘‘Requirements for Providers and
Suppliers to Establish and Maintain
Medicare Enrollment’’ final rule. This
final rule implemented section
1866(j)(1)(A) of the Act. In this final
rule, we required that all providers and
suppliers (other than physicians or
practitioners who have elected to ‘‘optout’’ of the Medicare program) must
complete an enrollment form and
submit specific information to CMS in
order to obtain Medicare billing
privileges. Section 424.515 required that
ambulance service providers continue to
resubmit enrollment information in
accordance with § 410.41(c)(2), which
states, ‘‘Upon a carrier’s request,
complete and return the ambulance
supplier form designated by CMS and
provide Medicare carrier with
documentation of compliance with
emergency vehicle and staff licensure
and certification requirements in
accordance with State and local laws.’’
This final rule also established
PO 00000
Frm 00184
Fmt 4701
Sfmt 4702
§ 424.510(d)(2)(iii) which states,
‘‘Submission of all documentation,
including all applicable Federal and
State licensure and regulatory
requirements that apply to the specific
provider or supplier type that related to
providing health care services, required
by CMS under this or other statutory or
regulatory authority, or under the
Paperwork Reduction Act of 1995, to
establish the provider or supplier’s
eligibility to furnish Medicare covered
items or services to beneficiaries in the
Medicare program.’’
While the Airline Deregulation Act
(Pub. L. 95–504) preempts a State,
political subdivision of a State, or
political authority of at least 2 States
from enacting or enforcing a law,
regulation, or other provision having the
force and effect of law related to a price,
route, or service of an air carrier that
may provide air transportation, air
ambulances remain subject to Federal
laws and regulations. In accordance
with § 424.516(a)(2), providers and
suppliers must adhere to all Federal
regulations and State laws and
regulations, as required, based on the
type of services or supplies the provider
or supplier type will furnish and bill
Medicare.
In § 424.510(d)(iii), we are proposing
to clarify that ambulance suppliers and
other providers and suppliers include
documentation regarding all applicable
Federal and State certifications.
Accordingly we are propsing to revise
§ 424.510(d)(iii) from ‘‘Submission of all
documentation, including all applicable
Federal and State licenses and
regulatory requirements that apply to
the specific provider or supplier type
that relate to providing health care
service, required by CMS under this or
other statutory or regulatory authority,
or under the Paperwork Reduction Act
of 1995, to establish the provider or
supplier’s eligibility to furnish Medicare
covered items or services to
beneficiaries in the Medicare program,’’
to ‘‘Submission of all documentation,
including all applicable Federal and
State licenses, certifications (including,
but not limited to Federal Aviation
Administration and Clinical Laboratory
Improvement Act certifications), and
regulatory requirements that apply to
the specific provider or supplier type
that relate to providing health care
service, required by CMS under this or
other statutory or regulatory authority,
or under the Paperwork Reduction Act
of 1995, to establish the provider or
supplier’s eligibility to furnish Medicare
covered items or services to
beneficiaries in the Medicare program.’’
We are also proposing to revise
§ 424.516(e)(2) and add new paragraph
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(e)(3) to clarify that Medicare enrolled
providers and suppliers must report a
revocation or suspension of a Federal or
State license or certification, including
but not limited to FAA and Clinical
Laboratory Improvement Act (CLIA)
certifications. This revision will clarify
that fixed-wing ambulance operators
and HEMS operators are responsible for
notifying the designated Medicare
contractor for their State when FAA
revokes or suspends any license or
certification. Moreover, fixed-wing
ambulance operators and HEMS
operators must maintain all
requirements as specified in 14 CFR part
135.
We believe that requiring fixed-wing
ambulance and HEMS operators to
notify their Medicare contractor of a
suspension or revocation of a license or
certification will ensure that any action
taken by the FAA or other regulating
authority will have a direct linkage to
the operator’s ability to maintain their
Medicare enrollment. We believe that
such a policy will help improve aircraft
safety for operators that are enrolled in
Medicare and providing services to
Medicare beneficiaries. In addition,
since the FAA is responsible for the
issuance and enforcement of regulations
and minimum standards covering
manufacturing, operating, and
maintaining aircraft, we will work with
the FAA to confirm that fixed-wing
ambulance operators and HEMS
operators remain in compliance with
FAA safety regulations (including, but
not limited to Federal Aviation
Administration and certifications) to the
Medicare contractor within 30 days of
the revocation or suspension of the
license or certification, the provider or
supplier is making the decision to
voluntarily terminate its Medicare
billing privileges because the provider
or supplier is no longer in compliance
with the applicable licensing or
certification requirements for their
provider or supplier type. We believe
that allowing providers and suppliers to
self-report licensure or certification
revocations and suspensions within a 30
day period via the Medicare enrollment
application (such as, the Internet-based
Provider Enrollment Chain and
Ownership System (PECOS) or the
paper CMS–855) promotes compliance
with the Medciare reporting
requirements found in § 424.516. In
addition, by reporting a licensure or
certification revocation or suspension
within 30 days, the provider or supplier
avoids the Medicare contractor bringing
an action to revoke its Medicare billing
privileges and establishing and
Medicare enrollment bar, see
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
§ 424.535(c). Thus, by complying with
the reporting responsibilities found in
§ 424.516 and voluntarily terminating
from the Medicare program, the air
ambulance supplier can submit an
initial application to enroll in the
Medicare program as soon as the
licensure or certification revocation or
suspension action is resolved with the
applicable licensing or certification
organization.
In § 424.502, we are proposing to
define the term, ‘‘voluntary termination’’
as it is currently used in the Medicare
program and throughout this regulation
in the context of the provider
enrollment requirements: We are
proposing that the term, ‘‘voluntary
termination’’ to mean an air ambulance
supplier, that submits written
confirmation to CMS of its decision to
discontinue enrollment in the Medicare
program.
Futhermore, we belive that an air
ambulance supplier, can make the
decision to voluntary terminate their
business relationship with the Medicare
program at any time, including when
the provider or supplier makes the
decision that they will no longer furnish
services to Medicare beneficiaries.
In those situations, where an air
ambulance supplier does not meet their
reporting responsibilities and notify the
Medicare program of a Federal or State
licensure or certification revocation or
suspension within 30 days of the
reportable event, we believe that it is
appropriate to that CMS or the Medicare
contractor revoke the supplier’s
Medicare billing privileges using
§ 424.535(a)(1). We believe that this
change will clarify that CMS or our
Medicare contractor may revoke
Medicare billing privileges when these
types of suppliers do not report a
revocation or suspension of a Federal or
State license or certification.
I. Technical Corrections
1. Physical Therapy, Occupational
Therapy and Speech-language Pathology
We are proposing to revise § 409.23(c)
by making a minor technical correction
to remove an extraneous cross-reference
which was initially proposed in the CY
2008 PFS proposed rule (72 FR 38122,
72 FR 38193, and 72 FR 38221). This
cross-reference refers the reader to
‘‘paragraph (c)(1)(ii) of this section,’’ a
paragraph also proposed in the CY 2008
PFS proposed rule, but never finalized.
In the CY 2008 PFS final rule with
comment period, we inadvertently
neglected to remove the associated
cross-reference from the regulations
text. Accordingly, we now propose to
rectify that oversight by making an
PO 00000
Frm 00185
Fmt 4701
Sfmt 4702
40223
appropriate correction in the regulations
text, along with other minor formatting
revisions. We are also proposing to
make a minor clarification to the section
heading and introductory text of
§ 409.23 (along with a conforming
revision to the corresponding
regulations text at § 409.20(a)(3)) by
revising the existing phrase ‘‘speech
therapy’’ to read ‘‘speech-language
pathology services,’’ so that it more
accurately reflects the currently used
terminology for this type of therapeutic
treatment.
In addition, we are also proposing to
make a minor wording change in the
provision at § 409.17(d) (which is
incorporated by reference in
§ 409.23(c)(2)), in order to clarify that
the former provision’s reference to
‘‘hospital’’ policies and procedures can
alternatively refer, depending on the
particular context, to SNF policies and
procedures.
2. Scope of Benefits
In § 410.3, we are proposing a
technical correction to paragraph (b)(2).
Currently, § 410.3(b)(2) states that the
specific rules on payment are set forth
in subpart E of part 410. However, the
specific payment rules are actually
listed in subpart I of part 410. Therefore,
we are proposing to correct § 410.3(b)(2)
in this proposed rule.
VII. Collection of Information
Requirements
Under the Paperwork Reduction Act
of 1995, we are required to provide 60day notice in the Federal Register and
solicit public comment before a
collection of information requirement is
submitted to the Office of Management
and Budget (OMB) for review and
approval. In order to fairly evaluate
whether an information collection
should be approved by OMB, section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires that we
solicit comment on the following issues:
• The need for the information
collection and its usefulness in carrying
out the proper functions of our agency.
• The accuracy of our estimate of the
information collection burden.
• The quality, utility, and clarity of
the information to be collected.
• Recommendations to minimize the
information collection burden on the
affected public, including automated
collection techniques.
We are soliciting public comment on
each of these issues for the following
sections of this document that contain
information collection requirements
(ICRs):
E:\FR\FM\13JYP2.SGM
13JYP2
40224
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
A. ICRs Regarding Diagnostic X-ray
Tests, Diagnostic Laboratory Tests, and
Other Diagnostic Tests: Conditions
(§ 410.32)
Proposed § 410.32(d)(2)(i) would
require the physician or qualified non
physician practitioner (as defined in
§ 410.32(a)(2)) who orders the service
must maintain documentation of
medical necessity in the beneficiary’s
medical record. In addition, both the
medical record and the laboratory
requisition (or order) would be required
to be signed by the physician or
qualified non physician practitioner (as
defined in § 410.32(a)(2) of this section)
who orders the service. The burden
associated with these requirements
would be the time and effort necessary
for a physician or qualified
nonphysician practitioner to sign the
medical record or laboratory requisition
(or order). There would also be a
recordkeeping requirement associated
with maintaining the documentation of
medical necessity in the beneficiary
medical record. While these
requirements are subject to the PRA, we
believe the associated burden is exempt
from the PRA in accordance with 5 CFR
1320.3(b)(2). We believe that the time,
effort, and financial resources necessary
to comply with the aforementioned
information collection requirements
would be incurred by persons in the
normal course of their activities and
therefore considered to be usual and
customary business practices.
B. ICRs Regarding General Exceptions to
the Referral Prohibition Related to Both
Ownership/Investment and
Compensation (§ 411.355)
Proposed § 411.355(b)(7)(i) states that
with respect to magnetic resonance
imaging, computed tomography, and
positron emission tomography, the
referring physician shall provide written
notice to the patient at the time of the
referral that the patient may receive the
same services from a person other than
one described in § 411.355(b)(1). The
written notice shall include a list of
other suppliers (as defined in § 400.202
of this title) that provide the services for
which the individual is being referred.
The list shall include a minimum of 10
suppliers within a 25-mile radius of the
referring physician’s office location at
the time of the referral. The notice
should be written in a manner sufficient
to be reasonably understood by all
patients and should include for each
supplier on the list, at a minimum, the
supplier’s name, address, telephone
number, and distance from the referring
physician’s office. A record of the
disclosure notification, signed by the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
patient, shall be maintained as a part of
the patient’s medical record.
Section 411.355(b)(7)(ii) proposes that
if the referring physician makes a
referral within an area with fewer than
10 other suppliers within the 25-mile
radius of the physician’s office location
at the time of the referral, the physician
shall list all of the other suppliers of the
imaging service that are present within
a 25-mile radius of the referring
physician’s office location, including up
to 10 suppliers. Provision of the written
list of alternate suppliers will not be
required if no other suppliers provide
the services for which the individual is
being referred within the 25-mile radius.
These physicians must still disclose to
the patient that the patient may receive
these services from a person other than
one described in § 411.355(b)(1) in a
manner sufficient to reasonably be
understood by all patients. A record of
the disclosure notification, signed by
the patient and the referring physician,
shall be maintained as a part of the
patient’s medical record.
The burden associated with the
requirements contained in this section
would be the time and effort necessary
for a physician to develop a standard
disclosure. There would also be burden
associated with the time and effort
necessary for a physician to provide the
disclosure to the patient, to obtain the
patient’s signature, and to record the
paper as part of the patient’s medical
record. We estimate that it would take
1 hour for a physician’s office to
develop a standard disclosure. We
further estimate that 71,000 physicians
will be required to comply with these
requirements. The total burden
associated with the development of the
standard disclosure is 71,000 hours at a
cost of $1,042,280. Similarly, we
estimate that it will take each physician
1 minute to provide the disclosure to
the patient, to obtain the patient’s
signature, and to record the paper as
part of the patient’s medical record. We
believe that each provider will make
approximately 106 disclosures. The
total estimated annual for this
requirement is 125,433 hours at a cost
of $10,536,400.
C. ICRs Regarding Appeals Process for
Termination of Competitive Bidding
Contract (§ 414.423)
Proposed § 414.423(c)(1)(i) states that
CMS has the option to allow a DMEPOS
supplier to provide a written CAP to
remedy the deficiencies identified in the
notice, when CMS determines that the
delay in the termination date caused by
allowing a CAP will not cause harm to
beneficiaries. As stated in proposed
§ 414.423(c)(2)(i) a CAP must be
PO 00000
Frm 00186
Fmt 4701
Sfmt 4702
submitted within 30 calendar days from
the date on the notification letter. If the
supplier decides not to submit a CAP
the supplier may within 30 days of the
date on the termination letter request a
hearing by a CBIC hearing officer.
The burden associated with this
requirement is the time and effort
necessary for a supplier that has
received a termination notice to develop
and submit a CAP. We estimate that 10
suppliers will need to comply with this
requirement annually. Similarly, we
estimate that it will take a supplier an
average of 3 hours to develop a CAP.
The total estimated annual burden
associated with this requirement is 30
hours at a cost of $2,250.
Proposed § 414.423(e)(2) would
require that if CMS accepts the CAP,
including supplier’s designated
timeframe for its completion, the
supplier must provide a follow-up
report within 5 days after the supplier
has fully implemented the CAP that
verifies that all of the deficiencies
identified in the CAP have been
corrected in accordance with the
timeframes accepted by CMS. The
burden associated with this requirement
is the time and effort necessary for a
supplier to develop and submit a
follow-up report. While this
requirement is subject to the PRA, we
believe the associated burden is exempt
under 5 CFR 1320.3(h)(6). In accordance
with 5 CFR 1320.3(h)(6), a request for
facts or opinions addressed to a single
person is not defined as information
collection requirements and is therefore
exempt from the PRA.
Proposed § 414.423(f)(1) states that a
supplier who has received a notice that
CMS considers them in breach of
contract or that their CAP is not
acceptable has the right to request a
hearing before a CBIC HO who was not
involved with the original
determination. Section 414.423(f)(2)
further proposes that a supplier who
wishes to appeal the termination notice
must submit a written request to the
CBIC. The request for a hearing must be
received by the CBIC within 30 calendar
days from the date of the notice to
terminate.
The burden associated with this
section is the time and effort necessary
for a supplier to develop and submit a
written request for a hearing by a CBIC
Hearing Officer. We estimate that it will
take a supplier 8 hours to develop and
submit a request for a hearing. We
believe 5 suppliers will be subject to
this requirement on an annual basis.
The total estimated annual burden
associated with developing and
submitting a written request for a
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
hearing by a CBIC Hearing Officer is 40
hours at a cost of $3,000.
Proposed § 414.423 would require a
contract suppliers whose contract has
been terminated to notify all
beneficiaries who are receiving rented
competitive bid items or competitive
bid items received on a recurring basis,
of the termination of their contract. The
notice to the beneficiary from the
supplier whose contract was terminated
must be provided within 5 days of
receipt of the notice of termination. The
notification to the beneficiaries must
inform the beneficiaries that they are
going to have to select a new contract
supplier for these items.
The burden associated with this
section is the time and effort necessary
for a supplier to develop and distribute
notification of its termination to all
beneficiaries receiving rented
competitive bid items or competitive
bid items received on a recurring basis.
We estimate that it will take a supplier
3 hours to develop and distribute a
notice announcing its termination to all
of its beneficiaries receiving rented
competitive bid items or competitive
bid items received on a recurring basis.
We believe 2 suppliers will be subject
40225
each submission will be evaluated on a
case-by-case basis.
to this requirement on an annual basis.
The total estimated annual burden
associated with this requirement is 6
hours at a cost of $450.
D. ICRs Regarding Additional Provider
and Supplier Requirements for Enrolling
and Maintaining Active Enrollment
Status in the Medicare Program
(§ 424.516)
Proposed § 424.516(e)(2) would
require a provider or supplier to report
a revocation or suspension to the
applicable Medicare contractor within
30 days any revocation or suspension of
a Federal or State license or
certification. Similarly, proposed
§ 424.516(e)(2) states that within 30
days of voluntary withdrawal or
involuntary termination from the
Medicare program, the provider or
supplier must report voluntary
withdraw or involuntary termination to
the applicable Medicare contractor. The
burden associated with the
requirements in § 424.516(e)(2) and (3)
is the time and effort necessary for a
provider or supplier to report the
required information to the applicable
Medicare contractor. While these
requirements are subject to the PRA,
E. ICRs Regarding Additional Provider
and Supplier Requirements for Enrolling
and Maintaining Active Enrollment
Status in the Medicare Program
(§ 424.516)
Proposed § 424.516(e)(2) would
require a provider or supplier to report
a revocation or suspension to the
applicable Medicare contractor within
30 days any revocation or suspension of
a Federal or State license or
certification. Similarly, proposed
§ 424.516(e)(2) states that within 30
days of voluntary withdrawal or
involuntary termination from the
Medicare program, the provider or
supplier must report voluntary
withdraw or involuntary termination to
the applicable Medicare contractor. The
burden associated with the
requirements in § 424.516(e)(2) and (3)
is the time and effort necessary for a
provider or supplier to report the
required information to the applicable
Medicare contractor. While these
requirements are subject to the PRA,
each submission will be evaluated on a
case-by-case basis.
TABLE 72—ESTIMATED ANNUAL RECORDKEEPING AND REPORTING BURDEN
Regulation section(s)
OMB Control No.
§ 411.355 ................................
0938–New ..
§ 414.423 ................................
Total .................................
Respondents
Responses
Burden per
response
(hours)
Total annual
burden
(hours)
Hourly
labor cost of
reporting
(in $)
Total
labor cost of
reporting
(in $)
Total capital/maintenance
costs (in $)
Total cost
(in $)
0938–New ..
71,000
71,000
10
5
2
71,000
7,454,760
10
5
2
1
0.0167
3
8
3
71,000
125,433
30
40
6
14.68
83.79
75.00
75.00
75.00
1,042,280
10,536,400*
2,250
3000
450
0
0
0
....................
....................
1,042,280
10,536,400
2,250
3000
450
....................
71,017
7,525,777
......................
196,509
....................
....................
....................
11,584,380
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
* The annual cost burden for this provision was calculated by taking 106 disclosures per year per physician × $1.40 per disclosure = $148.40 a year per physician ×
71,000 physicians = $10,536,400.
If you comment on these information
collection and recordkeeping
requirements, please do either of the
following:
1. Submit your comments
electronically as specified in the
ADDRESSES section of this proposed rule;
or
2. Submit your comments to the
Office of Information and Regulatory
Affairs, Office of Management and
Budget, Attention: CMS Desk Officer,
[CMS–1503–P] Fax: (202) 395–6974; or
E-mail: OIRA_submission@omb.eop.gov.
F. Additional Information Collection
Requirements
This proposed rule imposes collection
of information requirements as outlined
in the regulation text and specified
above. However, this proposed rule also
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
makes reference to several associated
information collections that are not
discussed in the regulation text
contained in this document. The
following is a discussion of these
information collections, some of which
have already received OMB approval.
1. Part B Drug Payment
The discussion of average sales price
(ASP) issues in section VI.A.1 of this
proposed rule does not contain any new
information collection requirements
with respect to payment for Medicare
Part B drugs and biologicals under the
ASP methodology. Drug manufacturers
are required to submit ASP data to us
on a quarterly basis. The ASP reporting
requirements are set forth in section
1927(b) of the Act. The burden
associated with this requirement is the
PO 00000
Frm 00187
Fmt 4701
Sfmt 4702
time and effort required by
manufacturers of Medicare Part B drugs
and biologicals to calculate, record, and
submit the required data to CMS. While
the burden associated with this
requirement is subject to the PRA, it is
currently approved under OMB control
number 0938–0921.
3. Physician Quality Reporting Initiative
(PQRI)
Section VI.F.1. of this proposed rule
discusses the background of the PQRI,
provides information about the
proposed measures and reporting
mechanisms to be available to eligible
professionals (EPs) and group practices
who choose to participate in the 2011
PQRI, and the proposed criteria for
satisfactory reporting in 2011.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40226
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
With respect to satisfactory
submission of data on quality measures
by EPs, EPs include physicians, other
practitioners as described in section
1842(b)(18)(c) of the Act, physical and
occupational therapists, qualified
speech-language pathologists, and
qualified audiologists. EPs may choose
whether to participate and, to the extent
they satisfactorily submit data on
quality measures for covered
professional services, they can qualify to
receive an incentive payment. To
qualify to receive an incentive payment
for 2011, the EP (or group practice) must
meet one of the proposed criteria for
satisfactory reporting described in
sections VI.F.1.e. or VI.F.1.f. of this
proposed rule (or section VI.F.1.g. for
group practices).
Because this is a voluntary program,
it is difficult to accurately estimate how
many EPs will opt to participate in the
PQRI in CY 2011. Information from the
‘‘PQRI 2007 Reporting Experience
Report,’’ which is available on the PQRI
section of the CMS Web site at https://
www.cms.hhs.gov/PQRI, indicates that
nearly 110,000 unique TIN/NPI
combinations attempted to submit PQRI
quality measures data via claims for the
2007 PQRI. Therefore, for purposes of
conducting a burden analysis for the
2011 PQRI, we will assume that all EPs
who attempted to participate in the
2007 PQRI will also attempt to
participate in the 2011 PQRI.
Furthermore, we believe that the burden
for EPs who are participating in the
PQRI for the first time in 2011 will be
considerably higher than the burden for
EPs who have participated in PQRI in
prior years.
For individual EPs, the burden
associated with the requirements of this
reporting initiative is the time and effort
associated with EPs identifying
applicable PQRI quality measures for
which they can report the necessary
information, collecting the necessary
information, and reporting the
information needed to report the EP’s or
group practice’s measures. We believe it
is difficult to accurately quantify the
burden because EPs may have different
processes for integrating the PQRI into
their practice’s work flows. Moreover,
the time needed for an EP to review the
quality measures and other information,
select measures applicable to his or her
patients and the services he or she
furnishes to them, and incorporate the
use of quality data codes into the office
work flows is expected to vary along
with the number of measures that are
potentially applicable to a given
professional’s practice. Since EPs are
generally required to report on at least
3 measures to earn a PQRI incentive, we
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
will assume that each EP who attempts
to submit PQRI quality measures data is
attempting to earn a PQRI incentive
payment and reports on an average of 3
measures for this burden analysis.
Because we anticipate even greater
participation in the 2011 PQRI than in
previous years, including participation
by EPs who are participating in PQRI for
the first time in 2011, we will assign 5
hours as the amount of time needed for
EPs to review the 2011 PQRI Measures
List, review the various reporting
options, select the most appropriate
reporting option, identify the applicable
measures or measures groups for which
they can report the necessary
information, review the measure
specifications for the selected measures
or measures groups, and incorporate
reporting of the selected measures or
measures groups into the office work
flows. This estimate is based on our
assumption that an EP will need up to
2 hours to review the 2011 PQRI
Measures List, review the reporting
options, and select a reporting option
and measures on which to report and 3
hours to review the measure
specifications for up to 3 selected
measures or up to 1 selected measures
group and to develop a mechanism for
incorporating reporting of the selected
measures or measures group into the
office work flows.
Information from the Physician
Voluntary Reporting Program (PVRP),
which was a predecessor to the PQRI,
indicated an average labor cost of $50
per hour. To account for salary increases
over time, we will use an average
practice labor cost of $58 per hour in
our estimates based on an assumption of
an average annual increase of
approximately 3 percent. Thus, we
estimate the cost for EP associated with
preparing to report PQRI quality
measures would be approximately $290
per EP ($58 per hour x 5 hours).
We continue to expect the ongoing
costs associated with PQRI participation
to decline based on an EP’s familiarity
with and understanding of the PQRI,
experience with participating in the
PQRI, and increased efforts by CMS and
stakeholders to disseminate useful
educational resources and best
practices.
We believe the burden associated
with actually reporting the PQRI quality
measures will vary depending on the
reporting mechanism selected by the EP.
For claims-based reporting, EPs must
gather the required information, select
the appropriate quality data codes
(QDCs), and include the appropriate
QDCs on the claims they submit for
payment. The PQRI will collect QDCs as
additional (optional) line items on the
PO 00000
Frm 00188
Fmt 4701
Sfmt 4702
existing HIPAA transaction 837–P and/
or CMS Form 1500 (OCN: 0938–0999).
We do not anticipate any new forms and
no modifications to the existing
transaction or form. We also do not
anticipate changes to the 837–P or CMS
Form 1500 for CY 2011.
Based on our experience with the
PVRP, we continue to estimate that the
time needed to perform all the steps
necessary to report each measure (that
is, reporting the relevant quality data
code(s) for a measure) on claims ranges
from 15 seconds (0.25 minutes) to over
12 minutes for complicated cases and/
or measures, with the median time
being 1.75 minutes. At an average labor
cost of $58 per hour per practice, the
cost associated with this burden ranges
from $0.24 in labor to about $11.60 in
labor time for more complicated cases
and/or measures, with the cost for the
median practice being $1.69.
The total estimated annual burden for
this requirement will also vary along
with the volume of claims on which
quality data is reported. In previous
years, when we required reporting on 80
percent of eligible cases for claimsbased reporting, we found that on
average, the median number of reporting
instances for each of the PQRI measures
was 9. Since we propose to reduce the
required reporting rate by over one-third
to 50 percent, then for purposes of this
burden analysis we will assume that an
EP will need to report each selected
measure for 6 reporting instances. The
actual number of cases on which an
eligible professional would be required
to report quality measures data will
vary, however, with the EP’s patient
population and the types of measures on
which the EP chooses to report (each
measure’s specifications includes a
required reporting frequency).
Based on the assumptions discussed
above, we estimate the total annual
reporting burden per EP associated with
claims-based reporting to range from 4.5
minutes (0.25 minutes per measure × 3
measures × 6 cases per measure) to 180
minutes (12 minutes per measure × 3
measures × 6 cases per measure), with
the burden to the median practice being
31.5 minutes (1.75 minutes per measure
× 3 measures × 6 cases). We estimate the
total annual reporting cost per EP
associated with claims-based reporting
to range from $4.32 ($0.24 per measure
× 3 measures × 6 cases per measure) to
$208.80 ($11.60 per measure × 3
measures × 6 cases per measure), with
the cost to the median practice being
$30.42 per EP ($1.69 per measure × 3
measures × 6 cases per measure).
For registry-based reporting, there
would be no additional time burden for
EP to report data to a registry as EP
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
opting for registry-based reporting
would more than likely already be
reporting data to the registry for other
purposes. Little, if any, additional data
would need to be reported to the
registry for purposes of participation in
the 2011 PQRI. However, EPs would
need to authorize or instruct the registry
to submit quality measures results and
numerator and denominator data on
quality measures to CMS on their
behalf. We estimate that the time and
effort associated with this would be
approximately 5 minutes per EP.
Registries interested in submitting
quality measures results and numerator
and denominator data on quality
measures to CMS on their participants’
behalf in 2011 would need to complete
a self-nomination process in order to be
considered ‘‘qualified’’ to submit on
behalf of EPs unless the registry was
qualified to submit on behalf of EPs for
prior years and did so successfully. We
estimate that the self-nomination
process for qualifying additional
registries to submit on behalf of EPs for
the 2011 PQRI involves approximately 1
hour per registry to draft the letter of
intent for self-nomination. It is
estimated that each self-nominated
entity will also spend 2 hours for the
interview with CMS officials and 2
hours calculating numerators,
denominators, and measure results for
each measure the registry wishes to
report using a CMS-provided measure
flow. However, the time it takes to
complete the measure flow could vary
depending on the registry’s experience
and the number and type of measures
for which the registry wishes to submit
on behalf of EPs. Additionally, part of
the self-nomination process involves the
completion of an XML submission by
the registry, which is estimated to take
approximately 5 hours, but may vary
depending on the registry’s experience.
We estimate that the registry staff
involved in the registry self-nomination
process have an average labor cost of
$50 per hour. Therefore, assuming the
total burden hours per registry
associated with the registry selfnomination process is 10 hours, we
estimate the total cost to a registry
associated with the registry selfnomination process to be approximately
$500 ($50 per hour × 10 hours per
registry).
The burden associated with the
registry-based reporting requirements of
this voluntary reporting initiative is the
time and effort associated with the
registry calculating quality measure
results from the data submitted to the
registry by its participants and
submitting the quality measures results
and numerator and denominator data on
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
quality measures to CMS on behalf of
their participants. The time needed for
a registry to review the quality measures
and other information, calculate the
measures results, and submit the
measures results and numerator and
denominator data on the quality
measures on their participants behalf is
expected to vary along with the number
of EPs reporting data to the registry and
the number of applicable measures.
However, we believe that registries
already perform many of these activities
for their participants. The number of
measures that the registry intends to
report to CMS and how similar the
registry’s measures are to CMS’ PQRI
measures will determine the time
burden to the registry.
For EHR-based reporting, the EP must
have an IACS account, which we
believe takes less than 1 hour to obtain.
Once an EP has an IACS account, he or
she must extract the necessary clinical
data from his or her EHR, and submit
the necessary data to the CMSdesignated clinical data warehouse.
With respect to our proposal to require
an EP to submit a test file, we believe
that doing so would take less than 1
hour. With respect to submitting the
actual 2011 data file in 2012, we believe
that this would take an EP no more than
2 hours, depending on the number of
patients on which the EP is submitting.
We believe that once the EHR is
programmed by the vendor to allow data
submission to CMS, the burden to the
EP associated with submission of data
on PQRI quality measures should be
minimal. Because this manner of
reporting quality data to CMS was new
to PQRI for 2010 and no EHR data
submissions have taken place yet, it is
difficult to estimate how many EPs will
opt to participate in the PQRI through
the EHR mechanism in CY 2011.
An EHR vendor interested in having
their product(s) be used by EPs to
submit PQRI quality measures data to
CMS were required to complete a selfnomination process in order for the
vendor’s product(s) to be considered
‘‘qualified’’ for 2011. It is difficult to
accurately quantify the burden
associated with the EHR selfnomination process as there is variation
regarding the technical capabilities and
experience among vendors. For
purposes of this burden analysis,
however, we estimate that the time
required for an EHR vendor to complete
the self-nomination process will be
similar to the time required for registries
to self-nominate that is approximately
10 hours at $50 per hour for a total of
$500 per EHR vendor ($50 per hour x
10 hours per EHR vendor).
PO 00000
Frm 00189
Fmt 4701
Sfmt 4702
40227
The burden associated with the EHR
vendor programming its EHR product(s)
to extract the clinical data that the EP
needs to submit to CMS for purposes of
reporting 2010 PQRI quality measures
will be dependent on the EHR vendor’s
familiarity with PQRI, the vendor’s
system capabilities, as well as the
vendor’s programming capabilities.
Some vendors already have these
necessary capabilities and for such
vendors, we estimate the total burden
hours to be 40 hours at a rate of $50 per
hour for a total burden estimate of
$2,000 ($50 per hour x 40 hours per
vendor). However, given the variability
in the capabilities of the vendors, those
vendors with minimal experience
would have a burden of approximately
200 hours at $50 per hour, for a total
estimate of $10,000 per vendor ($50 per
hour x 200 hours per EHR vendor).
With respect to the process for group
practices to be treated as satisfactorily
submitting quality measures data under
the 2011 PQRI discussed in section
VI.F.1. of this proposed rule, group
practices interested in participating in
the 2011 PQRI through one of the
proposed group practice reporting
options would need to complete a selfnomination process similar to the selfnomination process required of
registries and EHR vendors. Therefore,
assuming 2 hours for a group practice to
decide whether to participate as a group
or individually, approximately 2 hours
per group practice to draft the letter of
intent for self-nomination, gather the
requested information, and provide this
requested information, and an
additional 2 hours undergoing the
vetting process with CMS officials, we
estimate a total of 6 hours associated
with the self-nomination process.
Assuming that the group practice staff
involved in the group practice selfnomination process have the same
average practice labor cost as the
average practice labor cost estimates we
used for individual EPs of $58 per hour,
we estimate the total cost to a group
practice associated with the group
practice self-nomination process to be
approximately $348 ($58 per hour x 6
hours per group practice).
The burden associated with the group
practice reporting requirements of this
voluntary reporting initiative is the time
and effort associated with the group
practice submitting the quality measures
data. For practices participating under
the proposed GPRO I process, this
would be the time associated with the
physician group completing the data
collection tool. The information
collection components of this data
collection tool have been reviewed by
OMB and are currently approved under
E:\FR\FM\13JYP2.SGM
13JYP2
40228
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
OMB control number 0938–0941, with
an expiration date of December 31,
2011, for use in the Physician Group
Practice, Medicare Care Management
Performance (MCMP), and EHR
demonstrations. Based on burden
estimates for the PGP demonstration,
which uses the same data submission
methods, we estimate the burden
associated with a physician group
completing the data collection tool
would be approximately 79 hours per
physician group. Based on an average
labor cost of $58 per physician group,
we estimate the cost of data submission
per physician group associated with
participating in the proposed PQRI
GPRO I would be $4,582 ($58 per hour
x 79 hours per group practice).
For group practices participating
under the proposed GPRO II process,
the burden associated with submitting
the PQRI quality measures data would
be the time associated with the group
practice submitting the required data to
CMS via claims or a registry. We would
expect that data submission under
GPRO II would take no more time than
the time it would take an individual EP
to submit via claims or registry. We
believe it would be appropriate to
multiply the appropriate burden
estimates for each reporting mechanism
for individual EPs by the number of EPs
in a group to obtain the burden
estimates for data submission under
GPRO II. For example, based on our
estimate of 15.75 minutes per EP under
claims-based reporting, we would
expect that a 2-person group would
have a burden of 31.50 minutes for
claims-based submission under GPRO
II.
We invite comments on this burden
analysis, including the underlying
assumptions used in developing our
burden estimates.
3. Electronic Prescribing (eRx) Incentive
Program
We believe it is difficult to accurately
estimate how many EPs will opt to
participate in the eRx Incentive Program
in CY 2011. Final participation numbers
from the first year of the eRx Incentive
Program (2009) are not available.
Information from the ‘‘PQRI 2007
Reporting Experience Report,’’ which is
available on the PQRI section of the
CMS Web site at https://
www.cms.hhs.gov/PQRI, however,
indicates that nearly 110,000 unique
TIN/NPI combinations attempted to
submit PQRI quality measures data via
claims for the 2007 PQRI. Therefore, for
purposes of conducting a burden
analysis for the 2011 eRx Incentive
Program, we will assume that as many
EPs who attempted to participate in the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
2007 PQRI will attempt to participate in
the 2011 eRx Incentive Program. As
such, we can estimate that nearly
110,000 unique TIN/NPI combinations
will participate in the 2011 eRx
Incentive Program.
Section VI.F.2 of this proposed rule
discusses the background of the eRx
Incentive Program. Section VI.F.2.b.(2)
of this proposed rule provides
information on how we propose EPs and
group practices can qualify to be
considered a successful electronic
prescriber in 2011 in order to earn an
incentive payment. For 2011, EPs and
group practices may choose whether to
participate and, to the extent they
meet— (1) certain thresholds with
respect to the volume of covered
professional services furnished; and (2)
the criteria to be considered a successful
electronic prescriber described in
section VI.F.2.b.(2) of this proposed
rule, they can qualify to receive an
incentive payment for 2011 and/or
avoid being subject to a penalty that
goes into effect in 2012.
For the 2011 eRx Incentive Program,
as discussed in section VI.F.2. of this
proposed rule, we propose that each EP
would need to report the G-code
indicating that at least one prescription
generated during an encounter was
electronically submitted at least 25
instances during the reporting period.
We expect the ongoing costs associated
with participation in the eRx Incentive
Program to decline based on an EP’s
familiarity with and understanding of
the eRx Incentive Program, experience
with participating in the eRx Incentive
Program, and increased efforts by CMS
and stakeholders to disseminate useful
educational resources and best
practices.
Similar to PQRI, one factor in the
burden to individual EPs would be the
time and effort associated with
individual EPs reviewing the electronic
prescribing measure to determine
whether it is applicable to them,
reviewing the available reporting
options (we propose this measure would
be reportable through claims-based
reporting, registry-based reporting, or
through EHRs) and selecting one,
gathering the required information, and
incorporating reporting of the measure
into their office work flows. Since the
eRx Incentive Program consists of only
1 measure to report, we estimate 2 hours
as the amount of time needed for
individual EPs to prepare for
participation in the eRx Incentive
Program. At an average cost of
approximately $58 per hour per
practice, we estimate the total
preparation costs to individual EPs to be
PO 00000
Frm 00190
Fmt 4701
Sfmt 4702
approximately $116 (2 hours × $58 per
hour).
Another factor that influences the
burden to EPs is how they choose to
report the electronic prescribing
measure. For EPs who choose to do so
via claims, we estimate that the burden
associated with the requirements of this
incentive program is the time and effort
associated with gathering the required
information, selecting the appropriate
quality data codes (QDCs), and
including the appropriate QDCs on the
claims they submit for payment. For
claims-based reporting, the QDCs will
be collected as additional (optional) line
items on the existing HIPAA transaction
837–P and/or CMS Form 1500. We do
not anticipate any new forms and no
modifications to the existing transaction
or form. We also do not anticipate
changes to the 837–P or CMS Form 1500
for CY 201.
Based on the information from the
PVRP described above for the amount of
time it takes a median practice to report
one measure one time on claims (1.75
minutes) and our proposal to require
EPs to report the measure 25 times, we
estimate the burden associated with
claims-based data submission to be
43.75 minutes (1.75 minutes per case ×
1 measure × 25 cases per measure). This
equates to a cost of approximately
$42.29 (1.75 minutes per case × 1
measure × 25 cases per measure × $58
per hour) per individual EP.
Because registry-based reporting of
the electronic prescribing measure to
CMS was added to the eRx Incentive
Program for 2010 and EPs are not
required to indicate to us how they plan
to report the electronic prescribing
measure each year, it is difficult to
accurately estimate how many EPs will
opt to participate in the eRx Incentive
Program through the registry-based
reporting mechanism in CY 2011. We do
not anticipate, however, any additional
burden for EPs to report data to a
registry as EPs opting for registry-based
reporting would more than likely
already be reporting data to the registry
for other purposes. Little, if any,
additional data would need to be
reported to the registry for purposes of
participation in the 2011 eRx Incentive
Program. However, EPs would need to
authorize or instruct the registry to
submit quality measures results and
numerator and denominator data on the
electronic prescribing measure to CMS
on their behalf. We estimate that the
time and effort associated with this
would be approximately 5 minutes for
each EP that wishes to authorize or
instruct the registry to submit quality
measures results and numerator and
denominator data on the electronic
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
prescribing measure to CMS on their
behalf.
Based on our proposal to consider
only registries qualified to submit PQRI
quality measures results and numerator
and denominator data on quality
measures to CMS on their participants’
behalf for the 2010 PQRI to be qualified
to submit results and numerator and
denominator data on the electronic
prescribing measure for the 2010 eRx
Incentive Program, there would be no
need for a registry to undergo a separate
self-nomination process for the eRx
Incentive Program and therefore, no
additional burden associated with the
registry self-nomination process.
There would also be a burden to the
registry associated with the registry
calculating results for the electronic
prescribing measure from the data
submitted to the registry by its
participants and submitting the quality
measures results and numerator and
denominator data on the electronic
prescribing quality measure to CMS on
behalf of their participants. The time
needed for a registry to review the
electronic prescribing measure and
other information, calculate the
measure’s results, and submit the
measure’s results and numerator and
denominator data on the measure on
their participants behalf is expected to
vary along with the number of EPs
reporting data to whom the measure
applies. However, we believe that
registries already perform many of these
activities for their participants. Since
the E–Prescribing Incentive Program
consists of only one measure, we believe
that the burden associated with the
registry reporting the measure’s results
and numerator and denominator to CMS
on behalf of their participants would be
minimal.
For EHR-based reporting, the EP must
extract the necessary clinical data from
his or her EHR and submit the necessary
data to the CMS-designated clinical data
warehouse. Because this manner of
reporting quality data to CMS was first
added to the eRx Incentive Program in
2010 and EPs are not required to
indicate to us how they intend to report
the electronic prescribing measure, it is
difficult to estimate how many EPs will
opt to participate in the eRx Incentive
Program through the EHR-based
reporting mechanism in CY 2011. We
believe that once an EP’s EHR is
programmed by the vendor to allow data
submission to CMS, the burden to the
EP associated with submission of data
on the electronic prescribing measure
should be minimal.
Since we are considering only EHR
products qualified for the 2010 PQRI to
be qualified for the 2011 eRx Incentive
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
Program, there would be no need for
EHR vendors to undergo a separate selfnomination process for the 2011 eRx
Incentive Program and therefore, no
additional burden associated with the
self-nomination process.
There would also be a burden to the
EHR vendor associated with the EHR
vendor programming its EHR product(s)
to extract the clinical data that the EP
needs to submit to CMS for purposes of
reporting the proposed 2011 electronic
prescribing measure. The time needed
for an EHR vendor to review the
measure and other information and
program each qualified EHR product to
enable EPs to submit data on the
measure to the CMS-designated clinical
data warehouse will be dependent on
the EHR vendor’s familiarity with the
electronic prescribing measure, the
vendor’s system capabilities, as well as
the vendor’s programming capabilities.
Since only EHR products qualified for
the 2011 PQRI would be qualified for
the 2011 eRx Incentive Program and the
eRx Incentive Program consists of only
one measure, we believe that any
burden associated with the EHR vendor
to program its product(s) to enable EPs
to submit data on the electronic
prescribing measure to the CMSdesignated clinical data warehouse
would be minimal.
Finally, with respect to the process for
group practices to be treated as
successful electronic prescribers under
the 2011 eRx Incentive Program
discussed in section VI.F.2. of this
proposed rule, we propose that group
practices would have the same options
as individual EPs in terms of the form
and manner for reporting the electronic
prescribing measure (that is, group
practices would have the option of
reporting the measure through claims, a
qualified registry, or a qualified EHR
product). There are only 2 differences
between the proposed requirements for
an individual EP and a group practice:
(1) The fact that a group practice would
have to self-nominate; and(2) the
number of times that a group practice
would be required to report the
electronic prescribing measure.
We do not anticipate any additional
burden associated with the group
practice self-nomination practice since
we propose to limit the group practices
to those selected to participate in the
2011 PQRI GPRO I or PQRI GPRO II.
The practice only would need to
indicate their desire to participate in the
eRx GPRO at the same time they selfnominate for either PQRI GPRO I or
PQRI GPRO II and indicate how they
intend to report the electronic
prescribing measure.
PO 00000
Frm 00191
Fmt 4701
Sfmt 4702
40229
In terms of the burden to group
practices associated with submission of
the electronic prescribing measure, we
believe that this would be similar to the
burden to individual EPs for submitting
the electronic prescribing measure. In
fact, overall, there could be less burden
associated with a practice participating
as a group rather than as individual EPs
because the total number of reporting
instances required by the group could
be less than the total number of
reporting instances that would be
required if each member of the group
separately reported the electronic
prescribing measure. Thus, we believe
that the burden to a group practice
associated with reporting the electronic
prescribing measure could range from
almost no burden (for groups who
choose to do so through a qualified EHR
or registry) to 72.92 hours (1.75 minutes
per measure × 1 measure × 2,500 cases
per measure) for a GPRO I group who
chooses to report the electronic
prescribing measures through claims
submission. Consequently, the total
estimated cost per group practice to
report the electronic prescribing
measure could be as high as $4,225
($1.69 per measure × 1 measure × 2,500
cases per measure).
As with individual EPs, we believe
that group practices that choose to
participate in the 2011 eRx GPRO
through registry-based reporting of the
electronic prescribing measure would
more than likely already be reporting
data to the registry. Little, if any,
additional data would need to be
reported to the registry for purposes of
participation in the 2011 eRx Incentive
Program beyond authorizing or
instructing the registry to submit quality
measures results and numerator and
denominator data on the electronic
prescribing measure to CMS on their
behalf. We estimate that the time and
effort associated with this would be
approximately 5 minutes for each group
practice that wishes to authorize or
instruct the registry to submit quality
measures results and numerator and
denominator data on the electronic
prescribing measure to CMS on their
behalf.
For group practices that choose to
participate in the 2011 eRx Incentive
Program through EHR-based reporting of
the electronic prescribing measure, once
the EHR is programmed by the vendor
to allow data submission to CMS, the
burden to the group practice associated
with submission of data on the
electronic prescribing measure should
be minimal.
We invite comments on this burden
analysis, including the underlying
E:\FR\FM\13JYP2.SGM
13JYP2
40230
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
assumptions used in developing our
burden estimates.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
VIII. Response to Comments
Because of the large number of public
comments we normally receive on
Federal Register documents, we are not
able to acknowledge or respond to them
individually. We will consider all
comments we receive by the date and
time specified in the DATES section of
this preamble, and, when we proceed
with a subsequent document, we will
respond to the comments in the
preamble to that document.
IX. Regulatory Impact Analysis
We have examined the impacts of this
rule as required by Executive Order
12866 on Regulatory Planning and
Review (September 30, 1993), the
Regulatory Flexibility Act (RFA)
(September 19, 1980, Pub. L. 96–354),
section 1102(b) of the Social Security
Act, section 202 of the Unfunded
Mandates Reform Act of 1995 (Pub. L.
104–4), Executive Order 13132 on
Federalism (August 4, 1999), and the
Congressional Review Act (5 U.S.C.
804(2)).
Executive Order 12866 directs
agencies to assess all costs and benefits
of available regulatory alternatives and,
if regulation is necessary, to select
regulatory approaches that maximize
net benefits (including potential
economic, environmental, public health
and safety effects, distributive impacts,
and equity). A regulatory impact
analysis (RIA) must be prepared for
major rules with economically
significant effects ($100 million or more
in any 1 year). We estimate, as
discussed below in this section, that the
PFS provisions included in this
proposed rule will redistribute more
than $100 million in 1 year. Therefore,
we estimate that this rulemaking is
‘‘economically significant’’ as measured
by the $100 million threshold, and
hence also a major rule under the
Congressional Review Act. Accordingly,
we have prepared a Regulatory Impact
Analysis that to the best of our ability
presents the costs and benefits of the
rulemaking.
The RFA requires agencies to analyze
options for regulatory relief of small
businesses, if a rule has a significant
impact on a substantial number of small
entities. For purposes of the RFA, we
estimate that most hospitals and most
other providers are small entities as that
term is used in the RFA (including
small businesses, nonprofit
organizations, and small governmental
jurisdictions). The great majority of
hospitals and most other health care
providers and suppliers are small
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
entities, either by being nonprofit
organizations or by meeting the SBA
definition of a small business (having
revenues of less than $34.5 million in
any 1 year) (for details see the SBA’s
Web site at https://sba.gov/idc/groups/
public/documents/sba_homepage/
serv_sstd_tablepdf.pdf (refer to the
620000 series). Individuals and States
are not included in the definition of a
small entity. The RFA requires that we
analyze regulatory options for small
businesses and other entities. We
prepare a regulatory flexibility analysis
unless we certify that a rule would not
have a significant economic impact on
a substantial number of small entities.
The analysis must include a justification
concerning the reason action is being
taken, the kinds and number of small
entities the rule affects, and an
explanation of any meaningful options
that achieve the objectives with less
significant adverse economic impact on
the small entities.
For purposes of the RFA, physicians,
NPPs, and suppliers including IDTFs
are considered small businesses if they
generate revenues of $10 million or less
based on SBA size standards.
Approximately 95 percent of physicians
are considered to be small entities.
There are over 1 million physicians,
other practitioners, and medical
suppliers that receive Medicare
payment under the PFS.
For purposes of the RFA
approximately 85 percent of suppliers of
durable medical equipment, prosthetics,
orthotics, and supplies (DMEPOS) are
considered small businesses according
to the SBA size standards. Our most
recent claims information includes
47,000 entities billing Medicare for
DMEPOS each year. Total annual
estimated Medicare expenditures for
DMEPOS suppliers are approximately
$10.1 billion in CY 2009, for which $8.1
billion was fee-for-service (FFS) and $2
billion was for managed care.
For purposes of the RFA,
approximately 80 percent of clinical
diagnostic laboratories are considered
small businesses according to the SBA
size standards.
Ambulance providers and suppliers
for purposes of the RFA are also
considered to be small entities.
In addition, most ESRD facilities are
considered small entities for purposes of
the RFA, either based on nonprofit
status or by having revenues of $34.5
million or less in any year. We note that
a considerable number of ESRD
facilities are owned and operated by
large dialysis organizations (LDOs) or
regional chains, which would have total
revenues more than $34.5 million in any
year if revenues from all locations are
PO 00000
Frm 00192
Fmt 4701
Sfmt 4702
combined. However, the claims data we
use to estimate payments for this RFA
and RIA does not identify which
dialysis facilities are parts of an LDO,
regional chain, or other type of
ownership. Each individual dialysis
facility has its own provider number
and bills Medicare using this number.
Therefore, we consider each ESRD
facility to be a small entity for purposes
of the RFA. We consider a substantial
number of entities to be significantly
affected if the proposed rule has an
annual average impact on small entities
of 3 to 5 percent or more. The majority
of ESRD facilities will experience
impacts of approximately 2 percent of
total revenues. There are 954 nonprofit
ESRD facilities with a combined
increase of 2.1 percent in overall
payments relative to current overall
payments. We note that although the
overall effect of the wage index changes
is budget neutral, there are increases
and decreases based on the location of
individual facilities. The analysis and
discussion provided in this section and
elsewhere in this proposed rule
complies with the RFA requirements.
Because we acknowledge that many of
the affected entities are small entities,
the analysis discussed throughout the
preamble of this proposed rule
constitutes our regulatory flexibility
analysis for the remaining provisions
and addresses comments received on
these issues.
In addition, section 1102(b) of the Act
requires us to prepare a regulatory
impact analysis, if a rule may have a
significant impact on the operations of
a substantial number of small rural
hospitals. Any such regulatory impact
analysis must conform to the provisions
of section 603 of the RFA. For purposes
of section 1102(b) of the Act, we define
a small rural hospital as a hospital that
is located outside of a metropolitan
statistical area and has fewer than 100
beds. We do not believe this proposed
rule has impact on significant
operations of a substantial number of
small rural hospitals because most
dialysis facilities are freestanding.
While there are 184 rural hospital-based
dialysis facilities, we do not know how
many of them are based at hospitals
with fewer than 100 beds. However,
overall, the 184 rural hospital-based
dialysis facilities will experience an
estimated 2.1 percent increase in
payments. As a result, this rule will not
have a significant impact on small rural
hospitals. Therefore, the Secretary has
determined that this proposed rule will
not have a significant impact on the
operations of a substantial number of
small rural hospitals.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Section 202 of the Unfunded
Mandates Reform Act of 1995 (UMRA)
also requires that agencies assess
anticipated costs and benefits before
issuing any rule whose mandates
require spending in any 1 year of $100
million in 1995 dollars, updated
annually for inflation. In 2010, that
threshold is approximately $135
million. This proposed rule will not
mandate any requirements for State,
local, or tribal governments in the
aggregate, or by the private sector, of
$135 million. Medicare beneficiaries are
considered to be part of the private
sector and as a result a more detailed
discussion is presented on the Impact of
Beneficiaries in section IX.G. of this
regulatory impact analysis.
Executive Order 13132 establishes
certain requirements that an agency
must meet when it promulgates a
proposed rule (and subsequent final
rule) that imposes substantial direct
requirement costs on State and local
governments, preempts State law, or
otherwise has Federalism implications.
We have examined this proposed rule in
accordance with Executive Order 13132
and have determined that this
regulation would not have any
substantial direct effect on State or local
governments, preempt States, or
otherwise have a Federalism
implication.
We have prepared the following
analysis, which together with the
information provided in the rest of this
preamble, meets all assessment
requirements. The analysis explains the
rationale for and purposes of this
proposed rule; details the costs and
benefits of the rule; analyzes
alternatives; and presents the measures
we will use to minimize the burden on
small entities. As indicated elsewhere in
this rule, we are implementing a variety
of changes to our regulations, payments,
or payment policies to ensure that our
payment systems reflect changes in
medical practice and the relative value
of services. We provide information for
each of the policy changes in the
relevant sections of this proposed rule.
We are unaware of any relevant Federal
rules that duplicate, overlap, or conflict
with this proposed rule. The relevant
sections of this rule contain a
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
description of significant alternatives if
applicable.
A. RVU Impacts
1. Resource-Based Work, PE, and
Malpractice RVUs
Section 1848(c)(2)(B)(ii) of the Act
requires that increases or decreases in
RVUs may not cause the amount of
expenditures for the year to differ by
more than $20 million from what
expenditures would have been in the
absence of these changes. If this
threshold is exceeded, we make
adjustments to preserve budget
neutrality.
Our estimates of changes in Medicare
revenues for PFS services compare
payment rates for CY 2010 with
proposed payment rates for CY 2011
using CY 2009 Medicare utilization for
all years. To the extent that there are
year-to-year changes in the volume and
mix of services provided by physicians,
the actual impact on total Medicare
revenues will be different than those
shown in Table 73. The payment
impacts reflect averages for each
specialty based on Medicare utilization.
The payment impact for an individual
physician would be different from the
average, based on the mix of services the
physician furnishes. The average change
in total revenues would be less than the
impact displayed here because
physicians furnish services to both
Medicare and non-Medicare patients
and specialties may receive substantial
Medicare revenues for services that are
not paid under the PFS. For instance,
independent laboratories receive
approximately 85 percent of their
Medicare revenues from clinical
laboratory services that are not paid
under the PFS.
Table 73 shows only the payment
impact on PFS services. We note that
these impacts do not include the effect
of the current law ¥6.1 percent CY
2011 PFS update. The following is an
explanation of the information
represented in Table 73:
• Column A (Specialty): The
Medicare specialty code as reflected in
our physician/supplier enrollment files.
• Column B (Allowed Charges): The
aggregate estimated PFS allowed
charges for the specialty based on CY
2009 utilization and CY 2010 rates. That
PO 00000
Frm 00193
Fmt 4701
Sfmt 4702
40231
is, allowed charges are the PFS amounts
for covered services and include
coinsurance and deductibles (which are
the financial responsibility of the
beneficiary). These amounts have been
summed across all services furnished by
physicians, practitioners, or suppliers
within a specialty to arrive at the total
allowed charges for the specialty.
• Column C (Impact of Work and
Malpractice (MP) RVU Changes): This
column shows the estimated CY 2011
impact on total allowed charges of the
changes in the work and malpractice
RVUs.
• Column D (Impact of PE RVU and
Multiple Procedure Payment Reduction
Changes—Full): This column shows the
estimated CY 2011 impact on total
allowed charges of the changes in the PE
RVUs if there were no remaining
transition to the full use of the new PPIS
data. This column also includes the
impact of the various MPPR and
imaging equipment utilization policies.
• Column E (Impact of PE RVU and
MPPR Changes—Tran): This column
shows the estimated CY 2011 impact on
total allowed charges of the changes in
the PE RVUs under the second year of
the 4-year transition to the full use of
the new PPIS data. This column also
includes the impact of the various
MPPR and imaging equipment
utilization policies.
• Column F (Impact of MEI Rebasing):
This column shows the estimated CY
2011 impact on total allowed charges of
the proposed CY 2011 rescaling of the
RVUs so that the proportions of total
payments based on the work, PE, and
malpractice RVUs match the
proportions proposed in the rebased CY
2006 MEI.
• Column G (Combined Impact—
Full): This column shows the estimated
CY 2011 combined impact on total
allowed charges of all the changes in the
previous columns if there were no
remaining transition to the new PE
RVUs using the PPIS data.
• Column H (Combined Impact—
Tran): This column shows the estimated
CY 2011 combined impact on total
allowed charges of all the changes in the
previous columns under the second year
of the 4-year transition to the new PE
RVUs using the PPIS data.
E:\FR\FM\13JYP2.SGM
13JYP2
40232
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 73—CY 2011 PFS PROPOSED RULE TOTAL ALLOWED CHARGE ESTIMATED IMPACT FOR RVU, MPPR, AND MEI
REBASING CHANGES*
Allowed
charges
(mil)
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
(A)
TOTAL ......................................................
01—ALLERGY/IMMUNOLOGY ...............
02—ANESTHESIOLOGY ........................
03—CARDIAC SURGERY ......................
04—CARDIOLOGY ..................................
05—COLON AND RECTAL SURGERY ..
06—CRITICAL CARE ..............................
07—DERMATOLOGY ..............................
08—EMERGENCY MEDICINE ................
09—ENDOCRINOLOGY ..........................
10—FAMILY PRACTICE .........................
11—GASTROENTEROLOGY .................
12—GENERAL PRACTICE .....................
13—GENERAL SURGERY .....................
14—GERIATRICS ....................................
15—HAND SURGERY ............................
16—HEMATOLOGY/ONCOLOGY ..........
17—INFECTIOUS DISEASE ...................
18—INTERNAL MEDICINE .....................
19—INTERVENTIONAL PAIN MGMT .....
20—INTERVENTIONAL RADIOLOGY ....
21—MULTISPECIALTY CLINIC/OTHER
22—NEPHROLOGY ................................
23—NEUROLOGY ...................................
24—NEUROSURGERY ...........................
25—NUCLEAR MEDICINE ......................
27—OBSTETRICS/GYNECOLOGY ........
28—OPHTHALMOLOGY .........................
29—ORTHOPEDIC SURGERY ...............
30—OTOLARNGOLOGY .........................
31—PATHOLOGY ...................................
32—PEDIATRICS ....................................
33—PHYSICAL MEDICINE .....................
34—PLASTIC SURGERY ........................
35—PSYCHIATRY ...................................
36—PULMONARY DISEASE ..................
37—RADIATION ONCOLOGY ................
38—RADIOLOGY ....................................
39—RHEUMATOLOGY ...........................
40—THORACIC SURGERY ....................
41—UROLOGY ........................................
42—VASCULAR SURGERY ...................
43—AUDIOLOGIST .................................
44—CHIROPRACTOR ............................
45—CLINICAL PSYCHOLOGIST ............
46—CLINICAL SOCIAL WORKER ..........
47—DIAGNOSTIC TESTING FACILITY
48—INDEPENDENT LABORATORY ......
49—NURSE ANES/ANES ASST .............
50—NURSE PRACTITIONER .................
51—OPTOMETRY ...................................
52—ORAL/MAXILLOFACIAL SURGERY
53—PHYSICAL/OCCUPATIONAL
THERA .................................................
54—PHYSICIAN ASSISTANT .................
55—PODIATRY .......................................
56—PORTABLE X-RAY SUPPLIER .......
57—RADIATION THERAPY CENTERS
OTHER .....................................................
Impact of
work and
MP RVU
changes
(B)
Specialty
(C)
Impact of PE RVU and
MPPR changes
Full
Tran
Impact of
MEI rebasing
(D)
(E)
(F)
20:23 Jul 12, 2010
Jkt 220001
Full
Tran
(G)
(H)
$79,731
$176
$1,729
$373
$6,801
$134
$233
$2,678
$2,527
$382
$5,351
$1,752
$704
$2,221
$182
$100
$1,870
$567
$10,381
$379
$222
$44
$1,891
$1,415
$622
$57
$649
$5,154
$3,339
$915
$1,040
$65
$868
$306
$1,105
$1,736
$1,889
$4,975
$496
$388
$1,909
$702
$52
$732
$557
$376
$851
$1,009
$706
$1,175
$937
$38
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
3%
¥1%
¥5%
4%
2%
1%
1%
3%
3%
2%
2%
3%
5%
3%
¥5%
4%
3%
4%
¥9%
¥5%
0%
4%
2%
¥7%
1%
7%
2%
3%
¥1%
2%
4%
4%
1%
2%
¥5%
¥12%
0%
¥1%
¥6%
¥2%
¥7%
3%
¥6%
¥5%
¥26%
¥6%
2%
4%
7%
3%
0%
0%
1%
0%
¥2%
1%
1%
1%
1%
1%
1%
1%
1%
1%
2%
1%
¥2%
2%
1%
2%
¥4%
¥4%
0%
1%
1%
¥4%
0%
3%
1%
1%
0%
1%
1%
2%
1%
1%
¥2%
¥6%
0%
0%
¥2%
¥1%
¥2%
1%
¥2%
¥2%
¥13%
¥2%
2%
1%
3%
2%
0%
4%
¥3%
0%
0%
0%
¥2%
2%
¥3%
¥1%
0%
¥1%
0%
0%
¥2%
2%
1%
¥2%
¥1%
1%
0%
1%
¥1%
0%
1%
1%
1%
1%
1%
1%
¥1%
0%
¥1%
1%
¥3%
¥1%
4%
0%
1%
0%
1%
2%
1%
¥2%
¥5%
¥5%
6%
4%
¥3%
¥1%
1%
2%
0%
4%
0%
¥1%
¥5%
4%
0%
3%
¥2%
2%
3%
1%
2%
3%
3%
5%
¥4%
2%
2%
5%
¥9%
¥4%
¥1%
4%
3%
¥6%
2%
8%
3%
4%
¥2%
2%
3%
5%
¥2%
1%
¥1%
¥12%
1%
¥1%
¥5%
0%
¥6%
1%
¥11%
¥10%
¥20%
¥2%
¥1%
3%
8%
5%
0%
4%
¥2%
0%
¥2%
1%
¥1%
3%
¥2%
0%
1%
0%
1%
1%
0%
3%
¥1%
0%
0%
3%
¥4%
¥3%
¥1%
1%
2%
¥3%
1%
4%
2%
2%
¥1%
1%
0%
3%
¥2%
0%
2%
¥6%
1%
0%
¥1%
1%
¥1%
¥1%
¥7%
¥7%
¥7%
2%
¥1%
0%
4%
4%
$2,138
$868
$1,738
$91
$69
$67
0%
0%
0%
0%
0%
0%
¥7%
3%
4%
3%
¥9%
2%
¥11%
1%
2%
2%
¥3%
1%
¥1%
0%
1%
6%
8%
¥1%
¥8%
3%
5%
9%
¥1%
2%
¥12%
1%
3%
8%
5%
2%
* Does not include the impact of the current law ¥6.1 percent CY 2011 update.
VerDate Mar<15>2010
Combined impact
PO 00000
Frm 00194
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40233
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
2. CY 2011 PFS Impact Discussion
a. Changes in RVUs
The most widespread specialty
impacts of the RVU changes are
generally related to two factors. First, as
discussed in section II.A.2. of this
proposed rule, we are currently
implementing the second year of the 4year transition to new PE RVUs using
the new PPIS data that were adopted in
the CY 2010 PFS final rule with
comment period (74 FR 61751). The
impacts of using the new PPIS data are
generally consistent with the impacts
discussed in the CY 2010 PFS final rule
with comment period (74 FR 61983
through 61984).
The second general factor
contributing to the CY 2011 impacts
shown in Table 73 is the proposed CY
2011 rescaling of the RVUs so that in the
aggregate they match the proposed
work, PE, and malpractice proportions
in the rebased CY 2006 MEI. That is, as
discussed in section II.E.1. of this
proposed rule, the proposed rebased
MEI has a greater proportion attributable
to malpractice and PE and,
correspondingly, a lesser proportion
attributable to work. Specialties that
have a high proportion of total RVUs
attributable to work, such as
anesthesiology, are estimated to
experience a decrease in aggregate
payments as a result of this rescaling,
while specialties that have a high
proportion attributable to PE, such as
radiation oncology, are estimated to
experience an increase in aggregate
payments. Malpractice generally
represents a small proportion of total
payments and the rescaling of the
malpractice RVUs is not the primary
driver of the specialty impacts. As
discussed in section II.E.1. of this
proposed rule, the proposed rescaling of
the RVUs to match the proposed rebased
MEI is budget neutral overall.
proposed rule, while the discussions of
the provisions of section 3135 of the
ACA are found in sections V.M. and
II.A.3.a. of this proposed rule. As
required by sections 1848(c)(2)(B)(v)(V)
and (VI) of the Act (as added by sections
3135(a) and (b) of the ACA), these
changes are not budget neutral and
result in program savings. See section
IX.D below for a discussion of the
budget impacts of the ACA provisions.
We note that the payment impact for
an individual physician may be
different from the average, based on the
mix of services the physician furnishes.
Table 73 also includes the impacts
resulting from our proposed regulatory
change to apply the current 50 percent
MPPR policy to therapy services. Under
the PFS, we estimate that this change
would primarily reduce payments to the
specialties of physical therapy and
occupational therapy. In order to
maintain budget neutrality, we are
proposing to redistribute the PFS
savings back into other services paid
under the PFS by increasing all PE
RVUs by approximately 1 percent.
Because providers in settings outside
of the PFS, such as outpatient hospital
departments, are also paid using the
PFS payment rates and policies for
physical therapy services, we estimate
that this proposal would reduce (not
redistribute) payments in those settings
for therapy services by approximately
13 percent in CY 2011.
In addition, Table 73 includes the
impacts resulting from the proposed
regulatory change to the scope of the
current contiguous body area MPPR
policy for imaging services from
contiguous body areas to include
noncontiguous body areas. We estimate
that this change would primarily reduce
payments to the specialties of IDTF and
radiology. In order to maintain budget
neutrality, we are proposing to
redistribute these savings back into
other services paid under the PFS by
increasing all PE RVUs by
approximately 0.1 percent.
Table 73 also reflects the impacts
resulting from certain ACA provisions,
including section 3135 that amends
section 1848(b)(4) of the Act to reduce
the payment for expensive diagnostic
imaging equipment, and, effective July
1, 2010, increases the level of the MPPR
for contiguous body areas from 25
percent to 50 percent. The proposed
expansion of the MPPR policy is further
discussed in section II.C.4. of this
b. Combined Impact
Column H of Table 73 displays the
estimated CY 2011 combined impact on
total allowed charges by specialty of all
the proposed RVU and MPPR changes.
These impacts range from an increase of
8 percent for portable x-ray suppliers, to
a decrease of 12 percent for physical/
occupational therapy. There is generally
a slightly positive net effect of our
proposals on primary care specialties,
such as family practice, internal
medicine, and geriatrics. Again, these
impacts are estimated prior to the
application of the negative CY 2011 CF
update specified under the current
statute.
Table 74 shows the estimated impact
on total payments for selected highvolume procedures of all of the changes
discussed previously, including the
effect of the CY 2011 negative PFS CF
update. We selected these procedures
because they are the most commonly
furnished by a broad spectrum of
physician specialties. There are separate
columns that show the change in the
facility rates and the nonfacility rates.
For an explanation of facility and
nonfacility PE, we refer readers to
Addendum A of this proposed rule.
TABLE 74.—IMPACT OF PROPOSED RULE AND ESTIMATED PHYSICIAN UPDATE ON CY 2011 PAYMENT FOR SELECTED
PROCEDURES
Facility
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
CPT 1HCPCS
Code
11721
17000
27130
27244
27447
33533
35301
43239
66821
66984
67210
71010
71010
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
...........
VerDate Mar<15>2010
MOD
CT 2010 2
............
............
............
............
............
............
............
............
............
............
............
............
26
Nonfacility
Short descriptor
Debride nail, 6 or more ..........
Destruct premalg lesion .........
Total hip arthroplasty .............
Treat thigh fracture ................
Total knee arthroplasty ..........
CABG, arterial, single ............
Rechanneling of artery ...........
Upper GI endoscopy, biopsy
After cataract laser surgery ...
Cataract surg w/iol, 1 stage ...
Treatment of retinal lesion .....
Chest x-ray .............................
Chest x-ray .............................
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00195
$20.72
40.88
1,084.09
918.31
1,159.32
1,536.01
869.49
133.42
216.59
549.57
479.17
NA
7.10
Fmt 4701
CY 2011 3
$18.41
39.04
1,005.16
854.90
1,074.64
1,374.42
783.95
122.76
210.41
524.43
457.89
NA
6.38
Sfmt 4702
Percent
change
¥11
¥4
¥7
¥7
¥7
¥11
¥10
¥8
¥3
¥5
¥4
NA
¥10
E:\FR\FM\13JYP2.SGM
CY 2010 2
$31.23
57.91
NA
NA
NA
NA
NA
256.05
228.80
NA
494.21
18.17
7.10
13JYP2
CY 2011 3
$29.71
55.98
NA
NA
NA
NA
NA
243.80
222.69
NA
473.12
16.94
6.38
Percent
change
¥5
¥3
NA
NA
NA
NA
NA
¥5
¥3
NA
¥4
¥7
¥10
40234
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
TABLE 74.—IMPACT OF PROPOSED RULE AND ESTIMATED PHYSICIAN UPDATE ON CY 2011 PAYMENT FOR SELECTED
PROCEDURES—Continued
Facility
CPT 1HCPCS
Code
MOD
77056 ...........
77056 ...........
77057 ...........
77057 ...........
77427 ...........
88305 ...........
90801 ...........
90862 ...........
90935 ...........
92012 ...........
92014 ...........
92980 ...........
93000 ...........
93010 ...........
93015 ...........
93307 ...........
93510 ...........
98941 ...........
99203 ...........
99213 ...........
99214 ...........
99222 ...........
99223 ...........
99231 ...........
99232 ...........
99233 ...........
99236 ...........
99239 ...........
99283 ...........
99284 ...........
99291 ...........
99292 ...........
99348 ...........
99350 ...........
G0008 ..........
............
26
............
26
............
26
............
............
............
............
............
............
............
............
............
26
26
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
............
Nonfacility
Short descriptor
CT 2010 2
Mammogram, both breasts ....
Mammogram, both breasts ....
Mammogram, screening ........
Mammogram, screening ........
Radiation tx management, ×5
Tissue exam by pathologist ...
Psy dx interview .....................
Medication management ........
Hemodialysis, one evaluation
Eye exam established pat .....
Eye exam & treatment ...........
Insert intracoronary stent .......
Electrocardiogram, complete
Electrocardiogram report .......
Cardiovascular stress test .....
Echo exam of heart ...............
Left heart catheterization .......
Chiropractic manipulation ......
Office/outpatient visit, new .....
Office/outpatient visit, est .......
Office/outpatient visit, est .......
Initial hospital care .................
Initial hospital care .................
Subsequent hospital care ......
Subsequent hospital care ......
Subsequent hospital care ......
Observ/hosp same date .........
Hospital discharge day ..........
Emergency dept visit .............
Emergency dept visit .............
Critical care, first hour ............
Critical care, add’l 30 min ......
Home visit, est patient ...........
Home visit, est patient ...........
Admin influenza virus vac ......
NA
34.63
NA
27.82
153.00
28.67
100.21
35.77
53.08
38.32
58.48
689.80
NA
7.10
NA
38.32
198.71
24.13
57.34
38.04
58.48
101.62
149.60
29.81
53.93
77.50
166.06
77.78
48.26
91.41
170.04
85.16
NA
NA
NA
CY 2011 3
Percent
change
NA
30.69
NA
24.80
141.17
26.03
88.14
32.16
48.37
36.09
55.00
608.64
NA
6.38
NA
34.13
174.81
21.85
52.79
35.11
53.77
93.54
137.25
27.25
49.35
70.96
151.73
71.94
43.21
81.76
153.94
77.09
NA
NA
NA
CY 2010 2
NA
¥11
NA
¥11
¥8
¥9
¥12
¥10
¥9
¥6
¥6
¥12
NA
¥10
NA
¥11
¥12
¥9
¥8
¥8
¥8
¥8
¥8
¥9
¥9
¥8
¥9
¥8
¥10
¥11
¥9
¥9
NA
NA
NA
82.61
34.63
61.60
27.82
153.00
28.67
120.93
44.28
NA
58.48
85.44
NA
15.61
7.10
72.67
38.32
198.71
27.25
76.93
51.38
76.93
NA
NA
NA
NA
NA
NA
NA
NA
NA
203.25
91.97
63.59
130.58
16.75
CY 2011 3
78.08
30.69
57.45
24.80
141.17
26.03
109.75
41.00
NA
56.96
82.74
NA
14.24
6.38
66.29
34.13
174.81
25.29
72.67
48.86
72.43
NA
NA
NA
NA
NA
NA
NA
NA
NA
187.33
83.97
58.19
120.30
16.45
Percent
change
¥5
¥11
¥7
¥11
¥8
¥9
¥9
¥7
NA
¥3
¥3
NA
¥9
¥10
¥9
¥11
¥12
¥7
¥6
¥5
¥6
NA
NA
NA
NA
NA
NA
NA
NA
NA
¥8
¥9
¥8
¥8
¥2
1 CPT
codes and descriptions are copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
based upon corrected CY 2010 conversion factor of $28.3868 under the statute as of October 30, 2009 that would be in effect on
December 31, 2010 under current law.
3 Payments based upon the projected CY 2011 conversion factor of $26.6574 adjusted by the proposed MEI rescaling factor of 0.921.
2 Payments
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
B. Geographic Practice Cost Indices
(GPCIs)
As discussed in section II.D. of this
proposed rule, we are required to
update the GPCI values at least every 3
years and phase in the adjustment over
2 years (if there has not been an
adjustment in the past year). For CY
2011, we are proposing new GPCIs for
each Medicare locality. The updated
GPCIs reflect the first year of the 2-year
phase in. The new GPCIs rely upon the
2010 HUD data for determining the
relative cost differences in the office
rent component of the PE GPCIs, as well
as the 2006 through 2007 professional
malpractice premium data for
determining the malpractice GPCIs. The
2006 through 2008 Bureau of Labor and
Statistics (BLS) Occupational
Employment Statistics (OES) data were
used as a replacement for 2000 Census
data for determining the physician work
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
GPCIs and the employee compensation
component of the PE GPCIs. As
discussed in section II.D. of this
proposed rule, the cost share weights for
each GPCI value, that is, work, PE, and
malpractice, reflect the same
proportions determined for the
proposed 2006-based MEI.
Additionally, the proposed GPCIs
reflect several provisions required by
the ACA. Section 1848(e)(1)(H) of the
Act (as added by section 3102(b) of the
ACA) specifies that for CY 2010 and CY
2011, the employee wage and rent
portions of the PE GPCIs reflect only
one-half of the relative cost differences
for each locality compared to the
national average and includes a ‘‘hold
harmless’’ provision for any PFS locality
that would receive a reduction to its PE
GPCI resulting from the limited
recognition of cost differences. Section
1848(e)(1)(E) of the Act (as amended by
section 3102(a) of the ACA) extends the
PO 00000
Frm 00196
Fmt 4701
Sfmt 4702
1.000 work GPCI floor only through
December 31, 2010. Therefore, the
proposed CY 2011 GPCIs reflect the
sunset of the 1.000 work GPCI floor.
Section 1848(e)(1)(G) of the Act (as
amended by section 134(b) of the
MIPPA) established a permanent 1.500
work GPCI floor in Alaska, beginning
January 1, 2009 and, therefore, the 1.500
work GPCI floor in Alaska will remain
in place for CY 2011. Moreover, section
1848(e)(1)(I) of the Act (as added by
section 10324(c) of the ACA) establishes
a 1.000 PE GPCI floor for services
furnished in frontier states effective
January 1, 2011. OACT estimates the
combined impact of these provisions on
a fiscal year cash basis as $580 million
for FY 2011.
As required by the statute, the
updated GPCIs would be phased in over
a 2-year period. Addendum D to this
proposed rule shows the estimated
effects of the revised GPCIs on locality
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
GAFs for the transitional year (CY 2011)
in descending order. The GAFs reflect
the use of updated underlying GPCI
data, updated cost share weights, and
the ACA provisions. The GAFs are a
weighted composite of each area’s work,
PE, and malpractice GPCIs using the
national GPCI cost share weights. While
we do not actually use the GAFs in
computing the PFS payment for a
specific service, they are useful in
comparing the estimated overall costs
and payments for different localities.
The actual effect on payment for any
specific service would deviate from the
estimated payment based on the GAF to
the extent that the proportions of work,
PE, and malpractice expense RVUs for
the specific service differ from those of
the GAF. The most significant changes
would occur in 12 payment localities,
where the GAF increases by more than
1 percent or decreases by more than 2
percent. The cumulative effects of all of
the GPCI revisions, including the
updated underlying GPCI data, updated
cost share weights, and provisions of the
ACA, are reflected in the CY 2012 GPCI
values that are displayed in Addendum
E to this proposed rule.
C. Rebasing and Revising of the MEI
As discussed in section II.E.1. of this
proposed rule, we are proposing to
rebase and revise the MEI for the CY
2011 PFS. Substituting the proposed
2006 MEI weights in place of the 2000
weights and implementing the proposed
revisions to the MEI has no impact on
the projected MEI increase for CY 2011.
The projected MEI update for CY 2011
is 0.3 percent under both the 2000-based
and 2006-based MEI. After CY 2011, the
MEI updates are slightly higher (0.1
percentage point) in the early part of the
forecast, unchanged in the medium
term, and slightly lower in the long term
(between 0.1 to 0.2 percentage points).
D. The Affordable Care Act Provisions
1. Section 3103: Extension of Exceptions
Process for Medicare Therapy Caps
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
This provision extends the exceptions
process for therapy caps through
December 31, 2010. Therapy caps are
discussed in detail in section III.A.1. of
this proposed rule. OACT estimates the
impact on a fiscal year cash basis as
$1.16 billion for FY 2011.
2. Section 3104: Extension of Payment
for Technical Component of Certain
Physician Pathology Services
As discussed in section V.E. of this
proposed rule, this provision continues
payment to independent laboratories for
the TC of physician pathology services
for fee-for-service Medicare
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
beneficiaries who are inpatients or
outpatients of a covered hospital
through CY 2010. OACT estimates the
impact on a fiscal year cash basis as $80
million for FY 2011.
3. Sections 3105 and 10311: Extension
of Ambulance Add-Ons
As discussed in section V.F. of this
proposed rule, these provisions require
the extension of certain add-on
payments for ground ambulance
services, and the extension of certain
rural area designations for purposes of
air ambulance payment. As further
discussed in section V.F., we are
amending the Medicare program
regulations to conform the regulations to
these provisions of the ACA. These
statutory provisions are essentially
prescriptive and do not allow for
discretionary alternatives on the part of
the Secretary.
As discussed in the July 1, 2004
interim final rule (69 FR 40288), in
determining the super-rural bonus
amount under section 1834(l)(12) of Act,
we followed the statutory guidance of
using the data from the Comptroller
General (GAO) of the U.S. We obtained
the same data as the data that were used
in the GAO’s September 2003 Report
titled ‘‘Ambulance Services: Medicare
Payments Can Be Better Targeted to
Trips in Less Densely Populated Rural
Areas’’ (GAO report number GAO–03–
986) and used the same general
methodology in a regression analysis as
was used in that report. The result was
that the average cost per trip in the
lowest quartile of rural county
populations was 22.6 percent higher
than the average cost per trip in the
highest quartile. As required by section
1834(l)(12) of the Act, this percent
increase is applied to the base rate for
ground ambulance transports that
originate in qualified rural areas, which
were identified using the methodology
set forth in the statute. Payments for
ambulance services under Medicare are
determined by the point of pick-up (by
zip code area) where the beneficiary is
loaded on board the ambulance. We
determined that ground ambulance
transports originating in 7,842 zip code
areas (which were determined to be in
‘‘qualified rural areas’’) out of 42,879 zip
code areas, according to the July 2010
zip code file, will realize increased base
rate payments under this provision;
however, the number and level of
services that might occur in these areas
for CY 2011 is unknown at this time.
While many elements may factor into
the final impact of sections 3105(a), (b),
and (c) and 10311(a), (b), and (c) of the
ACA, our Office of the Actuary (OACT)
estimates the impact of all these
PO 00000
Frm 00197
Fmt 4701
Sfmt 4702
40235
provisions to be $10 million for FY
2011.
4. Section 3107: Extension of Physician
Fee Schedule Mental Health Add-On
As discussed in section V.G. of this
proposed rule, this provision extends
the period of time for the five percent
increase in Medicare payment for
specified mental health services through
CY 2010. OACT estimates the impact on
a fiscal year cash basis as $20 million
for FY 2011.
5. Section 3111: Payment for Bone
Density Tests
As discussed in section V.I. of this
proposed rule, this provision restores
payment for dual-energy x-ray
absorptiometry (DXA) services
furnished during CYs 2010 and 2011 to
70 percent of the Medicare rate paid in
CY 2006. OACT estimates the impact on
a fiscal year cash basis as $60 million
for FY 2011.
6. Section 3122: Extension of Medicare
Reasonable Costs Payments for Certain
Clinical Diagnostic Laboratory Tests
Furnished to Hospital Patients in
Certain Rural Areas
As discussed in section V.K. of this
proposed rule, this provision
reinstitutes reasonable cost payment for
clinical diagnostic laboratory tests
performed by hospitals with fewer than
50 beds that are located in qualified
rural areas as part of their outpatient
services for cost reporting periods
beginning on or after July 1, 2010
through June 30, 2011. For some
hospitals with cost reports that begin as
late as June 30, 2011, this reinstitution
of reasonable cost payment could affect
services performed as late as June 29,
2012, because this is the date those cost
reports will close.
7. Section 3135: Modification of
Equipment Utilization Factor For
Advanced Imaging Services
As discussed in section V.M. of this
proposed rule, for services furnished on
or after July 1, 2010, section
1848(b)(4)(D) of the Act (as added by
section 3135(b) of the ACA) adjusts the
technical component MPPR for multiple
imaging studies provided in a single
imaging session on contiguous body
parts within families of codes from 25
percent to 50 percent as of July 1, 2010.
For services furnished on or after
January 1, 2011, section 1848(b)(4)(C) of
the Act (as added by section 3135(a) of
the ACA) increases the equipment
utilization rate to 75 percent for
expensive diagnostic imaging
equipment, changing the CY 2011
transitional utilization rate adopted in
E:\FR\FM\13JYP2.SGM
13JYP2
40236
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
the CY 2010 PFS final rule with
comment period to the 75 percent rate.
Both of these provisions are not budget
neutral. OACT estimates the impact on
a fiscal year cash basis to be savings to
the Medicare program of $160 million
for FY 2011.
8. Section 3136: Revisions in Payments
for Power Wheelchairs
As discussed in section V.N. of this
proposed rule, this provision requires
the Secretary to revise the capped rental
fee schedule amounts for all power
wheelchairs effective for power
wheelchairs furnished on or after
January 1, 2011. Under the monthly
capped rental payment structure, the fee
schedule will pay 15 percent (instead of
10 percent) of the purchase price for the
first three months and 6 percent (instead
of 7.5 percent) for the remaining rental
months not to exceed 13 months. In
addition, the lump sum (up front)
purchase payment will be eliminated for
standard power-driven wheelchairs. For
complex rehabilitative power-driven
wheelchairs, the provision permits
payment to be made on a lump sum
purchase method or a monthly rental
method. These changes are prescriptive
in the statute and does not allow for
discretionary alternatives.
We expect the changes mandated by
section 3136 of the ACA as a whole to
achieve program savings as a result of
total payments per standard power
wheelchair being less than 100 percent
of the purchase fee schedule amount.
This decrease in expenditures is
expected for two reasons. Primarily, the
provision will eliminate the lump sum
payment method for standard powerdriven wheelchairs and instead
payment will be made under the
monthly rental method resulting in
lower aggregate payments because many
beneficiaries who use standard power
wheelchairs do not use them for as long
as 13 months. In addition, we note that
currently a significantly lower volume
of power-driven wheelchairs are paid
under the monthly payment method.
The payment impact of increasing
monthly rental payments in the initial 3
months will be offset both by the
savings achieved from eliminating the
lump sum payment method for standard
power-driven wheelchairs and by
decreasing payments for the remaining
months of rental from 7.5 percent to 6
percent of the purchase price for all
power-driven wheelchairs. We
compared the estimates of current
payments for power-driven wheelchairs
to estimates of payments resulting from
the changes which showed an estimated
payment impact of a decrease in
expenditures of approximately $780
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
million over a 5-year period. The FY
2011 cash savings was $120 million.
9. Section 3401: Revisions of Certain
Market Basket Updates and
Incorporation of Productivity
Adjustments
As discussed in section V.P. of this
proposed rule, section 3401 of the ACA
incorporates a productivity adjustment
into the update factors for certain
payment systems. Specifically, section
3401 requires that in CY 2011 (and in
subsequent years), update factors under
the ambulatory surgical center payment
system, the ambulance fee schedule,
and the clinical laboratory fee schedule
be adjusted by the productivity
adjustment. OACT estimates the impact
to be savings to the Medicare program
of $20 million, $30 million, and $50
million for the ambulatory surgical
center payment system, the ambulance
fee schedule, and the clinical laboratory
fee schedule, respectively, for FY 2011.
Furthermore section 3401 changed the
2011 ESRD composite rate Market
Basket minus one increase to a Market
Basket increase. This provision would
be a cost to the Medicare program of $40
million (does not include coinsurance).
10. Section 4103: Medicare Coverage of
Annual Wellness Visit Providing a
Personalized Prevention Plan
As discussed in section V.Q. of this
proposed rule, for services furnished on
or after January 1, 2011, section
1861(s)(2)(FF) of the Act (as added by
section 4103 of the ACA) provides
Medicare coverage, with no coinsurance
or deductible, for an annual wellness
visit. The annual wellness visit entails
the creation of a personalized
prevention plan for an individual that
includes a health risk assessment and
may include other elements, such as
updating the family history, identifying
providers that regularly provide medical
care to the individual, body mass index
measurement, development of a
screening service schedule, and
identification of risk factors. OACT
estimates the impact on a fiscal year
cash basis to be $110 million for FY
2011.
11. Section 4104: Removal of Barriers to
Preventive Services in Medicare
As discussed in section V.R. of this
proposed rule, for services furnished on
or after January 1, 2011, sections
1833(a)(1) and 1833(b) of the Act (as
amended by section 4104 of the ACA)
waive the deductible and coinsurance
requirements for most preventive
services, and waive the deductible for
colorectal cancer screening tests that are
reported with other codes. Services to
PO 00000
Frm 00198
Fmt 4701
Sfmt 4702
which no coinsurance or deductible
would be applied are the annual
wellness visit, the initial preventive
physical examination, and any covered
preventive service if it is recommended
with a grade of A or B by the United
States Preventive Services Task Force.
We estimate that this new benefit will
result in an increase in Medicare
payments. OACT estimates the impact
on a fiscal year cash basis to be $110
million for FY 2011.
12. Section 5501: Expanding Access to
Primary Care Services and General
Surgery Services
As discussed in section V.S. of this
proposed rule, for services furnished on
or after January 1, 2011 and before
January 1, 2016, sections 1833(x) and (y)
of the Act (as added by section 5501 of
the ACA) provide primary care
practitioners, as well as general
surgeons practicing in geographic health
professional shortage areas, with 10
percent incentive payments based on
their provision of primary care or major
surgical services, respectively. OACT
estimates the impact on a fiscal year
cash basis to be $170 million for FY
2011.
13. Section 6003: Disclosure
Requirements for In-office Ancillary
Services Exception to the Prohibition of
Physician Self-Referral for Certain
Imaging Services
In section V.T of the preamble of this
proposed rule, we propose to amend
§ 411.355(b)(2) to include a new
disclosure requirement created by
section 6003 of the ACA and related to
the in-office ancillary services exception
to the physician self-referral
prohibition. Specifically, the statute
requires that, with respect to magnetic
resonance imaging, computed
tomography, and positron emission
tomography, the referring physician
must inform the patient in writing at the
time of the referral that the patient may
obtain the same imaging services from
another supplier. In addition, the statute
requires physicians to provide a written
list of other suppliers who furnish the
same imaging services in the area in
which the patient resides.
We propose that the written notice
shall include a list of at least 10 other
suppliers who provide the services for
which the individual is being referred
and which are located within a 25-mile
radius of the referring physician’s office
location. If there are fewer than 10 other
suppliers located within a 25-mile
radius of the physician’s office location,
the physician shall list all of the other
suppliers of the imaging service that are
present within a 25-mile radius of the
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
referring physician’s office location,
including up to 10 suppliers. Provision
of the written list of alternate suppliers
will not be required if no other
suppliers provide the services for which
the individual is being referred within
a 25-mile radius. We also propose that
the notice should be written in a
manner sufficient to be reasonably
understood by all patients and should
include for each supplier on the list, at
a minimum, the supplier’s name,
address, telephone number, and
distance from the referring physician’s
office location. A record of the
disclosure notification, signed by the
patient, shall be maintained as a part of
the patient’s medical record.
Our proposal minimizes the
administrative burden for the physician
by requiring the development of only
one list of alternative suppliers for each
office location, rather than multiple lists
targeting the various areas in which the
physician’s patients reside.
We do not anticipate that our
proposals in section V.T. of the
preamble of this proposed rule would
have a significant economic impact on
a substantial number of physicians,
other health care providers and
suppliers, or the Medicare or Medicaid
programs and their beneficiaries.
Specifically, we believe that this
proposed rule would affect only those
physicians who provide MRI, CT, PET
services under the in-office ancillary
services exception and beneficiaries
receiving those services. We are
uncertain of the number of physicians
who will have to comply with this
disclosure requirement. Using data from
the 2009 CMS Statistics booklet, we
propose an estimate of 71,000 Medicare
enrolled physicians would have to
comply with this new requirement. This
figure represents 20 percent of primary
care and medical specialty physicians
enrolled in Medicare Part B. In order to
ensure accuracy of the effect of this
provision on physician practices, we are
soliciting comments regarding the
appropriateness of this estimate. The
burden associated with disclosing the
information, receiving the patient’s
signature on the form and maintaining
a record of such disclosure will be de
minimis for the individual physician.
Our proposed criteria for the new
disclosure requirement would present a
negligible economic impact on the
physician or group practice required to
create the disclosure notice. The
physician or group practice would incur
only a one-time cost associated with
developing a disclosure notice that
informs patients that they may receive
the same imaging services from another
supplier and also lists other suppliers
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
located within a 25-mile radius of the
physician’s office location at the time of
the referral. We believe it would take an
individual 1 hour to create the notice
informing patients that they may receive
imaging services from another supplier
as well as to compile the list of 10 other
suppliers. In addition, we believe it
would require a negligible amount of
time to provide the notice and list of
suppliers to the patient and to maintain
a copy of the notice in the patient’s
medical record.
We believe that beneficiaries would
be impacted positively by this new
provision. The disclosure that the
patient may receive the referred imaging
services from another supplier
contributes to informed decisionmaking about the availability of such
imaging services from other suppliers.
We also believe that furnishing a list of
other suppliers who provide the same
services in the vicinity of the referring
physician serves patient convenience.
The proposed regulation makes no
significant changes that would impede
patient access to health care services,
and it will likely improve patients’
awareness of options in deciding where
to receive imaging services.
14. Section 6404: Maximum Period for
Submission of Medicare Claims
Reduced to Not More Than 12 Months
As discussed in section V.U. of this
proposed rule, section 6404 of the ACA
reduces the maximum time period for
filing Medicare claims to no more than
12 months after the date of service.
Under the new law, claims for services
furnished on or after January 1, 2010,
must be filed within 1 calendar year
after the date of service. In addition,
section 6404 of the ACA provides that
claims for services furnished before
January 1, 2010, must be filed no later
than December 31, 2010.
Section 6404 of the ACA also permits
the Secretary to make certain exceptions
to the 1-year filing deadline. This
proposed rule would create two new
exceptions to the 1-year filing deadline.
The first exception would permit the
time limits for filing claims to be
extended where a beneficiary becomes
retroactively entitled to Medicare
benefits, but was not entitled to
Medicare benefits at the time the
services were furnished. Under this
exception, the time to file a claim would
be extended through the last day of the
sixth month following the month in
which the beneficiary received
notification of the retroactive Medicare
entitlement to the date of the furnished
service.
The second exception would permit
the time limits for filing claims to be
PO 00000
Frm 00199
Fmt 4701
Sfmt 4702
40237
extended where: (1) At the time the
service was furnished, the beneficiary
was not entitled to Medicare; (2)
subsequently, the beneficiary received
notification of Medicare entitlement,
retroactively effective to the date of the
furnished service; and (3) subsequently
the State Medicaid agency recovered the
Medicaid payment for the furnished
service from a provider or supplier 11
months or more after date the service
was furnished. Under this exception,
the time to file a claim would be
extended through the last day of the
sixth month following the month in
which the State recovered the Medicaid
payment from the provider or supplier.
The budgetary impact related to this
provision is significant as future
payment of claims for services incurred
will now be made at an earlier date,
relative to the 12-month submission
expiration. This is reflected by the Part
A and Part B payment amounts of $60
and $50 million for FY 2011. However,
for purposes of the Regulatory Impact
Analysis, the economic impact of this
provision is non-economically
significant, as to the interest lost on
money now required to pay claims prior
to the 12-month submission expiration
is minimal.
Providers and suppliers have
established billing practices for the
submission of claims for payment to the
Medicare program. Although this
proposed rule would require providers
and suppliers to submit Medicare feefor-service claims within 12 months
from the date of service, we believe
providers and suppliers would easily
revise their billing practices on a onetime basis, and suffer no economic
impact. In fact, analysis of Medicare
claims data shows that more than 99
percent of Part A and Part B claims are
filed in 12 months or less. In addition,
some providers and suppliers will
receive payment and interest on claims
that are filed at an earlier date.
Lastly, providers, suppliers, or the
small number of beneficiaries that
occasionally submit claims may benefit
from the availability of the two
proposed new exceptions to the timely
filing rule; however, we believe the
impact on program costs would be
negligible.
E. Other Provisions of the Proposed
Regulation
1. Part B Drug Payment: ASP Issues
Application of our proposed policies
for ‘‘Carry Over ASP’’ and ‘‘Partial
Quarter ASP Data,’’ as discussed in
section VI.A. of this proposed rule, are
dependent on the status and quality of
quarterly manufacturer data
E:\FR\FM\13JYP2.SGM
13JYP2
40238
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
submissions, so we cannot quantify
associated savings.
Furthermore, we do not expect that
our proposed policy for determining the
payment amount for drugs and
biologicals which include intentional
overfill, as discussed in section VI.A of
this proposed rule, will impact
payments made by the Medicare
program.
Finally, as discussed in section VI.A
of this proposed rule, we are proposing
to provide for appropriate price
substitutions that account for marketrelated pricing changes and would
allow Medicare to pay based off lower
market prices for those drugs and
biologicals that consistently exceed the
applicable threshold percentage. We
believe that this proposal will generate
some savings for the Medicare program
and its beneficiaries since any
substituted prices would be for amounts
less than the calculated 106 percent of
the ASP.
2. Ambulance Fee Schedule: Proposed
Policy for Reporting Units When Billing
for Ambulance Fractional Mileage
As discussed in section VI.B. of this
proposed rule, we are proposing to
implement fractional mileage billing for
all providers and suppliers of
ambulance services. For all claims for
mileage totaling up to 100 covered
miles, we are proposing to require all
providers and suppliers of ambulance
services to bill mileage rounded up to
the nearest tenth of a mile rather than
the nearest whole mile and are
proposing to pay based on that amount.
By requiring that providers and
suppliers round up to the nearest tenth
of a mile rather than the nearest whole
mile, providers and suppliers would be
submitting claims for anywhere between
0.1 and 0.9 of a mile less per claim and
Medicare would pay based on that
amount. We anticipate that requiring
greater accuracy in billing for
ambulance mileage will generate modest
cost savings for the Medicare program.
Based on our rough estimates using CY
2008 claims data, Medicare could
potentially save at least $45 million per
year in payments for base mileage billed
by suppliers, and perhaps as much as
$80 million per year when considering
other types of ambulance mileage
payments such as those for rural
mileage and those made to institutional
providers.
3. Chiropractic Services Demonstration
As discussed in section VI.D. of this
proposed rule, we are continuing the
recoupment of the $50 million in
expenditures from this demonstration in
order to satisfy the budget neutrality
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
requirement in section 651(f)(1)(b) of the
MMA. We initiated this recoupment in
CY 2010 and this will be the second
year. As discussed in the CY 2010 PFS
final rule with comment period, we
finalized a policy to recoup $10 million
each year through adjustments to the
PFS for all chiropractors in CYs 2010
through 2014. To implement this
required budget neutrality adjustment,
we are recouping $10 million in CY
2011 by reducing the payment amount
under the PFS for the chiropractic CPT
codes (that is, CPT codes 98940, 98941,
and 98942) by approximately 2 percent.
4. Renal Dialysis Services Furnished by
ESRD Facilities
The ESRD related provisions are
discussed in sections V.P. and VI.E. of
this proposed rule. To understand the
impact of the changes affecting
payments to different categories of
ESRD facilities, it is necessary to
compare estimated payments under the
current year (CY 2010 payments) to
estimated payments under the revisions
to the composite rate payment system
(CY 2011 payments) as discussed in
section VI.E. of this proposed rule. To
estimate the impact among various
classes of ESRD facilities, it is
imperative that the estimates of current
payments and estimates of proposed
payments contain similar inputs.
Therefore, we simulated payments only
for those ESRD facilities for which we
are able to calculate both current CY
2010 payments and proposed CY 2011
payments.
Also, as explained in the ESRD PPS
proposed rule (74 FR 50019), section
1881(b)(14)(E)(i) of the Act requires a 4year transition (phase-in) from the
current composite payment system to
the ESRD PPS, and section
1881(b)(14)(E)(ii) allows ESRD facilities
to make a one-time election to be
excluded from the transition. As of
January 1, 2011, ESRD facilities that
elect to go through the transition would
be paid a blended amount that will
consist of 75 percent of the basic casemix adjusted composite payment system
and the remaining 25 percent would be
based on the ESRD PPS payment.
Therefore, these proposed rates listed in
the impact table below reflect only the
composite rate portion of the blended
payment amounts for facilities going
through the first year of the 4-year
transition under the new ESRD PPS. A
full analysis of the projected impact of
the ESRD PPS will be addressed in the
ESRD PPS final rule which will be
published in the summer.
ESRD providers were grouped into the
categories based on characteristics
provided in the Online Survey and
PO 00000
Frm 00200
Fmt 4701
Sfmt 4702
Certification and Reporting (OSCAR)
file and the most recent cost report data
from the Healthcare Cost Report
Information System (HCRIS). We also
used the December 2009 update of CY
2009 National Claims History file as a
basis for Medicare dialysis treatments
and separately billable drugs and
biologicals. Since the December 2009
update of the CY 2009 National Claims
History File is incomplete, we updated
the data. The description of the updates
for the separately billable drugs is
described in section IV.E. of this
proposed rule. To update the treatment
counts we used the ratio of the June
2009 to the December 2008 updates of
the CY 2008 National Claims History
File figure for treatments. This was an
increase of 12.4 percent. Due to data
limitations, we are unable to estimate
current and proposed payments for 32
of the 5318 ESRD facilities that bill for
ESRD dialysis treatments.
Table 75 shows the impact of this
year’s proposed changes to CY 2011
payments to hospital-based and
independent ESRD facilities. The first
column of Table 75 identifies the type
of ESRD provider, the second column
indicates the number of ESRD facilities
for each type, and the third column
indicates the number of dialysis
treatments. The fourth column shows
the effect of all proposed changes to the
ESRD wage index for CY 2011 as it
affects the composite rate payments to
ESRD facilities. The fourth column
compares aggregate ESRD wage-adjusted
composite rate payments in CY 2011 to
aggregate ESRD wage-adjusted
composite rate payments in CY 2010. In
CY 2010, ESRD facilities receive 100
percent of the CBSA wage-adjusted
composite rate. The overall effect to all
ESRD providers in aggregate is zero
because the CY 2011 ESRD wage index
has been multiplied by a budget
neutrality adjustment factor to comply
with the statutory requirement that any
wage index revisions be done in a
manner that results in the same
aggregate amount of expenditures as
would have been made without any
changes in the wage index. The fifth
column shows the effect of proposed
changes to the ESRD wage index in CY
2011 and the effect of section 3401(h) of
the ACA, which amends section
1881(b)(14)(F) of the Act to revise the
ESRD market basket increase factor.
Effective January 1, 2011, there is a full
ESRD bundled market basket update to
the composite rate component of the
blended payment amount under the
payment system. We anticipate an
estimated ESRD market basket increase
factor of 2.5 percent for those facilities
E:\FR\FM\13JYP2.SGM
13JYP2
40239
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
electing to go through the ESRD PPS
transition. The sixth column shows the
overall effect of the proposed changes in
composite rate payments to ESRD
providers, including the drug add-on.
The overall effect is measured as the
difference between the proposed CY
2011 payment with all changes as
proposed in this rule and current CY
2010 payment. This payment amount is
computed by multiplying the wageadjusted composite rate with the drug
add-on for each provider times the
number of dialysis treatments from the
CY 2009 claims. The CY 2011 proposed
payment is the composite rate for each
provider (with the proposed 14.7
percent drug add on) times dialysis
treatments from CY 2009 claims. The
CY 2010 current payment is the
composite rate for each provider (with
the current 15.0 percent drug add on)
times dialysis treatments from CY 2009
claims.
The overall impact to ESRD providers
in aggregate is 2.2 percent as shown in
Table 75. Most ESRD facilities will see
an increase in payments as a result of
the ACA provision. While section
3401(h) of the ACA modifies the ESRD
bundled market basket, which we
anticipate will be a 2.5 percent increase
to the ESRD composite rate portion of
the blended payment amount, this 2.5
percent increase does not apply to the
drug add-on to the composite rate. For
this reason, the impact of all changes in
this proposed rule is a 2.2 percent
increase for all ESRD providers. Overall,
payments to independent ESRD
facilities will increase by 2.2 percent
and payments to hospital-based ESRD
facilities will increase by 2.1 percent.
TABLE 75—IMPACT OF CY 2012 CHANGES IN PAYMENTS TO HOSPITAL-BASED AND INDEPENDENT ESRD FACILITIES
[Percent change in composite rate payments to ESRD facilities]
1
2
3
4
5
6
Number of
facilities
Number of dialysis
treatments
(in millions)
Effect of changes
in wage index 1
Effect of changes
in wage index and
of affordable care
act provision 2
Overall effect of
wage index
affordable care act
& drug add-on 3
5,286
4,715
571
38.8
35.1
3.7
0.0%
0.0%
¥0.1%
2.5%
2.5%
2.4%
2.2%
2.2%
2.1%
1,973
2,042
1,271
5.6
14.8
18.3
0.1%
0.1%
¥0.1%
2.6%
2.6%
2.4%
2.3%
2.3%
2.1%
4,332
954
32.1
6.7
0.0%
¥0.1%
2.5%
2.4%
2.3%
2.1%
1,167
4,119
6.3
32.5
0.2%
0.0%
2.7%
2.5%
2.4%
2.2%
163
591
869
397
1,188
415
712
310
603
38
1.3
4.8
6.0
2.1
8.8
2.9
5.6
1.8
5.1
0.4
¥0.6%
¥0.4%
0.2%
¥0.1%
0.0%
0.0%
0.4%
0.2%
0.0%
¥2.4%
1.9%
2.1%
2.7%
2.4%
2.5%
2.5%
2.9%
2.7%
2.5%
0.0%
1.6%
1.8%
2.4%
2.2%
2.2%
2.3%
2.7%
2.4%
2.3%
¥0.2%
All Providers ...........................................
Independent ....................................
Hospital Based ...............................
By Facility Size
Less than 5000 treatments .............
5000 to 9999 treatments ................
Greater than 9999 treatments ........
Type of Ownership
Profit ...............................................
Nonprofit .........................................
By Geographic Location
Rural ...............................................
Urban ..............................................
By Region
New England ..................................
Middle Atlantic ................................
East North Central ..........................
West North Central .........................
South Atlantic .................................
East South Central .........................
West South Central ........................
Mountain .........................................
Pacific .............................................
Puerto Rico & Virgin Islands ..........
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Notes: Payments have been adjusted to reflect budget neutrality. 2010 includes the MIPPA 1 percent increase and site neutral rates. 2010 &
2011 are 100 percent new CBSA wage adjusted compsite rate.
1 This column shows the overall effect of wage index changes on ESRD providers. Composite rate payments are computed using the proposed CY 2011 wage indexes which are compared to composite rate payments using the current CY 2010 wage indexes.
2 This column shows the effect of the changes in the Wage Indexes and the ACA provision which includes an ESRD Bundled Market Basket
(anticipated 2.5 percent) increase to the composite rate. This provision is effective January 1, 2011.
3 This column shows the percent change between CY 2011 and CY 2010 composite rate payments to ESRD facilities.
4 The CY 2011 payments include the CY 2011 wage adjusted composite rate, an anticipated 2.5 percent increase due to the ACA effective
January 1, 2011, and the drug add-on of 14.7 percent. The CY 2010 payments include the CY 2010 wage adjusted composite rate, a 1 percent
increase and site neutral rates effective January 1, 2009, and the drug add-on of 15.0 percent. This column shows the effect of wage index,
ACA, and drug add-on changes. Although as a result of the ACA provision we anticipate a 2.5 percent increase to the composite rate in CY
2011, this increase does not apply to the drug add-on to the composite rate. For this reason, the impact of all changes in this proposed rule is a
2.2 percent increase for all ESRD providers.
5. Section 131(b) of the MIPPA:
Physician Payment, Efficiency, and
Quality Improvements—Physician
Quality Reporting Initiative (PQRI)
As discussed in section VI.F.1 of this
proposed rule, we propose several
different reporting options for EPs who
wish to participate in the 2011 PQRI.
Although there may be some cost
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
incurred in the PQRI and their
associated code sets, and for expanding
an existing clinical data warehouse to
accommodate registry-based reporting
and EHR-based reporting for the PQRI,
we do not anticipate a significant cost
impact on the Medicare program.
Participation in the CY 2011 PQRI by
individual EPs is voluntary and
PO 00000
Frm 00201
Fmt 4701
Sfmt 4702
individual EPs and group practices may
have different processes for integrating
the PQRI into their practice’s work
flows. Given this variability and the
multiple reporting options that we
propose to provide, it is difficult to
accurately estimate the impact of the
PQRI on providers. Furthermore, we
believe that costs for EPs who are
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40240
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
participating in the PQRI for the first
time in 2011 will be considerably higher
than the cost for EPs who participated
in PQRI in prior years. In addition, for
many EPs, the cost of participating in
the PQRI is offset by the incentive
payment received.
With respect to the potential incentive
payment that will be made for the 2011
PQRI, we estimate this amount to be
approximately $100 million. This
estimate is derived from looking at our
2008 incentive payment of more than
$93 million and then accounting for the
fact that the 2008 incentive payment
was 1.5 percent of an EP’s total
estimated Medicare Part B PFS allowed
charges for all covered professional
services furnished during the 2008
reporting period. For 2011, the incentive
payment is 1.0 percent of an EP’s total
estimated Medicare Part B PFS allowed
charges for all covered professional
services furnished during the 2011
reporting period. Although we expect
that the lower incentive payment
amount for 2011 would reduce the total
outlay by approximately one-third, we
also expect more EPs to participate in
the 2011 PQRI as there are more
methods of data submission and
additional alternative reporting periods.
One factor that influences the cost to
individual EPs is the time and effort
associated with individual EPs
identifying applicable PQRI quality
measures and reviewing and selecting a
reporting option. This burden will vary
with each individual EP by the number
of applicable measures, the EP’s
familiarity and understanding of the
PQRI, experience with PQRI
participation, and the method(s)
selected by the EP for reporting of the
measures, and incorporating the
reporting of the measures into the office
work flows. Information obtained from
the Physician Voluntary Reporting
Program (PVRP), which was a
predecessor to the PQRI and was the
first step for the reporting of physician
quality of care through certain quality
metrics, indicated an average labor cost
per practice of approximately $50 per
hour. To account for salary increases
over time, we will use an average
practice labor cost of $58 per hour for
our estimates, based on an assumption
of an average annual increase of
approximately 3 percent. Therefore,
assuming that it takes an individual EP
approximately 5 hours to review the
PQRI quality measures, review the
various reporting options, select the
most appropriate reporting option,
identify the applicable measures for
which they can report the necessary
information, and incorporate reporting
of the selected measures into their office
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
work flows, we estimate that the cost to
EPs associated with preparing to report
PQRI quality measures would be
approximately $290 per individual EP
($58 per hour × 5 hours).
Another factor that influences the cost
to individual EPs is how they choose to
report the PQRI measures (that is,
whether they select the claims-based,
registry-based or EHR-based reporting
mechanism). For claims-based PQRI
reporting, estimates from the PVRP
indicate the time needed to perform all
the steps necessary to report quality
data codes (QDCs) for 1 measure on a
claim ranges from 15 seconds (0.25
minutes) to 12 minutes for complicated
cases or measures. In previous years,
when we required reporting on 80
percent of eligible cases for claimsbased reporting, we found that on
average, the median number of reporting
instances for each of the PQRI measures
was 9. Since we propose to reduce the
required reporting rate by over one-third
to 50 percent, then for purposes of this
impact analysis we will assume that an
EP will need to report each selected
measure for 6 reporting instances, or 6
cases. Assuming that an EP, on average,
will report 3 measures and that an EP
reports on an average of 6 reporting
instances per measure, we estimate that
the cost to an individual EP associated
with claims-based reporting of PQRI
measures would range from
approximately $4.35 (0.25 min per
reporting instance × 6 reporting
instances per measure × 3 measures ×
$58 per hour) to $208.80 (12 min per
reporting instance × 6 reporting
instances per measure × 3 measures ×
$58 per hour). If an EP satisfactorily
reports, these costs will more than likely
be negated by the incentive earned. For
the 2007 PQRI, which had a 1.5 percent
incentive for a 6-month reporting
period, the mean incentive amount was
close to $700 for an individual EP and
the median incentive payment amount
was over $300.
For registry-based reporting,
individual EPs must generally incur a
cost to submit data to registries.
Estimated fees for using a qualified
registry range from no charge, or a
nominal charge, for an individual EP to
use a registry to several thousand
dollars, with a majority of registries
charging fees ranging from $500–$1000.
However, our impact analysis should be
limited to the incremental costs
associated with PQRI reporting, which
we believe are minimal. Many EPs who
select registry-based reporting were
already utilizing the registry for other
purposes and would not need to report
additional data to the registry
specifically for PQRI. The registries also
PO 00000
Frm 00202
Fmt 4701
Sfmt 4702
often provide the EP services above and
beyond what is required for PQRI.
For EHR-based reporting, an
individual EP generally would incur a
cost associated with purchasing an EHR
product. Although we do not believe
that the majority of EPs would purchase
an EHR solely for the purpose of
participating in PQRI, we estimate that
an individual EP who chooses to do so
would have to spend anywhere from
$25,000–$54,000 to purchase and
implement a certified EHR and $10,000
annually for ongoing maintenance.
Although we believe that the majority
of EPs attempting to qualify for the
additional 0.5 percent incentive
payment authorized by section
1848(m)(7) of the Act would be those
who are already required by their
Boards to participate in an MOCP,
individual EPs who wish to qualify for
the additional 0.5 percent incentive
payment and are not currently
participating in an MOCP would also
have to incur a cost for participating in
an MOCP. The manner in which fees are
charged for participating in an MOCP
vary by specialty. Some Boards charge
a single fee for participation in the full
cycle of MOC. Such fees appear to range
anywhere from over $1,100 to nearly
$1,800 per cycle. Some Boards have
annual fees that are paid by their
diplomates. On average, ABMS
diplomates pay approximately $200.00
per year for participating in MOC. Some
Boards have an additional fee for the
MOC Part III secure examination, but
most Boards do not have additional
charges for participation in the Part IV
practice/quality improvement activities.
With respect to the proposed process
for group practices to be treated as
satisfactorily submitting quality
measures data for the CY 2011 PQRI
discussed in section VI.F.1 of this
proposed rule, group practices
interested in participating in the CY
2011 PQRI through the group practice
reporting option (GPRO) I or GPRO II
may also incur a cost. However, for
groups that satisfactorily report for 2011
PQRI, we believe these costs would be
completely offset by the incentive
payment earned since the group practice
would be eligible for an incentive
payment equal to 1 percent of the entire
group’s total estimated Medicare Part B
PFS allowed charges for covered
professional services furnished during
the reporting period.
One factor in the cost to group
practices would be the costs associated
with the self-nomination process.
Similar to our estimates for staff
involved with the claims-based
reporting option for individual EPs, we
also estimate that the group practice
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
staff involved in the group practice selfnomination process has an average labor
cost of $58 per hour. Therefore,
assuming 2 hours for a group practice to
decide whether to participate
individually or as a group and 4 hours
for the self-nomination process, we
estimate the total cost to a group
practice associated with the group
practice self-nomination process to be
approximately $348 ($58 per hour × 6
hours per group practice).
For groups participating under the
proposed GPRO I process, another factor
in the cost to the group would be the
time and effort associated with the
group practice completing and
submitting the proposed data collection
tool. The information collection
components of this data collection tool
have been reviewed by OMB and are
currently approved under OMB control
number 0938–0941, with an expiration
date of December 31, 2011. Based on the
Physician Group Practice (PGP)
demonstration’s estimate that it takes
approximately 79 hours for a group
practice to complete the data collection
tool, which uses the same data
submission methods as those we have
proposed, we estimate the cost
associated with a physician group
completing the data collection tool
would be approximately $4,582 ($58 per
hour × 79 hours per group practice).
For group practices participating
under the proposed GPRO II process,
the costs associated with submitting the
PQRI quality measures data would be
the time associated with the group
practice submitting the required data to
CMS via claims or a registry. The costs
for a group practice reporting to a
registry should be similar to the costs
associated with registry reporting for an
individual EP, as the process is the same
with the exception that more patients
and more measures must be reported in
GPRO II compared to an individual EP.
For similar reasons, the costs for a group
practice reporting via claims should also
be similar to the costs associated with
claims-based reporting for an individual
EP. Overall, there is significantly less
burden associated with a group practice
participating in PQRI via GPRO II than
doing so as individual EPs. Participation
in GPRO II requires the group practice
as a whole to report a fewer number of
measures on a fewer number of people
since EPs within a group who share
patients would not be required to
separately report measures for those
shared patients. Therefore, assuming
that an average group practice would
spend 20 hours for data submission, we
estimate the cost of data submission
under GPRO II would be approximately
$1,160 (20 hours for data submission ×
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
$58 per hour). Smaller groups may need
less time for data submission as they
would be required to report fewer
measures and presumably have a
smaller patient population while larger
groups may need more time for data
submission since they would be
required to report more measures and
presumably have a larger patient
population.
In addition to costs incurred by EPs
and group practices, registries and EHR
vendors may also incur some costs
related to the PQRI. Registries interested
in becoming ‘‘qualified’’ to submit on
behalf of individual EPs would also
have to incur a cost associated with the
vetting process and with calculating
quality measures results from the data
submitted to the registry by its
participants and submitting the quality
measures results and numerator and
denominator data on quality measures
to CMS on behalf of their participants.
We estimate the registry self-nomination
process would cost approximately $500
per registry ($50 per hour × 10 hours per
registry). This cost estimate includes the
cost of submitting the self-nomination
letter to CMS and completing the CMS
vetting process. Our estimate of $50 per
hour average labor cost for registries is
based on the assumption that registry
staff include IT professionals whose
average hourly rates range from $36 to
$84 per hour depending on experience,
with an average rate of nearly $50 per
hour for a mid-level programmer.
However, the 2010 qualified registries
would not incur any costs associated
with the self-nomination process unless
they are unsuccessful at submitting
2010 PQRI results, they wish to be
qualified to submit additional measures
or for additional methods, or we finalize
new requirements for 2011. We do not
believe that there are any additional
costs for registries associated with a
registry calculating quality measures
results from the data submitted to the
registry by its participants and
submitting the quality measures results
and numerator and denominator data on
quality measures to CMS on behalf of
their participants. We believe that the
majority of registries already perform
these functions for their participants.
An EHR vendor interested in having
its product(s) be used by individual EPs
to submit PQRI measures to CMS for
2012 would have to complete a vetting
process during 2011 and program its
EHR product(s) to extract the clinical
data that the EP needs to submit to CMS
for purposes of reporting 2012 quality
measures as well. We propose that
previously qualified vendors would
need to only update their electronic
measure specifications and data
PO 00000
Frm 00203
Fmt 4701
Sfmt 4702
40241
transmission schema to incorporate any
new EHR measures to maintain their
qualification for the 2012 PQRI.
Therefore, for EHR vendors that were
not previously qualified, the cost
associated with completing the selfnomination process, including the
vetting process with CMS officials, is
estimated to be $500 ($50 per hour × 10
hours per EHR vendor). Our estimate of
a $50 per hour average labor cost for
EHR vendors is based on the
assumption that vendor staff include IT
professionals whose average hourly
rates range from $36 to $84 per hour
depending on experience, with an
average rate of nearly $50 per hour for
a mid-level programmer. We believe
that the cost associated with the time
and effort needed for an EHR vendor to
review the quality measures and other
information and program the EHR
product to enable individual EPs to
submit PQRI quality measures data to
the CMS-designated clinical warehouse
will be dependent on the EHR vendor’s
familiarity with PQRI, the vendor’s
system’s capabilities, as well as the
vendor’s programming capabilities.
Some vendors already have the
necessary capabilities and for such
vendors, we estimate the total cost to be
approximately $2,000 ($50 per hour ×
40 hours per vendor). However, given
the variability in the capabilities of the
vendors, we believe an estimate for
those vendors with minimal experience
would be approximately $10,000 per
vendor ($50 per hour × 200 hours per
EHR vendor).
6. Section 132 of the MIPPA: Incentives
for Electronic Prescribing (eRx)—The
eRx Incentive Program
Section VI.F.2. of this proposed rule
describes the proposed 2011 Electronic
Prescribing (eRx) Incentive Program. To
be considered a successful electronic
prescriber in CY 2011, an individual EP
would need to meet the requirements
proposed in section VI.F.2. of this
proposed rule.
We anticipate that the cost impact of
the eRx Incentive Program on the
Medicare program would be the cost
incurred for maintaining the electronic
prescribing measure and its associated
code set, and for maintaining the
existing clinical data warehouse to
accommodate registry-based reporting
and EHR-based reporting for the
electronic prescribing measure.
However, we do not anticipate a
significant cost impact on the Medicare
program since much of this
infrastructure has already been
established for the PQRI program.
Individual EPs and group practices
may have different processes for
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40242
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
integrating the eRx Incentive Program
into their practices’ work flows. Given
this variability and the multiple
reporting options that we propose to
provide, it is difficult to accurately
estimate the impact of the eRx Incentive
Program on providers. Furthermore, we
believe that costs for EPs who are
participating in the eRx Incentive
Program for the first time in 2011 will
be considerably higher than the cost for
EPs who participated in the eRx
Incentive Program in prior years. In
addition, for many EPs (especially those
who participated in the eRx Incentive
Program in prior years), the cost of
participating in the eRx Incentive
Program will be offset by the incentive
payment received.
At this time, no eRx incentive
payments have been made yet. We are
currently analyzing 2009 eRx data,
which was the first year of the program,
and anticipate making the 2009
incentive payments later this year. We
estimate that the incentive payments for
the 2011 eRx Incentive Program (which
will be paid in 2012) will be
approximately $81 million. This
estimate is based on preliminary
participation numbers from the early
part of 2010 and incentive payments
that have been made for PQRI. We
anticipate that despite a decrease in the
incentive payment amount from 2
percent in 2010 to 1 percent of total
estimated Medicare Part B allowed
charges for covered professional
services in 2011, more EPs (and groups)
will choose to participate in the 2011
eRx Incentive Program to avoid a
prospective 1 percent payment penalty
in 2012 for not demonstrating that they
are successful electronic prescribers.
Even though the incentive payment
amount for the 2011 eRx Incentive
Program is equal to the incentive
payment amount for the 2011 PQRI, we
believe that the total incentive amount
that will be paid for the 2011 eRx
Incentive Program will be less than the
total incentive payment amount that
will be paid for the PQRI discussed
above. The eRx Incentive Program does
not apply to all EPs. For example, EPs
who do not have prescribing privileges
or EPs who do not practice in a
particular care setting would not be able
to participate in the eRx Incentive
Program even though they can
participate in PQRI.
Any EP who wishes to participate in
the eRx Incentive Program must have a
qualified electronic prescribing system
in order to participate. Therefore, a onetime potential cost to some individual
EPs would be the cost of purchasing and
using an eRx system, which varies by
the commercial software package
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
selected, the level at which the
professional currently employs
information technology in his or her
practice and the training needed. One
study indicated that a midrange
complete electronic medical record with
electronic prescribing functionality
costs $2,500 per license with an annual
fee of $90 per license for quarterly
updates of the drug database after setup
costs while standalone prescribing,
messaging, and problem list system may
cost $1,200 per physician per year after
setup costs. Hardware costs and setup
fees substantially add to the final cost of
any software package. (Corley, S.T.
(2003). ‘‘Electronic prescribing: a review
of costs and benefits.’’ Topics in Health
Information Management 24(1):29–38.).
These are the estimates that we propose
to use for our impact analysis.
Similar to PQRI, one factor in the cost
to individual EPs is the time and effort
associated with individual EPs
reviewing the electronic prescribing
measure to determine whether it is
applicable to them, reviewing the
available reporting options and selecting
one, gathering the required information,
and incorporating reporting of the
measure into their office work flows.
Since the eRx Incentive Program
consists of only 1 quality measure, we
propose to estimate 2 hours as the
amount of time needed for individual
EPs to prepare for participation in the
eRx Incentive Program. Information
obtained from the Physician Voluntary
Reporting Program (PVRP), which was a
predecessor to the PQRI and was the
first step for the reporting of physician
quality of care through certain quality
metrics, indicated an average labor cost
per practice of approximately $50 per
hour. To account for salary increases
over time, we will use an average
practice labor cost of $58 per hour for
our estimates, based on an assumption
of an average annual increase of
approximately 3 percent. At an average
cost of approximately $58 per hour, we
estimate the total preparation costs to
individual EPs to be approximately
$116 ($58 per hour × 2 hours).
Another factor that influences the cost
to individual EPs is how they choose to
report the electronic prescribing
measure (that is, whether they select the
claims-based, registry-based or EHRbased reporting mechanism). For
claims-based reporting, there would be
a cost associated with reporting the
appropriate QDC on the claims an
individual EP submits for payment.
Based on the information from the PVRP
described above for the amount of time
it takes a median practice to report one
measure one time (1.75 min) and the
proposed requirement to report 25
PO 00000
Frm 00204
Fmt 4701
Sfmt 4702
electronic prescribing events during
2011, we estimate the annual estimated
cost per individual EP to report the
electronic prescribing measure via
claims-submission to be $42.29 (1.75
min per case × 1 measure × 25 cases per
measure × $58 per hour). Assuming that
the mean and median incentive
payment amounts per individual EP
would be comparable to those for the
PQRI since the incentive payments are
calculated in the same manner, we
believe that for most successful
electronic prescribers who earn an
incentive, these costs would be negated
by the incentive payment received.
For EPs who select the registry-based
reporting mechanism, we do not
anticipate any additional cost for
individual EPs to report data to a
registry, as individual EPs opting for
registry-based reporting are more than
likely already reporting data to the
registry. Little if any, additional data
would need to be reported to the
registry for purposes of participation in
the CY 2011 eRx Incentive Program.
Individual EPs using registries for PQRI
will likely experience minimal, if any,
increased costs charged by the registry
to report this 1 additional measure.
For EHR-based reporting, the EP must
extract the necessary clinical data from
his or her EHR, and submit the
necessary data to the CMS-designated
clinical data warehouse. Once the EHR
is programmed by the vendor to allow
data submission to CMS, the cost to the
individual EP associated with the time
and effort to submit data on the
electronic prescribing measure should
be minimal.
With respect to the proposed process
for group practices to be treated as
successful electronic prescribers under
the CY 2011 eRx Incentive Program
discussed in section VI.F.2 of this
proposed rule, group practices have the
same option as individual eligible
professionals in terms of the form and
manner for reporting the eRx measure
(that is, group practices have the option
of reporting the measure through claims,
a qualified registry, or a qualified EHR
product). There are only 2 differences
between the requirements for an
individual EP and a group practice: (1)
The fact that a group practice would
have to self-nominate; and (2) the
number of times a group practice would
be required to report the eRx measure.
Overall, there could be less cost
associated with a practice participating
in the eRx Incentive Program as a group
rather than the individual members of
the group separately participating. We
do not anticipate any additional costs
associated with the group practice selfnomination process since we propose to
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
limit the group practices to those
selected to participate in the 2011 PQRI
GPRO I or PQRI GPRO II. The practices
only would need to indicate their desire
to participate in the eRx GPRO at the
time they self-nominate for either PQRI
GPRO I or PQRI GPRO II.
The costs for a group practice
reporting to an EHR or registry should
be similar to the costs associated with
registry and EHR reporting for an
individual EP, as the process is the same
with the exception that more electronic
prescribing events must be reported by
the group. For similar reasons, the costs
for a group practice reporting via claims
should also be similar to the costs
associated with claims-based reporting
for an individual EP. Therefore, we
estimate that the costs for group
practices who are selected to participate
in the CY 2011 eRx Incentive Program
as a group would range from $126.88
(1.75 min per case × 1 measure × 75
cases per measure × $58 per hour) for
the smallest groups participating under
GPRO II to $4,229.17 (1.75 min per case
× 2500 cases per measure × $58 per
hour) for the groups participating under
GPRO I.
We believe that the costs to individual
EPs and group practices associated with
avoiding the eRx penalty that goes into
effect in 2012 would be similar to the
costs of an EP or group practice
reporting the electronic prescribing
measure for purposes of the 2011 eRx
incentive. The proposed requirements
for avoiding the 2012 eRx penalty,
including the reporting period,
essentially overlaps with the proposed
requirements for the 2011 eRx incentive.
Based on our proposal to consider
only registries qualified to submit
quality measures results and numerator
and denominator data on quality
measures to CMS on their participant’s
behalf for the 2011 PQRI to be qualified
to submit results and numerator and
denominator data on the eRx measure
for the CY 2011 eRx Incentive Program,
we do not anticipate any cost to the
registry associated with becoming a
registry qualified to submit the eRx
measure for CY 2011.
The cost for the registry would be the
time and effort associated with the
registry calculating results for the eRx
measure from the data submitted to the
registry by its participants and
submitting the quality measures results
and numerator and denominator data on
the eRx quality measure to CMS on
behalf of their participants. We believe
such costs would be minimal as
registries would already be required to
perform these activities for PQRI.
Likewise, based on our proposal to
consider only EHR products qualified
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
for the CY 2011 PQRI to be qualified to
submit results and numerator and
denominator data on the electronic
prescribing measure for the CY 2011
eRx Incentive Program, there would be
no need for EHR vendors to undergo a
separate self-nomination process for the
eRx Incentive Program. Therefore, there
would be no additional cost associated
with the self-nomination process.
The cost to the EHR vendor associated
with the EHR-based reporting
requirements of this reporting initiative
is the time and effort associated with the
EHR vendor programming its EHR
product(s) to extract the clinical data
that the individual EP needs to submit
to CMS for purposes of reporting the CY
2011 eRx measure. Since we propose
that only EHR products qualified for the
2011 PQRI would be qualified for the
CY 2011 eRx Incentive Program, and the
eRx Incentive Program consists of only
one measure, we believe that any
burden associated with the EHR vendor
to program its product(s) to enable
individual EPs to submit data on the
eRx measure to the CMS-designated
clinical data warehouse would be
minimal.
7. Durable Medical Equipment-Related
Issues
a. Off-the-Shelf (OTS) Orthotics
Exemption
In section VI.G. of this proposed rule,
we are proposing to expand the
exemptions from the Competitive
Bidding Program (CBP) for certain OTS
orthotics to physicians or other
practitioners (as defined by the
Secretary) if furnished to their own
patients as part of their professional
service.
The proposed exemption is a selfimplementing mandate required by
section 154(d) of MIPPA, which added
section 1847(a)(7) of the Act. Section
1847(a)(7)(A) of the Act expanded the
exemptions from the CBP for certain
OTS orthotics to physicians or other
practitioners (as defined by the
Secretary) if furnished to their own
patients as part of their professional
service. Section 1847(a)(7)(B) of the Act,
as added by section 154(d) of MIPPA,
also expanded the exemption from CBP
for certain OTS DME items (crutches,
canes, walkers, folding manual
wheelchairs, blood glucose monitors,
and infusion pumps) when furnished by
hospitals to the hospital’s own patients
during an admission or on the date of
discharge.
We believe this exemption would
have a negligible impact on physicians
and other providers. The exemption will
allow physicians to continue to provide
PO 00000
Frm 00205
Fmt 4701
Sfmt 4702
40243
these items to their own patients
without submitting a bid and becoming
a contract supplier. This will also allow
continued access to OTS items for
beneficiaries while being seen in their
physician’s office.
b. Changes to Payment for Oxygen
Equipment
The revisions pertaining to oxygen
and oxygen equipment in section VI.G.
of this proposed rule reflect changes
made by section 144(b) of MIPPA and
regulations implementing that
provision. In § 414.226(g), exceptions
are listed to the requirement that the
supplier that furnishes oxygen
equipment in the 1st month of the 36month period must continue to furnish
it until medical necessity ends or the
36-month of continuous use ends.
Section VI.G. changes one exception
(§ 414.226(g)(1)(ii)) to read that if a
beneficiary relocates to an area that is
outside the normal service area of the
supplier before the 18th month, then the
supplier does not have to continue to
furnish the item or make arrangements.
We expect that revising
§ 414.226(g)(1)(ii) so that only suppliers
that have received at least 18 months of
rental payments must continue to
furnish the oxygen equipment until
medical necessity ends or the end of the
reasonable useful lifetime should have a
minor impact on the supplier, but
should provide protection to
beneficiaries. The reason that we expect
the revised exception will have little
impact has foremost to do with the fact
that it applies in cases that are the
exception to the normal circumstances.
Only 38 percent of the beneficiaries are
still renting by the 18th month of the
rental period; only suppliers furnishing
oxygen equipment to this subgroup of
beneficiaries will be affected by this
proposed change. Further, relocation
between the 18th to the 36th month is
not a common occurrence. Such
relocation happens with less than 0.5
percent of the beneficiaries using
oxygen equipment. In addition, between
the 32nd and 35th month, relocation
happens with the beneficiaries in about
0.06 percent of the time on average.
c. Diabetic Testing Supplies
We are establishing requirements for
conducting a national competition for
furnishing diabetic supplies on a mail
order basis. Specifically this proposed
rule will establish 3 requirements: A
new definition for what constitutes mail
order; a rule that requires contract
suppliers to provide at a minimum 50
percent of all of the different types of
diabetic testing products on the market
by brand and model name; and a
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40244
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
prohibition against influencing and
incentivizing beneficiaries to switch
their brand of monitor and testing
suppliers.
Currently based on claims data from
fiscal year 2009 over 62 percent of
beneficiaries receive their replacement
diabetic testing supplies from mail order
suppliers. This definition will not
impact these beneficiaries because they
can continue to obtain their items
through mail order. The remaining 38
percent of beneficiaries may continue to
obtain these items from a local
storefront. We do not expect this rule to
have any adverse affects on beneficiaries
because the new definition of mail order
is reflective of the way that beneficiaries
currently get their testing supplies.
However, we believe that by clarifying
this definition we will protect
beneficiaries from paying higher copayment amounts and we anticipate
program savings that would have been
eroded by suppliers circumventing our
definition to continue to provide items,
even if not awarded a contract under
competitive bidding and to obtain the
higher fee schedule payment amount.
This definition is also consistent with
the way that suppliers currently do
business by either providing items
through mail order or at a local
storefront. For these reasons we believe
this new definition will have minimal
impact.
Also, we considered the option to not
bifurcate bidding based on delivery
method and to bid for diabetic testing
suppliers regardless of how the items
were obtained. We rejected this
approach because it would force
companies with different business
models to compete against each other,
by requiring local pharmacies to
compete with national mail order
suppliers in order to win a contract to
be able to furnish testing supplies.
In order to implement a national mail
order competition for diabetic supplies,
we are also proposing to implement the
special ‘‘50 percent rule’’ mandated by
MIPPA. This rule requires a bidder to
demonstrate that its bid ‘‘covers types of
diabetic testing strip products that, in
the aggregate and taking into account
volume for the different products, cover
50 percent (or such higher percentage as
the Secretary may specify) of all such
types of products.’’ The 50 percent
threshold would ensure that
beneficiaries have access to mail order
delivery of the top-selling diabetic test
strip products from every contract
supplier. We plan to use the information
that bidding suppliers provide on their
bidding Form B where suppliers list the
products they plan to furnish. We
believe this requirement will have a
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
minimal impact on suppliers because
most suppliers currently provide a wide
range of the brands and models in order
to gain market share. The statute states
that suppliers are required to carry at
least 50 percent of all brands on the
market. However, the Secretary can
establish suppliers to carry a higher
percentage of brands. We have adopted
50 percent criteria because we believe
this is reflective of what suppliers are
currently doing and ensures appropriate
access for beneficiaries.
In addition to the 50 percent rule, we
are also proposing to establish an antiswitching requirement. This provision
would prevent contract suppliers from
switching beneficiaries from their
current brand to a brand provided by
the supplier. We believe this
requirement will protect the beneficiary
and physician choice of glucose
monitoring systems. The decision
concerning the type of monitor and
testing supplies that a beneficiary
chooses should not be made by the
supplier but rather by the beneficiary
and their physician. We believe that this
provision will have a minimal impact
on suppliers because suppliers currently
offer a variety of products and generally
do require beneficiaries to switch from
the brands they are familiar with and
customarily use.
d. Metropolitan Statistical Areas
We believe that the provisions
pertaining to subdividing metropolitan
statistical areas (MSAs) with
populations of at least 8,000,000 for the
purpose of establishing competitive
bidding areas (CBAs) under Round 2 of
the DMEPOS Competitive Bidding
Program will have a positive impact on
most suppliers, particularly small
suppliers. The authority provided by
section 1847(a)(1)(D)(ii)(II) of the Act
would be used to create CBAs that are
smaller than the highly and densely
populated MSAs of: Chicago-NapervilleJoliet, IL–IN–WI; Los Angeles-Long
Beach-Santa Ana, CA; and New YorkNorthern New Jersey-Long Island, NY–
NJ–PA. This should result in more
manageable service areas for suppliers
to navigate when furnishing items. More
importantly, it should ensure more
timely delivery of items and services to
beneficiaries located throughout each of
the MSAs. It should also benefit small
suppliers because they would have
smaller geographic areas to cover as
contract suppliers than the large MSAs,
which in some cases, might prevent
them from being considered for
participation under the program. The
larger suppliers would still have the
opportunity to bid in all of the CBAs
within each MSA. We expect that
PO 00000
Frm 00206
Fmt 4701
Sfmt 4702
subdividing the large MSAs of Chicago,
Los Angeles, and New York would not
have a negative impact on program
savings, as long as each CBA is large
enough to be attractive to suppliers for
bidding purposes.
Table 76 considers FY cash impact on
the entire Medicare program, including
Medicare Advantage for FYs 2011 thru
2015 of the provisions of this proposed
rule related to the establishment of
CBAs during Round 2 and prior to
calendar year 2015. The FY–CY
distinction is an important one when
comparing savings. For example, the
savings for the Medicare DMEPOS
Competitive Bidding Program will be for
9 months of FY 2013, but for 12 months
of CY 2013. Table 76 considers the
impact on program expenditures, and
does not include beneficiary
coinsurance. Finally, the estimates in
Table 76 incorporate spillover effects
from the competitive acquisition
program onto the Medicare Advantage
program. The expectation is that the 21
additional MSAs added to the Medicare
DMEPOS Competitive Bidding Program
would lower prices for DME products in
FFS would lead to lower prices in the
Medicare Advantage market. The table
below considers FY cash impact of the
above provisions on the entire Medicare
program, including Medicare Advantage
for the FY.
TABLE 76—FISCAL YEAR COSTS TO
THE MEDICARE PROGRAM
FY
2011
2012
2013
2014
2015
..................................
..................................
..................................
..................................
..................................
Cost
(in $millions)
0
0
¥40
¥70
¥110
Subdividing the large MSAs of Chicago,
Los Angeles, and New York is
considered to have little to no fiscal
impact. The exceptions to the Medicare
DMEPOS Competitive Bidding program
involving rural areas, MSAs with
populations less than 250,000, and low
population density areas in selected
MSAs before 2015 are considered to
have little to no impact because the
baseline never considered these areas as
subject to competitive bidding prices.
8. Air Ambulance
In section VI.G. of this proposed rule,
we present our proposals regarding air
ambulance and provider and supplier
enrollment. We note that this proposal
is an administrative initiative that may
result in Medicare program savings but
at this time those savings are
inestimable. We believe the probable
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
costs providers or suppliers will incur
as a result of this rule to be negligible.
F. Alternatives Considered
This proposed rule contains a range of
policies, including some provisions
related to specific MIPPA and ACA
provisions. The preceding preamble
provides descriptions of the statutory
provisions that are addressed, identifies
those policies when discretion has been
exercised, presents rationale for our
proposals and, where relevant,
alternatives that were considered.
G. Impact on Beneficiaries
There are a number of changes in this
proposed rule that would have an effect
on beneficiaries. In general, we believe
that many of the proposed changes,
including the refinements of the PQRI
with its focus on measuring, submitting,
and analyzing quality data, the
expansion of the list of Medicareapproved telehealth services, the
incentive payments for primary care
services furnished by primary care
practitioners in any location and major
surgical procedures furnished by
general surgeons in HPSAs, the waiver
of beneficiary cost-sharing for most
preventive services, and the annual
wellness visit proposals, will have a
positive impact and improve the quality
and value of care provided to Medicare
beneficiaries.
The regulatory provisions may affect
beneficiary liability in some cases. For
example, the waiver of the deductible
and coinsurance for the annual wellness
visit, the IPPE, and preventive services
with a grade of A or B from the USPSTF
would reduce beneficiary liability for
these services. Most changes in
aggregate beneficiary liability due to a
particular provision would be a function
of the coinsurance (20 percent if
applicable for the particular provision
after the beneficiary has met the
deductible). To illustrate this point, as
shown in Table 74, the CY 2010
national payment amount in the
nonfacility setting for CPT code 99203
(Office/outpatient visit, new) under the
conversion factor that was consistent
with the statute as of October 30, 2009
and that would be in effect on December
31, 2010 under current law, is $76.93
which means that in CY 2010 a
beneficiary would be responsible for 20
percent of this amount, or $15.39. Based
on this proposed rule, the CY 2011
national payment amount in the
nonfacility setting for CPT code 99203,
as shown in Table 74, is $72.67, which
means that, in CY 2011, the beneficiary
coinsurance for this service would be
$14.53.
40245
Additionally, beneficiary liability
would also be impacted by the effect of
the aggregate cost (savings) of the
provisions on the standard calculation
of the Medicare Part B premium rate
(generally 25 percent of the provision’s
cost or savings).
Most policies discussed in this rule
that impact payment rates, such as the
expansion of the MPPR to therapy
services and the increased discount on
the TC of multiple imaging procedures
from 25 percent to 50 percent, would
similarly impact beneficiaries’
coinsurance.
H. Accounting Statement
As required by OMB Circular A–4
(available at https://
www.whitehouse.gov/omb/circulars/
a004/a-4.pdf), in Table 77, we have
prepared an accounting statement
showing the estimated expenditures
associated with this proposed rule. This
estimate includes the estimated FY 2011
cash benefit impact associated with
certain ACA and MIPPA provisions, and
the CY 2011 incurred benefit impact
associated with the estimated CY 2011
PFS conversion factor update based on
the FY 2011 President’s Budget
baseline.
TABLE 77—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED EXPENDITURES
Category
Transfers
CY 2011 Annualized Monetized
Transfers.
From Whom To Whom? .................
FY 2011 Annualized Monetized
Transfers.
From Whom To Whom? .................
Estimated decrease in expenditures of $5.7 billion for PFS conversion factor update.
Federal Government to physicians, other practitioners and providers and suppliers who receive payment
under Medicare.
Estimated increase in expenditures of $2 billion for Affordable Care Act provisions.
Federal Government to providers.
In accordance with the provisions of
Executive Order 12866, this proposed
rule was reviewed by the Office of
Management and Budget.
Medicare, Reporting and recordkeeping
requirements, Rural areas, X-rays.
42 CFR Part 411
List of Subjects
Kidney diseases, Medicare, Physician
Referral, Reporting and record keeping
requirements.
Health facilities, Health professions,
Medicare, Reporting and recordkeeping
requirements.
42 CFR Part 424
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
42 CFR Part 405
Administrative practice and
procedure, Health facilities, Health
professions, Kidney diseases, Medical
devices, Medicare, Reporting and
recordkeeping requirements, Rural
areas, X-rays.
42 CFR Part 409
42 CFR Part 413
Health facilities, Kidney diseases,
Medicare Reporting and recordkeeping
requirements.
42 CFR Part 414
Administrative practice and
procedure, Health facilities, Health
professions, Kidney diseases, Medicare,
Reporting and recordkeeping.
Health facilities, Medicare.
42 CFR Part 410
Health facilities, Health professions,
Kidney diseases, Laboratories,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
42 CFR Part 415
Emergency medical services, Health
facilities, Health professions, Medicare,
Reporting and recordkeeping
requirements.
For the reasons set forth in the
preamble, the Centers for Medicare &
Medicaid Services proposes to amend
42 CFR chapter IV as set forth below:
PART 405—FEDERAL HEALTH
INSURANCE FOR THE AGED AND
DISABLED
1. The authority citation for part 405
continues to read as follows:
Frm 00207
Fmt 4701
Sfmt 4702
E:\FR\FM\13JYP2.SGM
13JYP2
40246
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Authority: Secs. 1102, 1861, 1862(a), 1871,
1874, 1881, and 1886(k) of the Social
Security Act (42 U.S.C. 1302, 1395x,
1395y(a), 1395hh, 1395kk, 1395rr and
1395ww(k)), and sec. 353 of the Public
Health Service Act (42 U.S.C. 263a).
Subpart B—Inpatient Hospital Services
and Inpatient Critical Access Hospital
Services
§ 409.17
[Amended]
Subpart X—Rural Health Clinic and
Federally Qualified Health Center
Services
5. Amend § 409.17(d) by removing the
phrase ‘‘hospital policies and
procedures’’ and adding in its place the
phrase ‘‘the provider’s policies and
procedures.’’
2. A new § 405.2449 is added to read
as follows.
Subpart C—Posthospital SNF Care
§ 405.2449
Preventive services.
For services furnished on or after
January 1, 2011, preventive services
covered under the Medicare Federally
qualified health center benefit are those
preventive services defined in section
1861(ddd)(3) of the Act, and § 410.2 of
this chapter. Specifically, these include
the following:
(a) The specific services currently
listed in section 1861(ww)(2) of the Act,
with the explicit exclusion of
electrocardiograms;
(b) The Initial Preventive Physical
Examination (IPPE) (as specified by
section 1861(ww)(1) of the Act as added
by section 611 of the Medicare
Prescription Drug, Improvement and
Modernization Act of 2003 (Pub. L. 108–
173) and § 410.16 of this chapter); and
(c) The Personalized Prevention Plan
Services (PPPS), also known as the
‘‘Annual Wellness Visit’’ (as specified by
section 1861(hhh) of the Act as added
by section 4103 of the Affordable Care
Act (Pub. L. 111–148) and part 410,
subpart B, § 410.15 of this chapter).
3. Section 405.2470 is amended by
adding a new paragraph (d) to read as
follows:
§ 405.2470
records.
Reports and maintenance of
*
*
*
*
(d) Collection of additional claims
data. Beginning January 1, 2011, a
Medicare FQHC must report on its
Medicare claims such information as the
Secretary determines is needed to
develop and implement a prospective
payment system for FQHCs including,
but not limited to all pertinent HCPCS
(Healthcare Common Procedure Coding
System) code(s) corresponding to the
service(s) provided for each Medicare
FQHC visit (as defined in § 405.2463).
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*
PART 409—HOSPITAL INSURANCE
BENEFITS
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
§ 409.20
Coverage of services.
(a) * * *
(3) Physical therapy, occupational
therapy, and speech-language pathology
services.
*
*
*
*
*
7. Section 409.23 is revised to read as
follows:
§ 409.23 Physical therapy, occupational
therapy, and speech-language pathology
services.
Medicare pays for physical therapy,
occupational therapy, or speechlanguage pathology services as
posthospital SNF care if they are
furnished—
(a) By (or under arrangements made
by) the facility and billed by (or
through) the facility;
(b) By qualified physical therapists,
physical therapist assistants,
occupational therapists, occupational
therapy assistants, or speech-language
pathologists as defined in part 484 of
this chapter; and
(c) In accordance with a plan that
meets the requirements of § 409.17(b)
through (d) of this part.
PART 410—SUPPLEMENTARY
MEDICAL INSURANCE (SMI)
BENEFITS
8. The authority citation for part 410
continues to read as follows:
Authority: Secs. 1102, 1834, 1871, and
1893 of the Social Security Act (42 U.S.C.
1302, 1395m, 1395hh, and 1395ddd).
Subpart A—General Provisions
9. Section 410.2 is amended by
adding the definition of ‘‘Preventive
services’’ in alphabetical order to read as
follows:
§ 410.2
4. The authority citation for part 409
continues to read as follows:
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
6. Section 409.20 is amended by
revising paragraph (a)(3) to read as
follows:
Definitions.
*
*
*
*
*
Preventive services means all of the
following:
(1) The specific services listed in
section 1861(ww)(2) of the Act, with the
explicit exclusion of electrocardiograms;
PO 00000
Frm 00208
Fmt 4701
Sfmt 4702
(2) The Initial Preventive Physical
Examination (IPPE) (as specified by
section 1861(ww)(1) of the Act); and
(3) The Personalized Prevention Plan
Services (PPPS), also known as the
‘‘Annual Wellness Visit’’ (as specified by
section 1861(hhh) of the Act)
§ 410.3
[Amended]
10. Amend § 410.3(b)(2) by removing
the reference ‘‘subpart E’’ and adding in
its place the reference ‘‘subpart I.’’
Subpart B—Medical and Other Health
Services
11. Section 410.15 is added to read as
follows:
§ 410.15 Annual wellness visits providing
Personalized Prevention Plan Services:
Conditions for and limitations on coverage.
(a) Definitions.
Detection of any cognitive
impairment, for the purpose of this
section, means assessment of an
individual’s cognitive function by direct
observation, with due consideration of
information obtained by way of patient
report, concerns raised by family
members, friends, caretakers or others.
Eligible beneficiary for purposes of
this section means an individual who is
no longer within 12 months after the
effective date of his or her first Medicare
Part B coverage period and who has not
received either an initial preventive
physical examination or an annual
wellness visit providing a personalized
prevention plan within the past 12
months.
Establishment of, or an update to the
individual’s medical and family history
for purposes of this section means, at a
minimum, the collection and
documentation of the following:
(i) Past medical and surgical history,
including experiences with illnesses,
hospital stays, operations, allergies,
injuries and treatments.
(ii) Use or exposure to medications
and supplements, including calcium
and vitamins.
(iii) Medical events in the
beneficiary’s parents and any siblings
and children, including diseases that
may be hereditary or place the
individual at increased risk.
First annual wellness visit providing
personalized prevention plan services
for purposes of this section means the
following services furnished an eligible
beneficiary by a health professional as
those terms are defined in this section:
(i) Establishment of an individual’s
medical and family history.
(ii) Establishment of a list of current
providers and suppliers that are
regularly involved in providing medical
care to the individual.
E:\FR\FM\13JYP2.SGM
13JYP2
40247
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(iii) Measurement of an individual’s
height, weight, body-mass index (or
waist circumference, if appropriate),
blood pressure, and other routine
measurements as deemed appropriate,
based on the beneficiary’s medical and
family history.
(iv) Detection of any cognitive
impairment that the individual may
have, as that term is defined in this
section.
(v) Review of the individual’s
potential (risk factors) for depression,
including current or past experiences
with depression or other mood
disorders, based on the use of an
appropriate screening instrument for
persons without a current diagnosis of
depression, which the health
professional may select from various
available standardized screening tests
designed for this purpose and
recognized by national medical
professional organizations.
(vi) Review of the individual’s
functional ability and level of safety,
based on direct observation or the use
of appropriate screening questions or a
screening questionnaire, which the
health professional as defined in this
section may select from various
available screening questions or
standardized questionnaires designed
for this purpose and recognized by
national professional medical
organizations.
(vii) Establishment of the following:
(A) A written screening schedule for
the individual such as a checklist for the
next 5 to 10 years, as appropriate, based
on recommendations of the United
States Preventive Services Task Force
and the Advisory Committee on
Immunization Practices, and the
individual’s health status, screening
history, and age-appropriate preventive
services covered by Medicare.
(B) A list of risk factors and
conditions for which primary,
secondary or tertiary interventions are
recommended or are underway for the
individual, including any mental health
conditions or any such risk factors or
conditions that have been identified
through an initial preventive physical
examination (as described under
§ 410.16 of this subpart), and a list of
treatment options and their associated
risks and benefits.
(viii) Furnishing of personalized
health advice and a referral, as
appropriate, to health education or
preventive counseling services or
programs aimed at reducing identified
risk factors and improving selfmanagement, or community-based
lifestyle interventions to reduce health
risks and promote self-management and
wellness, including weight loss,
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
physical activity, smoking cessation, fall
prevention and nutrition.
(ix) Any other element determined
appropriate through the National
Coverage Determination process.
Health professional for purposes of
this section means:
(i) A physician who is a doctor of
medicine or osteopathy (as defined in
section 1861(r)(1) of the Social Security
Act); or
(ii) A physician assistant, nurse
practitioner, or clinical nurse specialist
(as defined in section 1861(aa)(5) of the
Act; or
(iii) A medical professional (including
a health educator, registered dietitian or
nutritionist) or a team of medical
professionals, who are working under
the supervision of a physician as
defined in paragraph (i) of this
definition.
Review of the individual’s functional
ability and level of safety for purposes
of this section includes, at minimum,
assessment of the following topics:
(i) Hearing impairment,
(ii) Ability to successfully perform
activities of daily living,
(iii) Fall risk and
(iv) Home safety.
Subsequent annual wellness visit
providing personalized prevention plan
services means the following services
furnished an eligible beneficiary by a
health professional as those terms are
defined in this section:
(i) An update of the individual’s
medical and family history.
(ii) An update of the list of current
providers and suppliers that are
regularly involved in providing medical
care to the individual as that list was
developed for the first annual wellness
visit providing personalized prevention
plan services.
(iii) Measurement of an individual’s
weight (or waist circumference), blood
pressure and other routine
measurements as deemed appropriate,
based on the individual’s medical and
family history.
(iv) Detection of any cognitive
impairment that the individual may
have, as that term is defined in this
section.
(v) An update to the following:
(A) The written screening schedule
for the individual as that schedule is
defined in paragraph (a) of this section
for the first annual wellness visit
providing personalized prevention plan
services.
(B) The list of risk factors and
conditions for which primary,
secondary or tertiary interventions are
recommended or are underway for the
individual as that list was developed at
the first annual wellness visit providing
personalized prevention plan services.
PO 00000
Frm 00209
Fmt 4701
Sfmt 4702
(vi) Furnishing of personalized health
advice to the individual and a referral,
as appropriate, to health education or
preventive counseling services or
programs as that advice and related
services are defined in paragraph (a) of
this section.
(vii) Any other element determined
appropriate through the National
Coverage Determination process.
(b) Conditions for coverage of annual
wellness visits providing personalized
prevention plan services. Medicare Part
B pays for first and subsequent annual
wellness visits providing personalized
prevention plan services that are
furnished to an eligible beneficiary, as
described in this section, if they are
furnished by a heath professional, as
defined in this section.
(c) Limitations on coverage of an
annual wellness visit providing
personalized prevention plan services.
(1) Payment may not be made for
either a first or a subsequent annual
wellness visit providing personalized
prevention plan services that is
performed for an individual who is not
an eligible beneficiary as described in
this section.
(2) Payment may not be made for
either a first or a subsequent annual
wellness visit providing personalized
prevention plan services that is
performed for an individual who is an
eligible beneficiary as described in this
section and who has had either an
initial preventive physical examination
as specified in section 410.16 of this
subpart or either a first or a subsequent
annual wellness visit providing
personalized prevention plan services
performed within the past 12 months.
(d) Effective date. Coverage for an
annual wellness visit providing
personalized prevention plan services is
effective for services furnished on or
after January 1, 2011.
12. Section 410.32 is amended by
adding paragraph (b)(2)(vii) to read as
follows:
§ 410.32 Diagnostic x-ray tests, diagnostic
laboratory tests, and other diagnostic tests:
Conditions.
*
*
*
*
*
(b) * * *
(2) * * *
(vii) Diagnostic tests performed by a
certified nurse-midwife authorized to
perform the tests under applicable State
laws.
*
*
*
*
*
13. Section 410.78 is amended by
revising the introductory text of
paragraph (b) to read as follows:
§ 410.78
*
E:\FR\FM\13JYP2.SGM
Telehealth services.
*
13JYP2
*
*
*
40248
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(b) General rule. Medicare Part B pays
for office or other outpatient visits,
subsequent hospital care services (with
the limitation of one telehealth visit
every 3 days), subsequent nursing
facility care services (not including the
Federally-mandated periodic visits
under § 483.40(c) of this chapter and
with the limitation of one telehealth
visit every 30 days), professional
consultations, psychiatric diagnostic
interview examination, neurobehavioral
status exam, individual psychotherapy,
pharmacologic management, end-stage
renal disease-related services included
in the monthly capitation payment
(except for one ‘‘hands on’’ visit per
month to examine the access site),
individual and group medical nutrition
therapy services, individual and group
kidney disease education services,
individual and group diabetes selfmanagement (DSMT) training services
(except for one hour of in-person
services to be furnished in the year
following the initial DSMT service to
ensure effective injection training), and
individual and group health and
behavior assessment and intervention
services furnished by an interactive
telecommunications system if the
following conditions are met:
*
*
*
*
*
Subpart I—Payment for SMI Benefits
14. Section 410.150 is amended by
adding paragraph (a)(20) to read as
follows:
§ 410.150
To whom payment is made.
(a) * * *
(20) To a certified nurse-midwife for
professional services furnished by the
certified nurse-midwife in all settings
and for services and supplies furnished
incident to those services. Payment is
made only if no facility or other
provider charges or is paid any amount
for the furnishing of the professional
services of the certified nurse-midwife.
15. Section 410.152 is amended by
revising paragraph (l) to read as follows:
§ 410.152
Amounts of payment.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*
*
*
*
*
(l) Amount of payment: Preventive
services. Medicare Part B pays 100
percent of the Medicare payment
amount established under the
applicable payment methodology for the
service setting for providers and
suppliers for the following preventive
services:
(1) Pneumococcal (as specified in
paragraph (h) of this section), influenza,
and hepatitis B vaccine and
administration.
(2) Screening mammography.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(3) Screening pap tests and screening
pelvic exam.
(4) Prostate cancer screening tests
(excluding digital rectal examinations).
(5) Colorectal cancer screening tests
(excluding barium enemas).
(6) Bone mass measurement.
(7) Medical nutrition therapy (MNT)
services.
(8) Cardiovascular screening blood
tests.
(9) Diabetes screening tests.
(10) Ultrasound screening for
abdominal aortic aneurysm (AAA).
(11) Additional preventive services
identified for coverage through the
national coverage determination (NCD)
process.
(12) Initial Preventive Physical
Examination (IPPE).
(13) Personalized Prevention Plan
Services (PPPS).
16. Section 410.160 is amended by—
A. Revising paragraph (b)(2).
B. Adding paragraphs (b)(10), (11),
(12), and (13).
The revisions and additions read as
follows:
§ 410.160
Part B annual deductible.
*
*
*
*
*
(b) * * *
(2) Pneumococcal, influenza, and
hepatitis b vaccines and their
administration.
*
*
*
*
*
(10) Bone mass measurement.
(11) Medical nutrition therapy (MNT)
services.
(12) Personalized prevention plan
services (PPPS).
(13) Additional preventive services
identified for coverage through the
national coverage determination (NCD)
process.
*
*
*
*
*
PART 411—EXCLUSIONS FROM
MEDICARE AND LIMITATIONS ON
MEDICARE PAYMENT
17. The authority citation for part 411
continues to read as follows:
Authority: Secs. 1102, 1860D–1 through
1860D–42, 1871, and 1877 of the Social
Security Act (42 U.S.C. 1302, 1395w–101
through 1395w–152, 1395hh, and 1395nn).
Subpart A—General Exclusions and
Exclusion of Particular Services
18. Section 411.15 is amended by—
A. Republishing the introductory text.
B. Revising paragraph (a)(1).
C. Adding new paragraph (k)(16).
The revision and addition read as
follows:
§ 411.15 Particular services excluded from
coverage.
The following services are excluded
from coverage.
PO 00000
Frm 00210
Fmt 4701
Sfmt 4702
(a) * * *
(1) Examinations performed for a
purpose other than treatment or
diagnosis of a specific illness,
symptoms, complaint, or injury, except
for screening mammography, colorectal
cancer screening tests, screening pelvic
exams, prostate cancer screening tests,
glaucoma screening exams, ultrasound
screening for abdominal aortic screening
for abdominal aortic aneurysms (AAA),
cardiovascular disease screening tests,
diabetes screening tests, a screening
electrocardiogram, initial preventive
physical examinations that meet the
criteria specified in paragraphs (k)(6)
through (k)(15) of this section,
additional preventive services that meet
the criteria in § 410.64 of this chapter,
or annual wellness visits providing
personalized prevention plan services
*
*
*
*
*
(k) * * *
(16) In the case of an annual wellness
visit providing a personalized
prevention plan, subject to the
conditions and limitations specified in
§ 410.15 of this chapter.
*
*
*
*
*
Subpart J—Financial Relationships
Between Physicians and Entities
Furnishing Designated Health Services
19. Section 411.355 is amended by
adding paragraph (b)(7) to read as
follows:
§ 411.355 General exceptions to the
referral prohibition related to both
ownership/investment and compensation.
*
*
*
*
*
(b) * * *
(7) Disclosure requirement for certain
imaging services.
(i) With respect to magnetic resonance
imaging, computed tomography, and
positron emission tomography, the
referring physician shall provide written
notice to the patient at the time of the
referral that the patient may receive the
same services from a person other than
one described in paragraph (b)(1) of this
section. Except as set forth in paragraph
(b)(7)(ii) of this section, the written
notice shall include a list of at least 10
other suppliers (as defined in § 400.202
of this chapter) that provide the services
for which the individual is being
referred and which are located within a
25-mile radius of the referring
physician’s office location at the time of
the referral. The notice should be
written in a manner sufficient to be
reasonably understood by all patients
and should include for each supplier on
the list, at a minimum, the supplier’s
name, address, telephone number, and
distance from the referring physician’s
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
office location. A record of the
disclosure notification, signed by the
patient, shall be maintained as a part of
the patient’s medical record.
(ii) If there are fewer than 10 other
suppliers located within a 25-mile
radius of the physician’s office location
at the time of the referral, the physician
shall list all of the other suppliers of the
imaging service that are present within
a 25-mile radius of the referring
physician’s office location, including up
to 10 suppliers. Provision of the written
list of alternate suppliers will not be
required if no other suppliers provide
the services for which the individual is
being referred within the 25-mile radius.
*
*
*
*
*
PART 413—PRINCIPLES OF
REASONABLE COST
REIMBURSEMENT; PAYMENT FOR
END-STAGE RENAL DISEASE
SERVICES; OPTIONAL
PROSPECTIVELY DETERMINED
PAYMENT RATES FOR SKILLED
NURSING FACILITIES
20. The authority citation for part 413
continues to read as follows:
Authority: Secs. 1102, 1812(d), 1814(b),
1815, 1833(a), (i), and (n), 1861(v), 1871,
1881, 1883, and 1886 of the Social Security
Act (42 U.S.C. 1302, 1395d(d), 1395f(b),
1395g, 1395l(a), (i), and (n), 1395x(v),
1395hh, 1395rr, 1395tt, and 1395ww); and
sec. 124 of Public Law 106–133 (113 Stat.
1501A–332).
Subpart E—Payments to Providers
21. Section 413.70 is amended by
adding a sentence at the end of
paragraph (b)(3)(ii)(B) to read as follows:
§ 413.70
Payment for services of a CAH.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*
*
*
*
*
(b) * * *
(3) * * *
(ii) * * *
(B) * * * Effective for primary care
services furnished by primary care
practitioners (as defined in § 414.80(a))
and major surgical procedures furnished
by general surgeons in health
professional shortage areas (as defined
in § 414.2) furnished on or after January
1, 2011 and before January 1, 2016,
incentive payments specified under
§ 414.80 and § 414.67(b), respectively, of
this chapter shall not be included in
determining payment made under this
paragraph.
*
*
*
*
*
PART 414—PAYMENT FOR PART B
MEDICAL AND OTHER HEALTH
SERVICES
22. The authority citation for part 414
continues to read as follows:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
40249
Authority: Secs. 1102, 1871, and 1881(b)(l)
of the Social Security Act (42 U.S.C. 1302,
1395hh, and 1395rr(b)(l)).
receiving a practice expense index floor
attributable to this provision.
*
*
*
*
*
Subpart A—General Provisions
Subpart B—Physicians and Other
Practitioners
23. Section 414.2 is amended by
adding the definitions of ‘‘Health
Professional Shortage Area’’ and ‘‘Major
surgical procedure’’ in alphabetical
order to read as follows:
§ 414.2
Definitions.
*
*
*
*
*
Health Professional Shortage Area
(HPSA) means an area designated under
section 332(a)(1)(A) of the Public Health
Service Act as identified by the
Secretary prior to the beginning of such
year.
Major surgical procedure means a
surgical procedure for which a 10-day or
90-day global period is used for
payment under the PFS and section
1848(b) of the Act.
*
*
*
*
*
24. Section 414.26 is amended by—
A. Redesignating paragraph (c) as
paragraph (d).
B. Adding a new paragraph (c).
The addition reads as follows:
§ 414.26
Determining the GAF.
*
*
*
*
*
(c) Adjusting the practice expense
index to account for the Frontier State
floor. (1) General criteria. Effective on or
after January 1, 2011, CMS will adjust
the practice expense index for
physicians’ services furnished in
qualifying States to recognize the
practice expense index floor established
for Frontier States. A qualifying State
must meet the following criteria:
(i) At least 50 percent of counties
located within the State have a
population density less than 6 persons
per square mile.
(ii) The State does not receive a nonlabor related share adjustment
determined by the Secretary to take into
account the unique circumstances of
hospitals located in Alaska and Hawaii.
(2) Amount of adjustment. The
practice expense value applied for
physicians’ services furnished in a
qualifying State will be not less than
1.00.
(3) Process for determining
adjustment. (i) CMS will use the most
recent Population Estimate data
published by the U.S. Census Bureau to
determine county definitions and
population density. This analysis will
be periodically revised, such as for
updates to the decennial census data.
(ii) CMS will publish annually a
listing of qualifying Frontier States
PO 00000
Frm 00211
Fmt 4701
Sfmt 4702
25. Section 414.54 is revised to read
as follows:
§ 414.54 Payment for certified nursemidwives’ services.
(a) For services furnished after
December 31, 1991, allowed amounts
under the fee schedule established
under section 1833(a)(1)(K) of the Act
for the payment of certified nursemidwife services may not exceed 65
percent of the physician fee schedule
amount for the service.
(b) For certified nurse midwife
services furnished on or after January 1,
2011, allowed amounts may not exceed
100 percent of the physician fee
schedule amount for the services.
26. Section 414.65 is amended by
revising the introductory text of
paragraph (a)(1) to read as follows:
§ 414.65
Payment for telehealth services.
(a) * * *
(1) The Medicare payment amount for
office or other outpatient visits,
subsequent hospital care services (with
the limitation of one telehealth
subsequent hospital care service every 3
days), subsequent nursing facility care
services (not including the Federallymandated periodic visits under
§ 483.40(c) and with the limitation of
one telehealth nursing facility care
service every 30 days), professional
consultations, psychiatric diagnostic
interview examination, neurobehavioral
status exam, individual psychotherapy,
pharmacologic management, end-stage
renal disease-related services included
in the monthly capitation payment
(except for one ‘‘hands on’’ visit per
month to examine the access site),
individual and group medical nutrition
therapy services, individual and group
kidney disease education services,
individual and group diabetes selfmanagement training (DSMT) services
(except for 1 hour of in-person DSMT
services to be furnished in the year
following the initial DSMT service to
ensure effective injection training), and
individual and group health and
behavior assessment and intervention
furnished via an interactive
telecommunications system is equal to
the current fee schedule amount
applicable for the service of the
physician or practitioner.
*
*
*
*
*
27. Section 414.67 is revised to read
as follows:
E:\FR\FM\13JYP2.SGM
13JYP2
40250
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
§ 414.67 Incentive payments for services
furnished in Health Professional Shortage
Areas.
(a) Health Professional Shortage Area
(HPSA) physician bonus program. A
HPSA physician incentive payment will
be made subject to the following:
(1) HPSA bonuses are payable for
services furnished by physicians as
defined in section 1861(r) of the Act in
areas designated as of December 31 of
the prior year as geographic primary
medical care HPSAs as defined in
section 332(a)(1)(A) of the Public Health
Service Act.
(2) HPSA bonuses are payable for
services furnished by psychiatrists in
areas designated as of December 31 of
the prior year as geographic mental
health HPSAs if the services are not
already eligible for the bonus based on
being in a geographic primary care
HPSA.
(3) Physicians eligible for the HPSA
physician bonus are entitled to a 10
percent incentive payment above the
amount paid for their professional
services under the physician fee
schedule.
(4) Physicians furnishing services in
areas that are designated as geographic
HPSAs prior to the beginning of the year
but not included on the published list
of zip codes for which automated HPSA
bonus payments are made should use
the AQ modifier to receive the HPSA
physician bonus payment.
(b) HPSA surgical incentive payment
program. A HPSA surgical incentive
payment will be made subject to the
following:
(1) A major surgical procedure as
defined in § 414.2 of this part is
furnished by a general surgeon on or
after January 1, 2011 and before January
1, 2016 in an area recognized for the
HPSA physician bonus program under
paragraph (a)(1) of this section.
(2) Payment will be made on a
quarterly basis in an amount equal to 10
percent of the Part B payment amount
for major surgical procedures furnished
as described in paragraph (1), in
addition to the amount the physician
would otherwise be paid.
(3) Physicians furnishing services in
areas that are designated as geographic
HPSAs eligible for the HPSA physician
bonus program under paragraph (a)(1) of
this section prior to the beginning of the
year but not included on the published
list of zip codes for which automated
HPSA surgical bonus payments are
made should report a specified HCPCS
code modifier to receive the HPSA
surgical bonus payment.
(4) The payment described in
paragraph (b)(2) of this section is made
to the surgeon or, where the surgeon has
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
reassigned his or her benefits to a
critical access hospital (CAH) paid
under the optional method, to the CAH
based on an institutional claim.
28. Section 414.80 is added to subpart
B to read as follows:
§ 414.80 Incentive payment for primary
care services.
(a) Definitions. As defined in this
section—
Eligible primary care practitioner
means one of the following:
(i) A physician (as defined in section
1861(r)(1)) who meets all of the
following criteria:
(A) Enrolled in Medicare with a
primary specialty designation of 08family practice, 11-internal medicine,
37-pediatrics, or 38-geriatrics.
(B) At least 60 percent of the
physician’s allowed charges during a
reference period specified by the
Secretary are for primary care services.
(ii) A nurse practitioner, clinical
nurse specialist, or physician assistant
(as defined in section 1861(aa)(5)) who
meets all of the following criteria:
(A) Enrolled in Medicare with a
primary specialty designation of 50nurse practitioner, 89-certified clinical
nurse, or 97-physician assistant.
(B) At least 60 percent of the
practitioner’s allowed charges during a
reference period specified by the
Secretary are for primary care services.
Primary care services means new and
established patient office or other
outpatient evaluation and management
(E/M) visits; initial, subsequent,
discharge, and other nursing facility E/
M services; new and established patient
domiciliary, rest home (e.g., boarding
home), or custodial care E/M services;
domiciliary, rest home (e.g., assisted
living facility), or home care plan
oversight services; and new and
established patient home E/M visits.
(b) Payment.
(1) For primary care services
furnished by an eligible primary care
practitioner on or after January 1, 2011
and before January 1, 2016, payment is
made on a quarterly basis in an amount
equal to 10 percent of the payment
amount for the primary care services
under Part B, in addition to the amount
the primary care practitioner would
otherwise be paid for the primary care
services under Part B.
(2) The payment described in
paragraph (b)(1) of this section is made
to the eligible primary care practitioner
or, where the physician has reassigned
his or her benefits to a critical access
hospital (CAH) paid under the optional
method, to the CAH based on an
institutional claim.
PO 00000
Frm 00212
Fmt 4701
Sfmt 4702
29. A new § 414.90 is added to
subpart B to read as follows:
§ 414.90 Physician quality reporting
initiative (PQRI).
(a) Basis and Scope. This part
implements the following provisions of
the Act:
(1) 1848(a)—Payment Based on Fee
Schedule.
(2) 1848(k)—Quality Reporting
System.
(3) 1848(m)—Incentive Payments for
Quality Reporting.
(b) Definitions. As used in this
section, unless otherwise indicated—
Covered professional services means
services for which payment is made
under, or is based on, the Medicare
physician fee schedule as provided
under section 1848(k)(3) of the Act and
which are furnished by an eligible
professional.
Eligible professional (EP) means any
of the following:
(i) A physician.
(ii) A practitioner described in section
1842(b)(18)(C) of the Act.
(iii) A physical or occupational
therapist or a qualified speech-language
pathologist.
(iv) A qualified audiologist (as
defined in section 1861(ll)(3)(B) of the
Act).
Group practice means a single
Taxpayer Identification Number (TIN)
with 2 or more eligible professionals, as
identified by their individual National
Provider Identifier (NPI), who have
reassigned their Medicare billing rights
to the TIN. This term also includes
group practices participating in
Medicare demonstration projects
approved by the Secretary.
Maintenance of certification program
means a continuous assessment
program, such as qualified American
Board of Medical Specialties
Maintenance of Certification Program or
an equivalent program (as determined
by the Secretary), that advances quality
and the lifelong learning and selfassessment of board certified specialty
physicians by focusing on the
competencies of patient care, medical
knowledge, practice-based learning,
interpersonal and communication skills
and professionalism. Such a program
must include the following:
(i) The program requires the physician
to maintain a valid unrestricted license
in the United States.
(ii) The program requires a physician
to participate in educational and selfassessment programs that require an
assessment of what was learned.
(iii) The program requires a physician
to demonstrate, through a formalized
secure examination, that the physician
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
has the fundamental diagnostic skills,
medical knowledge, and clinical
judgment to provide quality care in their
respective specialty.
(iv) The program requires successful
completion of a qualified Maintenance
of Certification Program practice
assessment.
Maintenance of certification program
practice assessment means an
assessment of a physician’s practice
that—
(i) Includes an initial assessment of an
eligible professional’s practice that is
designed to demonstrate the physician’s
use of evidence-based medicine;
(ii) Includes a survey of patient
experience with care; and
(iii) Requires a physician to
implement a quality improvement
intervention to address a practice
weakness identified in the initial
assessment under paragraph (i) and then
to remeasure to assess performance
improvement after such intervention.
Measures group means a subset of
four or more PQRI measures that have
a particular clinical condition or focus
in common. The denominator definition
and coding of the measures group
identifies the condition or focus that is
shared across the measures within a
particular measures group.
Performance rate means the
percentage of a defined population who
receives a particular process of care or
achieve a particular outcome for a
particular quality measure.
Physician quality reporting initiative
(PQRI) means the physician reporting
system under section 1848(k) of the Act
for the reporting by eligible
professionals of data on quality
measures and the incentive payment
associated with this physician reporting
system.
Qualified electronic health record
(EHR) means an EHR vendor’s product
and version that, with respect to a
particular program year, has selfnominated and successfully completed
a vetting process (as specified by CMS)
to demonstrate the product’s
compliance with the PQRI qualification
requirements specified by CMS for a
program year.
Qualified registry means a medical
registry or a Maintenance of
Certification Program operated by a
specialty body of the American Board of
Medical Specialties that, with respect to
a particular program year, has selfnominated and successfully completed
a vetting process (as specified by CMS)
to demonstrate its compliance with the
PQRI qualification requirements
specified by CMS for that program year.
The registry may act as a data
submission vendor, which has the
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
requisite legal authority to provide PQRI
data (as specified by CMS) on behalf of
an eligible professional to CMS.
Quality reporting period means with
respect to a year, a period specified by
the Secretary.
Reporting rate means the percentage
of patients that the eligible professional
indicated a quality action was or was
not performed divided by the total
number of patients in the denominator
of the measure.
(c) Incentive payments. With respect
to covered professional services
furnished during a reporting period by
an eligible professional, if—
(1) There are any quality measures
that have been established under the
PQRI that are applicable to any such
services furnished by such professional
(or in the case of a group practice under
paragraph (h) of this section, such group
practice) for such reporting period; and
(2) The eligible professional (or in the
case of a group practice under paragraph
(h) of this section, the group practice)
satisfactorily submits (as determined
under paragraph (g) of this section for
eligible professionals and paragraph (h)
of this section for group practices) to the
Secretary data on such quality measures
in accordance with the PQRI for such
reporting period, in addition to the
amount otherwise paid under section
1848 of the Act, there also shall be paid
to the eligible professional (or to an
employer or facility in the cases
described in section 1842(b)(6)(A) of the
Act or, in the case of a group practice)
under paragraph (h) of this section, to
the group practice, from the Federal
Supplementary Medical Insurance Trust
Fund established under section 1841 an
amount equal to the applicable quality
percent (as specified in paragraph (c)(3)
of this section) of the eligible
professional’s (or, in the case of a group
practice under paragraph (h) of this
section, the group practice’s) total
estimated allowed charges for all
covered professional services furnished
by the eligible professional (or, in the
case of a group practice under paragraph
(h) of this section, by the group practice)
during the applicable reporting period.
For purposes of this paragraph,
(i) The eligible professional’s (or, in
the case of a group practice under
paragraph (h) of this section, the group
practice’s) total estimated allowed
charges for covered professional
services furnished during a reporting
period are determined based on claims
processed in the National Claims
History (NCH) no later than 2 months
after the end of the applicable reporting
period;
(ii) In the case of an eligible
professional who furnishes covered
PO 00000
Frm 00213
Fmt 4701
Sfmt 4702
40251
professional services in more than one
practice, incentive payments are
separately determined for each practice
based on claims submitted for the
eligible professional for each practice;
(iii) Incentive payments earned by an
eligible professional (or in the case of a
group practice under paragraph (h) of
this section, by a group practice) for a
particular program year will be paid as
a single consolidated payment to the
TIN holder of record.
(3) Applicable quality percent. The
applicable quality percent is as follows:
(i) For 2011, 1.0 percent; and
(ii) For 2012, 2013, and 2014, 0.5
percent;
(d) Additional incentive payment. (1)
Through 2014, if an eligible professional
meets the requirements described in
paragraph (d)(2) of this section, the
applicable percent for such year, as
described in paragraphs (c)(3)(i) and (ii)
of this section, must be increased by 0.5
percentage points.
(2) In order to qualify for the
additional incentive payment described
in paragraph (d)(1) of this section, an
eligible professional shall meet the
following requirements:
(i) The eligible professional must—
(A) Satisfactorily submit data on
quality measures for purposes of this
section for a year; and
(B) Have such data submitted on their
behalf through a Maintenance of
Certification program (as defined in
paragraph (b) of this section) that meets:
(1) The criteria for a registry (as
specified by CMS)); or
(2) An alternative form and manner
determined appropriate by the
Secretary.
(ii) The eligible professional, more
frequently than is required to qualify for
or maintain board certification status—
(A) Participates in such a
Maintenance of Certification Program
for a year; and
(B) Sucessfully completes a qualified
Maintenance of Certification Program
practice assessment (as defined in
paragraph (b) of this section) for such
year.
(iii) A Maintenance of Certification
program submits to the Secretary, on
behalf of the eligible professional,
information —
(A) In a form and manner specified by
the Secretary, that the eligible
professional has successfully met the
requirements of paragraph (d)(2)(ii) of
this section which may be in the form
of a structural measure);
(B) If requested by the Secretary, on
the survey of patient experience with
care (as described in paragraph (b) of
this section); and
(C) As the Secretary may require, on
the methods, measures, and data used
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40252
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
under the Maintenance of Certification
Program and the qualified Maintenance
of Certification Program practice
assessment.
(e) Incentive payment adjustment. (1)
With respect to covered professional
services furnished by an eligible
professional during 2015 or any
subsequent year, if the eligible
professional does not satisfactorily
submit data on quality measures for
covered professional services for the
quality reporting period for the year (as
determined under paragraph (g) for
eligible professionals and paragraph (h)
of this section for group practices), the
fee schedule amount for such services
furnished by such professional during
the year (including the fee schedule
amount for purposes of determining a
payment based on such amount) must
be equal to the applicable percent of the
fee schedule amount that would
otherwise apply to such services under
section 1848(m) of the Act.
(2) Applicable percent. For purposes
of paragraph (1) of this section, the term
‘applicable percent’ means—
(i) For 2015, 98.5 percent; and
(ii) For 2016 and each subsequent
year, 98 percent.
(f) Use of consensus-based quality
measures. For each program year, CMS
will publish the final list of measures
and the final detailed measure
specifications for all quality measures
selected for inclusion in the PQRI
quality measure set for a given program
year on a CMS Web site by no later than
December 31 of the prior year.
(1) Subject to paragraph (f)(2) of this
section, for purposes of reporting data
on quality measures for covered
professional services furnished during a
year, subject to paragraph (g) of this
section, the quality measures specified
under this paragraph must be such
measures selected by the Secretary from
measures that have been endorsed by
the entity with a contract with the
Secretary under section 1890(a) of the
Act.
(2) Exception. In the case of a
specified area or medical topic
determined appropriate by the Secretary
for which a feasible and practical
measure has not been endorsed by the
entity with a contract under section
1890(a) of the Act, the Secretary may
specify a measure that is not so
endorsed as long as due consideration is
given to measures that have been
endorsed or adopted by a consensus
organization identified by the Secretary,
such as the AQA alliance.
(3) Opportunity to provide input on
measures. For each quality measure
adopted by the Secretary under this
paragraph, the Secretary shall ensure
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
that eligible professionals have the
opportunity to provide input during the
development, endorsement, or selection
of quality measures applicable to
services they furnish.
(g) Requirements for individual
eligible professionals to qualify to
receive an incentive payment. In order
to qualify to earn a PQRI incentive
payment for a particular program year,
an individual eligible professional, as
identified by a unique TIN/NPI
combination, must meet the criteria for
satisfactory reporting specified by CMS
for such year by reporting on either
individual PQRI quality measures or
PQRI measures groups identified by
CMS during a reporting period specified
in paragraph (g)(1) of this section and
using one of the reporting mechanisms
specified in paragraph (g)(2) of this
section. Although an eligible
professional may attempt to qualify for
the PQRI incentive payment by
reporting on both individual PQRI
quality measures and measures groups,
using more than one reporting
mechanism (as specified in paragraph
(g)(2) of this section), or reporting for
more than one reporting period, he or
she will receive only one PQRI
incentive payment per TIN/NPI
combination for a program year.
(1) Reporting periods. For purposes of
this paragraph, the reporting period
with respect to a program year are—
(i) The 12-month period from January
1 through December 31 of each program
year; or
(ii) The 6-month period from July 1
through December 31 of each program
year.
(iii) Exceptions. The 6-month
reporting period is not available for
EHR-based reporting of individual PQRI
quality measures or for reporting by
group practices under the process
described in paragraph (h) of this
section.
(2) Reporting mechanisms. For each
program year, an eligible professional
who wishes to participate in the PQRI
must report information on the
individual PQRI quality measures or
PQRI measures groups identified by
CMS in the following manner:
(i) Reporting the individual PQRI
quality measures or PQRI measures
groups to CMS, by no later than 2
months after the end of the applicable
reporting period, on the eligible
professional’s Medicare Part B claims
for covered professional services
furnished during the applicable
reporting period;
(ii) Reporting the individual PQRI
quality measures or PQRI measures
groups to a qualified registry (as
specified in paragraph (b) of this
PO 00000
Frm 00214
Fmt 4701
Sfmt 4702
section) in the form and manner and by
the deadline specified by the qualified
registry selected by the eligible
professional. The selected registry will
submit information, as required by
CMS, for covered professional services
furnished by the eligible professional
during the applicable reporting period
to CMS on the eligible professional’s
behalf; or
(iii) Reporting the individual PQRI
quality measures to CMS by extracting
clinical data using a secure data
submission method, as required by
CMS, from a qualified EHR product (as
defined in paragraph (b) of this section)
by the deadline specified by CMS for
covered professional services furnished
by the eligible professional during the
applicable reporting period. Prior to
actual data submission for a given
program year and by a date specified by
CMS, the eligible professional must
submit a test file containing real or
dummy clinical quality data extracted
from the qualified EHR product selected
by the eligible professional using a
secure data submission method, as
required by CMS.
(h) Requirements for group practices
to qualify to receive an incentive
payment. A group practice (as defined
in paragraph (b) of this section) will be
treated as satisfactorily submitting data
on quality measures under PQRI for
covered professional services for a
reporting period (or for purposes of
paragraph (e) of this section, for a
quality reporting period for the year), if,
in lieu of reporting PQRI measures, the
group practice—
(1) Meets the participation
requirements specified by CMS for the
PQRI group practice reporting option
(GPRO);
(2) Is selected by CMS to participate
in the PQRI GPRO;
(3) Reports measures specified by
CMS in the form and manner, and at a
time specified by CMS; and
(4) Meets the criteria for satisfactory
reporting specified by CMS.
(5) No double payments. Payments to
a group practice under this paragraph
must be in lieu of the payments that
would otherwise be made under the
PQRI to eligible professionals in the
group practice for meeting the criteria
for satisfactory reporting for individual
eligible professionals.
(i) If an eligible professional, as
identified by an individual NPI, has
reassigned his or her Medicare billing
rights to a TIN selected to participate in
the PQRI GPRO for a program year, then
for that program year the eligible
professional must participate in the
PQRI via the GPRO. For any program
year in which the TIN is selected to
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
participate in the PQRI GPRO, the
eligible professional cannot individually
qualify for a PQRI incentive payment by
meeting the requirements specified in
paragraph (g) of this section.
(ii) If, for the program year, the
eligible professional participates in the
PQRI under another TIN that is not
selected to participate in the PQRI
GPRO for that program year, then the
eligible professional may individually
qualify for a PQRI incentive by meeting
the requirements specified in paragraph
(g) of this section under that TIN.
(i) Limitations on review. (1) Except as
specified in paragraph (h)(2) of this
section, there is no administrative or
judicial review under section 1869,
section 1879, or otherwise of—
(i) The determination of measures
applicable to services furnished by
eligible professionals under PQRI;
(ii) The determination of the payment
limitation; and
(iii) The determination of any PQRI
incentive payment and the PQRI
payment adjustment.
(j) Informal review. Except as
specified in paragraph (i) of this section
eligible professionals (or in the case of
reporting under paragraph (h) of this
section, group practices) may seek a
review of the determination that an
eligible professional (or in the case of
reporting under paragraph (h) of this
section, group practices) did not
satisfactorily submit data on quality
measures under the PQRI.
(1) To request an informal review, an
eligible professional (or in the case of
reporting under paragraph (h) of this
section, group practices) must submit a
written request to CMS within 90 days
of the release of the feedback reports.
The request must summarize the
concern(s) and reasons for requesting an
informal review and may also include
information to assist in the review.
(2) CMS will provide a written
response within 60 days of the receipt
of the original request. All decisions
based on the informal review will be
final. There will be no further review or
appeal.
(k) Public reporting of an eligible
professional’s or group practice’s PQRI
data. For each program year, CMS will
post on a public Web site, in an easily
understandable format, a list of the
names of eligible professionals (or in the
case of reporting under paragraph (h),
group practices) who satisfactorily
submitted PQRI quality measures.
30. A new § 414.92 is added to
subpart B to read as follows:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
§ 414.92 Electronic prescribing incentive
program.
(a) Basis and scope. This part
implements the following provisions of
the Act:
(1) Section 1848(a)—Payment Based
on Fee Schedule.
(2) Section 1848(m)—Incentive
Payments for Quality Reporting.
(b) Definitions. As used in the part,
unless otherwise indicated—
Covered professional services means
services for which payment is made
under, or is based on, the Medicare
physician fee schedule as provided
under section 1848(k)(3) of the Act and
which are furnished by an eligible
professional.
Electronic prescribing (eRx) incentive
program means the incentive payment
program established under section
1848(m) of the Act for the adoption and
use of electronic prescribing technology
by eligible professionals.
Eligible professional means any of the
following healthcare professionals who
have prescribing authority:
(i) A physician.
(ii) A practitioner described in section
1842(b)(18)(C) of the Act.
(iii) A physical or occupational
therapist or a qualified speech-language
pathologist.
(iv) A qualified audiologist (as
defined in section 1861(ll)(3)(B) of the
Act).
Group practice means a group
practice, as defined at § 414.90(b), that—
(i) Is or is deemed to be participating
in the Physician Quality Reporting
Initiative (PQRI) group practice
reporting option (GPRO) under § 414.90;
and
(ii) Has indicated its desire to
participate in the eRx GPRO.
Qualified electronic health record
(EHR) means an EHR product and
version that, with respect to a particular
program year, is designated by CMS as
a qualified EHR for the purpose of the
PQRI (as described in § 414.90) and the
product’s vendor has indicated a desire
to have the product qualified for
purposes of the product’s users to
submit information related to the eRx
measure.
Qualified registry means a medical
registry or a Maintenance of
Certification Program operated by a
specialty body of the American Board of
Medical Specialties that, with respect to
a particular program year, is designated
by CMS as a qualified registry for the
purpose of the PQRI (as described in
§ 414.90) and that has indicated its
desire to be qualified to submit the eRx
measure on behalf of eligible
professionals for the purposes of the eRx
Incentive Program.
PO 00000
Frm 00215
Fmt 4701
Sfmt 4702
40253
(c) Incentive payments. (1) Subject to
paragraph (c)(3) of this section, with
respect to covered professional services
furnished during a reporting period by
an eligible professional, if the eligible
professional is a successful electronic
prescriber for such reporting period, in
addition to the amount otherwise paid
under section 1848 of the Act, there also
shall be paid to the eligible professional
(or to an employer or facility in the
cases described in paragraph (A) of
section 1842(b)(6)) or, in the case of a
group practice under paragraph (e) of
this section, to the group practice, from
the Federal Supplementary Medical
Insurance Trust Fund established under
section 1841 of the Act an amount equal
to the applicable eRx percent (as
specified in paragraph (c)(1)(ii) of this
section) of the eligible professional’s (or,
in the case of a group practice under
paragraph (e) of this section, the group
practice’s) total estimated allowed
charges for all covered professional
services furnished by the eligible
professional (or, in the case of a group
practice under paragraph (e) of this
section, by the group practice) during
the applicable reporting period.
(i) For purposes of this paragraph,
(A) The eligible professional’s (or, in
the case of a group practice under
paragraph (e) of this section, the group
practice’s) total estimated allowed
charges for covered professional
services furnished during a reporting
period are determined based on claims
processed in the National Claims
History (NCH) no later than 2 months
after the end of the applicable reporting
period;
(B) In the case of an eligible
professional who furnishes covered
professional services in more than one
practice, incentive payments are
separately determined for each practice
based on claims submitted for the
eligible professional for each practice;
(C) Incentive payments earned by an
eligible professional (or in the case of a
group practice under paragraph (e) of
this section, by a group practice) for a
particular program year will be paid as
a single consolidated payment to the
TIN holder of record.
(ii) Applicable eRx percent. The
applicable eRx percent is as follows:
(A) For the 2011 and 2012 program
years, 1.0 percent; and
(B) For the 2013 program year, 0.5
percent.
(iii) Limitation with respect to
electronic health record (EHR) incentive
payments. The provisions of this
paragraph do not apply to an eligible
professional (or, in the case of a group
practice under paragraph (e) of this
section, a group practice) if, for the EHR
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40254
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
reporting period the eligible
professional (or group practice) receives
an incentive payment under section
1848(o)(1)(A) of the Act with respect to
a certified EHR technology (as defined
in section 1848(o)(4) of the Act) that has
the capability of eRx.
(2) Incentive payment adjustment.
Subject to paragraph (c)(1)(ii) and
paragraph (c)(3) of this section, with
respect to covered professional services
furnished by an eligible professional
during 2012, 2013, or 2014, if the
eligible professional (or in the case of a
group practice under paragraph (e) of
this section, the group practice) is not a
successful electronic prescriber (as
specified by CMS for purposes of the
payment adjustment) for an applicable
reporting period (as specified by CMS)
the fee schedule amount for such
services furnished by such professional
(or group practice) during the program
year (including the fee schedule amount
for purposes of determining a payment
based on such amount) is equal to the
applicable percent (as specified in
paragraph (c)(2)(i) of this section) of the
fee schedule amount that would
otherwise apply to such services under
section 1848 of the Act.
(i) Applicable percent. The applicable
percent is as follows:
(A) For 2012, 99 percent;
(B) For 2013, 98.5 percent; and
(C) For 2014, 98 percent.
(ii) Significant hardship exception.
An eligible professional (or in the case
of a group practice under paragraph (e)
of this section, a group practice) may be
exempt from the application of the
payment adjustment under this
paragraph if, subject to annual renewal,
CMS determines that compliance with
the requirement for being a successful
electronic prescriber (as specified by
CMS for purposes of the payment
adjustment) would result in a significant
hardship. For purposes of this
paragraph, any of the following
circumstances constitute a ‘‘significant
hardship:’’
(A) An eligible professional (or group
practice) who practices in a rural area
with limited high speed Internet access.
(B) An eligible professional (or group
practice) who practices in an area with
limited available pharmacies for
electronic prescribing.
(C) Other circumstances identified by
CMS.
(3) Limitation with respect to
electronic prescribing quality measures.
The provisions of paragraphs (c)(1) and
(c)(2) of this section do not apply to an
eligible professional (or, in the case of
a group practice under paragraph (e) of
this section, a group practice) if for the
reporting period the allowed charges
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
under section 1848 of the Act for all
covered professional services furnished
by the eligible professional (or group, as
applicable) for the codes to which the
electronic prescribing measure (as
identified by CMS) applies are less than
10 percent of the total of the allowed
charges under section 1848 of the Act
for all such covered professional
services furnished by the eligible
professional (or the group practice, as
applicable).
(d) Requirements for individual
eligible professionals to qualify to
receive an incentive payment. In order
to be considered a successful electronic
prescriber and qualify to earn an eRx an
incentive payment (subject to paragraph
(c)(3) of this section), an individual
eligible professional, as identified by a
unique TIN/NPI combination, must
meet the criteria for successful
electronic prescriber specified by CMS
during the reporting period specified in
paragraph (d)(1) of this section and
using one of the reporting mechanisms
specified in paragraph (d)(2) of this
section. Although an eligible
professional may attempt to qualify for
the eRx incentive payment using more
than one reporting mechanism (as
specified in paragraph (d)(2) of this
section), he or she will receive only one
eRx incentive payment per TIN/NPI
combination for a program year.
(1) Reporting period. For purposes of
this paragraph, the reporting period
with respect to a program year is the
entire calendar year.
(2) Reporting mechanisms. An eligible
professional who wishes to participate
in the eRx Incentive Program must
report information on the eRx measure
identified by CMS to—
(i) CMS, by no later than 2 months
after the end of the applicable reporting
period, on the eligible professional’s
Medicare Part B claims for covered
professional services furnished by the
eligible professional during the
reporting period specified in paragraph
(d)(1) of this section;
(ii) A qualified registry (as defined in
paragraph (b)) in the form and manner
and by the deadline specified by the
qualified registry selected by the eligible
professional. The selected registry will
submit information, as required by
CMS, for covered professional services
furnished by the eligible professional
during the reporting period specified in
paragraph (d)(1) of this section to CMS
on the eligible professional’s behalf; or
(iii) CMS by extracting clinical data
using a secure data submission method,
as required by CMS, from a qualified
EHR product (as defined in paragraph
(b) of this section) by the deadline
specified by CMS for covered
PO 00000
Frm 00216
Fmt 4701
Sfmt 4702
professional services furnished by the
eligible professional during the
reporting period specified in paragraph
(d)(1) of this section. Prior to actual data
submission for a given program year and
by a date specified by CMS, the eligible
professional must submit a test file
containing real or dummy clinical
quality data extracted from the qualified
EHR product selected by the eligible
professional using a secure data
submission method, as required by
CMS.
(e) Requirements for group practices
to qualify to receive an incentive
payment.
(1) A group practice (as defined in
paragraph (b) of this section) will be
treated as a successful electronic
prescriber for covered professional
services for a reporting period if the
group practice meets the criteria for
successful electronic prescriber
specified by CMS in the form and
manner and at the time specified by
CMS.
(2) No double payments. Payments to
a group practice under this paragraph
must be in lieu of the payments that
would otherwise be made under the eRx
Incentive Program to eligible
professionals in the group practice for
being a successful electronic prescriber.
(i) If an eligible professional, as
identified by an individual NPI, has
reassigned his or her Medicare billing
rights to a TIN selected to participate in
the eRx GPRO for a program year, then
for that program year the eligible
professional must participate in the eRx
Incentive Program via the GPRO. For
any program year in which the TIN is
selected to participate in the eRx
Incentive Program GPRO, the eligible
professional cannot individually qualify
for an eRx incentive payment by
meeting the requirements specified in
paragraph (d) of this section.
(ii) If, for the program year, the
eligible professional participates in the
eRx Incentive Program under another
TIN that is not selected to participate in
the eRx Incentive Program GPRO for
that program year, then the eligible
professional may individually qualify
for an eRx incentive by meeting the
requirements specified in paragraph (d)
of this section under that TIN.
(f) Public reporting of an eligible
professional’s or group practice’s erx
incentive program data. For each
program year, CMS will post on a public
Web site, in an easily understandable
format, a list of the names of eligible
professionals (or in the case of reporting
under paragraph (e) of this section,
group practices) who are successful
electronic prescribers.
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
Subpart D—Payment for Durable
Medical Equipment and Prosthetic and
Orthotic Devices
31. Section 414.202 is amended by
adding a definition of ‘‘complex
rehabilitative power-driven wheelchair’’
in alphabetical order to read as follows:
§ 414.202
Definitions.
*
*
*
*
*
Complex rehabilitative power-driven
wheelchair means a power-driven
wheelchair that is classified as—
(1) Group 2 power wheelchair with
power options that can accommodate
rehabilitative features (for example, tilt
in space); or
(2) Group 3 power wheelchair.
*
*
*
*
*
32. Section 414.226 is amended by
revising paragraph (g)(1) to read as
follows:
§ 414.226
Oxygen and oxygen equipment.
*
*
*
*
(g) * * *
(1) The supplier that furnishes oxygen
equipment for the first month during
which payment is made under this
section must continue to furnish the
equipment until medical necessity ends,
or the 36-month period of continuous
use ends, whichever is earlier, unless—
(i) The item becomes subject to a
competitive acquisition program
implemented in accordance with
section 1847(a) of the Act;
(ii) Before the 18th month of
continuous use, the beneficiary
relocates to an area that is outside the
normal service area of the supplier that
initially furnished the equipment;
(iii) The beneficiary elects to obtain
oxygen equipment from a different
supplier prior to the expiration of the
36-month rental period; or
(iv) CMS or the carrier determines
that an exception should apply in an
individual case based on the
circumstances.
*
*
*
*
*
33. Section 414.229 is amended by—
A. Revising paragraphs (a)(3), (d)(1),
and (h).
B. Adding paragraphs (a)(4), (a)(5),
and (b)(3).
The revisions and additions read as
follows:
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*
§ 414.229 Other durable medical
equipment-capped rental items.
(a) * * *
(3) For power-driven wheelchairs
furnished on or after January 1, 2006
through December 31, 2010, payment is
made in accordance with the rules set
forth in paragraphs (f) or (h) of this
section.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(4) For power-driven wheelchairs that
are not classified as complex
rehabilitative power-driven
wheelchairs, furnished on or after
January 1, 2011, payment is made in
accordance with the rules set forth in
paragraph (f) of this section.
(5) For power-driven wheelchairs
classified as complex rehabilitative
power-driven wheelchairs, furnished on
or after January 1, 2011, payment is
made in accordance with the rules set
forth in paragraphs (f) or (h) of this
section.
(b) * * *
(3) For power-driven wheelchairs
furnished on or after January 1, 2011,
the monthly fee schedule amount for
rental equipment equals 15 percent of
the purchase price recognized as
determined under paragraph (c) of this
section for each of the first 3 months
and 6 percent of the purchase price for
each of the remaining months.
*
*
*
*
*
(d) * * *
(1) Suppliers must offer beneficiaries
the option of purchasing power-driven
wheelchairs at the time the supplier first
furnishes the item. On or after January
1, 2011, this option is available only for
complex rehabilitative power-driven
wheelchairs. Payment must be on a
lump-sum fee schedule purchase basis if
the beneficiary chooses the purchase
option. The purchase fee is the amount
established in paragraph (c) of this
section.
*
*
*
*
*
(h) Purchase of power-driven
wheelchairs furnished on or after
January 1, 2006.
(1) Suppliers must offer beneficiaries
the option to purchase power-driven
wheelchairs at the time the equipment
is initially furnished.
(2) Payment is made on a lump-sum
purchase basis if the beneficiary chooses
this option.
(3) On or after January 1, 2011, this
option is available only for complex
rehabilitative power-driven
wheelchairs.
Subpart F—Competitive Bidding for
Certain Durable Medical Equipment,
Prosthetics, Orthotics, and Supplies
(DMEPOS)
34. Section 414.402 is amended by
adding the definitions of ‘‘Affected
party,’’ ‘‘Breach of contract,’’ ‘‘Corrective
Action Plan,’’ ‘‘Hearing Officer,’’ ‘‘Mail
order item,’’ ‘‘National mail order
competitive bidding program,’’
‘‘Nonmail order item’’ and ‘‘Parties to the
hearing’’ in alphabetical order to read as
follows:
PO 00000
Frm 00217
Fmt 4701
Sfmt 4702
§ 414.402
40255
Definitions.
Affected party means a contract
supplier that has been notified that their
DMEPOS CBP contract will be
terminated for a breach of contract.
*
*
*
*
*
Breach of contract means any
deviation from contract requirements,
including a failure to comply with a
governmental agency or licensing
organization requirements, constitutes a
breach of contract.
*
*
*
*
*
Corrective action plan (CAP) means a
contract supplier’s written document
with supporting information that
describes the actions the contract
supplier will take within a specified
timeframe to remedy a breach of
contract.
*
*
*
*
*
Hearing Officer (HO) means an
individual, who was not involved with
the CBIC recommendation to terminate
a DMEPOS Competitive Bidding
Program contract, who is designated by
CMS to review and make an unbiased
and independent determination
following the Competitive Bidding
Implementation Contractor’s (CBIC’s)
recommendation to terminate a
DMEPOS Competitive Bidding Program
contract.
*
*
*
*
*
Mail order item means any item (for
example, diabetic testing supplies)
shipped or delivered to the beneficiary’s
home, regardless of the method of
delivery.
*
*
*
*
*
National mail order competitive
bidding program means a program and
competition resulting in the award of
contracts to suppliers for furnishing
mail order items throughout the nation.
*
*
*
*
*
Nonmail order item means any item
(for example, diabetic testing supplies)
that a beneficiary or caregiver picks up
in person at a local pharmacy or
supplier storefront.
Parties to the hearing means the
DMEPOS contract supplier and CMS.
*
*
*
*
*
35. Section 414.404 is amended by
revising paragraph (b)(1)(i) to read as
follows:
§ 414.404
Scope and applicability.
*
*
*
*
*
(b) * * *
(1) * * *
(i) The items furnished are limited to
crutches, canes, walkers, folding manual
wheelchairs, blood glucose monitors,
and infusion pumps that are DME, and,
E:\FR\FM\13JYP2.SGM
13JYP2
40256
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
in addition, off-the-shelf (OTS)
orthotics.
*
*
*
*
*
36. Section 414.408 is amended by-–
A. Revising paragraph (f)(1).
B. Redesignating paragraphs (h)(2)
through (h)(7) as paragraphs (h)(3)
through (h)(8) respectively.
C. Adding new paragraph (h)(2).
D. In newly designated paragraphs
(h)(3)(i) and (ii), remove the phrase
‘‘(h)(2)’’ and add in its place the phrase
‘‘(h)(3).’’
The revision and addition reads as
follows:
§ 414.408
Payment rules.
*
*
*
*
*
(f) * * *
(1) The single payment amounts for
new purchased durable medical
equipment, including power
wheelchairs that are purchased when
the equipment is initially furnished, and
enteral nutrition equipment are
calculated based on the bids submitted
and accepted for these items. For
contracts entered into beginning on or
after January 1, 2011, payment on a
lump sum purchase basis is only
available for power wheelchairs
classified as complex rehabilitative
power wheelchairs.
*
*
*
*
*
(h) * * *
(2) For contracts entered into
beginning on or after January 1, 2011,
the monthly fee schedule amount for
rental of power wheelchairs equals 15
percent of the single payment amounts
calculated for new durable medical
equipment under paragraph (f)(1) of this
section for each of the first 3 months,
and 6 percent of the single payment
amounts calculated for these items for
each of the remaining months 4 through
13.
*
*
*
*
*
37. Section 414.410 is amended as
follows:
A. Revising paragraphs (a)(2) and
(a)(3).
B. Adding a new paragraph (a)(4).
The revisions and addition read as
follows:
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
§ 414.410 Phase-in implementation of
competitive bidding programs.
(a) * * *
(2) In CY 2011, in an additional 91
MSAs (the additional 70 MSAs selected
by CMS as of June 1, 2008, and the next
21 largest MSAs by total population
based on 2009 population estimates,
and not already phased in as of June 1,
2008). CMS may subdivide any of the 91
MSAs with a population of greater than
8,000,000 into separate CBAs, thereby
resulting in more than 91 CBAs.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(3) After CY 2011, additional CBAs
(or, in the case of national mail order for
items and services, after CY 2010).
(4) For competitions (other than for
national mail order items and services)
after CY 2011 and prior to CY 2015, the
following areas are excluded:
(i) Rural areas.
(ii) MSAs not selected under
paragraphs (a)(1) or (a)(2) of this section
with a population of less than 250,000.
(iii) An area with low population
density within an MSA not selected
under paragraphs (a)(1) or (a)(2) of this
section.
*
*
*
*
*
38. Section 414.411 is added to read
as follows:
§ 414.411 Special rule in case of
competitions for diabetic testing strips
conducted on or after January 1, 2011.
(a) National mail order competitions.
A supplier must demonstrate that their
bid submitted as part of a national mail
order competition for diabetic testing
strips covers the furnishing of a
sufficient number of different types of
diabetic testing strip products that, in
the aggregate, and taking into account
volume for the different products,
includes at least 50 percent of all the
different types of products on the
market. A type of diabetic testing strip
means a specific brand and model of
testing strips.
(b) Other competitions. CMS may
apply this special rule to non-mail order
or local competitions for diabetic testing
strips.
39. Section 414.422 is amended by
adding paragraph (e)(3) to read as
follows:
§ 414.422
Term of contracts.
*
*
*
*
*
(e) * * *
(3) Contract suppliers for diabetic
testing supplies must furnish the brand
of diabetic testing supplies that works
with the home blood glucose monitor
selected by the beneficiary. The contract
supplier is prohibited from influencing
or incentivizing the beneficiary by
persuading, pressuring, or advising
them to switch from their current brand
or for new beneficiaries from their
preferred brand of glucose monitor and
testing supplies. The contract supplier
may not furnish information about
alternative brands to the beneficiary
unless the beneficiary requests such
information.
*
*
*
*
*
40. Section 414.423 is added to read
as follows:
PO 00000
Frm 00218
Fmt 4701
Sfmt 4702
§ 414.423 Appeals process for termination
of competitive bidding contract.
This section implements an appeals
process for suppliers that CMS has
determined are in breach of their
Medicare DMEPOS Competitive Bidding
Program contracts and where CMS has
taken action to terminate the supplier’s
contract. Except as specified in this
regulation termination decisions made
under this section are final and binding.
(a) Terminations for breach of
contract. CMS may terminate a
supplier’s DMEPOS Competitive
Bidding Program contract when it
determines that the supplier has
violated any of the terms of its contract.
(b) Notice of termination—(1) CMS
notification. If CMS determines a
supplier to be in breach of its contract
either in part or in whole, it will notify
the Medicare DMEPOS supplier of the
termination by certified mail.
(2) Content of the notice. The CMS
notice sent by the CBIC will include the
following:
(i) The reasons for the termination.
(ii) The right to request a hearing by
a CBIC Hearing Officer, and depending
on the nature of the breach, the supplier
may also be allowed to submit a CAP in
lieu of requesting a hearing by a CBIC
Hearing Officer, as specified in
paragraph (c)(1)(i) of this section.
(iii) The address to which the written
request for a hearing must be mailed.
(iv) The address to which the CAP
must be mailed, if applicable.
(v) Penalties that will accompany the
termination, such as not being eligible
to bid in future rounds of competitive
bidding.
(vi) The effective date of termination
is 45 days from the date of the
notification letter unless a timely
hearing request has been filed or a
Corrective Action Plan (CAP) has been
submitted within 30 days of the date on
the notification letter.
(c) Corrective Action Plan.
(1) Option for Corrective Action Plan
(CAP).
(i) CMS has the option to allow a
DMEPOS supplier to provide a written
Corrective Action Plan (CAP) to remedy
the deficiencies identified in the notice,
when CMS determines that the delay in
the termination date caused by allowing
a CAP will not cause harm to
beneficiaries, for example, we would
not allow a CAP if the supplier has been
excluded, debarred, or convicted of a
healthcare related crime.
(ii) If a supplier chooses not to submit
a CAP or if CMS determines that a
supplier’s CAP is insufficient, the
supplier may request a hearing on the
termination.
(2) Submission of a CAP.
E:\FR\FM\13JYP2.SGM
13JYP2
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(i) A Corrective Action Plan must be
submitted within 30 calendar days from
the date on the notification letter. If the
supplier decides not to submit a
Corrective Action Plan the supplier may
within 30 days of the date on the
termination letter may request a hearing
by a CBIC hearing officer.
(ii) Suppliers will only have the
opportunity to submit a CAP when they
are first notified that they have been
determined to be in breach of contract.
If the CAP is not acceptable or properly
implemented, suppliers will receive a
termination notice.
(d) The purpose of the Corrective
Action Plan.
(1) For the supplier to eliminate all of
the deficiencies that were identified in
the CBIC notice to terminate its contract
to avoid contract termination.
(2) To identify the timeframes by
which the supplier will implement each
of the components of the CAP.
(e) Review of the CAP.
(1) The CBIC will review the CAP and
submit a recommendation to CMS
concerning whether the CAP includes
the steps necessary to remedy the
contract deficiencies as identified in the
notice.
(2) If CMS accepts the CAP, including
supplier’s designated timeframe for its
completion; the supplier must provide a
follow-up report within 5 days after the
supplier has fully implemented the CAP
that verifies that all of the deficiencies
identified in the CAP have been
corrected in accordance with the
timeframes accepted by CMS.
(3) If the supplier does not implement
an acceptable CAP the supplier will
receive a new notice that their contract
will be terminated within 45 calendar
days of the date on the notice to
terminate.
(f) Right to request a hearing by the
CBIC hearing officer (HO).
(1) A supplier who has received a
notice that CMS considers the supplier
in breach of contract or that the
supplier’s CAP is not acceptable has the
right to request a hearing before a HO
who was not involved with the original
determination.
(2) A supplier who wishes to appeal
the termination notice must submit a
written request to the CBIC. The request
for a hearing must be received by the
CBIC within 30 calendar days from the
date of the notice to terminate.
(3) A request for hearing must be in
writing and submitted by an authorized
official of the supplier.
(4) The appeals process for the
Medicare DMEPOS Competitive Bidding
Program is not to be used in place of
other existing appeals processes that
apply to other parts of Medicare.
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(5) In the absence of submitting a CAP
when the supplier is offered the
opportunity to submit a CAP within 30
days of the notice in accordance with
paragraph (c)(1) of this section, a
supplier’s failure to timely request a
hearing will result in a termination of
the supplier’s DMEPOS Competitive
Bidding Program contract effective 45
days from the date on the notice to
terminate.
(g) The CBIC Hearing Officer
schedules and conducts the hearing.
(1) Within 30 calendar days from the
receipt of the supplier’s timely request
for a hearing the hearing officer will
contact the parties to schedule the
hearing.
(2) The hearing may be held in person
or by telephone at the supplier’s
request.
(3) The scheduling notice to the
parties must indicate the time and place
for the hearing and must be sent to the
supplier 30 days before the date of the
hearing.
(4) The HO may, on his or her own
motion, or at the request of a party,
change the time and place for the
hearing, but must give the parties to the
hearing 30 day notice of the change.
(5) The HO’s scheduling notice must
provide the parties to the hearing and
the CBIC the following information:
(i) Description of the hearing
procedure.
(ii) The general and specific issues to
be resolved.
(iii) The supplier has the burden to
prove it is not in violation of the
contract.
(iv) The opportunity for parties to the
hearing to submit evidence to support
their positions.
(v) All evidence submitted, both from
the supplier and CMS, in preparation
for the hearing with all affected parties
within 15 days prior to the scheduled
dated of the hearing.
(h) Burden of proof.
(1) The burden of proof is on the
Competitive Bidding Program contract
supplier to demonstrate to the HO with
convincing evidence that it has not
breached its contract or that termination
is not appropriate.
(2) The supplier’s supporting
evidence must be submitted with its
request for a hearing.
(3) If the Medicare DMEPOS supplier
fails to submit this evidence at the time
of its submission, the Medicare
DMEPOS supplier is precluded from
introducing new evidence later during
the hearing process, unless permitted by
the hearing officer.
(4) The CBIC and CMS also have the
opportunity to submit evidence to the
HO within 10 days of receiving a notice
announcing the hearing.
PO 00000
Frm 00219
Fmt 4701
Sfmt 4702
40257
(5) The HO will share all evidence
submitted, both from the supplier and/
or CMS, in preparation for the hearing
with all affected parties within 15 days
prior to the scheduled date of the
hearing.
(i) Role of the Hearing Officer. The
HO will conduct a thorough and
independent review of the evidence
including the information and
documentation submitted for the
hearing and other information that the
HO considers pertinent for the hearing.
The role of the HO includes, at a
minimum, the following:
(1) Conducts the hearing and decides
the order in which the evidence and the
arguments of the parties are presented;
(2) Determine the rules on
admissibility of the evidence;
(3) Examines the witnesses, in
addition to the examinations conducted
by CMS, CBIC and the contract supplier;
(4) The CBIC may assist CMS in the
appeals process including being present
at the hearing, testifying as a witness, or
performing other, related ministerial
duties.
(5) Determines the rules for requesting
documents and other evidence from
other parties;
(6) Ensures a complete record of the
hearing is made available to all parties
to the hearing;
(7) Prepares a file of the record of the
hearing which includes all evidence
submitted as well as any relevant
documents identified by the HO and
considered as part of the hearing; and
(8) Complies with all applicable
provisions of 42 U.S.C. Title 18 and
related provisions of the Act, the
applicable regulations issued by the
Secretary, and manual instructions
issued by CMS.
(j) Hearing Officer recommendation.
(1) The HO will issue a written
recommendation to CMS within 30 days
of the close of the hearing or as soon as
practical after the hearing.
(2) The recommendation will explain
the basis and the rationale for the HO’s
recommendation.
(3) The hearing officer must include
the record of the hearing, along with
evidence and documents produced
during the hearing along with its
recommendation.
(k) CMS’ consideration of a HO’s
recommendation.
(1) CMS’ review of the HO
recommendation will not allow the
supplier to submit new information.
(2) After reviewing the HO
recommendation, CMS’ decision will be
made within 30 days from the date of
receipt of the HO’s recommendation.
(3) A CMS decision to terminate will
indicate the effective date of the
termination.
E:\FR\FM\13JYP2.SGM
13JYP2
40258
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(4) This decision is final and binding.
(l) Effect of contract termination.
(1) A contract supplier whose contract
has been terminated may no longer
furnish competitive bid items to
beneficiaries within a CBA and be
reimbursed by Medicare for these items
after the effective date of the
termination.
(2) A contract supplier whose contract
has been terminated must notify all
beneficiaries who are receiving rented
competitive bid items or competitive
bid items received on a recurring basis,
of the termination of their contract. The
notice to the beneficiary from the
supplier whose contract was terminated
must be provided within 5 days of
receipt of the final notice of termination.
The notification to the beneficiaries
must inform the beneficiaries that they
are going to have to select a new
contract supplier to furnish these items
in order for Medicare to pay these items.
(m) Effective date of the contract
termination.
(1) A supplier’s DMEPOS CBP
contract is terminated effective on the
termination date specified in the CBIC
notice to the supplier, unless the
supplier timely requests a hearing with
the HO or the supplier has submitted a
CAP under paragraph (x) of this section.
(2) If a supplier requests an HO
review of the CMS decision to terminate
its contract, and CMS based upon on the
HO recommendation terminates the
supplier’s contract, the effective date of
the termination will be the date
specified in the CBIC notice to the
supplier.
(3) For violations of the terms of the
supplier’s DMEPOS CBP contract that
may harm beneficiaries, such as a
supplier providing an inferior product
that causes harm to the beneficiary, no
delays of the effective date of the
termination will be allowed.
Subpart H–Fee Schedule for
Ambulance Services
39. Section 414.610 is amended by
revising paragraphs (c)(1)(i), (c)(5)(ii),
(f), and (h) to read as follows:
§ 414.610
Basis of payments.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
*
*
*
*
*
(c) * * *
(1) Ground ambulance service levels.
(i) The CF is multiplied by the
applicable RVUs for each level of
service to produce a service-level base
rate. For services furnished during the
period July 1, 2004 through December
31, 2006, ambulance services originating
in urban areas (both base rate and
mileage) are paid based on a rate that is
one percent higher than otherwise is
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
applicable under this section, and
ambulance services originating in rural
areas (both base rate and mileage) are
paid based on a rate that is two percent
higher than otherwise is applicable
under this section. For services
furnished during the period July 1, 2008
through December 21, 2010, ambulance
services originating in urban areas (both
base rate and mileage) are paid based on
a rate that is two percent higher than
otherwise is applicable under this
section, and ambulance services
originating in rural areas (both base rate
and mileage) are paid based on a rate
that is three percent higher than
otherwise is applicable under this
section.
*
*
*
*
*
(5) * * *
(ii) For services furnished during the
period July 1, 2004 through December
31, 2010, the payment amount for the
ground ambulance base rate is increased
by 22.6 percent where the point of
pickup is in a rural area determined to
be in the lowest 25 percent of rural
population arrayed by population
density. The amount of this increase is
based on CMS’s estimate of the ratio of
the average cost per trip for the rural
areas in the lowest quartile of
population compared to the average cost
per trip for the rural areas in the highest
quartile of population. In making this
estimate, CMS may use data provided
by the GAO.
*
*
*
*
*
(f) Updates. The CF, the air
ambulance base rates, and the mileage
rates are updated annually by an
inflation factor established by law. The
inflation factor is based on the
consumer price index for all urban
consumers (CPI–U) (U.S. city average)
for the 12-month period ending with
June of the previous year and, as of
January 1, 2011, is reduced by the 10year moving average of changes in
annual economy-wide private nonfarm
business multi-factor productivity
(MFP) (as projected by the Secretary for
the 10-year period ending with the
applicable fiscal year, year, cost
reporting period, or other annual
period.)
*
*
*
*
*
(h) Treatment of certain areas for
payment for air ambulance services.
Any area that was designated as a rural
area for purposes of making payments
under the ambulance fee schedule for
air ambulance services furnished on
December 31, 2006, must be treated as
a rural area for purposes of making
payments under the ambulance fee
schedule for air ambulance services
PO 00000
Frm 00220
Fmt 4701
Sfmt 4702
furnished during the period July 1, 2008
through December 31, 2010.
40. Section 414.620 is revised to read
as follows:
§ 414.620 Publication of the ambulance fee
schedule.
(a) Changes in payment rates resulting
from incorporation of the annual
inflation factor and the multi-factor
productivity adjustment as described in
§ 414.610(f) will be announced by CMS
by instruction and on the CMS Web site.
(b) CMS will follow applicable
rulemaking procedures in publishing
revisions to the fee schedule for
ambulance services that result from any
factors other than those described in
§ 414.610(f).
Subpart J—Submission of
Manufacturer’s Average Sales Price
Data
41. Section 414.804 is amended by—
A. Redesignating paragraph (a)(6) as
(a)(7).
B. Adding new paragraph (a)(6).
The addition reads as follows:
§ 414.804
Basis of payment.
(a) * * *
(6) The manufacturer’s average sales
price must be calculated based on the
amount of product in a vial or other
container as conspicuously reflected on
the FDA approved label as defined by
section 201(k) of the Food, Drug, and
Cosmetic Act.
*
*
*
*
*
Subpart K—Payment for Drugs and
Biologicals Under Part B
42. Section 414.902 is amended by
adding the definitions of ‘‘Biosimilar
biological product’’ and ‘‘Reference
biological product’’ in alphabetical order
to read as follows:
§ 414.902
Definitions.
*
*
*
*
*
Biosimilar biological product means a
biological product approved under an
abbreviated application for a license of
a biological product that relies in part
on data or information in an application
for another biological product licensed
under section 351 of the Public Health
Service Act (PHSA) as defined at section
1847A(c)(6)(H) of the Act.
*
*
*
*
*
Reference biological product means
the biological product licensed under
such section 351 of the PHSA that is
referred to in the application of the
biosimilar biological product as defined
at section 1847A(c)(6)(I) of the Act.
*
*
*
*
*
43. Section 414.904 is amended by—
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
A. Adding paragraphs (a)(3), (i), and
(j).
B. Revising paragraph (d)(3).
The revisions and additions read as
follows:
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
§ 414.904 Average sales price as the basis
for payment.
(a) * * *
(3) For purposes of this section—
(i) CMS calculates an average sales
price payment limit based on the
amount of product included in a vial or
other container as reflected on the FDAapproved label.
(ii) Additional product contained in
the vial or other container does not
represent a cost to providers and is not
incorporated into the ASP payment
limit.
(iii) No payment shall be made for
amounts of product in excess of that
reflected on the FDA-approved label.
*
*
*
*
*
(d) * * *
(3) Widely available market price and
average manufacturer price. If the
Inspector General finds that the average
sales price exceeds the widely available
market price or the average
manufacturer price by the applicable
threshold percentage specified in
paragraph (d)(3)(iii) of this section, the
Inspector General is responsible for
informing the Secretary (at such times
as specified by the Secretary) and the
payment amount for the drug or
biological will be substituted by the
lesser of the widely available market
price or 103 percent of the average
manufacturer price as subject to the
following adjustments:
(i) The payment amount substitution
will be applied at the next ASP payment
amount calculation period after the
Inspector General informs the Secretary
(at such times specified by the
Secretary) about drugs or biologicals
that have exceeded the applicable
threshold percentage, and will remain
in effect for one quarter after
publication.
(ii) Payment at 103 percent of the
average manufacturer price for a billing
code will be applied at such times
when:
(A) The threshold for making price
substitutions, as defined in section (iii)
is met; and,
(B) When 103 percent of the AMP is
less than the 106 percent of the ASP
during the quarter in which the average
manufacturer price would be applied.
(iii) The applicable threshold for AMP
comparisons for calendar years 2005,
2006, 2007, 2008, 2009, 2010, is 5
percent. For CY 2011, the threshold for
ASP comparisons is reached when:
(A) The ASP for the billing code has
exceeded the AMP for the billing code
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
by 5 percent or more in two consecutive
quarters, or three of the last four
quarters; immediately preceding the
quarter to which the price substitution
recommendation would apply; and,
(B) The average manufacturer price
for the billing code is calculated using
the same set of NDCs used for the
average sales price calculation as per
this section for the billing code;
(iv) The applicable threshold for
WAMP comparisons for calendar years
2005 through 2011 is 5 percent.
(v) No payment amount substitutions
will occur before the preliminary
injunction issued on December 19,
2007, by the United States District of
Columbia in National Association of
Chain Drug Stores et al. v. Health and
Human Services, Civil Action No. 1:07–
cv–02017 (RCL), is vacated.
*
*
*
*
*
(i) If manufacturer ASP data is not
available prior to the publication
deadline for quarterly payment limits,
the payment limit is calculated by
carrying over the most recent available
manufacturer ASP price from a previous
quarter for an NDC, adjusted by the
weighted average of the change in the
manufacturer ASPs for the NDCs that
were reported during both the most
recently available quarter and the
current quarter.
(j) Biosimilar biological products.
Effective July 1, 2010, the payment
amount for a biosimilar biological drug
product (as defined in § 414.902 of this
subpart) is the sum of the average sales
price of all NDCs assigned to the
biosimilar biological product as
determined under section 1847A(b)(6)
of the Act and 6 percent of the amount
determined under section 1847A(b)(4)
of the Act for the reference drug product
(as defined in § 414.902 of this subpart).
PART 415—SERVICES FURNISHED BY
PHYSICIANS IN PROVIDERS,
SUPERVISING PHYSICIANS IN
TEACHING SETTINGS, AND
RESIDENTS IN CERTAIN SETTINGS
44. The authority citation for part 415
continues to read as follows:
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
Subpart C—Part B Carrier Payments
for Physician Services to Beneficiaries
in Providers
45. Section 415.130 is amended by
revising paragraph (d) to read as
follows:
§ 415.130 Conditions for payment:
Physician pathology services.
*
PO 00000
*
Frm 00221
*
*
Fmt 4701
*
Sfmt 4702
40259
(d) Physician pathology services
furnished by an independent laboratory.
(1) The technical component of
physician pathology services furnished
by an independent laboratory to a
hospital inpatient or outpatient on or
before December 31, 2010, may be paid
to the laboratory by the contractor under
the physician fee schedule if the
Medicare beneficiary is a patient of a
covered hospital as defined in
paragraph (a)(1) of this section.
(2) For services furnished after
December 31, 2010, an independent
laboratory may not bill the Medicare
contractor for the technical component
of physician pathology services
furnished to a hospital inpatient or
outpatient.
(3) For services furnished on or after
January 1, 2008, the date of service
policy in § 414.510 of this chapter
applies to the TC of specimens for
physician pathology services.
PART 424—CONDITIONS FOR
MEDICARE PAYMENT
46. The authority citation for part 424
continues to read as follows:
Authority: Secs. 1102 and 1871 of the
Social Security Act (42 U.S.C. 1302 and
1395hh).
Subpart B—Certification and Plan of
Treatment Requirements
47. Section 424.20 is amended by
revising paragraph (e)(2) to read as
follows:
§ 424.20 Requirements for posthospital
SNF care.
*
*
*
*
*
(e) * * *
(2) A physician extender (that is, a
nurse practitioner, a clinical nurse
specialist, or a physician assistant as
those terms are defined in section
1861(aa)(5) of the Act) who does not
have a direct or indirect employment
relationship with the facility but who is
working in collaboration with a
physician. For purposes of this
section—
(i) Collaboration.
(A) Collaboration means a process
whereby a physician extender works
with a doctor of medicine or osteopathy
to deliver health care services.
(B) The services are delivered within
the scope of the physician extender’s
professional expertise, with medical
direction and appropriate supervision as
provided for in guidelines jointly
developed by the physician extender
and the physician or other mechanisms
defined by Federal regulations and the
law of the State in which the services
are performed.
E:\FR\FM\13JYP2.SGM
13JYP2
40260
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
(ii) Types of employment
relationships.
(A) Direct employment relationship. A
direct employment relationship with the
facility is one in which the physician
extender meets the common law
definition of the facility’s ‘‘employee,’’
as specified in 20 CFR 404.1005,
404.1007, and 404.1009. When a
physician extender meets this definition
with respect to an entity other than the
facility itself, and that entity has an
agreement with the facility for the
provision of nursing services under
§ 409.21 of this subchapter, the facility
is considered to have an indirect
employment relationship with the
physician extender.
(B) Indirect employment relationship.
(1) When a physician extender meets
the definition of a direct employment
relationship in paragraph (e)(2)(ii)(A) of
this section with respect to an entity
other than the facility itself, and that
entity has an agreement with the facility
for the provision of nursing services
under § 409.21 of this subchapter, the
facility is considered to have an indirect
employment relationship with the
physician extender.
(2) An indirect employment
relationship does not exist if the
agreement between the entity and the
facility involves only the performance of
delegated physician tasks under
§ 483.40(e) of this chapter.
*
*
*
*
*
Subpart C—Claims for Payment
48. Section 424.44 is amended by
revising paragraphs (a), (b), and (e) to
read as follows:
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
§ 424.44
Time limits for filing claims.
(a) Time limits.
(1) For services furnished on or after
January 1, 2010, except as provided in
paragraphs (b) and (e) of this section,
the claim must be filed no later than the
close of the period ending 1 calendar
year after the date of service.
(2) For services furnished before
January 1, 2010, except as provided in
paragraphs (b) and (e) of this section,
the claim must be filed on or before
December 31 of the following year for
services that were furnished during the
first 9 months of a calendar year, and on
or before December 31st of the second
following year for services that were
furnished during the last 3 months of
the calendar year, except that for
services furnished during the last 3
months of 2009 all claims must be filed
no later than December 31, 2010.
(b) Exceptions to time limits.
Exceptions to the time limits for filing
claims include the following:
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
(1) The time for filing a claim will be
extended if CMS or one of its
contractors determines that a failure to
meet the deadline in paragraph (a) of
this section was caused by error or
misrepresentation of an employee,
Medicare contractor (including
Medicare Administrative Contractor,
intermediary, or carrier), or agent of the
Department that was performing
Medicare functions and acting within
the scope of its authority.
(2) The time for filing a claim will be
extended if CMS or one of its
contractors determines that a failure to
meet the deadline in paragraph (a) of
this section is caused by all of the
following conditions:
(i) At the time the service was
furnished the beneficiary was not
entitled to Medicare.
(ii) The beneficiary subsequently
received notification of Medicare
entitlement effective retroactively to or
before the date of the furnished service.
(3) The time for filing a claim will be
extended if CMS or one of its
contractors determines that a failure to
meet the deadline in paragraph (a) of
this section is caused by all of the
following conditions:
(i) At the time the service was
furnished the beneficiary was not
entitled to Medicare.
(ii) The beneficiary subsequently
received notification of Medicare
entitlement effective retroactively to or
before the date of the furnished service.
(iii) A State Medicaid agency
recovered the Medicaid payment for the
furnished service from a provider or
supplier 11 months or more after the
service was furnished.
(4) Extension of time. (i) The time to
file a claim will be extended through the
last day of the 6th calendar month
following the month in which the error
or misrepresentation referenced in
paragraph (b)(1) of this section, is
corrected. However, no extension of
time will be granted for paragraph (b)(1)
when the request for that exception is
made to CMS or one of its contractors
more than 4 years after the date of
service.
(ii) If CMS or one of its contractors
determines that both of the conditions
are met in paragraph (b)(2) of this
section but that all of the conditions in
paragraph (b)(3) are not satisfied, the
time to file a claim will be extended
through the last day of the 6th calendar
month following the month in which
the beneficiary received notification of
Medicare entitlement effective
retroactively to or before the date of the
furnished service.
(iii) If CMS or one of its contractors
determines that all of the conditions are
PO 00000
Frm 00222
Fmt 4701
Sfmt 4702
met in paragraph (b)(3) of this section,
the time to file a claim will be extended
through the last day of the 6th calendar
month following the month in which
the State Medicaid agency recovered the
Medicaid payment for the furnished
service from the provider or supplier.
*
*
*
*
*
(e) As specified in §§ 424.520 and
424.521 of this subpart, there are
restrictions on the ability of the
following newly-enrolled suppliers to
submit claims for items or services
furnished prior to the effective date of
their Medicare billing privileges:
(1) Physician or non-physician
practitioner organizations.
(2) Physicians.
(3) Nonphysician practitioners.
(4) Independent diagnostic testing
facilities.
*
*
*
*
*
Subpart P—Requirements for
Establishing and Maintaining Medicare
Billing Privileges
49. Section 424.502 is amended by
adding a definition of ‘‘Voluntary
termination’’ in alphabetical order to
read as follows:
§ 424.502
Definitions.
*
*
*
*
*
Voluntary termination means that a
provider or supplier, including an
individual physician or non-physician
practitioner, submits written
confirmation to CMS of its decision to
discontinue enrollment in the Medicare
program.
50. Section 424.510 is amended by
revising paragraph (d)(1)(iii) to read as
follows:
§ 424.510 Requirements for enrolling in
the Medicare program.
*
*
*
*
*
(d) * * *
(1) * * *
(iii) Submission of all documentation,
including all applicable Federal and
State licenses, certifications (including,
but not limited to Federal Aviation
Administration and Clinical Laboratory
Improvement Act certifications), and
regulatory requirements that apply to
the specific provider or supplier type
that relate to providing health care
service, required by CMS under this or
other statutory or regulatory authority,
or under the Paperwork Reduction Act
of 1995, to establish the provider or
supplier’s eligibility to furnish Medicare
covered items or services to
beneficiaries in the Medicare program.
*
*
*
*
*
51. Section 424.516 is amended by
adding paragraph (e)(3) to read as
follows:
E:\FR\FM\13JYP2.SGM
13JYP2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
§ 424.516 Additional provider and supplier
requirements for enrolling and maintaining
active enrollment status in the Medicare
program.
*
*
*
*
*
(e) * * *
(3) Within 30 days any revocation or
suspension of a Federal or State license
or certification (including Federal
Aviation Administration and Clinical
Laboratory Improvement Act
certifications), an air ambulance
supplier must report a revocation or
suspension of its license or certification
to the applicable Medicare contractor.
*
*
*
*
*
Authority: (Catalog of Federal Domestic
Assistance Program No. 93.773, Medicare—
Hospital Insurance; and Program No. 93.774,
Medicare—Supplementary Medical
Insurance Program).
Dated: June 18, 2010.
Marilyn Tavenner,
Acting Administrator and Chief Operating
Officer, Centers for Medicare & Medicaid
Services.
Approved: June 24, 2010.
Kathleen Sebelius,
Secretary.
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
ADDENDUM A: Explanation and Use of
Addendum B
The Addenda on the following pages
provide various data pertaining to the
Medicare fee schedule for physicians’
services furnished in CY 2011. Addendum B
contains the RVUs for work, nonfacility PE,
facility PE, and malpractice expense, and
other information for all services included in
the PFS.
In previous years, we have listed many
services in Addendum B that are not paid
under the PFS. To avoid publishing as many
pages of codes for these services, we are not
including clinical laboratory codes or the
alpha-numeric codes (Healthcare Common
Procedure Coding System (HCPCS) codes not
included in CPT) not paid under the PFS in
Addendum B.
Addendum B contains the following
information for each CPT code and alphanumeric HCPCS code, except for: Alphanumeric codes beginning with B (enteral and
parenteral therapy); ‘‘E’’ (durable medical
equipment); ‘‘K’’ (temporary codes for
nonphysicians’ services or items); or ‘‘L’’
(orthotics); and codes for anesthesiology.
Please also note the following:
• An ‘‘NA’’ in the ‘‘Nonfacility PE RVUs’’
column of Addendum B means that CMS has
not developed PE RVUs in the nonfacility
setting for the service because it is typically
performed in the hospital (for example, an
open heart surgery is generally performed in
the hospital setting and not a physician’s
office). If there is an ‘‘NA’’ in the nonfacility
PE RVU column, and the contractor
determines that this service can be performed
in the nonfacility setting, the service will be
paid at the facility PE RVU rate.
• Services that have an ‘‘NA’’ in the
‘‘Facility PE RVUs’’ column of Addendum B
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
are typically not paid under the PFS when
provided in a facility setting. These services
(which include ‘‘incident to’’ services and the
technical portion of diagnostic tests) are
generally paid under either the hospital
outpatient prospective payment system or
bundled into the hospital inpatient
prospective payment system payment. In
some cases, these services may be paid in a
facility setting at the PFS rate (for example,
therapy services), but there would be no
payment made to the practitioner under the
PFS in these situations.
1. CPT/HCPCS code. This is the CPT or
alpha-numeric HCPCS number for the
service. Alpha-numeric HCPCS codes are
included at the end of this Addendum.
2. Modifier. A modifier is shown if there
is a technical component (modifier TC) and
a professional component (PC) (modifier-26)
for the service. If there is a PC and a TC for
the service, Addendum B contains three
entries for the code, specifically a code for:
The global values (both professional and
technical); modifier—26 (PC); and modifier—
TC. The global service is not designated by
a modifier, and physicians must bill using
the code without a modifier if the physician
furnishes both the PC and the TC of the
service. Modifier-53 is shown for a
discontinued procedure, for example a
colonoscopy that is not completed. There
will be RVUs for a code with this modifier.
3. Status indicator. This indicator shows
whether the CPT/HCPCS code is included in
the PFS and whether it is separately payable
if the service is covered.
A = Active code. These codes are
separately payable under the PFS if covered.
There will be RVUs for codes with this
status. The presence of an ‘‘A’’ indicator does
not mean that Medicare has made a national
coverage determination regarding the service.
Contractors remain responsible for coverage
decisions in the absence of a national
Medicare policy.
B = Bundled code. Payments for covered
services are always bundled into payment for
other services not specified. If RVUs are
shown, they are not used for Medicare
payment. If these services are covered,
payment for them is subsumed by the
payment for the services to which they are
incident (an example is a telephone call from
a hospital nurse regarding care of a patient).
C = Contractors price the code. Contractors
establish RVUs and payment amounts for
these services, generally on an individual
case basis following review of
documentation, such as an operative report.
E = Excluded from the PFS by regulation.
These codes are for items and services that
CMS chose to exclude from the PFS by
regulation. No RVUs are shown, and no
payment may be made under the PFS for
these codes. Payment for them, when
covered, continues under reasonable charge
procedures.
I = Not valid for Medicare purposes.
Medicare uses another code for the reporting
of, and the payment for these services. (Codes
not subject to a 90-day grace period.)
M = Measurement codes, used for reporting
purposes only. There are no RVUs and no
payment amounts for these codes. CMS uses
them to aid with performance measurement.
PO 00000
Frm 00223
Fmt 4701
Sfmt 4702
40261
No separate payment is made. These codes
should be billed with a zero (($0.00) charge
and are denied) on the MPFSDB.
N = Noncovered service. These codes are
noncovered services. Medicare payment may
not be made for these codes. If RVUs are
shown, they are not used for Medicare
payment.
R = Restricted coverage. Special coverage
instructions apply. If the service is covered
and no RVUs are shown, it is contractorpriced.
T = There are RVUs for these services, but
they are only paid if there are no other
services payable under the PFS billed on the
same date by the same provider. If any other
services payable under the PFS are billed on
the same date by the same provider, these
services are bundled into the service(s) for
which payment is made.
X = Statutory exclusion. These codes
represent an item or service that is not within
the statutory definition of ‘‘physicians’
services’’ for PFS payment purposes. No
RVUs are shown for these codes, and no
payment may be made under the PFS.
(Examples are ambulance services and
clinical diagnostic laboratory services.)
4. Description of code. This is an
abbreviated version of the narrative
description of the code.
5. Physician work RVUs. These are the
RVUs for the physician work in CY 2011.
6. Fully implemented nonfacility PE RVUs.
These are the fully implemented resourcebased PE RVUs for nonfacility settings.
7. CY 2011 transitional nonfacility PE
RVUs. These are the CY 2011 resource-based
PE RVUs for nonfacility settings.
8. Fully implemented facility PE RVUs.
These are the fully implemented resourcebased PE RVUs for facility settings.
9. CY 2011 Transitional facility PE RVUs.
These are the CY 2011 resource-based PE
RVUs for facility settings.
10. Malpractice expense RVUs. These are
the RVUs for the malpractice expense for CY
2011.
Note: The BN reduction resulting from the
chiropractic demonstration is not reflected in
the RVUs for CPT codes 98940, 98941 and
98942. The required reduction will only be
reflected in the files used for Medicare
payment.
11. Global period. This indicator shows the
number of days in the global period for the
code (0, 10, or 90 days). An explanation of
the alpha codes follows:
MMM = Code describes a service furnished
in uncomplicated maternity cases, including
antepartum care, delivery, and postpartum
care. The usual global surgical concept does
not apply. See the Physicians’ Current
Procedural Terminology for specific
definitions.
XXX = The global concept does not apply.
YYY = The global period is to be set by the
contractor (for example, unlisted surgery
codes).
ZZZ = Code related to another service that
is always included in the global period of the
other service. (Note: Physician work and PE
are associated with intra-service time and, in
some instances, with the post-service time.)
E:\FR\FM\13JYP2.SGM
13JYP2
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00224
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.004
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40262
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00225
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40263
EP13JY10.005
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00226
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.006
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40264
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00227
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40265
EP13JY10.007
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00228
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.008
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40266
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00229
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40267
EP13JY10.009
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00230
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.010
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40268
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00231
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40269
EP13JY10.011
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00232
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.012
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40270
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00233
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40271
EP13JY10.013
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00234
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.014
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40272
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00235
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40273
EP13JY10.015
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00236
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.016
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40274
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00237
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40275
EP13JY10.017
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00238
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.018
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40276
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00239
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40277
EP13JY10.019
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00240
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.020
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40278
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00241
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40279
EP13JY10.021
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00242
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.022
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40280
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00243
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40281
EP13JY10.023
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00244
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.024
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40282
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00245
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40283
EP13JY10.025
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00246
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.026
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40284
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00247
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40285
EP13JY10.027
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00248
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.028
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40286
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00249
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40287
EP13JY10.029
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00250
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.030
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40288
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00251
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40289
EP13JY10.031
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00252
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.032
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40290
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00253
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40291
EP13JY10.033
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00254
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.034
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40292
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00255
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40293
EP13JY10.035
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00256
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.036
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40294
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00257
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40295
EP13JY10.037
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00258
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.038
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40296
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00259
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40297
EP13JY10.039
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00260
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.040
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40298
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00261
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40299
EP13JY10.041
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00262
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.042
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40300
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00263
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40301
EP13JY10.043
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00264
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.044
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40302
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00265
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40303
EP13JY10.045
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00266
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.046
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40304
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00267
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40305
EP13JY10.047
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00268
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.048
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40306
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00269
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40307
EP13JY10.049
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00270
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.050
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40308
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00271
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40309
EP13JY10.051
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00272
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.052
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40310
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00273
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40311
EP13JY10.053
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00274
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.054
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40312
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00275
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40313
EP13JY10.055
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00276
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.056
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40314
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00277
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40315
EP13JY10.057
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00278
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.058
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40316
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00279
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40317
EP13JY10.059
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00280
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.060
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40318
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00281
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40319
EP13JY10.061
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00282
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.062
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40320
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00283
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40321
EP13JY10.063
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00284
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.064
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40322
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00285
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40323
EP13JY10.065
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00286
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.066
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40324
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00287
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40325
EP13JY10.067
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00288
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.068
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40326
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00289
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40327
EP13JY10.069
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00290
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.070
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40328
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00291
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40329
EP13JY10.071
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00292
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.072
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40330
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00293
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40331
EP13JY10.073
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00294
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.074
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40332
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00295
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40333
EP13JY10.075
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00296
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.076
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40334
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00297
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40335
EP13JY10.077
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00298
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.078
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40336
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00299
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40337
EP13JY10.079
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00300
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.080
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40338
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00301
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40339
EP13JY10.081
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00302
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.082
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40340
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00303
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40341
EP13JY10.083
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00304
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.084
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40342
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00305
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40343
EP13JY10.085
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00306
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.086
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40344
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00307
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40345
EP13JY10.087
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00308
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.088
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40346
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00309
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40347
EP13JY10.089
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00310
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.090
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40348
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00311
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40349
EP13JY10.091
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00312
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.092
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40350
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00313
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40351
EP13JY10.093
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00314
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.094
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40352
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00315
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40353
EP13JY10.095
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00316
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.096
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40354
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00317
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40355
EP13JY10.097
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00318
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.098
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40356
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00319
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40357
EP13JY10.099
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00320
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.100
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40358
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00321
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40359
EP13JY10.101
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00322
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.102
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40360
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00323
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40361
EP13JY10.103
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00324
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.104
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40362
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00325
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40363
EP13JY10.105
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00326
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.106
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40364
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00327
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40365
EP13JY10.107
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00328
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.108
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40366
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00329
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40367
EP13JY10.109
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00330
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.110
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40368
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00331
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40369
EP13JY10.111
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00332
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.112
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40370
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00333
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40371
EP13JY10.113
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00334
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.114
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40372
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00335
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40373
EP13JY10.115
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00336
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.116
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40374
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00337
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40375
EP13JY10.117
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00338
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.118
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40376
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00339
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40377
EP13JY10.119
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00340
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.120
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40378
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00341
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40379
EP13JY10.121
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00342
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.122
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40380
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00343
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40381
EP13JY10.123
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00344
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.124
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40382
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00345
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40383
EP13JY10.125
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00346
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.126
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40384
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00347
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40385
EP13JY10.127
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00348
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.128
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40386
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00349
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40387
EP13JY10.129
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00350
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.130
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40388
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00351
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40389
EP13JY10.131
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00352
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.132
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40390
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00353
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40391
EP13JY10.133
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00354
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.134
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40392
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00355
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40393
EP13JY10.135
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00356
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.136
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40394
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00357
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40395
EP13JY10.137
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00358
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.138
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40396
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00359
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40397
EP13JY10.139
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00360
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.140
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40398
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00361
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40399
EP13JY10.141
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00362
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.142
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40400
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00363
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40401
EP13JY10.143
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00364
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.144
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40402
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00365
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40403
EP13JY10.145
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00366
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.146
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40404
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00367
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40405
EP13JY10.147
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00368
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.148
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40406
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00369
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40407
EP13JY10.149
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00370
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.150
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40408
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00371
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40409
EP13JY10.151
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00372
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.152
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40410
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00373
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40411
EP13JY10.153
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00374
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.154
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40412
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00375
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40413
EP13JY10.155
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00376
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.156
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40414
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00377
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40415
EP13JY10.157
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00378
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.158
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40416
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00379
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40417
EP13JY10.159
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00380
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.160
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40418
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00381
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40419
EP13JY10.161
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00382
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.162
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40420
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00383
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40421
EP13JY10.163
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00384
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.164
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40422
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00385
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40423
EP13JY10.165
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00386
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.166
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40424
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00387
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40425
EP13JY10.167
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00388
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.168
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40426
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00389
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40427
EP13JY10.169
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00390
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.170
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40428
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00391
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40429
EP13JY10.171
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00392
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.172
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40430
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00393
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40431
EP13JY10.173
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00394
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.174
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40432
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00395
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40433
EP13JY10.175
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00396
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.176
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40434
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00397
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40435
EP13JY10.177
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00398
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.178
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40436
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00399
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40437
EP13JY10.179
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00400
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.180
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40438
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00401
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40439
EP13JY10.181
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00402
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.182
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40440
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00403
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40441
EP13JY10.183
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00404
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.184
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40442
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00405
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40443
EP13JY10.185
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00406
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.186
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40444
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00407
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40445
EP13JY10.187
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00408
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.188
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40446
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00409
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40447
EP13JY10.189
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00410
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.190
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40448
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00411
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40449
EP13JY10.191
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00412
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.192
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40450
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00413
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40451
EP13JY10.193
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00414
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.194
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40452
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00415
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40453
EP13JY10.195
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00416
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.196
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40454
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00417
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40455
EP13JY10.197
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00418
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.198
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40456
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00419
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40457
EP13JY10.199
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00420
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.200
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40458
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00421
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40459
EP13JY10.201
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00422
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.202
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40460
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00423
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40461
EP13JY10.203
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00424
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.204
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40462
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00425
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40463
EP13JY10.205
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00426
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.206
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40464
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00427
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40465
EP13JY10.207
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00428
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.208
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40466
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00429
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40467
EP13JY10.209
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00430
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.210
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40468
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00431
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40469
EP13JY10.211
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00432
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.212
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40470
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00433
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40471
EP13JY10.213
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00434
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.214
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40472
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00435
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40473
EP13JY10.215
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00436
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.216
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40474
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00437
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40475
EP13JY10.217
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00438
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.218
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40476
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00439
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40477
EP13JY10.219
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00440
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.220
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40478
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00441
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40479
EP13JY10.221
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00442
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.222
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40480
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00443
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40481
EP13JY10.223
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00444
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.224
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40482
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00445
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40483
EP13JY10.225
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00446
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.226
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40484
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00447
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40485
EP13JY10.227
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00448
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.228
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40486
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00449
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40487
EP13JY10.229
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00450
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.230
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40488
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00451
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40489
EP13JY10.231
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00452
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.232
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40490
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00453
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40491
EP13JY10.233
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00454
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.234
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40492
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00455
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40493
EP13JY10.235
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00456
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.236
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40494
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00457
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40495
EP13JY10.237
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00458
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.238
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40496
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00459
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40497
EP13JY10.239
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00460
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.240
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40498
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00461
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40499
EP13JY10.241
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00462
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.242
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40500
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00463
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40501
EP13JY10.243
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00464
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.244
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40502
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00465
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40503
EP13JY10.245
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00466
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.246
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40504
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00467
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40505
EP13JY10.247
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00468
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.248
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40506
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00469
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40507
EP13JY10.249
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00470
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.250
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40508
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00471
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40509
EP13JY10.251
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00472
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.252
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40510
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00473
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40511
EP13JY10.253
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00474
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.254
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40512
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00475
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40513
EP13JY10.255
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00476
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.256
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40514
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00477
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40515
EP13JY10.257
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00478
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.258
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40516
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00479
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40517
EP13JY10.259
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00480
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.260
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40518
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00481
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40519
EP13JY10.261
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00482
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.262
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40520
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00483
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40521
EP13JY10.263
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00484
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.264
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40522
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00485
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40523
EP13JY10.265
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00486
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.266
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40524
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00487
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40525
EP13JY10.267
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00488
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.268
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40526
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00489
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40527
EP13JY10.269
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00490
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.270
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40528
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00491
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40529
EP13JY10.271
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00492
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.272
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40530
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00493
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40531
EP13JY10.273
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00494
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.274
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40532
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00495
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40533
EP13JY10.275
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00496
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.276
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40534
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00497
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40535
EP13JY10.277
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00498
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.278
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40536
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00499
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40537
EP13JY10.279
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00500
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.280
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40538
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00501
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40539
EP13JY10.281
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00502
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.282
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40540
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00503
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40541
EP13JY10.283
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00504
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.284
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40542
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00505
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40543
EP13JY10.285
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00506
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.286
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40544
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00507
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40545
EP13JY10.287
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00508
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.288
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40546
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00509
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40547
EP13JY10.289
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00510
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.290
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40548
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00511
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40549
EP13JY10.291
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00512
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.292
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40550
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00513
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40551
EP13JY10.293
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00514
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.294
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40552
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00515
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40553
EP13JY10.295
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00516
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.296
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40554
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00517
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40555
EP13JY10.297
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00518
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.298
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40556
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00519
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40557
EP13JY10.299
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00520
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.300
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40558
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00521
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40559
EP13JY10.301
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00522
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.302
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40560
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00523
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40561
EP13JY10.303
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00524
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.304
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40562
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00525
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40563
EP13JY10.305
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00526
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.306
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40564
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00527
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40565
EP13JY10.307
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00528
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.308
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40566
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00529
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40567
EP13JY10.309
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00530
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.310
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40568
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00531
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40569
EP13JY10.311
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00532
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.312
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40570
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00533
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40571
EP13JY10.313
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00534
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.314
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40572
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00535
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40573
EP13JY10.315
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00536
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.316
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40574
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00537
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40575
EP13JY10.317
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00538
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.318
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40576
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00539
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40577
EP13JY10.319
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00540
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.320
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40578
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00541
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40579
EP13JY10.321
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00542
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.322
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40580
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00543
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40581
EP13JY10.323
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00544
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.324
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40582
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00545
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40583
EP13JY10.325
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00546
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.326
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40584
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00547
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40585
EP13JY10.327
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00548
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.328
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40586
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00549
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40587
EP13JY10.329
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00550
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.330
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40588
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00551
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40589
EP13JY10.331
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00552
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.332
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40590
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00553
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40591
EP13JY10.333
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00554
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.334
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40592
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00555
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40593
EP13JY10.335
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00556
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.336
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40594
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00557
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40595
EP13JY10.337
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00558
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.338
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40596
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00559
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40597
EP13JY10.339
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00560
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.340
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40598
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00561
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40599
EP13JY10.341
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00562
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.342
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40600
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00563
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40601
EP13JY10.343
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00564
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.344
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40602
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00565
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40603
EP13JY10.345
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00566
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.346
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40604
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00567
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40605
EP13JY10.347
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00568
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.348
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40606
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00569
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40607
EP13JY10.349
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00570
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.350
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40608
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00571
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40609
EP13JY10.351
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00572
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.352
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40610
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00573
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40611
EP13JY10.353
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00574
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.354
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40612
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00575
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40613
EP13JY10.355
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00576
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.356
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40614
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00577
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40615
EP13JY10.357
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00578
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.358
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40616
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00579
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40617
EP13JY10.359
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00580
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.360
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40618
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00581
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40619
EP13JY10.361
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00582
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.362
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40620
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00583
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40621
EP13JY10.363
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00584
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.364
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40622
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00585
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40623
EP13JY10.365
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00586
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.366
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40624
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00587
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40625
EP13JY10.367
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00588
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.368
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40626
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00589
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40627
EP13JY10.369
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00590
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.370
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40628
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00591
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40629
EP13JY10.371
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00592
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.372
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40630
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00593
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40631
EP13JY10.373
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00594
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.374
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40632
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00595
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40633
EP13JY10.375
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00596
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.376
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40634
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00597
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40635
EP13JY10.377
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00598
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.378
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40636
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00599
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40637
EP13JY10.379
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00600
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.380
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40638
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00601
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40639
EP13JY10.381
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00602
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.382
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40640
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00603
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40641
EP13JY10.383
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00604
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.384
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40642
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00605
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40643
EP13JY10.385
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00606
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.386
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40644
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00607
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40645
EP13JY10.387
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00608
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.388
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40646
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00609
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40647
EP13JY10.389
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00610
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.390
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40648
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00611
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40649
EP13JY10.391
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00612
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.392
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40650
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00613
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40651
EP13JY10.393
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00614
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.394
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40652
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00615
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40653
EP13JY10.395
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00616
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.396
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40654
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00617
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40655
EP13JY10.397
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00618
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.398
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40656
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00619
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40657
EP13JY10.399
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00620
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.400
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40658
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00621
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40659
EP13JY10.401
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00622
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.402
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40660
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00623
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40661
EP13JY10.403
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00624
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.404
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40662
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00625
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40663
EP13JY10.405
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00626
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.406
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40664
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00627
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40665
EP13JY10.407
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00628
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.408
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40666
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00629
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40667
EP13JY10.409
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00630
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.410
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40668
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00631
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40669
EP13JY10.411
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00632
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.412
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40670
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00633
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40671
EP13JY10.413
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00634
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.414
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40672
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00635
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40673
EP13JY10.415
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00636
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.416
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40674
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00637
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40675
EP13JY10.417
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00638
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.418
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40676
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00639
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40677
EP13JY10.419
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00640
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.420
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40678
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00641
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40679
EP13JY10.421
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00642
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.422
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40680
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00643
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40681
EP13JY10.423
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00644
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.424
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40682
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00645
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40683
EP13JY10.425
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00646
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.426
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40684
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00647
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40685
EP13JY10.427
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00648
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.428
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40686
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00649
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40687
EP13JY10.429
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00650
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.430
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40688
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00651
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40689
EP13JY10.431
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00652
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.432
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40690
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00653
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40691
EP13JY10.433
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00654
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.434
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40692
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00655
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40693
EP13JY10.435
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00656
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.436
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40694
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00657
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40695
EP13JY10.437
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00658
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.438
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40696
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00659
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40697
EP13JY10.439
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00660
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.440
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40698
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00661
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40699
EP13JY10.441
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00662
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.442
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40700
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00663
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40701
EP13JY10.443
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00664
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.444
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40702
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00665
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40703
EP13JY10.445
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00666
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.446
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40704
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00667
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40705
EP13JY10.447
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00668
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.448
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40706
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00669
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
40707
EP13JY10.449
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
VerDate Mar<15>2010
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00670
Fmt 4701
Sfmt 4725
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.450
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
40708
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Proposed Rules
40709
[FR Doc. 2010–15900 Filed 6–25–10; 4:15 pm]
VerDate Mar<15>2010
20:23 Jul 12, 2010
Jkt 220001
PO 00000
Frm 00671
Fmt 4701
Sfmt 9990
E:\FR\FM\13JYP2.SGM
13JYP2
EP13JY10.451
jlentini on DSKJ8SOYB1PROD with PROPOSALS2
BILLING CODE 4120–01–P
Agencies
[Federal Register Volume 75, Number 133 (Tuesday, July 13, 2010)]
[Proposed Rules]
[Pages 40040-40709]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15900]
[[Page 40039]]
-----------------------------------------------------------------------
Part II
Book 2 of 2 Books
Pages 40039-40718
Department of Health and Human Services
-----------------------------------------------------------------------
Centers for Medicare & Medicaid Services
-----------------------------------------------------------------------
42 CFR Parts 405, 409, et al.
Medicare Program; Payment Policies Under the Physician Fee Schedule and
Other Revisions to Part B for CY 2011; Proposed Rule
Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 /
Proposed Rules
[[Page 40040]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 405, 409, 410, 411, 413, 414, 415, and 424
[CMS-1503-P]
RIN 0938-AP79
Medicare Program; Payment Policies Under the Physician Fee
Schedule and Other Revisions to Part B for CY 2011
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Proposed rule.
-----------------------------------------------------------------------
SUMMARY: This proposed rule addresses proposed changes to the physician
fee schedule and other Medicare Part B payment policies to ensure that
our payment systems are updated to reflect changes in medical practice
and the relative value of services. It also addresses, implements or
discusses certain provisions of both the Affordable Care Act and the
Medicare Improvements for Patients and Providers Act of 2008. In
addition, this proposed rule discusses payments under the Ambulance Fee
Schedule, Clinical Laboratory Fee Schedule, payments to ESRD
facilities, and payments for Part B drugs. Finally, the proposed rule
includes a discussion regarding the Chiropractic Services Demonstration
program, the Competitive Bidding Program for Durable Medical Equipment
and Provider and Supplier Enrollment Issues associated with Air
Ambulances. (See the Table of Contents for a listing of the specific
issues addressed in this proposed rule.)
DATES: To be assured consideration, comments must be received at one of
the addresses provided below, no later than 5 p.m. on August 24, 2010.
ADDRESSES: In commenting, please refer to file code CMS-1503-P. Because
of staff and resource limitations, we cannot accept comments by
facsimile (FAX) transmission.
You may submit comments in one of four ways (please choose only one
of the ways listed):
1. Electronically. You may submit electronic comments on this
regulation to https://www.regulations.gov. Follow the instructions for
``submitting a comment.''
2. By regular mail. You may mail written comments to the following
address only:
Centers for Medicare & Medicaid Services, Department of Health and
Human Services, Attention: CMS-1503-P, P.O. Box 8013, Baltimore, MD
21244-8013.
Please allow sufficient time for mailed comments to be received
before the close of the comment period.
3. By express or overnight mail. You may send written comments to
the following address only:
Centers for Medicare & Medicaid Services, Department of Health and
Human Services, Attention: CMS-1503-P, Mail Stop C4-26-05, 7500
Security Boulevard, Baltimore, MD 21244-1850.
4. By hand or courier. If you prefer, you may deliver (by hand or
courier) your written comments before the close of the comment period
to either of the following addresses:
a. For delivery in Washington, DC--Centers for Medicare & Medicaid
Services, Department of Health and Human Services, Room 445-G, Hubert
H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC
20201.
(Because access to the interior of the Hubert H. Humphrey Building
is not readily available to persons without Federal government
identification, commenters are encouraged to leave their comments in
the CMS drop slots located in the main lobby of the building. A stamp-
in clock is available for persons wishing to retain a proof of filing
by stamping in and retaining an extra copy of the comments being
filed.)
b. For delivery in Baltimore, MD--Centers for Medicare & Medicaid
Services, Department of Health and Human Services, 7500 Security
Boulevard, Baltimore, MD 21244-1850.
If you intend to deliver your comments to the Baltimore address,
please call telephone number (410) 786-9994 in advance to schedule your
arrival with one of our staff members.
Comments mailed to the addresses indicated as appropriate for hand
or courier delivery may be delayed and received after the comment
period.
FOR FURTHER INFORMATION CONTACT:
Rebecca Cole, (410) 786-4497, for issues related to physician payment
and for all other issues not identified below.
Cheryl Gilbreath, (410) 786-5919, for issues related to payment for
covered outpatient drugs and biologicals.
Roechel Kujawa, (410) 786-9111, for issues related to ambulance
services.
Glenn McGuirk, (410) 786-5723, for clinical laboratory issues.
Randall Ricktor, (410) 786-4632, for Federally Qualified Health Center
Issues.
Pauline Lapin, (410) 786-6883, for issues related to the chiropractic
services demonstration BN issue.
Troy Barsky, (410)786-8873, or Kristin Bohl, (410)786-8680, for issues
related to physician self-referral.
Troy Barsky, (410)786-8873, or Fred Grabau (410)786-0206, for issues
related to timely filing rules.
Henry Richter, (410)786-4562, or Lisa Hubbard, (410)786-5472, for
issues related to renal dialysis provisions and payments for end-stage
renal disease facilities.
Diane Stern, (410)786-1133, for issues related to the physician quality
reporting initiative and incentives for e-prescribing.
Sheila Roman, 410-786-6004, or Pamela Cheetham, 410-786-2259, for
issues related to the Physician Resource Use Feedback Program and
value-based purchasing.
Joel Kaiser, (410)786-4499, for issues related to the DME provisions.
Jim Bossenmeyer, (410)786-9317, for issues related to provider and
supplier enrollment issues.
SUPPLEMENTARY INFORMATION:
Inspection of Public Comments: All comments received before the
close of the comment period are available for viewing by the public,
including any personally identifiable or confidential business
information that is included in a comment. We post all comments
received before the close of the comment period on the following Web
site as soon as possible after they have been received: https://www.regulations.gov. Follow the search instructions on that Web site to
view public comments.
Comments received timely will also be available for public
inspection as they are received, generally beginning approximately 3
weeks after publication of a document, at the headquarters of the
Centers for Medicare & Medicaid Services, 7500 Security Boulevard,
Baltimore, Maryland 21244, Monday through Friday of each week from 8:30
a.m. to 4 p.m. To schedule an appointment to view public comments,
phone 1-800-743-3951.
Table of Contents
To assist readers in referencing sections contained in this
preamble, we are providing a table of contents. Some of the issues
discussed in this preamble affect the payment policies, but do not
require changes to the regulations in the Code of Federal Regulations
(CFR). Information on the regulation's impact appears throughout the
preamble, and therefore, is not discussed exclusively in section V. of
this proposed rule.
I. Background
A. Development of the Relative Value System
[[Page 40041]]
1. Work RVUs
2. Practice Expense Relative Value Units (PE RVUs)
3. Resource-Based Malpractice (MP) RVUs
4. Refinements to the RVUs
5. Adjustments to RVUs Are Budget Neutral
B. Components of the Fee Schedule Payment Amounts
C. Most Recent Changes to Fee Schedule
II. Provisions of the Proposed Rule for the Physician Fee Schedule
A. Resource-Based Practice Expense (PE) Relative Value Units
(RVUs)
1. Overview
2. Practice Expense Methodology
a. Direct Practice Expense
b. Indirect Practice Expense per Hour Data
c. Allocation of PE to Services
(i) Direct Costs
(ii) Indirect Costs
d. Facility and Nonfacility Costs
e. Services with Technical Components (TCs) and Professional
Components (PCs)
f. Alternative Data Sources and Public Comments on Final Rule
for 2010
g. PE RVU Methodology
(i) Setup File
(ii) Calculate the Direct Cost PE RVUs
(iii) Create the Indirect Cost PE RVUs
(iv) Calculate the Final PE RVUs
(v) Setup File Information
(vi) Equipment Cost per Minute
3. Proposed PE Revisions for CY 2011
a. Equipment Utilization Rate
b. HCPCS Code-Specific PE Proposals
(1) Biohazard Bags
(2) PE Inputs for Professional Component (PC) Only and Technical
Component (TC) Only Codes Summing to Global Only Codes
(3) Equipment Time Inputs for Certain Diagnostic Tests
(4) Cobalt-57 Flood Source
(5) Venom Immunotherapy
(6) Equipment Redundancy
(7) Equipment Duplication
(8) Establishing Overall Direct PE Supply Price Inputs Based on
Unit Prices and Quantities
c. AMA RUC Recommendations in CY 2010 for Changes to Direct PE
Inputs
(1) Electrogastrography and Esophageal Function Test
(2) 64-Slice CT Scanner and Software
(3) Cystometrogram
(4) Breath Hydrogen Test
(5) Radiographic Fluoroscopic Room
d. Referral of Existing CPT Codes for AMA RUC Review
e. Updating Equipment and Supply Price Inputs for Existing Codes
B. Malpractice Relative Value Units (RVUs)
1. Background
2. Malpractice RVUs for New and Revised Services Effective
Before the Next 5-Year Review
3. Revised Malpractice RVUs for Selected Disc Arthroplasty
Services
C. Potentially Misvalued Codes Under the Physician Fee Schedule
1. Valuing Services Under the PFS
2. Identifying, Reviewing, and Validating the RVUs of
Potentially Misvalued Services Under the PFS
a. Background
b. Progress in Identifying and Reviewing Potentially Misvalued
Codes
c. Validating RVUs of Potentially Misvalued Codes
3. CY 2011 Identification and Review of Potentially Misvalued
Services
a. Codes on the Multi-Specialty Points of Comparison List
b. Codes With Low Work RVUs Commonly Billed in Multiple Units
Per Single Encounter
c. Codes With High Volume and Low Work RVUs
d. Codes With Site-of-Service-Anomalies
e. Codes With ``23-hour'' Stays
4. Expanding the Multiple Procedure Payment Reduction (MPPR)
Policy to Additional Nonsurgical Services
a. Background
b. Proposed CY 2011 Expansion of the Imaging Technical Component
MPPR Policy to Additional Combinations of Imaging Services
c. Proposed CY 2011 Expansion of the MPPR Policy to Therapy
Services
5. High Cost Supplies
a. Background
b. Future Updates to the Prices of High-Cost Supplies
D. Geographic Practice Cost Indices (GPCIs)
1. Background
2. GPCI Update
a. Physician Work GPCIs
b. Practice Expense GPCIs
(1) The Affordable Care Act Requirements for PE GPCIs
(2) Summary of CY 2011 Proposed PE GPCIs
c. Malpractice GPCIs
d. General GPCI Update Process
3. Payment Localities
E. Physician Fee Schedule Update for CY 2011
1. Rebasing the Medicare Economic Index (MEI)
a. Background
b. Use of More Current Data
c. Rebasing and Revising Expense Categories in the MEI
(1) Developing the Weights for Use in the MEI
(2) Physician's Own Time
(3) Physician's Practice Expenses
(A) Non-Physician Employee Compensation
(B) Office Expenses
(C) Professional Liability Insurance (PLI) Expense
(D) Medical Equipment Expenses
(E) Medical Supplies Expenses
(F) All Other Professional Expenses
d. Selection of Price Proxies for Use in the MEI
(1) Expense Categories in the MEI
(A) Physician's Own Time (Physician Compensation)
(B) Nonphysician Employee Compensation
(C) Utilities
(D) Chemicals
(E) Paper
(F) Rubber and Plastics
(G) Telephone
(H) Postage
(I) All Other Labor-Intensive Services
(J) Fixed Capital
(K) Moveable Capital
(L) Professional Liability Insurance
(M) Medical Equipment
(N) Other Professional Expenses
(2) Productivity Adjustment to the MEI
e. Results of Rebasing
f. Adjustments to the RVU Shares to Match the Proposed Rebased
MEI Weights
III. Code-Specific Issues for the PFS
A. Therapy Services
1. Outpatient Therapy Caps for CY 2011
2. Alternatives to Therapy Caps
a. Background
b. Current Activities
c. Potential Short-Term Approaches to Therapy Caps
B. Diabetes Self-Management Training (DSMT) Services (HCPCS
Codes G0108 and G0109)
1. Background
2. Proposed Payment for DSMT Services
C. End-State Renal Disease Related Services for Home Dialysis
(CPT Codes 90963, 90964, 90965, and 90966)
1. End-Stage Renal Disease Home Dialysis Monthly Capitation
Payment Services (CPT Codes 90963, 90964, 90965, and 90966)
2. Daily and Monthly ESRD-Related Services (CPT Codes 90951
Through 90970)
D. Portable X-Ray Set-Up (HCPCS Code Q0092)
E. Pulmonary Rehabilitation Services (HCPCS Code G0424)
F. Application of Tissue-Cultured Skin Substitutes to Lower
Extremities (HCPCS Codes GXXX1 and GXXX2)
G. Canalith Repositioning (CPT Code 95992)
H. Intranasal/Oral Immunization Codes (CPT Codes 90467, 90468,
90473, and 90474)
I. Refinement Panel Process
J. Remote Cardiac Monitoring Services (CPT Codes 93012, 93229,
93268, and 93271)
IV. Medicare Telehealth Services for the Physician Fee Schedule
A. Billing and Payment for Telehealth Services
1. History
2. Current Telehealth Billing and Payment Policies
B. Requests for Adding Services to the List of Medicare
Telehealth Services
C. Submitted Requests for Addition to the List of Telehealth
Services for CY 2011
(1) Individual KDE Services
(2) Individual DSMT Services
(3) Group KDE, MNT, DSMT, and HBAI Services
(4) Initial, Subsequent, and Discharge Day Management Hospital
Care Services
(5) Initial, Subsequent, Discharge Day Management, and Other
Nursing Facility Care Services
(6) Neuropsychological Testing Services
(7) Speech-Language Pathology Services
(8) Home Wound Care Services
D. Summary of CY 2011 Telehealth Proposals
V. Provisions of the Patient Protection and Affordable Care Act of
2010
A. Section 3002: Improvements to the Physician Quality Reporting
System
[[Page 40042]]
B. Section 3003: Improvements to the Physician Feedback Program
and Section 3007: Value-Based Payment Modifier Under the Physician
Fee Schedule
1. Background
2. Effect of the Patient Protection and Affordable Care Act on
the Program
3. Implementation of Sections 3003 and 3007 of the Affordable
Care Act
4. Comments Sought on Specific Policy Topics Related to Both
PPACA Sections 3003 and 3007
a. Risk Adjustment
b. Attribution
c. Benchmarking and Peer Groups
d. Cost and Quality Measures and Composite Measurement
C. Section 3102: Extension of the Work Geographic Index Floor
and Revisions to the Practice Expense Geographic Adjustment Under
the Medicare Physician Fee Schedule, and Protections for Frontier
States as Amended by Section 10324 of the Affordable Care Act
D. Section 3103: Extension of Exceptions Process for Medicare
Therapy Caps
E. Section 3104: Extension of Payment for Technical Component of
Certain Physician Pathology Services
F. Section 3105: Extension of Ambulance Add-On
G. Section 3107: Extension of Physician Fee Schedule Mental
Health Add-On
H. Section 3108: Permitting Physician Assistants to Order Post-
Hospital Extended Care Services
I. Section 3111: Payment for Bone Density Tests
J. Section 3114: Improved Access for Certified Nurse Midwife
Services
K. Section 3122: Extension of Medicare Reasonable Costs Payments
for Certain Clinical Diagnostic Laboratory Tests Furnished to
Hospital Patients in Certain Rural Areas
L. Section 3134: Misvalued Codes Under the Physician Fee
Schedule
M. Section 3135: Modification of Equipment Utilization Factor
for Advanced Imaging Services
1. Adjustment in Practice Expense to Reflect Higher Presumed
Utilization
2. Adjustment in Technical Component ``Discount'' on Single-
Session Imaging to Consecutive Body Parts
N. Section 3136: Revision for Payment for Power-Driven
Wheelchairs
a. Payment Rules for Power Wheelchairs
b. Elimination of Lump Sum Payment for Standard Power
Wheelchairs
c. Revision of Payment Amounts for Power Wheelchairs
O. Section 3139: Payment for Biosimilar Biological Products
P. Section 3401: Revision of Certain Market Basket Updates and
Incorporation of Productivity Improvements Into Market Basket
Updates That Do Not Already Incorporate Such Improvements
1. ESRD Market Basket Discussion
2. Productivity Adjustment Regarding Ambulance and Clinical
Laboratory Fee Schedules
a. Ambulatory Surgery Centers (ASCs)
b. Ambulance Fee Schedule (AFS)
c. Clinical Lab Fee Schedule
Q. Section 4103: Medicare Coverage of Annual Wellness Visit
Providing a Personalized Prevention Plan
1. Background
a. Medicare Coverage of Preventive Physical Examinations and
Routine Checkups
b. Requirements for Coverage of an Annual Wellness Visit
2. Proposed Revisions
a. Proposed Revisions to Sec. 411.15, Particular Services
Excluded From Coverage
b. Proposed Revisions to Part 410, Subpart B--Medical and Other
Health Services
(1) Definitions
(2) Requirements of the First Visit for Personalized Prevention
Plan Services
(3) Requirements of Subsequent Visits for Personalized
Prevention Plan Services
3. Payment for the Annual Wellness Visit Providing Personalized
Prevention Plan Services (PPPS)
R. Section 4104: Removal of Barriers to Preventive Services in
Medicare
1. Definition of ``Preventive Services''
2. Deductible and Coinsurance for Preventive Services
3. Extension of Waiver of Deductible to Services Furnished in
Connection With or in Relation to a Colorectal Cancer Screening Test
that Becomes Diagnostic or Therapeutic
S. Section 5501: Expanding Access to Primary Care Services and
General Surgery Services
1. Section 5501(a): Incentive Payment Program for Primary Care
Services
a. Background
b. Proposed Primary Care Incentive Payment Program (PCIP)
2. Section 5501(b): Incentive Payment Program for Major Surgical
Procedures Furnished in Health Professional Shortage Areas
a. Background
b. Proposed HPSA Surgical Incentive Payment Program (HSIP)
3. Sections 5501(a) and (b) of the Affordable Care Act and
Payment for Critical Access Hospital Professional Services Under the
Optional Method
T. Section 6003: Disclosure Requirements for In-Office Ancillary
Services Exception to the Prohibition on Physician Self-Referral for
Certain Imaging Services
1. Background
2. Proposed Disclosure Requirement
U. Section 6404: Maximum Period for Submission of Medicare
Claims Reduced to Not More Than 12 Months
1. Background
2. Provisions of Affordable Care Act
V. Section 6410 and MIPPA: Adjustments to the Medicare Durable
Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive
Acquisition Program
1. Background
2. Subdividing Large MSAs Under Round 2
3. Exclusions of Certain Areas After Round 2 and Prior to 2015
4. Expansion of Round 2
W. Section 10501(i)(3)--Proposed Collection of HCPCS Data for
Development and Implementation of a Prospective Payment System for
the Medicare Federally Qualified Health Center Program
VI. Other Provisions of the Proposed Regulation
A. Part B Drug Payment: Average Sales Price (ASP) Issues
1. ``Carry Over'' ASP
2. Partial Quarter ASP Data
3. Determining the Payment Amount for Drugs and Biologicals
Which Include Intentional Overfill
4. WAMP/AMP
5. Price Substitutions
a. AMP threshold
b. AMP Price Substitution
B. Ambulance Fee Schedule: Proposed Policy for Reporting Units
When Billing for Ambulance Fractional Mileage
1. Policy for Reporting Units When Billing for Ambulance
Fractional Mileage or Other Services
a. History of Medicare Ambulance Services
(1) Statutory Coverage of Ambulance Services
(2) Medicare Regulations for Ambulance Services
b. Mileage Reporting
(1) Background and Current Process for Reporting Ambulance
Mileage
(2) Potential for Inaccuracies in Reporting Units and Associated
Risks
(3) Billing of Fractional Units for Mileage
C. Clinical Laboratory Fee Schedule: Signature on Requisition
D. Discussion of Chiropractic Services Demonstration
E. Provisions Related to Payment for Renal Dialysis Services
Furnished by End-Stage Renal Disease (ESRD) Facilities
1. CY 2005 Provisions
2. CY 2006 Provisions
3. CY 2007 Provisions
4. CY 2008 Provisions
5. CY 2009 Updates
6. CY 2010 Updates
7. Proposals for CY 2011
a. MIPPA Provisions
b. Affordable Care Act Provision
8. Proposed Update to the Drug Add-On Adjustment to the
Composite Rate
a. Estimating Growth in Expenditures for Drugs and Biologicals
for CY 2010
b. Estimating Growth in Expenditures for Drugs and Biologicals
in CY 2011
c. Estimating Per Patient Growth
d. Applying the Proposed Growth Update to the Drug Add-On
Adjustment
e. Proposed Update to the Drug Add-On Adjustment
f. Proposed Update to the Geographic Adjustments to the
Composite Rate
g. Proposed Updates to Core-Based Statistical Area (CBSA)
Definitions
h. Proposed Updated Wage Index Values
i. Reduction to the ESRD Wage Index Floor
j. Proposed Wage Index Values for Areas With No Hospital Data
k. Budget Neutrality Adjustment
l. ESRD Wage Index Tables
F. Issues Related to the Medicare Improvements for Patients and
Providers Act of 2008 (MIPPA)
1. Section 131: Physician Payment, Efficiency, and Quality
Improvements--
[[Page 40043]]
Physician Quality Reporting Initiative (PQRI)
a. Program Background and Statutory Authority
b. Incentive Payments for the 2011 PQRI
c. Proposed 2011 Reporting Periods for Individual Eligible
Professionals
d. Proposed 2011 PQRI Reporting Mechanisms for Individual
Eligible Professionals
(1) Proposed Requirements for Individual Eligible Professionals
Who Choose the Claims-Based Reporting Mechanism
(2) Proposed Requirements for Individual Eligible Professionals
Who Choose the Registry-Based Reporting Mechanism
(3) Proposed Requirements for Individual Eligible Professionals
Who Choose the EHR-Based Reporting Mechanism
(4) Proposed Qualification Requirements for Registries
(5) Proposed Qualification Requirements for EHR Vendors and
Their Products
e. Proposed Criteria for Satisfactory Reporting of Individual
Quality Measures for Individual Eligible Professionals
f. Proposed Criteria for Satisfactory Reporting Measures Groups
for Individual Eligible Professionals
g. Proposed Reporting Option for Satisfactory Reporting on
Quality Measures by Group Practices
(1) Group Practice Reporting Option--GPRO I
(2) Process for Physician Group Practices to Participate as
Group Practices and Criteria for Satisfactory Reporting
h. Statutory Requirements and Other Considerations for 2011 PQRI
Measures
(1) Statutory Requirements for 2011 PQRI Measures
(2) Other Considerations for Measures Proposed for Inclusion in
the 2011 PQRI
i. Proposed 2011 PQRI Quality Measures for Individual Eligible
Professionals
(1) Proposed 2011 Individual Quality Measures Selected From the
2010 PQRI Quality Measures Set Available for Claims Based Reporting
and Registry-Based Reporting
(2) Proposed 2011 Individual Quality Measures Selected From the
2010 PQRI Quality Measures Set Available for Registry Based
Reporting Only
(3) New Individual Quality Measures Selected for Proposed for
2011
(4) Proposed 2011 Measures Available for EHR-Based Reporting
(5) Measures Proposed for Inclusion in 2011 Measures Groups
j. Proposed 2011 PQRI Quality Measures for Physician Groups
Selected to Participate in the Group Practice Reporting Option
k. Public Reporting of PQRI Data
l. Affordable Care Act Extension of Incentive for PQRI Program
m. Affordable Care Act Timely Feedback Reports
n. Affordable Care Act Informal Appeals Process
o. Affordable Care Act Maintenance of Certification Program
p. Affordable Care Act Physician Compare Web Site
q. Affordable Care Act Integration of PQRI EHR Measures and
HITECH Measures in Years After 2011
2. Section 132: Incentives for Electronic Prescribing (eRx)--The
Electronic Prescribing Incentive Program
a. Program Background and Statutory Authority
b. The 2011 Reporting Period for the eRx Incentive Program
c. Proposed Criteria for Determination of Successful Electronic
Prescriber for Eligible Professionals
(1) Reporting the Electronic Prescribing Measure
(2) The Reporting Denominator for the Electronic Prescribing
Measure
(3) Qualified Electronic Prescribing System--Required
Functionalities and Part D eRx Standards
(4) The Reporting Numerator for the Electronic Prescribing
Measure
(5) Criteria for Successful Reporting of the Electronic
Prescribing Measure
d. Determination of the 2011 Incentive Payment Amount for
Individual Eligible Professionals Who Are Successful Electronic
Prescribers
e. Proposed Reporting Option for Satisfactory Reporting of the
Electronic Prescribing Measure by Group Practices
(1) Definition of ``Group Practice''
(2) Process for Group Practices to Participate as Group
Practices and Criteria for Successful Reporting of the Electronic
Prescribing Measure by Group Practices
f. Public Reporting of Names of Successful Electronic
Prescribers
G. DMEPOS Competitive Bidding Program Issues
1. Implementation of a National Mail Order Competitive Bidding
Program for Diabetic Testing Supplies
a. Revision of the Definition of ``Mail Order''
(1) Legislative and Regulatory History of the Medicare Durable
Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
Competitive Bidding Program
(2) National Mail Order Competitive Bidding Program
(3) The MIPPA and the Medicare DMEPOS Competitive Bidding
Program
(4) Competition for Mail Order Diabetic Supplies Under Round 1
of the Medicare DMEPOS Competitive Bidding Program
b. Overview of Proposed Rule
c. Future Competitions for Diabetic Testing Supplies
d. Definition of Mail Order Item
e. Special Rule in Case of National Mail Order Competition for
Diabetic Testing Strips
f. Anti-Switching Rule in Case of National Mail Order
Competition for Diabetic Test Strips
2. Off-the-Shelf (OTS) Orthotics Exemption
3. Changes to Payment for Oxygen and Oxygen Equipment
a. Background
b. Furnishing Oxygen Equipment After the 36-Month Rental Period
(Cap)
c. Furnishing Oxygen Equipment During the 36-Month Rental Period
(Cap)
4. Grandfathering Rules Resulting in Extra Payments to Contract
Suppliers Under the DMEPOS Competitive Bidding Program
5. Appeals Process
a. Background
b. Proposed Appeals Process
(1) Purpose and Definitions: (Sec. 414.402)
(2) Applicability
(3) Contract Termination
(4) Notice of Termination
(5) Corrective Action Plan
(6) Right to Request a Hearing by the CBIC Hearing Officer
(7) Scheduling of the Hearing
(8) Burden of Proof
(9) Role of the Hearing Officer
(10) CMS's Final Determination
(11) Effective Date of the Contract Termination
(12) Effect of Contract Termination
H. Provider and Supplier Enrollment Issue: Air Ambulance
Provision
I. Technical Corrections
1. Physical Therapy, Occupational Therapy, and Speech-Language
Pathology
2. Scope of Benefits
VII. Collection of Information Requirements
VIII. Response to Comments
IX. Regulatory Impact Analysis
A. RVU Impacts
1. Resource Based Work, PE, and Malpractice RVUs
2. CY 2011 PFS Impact Discussion
a. Changes in RVUs
b. Combined Impact
B. Geographic Practice Cost Indices (GPCIs)
C. Rebasing and Revising of the MEI
D. The Affordable Care Act Provisions
1. Section 3103: Extension of Exceptions Process for Medicare
Therapy Caps
2. Section 3104: Extension of Payment for Technical Component of
Certain Physician Pathology Services
3. Sections 3105 and 10311: Extension of Ambulance Add-Ons
4. Section 3107: Extension of Physician Fee Schedule Mental
Health Add-On
5. Section 3111: Payment for Bone Density Tests
6. Section 3122: Extension of Medicare Reasonable Costs Payments
for Certain Clinical Diagnostic Laboratory Tests Furnished to
Hospital Patients in Certain Rural Areas
7. Section 3135: Modification of Equipment Utilization Factor
for Advanced Imaging Services
8. Section 3136: Revisions in Payments for Power Wheelchairs
9. Section 3401: Revisions of Certain Market Basket Updates and
Incorporation of Productivity Adjustments
10. Section 4103: Medicare Coverage of Annual Wellness Visit
Providing a Personalized Prevention Plan
11. Section 4104: Removal of Barriers to Preventive Services in
Medicare
12. Section 5501: Expanding Access to Primary Care Services and
General Surgery Services
13. Section 6003: Disclosure Requirements for In-Office
Ancillary Services Exception to the Prohibition of Physician Self-
referral for Certain Imaging Services
[[Page 40044]]
14. Section 6404: Maximum Period for Submission of Medicare
Claims Reduced to Not More Than 12 Months
E. Other Provisions of the Proposed Regulation
1. Part B Drug Payment: ASP Issues
2. Ambulance Fee Schedule: Proposed Policy for Reporting Units
When Billing for Ambulance Fractional Mileage
3. Chiropractic Services Demonstration
4. Renal Dialysis Services Furnished by ESRD Facilities
5. Section 131(b) of the MIPPA: Physician Payment, Efficiency,
and Quality Improvements--Physician Quality Reporting Initiative
(PQRI)
6. Section 132 of the MIPPA: Incentives for Electronic
Prescribing (eRx)--The eRx Incentive Program
7 RHC/FQHC Issues
8. Durable Medical Equipment-Related Issues
a. Off-the-Shelf (OTS) Orthotics Exemption
b. Changes to Payment for Oxygen Equipment
F. Alternatives Considered
G. Impact on Beneficiaries
H. Accounting Statement
Regulation Text
Addendum A--Explanation and Use of Addendum B
Addendum B--Proposed Relative Value Units and Related Information
Used in Determining Medicare Payments for CY 2011
Addendum C--[Reserved]
Addendum D--Proposed CY 2011 Geographic Adjustment Factors (GAFs)
Addendum E--Proposed CY 2011 Geographic Practice Cost Indices
(GPCIs) by State and Medicare Locality
Addendum F--Proposed CY 2011 Diagnostic Imaging Services Subject to
the Multiple Procedure Payment Reduction
Addendum G--CPT/HCPCS Imaging Codes Defined by Section 5102(b) of
the DRA
Addendum H--Proposed CY 2011 ``Always Therapy'' Services* Subject to
the Multiple Procedure Payment Reduction
Addendum I--[Reserved]
Addendum J--[Reserved]
Addendum K--Proposed CY 2011 ESRD Wage Index for Urban Areas Based
on CBSA Labor Market Areas
Addendum L--Proposed CY 2011 ESRD Wage Index for Rural Areas Based
on CBSA Labor Market Areas
Acronyms
In addition, because of the many organizations and terms to which
we refer by acronym in this proposed rule, we are listing these
acronyms and their corresponding terms in alphabetical order below:
AA Anesthesiologist assistant
AACVPR American Association of Cardiovascular and Pulmonary
Rehabilitation
AANA American Association of Nurse Anesthetists
ABMS American Board of Medical Specialties
ABN Advanced Beneficiary Notice
ACA ``Affordable Care Act''
ACC American College of Cardiology
ACGME Accreditation Council on Graduate Medical Education
ACLS Advanced cardiac life support
ACR American College of Radiology
AED Automated external defibrillator
AFROC Association of Freestanding Radiation Oncology Centers
AHA American Heart Association
AHFS-DI American Hospital Formulary Service--Drug Information
AHRQ [HHS'] Agency for Healthcare Research and Quality
AMA American Medical Association
AMA-DE American Medical Association Drug Evaluations
AMP Average manufacturer price
AO Accreditation organization
AOA American Osteopathic Association
APA American Psychological Association
APTA American Physical Therapy Association
ARRA American Recovery and Reinvestment Act (Pub. L. 111-5)
ASC Ambulatory surgical center
ASP Average sales price
ASRT American Society of Radiologic Technologists
ASTRO American Society for Therapeutic Radiology and Oncology
ATA American Telemedicine Association
AWP Average wholesale price
BBA Balanced Budget Act of 1997 (Pub. L. 105-33)
BBRA [Medicare, Medicaid and State Child Health Insurance Program]
Balanced Budget Refinement Act of 1999 (Pub. L. 106-113)
BIPA Medicare, Medicaid, and SCHIP Benefits Improvement Protection
Act of 2000 (Pub. L. 106-554)
BLS Basic Life support
BN Budget neutrality
BPM Benefit Policy Manual
CABG Coronary artery bypass graft
CAD Coronary artery disease
CAH Critical access hospital
CAHEA Committee on Allied Health Education and Accreditation
CAP Competitive acquisition program
CBIC Competitive Bidding Implementation Contractor
CBP Competitive Bidding Program
CBSA Core-Based Statistical Area
CF Conversion factor
CfC Conditions for Coverage
CFR Code of Federal Regulations
CKD Chronic kidney disease
CLFS Clinical laboratory fee schedule
CMA California Medical Association
CMHC Community mental health center
CMP Civil money penalty
CMS Centers for Medicare & Medicaid Services
CNS Clinical nurse specialist
CoP Condition of participation
COPD Chronic obstructive pulmonary disease
CORF Comprehensive Outpatient Rehabilitation Facility
COS Cost of service
CPEP Clinical Practice Expert Panel
CPI Consumer Price Index
CPI-U Consumer price index for urban customers
CPR Cardiopulmonary resuscitation
CPT [Physicians'] Current Procedural Terminology (4th Edition, 2002,
copyrighted by the American Medical Association)
CR Cardiac rehabilitation
CRNA Certified registered nurse anesthetist
CRP Canalith repositioning
CRT Certified respiratory therapist
CSW Clinical social worker
CY Calendar year
DEA Drug Enforcement Agency
DHS Designated health services
DME Durable medical equipment
DMEPOS Durable medical equipment, prosthetics, orthotics, and
supplies
DOQ Doctor's Office Quality
DOS Date of service
DRA Deficit Reduction Act of 2005 (Pub. L. 109-171)
DSMT Diabetes self-management training
E/M Evaluation and management
EDI Electronic data interchange
EEG Electroencephalogram
EHR Electronic health record
EKG Electrocardiogram
EMG Electromyogram
EMTALA Emergency Medical Treatment and Active Labor Act
EOG Electro-oculogram
EPO Erythopoeitin
ESRD End-stage renal disease
FAX Facsimile
FDA Food and Drug Administration (HHS)
FFS Fee-for-service
FR Federal Register
GAF Geographic adjustment factor
GAO General Accounting Office
GEM Generating Medicare [Physician Quality Performance Measurement
Results]
GFR Glomerular filtration rate
GPO Group purchasing organization
GPCI Geographic practice cost index
HAC Hospital-acquired conditions
HBAI Health and behavior assessment and intervention
HCPAC Health Care Professional Advisory Committee
HCPCS Healthcare Common Procedure Coding System
HCRIS Healthcare Cost Report Information System
HDRT High dose radiation therapy
HH PPS Home Health Prospective Payment System
HHA Home health agency
HHRG Home health resource group
HHS [Department of] Health and Human Services
HIPAA Health Insurance Portability and Accountability Act of 1996
(Pub. L. 104-191)
HIT Health information technology
HITECH Health Information Technology for Economic and Clinical
Health Act (Title IV of Division B of the Recovery Act, together
with Title XIII of Division A of the Recovery Act)
HITSP Healthcare Information Technology Standards Panel
HIV Human immunodeficiency virus
HOPD Hospital outpatient department
HPSA Health Professional Shortage Area
HRSA Health Resources Services Administration (HHS)
IACS Individuals Access to CMS Systems
ICD International Classification of Diseases
[[Page 40045]]
ICF Intermediate care facilities
ICR Intensive cardiac rehabilitation
ICR Information collection requirement
IDTF Independent diagnostic testing facility
IFC Interim final rule with comment period
IMRT Intensity-Modulated Radiation Therapy
IPPE Initial preventive physical examination
IPPS Inpatient prospective payment system
IRS Internal Revenue Service
ISO Insurance services office
IVD Ischemic Vascular Disease
IVIG Intravenous immune globulin
IWPUT Intra-service work per unit of time
JRCERT Joint Review Committee on Education in Radiologic Technology
KDE Kidney disease education
LCD Local coverage determination
MA Medicare Advantage
MA-PD Medicare Advantage--Prescription Drug Plans
MAV Measure Applicability Validation
MCMP Medicare Care Management Performance
MDRD Modification of Diet in Renal Disease
MedCAC Medicare Evidence Development and Coverage Advisory Committee
(formerly the Medicare Coverage Advisory Committee (MCAC))
MedPAC Medicare Payment Advisory Commission
MEI Medicare Economic Index
MIEA-TRHCA Medicare Improvements and Extension Act of 2006 (that is,
Division B of the Tax Relief and Health Care Act of 2006 (TRHCA))
(Pub. L. 109-432)
MIPPA Medicare Improvements for Patients and Providers Act of 2008
(Pub. L. 110-275)
MMA Medicare Prescription Drug, Improvement, and Modernization Act
of 2003 (Pub. L. 108-173)
MMSEA Medicare, Medicaid, and SCHIP Extension Act of 2007 (Pub. L.
110-173)
MNT Medical nutrition therapy
MOC Maintenance of certification
MP Malpractice
MPPR Multiple procedure payment reduction
MQSA Mammography Quality Standards Act of 1992 (Pub. L. 102-539)
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
NBRC National Board for Respiratory Care
NCD National Coverage Determination
NCQDIS National Coalition of Quality Diagnostic Imaging Services
NDC National drug code
NF Nursing facility
NISTA National Institute of Standards and Technology Act
NP Nurse practitioner
NPI National Provider Identifier
NPP Nonphysician practitioner
NQF National Quality Forum
NRC Nuclear Regulatory Commission
OACT [CMS'] Office of the Actuary
OBRA Omnibus Budget Reconciliation Act
ODF Open door forum
OGPE Oxygen generating portable equipment
OIG Office of Inspector General
OMB Office of Management and Budget
ONC [HHS'] Office of the National Coordinator for Health IT
OPPS Outpatient prospective payment system
OSCAR Online Survey and Certification and Reporting
PA Physician assistant
PAT Performance assessment tool
PC Professional component
PCI Percutaneous coronary intervention
PDP Prescription drug plan
PE Practice expense
PE/HR Practice expense per hour
PEAC Practice Expense Advisory Committee
PERC Practice Expense Review Committee
PFS Physician Fee Schedule
PGP [Medicare] Physician Group Practice
PHI Protected health information
PHP Partial hospitalization program
PIM [Medicare] Program Integrity Manual
PLI Professional liability insurance
POA Present on admission
POC Plan of care
PPI Producer price index
PPIS Physician Practice Information Survey
PPS Prospective payment system
PPTA Plasma Protein Therapeutics Association
PQRI Physician Quality Reporting Initiative
PR Pulmonary rehabilitation
PRA Paperwork Reduction Act
PSA Physician scarcity areas
PT Physical therapy
PTCA Percutaneous transluminal coronary angioplasty
PVBP Physician and Other Health Professional Value-Based Purchasing
Workgroup
RA Radiology assistant
RBMA Radiology Business Management Association
RFA Regulatory Flexibility Act
RHC Rural health clinic
RIA Regulatory impact analysis
RN Registered nurse
RNAC Reasonable net acquisition cost
RPA Radiology practitioner assistant
RRT Registered respiratory therapist
RUC [AMA's Specialty Society] Relative (Value) Update Committee
RVU Relative value unit
SBA Small Business Administration
SGR Sustainable growth rate
SLP Speech-language pathology
SMS [AMA's] Socioeconomic Monitoring System
SNF Skilled nursing facility
SOR System of record
SRS Stereotactic radiosurgery
STARS Services Tracking and Reporting System
TC Technical Component
TIN Tax identification number
TRHCA Tax Relief and Health Care Act of 2006 (Pub. L. 109-432)
TTO Transtracheal oxygen
UPMC University of Pittsburgh Medical Center
USDE United States Department of Education
USP-DI United States Pharmacopoeia-Drug Information
VBP Value-based purchasing
WAMP Widely available market price
I. Background
Since January 1, 1992, Medicare has paid for physicians' services
under section 1848 of the Social Security Act (the Act), ``Payment for
Physicians' Services.'' The Act requires that payments under the
physician fee schedule (PFS) are based on national uniform relative
value units (RVUs) based on the relative resources used in furnishing a
service. Section 1848(c) of the Act requires that national RVUs be
established for physician work, practice expense (PE), and malpractice
expense. Before the establishment of the resource-based relative value
system, Medicare payment for physicians' services was based on
reasonable charges. We note that throughout this proposed rule, unless
otherwise noted, the term ``practitioner'' is used to describe both
physicians and eligible nonphysician practitioners (such as physician
assistants, nurse practitioners, clinical nurse specialists, certified
nurse midwives, psychologists, or social workers) that are permitted to
furnish and bill Medicare under the PFS for the services under
discussion.
A. Development of the Relative Value System
1. Work RVUs
The concepts and methodology underlying the PFS were enacted as
part of the Omnibus Budget Reconciliation Act (OBRA) of 1989 (Pub. L.
101-239), and OBRA 1990, (Pub. L. 101-508). The final rule, published
on November 25, 1991 (56 FR 59502), set forth the fee schedule for
payment for physicians' services beginning January 1, 1992. Initially,
only the physician work RVUs were resource-based, and the PE and
malpractice RVUs were based on average allowable charges.
The physician work RVUs established for the implementation of the
fee schedule in January 1992 were developed with extensive input from
the physician community. A research team at the Harvard School of
Public Health developed the original physician work RVUs for most codes
in a cooperative agreement with the Department of Health and Human
Services (DHHS). In constructing the code-specific vignettes for the
original physician work RVUs, Harvard worked with panels of experts,
both inside and outside the Federal government, and obtained input from
numerous physician specialty groups.
Section 1848(b)(2)(B) of the Act specifies that the RVUs for
anesthesia services are based on RVUs from a uniform relative value
guide, with appropriate adjustment of the
[[Page 40046]]
conversion factor (CF), in a manner to assure that fee schedule amounts
for anesthesia services are consistent with those for other services of
comparable value. We established a separate CF for anesthesia services,
and we continue to utilize time units as a factor in determining
payment for these services. As a result, there is a separate payment
methodology for anesthesia services.
We establish physician work RVUs for new and revised codes based on
our review of recommendations received from the American Medical
Association's (AMA) Specialty Society Relative Value Update Committee
(RUC).
2. Practice Expense Relative Value Units (PE RVUs)
Section 121 of the Social Security Act Amendments of 1994 (Pub. L.
103-432), enacted on October 31, 1994, amended section
1848(c)(2)(C)(ii) of the Act and required us to develop resource-based
PE RVUs for each physician's service beginning in 1998. We were to
consider general categories of expenses (such as office rent and wages
of personnel, but excluding malpractice expenses) comprising PEs.
Section 4505(a) of the Balanced Budget Act of 1997 (BBA) (Pub. L.
105-33), amended section 1848(c)(2)(C)(ii) of the Act to delay
implementation of the resource-based PE RVU system until January 1,
1999. In addition, section 4505(b) of the BBA provided for a 4-year
transition period from charge-based PE RVUs to resource-based RVUs.
We established the resource-based PE RVUs for each physicians'
service in a final rule, published November 2, 1998 (63 FR 58814),
effective for services furnished in 1999. Based on the requirement to
transition to a resource-based system for PE over a 4-year period,
resource-based PE RVUs did not become fully effective until 2002.
This resource-based system was based on two significant sources of
actual PE data: the Clinical Practice Expert Panel (CPEP) data; and the
AMA's Socioeconomic Monitoring System (SMS) data. The CPEP data were
collected from panels of physicians, practice administrators, and
nonphysicians (for example, registered nurses (RNs)) nominated by
physician specialty societies and other groups. The CPEP panels
identified the direct inputs required for each physician's service in
both the office setting and out-of-office setting. We have since
refined and revised these inputs based on recommendations from the RUC.
The AMA's SMS data provided aggregate specialty-specific information on
hours worked and PEs.
Separate PE RVUs are established for procedures that can be
performed in both a nonfacility setting, such as a physician's office,
and a facility setting, such as a hospital outpatient department. The
difference between the facility and nonfacility RVUs reflects the fact
that a facility typically receives separate payment from Medicare for
its costs of providing the service, apart from payment under the PFS.
The nonfacility RVUs reflect all of the direct and indirect PEs of
providing a particular service.
Section 212 of the Balanced Budget Refinement Act of 1999 (BBRA)
(Pub. L. 106-113) directed the Secretary of Health and Human Services
(the Secretary) to establish a process under which we accept and use,
to the maximum extent practicable and consistent with sound data
practices, data collected or developed by entities and organizations to
supplement the data we normally collect in determining the PE
component. On May 3, 2000, we published the interim final rule (65 FR
25664) that set forth the criteria for the submission of these
supplemental PE survey data. The criteria were modified in response to
comments received, and published in the Federal Register (65 FR 65376)
as part of a November 1, 2000 final rule. The PFS final rules published
in 2001 and 2003, respectively, (66 FR 55246 and 68 FR 63196) extended
the period during which we would accept these supplemental data through
March 1, 2005.
In the calendar year (CY) 2007 PFS final rule with comment period
(71 FR 69624), we revised the methodology for calculating direct PE
RVUs from the top-down to the bottom-up methodology beginning in CY
2007 and provided for a 4-year transition for the new PE RVUs under
this new methodology. This transition ended in CY 2010 and direct PE
RVUs are calculated in CY 2011 using this methodology, unless otherwise
noted.
In the CY 2010 PFS final rule with comment period, we updated the
PE/hour (HR) data that are used in the calculation of PE RVUs for most
specialties (74 FR 61749). For this update, we used the Physician
Practice Information Survey (PPIS) conducted by the AMA. The PPIS is a
multispecialty, nationally representative, PE survey of both physicians
and nonphysician practitioners (NPPs) using a survey instrument and
methods highly consistent with those of the SMS and the supplemental
surveys used prior to CY 2010. We note that in CY 2010, for oncology,
clinical laboratories, and independent diagnostic testing facilities
(IDTFs), we continued to use the supplemental survey data to determine
PE/HR values (74 FR 61752).
3. Resource-Based Malpractice (MP) RVUs
Section 4505(f) of the BBA amended section 1848(c) of the Act
requiring us to implement resource-based malpractice (MP) RVUs for
services furnished on or after 2000. The resource-based MP RVUs were
implemented in the PFS final rule published November 2, 1999 (64 FR
59380). The MP RVUs were based on malpractice insurance premium data
collected from commercial and physician-owned insurers from all the
States, the District of Columbia, and Puerto Rico.
4. Refinements to the RVUs
Section 1848(c)(2)(B)(i) of the Act requires that we review all
RVUs no less often than every 5 years. The first Five-Year Review of
the physician work RVUs was published on November 22, 1996 (61 FR
59489) and was effective in 1997. The second Five-Year Review was
published in the CY 2002 PFS final rule with comment period (66 FR
55246) and was effective in 2002. The third Five-Year Review of
physician work RVUs was published in the CY 2007 PFS final rule with
comment period (71 FR 69624) and was effective on January 1, 2007.
(Note: Additional codes relating to the third Five-Year Review of
physician work RVUs were addressed in the CY 2008 PFS final rule with
comment period (72 FR 66360).) The fourth Five-Year Review of physician
work RVUs was initiated in the CY 2010 PFS final rule with comment
period where we solicited candidate codes from the public for this
review (74 FR 61941). Changes due to the fourth Five-Year Review of
physician work RVUs will be effective January 1, 2012.
In 1999, the AMA's RUC established the Practice Expense Advisory
Committee (PEAC) for the purpose of refining the direct PE inputs.
Through March 2004, the PEAC provided recommendations to CMS for over
7,600 codes (all but a few hundred of the codes currently listed in the
AMA's Current Procedural Terminology (CPT) codes). As part of the CY
2007 PFS final rule with comment period (71 FR 69624), we implemented a
new bottom-up methodology for determining resource-based PE RVUs and
transitioned the new methodology over a 4-year period. A comprehensive
review of PE was undertaken prior to the 4-year transition period for
the new PE methodology from the top-down to the bottom-up methodology,
and this transition was completed in CY 2010. In
[[Page 40047]]
CY 2010, we also incorporated the new PPIS data to update the
specialty-specific PE/HR data used to develop PE RVUs. Therefore, the
next Five-Year Review of PE RVUs will be addressed in CY 2014.
In the CY 2005 PFS final rule with comment period (69 FR 66236), we
implemented the first Five-Year Review of the MP RVUs (69 FR 66263).
Minor modifications to the methodology were addressed in the CY 2006
PFS final rule with comment period (70 FR 70153). The second Five-Year
Review and update of resource-based malpractice RVUs was published in
the CY 2010 PFS final rule with comment period (74 FR 61758) and was
effective in CY 2010.
5. Adjustments to RVUs Are Budget Neutral
Section 1848(c)(2)(B)(ii)(II) of the Act provides that adjustments
in RVUs for a year may not cause total PFS payments to differ by more
than $20 million from what they would have been if the adjustments were
not made. In accordance with section 1848(c)(2)(B)(ii)(II) of the Act,
if revisions to the RVUs cause expenditures to change by more than $20
million, we make adjustments to ensure that expenditures do not
increase or decrease by more than $20 million.
As explained in the CY 2009 PFS final rule with comment period
(73FR 69730), as required by section 133(b) of the Medicare
Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L.
110-275), the separate budget neutrality (BN) adjustor resulting from
the third Five-Year Review of physician work RVUs is being applied to
the CF beginning in CY 2009 rather than to the work RVUs.
For CY 2010, we adopted a number of new payment policies for which
we estimated the potential for a redistributive effect under the PFS,
including the use of the new PPIS data to develop the specialty-
specific PE/HR used for the PE RVUs (74 FR 61749 through 61752) and the
elimination of the reporting of all CPT consultation codes in order to
allow for correct and consistent coding and appropriate payment for
evaluation and management services under the PFS (74 FR 61767 through
61775). We recognize that clinical experience with these new PFS
policies has been growing over the first 6 months of CY 2010 and, as we
seek to improve future PFS payment accuracy for services, we are
interested in public comments on the perspectives of physicians and
nonphysician practitioners caring for Medicare beneficiaries under the
current PFS coding and payment methodologies for physicians' services.
B. Components of the Fee Schedule Payment Amounts
To calculate the payment for every physicians' service, the
components of the fee schedule (physician work, PE, and MP RVUs) are
adjusted by a geographic practice cost index (GPCI). The GPCIs reflect
the relative costs of physician work, PE, and malpractice expense in an
area compared to the national average costs for each component.
RVUs are converted to dollar amounts through the application of a
CF, which is calculated by CMS' Office of the Actuary (OACT).
The formula for calculating the Medicare fee schedule payment
amount for a given service and fee schedule area can be expressed as:
Payment = [(RVU work x GPCI work) + (RVU PE x GPCI PE) + (RVU
malpractice x GPCI malpractice)] x CF
C. Most Recent Changes to the Fee Schedule
The CY 2010 PFS final rule with comment period (74 FR 61738)
implemented changes to the PFS and other Medicare Part B payment
policies. It also finalized some of the CY 2009 interim RVUs and
implemented interim RVUs for new and revised codes for CY 2010 to
ensure that our payment systems are updated to reflect changes in
medical practice and the relative value of services. The CY 2010 PFS
final rule with comment period also addressed other policies, as well
as certain provisions of the MIPPA.
As required by the statute at the time of its issuance on October
30, 2009, the CY 2010 PFS final rule with comment period announced the
following for CY 2010: The PFS update of -21.2 percent; the initial
estimate for the sustainable growth rate of -8.8 percent; and the CF of
$28.4061.
On December 10, 2009, we published a correction notice (74 FR
65449) to correct several technical and typographical errors that
occurred in the CY 2010 PFS final rule with comment period. This
correction notice announced a revised CF for CY 2010 of $28.3895.
On December 19, 2009, the Department of Defense Appropriations Act,
2010 (Pub. L. 111-118) was signed into law. Section 1011 of Pub. L.
111-118 provided a 2-month zero percent update to the CY 2010 PFS
effective only for dates of service from January 1, 2010 through
February 28, 2010.
On March 2, 2010, the Temporary Extension Act of 2010 (Pub. L. 111-
144) was signed into law. Section 2 of Pub. L. 111-144 extended the
zero percent update to the PFS through March 31, 2010 that was in
effect for claims with dates of service from January 1, 2010 through
February 28, 2010.
In addition, on April 15, 2010, the Continuing Extension Act of
2010 (Pub. L. 111-157) was signed into law. Section 4 of Public Law
111-157 extended through May 31, 2010 the zero percent update to the
PFS that was in effect for claims with dates of services from January
1, 2010 through March 31, 2010. The law is retroactive to April 1,
2010.
In the May 11, 2010 Federal Register (75 FR 26350), we published a
subsequent correction notice to correct several technical and
typographical errors that occurred in the CY 2010 PFS final rule with
comment period and the December 10, 2009 correction notice. The May 11,
2010 correction notice announced a revised CF for CY 2010 of $28.3895.
Finally, on March 23, 2010 the Patient Protection and Affordable
Care Act (Pub. L. 111-148) was signed into law. Shortly thereafter, on
March 30, 2010, the Health Care and Education Reconciliation Act of
2010 (Pub. L. 111-152) was signed into law. These two laws are
discussed in this proposed rule and are collectively referred to as the
``Affordable Care Act'' (ACA) throughout this proposed rule.
II. Provisions of the Proposed Rule for the Physician Fee Schedule
A. Resource-Based Practice Expense (PE) Relative Value Units (RVUs)
1. Overview
Practice expense (PE) is the portion of the resources used in
furnishing the service that reflects the general categories of
physician and practitioner expenses, such as office rent and personnel
wages but excluding malpractice expenses, as specified in section
1848(c)(1)(B) of the Act. Section 121 of the Social Security Amendments
of 1994 (Pub. L. 103-432), enacted on October 31, 1994, required CMS to
develop a methodology for a resource-based system for determining PE
RVUs for each physician's service. We develop PE RVUs by looking at the
direct and indirect physician practice resources involved in furnishing
each service. Direct expense categories include clinical labor, medical
supplies and medical equipment. Indirect expenses include
administrative labor, office expense, and all other expenses. The
sections that follow provide more
[[Page 40048]]
detailed information about the methodology for translating the
resources involved in furnishing each service into service-specific PE
RVUs. In addition, we note that section 1848(c)(2)(B)(ii)(II) of the
Act provides that adjustments in RVUs for a year may not cause total
PFS payments to differ by more than $20 million from what they would
have been if the adjustments were not made. Therefore, if revisions to
the RVUs cause expenditures to change by more than $20 million, we make
adjustments to ensure that expenditures do not increase or decrease by
more than $20 million. We refer readers to the CY 2010 PFS final rule
with comment period (74 FR 61743 through 61748) for a more detailed
history of the PE methodology.
2. Practice Expense Methodology
a. Direct Practice Expense
We use a bottom-up approach to determine the direct PE by adding
the costs of the resources (that is, the clinical staff, equipment, and
supplies) typically required to provide each service. The costs of the
resources are calculated using the refined direct PE inputs assigned to
each CPT code in our PE database, which are based on our review of
recommendations received from the American Medical Association's
(AMA's) Relative Value Update Committee (RUC). For a detailed
explanation of the bottom-up direct PE methodology, including examples,
we refer readers to the Five-Year Review of Work Relative Value Units
Under the PFS and Proposed Changes to the Practice Expense Methodology
proposed notice (71 FR 37242) and the CY 2007 PFS final rule with
comment period (71 FR 69629).
b. Indirect Practice Expense per Hour Data
We use survey data on indirect practice expenses incurred per hour
worked (PE/HR) in developing the indirect portion of the PE RVUs. Prior
to CY 2010, we primarily used the practice expense per hour (PE/HR) by
specialty that was obtained from the AMA's Socioeconomic Monitoring
Surveys (SMS). These surveys were conducted from 1995 through 1999. For
several specialties that collected additional PE/HR data through
supplemental surveys, we incorporated these data in developing the PE/
HR values used annually.
While the SMS was not specifically designed for the purpose of
establishing PE RVUs, we found these data to be the best available at
the time. The SMS was a multispecialty survey effort conducted using a
consistent survey instrument and method across specialties. The survey
sample was randomly drawn from the AMA Physician Masterfile to ensure
national representativeness. The AMA discontinued the SMS survey in
1999. As required by the Balanced Budget Refinement Act of 1999 (BBRA)
(Pub. L. 106-113), we also established a process by which specialty
groups could submit supplemental PE data. In the May 3, 2000 Federal
Register, we issued the Medicare Program; Criteria for Submitting
Supplemental Practice Expense Survey Data interim final rule (65 FR
25664) in which we established criteria for acceptance of supplemental
data. The criteria were modified in the CY 2001 and CY 2003 PFS final
rules with comment period (65 FR 65380 and 67 FR 79971, respectively).
In addition to the SMS, we previously used supplemental survey data for
the following specialties: Cardiology; dermatology; gastroenterology;
radiology; cardiothoracic surgery; vascular surgery; physical and
occupational therapy; independent laboratories; allergy/immunology;
independent diagnostic testing facilities (IDTFs); radiation oncology;
medical oncology; and urology.
Because the SMS data and the supplemental survey data were from
different time periods, we historically inflated them by the Medicare
Economic Index (MEI) to put them on as comparable a time basis as we
could when calculating the PE RVUs. This MEI proxy was necessary in the
past due to the lack of contemporaneous, consistently collected, and
comprehensive multispecialty survey data.
The AMA administered a new survey in CY 2007 and CY 2008, the
Physician Practice Expense Information Survey (PPIS), which was
expanded (relative to the SMS) to include nonphysician practitioners
(NPPs) paid under the PFS. The PPIS was designed to update the
specialty-specific PE/HR data used to develop PE RVUs. The AMA and the
CMS contractor, The Lewin Group (Lewin), analyzed the PPIS data and
calculated the PE/HR for physician and nonphysician specialties,
respectively. The AMA's summary worksheets and Lewin's final report are
available on the CMS Web site at https://www.cms.gov/PhysicianFeeSched/PFSFRN/itemdetail.asp?filterType=none&filterByDID=-99&sortByDID=4&sortOrder=descending&itemID=CMS1223902&intNumPerPage=10.
(See downloads labeled AMA PPIS Worksheets 1-3 and Physician Practice
Expense non MDDO Final Report)
The PPIS is a multispecialty, nationally representative, PE survey
of both physicians and NPPs using a consistent survey instrument and
methods highly consistent with those used for the SMS and the
supplemental surveys. The PPIS gathered information from 3,656
respondents across 51 physician specialty and healthcare professional
groups.
We believe the PPIS is the most comprehensive source of PE survey
information available to date. Therefore, we used the PPIS data to
update the PE/HR data for almost all of the Medicare-recognized
specialties that participated in the survey for the CY 2010 PFS. When
we changed over to the PPIS data beginning in CY 2010, we did not
change the PE RVU methodology itself or the manner in which the PE/HR
data are used in that methodology. We only updated the PE/HR data based
on the new survey. Furthermore, as we explained in the CY 2010 PFS
final rule with comment period (74 FR 61751), because of the magnitude
of payment reductions for some specialties resulting from the use of
the PPIS data, we finalized a 4-year transition (75/25 for CY 2010, 50/
50 for CY 2011, 25/75 for CY 2012, and 0/100 for CY 2013) from the
previous PE RVUs to the PE RVUs developed using the new PPIS data.
Section 303 of the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA) (Pub. L. 108-173) added section
1848(c)(2)(H)(i) of the Act, which requires us to use the medical
oncology supplemental survey data submitted in 2003 for oncology drug
administration services. Therefore, the PE/HR for medical oncology,
hematology, and hematology/oncology reflects the continued use of these
supplemental survey data.
We do not use the PPIS data for reproductive endocrinology, sleep
medicine, and spine surgery since these specialties are not separately
recognized by Medicare, and we do not know how to blend these data with
Medicare-recognized specialty data.
Supplemental survey data on independent labs, from the College of
American Pathologists, were implemented for payments in CY 2005.
Supplemental survey data from the National Coalition of Quality
Diagnostic Imaging Services (NCQDIS), representing IDTFs, were blended
with supplementary survey data from the American College of Radiology
(ACR